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Production of Universal Red Blood Cells via Enzymatic Conversion
Abstract

Red blood cell (RBC) transfusion units are considered one of the most essential healthcare components in
the world. In the United States alone, approximately 21 million transfusion units are required every year.
Despite this high demand, RBC units are becoming increasingly scarce since only a fraction of eligible donors
provide RBCs to for medical use. Additionally, RBC transfusions are limited to immune compatibility in
patients, making it difficult to serve all patients with such a limited supply. This proposed design provides a
method in which RBCs of any blood group can be converted into the universal blood type, O, to eliminate any
concerns regarding blood type compatibility between donor and patient. This conversion process uses
bacterial glycosidades to cleave the sugar groups on the surface of RBCs that defines our blood type. This
process will help increase hospitals’ supply of readily usable RBCs for any situation while also providing a
solution to hospitals’ struggle to use their blood bags before they expire.
This proposal seeks to design a start-up scale plant that will both prepare the glysocidases needed for the
treatment process and execute the conversion. This project design expects a production capacity of 200,000
tranfusion units of successfully converted RBCs per year and will be located in Medford, MA. With an initial
investment of $25.6 million, the designs yields a a twelve-year net present value of $8,461,700 and has an
investor’s rate of return of 21.73%. A limited twelve-year lifespan was chosen in an attempt to more accurately
represent the lifespan of a start-up and to more strictly analyze its financial feasibility. The proposed project is
forecasted to breakeven in early 2028, at the beginning of its eighth year of its operation, with a return on
investment of 17.17%. With initial evidence of profitability, this project design is recommended. Furthermore,
the financial analysis performed in this report limits the scope of this project to satisfying the blood demands
of one major hospital in a metropolitan area. In reality, however, it is expected that the start-up will expand to
other major hospitals or blood collecting organizations within the first several years of operation, further
increasing its potential value. It should be noted, however, that investors exercise caution as the blood market
has been in constant flux for the past seven years, making it difficult to predict how valuable RBC transfusion
units will be compared to other blood components. The process should be executed only if an acceptable
pricing can be established to sustain the large costs associated with guaranteeing endotoxin and
contamination free products.
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April 18, 2017
University of Pennsylvania
School of Engineering and Applied Science
Department of Chemical and Biomolecular Engineering
220 S. 33rd Street
Philadelphia, PA 19104
Dear Professors Vrana and Wattenbarger:
Enclosed is a process design to produce universal type O red blood cells (RBCs) via enzymatic
conversion on a startup scale. Type O RBCs, as the type of red blood cells most used in blood
transfusions, are in increasingly high demand and increasingly short supply. Successful FDA
approval is assumed for eventual market launch; it is hoped that our product will advance
movement towards a universal blood supply.
The design of the universal enzymatically converted (ECO) RBC involves two processes: growth
of the ECO-enzymes in E. coli and subsequent purification, and enzymatic conversion treatment
of the RBCs themselves. Upstream operations in the first process include an inoculum bioreactor
followed by a growth bioreactor and two production fermenters wherein E. coli grows in high
density in high-salt media supplemented with glucose, kanamycin, and chloramphenicol.
Downstream operations for the first process include disk stage centrifugation, high-pressure
homogenization to release cytoplasmic ECO-zymes, cobalt affinity, HIC, and endotoxin affinity
chromatography to ensure nearly complete removal of cell debris and endotoxins.
Ultrafiltration/diafiltration and bulk microfiltration follow to resuspend and sterilize the isolated
ECO-zymes. The RBC conversion process involves centrifugation of unconverted RBCs,
incubation of RBCs and ECO-zymes in a WAVE bioreactor to effect conversion, centrifugation,
diafiltration, and cryogel affinity chromatography to separate enzyme from converted ECO RBCs.
The process in theory yields 22.91 kg ECO-A-zyme, 0.376 kg ECO-B-zyme, and 200,000 units of
ECO RBCs produced annually. Internal rate of return (IRR) is 21.73%, net present value (NPV)
is $8.46 million in 2019, and return on investment (ROI) is 17.17%. Our process requires $27.3
million working capital for a 12-year facility life span.
All calculations within stem from suggestions from Dr. Jeffrey Cohen, Dr. Robert Luo, Dr. Daniel
Green, Mr. Gary Sawyer, and other industrial consultants or from the literature. Please do not
hesitate to reach out should any questions or the need for supplemental information arise.
Sincerely,

______________________
Carly Catella

______________________
Rachel Coler

______________________
Brandon Hayes
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1.

Abstract
Red blood cell (RBC) transfusion units are considered one of the most essential healthcare

components in the world. In the United States alone, approximately 21 million transfusion units
are required every year. Despite this high demand, RBC units are becoming increasingly scarce
since only a fraction of eligible donors provide RBCs to for medical use. Additionally, RBC
transfusions are limited to immune compatibility in patients, making it difficult to serve all patients
with such a limited supply. This proposed design provides a method in which RBCs of any blood
group can be converted into the universal blood type, O, to eliminate any concerns regarding blood
type compatibility between donor and patient. This conversion process uses bacterial glycosidades
to cleave the sugar groups on the surface of RBCs that defines our blood type. This process will
help increase hospitals’ supply of readily usable RBCs for any situation while also providing a
solution to hospitals’ struggle to use their blood bags before they expire.
This proposal seeks to design a start-up scale plant that will both prepare the glysocidases
needed for the treatment process and execute the conversion. This project design expects a
production capacity of 200,000 tranfusion units of successfully converted RBCs per year and will
be located in Medford, MA. With an initial investment of $25.6 million, the designs yields a a
twelve-year net present value of $8,461,700 and has an investor’s rate of return of 21.73%. A
limited twelve-year lifespan was chosen in an attempt to more accurately represent the lifespan of
a start-up and to more strictly analyze its financial feasibility. The proposed project is forecasted
to breakeven in early 2028, at the beginning of its eighth year of its operation, with a return on
investment of 17.17%. With initial evidence of profitability, this project design is recommended.
Furthermore, the financial analysis performed in this report limits the scope of this project to
satisfying the blood demands of one major hospital in a metropolitan area. In reality, however, it
is expected that the start-up will expand to other major hospitals or blood collecting organizations
within the first several years of operation, further increasing its potential value. It should be noted,
however, that investors exercise caution as the blood market has been in constant flux for the past
seven years, making it difficult to predict how valuable RBC transfusion units will be compared
to other blood components. The process should be executed only if an acceptable pricing can be
established to sustain the large costs associated with guaranteeing endotoxin and contamination
free products.
13
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2.

Introduction

2.1.

Project Background
Blood is an essential part of healthcare, listed on the World Health Organization’s

List of Essential Medicines1. Its components are always in high demand, of which red blood cells
(RBCs) are the most used in transfusions. Globally, around 85 million units of packed RBCs are
used annually, of which approximately 21 million are used in the United States alone2,3. Despite
the importance of RBC transfusions, the compatibility of donated blood, based on the ABO group
system, with patients’ immune systems often hinders treatment efficiency4. Plasma of blood group
A individuals contains naturally occurring antibodies to the B antigen present on group B RBCs,
marking them for destruction. Similarly, plasma of blood group B contains antibodies against A
antigen. This means that individuals with blood of group A cannot receive transfusions from group
B blood and vice-versa. Otherwise, patients will become anemic and suffer immune responses4.
Type-O RBCs, however, do not contain A or B antigens and can be safely transfused into
patients of any blood type, as shown in Figure 2.1. For this reason, type-O blood is considered the
“universal” blood type and is in high demand by blood banks and hospitals4.

Figure 2.1. Blood type compatibility chart. Note that type-O donors are able to donate to any other
RBC type when not considering the Rh factor.

1

World Health Organization. WHO Model List of Essential Medicines, 19 th List [Internet]. 2015 [cited 2018 Apr 15]. Available from:
http://www.who.int/medicines/publications/essentialmedicines/en/
2
American Red Cross. Blood Facts and Statistics [Internet]. 2018 [cited 2018 Apr 15]. Available from: https://www.redcrossblood.org/learnabout-blood/blood-facts-and-statistics
3
Carson JL et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Annals of Internal Medicine 2007; 157: 49–58.
4
Liu QP et al. Bacterial glycosidases for the production of universal red blood cells. Nature Biotechnology 2007; 25(4): 454-464.
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Donations from type-O donors are highly sought after, but a significant amount of type-A,
B and AB are also collected to be used with compatible recipients. However, a disproportionate
amount of type-O blood is used in trauma or situations with significant incompatibility risks, which
leads to a surplus of type-A, B and AB transfusion units5. RBCs are only stable and efficacious for
42 days when refrigerated at 4ºC, limiting their long-term viability and monetary value6. Improper
blood management strategies leads to a significant number of unused packed RBC units, which
tends to range from 20 to 30% of a hospital’s entire blood supply7.

Figure 2.2. Blood type distribution in the United States.

Although 49% of the population of the United States has type-O RBCs, as shown in Figure
2.2, only an estimated ten percent of the eligible U.S. population (38% of the total population)
donates blood2. In addition, the already limited number of willing donors has been affected by
changes in blood transfusion policies in the country in recent years. After a 15-year steady increase
in blood transfusions, the number of transfusions performed has been decreasing since 2011 due
to more strigent requirements for patients to receive tranfusions8. Hospitals have begun limiting
transfusions to patients only when their hemoglobin levels drop below 10 grams per deciliter,
nearly a two-fold change compared to the time prior to this policy’s implementation. This was
done to minimize hospital stays; to prevent the risk of infection, allergic reaction, or

5

Strobel E. Hemolytic transfusion reactions. Transfus. Med. Hemother. 2008; 35(5): 346-353.
Miraflor E et al. Emergency uncrossmatched transfusion effect on blood type alloantibodies. J. Trauma Acute Care Surg. 2012; 72(1): 48-52
7
Kurup R et al. A study on blood product usage and wastage at the public hospital, Guyana. BMC Res. Notes 2016 Jun; 9: 307.
8
Mohebbi Far R et al. Determination of rate and causes of wastage of blood and blood products in Iranian hospitals. Turk. J. Haematol. 2014 Jun;
31(2): 161-167
6
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contamination; and lessen treatment and operating costs imposed on hospitals for performing
unnecessary transfusions. As a result of this policy change, hospitals began to use significantly
fewer RBC transfusion units, leaving them with a surplus of transfusion units that only have a shelf
life of 42 days8. This eventually affected the blood collection industry, as sales began to drop since
hospitals now required fewer transfusion units. It also began to affect public awareness on the
issue, and both blood banks and the Red Cross began to receive fewer active donors.
The policy change has constrained current blood supplies significantly without properly
considering new health and medical treatment challenges in the present and upcoming years.
According to the World Health Organization, blood-intensive procedures are expected to grow,
such as solid organ transplants, hematopoietic stem cell transplants, and aggressive chemotherapy
against cancer, all of which will require increased blood supplies. The prevalence of cancer in the
American population, which is expected to surpass heart disease as the main cause of death in the
United States by as early as 2030, is specifically considered an area where RBC transfusion units
are predicted to be needed in a greater supply than what is currently available. According to the
American Cancer Society, more than 1.69 million people were diagnosed with cancer in 2017.
Many of them will need blood, sometimes daily, during their chemotherapy treatment. Lastly, the
continually growing population over 65 years of age is also expected to increase demand for blood
to combat anemia, aggressive immunogenic responses, and other health complications9,10.
Surgery cancellation at hospitals has become increasingly more common across the United
States and is often reported in mainstream media. Blood supply scarcity announcements from
hospitals are also becoming more frequent. An example of the poor blood supply occurred in
Puerto Rico in February 2016. Due to the growing prevalence of the Zika virus and FDA concerns
of it being possibly transmitted via transfusion, blood collections in Puerto Rico ceased until
nucleic acid testing could be implemented under investigational new drug protocols11. This forced
the territory to eventually import blood and packed RBCs.
The global blood collection market size was valued at $7.6 billion in 2015, to which RBC
transfusions contributed $1.8 billion12. Economic analyses predict that this market is projected to

9

Schulson M. Blood transfusions decline 2011-14, study finds [Internet]. Cornell Chronicle 2018. Web.
http://news.cornell.edu/stories/2018/02/blood-transfusions-decline-2011-14-new-study-finds
10
Olson ML, Clausen L. Modifying the red cell surface: towards an ABO-universal blood supply. British Journal of Haematology 2007;140,3-12.
11
Sullivan L. Blood Industry Gets A Transfusion From An Aging Population. BCC Research 2017 [cited 2018 Apr 15]. Available from:
http://blog.bccresearch.com/blood-industry-gets-a-transfusion-from-an-aging-population
12
Ellingson KD et al. Continued decline in blood collection and transfusion in the United States-2015. Transfusion 2017 Jun; 57(2); 1588-1598

17

Universal RBCs | Catella, Coler, Hayes

grow by 6.1% by the 2021-2022 period due to the increasing prevalence of infectious disease and
non-communicable disease, cancer, accidents, and trauma cases. This validates that there is a need
for improve the currently available supply. This proposal seeks to develop a platform in which
universal, type-O RBCs can be prepared from any other blood cell type, taking advantage of the
surplus of transfusion units that large hospitals usually have. These enzymatically converted typeO (ECO) RBCs will be usable in all patients, will function exactly the same as type-O cells, and
not generate adverse reactions in patients.
2.2.

Basis for Project and its Biochemistry
The ABO blood group system, which determines all transfusion compatibility, categorizes

blood based on the presence or absence of the A and B blood group antigens on the surfaces of
RBCs. The carbohydrate structures that make RBCs type-A, B, or O are designated A, B, and H
and are present at oligosaccharide chain termini of glycolipids and glycoproteins on RBC
surfaces4. A antigen structure and specificity are determined by a terminal α-1,3-linked Nacetylgalactosamine (GalNAc); B antigen specificity is derived from an α-1,3-linked galactose
(Gal). O RBCs are capped with the H antigen containing a terminal α-1,2-linked fucose (Fuc)4.
Enzymatic removal of the immunodominant monosaccharides from type-A and B RBCs
respectively, will uncover the H antigen and yield universal type-O RBCs. This biochemical
reaction is shown in Figure 2.3.

Figure 2.3. Biochemical reaction showing the terminal sugar groups that create human blood
group A and B antigens on RBCs. Note that R in the above image is shorthand for RBC.
18
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In the 1980s, a procedure was established to convert group B RBCs into group O
by using an α-galactosidase derived from green-roasted coffee beans (Coffea canephora). This
coffee bean-derived enzyme completed phase I and phase II clinical trials, and the treated RBCs
were shown to be safe and functional. Unfortunately, the amount of enzyme needed to treat a single
unit of group B RBCs was too high to create a cost-effective process (1 to 2 grams/unit packed
RBCs) with which these universal blood cells could be manufactured. Additionally, the coffee
bean-derived α-galactosidase could only treat group B RBCs, not group A, limiting its usability4.
In 2007, however, another research group identified two prokaryotic glycosidase gene
families that could be used to potentially convert any RBC type into the universal type: one
containing α-N-acetylgalactosaminidase (GH109), which has high activity with group A antigens,
and another containing α-galactosidase (GH110), which targets group B antigens4. Additional
progress in the field was made in 2015 when the family 98 glycoside hydrolase from Streptococcus
pneumoniae SP3-BS71 was found to cleave the entire terminal trisaccharide antigenic
determinants of both A and B antigens on the RBC surface13.

Figure 2.4. Illustration of the specific cleavages of A and B antigens and the uncovering of H
antigen via ECO-A and ECO-B enzymes, respectively. Color code for monosaccharides (hexagon
symbols): fucose (black), galactose (grey), N-acetylgalactosamine (hatched) and precursor chain
constituents (white).
The α-N-acetylgalactosaminidase and α-galactosidase genes will be used to enzymatically
convert groups A and B RBCs into ECO RBCs. These genes will be inserted into E. coli to produce

13

Kwan DH et al. Toward efficient enzymes for the generation of universal blood through structure-guided directed evolution. J. Am. Chem. Soc.
2015; 137(7): 5965-5705
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ECO-A and ECO-B enzymes for downstream treatment of RBCs. The cleavage process is detailed
in Figure 2.4, which highlights the targets that the ECO-zymes use to cleave the A and B antigens
to form the blunt H sugar group found on type-O RBCs. The resulting ECO RBCs will have the
terminal H antigen that is universal to all patients.
The conversion process that transforms group A and B RBCs to ECO RBCs is quick and
efficient. The incubation step is an hour at room temperature, and the buffers for both ECO-zymes
are the same. Approximately 60 mg of A ECO-zyme is needed to treat a liter of group A RBCs,
and 2 mg of B ECO-zyme is needed to treat a liter of group B RBCs.

Figure 2.4. General schematic of process for converting type-A, B, or AB red blood cells
to universal RBCs.

2.3

Introduction to Project Process Synthesis
The enzymatic treatment process of RBCs can be separated into upstream production of

the ECO-zymes, and the downstream conversion of the RBCs. In the upstream phase, the ECOzymes are produced through E. coli growth in a three-stage bioreactor system. The cells are lysed
using a microfluidizer to release the ECO-zymes, the broth is centrifuged. and the debris is
discarded. The ECO-zymes are then separated and purified through three chromatography stages.
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The first stage is an affinity chromatography column, which uses His6-tag technology to bind to
and separate the ECO-zymes from the other extracellular proteins. The last two columns, a
hydrophobic interaction chromatography column and an affinity column, are used to remove
endotoxins. The ECO-zyme product will be tested for endotoxins with the Lonza Endotoxin kit.
The downstream treatment of the RBCs uses the ECO-zymes produced upstream to
enzymatically convert type-A and B RBCs into non-immunogenic type-O RBCs. After the RBC
units are emptied and the packaging buffer is removed the RBCs are sent to a wave bioreactor for
conversion. The conversion process takes one hour at room temperature, with ECO-zymes and a
neutral buffer. Centrifugation and filtration are used to separate and remove the ECO-zymes from
the RBCs. Cryogel based affinity chromatography is used to capture and remove unconverted
RBCs, which could cause an immune response if left in the product. Finally, the RBCs are
resuspended in packaging buffer and filled into blood bags for distribution. Quality control
measures are in place to test and confirm the conversion of the RBC units prior to distribution.
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2.4.

Project Charter

Project Name
Leaders

Project Scope

Production of Universal Red Blood Cells via Enzymatic Conversion
Carly Catella, Rachel Coler, Brandon Hayes
In Scope:
 Manufacturing process for annual production of 205 g of α-Nacetylgalactosaminidase and 189 g of α-galactosidase, beginning with inoculum
preparation and concluding with large-scale fermentation
 Post-manufacturing purification and separation of product enzymes using
multiple chromatography and filtration steps
 Testing to verify enzyme product, determine purity, and quantify endotoxin
concentration to guarantee patient safety when using treated RBCs
 Production of 200,000 RBC transfusion units/year with selected enzymes
 Establishment of sterile unpacking/packaging mechanism of RBCs to be
processed to minimize human error and risk of contamination
 Adherence to current health and safety regulations for blood products
 Observance of process integrity and compliance by adhering to current good
manufacturing practices (cGMP)
Out of Scope:
 Removal of Rh factor to account for positive/negative typing of RBCs
 Research and development (performed in laboratory):
- General characterization and kinetics of α-galactosidase and α-Nacetylgalactosaminidase
- Specific design of hyperbaric chamber for blood bag emptying
- General characterization of cryogel polymer matrix used in cryogel-based
affinity chromatography
 Long-term storage of RBCs at customers’ facilities
 FDA approval for a Biological License Application (BLA) for conversion
process and blood product
 Establishment, funding, and success of clinical trials
 Pilot plant study to analyze cell growth rates and optimal conditions

Deliverables

Timeline

Business Opportunity Assessment
 What are the current and projected markets for type-O RBCs?
 What added value does our process provide over traditional RBC sources?
Technical Feasibility Assessment
 Is it feasible to produce enough enzyme for 200,000 ECO RBC units/year?
 Is it feasible to convert 200,000 units of RBCs/year with minimal RBC lysis and
build a sustainable business model?
Manufacturing Capability Assessment
 Will the process require significant capital investment to produce enzymatically
converted RBCs?
 Will the process meet FDA requirements for blood products?
Facility, process design, economic analysis will be completed in four months.
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3.

Innovation Map
Figure 3.1 shows the innovation map for enzymatically converted RBC units. Customers

value the non-immunogenic nature of type-O RBCs because they can be used in situations where
the blood type of the patient is not known4. Traditional RBC units come in a variety of blood types,
and only limited supplies of the non-immunogenic type-O are available10. Potential customers are
currently limited to the fluctuating supplies of type-A, B, AB, and O red blood cells available,
which have become more limited in the past decade due to transfusion medicine policy changes9.
Enzymatically converted universal RBCs utilize the traditional RBC supply chain but add
value by removing the immunogenic antigens from the surface of the RBCs with bacterial
glycosidases.

The

antigen-cleaving

glycosidases,

α-galactosidase

and

α-N-

acetylgalactosaminidase, function with high affinity and low consumption, making them suitable
choices for large-scale RBC treatment processes1. Enzymatically converted universal RBCs are
poised to enter the market to fill the need for a greater and steadier supply of non-immunogenic
units. In regards to potential competition, recent academic researchers presenting at stem cell
research conferences have claimed that they engineered an immortalized hematopoietic stem cell
line that can continuously produce red blood cells14. However, the production rates of this stem
cell line are still unknown, making it uncertain that they can produce RBCs at a fast enough rate
to satisfy global demand. Additionally, these RBCs have not yet undergone pre-clinical or clinical
trials yet, indicating that their potential use in human patients is still several decades away. The
RBC treatment process described here has already undergone several trials, in which certain of its
weaknesses were addressed and have since been occurred1,2. Prior data on the efficacy,
performance, and immunogenicity of ECO RBCs should allow the process and product to move
through Phase I-III clinical trials and the FDA approval process more smoothly. Thus, it can be
concluded that there are currently no other RBC products on the market that can offer nonimmunogenic properties in large quantities, so there would be no competition in this market
segment.

14

Shah S, Huang X, and Cheng L. Concise review: stem cell-based approaches to red blood cell production for transfusion. Stem Cells Transl.
Med. 2014 Mar; 3(3): 346-355.
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Figure 3.1. Innovation map for ECO RBC transfusion units. Enzymatically converted RBCs will be prepared as ready-to-administer
so they can directly enter the market due to their ability to meet market needs and differentiation from traditional RBC units.
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4.

Concept Stage

4.1.

Market Analysis
The global blood collection market size was valued at $7.6 billion in 2015, to which RBC

transfusions contribute $1.8 billion15. This market is projected to grow at 6.1% by the 2021-2022
period. RBC demand is also expected to increase due to the increasing prevalence of infectious
disease and non-communicable disease, cancer, accidents, and trauma cases10. The number of
blood-intensive procedures performed, such as solid organ transplants, hematopoietic stem cell
transplants, and aggressive chemotherapy against cancer, is also expected to grow; all of these
treatments require increased blood supplies10. Lastly, the continually growing population over 65
years of age is also expected to increase demand for blood10.
Despite the need for packed RBCs in transfusion medicine, supply has decreased
significantly, especially in the last decade. Although an estimated 38% of the US population is
eligible to donate blood at any given moment, less than 10% of that eligible population donates2.
Another problem for transfusion medicine is how quickly packed RBCs expire. Typically, any
given unit of RBCs is only usable for 42 days. Due to their short life span, packed RBC units are
constantly being discarded, forcing hospitals to replenish their stock. It has become increasingly
difficult to maintain inventories, because demand is expected to grow while supply is being
hindered by stricter donation regulations and fewer donors.
The current industry standard for RBC unit production is whole blood donation, separation,
purification, and repackaging. Supply is dependent on the donors’ blood types, willingness to
donate, and limited shelf life of the packaged RBC unit. Certain hospital wards, such as trauma
wings and emergency rooms, will transfuse O negative RBCs until properly cross matched blood
is available when there is no time to type a patient’s blood16. This leads to a disproportionate use
of O RBC units, which contributes to the wastage of the lesser used blood types, A, B, and AB.
Approximately 78% of wasted RBC units are thrown out due to time expiry17.

15

Ellingson KD et al. Continued decline in blood collection and transfusion in the United States-2015. Transfusion 2017 Jun; 57(2); 1588-1598.

16

Miraflor E et al. Emergency uncrossmatched transfusion effect on blood type alloantibodies. J. Trauma Acute Care Surg. 2012; 72(1): 48-52.
Miraflor E et al. Emergency uncrossmatched transfusion effect on blood type alloantibodies. J. Trauma Acute Care Surg. 2012; 72(1): 48-52.

17

Strobel E. Hemolytic transfusion reactions. Transfus. Med. Hemother. 2008; 35(5): 346-353.
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Additional concerns for RBC unit transfusions are the liabilities associated with transfusion
incompatibilities, which can lead to adverse events, such as acute hemolysis. Reactions can range
from mild to fatal, with rates of fatal reactions estimated to be between 1:70000 and 1:100000
units transfused5. Each transfusion incompatibility event can cost hospitals and their respective
insurance companies upwards of $500,00018. The most common cause of transfusion
incompatibility events is mismatched blood types from the donor and patient, which can be caused
by systemic problems and/or human error5. The former may be addressed by implementing more
rigorous quality assurance practices, while the latter is harder to control for, and will likely
continue to be a problem in the current system.
A universal RBC supply could solve both the wastage and liability concerns associated
with the standard RBC transfusion practices. Currently, there is no universal option for blood
products. Work has been done to produce RBCs ex vivo using differentiated stem cells. However,
these RBCs lack adult hemoglobin, their production relies on animal serum, and scale up has not
been successful thus far14. Enzymatically converted universal RBCs would be the first universal
blood product to go to market in this sector and would be highly desirable in situations where
blood typing is performed on a limited scale or there are incompatibility risks.
4.2.

Customer Requirements
Hospital systems are the primary users of RBC units and typically source them from

regional suppliers, the Red Cross, and internal blood drives.19 The enzymatically converted RBC
units will directly replace RBC units sourced from these three suppliers while providing additional
benefits, such as reduced liability and higher usage efficiency. In addition, these units must meet
the same safety guidelines set by the Food and Drug Administration (FDA) that traditional RBC
units meet.
In general, RBC units must be processed in a way that reduces activity loss and prevents
contamination. Thus, strict control of temperature and application of mechanical stress are
necessary. Cell lysis due to mechanical stress will be avoided by the use of carefully selected
reactors, pumps, and separation columns. Temperature control is the most important consideration
18

Ah-Moye D et al. Clinical Biochemistry: Metabolic and Clinical Aspects. London: Churchill Livingstone; c2014. Chapter 26, Introduction to
haematology and transfusion science; p. 497–514.
19
Siegel DL. Re: Costing of ECO-RBC units [Internet]. Message to: Carly Catella. 2018 Apr 3, 10:00 pm [cited 2019 Apr 15]. [about 6 paragraphs].
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for the handling of RBC units in this process. Hospitals typically adhere to the “thirty-minute”
and “four-hour” rules stipulating that RBC units should not be reissued after thirty minutes of room
temperature exposure, and that transfusions should be completed within four hours. The risks
associated with exposure to temperatures above 4ºC include bacteria proliferation and loss of
activity.20 However, studies have shown that bacteria proliferation is insignificant for times less
than two hours, and loss of activity is negligible.21 The enzymatic treatment process must maintain
proper temperature control throughout, and have a total time below two hours at a temperature
above 4ºC. Sterilization processes will be implemented to reduce the risk of contamination and
quality control testing will be performed prior to the distribution of the treated RBC units to ensure
that there is no measurable loss in activity or bacterial contamination.
Customers also require consistent packaging and delivery for efficient use in
hospitals. The most important considerations in this area are meeting FDA packaging guidelines,
salient labeling, and compatibility with existing storage options. The FDA requires that blood
storage bags be sterile and clear to allow for observation of hemolysis or change in color. They
must also be clearly labeled with antigen type and may be color coded.22 Delivery must be prompt
to maximize the usable shelf life of the RBC unit, which is capped at 42 days in most situations10.
Measures will be put in place to ensure a quick turnaround time for the treatment process to allow
the customer to have relatively fresh RBC units.
4.3.

Regulatory Requirements
The use of enzymatically converted RBC units in the place of traditional RBCs will require

approval from the FDA. Due to the extensively processed nature of this product and its
differentiation from traditional RBC products, it will need to undergo comprehensive clinical
testing. A Biologic License Application (BLA) for ECO-RBCs will need to be approved.13 The
FDA will look for good manufacturing practices associated with the large scale production and
proper quality control of the enzymatically converted RBCs in their approval process. Additional
concerns arise from the novel nature of the enzymatically converted RBCs, which include potential

20

Ramirez-Arcos S et al. Evaluating the 4-hour and 30-minute rules: effects of room temperature exposure on red blood cell quality and bacterial
growth. Transfusion 2013; 53(4); 851-859.
21
Vosta J. FDA Evaluation of Red Cell Products. Laboratory of Cellular Hematology, U.S. Food and Drug Administration, 2016.
22
Diamond SL. Re: Cost of FDA Approval of ECO-RBCs [Internet]. Message to: Carly Catella. 2018 Apr 2, 11:08 am [cited 2018 Apr 15]. [about
44 paragraphs].
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toxicity and efficacy issues. Studies will need to be performed to confirm that “immunogenicity,
reduced cell flexibility, increased fragility, low oxygen delivery capacity, and unanticipated
toxicities” are not properties of the enzymatically conveted RBCs.4 In vitro studies will need to
be performed to study the morphology, biochemistry, and the hemolysis of the enzymatically
converted RBCs. Phase I and II clinical trials must be performed to assess kinetics, and Phase III
clinical trials need to be performed to assess safety and efficacy of the enzymatically converted
RBCs.
The design and performance of clinical trials for FDA approval are out of the scope of this
project; however, it is important to consider what these trials would encompass. Clinical trials for
the enzymatic conversion using ECO-B have already shown the feasibility of the process, but more
rigorous studies inclusive of enzymatic conversion with ECO-A need to be performed14. These
studies would primarily look for safety and efficacy markers that match or surpass those of RBC
units collected via apheresis.

Safety studies would address the immunogenicity of the

enzymatically converted RBCs by looking for antibody formation. The efficacy markers would
include markers for hemolysis, hemoglobin concentration, and oxygen dissociation. Phase III
studies would address both safety and efficacy concerns, and additional Phase IV post market
safety studies would likely be necessary.4 Safety concerns would be addressed by testing for
mismatched immune response and the safety of the potentially augmented clearance
pathway. Phase III and IV studies would compare the efficacy of ECO-RBCs to that of wild-type
RBCs. They would also compare and contrast the circulatory half-life, hemoglobin clearance, and
storage stability of both wild-type and enzymatically converted RBCs.
While Phase I clinical trials can be performed in healthy patients to test for safety and dose
escalation, Phase II and III clinical trials must be done in patients with measurable indications of
need. These indications can range from bleeding from elective surgery to traumatic bleeding.
However, indications of need like traumatic bleeding are difficult criteria under which to enroll
patients because obtaining informed consent is challenging and the transfusion of the RBCs is
difficult to control12. Indications like anemia and bleeding from elective surgery are easier
indications as researchers have time to obtain informed consent prior to transfusion, and the
response to wild-type RBCs is well characterized, as both of these indications routinely utilize
RBC transfusions. Clinical trials can be performed for either or both of these indications; for the
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purposes of this report, the specific design of the clinical trials is not considered. The expected
cost to complete these trials is projected to be $100-200 million.22
4.4.

Summarized Project Description
The design described in the project consists of two separate processes: (1) the production

of the necessary bacterial glycosidases for the RBC conversion and (2) the RBC treatment process.
The production of bacterial glycosidases was determined to be done in-house rather than
purchasing the enzymes in bulk to reduce costs. Additionally, the implementation of this portion
of the design gives greater control over the E. coli strains which are used for upstream processing.
By establishing the upstream process design, if further research finds more suitable bacterial
glycosidases or enzymes that can perform the same function, the entire plant design will have
already been established. The only change required is the substitution of the cell line used for
enzyme production.
The upstream processing consists of three growth phases: (1) inoculum grow up, (2)
microbial fermentation in a seed reactor, and (3) production fermentation in two large stainless
steel fermenters. This production train was chosen to prevent overdiluting the cell samples and
accidentally inducing cell death. Additionally, this setup allows for high-cell density microbial
cultures, which is required since the enzyme product yield is still relatively low.
The downstream purification of the enzyme products involves numerous chromatography
and filtration steps to reduce endotoxin levels below the limitations established by the FDA. Since
the enzyme is cytoplasmic, cell membrane disruption is done using microfluidization to harvest
the internalized enzyme. Then the product solution undergoes three chromatography steps: (1)
cobalt ion affinity chromatography to remove cell debris and purify the enzymes, (2) hydrophobic
interaction chromatography to separate endotoxins, and (3) endotoxin affinity chromatography to
further separate endotoxins that may have unexpected hydrophobicity values. The product solution
will then undergo ultrafiltration/diafiltration using a tangential flow filtration system to remove
buffer components. Lastly, the product solution will undergo two bulk microfiltration passes to
further eliminate endotoxins and concentrate each enzyme.
The RBC treatment process is simple, requiring that the donor RBCs be charged into a
WAVE bioreactor to which ECO-zyme will be added. The RBCs will be agitated with the enzyme
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for one hour at 25ºC and at a pH of 7.4-7.6. Afterwards they will undergo
microfiltration/diafiltration to eliminate the enzyme from the treated RBC suspension, as the
presence of enzyme in unpurified samples has been found to show adverse reactions in pre-clinical
animal models. Lastly, to guarantee that the treated RBCs will not provoke an immunogenic
response in patients, a specialized, cryogel-based affinity chromatography step will be used to
separate purely converted RBCs from unconverted ones. This chromatography system uses a soft,
polymer gel matrix, instead of traditional resin, that is coated with a protein A and antigentargeting IgG antibody complex that will bind cells that still have A or B antigens. The soft cryogel
was chosen rather than traditional affinity chromatography resin because it is proven to have
minimal cell lysis (less than five percent), to release bound cells by applying mechanical stress,
and allowing multiple uses of the affinity binding IgG antibody.
The overall process flow diagram in Figure 4.4.1 illustrates the designed production
process macroscopically. All final RBC units will undergo numerous quality control tests (flow
cytometric analysis and thin layer chromatography (TLC) quantification of surface antigens) to
confirm that negligible amounts of non-converted RBCs remain in the transfusions units that will
be given to patients.
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Figure 4.4.1. Process flow diagram for the creation of universal RBC units via enzymatic
conversion.

4.5.

Facility Location and Requirements
An important decision that determines the feasibility is choosing the location in which the

plant design should be executed. Given that the production goal that this project seeks to fulfill
depends on hospitals requiring substantial blood supplies, establishing the facility in a metropolitan
area with a strong hospital system was deemed a necessity. Furthermore, given the biotechnology
nature of the project and the possibility for research collaborations to optimize the RBC treatment
process and perhaps explore alternative enzymatic treatments, it was decided that the facility
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should be established in a biotechnology hub. The Boston metropolitan area fits all of these
considerations, with significantly cheaper utilities pricing and space rental costs compared to the
biotechnology hub in California. It also has one of the largest and most well-funded hospital in the
United States, Massachusetts General Hospital, which allows for both service partnerships and
research opportunities. Additionally, developing this RBC treatment platform in the Boston
metropolitan area also allows expansion in additional metropolitan markets easier. There are other
major numerous hospital systems along the East Coast relatively close in proximity: New York
City, Philadelphia, Newark, among others.
Although many of the customers are expected to be directly in Boston, the new facility for
RBC treatment will be built in Medford, MA, which is located less than five miles away from
Cambridge, MA. This allows it to be in close proximity to Massachusetts General Hospital and
major universities such as Harvard University, Massachussetts Institute of Technology, Tufs
University, and more. The rental pricing per square foot of land is also significantly cheaper than
in Boston: $30 versus $60 per square foot, according to realtor Cummings Properties.
The rental space will come equipped with biosafety cabinet hoods for conducting sterile
cell culture and RBC management (if necessary). It also contains clean room spaces that can be
used for RBC handling and other sterile procedures. Lastly, the facility comes equipped with an
autoclave room to sterilize equipment, which will be fundamental in both research and the actual
upstream E. coli cell culture process, which uses an autoclavable glass bioreactor vessel. The use
of this autoclave is included in the facility’s rent. The property also features a construction-ready
zone with HVAC (heating, ventilation, and air conditioning) which will be used for sterile air.
Additionally, a vacuum system will be establishing for better biowaste management and to
eliminate exposing bloodborne pathogens to the environment. Additionally, Cummings Properties
has in-hous design and construction teams that can be employed to make necessary modifications
before beginning production. This helps outsource plant design while reducing costs. In particular,
the design of three 900 ft2 cold rooms (subject to change depending on factors such as equipment
size constrants and personnel maneuverability) will be organized with Cummings Properties and
possible third party contractors.
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5.

Critical-to-Quality (CTQ) Variables

5.1.

Endotoxin Concentrations
Endotoxins are the single most important class of pyrogens, substances that cause fevers

when injected into humans and animals. Although fevers induced by endotoxins are not life
threatening, endotoxin presence in blood transfusion units can have numerous adverse effects,
even potentially fatal consequences. Endotoxins are continuously shed from the outer membrane
of viable gram-negative bacteria, such as E. coli, and are also released when the bacterial cell dies.
In E. coli, endotoxins come in the form of complex aggregates of lipopolysaccharides (LPS). The
LPS consists of an innermost region composed of hydrophobic fatty acid groups, or lipid A, and a
central and outermost region composed of hydrophilic polysaccharides. They may cause
uncontrolled activation of mammalian immune systems, releasing a storm of pro-inflammatory
agents, such as cytokines and interleukins, which may lead to septic shock in patients.
Additionally, this inflammatory reaction may cause either damage to the endothelial layer of blood
vessels or vasodilation, both of which eventually lead to leakage from the vessel walls. The
substrates required to form a blood clot in the case of injury may be diminished or depleted. Given
that blood transfusion units are often used in scenarios in which hemorrhage will occur, patient
safety is at risk if the presence of endotoxins prevents proper clotting. Other common
consequences of endotoxin contamination are, but not limited to, cardiac malfunction, internal
organ failure (usually of the kidneys, adrenal glands, and the lungs), gangrene in the limbs, and
hemorrhage-induced Waterhouse-Friderichsen syndrome.23
Due to the serious risks associated with endotoxin contamination, the FDA has set limits
on concentration of endotoxin for medical devices, parenteral drugs, and any type of ingestible
substance for medical treatment. The endotoxin limits currently accepted by the FDA are
summarized in Table 5.1. For most medically injected and transfused substances, the limit is set at
<0.25 EU/mL, where EU is endotoxin units. One EU equals approximately 0.1 to 0.2 ng
endotoxin/mL of solution.24

23
24

Raetz CRH and Whitfield C. Lipopolysaccharide endotoxins. Annual Review of Biochemistry 2002 Jul; 71:635-700.
Bacterial Endotoxins/Pyrogens, Inspection Technical Guides. U.S. Food and Drug Administration (2015).
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Table 5.1. Endotoxin limits for various products, as established by the FDA.

Given that bacterial glycosidases are going to be used to cleave the A and B antigens from
the red blood cell surface to convert them to type-O, it is important to minimize the endotoxin
concentration in the enzyme solution that is going to be used to treat the RBCs. Any endotoxins
remaining in the enzyme solution could also end up in the transfusion units produced. For this
reason, three chromatography columns are used to maximize elimination of endotoxins from the
final enzyme product. Additionally, thorough quality control tests will be performed on all
converted RBC units, using Limulus Amebocyte

Lysate (LAL) assays. The LAL kinetic

turbidimetric assay25 will be used to detect endotoxin concentration down to 0.01 EU/mL. These
precautionary measures will help prevent adverse effects on patients and eliminate endotoxins
prior to treating RBCs. Literature has reported that minimal quantities of endotoxin in the blood
can alter RBC morphology and functionality and may even induce hemolysis.
The endotoxin concentration was a heavily considered variable in this process design. We
assume that for our product to receive FDA approval, it must satisfy the threshold values
established for water-for-injection (WFI), given that the RBCs will be resuspended in preservation
solution made from WFI. Even though this project is conceptualized as a start-up and funding is
highly dependent on available funding from investors and government subsidies, minimizing
endotoxin concentration was deemed a primary concern. While the costs associated with the
presence of two chromatography columns dedicated to endotoxin removal are high, they help
guarantee that the produced ECO RBCs will have endotoxin values well below FDA standards.

25

Lonza. Traditional Kinetic Limulus Amebocyte Lysate (LAL) Assay User Quick Guide. Walkersville, MD: Lonza Walkersville; 2014 [cited
2018 Apr 16]. Available from: https://www.lonza.com/products-services/pharma-biotech/endotoxin-detection/endotoxin-detection-assays/kineticturbidimetric-lal-assays.aspx
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5.2.

Final Universal RBC Product Purity
This project assumes that the bacterial glycosidases, α-galactosidase and α-N-

acetylgalactosaminidase, needed to convert type-A and type-B RBCs to type-O manage to convert
>90% of the treated RBC population. However, this assumption implies that there are still cells
with antigens that could cause immunogenic responses if transfused into incompatible patients.
Given that this project seeks to provide a product and service that can eliminate the concern of
blood transfusion incompatibility, a specialized chromatography column was designed for the sole
purpose of separating non-converted RBCs from successfully converted ones. From an ethical
standpoint, this imperfect conversion could not be ignored as it could lead to health problems and
potentially have fatal consequences in patients. Even though this additional chromatography
column adds significant additional operation and installation costs, its inclusion helps guarantee
patient safety, comply with ethical concerns, and provides a proper business model that future
venture capital investors may appreciate.

5.3.

Production Capacity
The most important variable in this project was the production capacity of this small-scale

RBC treatment plant. Given the limited size and finances of the project, the production goal for
enzymatically converted RBCs is used to determine all other key parameters in this process: annual
enzyme mass required, number of donor transfusion units that need to be treated to satisfy
production goal, physical and financial constraints to place on process design, sizing parameters,
among others. As a result, a realistic production goal of 200,000 transfusion units of enzymatically
converted RBCs was established. This production goal would satisfy approximately 25% of the
annual RBC transfusion unit demand required by a major metropolitan hospital. In a broader
perspective, this would satisfy nearly 1% of the annual blood demand in the United States.
Even though the production goal is realistic for the start-up scale of this project, it still
requires a relatively high cell density bacterial culture to produce sufficient enzyme to satisfy
production. The genetically engineered E. coli BL21(DE3) cells that produce the α-galactosidase
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and α-N-acetylgalactosaminidase enzymes have relatively low protein yield coefficients.26 To
minimize costs of purchasing more equipment and maximize return on investment, the cell density
was increased from a common 16 grams of biomass per liter of culture to 29 grams per liter. This
operating condition was then used as the second most important variable used in sizing all reactors
for upstream and downstream processes.

5.4.

RBC Storage Temperature
The optimal storage temperature value for RBCs outside of physiological conditions is 4ºC.

These storage conditions allows them to remain viable for the entirety of their 42-day shelf life. If
cells are kept at higher temperatures, they begin to degrade over time. Transfusion policies have
only recently become more stringent in the United States and have not established how long an
RBC transfusion unit may remain at room temperature. A common practice established by the
Medicines and Healthcare Products Regulatory Agency in the United Kingdom, however, states
that RBC transfusion units that have been exposed to an ambient temperature of 25ºC for four or
more hours should be discarded immediately27. Their decision to implement this policy comes
from medical reports that found that the oxygen-transfer capability of RBCs is drastically reduced
if the cells are not stored at 4ºC for more than four hours.
This project assumes that the methodology applied in the United Kingdom should be a
standard in transfusion medicine. Thus, the entire RBC treatment process, with the exception of
the enzymatic conversion to type-O, is performed at 4ºC. As a result, the design schematic
presented in this report includes calculations for numerous, large-sized cold rooms to satisfy the
strict temperature requirements needed to maintain RBC viability.

26

Sivashanmugam A et al. Practical protocols for production of very high yields of recombinant proteins using Escherichia coli. Protein Science

2009; 18: 936-948.
27

Brunskill S et al. What is the maximum time that a unit of red blood cells can be safely left out of controlled temperature storage? Transfus.
Med. Rev. 2012; 26(3): 209-223.
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6. Product Concepts
Not applicable.
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7. Superior Product Concepts
Not applicable.
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8.

Competitive/Patent Analysis

Not applicable.
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9.

Preliminary Process Synthesis

9.1.

Initial Considerations
Prior

to

upstream

production,

Esherichia

coli

strains

that

produce

α-N-

acetylgalactosaminidase or α-galactosidase need to be genetically engineered. These two enzymes
were originally discovered in Elizabethkingia meningosepticum and Streptomyces avermitilis,
respectively.4 For the purposes of this design, it was decided that the best approach for ensuring
high protein yielding bacterial cells are used in the fermentation process is to contract the
preparation of the E. coli cell lines to a contract research organization. Many of these organizations
have well-established gene editing platforms that can engineer a specific cell line in four to six
weeks. This will allow plant setup to occur simultaneous with cell line preparation. Additionally,
it eliminates expenses required to initially perfect and optimize an internal gene editing platform
to prepare the desired E. coli strains. Given the limited funds allotted to this project due its startup nature, it was determined that expediting the production stage should be prioritized over the
development of an internal gene editing system. Future sales funds can be allocated to research
once the project is established and is able to deliver functional universal blood cells.
The preparation of these bacterial cell lines will be contracted to GenScript, a contract
research organization that specializes in genetic engineering using the CRISPR-gene editing
system. The product of each cell line will cost $5,400. GenScript was chosen for their λ RedCRISPR/Cas9 gene editing platform, which uses a two vector system that enables editing accuracy
down to a single base pair. It is a seamless platform with high efficiency (>95%) and easy
precision.
The

entire

coding

region

of

Elizabethkingia

meningosepticum

α-N-

acetylgalactosaminidase, shown in Figure 9.1.1, will amplified by polymerase chain reaction
(PCR) from genomic DNA with the following primers4:
1. FLAV28: 5’-GCGGGATCCAATGGGTGCTTTAATTCCCTCGAGC-3’
2. FLAV13: 5’-CGGCGGCCGCTTAGTAGTCGTCATTTATTGCAAATG-3’.
The product will be ligated into the pCR4-Topo TA vector to give a full length
FLAV28/13US construct. A truncated construct lacking the N-terminal signal peptide will then be
amplified by PCR from the FLAV28/13US construct using the following primers/restriction sites:
FLAV34US,

5’-GCGGGATCCGAATTCTAAAAAGGTAAGAATAGCTTTTATAGC47
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3’/EcoRI; FLAV13, 5’-CGGCGGCCGCTTAGTAGTCGTCATTTATTGCAAATG-3’/NotI. The
PCR product will be inserted into EcoRI/NotI digested pET28 expression vector to create a Nterminal truncated construct with a histidine-6 (His6) tag at the N-terminus to be used for future
separations.4

Figure 9.1.1. The original gene sequence that encodes α-N-acetylgalactosaminidase (GH109),
which cleaves A antigens on the surface of RBCs.. This enzyme was originally discovered in
Elizabethkingia meningoseptica. This sequence will be engineered into a plasmid vector that also
encodes genes for kanamycin and chloramphenicol antibiotic resistance. The engineered plasmid
will knocked-in to E. coli using λ Red-CRISPR/Cas9 gene editing to develop a bacterial platform
that can be selected using antibiotic resistance to mass produce this enzyme.
The engineering of the α-galactosidase-producing strain of E. coli, originally from
Streptomyces avermitilis, will undergo a near identical gene editing process to also insert His6 tags
as previously described. The original gene sequence for α-galactosidase is shown in Figure 9.1.2.
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Figure 9.1.2. The gene sequence that encodes α-galactosidase (GH110), the enzyme that is
responsible for cleaving B antigens. This enzyme was originally discovered in Streptomyces
avermitilis. This sequence will also be engineered into a plasmid vector that also encodes genes
for kanamycin and chloramphenicol antibiotic resistance.
9.2.

Upstream E. coli Cell Culture Process

9.2.1. Reactor and Cell Density Considerations
The final iteration in determining the adequate equipment for culturing E. coli cells
required analyzing oxygen mass transfer limitations in the design setup. Originally, the system was
designed exclusively using single-use, disposable bioreactor systems (Figure 9.2.1), which are
becoming increasingly used in the biotechnology industry. However, single-use bioreactor systems
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have difficulty at operating above a volumetric oxygen transfer coefficient 𝑘𝐿 𝑎 of 40 hr-1. This low
value also has the tendency to fall below 20 hr-1 during operation. Jeffrey Cohen, Ph.D., from
Johnson & Johnson expressed concerns that this system would not be able to supply sufficient
oxygen to the cell culture and could result in massive cell death.

Figure 9.2.1. The original schematic used in the initial conceptualization of the project. The
original design consisted of using three single-use bioreactors, with working volumes of 0.110 L,
5.44 L, and 200 L, respectively. The production bioreactor was set to achieve a maximum cell
density of 100 grams per liter, as certain high microbial density protocols fermentation protocols
claim. The concept of using a single-use production bioreactor because it has limited oxygen
transfer capabilities and is unable to satisfactorily support high-density microbial cultures.

Many aggressive microbial cultures, however, require systems that can produce a
volumetric oxygen transfer coefficient greater than 360 hr-1 to satisfy the oxygen demand of fairly
high density bacterial cultures.28 Another complication associated with using single-use systems
is that these high volumetric oxygen transfer coefficients often require gas flows of two vessel
volumes per minute. Satisfying this gas flow demands is made difficulty since single-use systems
have constrained gas flow rates due to pressure safety limits of the single-use flexible container.
The required low operating backpressure decreases the gas flow capacity of exhaust filters. For

28

Sartorius Stedim Biotech GmbH. High-cell-density Cultivation of Escherichia coli in a BIOSTAT® D-DCU 10-3 Stainless Steel Bioreactor
[Internet]. High-cell-density Cultivation of Escherichia coli in a BIOSTAT® D-DCU 10-3 Stainless Steel Bioreactor. Goettingen,
Germany:
Sartorius
Stedim
Biotech
GmbH;
2013
[cited
2018
Apr
17].
Available
from:
https://www.sartorius.com/mediafile/Appl_BIOSTAT_D-DCU_High-cell-density-Cultivation_E_Coli_SBT1015-e.pdf
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these reasons, the use of single-use bioreactors were discarded for the purposes of our microbial
fermentation.
Recent progress has been made in developing single-use fermenters that vastly outperform
single-use bioreactors, potentially providing a solution to the lack of single-use technology for
bacterial growth. During equipment selection, however, it was noticed that there are major
discrepancies among different sources on the actual volumetric mass transfer coefficient. Some
reports stated that the single-use fermenters could operate achieve a 𝑘𝐿 𝑎 of 80 hr-1, while others
stated that it could be well above 400. Additionally, the experiments from which this data was
obtained often reported that there was difficulty in controlling cooling capacity and foaming levels,
both of which could cause enzyme denaturation upon protein expression. These considerations led
us to conclude that a stainless steel fermenter, which has well-studied volumetric oxygen transfer
coefficients and agitation configurations, would be a safer choice for conducting all cell growth.
Additionally, stainless steel reactors can be seen as permanent investments with no further major
operating costs (with the exception of maintenance, CIP, and SIP procedures). Using single-use
technology for microbial fermentation though will require continuous purchases of storage bags
and containers for the cell harvest, which quickly add on to operating costs.
The final unit chosen to serve as the production bioreactor was the BIOSTAT® D-DCU
from Sartorius28, which has a volumetric oxygen transfer coefficient of 308 hr-1. Additionally, due
to sizing limitations of available stainless steel fermenters, two fermenters are required per batch
to achieve the desired production goal. Please refer to Section 11 to see the final upstream process
configuration. Once this reactor unit was chosen, the maximum allowable cell density for the
fermentation process was calculated (see Appendix F) to be approximately 29 grams of cell per
liter of culture. These renewed calculations after taking into account the oxygen mass transfer
limitations of the reactor also helped resolve the concern on the high density at which the reactors
originally planned to reach (100 g cells/L). Many were considered that this cell density would be
too viscous and prevent the culture from being well mixed, which would have further hindered
oxygen availability to the cells.

9.2.2. Batch Timing
The original process setup applied cell growth parameters that are significantly different
from those more commonly seen in industrial fermentation. The growth rate of E. coli cells that
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was originally used for the mathematical modeling of cell growth was 0.60 hr-1. This value was
obtained from several online literature sources and from several pilot plant studies that used E. coli
to produce protein. The maximum cell density established for each culture was 100 grams cells/L,
which is considered the highest possible density that can be attained in microbial fermentations.
With these two parameters, the calculated batch times were 13.25 hours for the inoculum growth
reactor, 5.53 hours for the growth bioreactor, and 8.8 hours for the production bioreactor.
Numerous industrial consultants, however, revealed that these values are several fold lower than
what is usually observed in practice. Under ideal conditions in which E. coli are grown almost
exclusively on glucose, a growth rate between 0.60 and 0.70 hr-1 can be observed. In reality,
however, the substrate in the culture media changes over time. E. coli excrete acetate upon growth
on fermentable sugars. The addition of the acetate substrate causes the growth rate to drop to values
between 0.22 and 0.28 hr-1.
Under their recommendation, it was decided that the final process design would use a
growth rate of 0.25 hr-1, the average of the range in the presence of excreted acetate. Readjusting
the growth model with this new parameter, the batch times increased to 16.08, 23.86, and 28.49
hours for the inoculation growth, seed growth, and production units, respectively. Industrial
consultants confirmed that these values coincide with typically observed batch times in small-scale
biotechnology and pharmaceutical fermentation processes. Additional adjustments were later
made to the model (as explained in Section 10.2.1 once reactor limitations were considered),
changing the batch times to change to 17.86, 24.05, and 26.08 hours for the inoculation growth,
seed growth, and production units, respectively. These values are still in line with industrial
processes, confirming that the material balances for the E. coli growth

9.3.

Downstream Enzyme Purification
As discussed in Section 5.1, the presence of endotoxins in the enzyme product could have

numerous adverse effects. Not only have endotoxins found to affect RBC functionality and
viability, but their presence in the enzyme product that is used to treat RBCs may also cause
endotoxins to end up in the final packaged RBCs. To minimize the endotoxin concentration in the
packaged universal RBCs, the downstream purification process underwent several iterations to
explore different chromatography column uses.
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Patents recommended a hypothetical separation model that used a cation exchange, anion
exchange, and hydrophobic interaction chromatography train to purify α-galactosidase and α-Nacetylgalactosaminidase from endotoxins4,10. The original process flow diagram for the above
configuration is shown in Figure 9.3.1. However, a review of the biochemical properties,
specifically the electrical charge of both enzymes and endotoxins, revealed that all of these proteins
have a high net negative surface charge. Based on this finding, the notion of using any form of ion
exchange was discarded since the charge differences among the endotoxins and enzymes was too
little to exploit for a separation process. Another consideration was the possible use of sizeexclusion chromatography, but this idea was quickly discarded as the molecular weights of αgalactosidase, α-N-acetylgalactosaminidase, and endotoxins are roughly 45, 75, and 10-100 kDa,
respectively.4 After consulting with professional engineers, it was deemed that the size differences
were too small (less than ten-fold) to be useful for size-based separations.

Figure 9.3.1. Proposed process flow diagram from patents that explored the hypothetical
feasibility of scaling up enzymatic treatment of RBCs to create a universal blood supply.
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The last option explored was using an affinity chromatography column that would
specifically bind endotoxins using porous cellulose beads coated with poly(ε-lysine) as the resin.
Poly(ε-lysine) strongly binds endotoxins with relatively high specificity. Given that this resin does
not have the issues associated with surface charge and size that renders the other chromatography
techniques inapplicable for this particular separation, an endotoxin affinity chromatography
column was incorporated into the process design. The hydrophobic interaction chromatography
column was also kept in the design as an additional method to further eliminate endotoxins. Jeffrey
Cohen

(Johnson

&

Johnson),

Daniel

Green

(GlaxoKlineSmith),

and

Robert

Luo

(GlaxoKlineSmith) all recommended that both chromatography columns be included to ensure
that endotoxins were eliminated from the final product as much as possible. Given that the overall
goal is to produce universal RBCs that will be transfused into patients, safety and risk minimization
should be prioritized. This setup is shown in Figure 9.3.2.
In addition to the chromatography columns meant for separating the α-galactosidase and
α-N-acetylgalactosaminidase enzyme products, it was further recommended that an additional
chromatography column be incorporated into the design process prior to the other two to eliminate
organelles and cytoplasmic material from the bacterial lysis. Thus, an additional affinity
chromatography unit was added at the beginning of the separations process to bind all His6-tagged
enzyme.
The final iteration of the downstream purification design for α-galactosidase and α-Nacetylgalactosaminidase took into account in which order the endotoxin affinity and hydrophobic
interaction chromatography columns should be placed. This decision was made by performing a
financial analysis on the resin required for different setup configurations. It should be noted that
although there are endotoxins losses are associated with transport losses, we assume that no
endotoxin is lost for the design of the chromatography columns. This allows us to have a stricter
design that can treat more endotoxin than what may actually be present in the final enzyme product
solution. The first step in the separations process involves treating 11.5 grams of LPS endotoxin.
Assuming a conservative 90% elimination of endotoxins, the second step must process 1.15 grams
of LPS. Table 9.3.1 shows an initial general assessment of reagent costs if the endotoxin affinity
column is placed before the hydrophobic interaction column.
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Figure 9.3.1. Second major iteration of the downstream purification process of ECO-zymes. In this setup, endotoxin affinity
chromatography and hydrophobic interaction (HIC) chromatography are used to eliminate endotoxins from the final enzyme product.
The elimination of endotoxins is necessary to ensure endotoxin concentrations are low enough so that transfused ECO RBCs do not
cause adverse immune responses.
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Table 9.3.1. Preliminary reagent costing for a process design in which a separations train consists
of an endotoxin affinity chromatography column followed by a hydrophobic interaction
chromatography column for the removal of endotoxins. The resins in questions are highlighted in
light red.

Raw Material
AGE
Ammonium sulfate
APS
Detergent
DMAAm
Ethanol
Ethylenediamine
Glutaraldehyde
Guanadine HCl
HEPES
IgG
Imidazole
MBAAm
MES
Na2CO3
NaBH4
NaCl
NaOH
Protein A
Sodium phosphate
TEMED
Urea
HisPur® Cobalt Resin
Pierce Endotoxin Removal Resin
POROS Benzyl HIC Resin
Total

Annual Amount
Required
2.2
5017.6
285.6
431856.3
16.4
4154.3
78175.7
129.8
48563.2
66823.8
1298.2
312256.0
5712.2
105392.0
55044.9
9822.4
2838618.0
1113125.4
4154.3
579760.4
246.7
2146439.7
50.0
660.0
70.0

L
g
g
g
L
L
g
L
L
g
mg
g
g
g
g
g
g
g
g
g
mL
g
L
L
L

$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$

Cost of Raw
Material
173.00
51.76
78.60
62.60
93.00
4.18
73.50
99.50
246.75
223.00
790.00
265.00
1,044.00
1,003.00
137.00
118.18
10.38
36.00
366.00
42.00
168.00
67.40
4,980.00
20,200.00
3,800.00

Cost per
RBC Unit
$/L $
0.0019
$/kg $
0.0013
$/kg $
0.0001
$/kg $
0.1352
$/L $
0.0076
$/L $
0.0868
$/L $
0.0320
$/L $
0.0646
$/L $
6.9758
$/kg $
0.0745
$/mg $
5.1280
$/kg $
0.4137
$/kg $
0.0298
$/kg $
0.5285
$/kg $
0.0377
$/kg $
0.0058
$/kg $
0.1473
$/kg $
0.2004
$/g
$
7.6024
$/kg $
0.1217
$/L $
0.0002
$/kg $
0.7234
$/L $
1.2450
$/L $ 66.6600
$/L $
1.3300
$
91.55

$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$

Annual Cost
381.81
259.71
22.45
27,034.21
1,521.26
17,359.76
6,391.45
12,917.37
1,395,162.01
14,901.70
1,025,600.36
82,747.84
5,963.54
105,708.18
7,541.15
1,160.76
29,464.85
40,072.52
1,520,484.99
24,349.93
41.44
144,670.03
249,000.00
13,332,000.00
266,000.00
18,310,757.32

The costs for the endotoxin affinity resin alone in this configuration reached approximately
$13 million annually (600 L of resin are required annually at a price of $20,200 per liter). These
high costs motivated looking into a new configuration in which the hydrophobic interaction
column was placed before the endotoxin affinity column. The general reagent costs of this setup
are shown in Table 9.3.2. Altogether the costs of the required volumes of resin between these two
columns together only slightly exceeds $4 million, a three-fold reduction in costs compared to the
previous setup. This configuration was thus chosen for the final design.
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Table 9.3.2. Preliminary reagent costing for a process design in which a separations train consists
of a hydrophobic interaction chromatography column followed by an endotoxin affinity
chromatography column for the removal of endotoxins. The resins in questions are highlighted in
light red.

Raw Material
AGE
Ammonium sulfate
APS
Detergent
DMAAm
Ethanol
Ethylenediamine
Glutaraldehyde
Guanadine HCl
HEPES
IgG
Imidazole
MBAAm
MES
Na2CO3
NaBH4
NaCl
NaOH
Protein A
Sodium phosphate
TEMED
Urea
HisPur® Cobalt Resin
Pierce Endotoxin Removal Resin
POROS Benzyl HIC Resin
Total

9.4.

Annual Amount
Required
2.2
5017.6
285.6
431856.3
16.4
4154.3
78175.7
129.8
48563.2
66823.8
1298.2
312256.0
5712.2
105392.0
55044.9
9822.4
2838618.0
1113125.4
4154.3
579760.4
246.7
2146439.7
50.0
80.0
650.0

L
g
g
g
L
L
g
L
L
g
mg
g
g
g
g
g
g
g
g
g
mL
g
L
L
L

$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$

Cost of Raw
Material
173.00
51.76
78.60
62.60
93.00
4.18
73.50
99.50
246.75
223.00
790.00
265.00
1,044.00
1,003.00
137.00
118.18
10.38
36.00
366.00
42.00
168.00
67.40
4,980.00
20,200.00
3,800.00

Cost per
RBC Unit
$/L $
0.0019
$/kg $
0.0013
$/kg $
0.0001
$/kg $
0.1352
$/L $
0.0076
$/L $
0.0868
$/L $
0.0320
$/L $
0.0646
$/L $
6.9758
$/kg $
0.0745
$/mg $
5.1280
$/kg $
0.4137
$/kg $
0.0298
$/kg $
0.5285
$/kg $
0.0377
$/kg $
0.0058
$/kg $
0.1473
$/kg $
0.2004
$/g
$
7.6024
$/kg $
0.1217
$/L $
0.0002
$/kg $
0.7234
$/L $
1.2450
$/L $
8.0800
$/L $ 12.3500
$
43.99

$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$

Annual Cost
381.81
259.71
22.45
27,034.21
1,521.26
17,359.76
6,391.45
12,917.37
1,395,162.01
14,901.70
1,025,600.36
82,747.84
5,963.54
105,708.18
7,541.15
1,160.76
29,464.85
40,072.52
1,520,484.99
24,349.93
41.44
144,670.03
249,000.00
1,616,000.00
2,470,000.00
8,798,757.32

Universal RBC Purity and Separations
The final major consideration in the process design was the establishment of a unit

operation that could separate successfully prepared ECO RBCs from non-converted cells.
Originally it was assumed that the enzymes would accomplish a 100% conversion. Upon
recommendations from Daniel Green, Ph.D from GlaxoKlineSmith, however, it was decided that
this assumption could have potentially severe consequences. Although the kinetics of the bacterial
glycosidases have been studied at the bench-scale and shown near complete conversion, there may
still be concerns that the scale-up of this procedure may affect the enzymes’ contact area with the
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RBC, potentially lowering its conversion efficiency. If for any reason that the efficiency is low
enough for there to be a substantial presence of non-converted RBCs, then using unseparated RBCs
in transfusion units may introduce a high concentration of ABO-incompatible RBCs into the
patient. Not only would this be detrimental to one of the main selling points of this service and
product, but it could also cause severe health complications in treated patients, raising ethical
concerns.
Originally, the process design sought to explore using magnetic-activated cell sorting
(MACS) to separate non-converted RBCs, which still possess the A or B antigen, from
successfully converted cells (Figure 9.4.1). By using MACS cell depletion separation, nonconverted RBCs would be labeled with human blood group antigen-targeting IgG antibodies
attached to cellulosic magnetic microbeads. By passing the RBC suspension through a magnetic
field, ECO RBCs, which should not be labeled, will pass through while cells with attached
microbeads would be magnetically attracted and retained. However, there were two major
limitations associated with the use of this technology. First, the microbeads can only label 107 to
109 cells. The number of RBCs that each batch will process is on the order of 1015. The second
limitation is that the microbeads are only usable once, which would require new antibody and new
microbeads for each batch of RBC treatment. The amount of microbeads required, combined with
the fact that they are only single-use, would lead to exorbitant costs. For these reasons, this option
was discarded after numerous consultations with industrial engineers.
The next iteration of the purification and separation of RBCs replaced the MACS unit
operation with a cryogel-based affinity chromatography column. Instead of using a traditional
affinity chromatography column, in which its resin is coated in protein A from Staphylococcus
aureus. Protein A has a strong affinity to the fragment crystallizable (Fc) region of antibodies. In
the traditional setup, cells can be labeled with antigen-specific antibodies and passed through the
column. Labeled cells will bind to the resin while unlabeled ones will pass through for collection
or discarding. These basic principles are illustrated in Figure 9.4.2. A major disadvantage of this
setup is the amount of IgG antibody required for annual production, as new labeling antibody will
be required for each treatment. Often, the elution buffer used compromises the binding efficiency
of the antibody, which can affect later purification attempts. Another major disadvantage is that
traditional resins often show significant cell lysis. This last issue could potentially be a significant
hindrance in this process design, given that a significant number of RBCs are already lost in each
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unit operation. Given that we assume a total 35% loss of RBCs across the entire process, 307,693
RBC transfusion units already have to be requested to provide only 200,000 ECO RBC units in
return. Even though a significant number of those original blood bags would be discarded due to
no usage before expiration, this process should still attempt to minimize the number of units
required for production goals to incentivate hospitals to engage in our service. If lysis is higher
though, the 35% assumption may not be valid and more units may be needed, which may push
hospitals away.
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Figure 9.4.1. Simplified process flow diagram of the RBC conversion process in its initial conceptualization stages. While the basic
setup from the process flow diagram is used in the final iteration, note that the technique implemented to separate non-converted RBCs
is magnetic-activated cell sorting (MACS). It operates by labeling the antigens of non-converted cells with human blood group targeting
antibodies. The antibodies are also linked to magnetic microbeads, which can then be attracted to a magnetic field while non-labeled,
successfully converted RBCs can pass through to the next unit operation.
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Figure 9.4.2. Representation of the fundamental principles behind the cryogel-based affinity chromatography column. A protein Acoupled cryogen complex will be packed into a chromatography column. RBCs that were not converted still possess their A or B
antigens, so they can be labeled with antigen targeting antibodies. This labeled cell population is then introduced into the column and
allow to pass. Labeled cells will bind to the protein A coat on the cryogel due to IgG antibodies’ high affinity to protein A, while all
universal RBCs will pass through and be collected. The remaining cells can then be released using mechanical stimulation while the
antibodies stay bound for another treatment process.
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The cryogel-based method addresses both of these disadvantages and provides unique
solutions to each. The binding of protein A and IgG antibodies is typically is very strong, requiring
harsh buffers to release bound antibodies and cells in a traditional setting. However, the cryogel
takes advantage of this strong binding to only release bound cells while keeping the antibodies
attached to the protein A. The application of mechanical stress, recommended using a piston, and
compressing the cryogel is reported to detach all cells with antibodies remaining bound to the
cryogel-protein A complex for subsequent uses. This helps reduce costs associate with purchasing
labeling antibodies More specifics details on the composition of the cryogel and the operation of
the column are described in Section 14.
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Section 10:
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10.

Assembly of Database

10.1. RBC Conversion Treatment Parameters
The literature that serves as the basis for this project, which describes the methodology and
biochemistry of converting any RBC type into the universal type-O, reports that 60 mg of α-Nacetylgalactosaminidase and 2 mg of α-galactosidase for every 300 mL of blood are needed to
convert type-A and type-B cells, respectively.29 The average RBC count is 5x106 RBCs/µL of
blood. Although additional glycosidases have been used to accomplish the same conversion, the
mass of enzyme required to treat type-A and type-B cells is 30-fold and 1,000-fold less than the
next best alternative, respectively.

10.2. E. coli BL21(DE3) Growth and Protein Yield Parameters
A literature review was performed to determine what protein yield parameters are common
in industrial E. coli fermentation processes. Emphasis was placed on growth parameters reported
in high cell density cultures, which tend to vary from the values presented in cultures with densities
of 16 grams of cells per liter. Recent protocols have been published detailing how to obtain highdensity E. coli cells with yields of 15 to 25 mg of recombinant protein in 50-mL of culture at an
OD600 of 20.30 (They report that an OD of 1 is approximately 1.0x1010 cells/mL.) We assume that
our protein yield will be closer to the lower bound. Assuming that we can obtain 15 mg of enzyme
per 50-mL of culture, this value corresponds to a protein production rate of approximately 0.30 g
protein/L of culture. This corresponds to a yield of 1.88x10-2 g of enzyme per gram of cell mass.
Lastly, an additional literature review, both from academic and industrial sources, was
performed to determine key operating parameters for modeling the cellular growth of E. coli cell
cultures. Nearly all literature sources2 reported E. coli growth rates ranging between 0.25 and 0.30
hr-1. To have a conservative approach, a growth rate of 0.25 hr-1 was assumed for this process. The
specific oxygen uptake rate for E. coli is reported to be 12 mmole O2/g cells-hr. These numbers
were screened and approved by Jeffrey Cohen, Ph.D., from Johnson & Johnson, for further
verification that these values align with common industrial assumptions and yields.
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11.

Process Flow Diagrams and Material Balances

11.1. E. coli Upstream and Downstream Processing
Figure 11.1.1 represents the process flow diagram for the upstream processing of the E.
coli cell lines. Upstream processing refers to the microbial fermentation process in which the E.
coli cells are grown up to a high enough cell density to express the desired mass of recombinant
enzyme. The overall material balances for each reactor are shown in Table 11.1.1. The calculations
to determine batch times are found in Appendix A. A summary of all batch culture data for the
production of both α-galactosidase and α-N-acetylgalactosaminidase is included in Appendix D.
Table 11.1.1. Overall material balance for each bioreactor or fermenter in the upstream processing.

Figure 11.1.2 shows the downstream purification process of the ECO-zymes expressed in
the E. coli cells. The overall material balance of the downstream purification process is shown in
Table 11.1.2.
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Table 11.1.2. Overall material balance for the downstream purification of ECO-zymes.

Figure 11.1.3 shows a Gantt chart showing the time period in which two batches of enzyme
production can be completed.

Figure 11.1.3. Gantt chart for E. coli processing scheduling. Two batches can be achieved in
approximately a week. The bottlenecks of the setup are the production fermenters. The color black
represents CIP/SIP times. Orange is the first batch, blue is the second batch.
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Based on the equipment processing times, it was decided that 112 batches would be done for the
production of α-N-acetylgalactosaminidase and two batches for the production of α-galactosidase.
Additionally, in consultation with several industrial consultants, it was decided that the facility
would be operational throughout the entire year, seven days aweek. Although the Gantt chart
shows that only two batches can be prepared in roughly a week, six days a week is not sufficient
to accomplish the entire production goals. There would need to be weeks in which all seven days
required labor. For simplicity purposes, it was then decided that the facility should operate seven
days a week to meet production goals and to compensate for any delays.

11.2. RBC Treatment Processing
The final process flow diagram in Figure 11.2.1 (at the end of the section) represents the RBC
treatment process and its respective downstream purification. The overall material balance is
shown in Table 11.2.1.
Table 11.2.1. Overall material balance for the key components of the RBC treatment process.
Input (kg/batch)
For type-A
RBC suspension
GalNAc-ase
Waste
For type-B
RBC suspension
α-galactosidase
Waste

0.559
0.118
0

Output (kg/batch)
0.386
0
0.291

0.551
-3

3.95×10
0

0.381
0
0.174

A Gantt chart for the RBC treatment process is shown in Figure 11.2.2. Only one batch is
shown though, given that we are limiting ourselves to only three batches per week. There are
therefore very little time constraints to satisfy RBC production goals. Since it was decided that the
facility would operate seven days a week to fulfill enzyme production goals, then there will still
be sufficient time for three batches of RBC treatment to be carried out since they can be done in
parallel to the bacterial growth. Additionally, each batch takes approximately one day, meaning
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that conversion batches do not be need to occur back to back. However, this available free time
between each treatment process indicates that there is additional time that can used later on to
increase the number of batches per week if expansion occurs.

Figure 11.2.2. Gantt chart for a single batch for RBC conversion. Three batches can easily be
achieved in approximately a week, which is what production capacity will limit itself to for the
early years of the facility. The color black represents CIP/SIP times, while red represents an RBC
conversion process unit operation..
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Figure 11.1.1. The finalized process flow diagram for upstream cell culture processing of the engineered E. coli BL21(DE3) strains
expressing either α-galactosidase or α-N-acetylgalactosaminidase. Blue represents bulk media preparation and sterilization to charge
into fermeneters. For the smaller bioreactors, media will be pre-made and stored in sterile conditions.
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Figure 11.1.2. The finalized process flow diagram downstream purification of either α-galactosidase or α-N-acetylgalactosaminidase
that is harvested from the E. coli BL21(DE3) culture.
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Figure 11.2.1. The finalized process flow diagram for the RBC treatment conversion process.
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12.A. ECO-enzyme Production Process Description
The bioreactors and fermenters chosen for this process were designed by finding the
production volume required to satisfy production. It is assumed that for all vessels, the culture will
only occupy at most 80% of the vessel’s volume. It should also be noted that all bioreactors and
fermenters purchased in this step come equipped with sampling ports to measure cell density at
different sampling times throught the growth period. All cell density measurements will be done
using a Tecan Spark Microplate Reader, with all measurements being done in replicates to ensure
goal cell density has been achieved. It is assumed that any loss of microbial culture due to sampling
is negligible.

12.A.1.

E. coli Cell Growth Model for Batch Bioreactor
To analyze cell growth, it was assumed that Escherichia coli (E. coli) follows Monod

growth kinetics, a commonly accepted approach for industrial fermentation. The cell growth times
were selected based on a literature review of common experimental values for E. coli. The selected
growth rate, 𝑢𝑔 , was 0.25 hr-1. For simplicity of calculations, it was assumed that the first-order
death rate, 𝑘𝑑 is negligible. Therefore, the net growth specific rate was determined as follows:
𝜇𝑛𝑒𝑡 = 𝑢𝑔 − 𝑘𝑑

(12.1)

The mathematical model used to quantify the batch time for cell growth was:
𝜇𝑛𝑒𝑡 =

1 𝑑𝑋
𝑋 𝑑𝑡

(12.2)

Rearranging the above expression to have the cell concentration and time variables isolated on
the left and right-hand sides of the equations, respectively:
𝑑𝑋
= 𝜇𝑛𝑒𝑡 𝑡
𝑑𝑡

(12.3)

Given that the E. coli cells are thawed from a frozen stock with a specific concentration, the initial
concentration, 𝑋𝑜 , is known. Thus, to solve for the final cell concentration, 𝑋, the integral was
taken from t = 0 to t with their respective cell concentrations.
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𝑋

𝑡
𝑑𝑋
∫
= ∫ 𝜇𝑛𝑒𝑡 𝑑𝑡
𝑋𝑜 𝑋
0

Solving the integral:
𝑙𝑛

𝑋
= 𝜇𝑛𝑒𝑡 𝑡
𝑋𝑜

Isolating the batch time required to grow an inoculum of cells at a concentration of 𝑋𝑜 to a final
concentration, 𝑋, the resulting equation used was:
𝑡=

12.A.2.

1
𝜇𝑛𝑒𝑡

𝑙𝑛

𝑋
𝑋𝑜

(12.4)

Cell Culture Media Preparation
Literature on high-density microbial cell cultures recommends using high-mineral salt

culture media to sustain large cell concentrations.31 The composition of the culture is included in
Appendix Q. All mineral salts will be purchased in dry powder form, dissolved in ultrapure water,
and mixed at 300 rpm in a 500 L HyPerforma Single-Use Mixer from Thermo Fisher. The prepared
solution will be supplemented with 0.04% vol/vol glycerol and 0.01% vol/vol β-lactose. All
samples will then be passed through a 0.2 µm filter to sterilize and eliminate any foreign particles,
bacteria, or large viruses. All culture media will also be supplemented with 2 grams of glucose per
culture of media, as recommended by Jeffrey Cohen, Ph.D (Johnson & Johnson), prior to insertion
the microbial bioreactors and fermenters. The total time for this mixing step, including charging
all the high-salt powders and water, mixing and heating to 37ºC, and sterilization, will take roughly
five hours.
For the inoculum grow up and additional grow up in a seed reactor, antibiotics will also be
included to eliminate any E. coli cells that do not express the genes that code for either αgalactosidase and α-N-acetylgalactosaminidase. Successfully engineered E. coli strains that
express the genetic sequence to produce the enzymes of interest also include an attached antibiotic
resistance gene. If for any reason any of the E. coli cells do not have the genes for enzyme
31

Sivashanmugam A et al. Practical protocols for production of very high yields of recombinant proteins using Escherichia coli. Protein Science
2009; 18: 936-948.
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expression, they will not express the antibiotic resistance gene either. The use of antibiotics will
allow only enzyme-producing E. coli cells to be selected for the microbial cultures. The working
concentrations for kanamycin and chloramphenicol established in the literature are 50 and 34
µg/mL, respectively.31 It is assumed that after the first culturing steps, the microbial culture will
consist exclusively of enzyme-expressing bacterial cells. Therefore, the antibiotics are removed
from the production fermentation step to reduce costs.
12.A.3.

Inoculum Preparation
The inoculum for the growth bioreactor and production fermenter will initially be grown

up in a 0.250 L single-use, disposable stirred tank bioreactor operated in batch using the ambr®
250 modular system (Sartorius).32 The process will be carried out with a working volume of 0.11
L incoluated with 1.0 mL of a frozen stock of E. coli BL21(DE3) cells at a concentration of
7.95×106 cells/mL. It is assumed that only 80% of the cells in the frozen vial will survive the
freeze-thaw process. After insertion of the inoculum into the culture media and accounting for cell
death, the initial concentration of the cell population will be 5.09×106 cells/mL. The culture will
grow for 17.86 hours, regardless of the enzyme product, up until a final cell concentration of
4.42×108 cells/mL is obtained. The reactor will operate at 300 rpm with a dual 20 mm Rushton
impeller and at 37ºC achieved via electrical heating. Media in the bioreactor will contain 33.9 g
Na2HPO4·7H2O, 15.0 g KH2PO4, 5.0 g NH4Cl, 2.5 g NaCl, 7.1 g Na2SOL, 6.0 g MgSO4, 2 g
glucose, 34 mg chloramphenicol, and 50 mg kanamycin per liter of solution. During the
inoculation growth, it should be noted the cells will produce small amounts of endotoxin,
approximately 3.2 grams. Additionally, roughly 5 milliliters of water in the culture media will be
lost due to evaporation.
After the near 18-hour growth period, the inoculum culture will be transferred to a a seed
bioreactor via peristaltic pump for further grow up prior to insertion into the production fermenters.
All the contents of the unit will be transferred into the new growth bioreactor. If for any reason the
seed bioreactor is not available for immediate use, the inoculum culture will be transferred to a

32

Sartorius Stedim Biotech GmbH. Data sheet: ambr 250 modular bioreactor [Internet]. Data sheet: ambr 250 modular bioreactor. Goettingen,
Germany:
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Stedim
Biotech
GmbH;
2015
[cited
2018
Apr
16].
Available
from:
https://www.sartorius.com/_ui/images/h0c/h06/8870706315294.pdf
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single-use disposable bag and refrigerated at 4ºC to inhibit further cell growth until inoculation for
the growth bioreactor.
12.A.4.

Growth Bioreactor
The growth bioreactor will be inoculated from the E. coli culture grown in the single-use

bioreactor. The culture will be grown up in an autoclavable glass stirred tank bioreactor operated
in batch using a BIOSTAT® B control tower (Sartorius).33 The process will be carried out with a
working volume of 5.44 L in a 10 L UniVessel autoclavable glass vessels34, also purchased from
Sartorius. Prior to inoculation, 5.33 L of prepared and sterilized high-salt medium will be
transferred into the 10 L using a peristaltic pump. Immediately after, the remaining 0.11 L of
culture from the inoculum growth step will be charged into the reactor via peristaltic pump.
Assuming that approximately 95% of the active microbial population is transferred into the seed
bioreactor, after dilution with fresh media the initial cell concentration is 8.50×106 cells/mL. The
remaining five percent that is lost is due to either cell death or transfer losses. Growth will continue
for 24.03 hours and 23.69 hours for α-N-acetylgalactosaminidase and α-galactosidase,
respectively. A maximum cell concentration of 3.45×109 and 3.17×109 cells/mL will be obtained
in each culture. Media in the seed bioreactor will contain 33.9 g Na2HPO4·7H2O, 15.0 g KH2PO4,
5.0 g NH4Cl, 2.5 g NaCl, 7.1 g Na2SOL, 6.0 g MgSO4, 2 g glucose, 34 mg chloramphenicol, and
50 mg kanamycin per liter of solution. In addition to microbial growth, this setup will also increase
the final endotoxin yield thus far to approximately 0.16 grams. It is expected that after the near 24hour growth period elapses, approximately 23 milliliters of water will have evaporated.
The culture will be stirred continuously at 800 rpm with a 6-blade disk (Rushton turbine)
impeller to keep the culture well mixed and allow for an optimal volumetric oxygen transfer, as
indicated by the manufacturer’s protocol. The final biomass density in the cultures are 3.45 g/L
for α-N-acetylgalactosaminidase and 3.17 g/L for α-galactosidase, both of which are fairly low
density microbial fermentations. The manufacturer’s protocol indicates that the BIOSTAT® B

33
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system is capable of a volumetric oxygen transfer coefficient greater than 40 hr-1. Based off the
higher cell density, the oxygen transfer rate is 45.6 mmole O2/g cell-hr while the oxygen uptake
rate of the cells under these conditions is 41.4 mmole O2/g cell-hr. This calculation additionally
ensures that the oxygen transfer rates for this bioreactor setting is greater the oxygen uptake rate
of the E. coli cells, which maximize cell growth and promotes a healthy microbial population for
production fermentation. The pH of the culture will be maintained at 7.0; the temperature, at 37ºC
with electric heating. Sterile oxygen will be sparged to maintain a dissolved oxygen concentration
(pO2) of 40% throughout the whole growth period. All conditions will be stabilized using PID
feedback controllers.
If for any reason the production fermenters are not available for immediate use, the seed
bioreactor culture will be transferred to a single-use disposable bag and refrigerated at 4ºC to
inhibit further cell growth until inoculation for the growth bioreactor.
12.A.5.

Production Fermenter Preparation
The production fermenters will be inoculated with the E. coli culture from the growth

bioreactor in the previous step. The culture will be grown in two separate stainless steel
BIOSTAT® D-DCU fermenters (Sartorius).35 First, 391 L of high-salt culture media will be
prepared, sterilized, and then transferred into the two stainless steel fermenters in equal volumetric
quantities via peristaltic pump. Immediately after the fermenters have been charged with media,
the 5.44 L of culture from the growth bioreactor will be separated into two volumetrically equal
streams, both of which will be transferred into the fermenters through a peristaltic pump. It is once
again assumed that nearly five percent of the microbial population grown in the seed bioreactor
will be lost to cell death of transport losses. The culture will be stirred continuously at 800 rpm
with a 6-blade disk (Rushton turbine) impeller with an optimal oxygen transfer coefficient of 308
hr-1, allowing a maximum cell biomass density of 29 grams per liter to be supported (see Appendix
F). These operating conditions were chosen following the manufacturer’s protocol and published
data, which report optimal E. coli BL21(DE3) cell growth and viability when operating at high
impeller velocities.

35
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Production. Goettingen, Germany: Sartorius Stedim Biotech GmbH; 2015 [cited
2018 Apr 16]. Available from:
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The pH of the culture will be maintained at 7.0; the temperature, at 37ºC with the
fermenters’ integrated heat jackets. Sterile oxygen will be sparged to maintain a dissolved oxygen
concentration (pO2) of 40% throughout the whole growth period. All conditions will be stabilized
using PID feedback controllers.36 The culture will be grown for 25.89 hours to reach a final cell
concentration of 2.91×1010 cells/mL. This corresponds to a cell mass of approximately 11.5 kg.
Media in the all bioreactors will contain 33.9 g Na2HPO4·7H2O, 15.0 g KH2PO4, 5.0 g NH4Cl, 2.5
g NaCl, 7.1 g Na2SOL, 6.0 g MgSO4, and 2 g glucose per liter of culture media broth. Note that in
this unit operation, the kanamycin and chloramphenicol antibiotics are no longer included. After
the seed growth, it is assumed that any cells that do not contain the plasmid coding for the gene of
interest and antibiotic resistance are eliminated. If for any reason any of these cells do remain, they
are found in a exorbitantly small proportion compared to the engineered E. coli strain, meaning
that their growth in culture will be minimal. The exclusion of these expensive antibiotics in the
product fermentation step also reduces costs.
When the desired optical density measurements (OD600) value is obtained, isopropyl β-D1-thiogalactopyrranoside (IPTG) will be added to the culture to induce protein production. IPTG
will be transferred in the fermenters until a final concentration of 1.0 mM for the working volume
is achieved. Protein production will occur for five hours with the culture conditions at a
temperature of 25ºC, pH of 7.0, and a pO2 of 40%. The culture will continue to be mixed at 800
rpm. Assuming that the cell concentration remains approximately constant throughout the protein
production period, with a cell productivity of 85.4 ng of α-N-acetylgalactosaminidasper cell per
day, 216 grams of α-N-acetylgalactosaminidasenzyme can be produced. Under the same
assumption with a cell productivity of 85.6 ng of α-galactosidase per cell per day, one batch can
produce 199 grams of α-galactosidase. In addition to enzyme production, the microbial
fermentation produces 11.5 grams of lipopolysaccharide endotoxins.
After the five hour protein production period, the full cell culture will be transferred via
peristaltic pump to a 500 L HyPerforma Single-Use Mixer and cooled to 4ºC via the mixer’s heated
jacket. However, given the transport losses when passing the microbial culture to downstream
purification and processing, another five percent of the microbial population will lost. Therefore,
36
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the mass of enzyme available to harvest once the microbial culture is charged into the holding tank
is 205 grams of N-acetylgalactosaminidase or 189 grams of α-galactosidase. Once the fermenters’
contents are transferred out completely, CIP/SIP procedures will begin immediately afterwards.
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12.B. ECO-zyme Purification Process Description
It should be noted that for all chromatography column designs, a conservative assumption
made regarding the mass of enzyme that the column will treat. The amount of enzyme lost in the
previous downstream steps is neglected, leaving us to calculate required resin and column volumes
using the enzyme mass that originally entered the downstream process. This is done to calculate
the maximum volume of resin and column that would be required to accomplish the desired
separation. This serves as the upper bound for costing calculations, which will be usefully in
providing more constraints to gauge the financial feasibility of the project. Additionally, this
approach will help ensure that there is a surplus of resin if ever required.
Another important note for this section is that the values reported for resin and
chromatography

column

volumes

correspond

to

the

calculations

done

for

α-N-

acetylgalactosaminidase purification. Since a single batch of α-N-acetylgalactosaminidase has a
higher mass yield than a batch of α-galactosidase (205 grams versus 189 grams), it can be expected
that all designs parameters for α-N-acetylgalactosaminidase purification will be greater than the
minimum volume needed for α-galactosidase purification. Therefore a single chromatography
column can be used for the purification of both enzymes.
The last major calculation done in this section assumes that the hydrophobic interaction
chromatography column used to eliminate endotoxins from the enzyme product will process the
original endotoxin mass yield from the microbial fermentation. Similarly to how the resin volumes
were calculated, this assumption provides the upper bound on how much resin will be required for
the separation step. Additionally, this assumption allows for a more stringent purification process
to make sure that the process design’s enzymatic product complies with FDA endotoxin standards.
12.B.1.

Holding Vessel
Upon completion of upstream enzyme production, the entire spent media and culture with

the product from both stainless steel fermenters (396 L for α-N-acetylgalactosaminidase or 364 L
for α-galactosidase) will be transferred via peristaltic pump to a 500 L HyPerforma Single-Use
Mixer. This unit was chosen for its single-use technology, which consists of harvesting cells in
single-use disposable bags to reduce CIP times, and its heated jacket for temperature control. The
culture will be mixed at 300 rpm on a WAVE bioreactor rocker table to prevent settling of the cells
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and to minimize loss during transfer out of the holding tank via peristaltic pump to centrifugation.
The culture will also be lowered to 5ºC, the lower limit of the operating temperature for the vessel,
to completely inhibit further cell growth. The vessel will also operate at a pressure of 0.03 atm.37
12.B.2.

Centrifugation
The content held in the holding tank will be transferred into a Culturefuge100 disk stack

centrifuge, purchased from Alfa Laval. The unit will separate the solid parts of the culture,
including cell mass and debris, from the spent liquid media. The spent culture media will then be
directed into a waste tank, while the solid biomass will remain in a sludge that is 60% by mass
water and 40% by mass solids.38 The cell biomass will be directed to a disposable 3D bioprocess
container (Thermo Fisher Scientific)39 and kept at 4ºC until it undergoes homogenization via
microfluidization. The centrifuge will operate with a flowrate of 100 L/hr at a temperature of 25ºC.
It is assumed that 5% of the ECO-zyme will be lost in the liquid waste stream, leading to a product
yield of 95%. Centrifugation will last for approximately one hour, while CIP and SIP procedures
will require 5.8 hours as recommended by the manufacturer’s protocol.
It is assumed that approximately 4.5% of the biomass will be lost from the centrifugation
process. Thus, after centrifugation, roughly 10.9 kg of biomass will be available for harvesting,
meaning that the mass of enzyme that can be harvested lowers to 195 grams of α-Nacetylgalactosaminidase or 180 grams of α-galactosidase. It is also assumed that the same amount
of endotoxin is lost, leaving 10.9 grams of endotoxin. After the centrifugation process, the
expected mass of the cell sludge output is approximately 12.7 kg.
12.B.3.

High-Pressure Homogenization
The cell sludge from the centrifugation step will be sent through a high-pressure

microfluidizer processor (Microfluidics)40 to lyse the E. coli cells and release the internalized,
37
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cytoplasmic α-galactosidase or α-N-acetylgalactosaminidase. 326 L of bacterial protein extraction
agent (B-PER) and DNAse solution will be added to the disposable bioprocess container in which
the cell sludge from centrifugation is stored. (It is assumed that the BPER and DNAse solution has
the same density as water.) This membrane disrupting solution is added prior to entering the
microfluidizer to further weaken the cell membrane and promote cell lysis. The microfluidizer will
pump the cell sludge through a pressure differential of up to 20,000 psi in fixed-geometry
microchannels to generate high velocity and shear stress. The impact against the microchannels’
with the high shear conditions will cause cells membranes to break, releasing the internalized
protein. The microfluidizer will operate at 25ºC to prevent denaturing of the enzyme. The
temperature will be controlled and maintained using a digital PID controller. This process will
require three passes to create a uniform emulsion. The total homogenization process, including
SIP and CIP procedures, will require approximately 3.8 hours. CIP/SIP procedures are
recommended to last for two hours. It is once again assumed that the recovery of the product in
the unit operation is roughly 95%.
12.B.4.

Microfluidization Product Resuspension Tank and Container
The lysed cell mass and released enzyme product will be emptied into a new disposable

500 L 3D bioprocess container fitted into a 500 L HyPerforma Single-Use Mixer (Thermo Fisher
Scientific). The biomass suspension will be resuspended in 396 L of equilibration buffer to
maintain its pH at 7.4. It is once more assumed that product recoveyr in this step is 95.5%, meaning
that 185 grams of α-N-acetylgalactosaminidase or 171 grams of α-galactosidase will be collected.
To prevent the lysed biomass and product enzymes from settling, which could result in lower
product yield, the production suspension is gently agitated at 300 rpm on a WAVE bioreactor
rocker table. This agitation speed is reduced enough to not generate shear stress that could
otherwise compromise the biological functionality of the enzyme proteins. The operation time,
including CIP and SIP sterilization, will be approximately one hour. If the cobalt affinity
chromatography is not immediately available due to unexpected bottleneck constraints,
mechanical malfunctions, or other issues, the holding bag and its content will be kept in a cold
room at 4ºC.
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12.B.5.

Cobalt Affinity Chromatography
As previously mentioned, the gene sequence encoded into the E. coli BL21(DE3) cell

creates an N-terminal truncated construct of the enzymes with a His6 tag at the N-terminus that
can be used for separation procedures. After complete cell lysis and resuspension of both cell
debris and product in equilibration buffer, cobalt ion affinity chromatography will be performed
to separate α-galactosidase and α-N-acetylgalactosaminidase from the cell debris, BPER-DNAse
mixture, and other buffers. The His6 tags at the N-terminus of the enzymes will bind to the resin
in the chromatography column, while all non- His6 tagged particles, debris, and organelles will
pass through the column.
As previously mentioned, for the purpose of designing the chromatography, we assume
that the mass of enzyme that will be processed is equal to the mass of the enzyme at the beginning
of the downstream purification. This solves for the upper bound of resin and column volume that
would be needed for purification and separations. The total required chromatography column size
to treat one batch, which yields 205 grams of enzyme, is 14.6 L. Resolute® chromatography
columns will be used for this unit procedure and will be purchased from Pall Corporation. The
column will be packed with HisPur Cobalt Resin41, a tetradentate chelating agarose resin charged
with divalent cobalt (Co2+) for obtaining high-purity His6-tagged proteins, from Thermo Fisher
Scientific. The volume of resin required per batch is 10.25 L. Assuming product recovery of
95.5%, the mass collected is 176 grams of α-N-acetylgalactosaminidase or 162 grams of αgalactosidase. It is assumed that all cell debris and antibiotic mass is eliminated in this unit
operation. Lastly, the affinity chromatography column will operate a linear velocity of 150 cm/hr
and at a temperature of 25ºC. The chromatography separation, including resin set up, will require
5.27 hours. CIP and regeneration will take an additional 3.14 hours.
For operating, the column must first be run with ten column volumes of equilibration
buffer. The resuspended solution of cell debris and product in equilibration buffer will then be
added to the column to allow for protein binding to the resin. The resin has an expected binding
capacity of 20 grams of enzyme per liter of resin for both α-galactosidase and α-Nacetylgalactosaminidase. After binding, the column will then be washed with ten volumes of wash
41

Pall Life Sciences. Resolute® Manual Chromatography Columns [Internet]. Resolute® Manual Chromatography Columns. Port Washington,
NY: Pall Corporation; 2017 [cited 2018 Apr 16]. Available from: https://shop.pall.com/us/en/biotech/chromatography/columns-pilot-andprocess-scale/resolute-manual-chromatography-columns-zidgri78lcv
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buffer to eliminate any cell debris that may have bound to the resin. Lastly, ten column volumes
of elution buffer will be added to the column to release and collect all bound enzyme.
Regeneration of the resin will be done by washing the column and resin with ten column
volumes of regeneration buffer. According to the manufacturer’s protocol, the resin can be
regenerated a maximum of 25 times without decreasing the purity of the product below 90%.
12.B.6.

Hydrophobic Interaction Chromatography
The removal of endotoxins, the pyrogenic components of the outer cell wall of Gram-

negative bacteria such as E. coli, is necessary to prevent inducing immunogenic responses in
patients. Since α-galactosidase and α-N-acetylgalactosaminidase will be used to treat RBCs and
could possibly remain in solution with them after the conversion, transfusion of these units could
theoretically cause significant levels of endotoxin contamination. Although endotoxin removal is
reported when cell solutions are run through a cobalt affinity chromatography column, this process
operates under the assumption that the endotoxin removal is negligible. This assumption is made
given that the cobalt-chelate coordination core is reported to have off-target binding to endotoxins
and other protein host contaminants.
This column will be packed with POROS Benzyl HIC Resin 42, which consists of cross‐
linked poly(styrene-divinylbenzene) POROS base beads with aromatic hydrophobic benzyl ligand,
suited for both bind/elute and flow-through purifications. The benzyl resin system was chosen over
other available resins because binding affinity can easily be controlled even with relatively small
differences in hydrophobicity. Assuming that no endotoxin has been removed since the beginning
of the downstream purification to be stricter on design calculations, each batch of E. coli
BL21(DE3) culture produces 11.5 grams of endotoxin to be processed. Therefore, the volume of
resin required for each batch HIC chromatography operation is 57.5 L. The total required
chromatography column size to treat one batch is 96 L. Resolute® chromatography columns will
also be used for this unit procedure. Lastly, the endotoxin affinity chromatography column will
also operate a linear velocity of 150 cm/hr and at a temperature of 25ºC. The chromatography
separation, including resin set up, will require 3.79 hours. CIP and regeneration will take

Thermo Scientific. Instructions: HisPur™ Cobalt Resin [Internet]. Instructions: HisPur™ Cobalt Resin. Rockford, IL: Pierce Biotechnology;
2012 [cited 2018 Apr 16]. Available from: https://www.thermofisher.com/order/catalog/product/89964
42

85

approximately one hour. Although the manufacturer’s protocol for this resin reports a 99%
removal of endotoxins, other sources report that only a 90% removal was often obtained. For this
reason, it is assumed that the hydrophobic interaction column will only remove 90% of the
endotoxins from the enzyme product. After processing, 1.15 grams of endotoxin will remain.
Assuming approximately 95% enzyme product recovery, either 167 grams of α-Nacetylgalactosaminidase or 162 grams of α-galactosidase will be collected.
For operating, the column must first be run with five column volumes of equilibration
buffer. The collected product solution from the previous chromatography step will then be added
to the column to allow for endotoxin binding to the resin. After binding, the column will then be
washed with five volumes of wash buffer to eliminate any cell debris that may have bound to the
resin. Lastly, two column volumes of elution buffer will be added to the column to release and
collect all bound enzyme. CIP procedures include adding two column volumes of 6M guanidine
HCl43 and another two column volumes of 1% mass/volume Brij35 nonionic detergent. 44
Regeneration of the resin will be done by washing the column and resin with five column
volumes of regeneration buffer. According to the manufacturer’s protocol, the resin can be
regenerated a maximum of ten times without any loss in performance.
12.B.7.

Endoxotin Affinity Chromatography
The hydrophobic interaction chromatography (HIC) unit operation alone by itself cannot

sufficiently reduce the endotoxin concentration in the product suspension to the FDA standard of
0.1 EU/mL. Therefore, an endotoxin affinity chromatography operation was added to the process
to further remove endotoxins from the product.
The last column will be packed with Pierce High Capacity Endotoxin Removal Resin
(Thermo Fisher Scientific)45, which combines porous cellulose beads with poly(ε-lysine) as an
affinity ligand to selectively bind endotoxins. The binding affinity is also reported to be 2×106
EU/mL, where EU is shorthand for endotoxin units. After the HIC separation step, 1.15 grams of
Thermo Scientific. User Guide: POROS™ HIC Resins: Ethyl, Benzyl, and Benzyl Ultra [Internet]. User Guide: POROS™ HIC Resins: Ethyl,
Benzyl, and Benzyl Ultra. Waltham, MA: Thermo Scientific; 2017 [cited 2018 Apr 16]. Available from:
https://www.thermofisher.com/order/catalog/product/88272?SID=srch-srp-88272
44
Brij 35 for Synthesis; MSDS No. 801962 [Online]; EMD Millipore: Saint Louis, MO, Sep 16, 2014. http://www.emdmillipore.com/Web-USSite/en_CA/-/USD/ProcessMSDS-Start?PlainSKU=MDA_CHEM-801962&Origin=PDP (accessed Apr 10, 2018).
45
Thermo Scientific. Instructions: Pierce High-Capacity Endotoxin Removal Resin [Internet]. Instructions: Pierce High-Capacity Endotoxin
Removal Resin. Rockford, IL: Pierce Biotechnology; 2016 [cited 2018 Apr 16]. Available from:
https://www.thermofisher.com/order/catalog/product/88272?SID=srch-srp-88272
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endotoxin will need to be treated. Therefore, the volume of resin required per batch is 5.75 L. The
total required chromatography column size to treat one batch is 9.6 L. Resolute® chromatography
columns will be used for this unit procedure and will be purchased from Pall Corporation. Lastly,
the endotoxin affinity chromatography column will also operate a linear velocity of 150 cm/hr and
at a temperature of 25ºC. The chromatography separation, including set up, will require 3.01 hours,
while CIP and regeneration will last slightly over an hour. It is assumed that there is a 99% removal
of endotoxins in this unit operation, as indicated in the manufacturer’s protocol. After passing the
enzyme product solution from the previous unit, either 159 grams of α-N-acetylgalactosaminidase
or 146 grams of α-galactosidase will be collected.
For operating, the column must first be run with five column volumes of equilibration
buffer. The collected product solution from the previous chromatography step will then be added
to the column to allow for endotoxin binding to the resin. After binding, the column will then be
washed with five volumes of wash buffer to eliminate any cell debris that may have bound to the
resin. Lastly, two column volumes of elution buffer will be added to the column to release and
collect all bound enzyme. CIP procedures include adding two column volumes of 6M guanidine
HCl and another two column volumes of 1% mass/volume Brij35 nonionic detergent.
Regeneration of the resin will be done by washing the column and resin with two column
volumes of regeneration buffer. According to the manufacturer’s protocol, the resin can be
regenerated a maximum of five times without any loss in performance.
12.B.8.

Ultrafiltration/Diafiltration
After separating α-galactosidase and α-N-acetylgalactosaminidase from endotoxins via

several chromatography steps, the next major unit operation is separating these enzymes from any
remaining cellular debris and the buffer components from the endotoxin affinity chromatography
step. An ultrafiltration/diafiltration setup will be prepared using a Cogent Process-Scale Tangential
Flow Filtration System (EMD Millipore)46 loaded with Pellicon 3 Cassettes with Ultracel
Membrane.47 The membrane will have a 30 kD nomical molecular weight limit with C-screen. The

46

EMD Millipore. Data Sheet: Cogent® Process-Scale Tangential Flow Filtration System [Internet]. Data Sheet: Cogent® Process-Scale
Tangential Flow Filtration System. Darmstadt, Germany: EMD Millipore; 2015 [cited 2018 Apr 16]. Available from:
http://www.emdmillipore.com/US/en/product/Cogent-Process-Scale-Tangential-Flow-Filtration-System,MM_NF-C173675#documentation
47
Millipore Sigma. Pellicon® 3 Cassettes with Ultracel® Membrane [Internet]. Pellicon® 3 Cassettes with Ultracel® Membrane . Burlington,
MA: Millipore Sigma; 2018 [cited 2018 Apr 16]. Available from: http://www.emdmillipore.com/US/en/product/Pellicon-3-Cassettes,MM_NFC9947?CatalogCategoryID=#documentation
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Ultracel membranes have a surface area of 1.14 m2 and can be run with a flow rate of 4 L/min. As
the process is carried out, the feed tank will be continuously replenished with equilibration buffer.
It is assumed that roughly 95% percent of the product will be recovered, while the remaining five
percent will be lost to the permeate. This means that either 151 grams of α-Nacetylgalactosaminidase

or

139

grams

of

α-galactosidase

will

be

collected.

The

ultrafiltration/diafiltration step will require approximately two hours. The operation time of the
ultrafiltraton/diafiltration unit will be roughly two hours, with an equivalent amount of time used
for CIP/SIP procedures.
12.B.9.

Sterile, Bulk Microfiltration
Sterile filtration is used as the final purification step to remove endotoxins and any

remaining microscopic cell debris and organelles from the final product solution. This step is taken
to ensure that the final concentration of endotoxins in the ECO-zyme solution meets FDA
standards. The filters will be hydrophobic Durapore PVDF membranes with a 0.22 µm pore
diameter size.48 The PVDF filters and their respective holders are disposable, and one of each will
be used per batch. The filters have a 100 cm2 surface area and will run at a flowrate of 11 L/min.
Recovery of ECO-zyme product in this step is 95%. This unit procedure will be run twice as
additional precaution to ensure that FDA requirements for endotoxin removal are satisfied. It is
assumed that 99% of endotoxins are removed after each filtration pass. After this unit operation,
1.04×10-6 grams of endotoxin will remain. 136 grams of α-N-acetylgalactosaminidase or 125
grams of α-galactosidase will be collected. The final concentration of the enzyme product solution
after passing through bulk microfiltration will be 1 mg/mL and will be stored in 200 mM glycine
solution to prevent the protein from aggregating in solution. Several filters will be run in parallel
to allow this unit operation to last approximately 30 minutes. All filters are disposable, but
preparation of new units is estimated to last approximately two hours.

48

EMD Millipore. Data Sheet: Millidisk® Cartridges and Millipak® Disposable Capsules [Internet]. Data Sheet: Millidisk® Cartridges and
Millipak® Disposable Capsules. Westwood, MA: EMD Millipore; 2015 [cited 2018 Apr 16]. Available from:
http://www.emdmillipore.com/US/en/product/Durapore-Membrane-Filters,MM_NF-C7631?CatalogCategoryID=#documentation
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12.C. Red Blood Cell Conversion Process Description
To enzymatically convert type-A and type-B RBCs, α-N-acetylgalactosaminidase and αgalactosidase, respectively, will be added to pooled transfusion units. The RBC units will be
acquired in variable sized transfusion bags from suppliers such as hospitals, regional blood banks,
or the Red Cross, with an average size of 300 mL per transfusion unit. The production goal is
200,000 enzymatically converted RBC transfusion units. Across the entire treatment process,
however, there is an assumed 35% loss of RBCs due to lysis and transfer losses. Thus, additional
transfusion units will be required to account for the losses to be able to satisfy production goals.
Therefore, the process system is designed to operate with an annual working volume associated
with approximately 308,000 transfusion units.
One important aspect of this process is that all steps, with the exception of the actual
conversion step, are done at 4ºC to preserve the biological activity of the RBCs. This decision was
made following the most stringent medical standards for transfusion medicine, which are found in
the United Kingdom. There, transfusion units that have been outside of a controlled temperature
of 4ºC for longer than four hours are to be eliminated. This is done in precaution of adversely
altering the biological activity and functionality of the RBCs.
12.C.1.

Hyperbaric Chamber for Blood Bag Emptying
The first step in the RBC conversion process is the collection of the RBC units for future

treatment steps. Each batch of enzymatically converted RBCs uses 1,973 units, all of which need
to be pooled in a storage vessel prior to downstream treatment. Currently available methods for
emptying RBC units, however, are only meant for single bags. These include gravity aided
emptying, blood pressure cuffs, pressure infusers, or manual emptying. Given the scale of this
process, however, there is a high risk of human error and a requirement for a significant workforce
to accomplish this goal.
The proposed solution to efficiently empty many RBC units in parallel uses the same
mechanism as commercially available pressure infusers, which empty blood bags using a pressure
differential. They operate by surrounding a single RBC unit and increasing the pressure by 300
mmHg, achieve flow rates of 257±54 mL/min. Using this technology as a base, a hyperbaric
chamber will be developed to generate a pressure differential of 1.0 atm and generate pressure89

driven flow from the blood bags to the storage vessel. RBC units will be stored on carts that will
carry a total of 1,973 units per batch and will be rolled into the hyperbaric chamber. This is
approximately the same regardless of which blood type that is being treated. The chamber will be
similar to commercially available units but will be designed to contain a storage cart, an exit for
the tube bundle to which the blood bags will be connected, and reach an operating pressure of 1.5
atm and temperature of 4ºC. Eight rounds of pressurization will need to be performed per batch.
Each run will take approximately ten minutes. The entire RBC unit emptying step will take roughly
2.5 hours. Three hours will be allotted to proper CIP/SIP procedures to eliminate any bloodborne
biological waste that may remain in the system. This time also includes disposal of the original
blood bags. The chamber will be designed and constructed by a third party vendor, with an initial
estimated cost of $100,000 after consultation with numerous industrial consultants. 8.00% of sales
will also be allocated to research expenses, which will place a heavy emphasis on the optimization
of this process to enhance the speed with which the blood units are emptied.
12.C.2.

Centrifugation
The contents of the RBC storage vessel will be transferred into a Culturefuge 100 disk

stack centrifuge via a Quattroflow quaternary diaphragm pump. The centrifuge will separate the
solid RBC components from the additive solution waste in which they were suspended. The spent
additive solution will be directed to a waste tank for safe disposal. The RBC pellet will be
transferred to a new single-use, disposable holding bag and resuspended to its original volume in
a 0.9% NaCl solution with 140 mL of CPDA-1 anticoagulant for every liter of blood treated. The
stored contents will be kept at 4ºC until the next major unit step. The centrifuge will operate with
a minimal flowrate of 100L/hr to minimize RBC lysis at a temperature of 4ºC. It is assumed that
5% of the RBCs that pass through this unit operation will lyse, leading to a product yield of 95%.
Centrifugation will last for two hours to handle the entire blood volume but at lower velocities to
prevent shearing. CIP/SIP procedures will require 2.8 hours.
12.C.3.

Conversion WAVE Bioreactors
The RBCs from the disposable holding bag will be transferred into six 100 L WAVE

bioreactors via a Quattroflow quaternary diaphragm pump.49 The initial temperature of the reactor
49

Holland Applied Technologies. Spec Sheet QF1200S-CV [Internet]. Spec Sheet QF1200S-CV. Chicago, IL: Holland Applied Technologies;
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will be set at 4ºC. As soon as the RBC contents have been emptied into the WAVE bioreactors,
the temperature will be programmed to increase in increments of 0.5ºC every 45 seconds until a
final temperature of 25ºC has been reached. This temperature increase interval is the common
standard employed in blood warmers to prevent RBCs from lysing due to drastic temperature
changes. When the temperature of the contents in the WAVE bioreactors has reached 25ºC, prewarmed α-N-acetylgalactosaminidase for type-A RBCs, or α-galactosidase for type-B cells, will
be added to the WAVE bioreactors. 60 mg of α-N-acetylgalactosaminidase will be required for
every 0.3 L of type-A RBC solution treated (the equivalent of one transfusion unit), while only 2
mg of α-galactosidase will be needed to treat the same volume of type-B RBC solution. The
conversion reaction will take place for one hour. The WAVE bioreactors will operate at 25 rpm at
an angle of 8º to minimize foaming. The pH will be maintained between 7.4 and 7.6. Once the
reaction has been completed, the temperature of the WAVE bioreactor and its content will be
decreased to 4ºC in decreasing intervals of 0.5ºC every 45 seconds. For scheduling purposes, an
additional 30 minutes to the hour reaction time is allotted for charging all red blood cells into the
devices.
12.C.4.

Centrifugation
One hour after the enzymatic conversion has elapsed and as soon as the treated RBCs have

been cooled to 4ºC, the contents of the WAVE bioreactor will be transferred to a Culturefuge 100
disk stack centrifuge via a Quattroflow quaternary diaphragm pump to separate the treated RBCs
from the enzyme in solution. The centrifuge will operate at 100 L/hr and at 4ºC. The spent
anticoagulant-saline solution with the conversion enzyme will be charged to a waste tank for safe
disposal. The remaining solid RBC mass, expected to be 60% by mass saline-anticoagulant
solution and 40% by mass solids, will be transferred into a single-use, disposable HyPerforma
Smartainer 3D Bioprocess Container (BPC) and resuspended to its original volume again with in
a 0.9% NaCl solution with 140 mL of CPDA-1 anticoagulant for every liter of blood treated.
Centrifugation will last for two hours to handle the entire blood volume but at lower velocities to
prevent shearing. CIP/SIP procedures will require 2.8 hours.
12.C.5.

Diafiltration
To remove any remaining enzyme from the resuspended RBCs, diafiltration will be used.

Pellicon 2 Durapore PVDF microfiltration filters will be used with a 500 kD nominal molecular
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weight limit (NMWL) and will be run in tangential flow in a Cogent Process-Scale Tangential
Flow Filtration System. This filter size will allow RBCs to remain in the retentate while remaining
enzyme is eliminated through the permeate. The resuspended RBCs from the previous
centrifugation step will be transferred into the diafiltration system by a Quattroflow quaternary
diaphragm pump. The enzyme-free retentate will flow back into the original storage system feed
tank, and the permeate containing the enzymes will be discarded. While this process occurs, new
saline-anticoagulant solution will be continuously added into the system feed tank to maintain the
osmolality of the RBC solution equivalent to what is found in biological systems to prevent
hemolysis and RBC aggregation. As the diafiltration process is performed, the spent salinecoagulant solution that may contain traces of enzyme will be removed and will be replenished by
enzyme-free solution. It is assumed that 5% of the RBCs will be lost due to lysis during the
diafiltration step, leading to a 95% recovery of the converted RBCs. The diafiltration step will
require approximately 2.5 hours to complete and will be run at 4ºC. Cleaning time will be set at
two hours.
12.C.6.

Cryogel-based Affinity Chromatography
To separate RBCs successfully converted to type-O from those that did not undergo a

successful conversion, cryogel-based affinity chromatography will be used. This technique is used
instead of using the typical affinity chromatography approach of having protein A-coated resins to
which antibody-selected cells would bind. Traditional affinity chromatography for cell separations
has been proven to be harsh on RBCs and induce significant lysis. To minimize lysis and costs
associated with having to work with even more RBC transfusion units, the cryogel-based technique
was chosen given its success in separating blood cells with less than five percent lysis (shown in
Figure 12.C.6.1).50 Supermacroporous cryogel monoliths can have a pore diameter of up to 100
μm, which enables its application for chromatography of cells of varying size (between 1 and
15 μm) without being mechanically entrapped in the column. Convectively transported cells
also do not experience large shear forces because of laminar flow of liquid in the interconnected
pores in the monolithic cryogel, which helps prevent mechanically-induced cell lysis.

50

Kumar A, Srivastava A. Cell separation using cryogel-based affinity chromatography. Nature Protocols. 2010Oct7;5(11):1737–47.
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Figure 12.C.6.1. Blood passage through a cryogel-based affinity chromatography done in
academic research to quantify shearing and lysis. The literature reports less than five percent
hemolysis of the total RBC population that was introduced into the column.
The cryogel matrix for the column will be produced from different hydrophilic gel forming polymers either by polymerization of the appropriate monomers, polyacrylamide and
poly(dimethylacrylamide). A cryogel affinity matrix will then be developed by covalent
coupling of protein A on the surface of the pore wall, which can capture immunoglobulin (IgG)
antibodies or IgG-labeled specific cells. Protein A, which consists of a 40- to 60-kD protein
present in the cell wall of Staphylococcus aureus, has affinity to the Fc portion of the IgG from
a wide range of species. Protein A will be covalently coupled to epoxy-activated cryogel
monolith by two-step derivatization using functionalization of epoxy-activated cryogel with
ethylenediamine and then crosslinking of protein A using glutaraldehyde.
The protein A-bound monolithic cryogel will be used as a generic affinity adsorbent for
specific IgG antibodies against A or B antigens and loaded into the chromatography column.
The system will operate at a pressure of 1 atm, a temperature of 4ºC, and a linear velocity of
2,000 cm/hr. RBCs that have undergone the enzymatic treatment will then be loaded into the
cryogel-protein A column. Cells that still have their A or B antigens will bind to the IgG
antibodies bound on the cryogel-protein A matrix. The RBCs that were successfully converted,
which have no antigens, will not bind to the antibodies and pass through the column. These
cells will be collected into a disposable bioprocess container, in which the RBCs will be
resuspended to a working volume of 100 L with anticoagulant-saline solution, until the next
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centrifugation step. The RBCs will be placed on a WAVE bioreactor rocker table for gentle
agitation to prevent them from settling and aggregating.
Mechanical stress will then be applied to the cryogel to release cells that were bound to
the column. This system has the advantage though that the mechanical stress only releases
bound cells and not the antibodies bound to the protein A, allowing it to be re-used several
times before the antibodies begin to lose their binding affinity. This circumvents another issue
with using traditional resin: the costly replenishment of antibodies used for binding.
This column will operate for 4.51 hours at a linear velocity of 300 cm/hr. Cleansing and
regeneration of the resin will take 1.62 hours.
12.C.7.

Microfiltration/Diafiltration
An additional ultrafiltration/diafiltration step will be implemented after the cryogel-based

affinity chromatography step to remove the column buffer components from the final treated RBC
product suspension. Pellicone 3 Durapore PVDF microfiltration filters will be used with a 500 kD
nominal molecular weight limit (NMWL) and will be run in tangential flow in a Cogent ProcessScale Tangential Flow Filtration System. This filter size will allow RBCs to remain in the retentate
while all buffer components are eliminated through the permeate. The resuspended RBCs from the
previous centrifugation step will be transferred into the diafiltration system by a Quattroflow
quaternary diaphragm pump. The buffer-free retentate will flow back into the original storage
system feed tank, and the permeate containing buffer will be discarded. While this process occurs,
new saline-anticoagulant solution will be replenished to maintain physiological osmolality for the
RBCs. It is assumed that 5% of the RBCs will be lost due to lysis during the diafiltration step,
leading to a 95% recovery of the converted RBCs. The diafiltration step will require approximately
2.5 hours to complete and will be run at 4ºC. CIP/SIP will take two hours.
12.C.8.

Centrifugation
After the converted RBCs have been separated from non-converted RBCs, the collected

contents from the previous microfiltration/diafiltration step will be transferred to a Culturefuge
100 disk stack centrifuge via a Quattroflow quaternary diaphragm pump. The centrifuge will
operate at 100 L/hr and at 4ºC. The spent anticoagulant-saline solution will be charged to a waste
tank for safe disposal. The remaining solid RBC mass will be resuspended in 191 L of Adsol-1
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additive solution and transferred into a disposable bioprocess container. Centrifugation will last
for two hours to handle the entire blood volume but at lower velocities to prevent shearing. CIP/SIP
procedures will require 2.8 hours.
12.C.9.

Holding Tank
Upon completion of centrifugation of the contents that were processed in the

microfiltration/diafiltration step, the remaining solid RBC mass will be transferred into a 500 L
HyPerforma Smartainer 3D bioprocess container and resuspended in 191 L of Adsol-1 additive
solution. It is assumed that the the RBC sludge from the centrifugation process will make up
approximately 50% of the resuspended solution that will be packaged. The final RBC suspension
will have a 50% hematocrit (volumetric ratio of RBCs to total volume). The stored RBC solution
will be kept at 4ºC and placed on a gentle rocker at 25 rpm to prevent RBCs from settling until
final packaging.
12.C.10.

Preparation of Converted Red Blood Cell Transfusion Units

The hyperbaric chamber will be operated in reverse to create pressure driven flow from the
storage vessel to dry, empty blood bags connected to the central tubing line. The final output of
the RBC treatment process will be prepared as a ready-to-administer product. The converted RBCs
stored in the Adsol-1 additive solution will be packaged into TERUFLEX dry blood bags with a
working volume of 300 mL at a final concentration of 50% hematocrit. Each batch of the treatment
process will produce 1,283 transfusion units of ECO RBCs. The bags will be filled after five
pressurization runs, taking a total 1.62 hours to complete packaging. A maximum of 2.5 hours,
however, has been scheduled to account for the time needed to fit empty blood bags to the central
lines through the RBC suspension will travel. All filled transfusions units of enzymatically
converted RBCs will be stored at 4ºC at all times and have a maximum shelf-life of 42 days. Note
that there will be some variability in the shelf-life depending on the age of the donor RBCs.
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13.

Energy Balances and Utilities Requirements

Energy balances not applicable.

For utilities requirements, please see section 18.
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14.

Equipment List and Unit Descriptions

14.1. Common Units

14.1.1. Peristaltic Pumps
Peristaltic pumps will be used to transfer all fluids that contain E. coli cell mass or enzyme
product. These pumps are best for transferring viscous fluids such as cell suspensions and can
show better performances for fluid transport than centrifugal pumps under these operating
conditions. The peristaltic pumps will also handle all buffer transfers in the chromatography
column steps. Thirty-nine Masterflex (Model 77924-80) 600-rpm pumps will be purchased from
Cole-Parmer for $3,635 per pump. This value includes spares as well. The construction material
for each pump is stainless steel AISI 304. Each pump comes equipped with graphical LCD that
show four operating modes: continuous run, timed dispense, copy dispense, volume dispense. The
flow rate through each pump can vary between 0.001 and 3,400 mL/min with L/S tubing. The
sterile L/S tubing will also be provided by Cole-Parmer. Each pump will operate at room
temperature and at a pressure drop of 3.5 atm. The power requirement is 253 W. The CIP and SIP
processes can operate at a maximum temperature of 90 and 130ºC degrees, respectively.
For large volumes of chromatography buffer, primarily in the steps in which ten column
volumes must be passed through the unit, Watson Marlow 840 Series Hygienic Peristaltic Pumps
will be used. One unit was purchased for each chromatography column required in the facility.
Each one of these pumps will operate at room temperature and at a pressure drop of 3.5 atm.
GORE® STA-PURE® PFL tubing will be used here to ensure that the tubing can handle all
organic solvents and materials found in the buffers. These pumps are mounted on a steel frame
with fixed speed motor gearboxes that require a power input of 0.2 W for operation.

14.1.2. Quattroflow Quaternary Diaphragm Pumps
For the treatment of RBCs, nine Quattroflow quaternary diaphragm pumps (Model
QF1200S-CV) will be purchased for $10,772 per pump from PSG Dover. The Quattroflow pumps
are made of stainless steel AISI 304. These pumps were chosen due to their ability to mechanically
imitate the pumping of the heart. Each stroke of the 4-piston diaphragm is generated by an
eccentric shaft connected to an electric motor. The method of operation of the Quattroflow pumps
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allows them to transfer shear-sensitive biological molecules and cells with minimal impact, which
helps prevent additional cell lysis that could affect the RBC production goal. The flow rate through
each pump can vary between 10 and 1,200 L/hr with a 5º eccentric shaft. Each Quattroflow pump
will be operated at 800 rpm to achieve a flow rate of 350 L/hr and at a pressure drop of 6 atm. For
sterile sealing, all valves and O-rings are sealed with ethylene propylene diene monomer rubber.
The power requirement for each Quattroflow pump is 370 W. The CIP and SIP processes can
operate at a maximum temperature of 90 and 130ºC degrees, respectively.

14.1.3. Media Sterilization Filters
0.2 µm pore-sized Millipore Express® SHF filters will be used to purify bacterial culture
media by removing any impurities and toxins before introduction in the stainless steel fermenters.
Each filter has a nominal length of 30 inches, a diameter of 6.9 cm, and a filtration area of 1.62
m2. The devices uses polyethersulfone (PES) for the filtration chemistry. The device material is
polypropylene/polysulfone. The seal material is code 7 silicone. All filtration cartridges were
sterilized by 25 forward or 22 forward and 3 reverse SIP cycles of 30 min at 135 °C. Sterilization
can also be done using 25 autoclave cycles of 60 min at 126 °C. The maximum forward inlet
pressure is 7 bar and the maximum reverse inlet pressure is 2.07 bar, both at at 25ºC. The maximum
forward pressure differential is 6.9 bar and the maximum reverse pressure differential is 2.1, both
at 25ºC. Each filter costs $650/unit. The filters require a type of housing for security, which will
be contracted to Millipore for a one-time cost of $2,000. The filters are disposable and replaced
after every batch. Since they are disposable, no CIP or SIP will be required for the filter. SIP,
however, is required for the housing unit.

14.1.4. Digital Control Units
Digital control units will be purchased to conduct proportional integral derivative (PID)
feedback control. The PID controllers, purchased from Omega, will be used to control the agitation
speed and maintain temperature at 37ºC, pH between 7.0 and 7.2, constant percent oxygen at 40%,
and a constant liquid level to avoid excessive foaming for all bioreactor systems in the E. coli
BL21(DE3) upstream culture process. A total of 30 units will be purchased, including back-ups.
Each unit will be purchased at a price of $300/unit.
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14.2. Upstream Process for E. coli Growth

14.2.1. Inoculum Growth Bioreactor
The ambr 250 modular bioreactor system will be purchased from Sartorius at $45,799 for
the control tower and system. Each individual vessel will be purchased for $155. The bioreactor
tower and control system is made of stainless steel, while the bioreactor vessel is sterile plastic.
Each batch will begin with a new, sterile ambr 250® bioreactor with a freshly thawed vial of E.
coli BL221(DE3) cells. All bioreactor vessels are single-use and disposable. Agitation will occur
at 300 rpm using a dual 20 mm Rushton impeller. The ratio of the impeller diameter to the
bioreactor inner diameter is 0.5. The geometric ratio of height to inner diameter of the reactor
vessel is 1.8. The bioreactor vessel has a maximum working volume of 0.250 L; the chosen
working volume for this unit operation is 0.110 L. Temperature control will be done using
electrical heating. The vessel design incorporates disposables sensors to simplify system
preparation. The bioreactor package includes DO sensors to measure pO2, disposable pH
electrodes, integrated gas and liquid inlet filters, and an integrated condenser for output to exhaust
gas analysis. The bioreactor will operate at a temperature of 37ºC, a pressure of 1.0 atm, a pH of
7.0-7.2, and 40% pO2. Each vessel will be in operation, preferably overnight, for 17.68 hours,
regardless of the enzyme product. It is assumed that 5% of the bacterial population will die during
culture, due to shear-induced lysis or health complications, leading to a percent yield of 95%.

14.2.2. Growth Bioreactor
The cell suspension from the inoculum growth reactor will be transferred into a larger
bioreactor to continue cell growth in a larger culture volume to prepare for inoculation of the final
production fermenters. The growth bioreactor system will consist of a stainless steel AISI 316L
BIOSTAT® B control tower and an autoclavable borosilicate glass vessel. It also allows for four
peristaltic pumps integrated into the control unit, two external peristaltic pumps, and two balances
connections. The complete bioreactor system will be purchased for $100,000. The bioreactor
vessel has a maximum working volume capacity of 10 L; the chosen working volume for this
process is 5.44 L. The dimensions of the entire system are 330mm x 860mm x 420 mm. Agitation
will be performed at 800 rpm with a 6-blade disk Rushton turbine impeller to allow for an
volumetric oxygen transfer coefficient greater than 40 hr-1. Temperature control will be done using
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a single-wall heated jacket. The bioreactor will operate at a temperature of 37ºC, a pressure of 1.0
atm, a pH of 7.0-7.2, and 40% pO2. Each vessel will be in operation for 24.03 hours for α-Nacetylgalactosaminidase or for 23.69 hours for α-galactosidase. Standard CIP procedures will be
used for sterilization of control tower when necessary. The borosilicate glass vessel will be
autoclaved at 121ºC for one hour. It is assumed that 5% of the bacterial population will die during
culture, due to shear-induced lysis or health complications, leading to a percent yield of 95.5%.

14.2.3.

Production Bioreactors

The cell suspension from the growth bioreactor will be split between two stainless steel
(AISI 304) fermenters. The BIOSTAT® D-DCU, which includes the control tower and the two
fermenters, will be purchased from Sartorius for a total of $300,000. The bioreactor vessel has a
maximum working volume capacity of 200 L; the chosen working volume for this process is 198
L for each reactor. The dimensions of the entire system are 3.1m x 3.05m x 1.8m. Agitation will
be performed at 800 rpm with a 6-blade disk Rushton turbine impeller to allow for an volumetric
oxygen transfer coefficient of 308 hr-1. The ratio of the impeller diameter to the bioreactor inner
diameter is 0.5. The geometric ratio of height to inner diameter of the reactor vessel is 3.0. The
high performance servo drive motor assembly combines low shear, gentle agitation for cell
cultures and high speed mixing for microbial high cell density cultivation, ensuring high oxygen
transfer rates. Temperature control will be done using an integrated closed loop system with a
recirculation pump and heat exchanger. The bioreactors will operate at a temperature of 37ºC (for
growth) and 25ºC (for protein expression), a pressure of 1.0 atm, a pH of 7.0, and 40% pO2. Each
vessel will be in operation for 25.89 hours for cell growth and then an additional five hours for
enzyme protein expression. Standard CIP and SIP procedures will be used for sterilization. It is
assumed that 5% of the bacterial population will die during culture, due to shear-induced lysis or
cell viability complications, leading to a percent yield of 95.5%.

14.2.4.

Cell Culture Storage Vessel

The cell suspension from the production fermenters will be stored in a Thermo Fisher 500L
HyPerform Single-Use Mixer, which has a purchase cost of $165,000. Each disposable bag is
appraised at $300. The mixer is made of stainless steel AISI 304, while the single-use disposable
biocontainers will be made of CX5-14 multi-layer plastic. The dimensions of the unit are 122cm
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x 129cm x 198cm. The unit will be operated at a pressure of 0.03 atm and a temperature of 5ºC.
The liquid chill-down time for the mixer is 3.7 hours.

14.3. Downstream Purification Section

14.3.1. Disk stack centrifuge
The purpose of the centrifuge is to separate the solid biomass (E. coli cells with desired
enzyme product in their cytoplasm) from the spent liquid media. All spent culture media will be
directed to a waste holding tank while the solid E. coli cell pellet will be moved downstream to
harvest the α-galactosidase or α-N-acetylgalactosaminidase enzyme product. A Culturefuge 100
disk stack centrifuge will be purchased from Alfa Laval for $46,500 per unit. The solid biomass
product will be in the form of a cell sludge that is 40% by mass solids and 60% by mass water.
The centrifuge unit will consist of a molybdenum-bearing austenitic stainless steel bowl and a cast
iron grey bottom frame. The centrifuge has a maximum operating capacity of 2,000 L/hr, 12,220
g for G-force, and 9,550 rpm bowl speed. The volumetric flow rate that the Culturefuge 100 will
operate at is 100 L/hr. The unit will operate at a temperature of 25ºC and a pressure of 1.0 atm.
The process time, including CIP and SIP procedures, will take approximately 6.8 hours. It is
assumed that appromximately five percent of product enzyme will be lost in this unit operation.

14.3.2. High Pressure Homogenization
The cell sludge from the centrifugation step will be sent through a M175 Aseptic
Microfluidizer, purchased from Microfluidics, to disrupt the cell membrane of the E. coli bacterial
cells and release the internalized enzyme product. The device can operate at a maximum pressure
of 30,000 psi with a volumetric flow rate of 7.56 L/min. The hydraulic capacity of the fluidizer is
13 L/hr. The hold-up volume is less than one liter. The microfluidizer comes equipped with a heat
exchanger for product temperature control, using a pharma grade, double tubesheet style. For
cooling purposes, a chilled water loop will be used. The unit also comes equipped with a feed
pump for air and requires a flow rate of 0.65 m3/min at 6.2 atm. For product pathing cooling and
dry down, a sterile compressed air stream of 0.085 m3/min at 1 atm is required. The overall power
requirement for this device is 18.6 kW. The cell membrane disruption process via
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microfluidization will require approximately four hours. CIP and SIP procedures will last two
hours. Steam-in-place requirements are 22.6 kg/hr at 2.4 atm.
The microfluidizer will pump the sludge through a pressure differential of 20,000 psi, and
the cells will pass through fixed-geometry microchannels to induce high linear velocities. The high
velocities at which the cells travel generate impact and shear-inducing conditions to lyse the cells.
The shearing conditions are not sufficient to denature proteins, providing an effective method to
collect cytoplasmic protein product. It is assumed that product recovery is approximately 95%.

14.3.3. Microfluidization Product Resuspension Container
After centrifugation and homogenization, the resulting cell sludge with product will be
resuspended in equilibration buffer to a volume equal to the volume of culture media in which the
cells were originally suspended. This amount is added to ensure that the pH of the resulting
suspension is that the same as that of the equilibration buffer, a pH of 7.4. The cell sludge will be
resuspended in a HyPerforma Single-Use Mixer lined with a 500 L 3D bioprocess container, both
purchased from Thermo Fisher Scientific. The mixer unit is made of stainless steel AISI 304. The
disposable containers are sterile single-use CX5-14 multi-layer plastic. A volume equal to that of
the cell sludge will be first added to the mixer, after which the cell cludge will be pumped into the
device via peristaltic pump. Equilibration buffer will then be added until the pH and volumetric
conditions are satisfied. The HyPerforma Single-Use Mixer will be purchased at $150,000 per unit,
while each 3D bioprocess container will be purchased for $300/ per bag. A PID feedback controller
will be incorporated into this step to maintain the agitation speed of the mixer at 300 rpm, the
temperature at 25ºC, and the pressure at 0.003 atm. The process time, including CIP and SIP
procedures, will take approximately 3.6 hours. It is assumed that 5% of product enzyme will be
lost in this unit operation.

14.3.4. Cobalt Affinity Chromatography Column
A cobalt affinity chromatography system will be used as a first purification pass to separate
the enzyme product from cell debris and intracellular materials. A Resolute 280 chromatography
column, from Pall Corporation, will be purchased at $110,000 per unit. The column is comprised
of electropolished stainless steel and has a diameter of 280 mm. It will be packed with HisPur
Cobalt Resin, which contains a cobalt-chelate coordination core to bind His6-tagged proteins, and
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is applicable for treatment of both enzymes. The resin has a void fraction of 0.3. Each column is
designed to separate either 205 grams of α-N-acetylgalactosaminidase or 189 grams of αgalactosidase. 10.25 L of resin will be required to purify α-N-acetylgalactosaminidase, and 9.45 L
will be needed for purification of α-galactosidase. The required height for the column is 237 mm.
The column volume required to satisfy both resin volume requirements is 14.6 L. The resin allows
for an operating linear velocity of 150 cm/hr and has a binding capacity of 20 grams of proteins
per liter of resin. The resin can be used 25 times before losing efficiency and requiring replacement.
The column will be located in a cold room section of the work space so that operating conditions
are 4ºC and 1.0 atm. The entire column operating time, including regeneration and sterilization
procedures, is 7.46 hours. A product recovery of 95% is assumed.

14.3.5. Cobalt Affinity Chromatography Collection Container
All column flow-through will be directed to a waste tank for heat inactivation to eliminate
any remaining active bacterial cells. The eluted product from the column will be collected in a
separate single-use 200 L 3D Productainer bioprocess bag purchased from Thermo Fisher
Scientific at $250/bag. These disposable containers are sterile single-use CX5-14 multi-layer
plastic. The working volume of each container will be 147 L for α-galactosidase elute and 94.5 L
for α-N-acetylgalactosaminidase elute. The containers will be stored at 4ºC if the following
chromatography column is not immediately available for use.

14.3.6. Hydrophobic Interaction Chromatography Column
A hydrophobic interaction chromatography step will be used to separate endotoxins from
the α-galactosidase and α-N-acetylgalactosaminidase products to comply with FDA standards. A
Resolute 800 chromatography column, from Pall Corporation, will be purchased for $250,000.
The column is comprised of electropolished stainless steel and has a diameter of 800 mm. It will
be packed with POROS Benzyl HIC Resin, which contains beads with aromatic hydrophobic
benzyl ligand that strongly bind the highly hydrophobic endotoxins. The resin has a void fraction
of 0.4. Each batch will separate either 11.5 grams of endotoxin from the α-Nacetylgalactosaminidase culture or 10.6 grams from the α-galactosidase culture. 57.5 L of resin
will be required to purify α-N-acetylgalactosaminidase, and 52.9 L will be needed for purification
of α-galactosidase. The required height for the column is 191 mm. The column volume required
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to satisfy both resin volume requirements is 95.9 L. The resin allows for an operating linear
velocity of 150 cm/hr and has a binding capacity of 2×106 endotoxin units/mL resin. The resin can
be used ten times before losing efficiency and requiring replacement. The product purity,
according to the manufacturer’s protocol, is ≥ 90%. The column will be located in a cold room
section of the work space so that operating conditions are 4ºC and 1.0 atm. The entire column
operating time, including regeneration and sterilization procedures, is 4.68 hours. A product
recovery of 95% and an endotoxin removal of 90% are assumed.

14.3.7. Hydrophobic Interaction Chromatography Collection Container
All column flow-through will be directed to a waste tank for heat inactivation to eliminate
any possible remaining active bacterial cells. The eluted product will be collected in a separate
single-use 1500 L 3D Labtainer bioprocess container purchased from Thermo Fisher Scientific at
$500/bag. These disposable containers are sterile single-use CX5-14 multi-layer plastic. The
container will be stored at 4ºC if the following chromatography step is not immediately available
for use.

14.3.8. Endotoxin Affinity Chromatography Column
An endotoxin affinity chromatography system will be used to separate endotoxins from the
α-galactosidase

and

α-N-acetylgalactosaminidase

enzyme

products.

A

Resolute

280

chromatography column, from Pall Corporation, will be purchased at $110,000 per unit. It is
comprised of electropolished stainless steel and has a diameter of 280 mm. This column will be
packed with Pierce High-Capacity Endotoxin Removal Resin, which contains poly(ε-lysine)
coated beads that bind endotoxins. The resin has a void fraction of 0.4. Each batch will separate
either 1.15 grams of endotoxin from the α-N-acetylgalactosaminidase culture or 1.06 grams from
the α-galactosidase culture. 5.75 L of resin will be required to purify α-galactosidase, and 5.29 L
will be needed for purification of α-N-acetylgalactosaminidase. The required height for the column
is 156 mm. The column volume required to satisfy both resin volume requirements is 9.59 L. The
resin allows for an operating linear velocity of 150 cm/hr and has a binding capacity of 2×10 6
endotoxin units/mL resin. The resin can be used five times before losing efficiency and requiring
replacement. The product purity, according to the manufacturer’s protocol, is ≥ 90%. The column
will be located in a cold room section of the work space so that operating conditions are 4ºC and
106

1.0 atm. The entire column operating time, including regeneration and sterilization procedures, is
3.01 hours. A product recovery of 95% and an endotoxin removal of 99% are assumed.

14.3.9. Endotoxin Affinity Chromatography Collection Container
All additional column flow-through will be directed to a waste tank for heat inactivation to
eliminate any possible remaining active bacterial cells. The eluted product from the αgalactosidase separation will be collected and stored in a single-use 50 L 2D Productainer
bioprocess bag purchased from Thermo Fisher Scientific at $37.54/bag. These disposable
containers are sterile single-use CX5-14 multi-layer plastic. The containers will be stored at 4ºC if
the following chromatography column is not immediately available for use.

14.3.10. Ultrafiltration/Diafiltration Unit
An ultrafiltration/diafiltration process will be implemented using a Cogent M1 Process
Scale Tangential Flow Filtration System. It is manufactured by EMD Millipore and has a purchase
cost of $47,999, The system will be equipped with Pellicon 3 Ultracel filter cassettes made of
regenerated cellulose and polyethylene. The filtration area of the casettes is 1.14m2 and will handle
a flow rate of 4 L/min. The system can operate with a maximum pressure drop of 2 atm. The
stainless steel cassette holder will be purchased at $995. A pack of 100 Ultracell membranes will
also be purchased for $479.08. The system will be operated in a cold room at 4ºC and 1 atm.

14.3.11. Bulk Microfiltration Unit
A bulk microfiltration pack will be purchased from EMD Millipore for $503 for a pack of
three filters. The filters will be hydrophobic Durapore PVDF membranes with a 0.22 µm pore
diameter size. Given that there is two-fold difference in hydrophobicity between endotoxins and
the ECO-zymes, the use of bulk microfiltration allows endotoxins to be retained in the filter while
enzyme product is filtered. The enzyme product will go thorugh two passes of bulk microfiltration
to guarantee compliance of FDA standards regarding endotoxin concentration. It is assumed that
these filters remove 99% of endotoxins, as stated in the manufacturer’s protocol. The diameter and
thickness of the filter are 142 mm and 125 µm, respectively. The PVDF filters and their respective
holders are disposable, and one of each will be used per batch. The filters have a 100 cm2 surface
area and will run at a flowrate of 16.5 L/min. The porosity of the filters is 75%. Protein binding at
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the membrane is 150 µg/cm². Recovery of ECO-zyme product in this step is 95% for each pass.
All microfiltration units are single-use and disposable once the batch process has completed.

14.3.12. Final Product Holding Container
The final concentrated product from the bulk microfiltration step will be concentrated to 1
mg enzyme/mL and stored in a five 50 L 2D Labtainer bioprocess bags purchased from Thermo
Scientific for $37.54/bag. The bioprocess container is a made of sterile single-use CX5-14 multilayer plastic. Containers will be stored at 4ºC in a cold room if needed in the immediate future for
RBC conversion treatment. Otherwise, bags will kept at -20ºC for long-term storage.

14.4. RBC Conversion Treatment Process

14.4.1. Hyperbaric Chamber
A hyperbaric chamber will be used to empty 264 blood bags for every pressuration run into
a storage container. The chamber will be designed to sustain preferential differentials up to 1.5
atm. A total of 1,973 blood bags are expected to be processed, on average, for every batch. Each
batch treatment will take approximately 2.5 hours. The process will be carried out in a cold room
at 4ºC.

14.4.2. Hyperbaric Chamber Collection Container
The RBCs collected from donor transfusion units will be emptied by the hyperbaric
chamber into three 200 L 3D Productainer bioprocess bags, purchased from Thermo Fisher
Scientific at $250/bag, all of which are sterile single-use CX5-14 multi-layer plastic containers.
The RBCs will be kept at 4ºC until proceeding to the centrifugation step. They will also be kept
on a rocker to prevent the cells from settling and to maximize the RBC content drained from the
containers.

14.4.3. Disk Stack Centrifuge
Another Culturefuge 100 disk stack centrifuge, purchased from Alfa Laval for $46,500 per
unit, will be used to separate RBCs from their spent additive preservation solution. Upon
centrifugation, the solid RBCs will settle to the bottom of the centrifuge bowl. All spent
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preservation fluid will be directed to a biowaste holding tank for heat inactivation while the RBC
pellet will be directed to a WAVE bioreactor. The centrifuge unit will consist of a molybdenumbearing austenitic stainless steel bowl and a cast iron grey bottom frame. The centrifuge has a
maximum operating capacity of 2,000 L/hr, 12,220 g for G-force, and 9,550 rpm bowl speed. The
volumetric flow rate that the Culturefuge 100 will operate at is 100 L/hr. The unit will operate at
a temperature of 4ºC and a pressure of 1.0 atm. The process time, including CIP and SIP
procedures, will take approximately 4.8 hours. It is assumed that 5% of product enzyme will be
lost in this unit operation.

14.4.4. WAVE Bioreactor
The RBCs to be converted will be transferred from the disposable holding bag into five
WAVE bioreactors. The chosen model is the BIOSTAT® RM bioreactor system, which includes
the control tower and the disposable bag rocker. Each system will cost $20,000. Additionally, the
disposable bag necessary is the FLEXSAFE® RM. The control tower is made of stainless steel
AISI 304; the rocker, stainless steel ABS; and the disposable bags, polyethylene multilayer plastic.
The area dimensions of each individual system is 740 mm x 720mm. The temperature control
consists of an integrated open thermostat system with a ciruclation pump and an automatic cooling
water valve. Temperature can be increased and decreased in intervals of 0.5ºC every 45 seconds.
The power requirements are 1.20 kW per unit. Each WAVE bioreactor will operate at a
temperature of 25ºC, a pressure of 1.0 atm, a pH of 7.2 to 7.4, and 40% pO 2. Each bag has a total
volume of 200 L but only has a working capacity of 100 L, which is what approximately used in
each. The rocking base will perform 15 rocks/min at an angle of 10º.

14.4.5. Disk Stack Centrifuge
Another Culturefuge 100 disk stack centrifuge, purchased from Alfa Laval for $46,500 per
unit, will be used to separate the converted RBCs from the enzyme in solution. Upon
centrifugation, the solid RBCs will settle to the bottom of the centrifuge bowl while the αgalactosidase or α-N-acetylgalactosaminidase enzyme will remain in solution. All spent fluid with
enzyme will be directed to a waste holding tank while the RBC pellet will be collected into a
bioprocess container until sent transferred into the diafiltration unit. The centrifuge unit will
consist of a molybdenum-bearing austenitic stainless steel bowl and a cast iron grey bottom frame.
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The centrifuge has a maximum operating capacity of 2,000 L/hr, 12,220 g for G-force, and 9,550
rpm bowl speed. The volumetric flow rate that the Culturefuge 100 will operate at is 100 L/hr. The
unit will operate at a temperature of 4ºC and a pressure of 1.0 atm. The process time, including
CIP and SIP procedures, will take approximately 4.8 hours. It is assumed that 5% of product
enzyme will be lost in this unit operation.

14.4.6. Diafiltration Unit
A diafiltration unit operation will be implemented to remove ECO-zyme from the RBC
suspension. The unit operation will be done using a Cogent Process Scale Tangential Flow
Filtration System from EMD Millipore, with a purchase cost of $47,999. The system will
implement Pellicone 3 Durapore PVDF Ultracel microfiltration filters will be used with a 500 kD
NMWL, which is large enough for all enzymes to pass through but retain all RBCs. Each pack of
filters has a purchase cost of $479.08, while the sterile stainless steel cassette holder will cost $995.
The filters will be made of regenerated cellulose with a polyethylene frame. The filtration rea of
each filter is 1.14 m2 and will be operated at 4 L/min. It is assumed that 95% the treated RBCs will
be recovered in this step, with a 5% loss associated with filtration through the cassette membrane
or lysis. This entire process will be done at 4ºC in a cold room and at a pressure of 1 atm.

14.4.7. Cryogel-based Affinity Chromatography Column
A cryogel-based affinity chromatography column will be used to separate non-converted
RBCs from the successfully converted universal RBCs. A Resolute 280 chromatography column,
from Pall Corporation, will be purchased for $200,000. The column is comprised of
electropolished stainless steel and has a diameter of 280 mm. It will be packed with a cryogel
polymer made of polyacrylamide and poly(dimethylacrylamide) that is coated in protein A-IgG.
The protein A binds IgG antibodies that will target blood group antigens on RBCs. The cryogel
will be pre-loaded with 72.1 mg of blood group-specific IgG antibody per batch prior to running
RBCs through the column. Each column run will process 1,237 L of processed blood. The resin
has a void fraction of 0.4. For running the column, 14.42 L of cryogel will be needed for
purification processes. The cryogel will be used five times before replenishing and antibody
replacement. The required height for the column is 292 mm. The column volume required to satisfy
the cryogel volume requirement is 18.0 L. The cryogel allows for an maximum linear velocity of
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1,200 cm/hr but will operated at 300 cm/hr. The product purity is reported to be ≥ 95%. The column
will be located in a cold room section of the work space so that operating conditions are 4ºC and
1.0 atm. The entire column operating time, including regeneration and sterilization procedures, is
4.51 hours. A product recovery of 95% is assumed.

14.4.8. Disk Stack Centrifugation
A Culturefuge 100 disk stack centrifuge, purchased from Alfa Laval for $46,500 per unit,
will separate the converted RBCs from any remaining buffer solution. It is assumed that the output
of the centrifuge will be 60% by mass water and 40% by mass RBCs. All spent buffer and solution
will be directed to a waste holding tank while the RBCs will be collected into a final product
holding container. The centrifuge unit will consist of a molybdenum-bearing austenitic stainless
steel bowl and a cast iron grey bottom frame. The centrifuge has a maximum operating capacity
of 2,000 L/hr, 12,220 g for G-force, and 9,550 rpm bowl speed. The volumetric flow rate that the
Culturefuge 100 will operate at is 100 L/hr. The unit will operate at a temperature of 4ºC and a
pressure of 1.0 atm. The process time, including CIP and SIP procedures, will take approximately
4.8 hours. It is assumed that 5% of product enzyme will be lost in this unit operation.

14.4.9. Final Product Holding Container
After centrifugation, the converted RBCs will be transferred into a 500 L HyPerforma
Smartainer 3D bioprocess container made of sterile single-use CX5-14 multi-layer plastic. The
RBC mass will be resuspended to a volume of 191 L of Adsol-1 additive preservation solution.
The RBCs will be kept at 4ºC from this point forward to preserve their biological activity. The
container will be placed on a WAVE rocker set at an agitation speed of 25 rpm to prevent RBCs
from settling until final packaging.
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Section 15:
Specification Sheets
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15. Specification Sheets
The following pages contain the specification sheets for all unit operations. Description
and function, vendor, operation, characteristics, operating conditions, and purchase cost are all
detailed.

113

15. 1. Inoculum Bioreactor (P-1, PFD#1)
Description and Function

Inoculum for the growth bioreactor will be prepared and grown
in a 0.250 L single-use, stirred tank bioreactor, with a working
volume of 110 mL. The purchased unit will also include a control
tower to monitor aeration, pH, temperature, and rocking speed.
The vessels are made of single layer injection molded plastic and
are 15 kGy β-irradiated for sterilization.

Vendor

Sartorius Stedim Biotechnology Group

Operation

Batch

Materials Handled
Cells
Nutrients
Water
Kanamycin
Chloramphenicol
Endotoxin
Waste

Input (kg/batch)
5.60×10-7
9.74×10-5
0.110
5.50×10-6
3.40×10-6
0
0

Output (kg/batch)
4.87×10-5
0
0.105
5.50×10-6
3.40×10-6
3.20×10-3
3.39×10-4

Heating method:
Percent yield:
Sterilization:
Sparger:
Agitation speed:
Impeller configuration:
Ratio d:Di
Ratio H:Di
Volume:

ambr® 250 modular system
Sterile plastic vessel, stainless steel
control tower
Electric heating
95%
Disposable stirred tank
Microsparger
300 rpm
Dual 20 mm Rushton impeller
0.5
1.8
0.2 L

Operating Conditions

Temperature:
Pressure:
pH:
pO2:
Growth time:

37ºC
1.0 atm
7.0-7.2
40%
17.86 hours

Purchase Cost

Control tower:
Bioreactor vessel:

$45,799
$155/vessel

Characteristics

Model:
Material construction:
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15.2. Growth Bioreactor (P-2, PFD#1)
Description and Function

The growth bioreactor will consist of an autoclavable glass vessel
operated by a control tower. It will be used to further increase the
cell concentration before splitting the culture between two stainless
steel fermenters. The total reactor volume is 10L and will operate
with a working volume of 5.44 L. The PID controller, ez-Control
from Applikon, will be purchased separately to monitor and control
the pH, temperature, pO2, foam level, glucose and agitation rate.

Vendor

Sartorius Stedim Biotechnology Group

Operation

Batch

Materials Handled
Cells
Nutrients
Water
Kanamycin
Chloramphenicol
Endotoxin
Waste

Characteristics

Model:
Material Construction:
Dimensions:
Heating method:
Percent Yield:
Sterilization:
Agitation speed:
Impeller configuration:
Volume:

Input (kg/batch)

Output (kg/batch)

4.62×10-5
3.76×10-2
5.44
2.72×10-4
1.85×10-4
3.20×10-3
0

1.88×10-2
0
5.21
2.72×10-4
1.85×10-4
0.158
0.584

BIOSTAT® B
Borosilicate glass vessel, stainless
steel AISI 316L control tower
330mm x 860mm x 420mm
Single-wall heated jacket
95%
CIP/SIP
800 rpm
Dual 20 mm Rushton impeller
10 L

Operating Conditions

Temperature:
Pressure:
pH:
pO2:
Growth Time:

37ºC
1.0 atm
7.0
40%
24.03 hr for α-galactosidase, 23.69
hr for α-N-acetylgalactosaminidase

Purchase Cost

Bioreactor system:
Controller:

$100,000
$500
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15.3. Production Bioreactors (P-3, P-4; PFD#1)
Description and Function

The production bioreactor system will consist of two stainless steel
bioreactors with a volume of 323 L and a maximum working volume
of 200 L. Each reactor will handle a working volume of 198 L and
will be used to grow up cells to a desired cell concentration and for
induce protein production using induction by IPTG. The controller,
ez-Control from Applikon, will be purchased separately to monitor
and control the pH, temperature, pO2, foam level, glucose and
agitation rate.

Vendor

Sartorius Stedim Biotechnology Group

Operation

Batch

Materials Handled
(overall)

Characteristics
(for each reactor)

Operating Conditions

Cells
Nutrients
Water
IPTG
GalNAc-ase
OR α-galactosidase
Endotoxin
Waste

Input (kg/batch)
1.78×10-2
23.1
396
9.44×10-2
0
0
0.158
0

Output (kg/batch)
11.5
0
379
9.44×10-2
0.216
0.199
11.5×10-3
358

BIOSTAT® D-DCU
Stainless steel AISI 304
3.1m x 3.05m x 1.8m
Closed
loop
system
with
recirculation pump and heat
exchanger for heating and cooling
Percent Yield:
95%
Sterilization:
CIP/SIP
Agitation speed:
800 rpm
Impeller configuration:
6-blade disk Rushton turbine
Ratio d:Di
0.5
Ratio H:Di
3
Maximum working volume: 200 L
Total volume:
323 L
Model:
Material Construction:
Dimensions:
Heating method:

Temperature:
Pressure:
pH:
pO2:

37ºC (growth), 25ºC (production)
1.0 atm
7.0
40%
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Growth Time:
Protein Production Time:
Purchase Cost

Bioreactor:
Controller:

25.89 hours
5 hours
$150,000/reactor
$500
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15.4. Cell Culture Storage Tank (P-6, PFD#1)
Description and Function

Upon completion of fermentation and protein production, the cell
suspension with internalized enzyme product from the production
bioreactors will be quickly transferred into a 500 L HyPerforma
Single-Use Mixer. This will enable CIP and SIP procedures to
begin promptly. Additionally, the suspension will be gently
agitated to prevent cells from settling.

Vendor

Thermo Fisher Scientific

Operation

Batch

Characteristics

Material construction:

Liquid chill-down time:
Agitation speed:

Stainless steel AISI 304, sterile
single-use CX5-14 multi-layer
plastic
122cm x 129cm x 198 cm
500 L
Disposable single-use bags,
CIP/SIP for mixer when needed
3.7 hours
300 rpm

Operating Conditions

Temperature:
Pressure:

5ºC
0.03 atm

Purchase Cost

$100,000/mixer
$300/bag

Dimensions:
Volume:
Sterilization:
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15.5. Disk Stack Centrifuge (P-1, PFD#2)
Description and Function

The Culturefuge 100 disk stack centrifuge will be used to separate the
cells (solid biomass) from the spent media (liquid). The resulting cell
sludge will be 60% by mass water and 40% by mass solid. Five
percent of the cell suspension from the production fermenters are lost
due to transfer losses prior to centrifugation.

Vendor

Alfa Laval

Operation

Batch

Materials Handled
Cells
Media
IPTG
Kanamycin
Chloramphenicol
Endotoxin
Waste
GalNAc-ase
OR α-galactosidase
Characteristics

Model:
Centrifuge type:
Material construction:

Input (kg/batch)
11.5
379
9.44×10-2
2.72×10-4
1.85×10-4
11.5×10-3
0
0.205
0.189

Output (kg/batch)
10.9
12.7
8.97×10-2
2.59×10-4
1.76×10-4
10.9×10-3
368
0.195
0.180

Finish:
Hydraulic capacity:
G-force:
Bowl speed:
Percent Yield:
Sterilization:

Culturefuge 100
Disk stack
Mo-bearing austenitic steel
for body and cover; cast grey
iron bottom frame
Electro-polished
2,000 L/hr capacity
12,220 g maximum
9,550 rpm maximum
95%
CIP/SIP

Operating Conditions

Temperature:
Pressure:
Flowrate:

25ºC
1.0 atm
200 L/hr

Purchase Cost

$46,500/unit
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15.6. High Pressure Homogenizer/Microfluidizer (P-3, PFD#2)
Description and Function

The high-pressure M-7125 Microfluidizer is used to homogenize and
lyse cells after centrifugation to release expressed α-galactosidase or
α-N-acetylgalactosaminidase, along with cell debris and other excess
proteins. The microfluidizer generates a pressure differential of
20,000 psi, causing high-velocity pressure-driven flow of cells across
fixed-geometry channels. The geometry of the channels combined
with the high velocity generate high impact and shearing conditions
that disrupt the cell membrane and cause the E. coli cells to lyse.

Vendor

Microfluidics

Operation

Batch

Materials Handled
Cells
B-PER
Endotoxin
Water
IPTG
Kanamycin
Chloramphenicol
GalNAc-ase
OR α-galactosidase
Waste

Input (kg/batch)
10.9
326
10.9×10-3
12.7
8.97×10-2
2.78×10-4
1.85×10-4
0.195
0.180
0

Output (kg/batch)
10.4
0
10.4×10-3
12.1
8.52×10-2
2.64×10-4
1.76×10-4
0.185
0.171
328

Characteristics

Model:
Material construction:
Dimensions:
Hydraulic capacity:
Maximum pressure:
Percent yield:
Hold-up volume:
Power requirement:

M-7125 Series Microfluidizer
Stainless steel
272cm x 161cm x 211cm
13 L/hr capacity
2000 atm
95%
<1 L
18.6 kW

Operating Conditions

Temperature:
Pressure:
Flow rate:

25ºC
1,316 atm
13 L/hr

Purchase Cost

$38,740/unit
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15.7. Cell Sludge Resuspension Container (P-4, PFD#2)
Description and Function

A 3D bioprocess container will be used to collect the lysed
biomass and harvested enzyme product after the microfluidic
cell membrane disruption. The biomass and product will be
resuspended in equilibration buffer to prepare for binding in the
cobalt affinity chromatography column. A control unit will be
used to monitor the pH until the solution reaches a desired pH
of 7.4. Buffer will be continuously added until the cell
suspension achieves a volume of 396 L for α-galactosidase or
374 L α-N-acetylgalactosaminidase. The total volume of the
container will be 500 L and at least ten column volumes of
equilibration buffer will be added.

Vendor

Thermo Fisher Scientific

Operation

Batch

Characteristics

Material construction:
Volume:
Sterilization:

Sterile single-use CX5-14
multi-layer plastic
500 L
Disposable

Operating Conditions

Temperature:
Pressure:

4ºC in cold room
1.0 atm

Purchase Cost

$300/bag
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15.8. Cobalt Affinity Chromatography Column (P-5, PFD#2)
Description and Function

The cobalt affinity chromatography column will be used to bind
the His6-tagged α-galactosidase and α-N-acetylgalactosaminidase
enzymes and separate them from most of the cell debris, buffers,
and B-PER. HisPur Cobalt Superflow Agarose resin (Thermo
Fisher Scientific) will be used. Assumes no endotoxin removal.

Vendor

Pall Corporation

Operation

Batch

Materials Handled
Cells
Buffers
Endotoxin
Water
GalNAc-ase
OR α-galactosidase
Kanamycin
Chloramphenicol
Waste

Input (kg/batch)
10.4
1330
10.4×10-3
12.1
0.185
0.171
2.64×10-4
1.76×10-4
0

Output (kg/batch)
0
146
10.4×10-3
0
0.176
0.162
0
0
1140

Characteristics

Model:
Material construction:
Required volume:
Diameter:
Height:
Max linear flowrate:
Percent yield:
Sterilization:
Regeneration:
Purity:
Resin:
Resin volume:
Void fraction:
Binding capacity:

Resolute 280 Chromatography Column
Stainless steel, electropolished
14.6 L
280 mm
237 mm
1200 cm/hr
95%
CIP/SIP
25 times
≥ 90%
HisPur Cobalt Superflow Agarose
10.25 L
0.3
20 g enzyme/L resin

Operating Conditions

Temperature:
Pressure:
Linear Flowrate:

4ºC in cold room
5.0 atm
150 cm/hr

Purchase Cost

Column:

$110,000
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15.9. Affinity Chromatography Product Collection Container (P-6, PFD#2)
Description and Function

The product that is eluted from the cobalt affinity
chromatography column will be directed to a single-use,
disposable 3D bioprocess container. All other column flowthrough that came into contact with the cell culture materials
will be directed to the waste tank for biowaste heat inactivation
and neutralization. Buffers that did not come into contact with
biological material will be directed to a waste tank for
immediate neutralization.

Vendor

Thermo Fisher Scientific

Operation

Batch

Characteristics

Material construction:
Volume:
Sterilization:

Sterile single-use CX5-14
multi-layer plastic
200 L
Disposable

Operating Conditions

Temperature:
Pressure:

4ºC in cold room
1.0 atm

Purchase Cost

$250/bag
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15.10. Hydrophobic Interaction Chromatography Column (P-7, PFD#2)
Description and Function

The hydrophobic interaction chromatography column will be used
to exploit the two-fold difference in hydropathy between
endotoxins and the product enzymes and separate them based on
hydrophobicity. It serves as an additional step to eliminate any
remaining endotoxins in the product suspension and comply with
FDA endotoxin standards. POROS Benzyl HIC Resin, cross‐
linked poly(styrene-divinylbenzene) POROS base beads with
aromatic hydrophobic benzyl ligand, that bind highly hydrophobic
particles. It is assumed that 90% of endotoxins will be removed.

Vendor

Pall Corporation

Operation

Batch

Materials Handled
Buffers
Endotoxin
GalNAc-ase
OR α-galactosidase
Waste

Input (kg/batch)
3678
10.4×10-3
0.176
0.162
0

Output (kg/batch)
959
1.04×10-3
0.167
0.154
2709

Characteristics

Model:
Material construction:
Required volume:
Diameter:
Height:
Max linear flow rate:
Percent yield:
Sterilization:
Regeneration:
Purity:
Resin:
Resin volume:
Void fraction:
Binding capacity:

Resolute 800 Chromatography Column
Stainless steel, electropolished
95.9 L
800 mm
191 mm
1200 cm/hr
95%
CIP/SIP
10 times
≥ 90%
POROS Benzyl HIC Resin
57.5 L
0.4
2×106 EU/mL, 90% endotoxin removal

Operating Conditions

Temperature:
Pressure:
Linear Flowrate:

4ºC in cold room
3.0 atm
150 cm/hr

Purchase Cost

$250,000
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15.11. HIC Product Collection Containers (P-8, PFD#2)
Description and Function

The product that is eluted from the hydrophobic interaction
chromatography column will be directed to two single-use,
disposable 3D bioprocess containers. All other column flowthrough that came into contact with the cell culture materials
will be directed to the waste tank for biowaste heat inactivation
and neutralization. Buffers that did not come into contact with
biological material will be directed to a waste tank for
immediate neutralization.

Vendor

Thermo Fisher Scientific

Operation

Batch

Characteristics

Material Construction:
Volume:
Sterilization:

Sterile single-use CX5-14
multi-layer plastic
500 L
Disposable

Operating Conditions

Temperature:
Pressure:

4ºC in cold room
1.0 atm

Purchase Cost

$300/bag
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15.12. Endotoxin Affinity Chromatography Column (P-9, PFD#2)
Description and Function

The endotoxin affinity chromatography column will be used to
bind endotoxins remaining in the product suspension and separate
them from the α-galactosidase and α-N-acetylgalactosaminidase
products. Pierce High-Capacity Endotoxin Removal Resin
(Thermo Fisher Scientific), porous cellulose beads coated with
poly(ε-lysine) to act as affinity ligands to endotoxins, will be used.
It is assumed that 99% of endotoxins will be removed.

Vendor

Pall Corporation

Operation

Batch

Materials Handled
Buffers
Endotoxin
GalNAc-ase
OR α-galactosidase
Waste
Characteristics

Model:
Material construction:
Required volume:
Diameter:
Height:
Max linear flow rate:
Percent yield:
Sterilization:
Regeneration:
Purity:
Resin:

Input (kg/batch)
1240
1.04×10-3
0.167
0.154
0

Output (kg/batch)
19.2
1.04×10-5
0.159
0.146
1220

Resin volume:
Void fraction:
Binding capacity:

Resolute 280 Chromatography Column
Stainless steel, electropolished
9.60 L
280 mm
156 mm
1200 cm/hr
95%
CIP/SIP
10 times
≥ 90%
Pierce High-Capacity Endotoxin
Removal Resin
5.75 L
0.4
2×106 EU/mL, 99% endotoxin removal

Operating Conditions

Temperature:
Pressure:
Linear Flowrate:

4ºC in cold room
3.0 atm
150 cm/hr

Purchase Cost

$110,000
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15.13. Endotoxin Affinity Chromatography Product Collection Container (P-8, PFD#2)
Description and Function

The product that is eluted from the endotoxin affinity
chromatography column will be directed to a single-use,
disposable 2D bioprocess container. All other column flowthrough that came into contact with the cell culture materials
will be directed to the waste tank for biowaste heat inactivation
and neutralization. Buffers that did not come into contact with
biological material will be directed to a waste tank for
immediate neutralization.

Vendor

Thermo Fisher Scientific

Operation

Batch

Characteristics

Material Construction:
Volume:
Sterilization:

Sterile single-use CX5-14
multi-layer plastic
50 L
Disposable

Operating Conditions

Temperature:
Pressure:

4ºC in cold room
1.0 atm

Purchase Cost

$37.54/bag
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15.14. Ultrafiltration/Diafiltration (P-11, PFD#2)
Description and Function

Upon completion of the purification in the three chromatography
steps, the enzyme product will undergo a ultrafiltration-diafiltration
(UFDF) step using casette filters, stabilized with a cassette holder in
a Cogent Process Scale Tangential Flow Filtration (TFF) System.
The filter will have a 30 kD NMWL to allow for ECO-zymes to stay
in the retentate and allowing smaller particles, such as the
chromatography buffer components, to filter through. It is assumed
that 95% of ECO-zyme will be recovered in this step, with a five
percent loss associated with filtration through the cassette
membrane.

Vendor

EMD Millipore

Operation

Batch

Materials Handled
Buffer
GalNAc-ase
OR α-galactosidase
Endotoxin
Waste
Characteristics

Input (kg/batch)
31.0
0.159
0.146
1.04×10-5
0

Output (kg/batch)
30.5
0.151
0.139
1.04×10-5
4.71x10-1

Percent Yield:

Cogent Process ScaleTFF System,
Pellicon 3 Ultracel filter cassettes
Stainless steel AISI 304
Regenerated cellulose, polyethylene
1.14m2
4 L/min
2 atm
Disposable cassettes, SIP for
stainless steel holder
95%

Operating Conditions

Temperature:
Pressure:

4 ºC in cold room
1 atm

Purchase Cost

Cogent Process Scale TFF System:
Stainless steel cassette holder:
100 pack of Ultracel membranes:

Model:
TFF System material:
Membrane Filter Material:
Filtration Area:
Flow Rate:
Maximum Pressure Drop:
Sterilization:

$47,999
$995
$479.08/pack
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15.15. Bulk Filtration (Microfiltration) (P-12, PFD#2)
Description and
Function

The final step in purification after ultrafiltration-diafiltration (UFDF)
will be a microfiltration to dispose of any remaining endotoxins.
Disposable Durapore PVDF filter membranes with a pore size of
0.22 µm will be used. These filters are ideal for sterilization and
clarification of protein solutions, allowing ECO-zyme to pass
through the filter and be collected, while endotoxin remains bound
to the filter membrane. The filters are housed in a disposable
Millipak holder unit as well. Each batch will pass through the unit
twice, removing 99% of endotoxins each time.

Vendor

EMD Millipore

Operation

Batch

Materials Handled
Buffer
GalNAc-ase
OR α-galactosidase
Endotoxin
Waste

Input (kg/batch)
30.5
0.151
0.139
1.04×10-5
0

Output (kg/batch)
27.5
0.136
0.125
1.04×10-9
3.31

Characteristics

Model:
Membrane filter material:
Filtration area:
Maximum pressure drop:
Sterilization:
Percent yield:
Flow rate:
Protein binding:
Wettability:

Millipak® Disposable Units, 0.22um
Durapore PVDF
100 cm2
4.1 atm
Disposable
95%
16.5 L/min
150 µg/cm²
Hydrophobic

Operating Conditions

Temperature:
Pressure:

4 ºC in cold room
1 atm

Purchase Cost

Pack of 3 disposable
membranes and holders:

$503/pack
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15.16 Product Storage Tank (P-13, PFD#2)
Description and Function

A final 500 L 3D disposable biocontainer will be used to collect
the product solution from bulk microfiltration. The product will
be resuspended in 205 or 189 L of water for α-Nacetylgalactosaminidase and α-galactosidase, respectively. The
resuspension solution will have a concentration of 200 mM
glycine to prevent protein aggregation.

Vendor

Thermo Fisher Scientific

Operation

Batch

Characteristics

Material Construction:
Volume:
Sterilization:

Sterile single-use CX5-14
multi-layer plastic
500 L
Disposable

Operating Conditions

Temperature:
Pressure:

4ºC in cold room
1 atm

Purchase Cost

$300/bag
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15.4 Hyperbaric Chamber (not shown, PFD#3)
Description and Function

Donor packed RBCs that are designated for treatment will be
emptied in bulk into a storage vessel using a hyperbaric champer
to induce a pressure differential between 0.3 and 0.5 atm between
the blood bags and the collection vessel. This will generate
pressure-driven flow from the blood bags into the disposable
storage container. This unit operation will minimize both the labor
force required to empty the number of blood bags required in each
batch and the risk of human error and contamination during
emptying. Additionally, it allows blood to be emptied quickly and
minimize the amount of time it could be exposed to room
temperature.

Vendor

To be custom made by third party manufacturer after discussions
with Cummings Properties.

Operation

Batch

Characteristics

Material construction:

Pressure differential:
Number of bags to empty:
Blood bags emptying rate
Run time:

Stainless steel AISI 304, PVC
tubing for blood bags
Disposable dry blood bags and
tubing, CIP/SIP when needed
0.5-1.0 atm
1973 bags max.
264 bags/run
2.5 hours/batch

Operating Conditions

Temperature:
Pressure:

4ºC
0.5-1.5 atm

Purchase Cost

$100,000

Sterilization:
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15.5 Blood Collection Container (not shown, PFD#3)
Description and Function

The blood emptied from the blood bags by pressure-driven flow will
be collected in a 500 L 3D bioprocess container. The container will
be kept at 4ºC at all times to preserve the biological activity of the
RBCs.

Vendor

Thermo Fisher Scientific

Operation

Batch

Characteristics

Material Construction:
Volume:
Sterilization:

Sterile single-use CX5-14
multi-layer plastic
500 L
Disposable

Operating Conditions

Temperature:
Pressure:

4ºC in cold room
1 atm

Purchase Cost

$300/bag
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15.4 Disk Stack Centrifuge (P-1, PFD#3)
Description and Function

The centrifuge will be used to separate the RBCs (solids)
from the spent additive preservation solution (liquid). The
output will be 60% by mass water and 40% by mass RBCs.

Vendor

Alfa Laval

Operation

Batch

Materials Handled
For type-A
RBC suspension
For type-B
RBC suspension
Characteristics

Model:
Centrifuge type:
Material construction:

Finish:
Hydraulic capacity:
G-force:
Bowl speed:
Percent Yield:
Sterilization
Operating Conditions

Temperature:
Pressure:
Flowrate:

Purchase Cost

$46,500/unit

Input (kg/batch)

Output (kg/batch)

0.595

0.559

0.586

0.551

Culturefuge 100
Disk stack
Mo-bearing austenitic steel
for body and cover; cast grey
iron bottom frame
Electro-polished
2,000 L/hr capacity
12,220 g maximum
9550 rpm maximum
95%
CIP/SIP
4ºC
1 atm
200 L/hr
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15.5 WAVE Bioreactors (P-2, PFD#3)
Description and Function

The conversion process in which type-A and type-B RBCs will be
converted to type-O cells via enzymatic conversion will take place
in multiple WAVE bioreactors. The total working volume of
approximately 413 L will be divided among five WAVE bioreactors
that have a maximum working volume of 100 L. The reduced
volume in each reactor will also allow for better mixing of the RBCs
and conversion enzymes, hopefully increasing conversion efficacy.

Vendor

Sartorius Stedim Biotechnology Group

Operation

Batch

Materials Handled
For type-A
RBC suspension
GalNAc-ase
For type-B
RBC suspension
α-galactosidase
Characteristics
(for each reactor)

Input (kg/batch)

Output (kg/batch)

0.559
0.118

0.526
0.111

0.551
3.95×10-3

0.518
3.71×10-3

BIOSTAT® RM bioreactor system
linked to BIOSTAT® control tower,
FLEXSAFE® RM disposable bag
Material construction:
Stainless steel AISI 304 control
tower, stainless steel ABS rocker,
low-density polyethylene bags.
Dimensions:
740mm x 720mm
Heating method:
Open thermostat system with
circulation pump and automatic
cooling water valve
Heating capacity:
2 × 600 W
Percent Yield:
95%
Sterilization:
Disposable, single-use bags:
CIP/SIP for rocking base
Rocking speed:
15 rocks/min
Rocking angle:
10º
Maximum working volume: 100 L
Total volume:
200 L
Model:
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Operating Conditions

Temperature:
Pressure:
pH:
pO2:
Reaction time:

Purchase Cost

$20,000/unit
$200/bag

25ºC
1.0 atm
7.4-7.6
40%
1 hour
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15.4 Disk Stack Centrifuge (P-3, PFD#3)
Description and Function

The centrifuge will be used to separate the RBCs (solids) from
the spent enzymatic solution (liquid). The output will be 60% by
mass water and 40% by mass RBCs. This step is taken as a first
purification step to separate enzymes from converted RBCs,
given that remaining enzymes in solution have found to cause
toxicity in pre-clinical and early clinical studies.

Vendor

Alfa Laval

Operation

Batch

Materials Handled

Input (kg/batch)
For type-A
RBC suspension
GalNAc-ase
For type-B
RBC suspension
α-galactosidase

Characteristics

Model:
Centrifuge type:
Material construction:

Finish:
Hydraulic capacity:
G-force:
Bowl speed:
Percent Yield:
Sterilization
Operating Conditions

Temperature:
Pressure:
Flowrate:

Purchase Cost

$46,500/unit

Output (kg/batch)

0.525
0.111

0.494
0.104

0.518
3.71×10-3

0.487
3.49×10-3

Culturefuge 100
Disk stack
Mo-bearing austenitic steel for body
and cover; cast grey iron bottom
frame
Electro-polished
2,000 L/hr capacity
12,220 g maximum
9550 rpm maximum
95%
CIP/SIP
4ºC
1 atm
200 L/hr
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15.11 Diafiltration (P-4, PFD#3)
Description and Function

To remove any remaining enzyme from the converted RBCs to prevent
immunogenic responses in patients, diafiltration will be performed using a
Cogent Process-Scale Tangential Flow Filtration System with 500 kD
nominal molecular weight limit (NMWL) microfiltration filters. The
NMWL will allow RBCs to remain ni the retentate and return to the storage
tank while enzymes are continuously removed from the system. Saline will
continuously be added to the process to ensure the suspension buffer of the
RBCs has an osmolality equivalent to biological conditions to prevent
hemolysis. It is assumed that 95% the treated RBCs will be recovered in
this step, with a 5% loss associated with filtration through the cassette
membrane or lysis. We assume near complete removal of enzyme to the
point that remaining presence is negligible.

Vendor

EMD Millipore

Operation

Batch

Materials Handled

Input (kg/batch)
For type-A
RBC suspension
GalNAc-ase
Waste
For type-B
RBC suspension
α-galactosidase
Waste

Characteristics

Model:

Operating Conditions

Temperature:
Pressure:

Output (kg/batch)

0.494
0.104
0

0.465
0
0.133

0.503
3.49×10-3
0

0.458
0
4.85×10-2

Cogent Process ScaleTFF System, Pellicon 3
Ultracel filter cassettes
TFF system material:
Stainless steel AISI 304
Filter Material:
Regenerated cellulose, polyethylene
Filtration Area:
1.14m2
Flow Rate:
4 L/min
Maximum Pressure Drop: 2 atm
Sterilization:
Disposable cassettes, SIP for stainless steel
holder
Percent Yield:
95%
4 ºC in cold room
1 atm
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Purchase Cost

Cogent Process Scale TFF System:
Stainless steel cassette holder:
100 pack of Ultracel membranes:

$47,999
$995
$479.08/pack
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15.9 Cryogel-based Affinity Chromatography Column (P-6, PFD#3)
Description and Function

The cryogel-based affinity chromatography column will be used to bind
non-converted RBCs to separate them from successfully converted
RBCs. This is done as a precautionary measure to ensure that the
finalized product does not have antigen- incompatible RBCs that may
cause a harmful immunogenic response in patients. Instead of traditional
resin, the column will be packed with a polymer-based cryogel that is
coated in a protein A-IgG antibody coat that bind the antigens of either
type-A or type-B RBCs. It is assumed that there is a 95% recovery of
converted RBCs.

Vendor

Pall Corporation

Operation

Batch

Materials Handled
For type-A
RBC suspension
Buffers
Waste
For type-B
RBC suspension
Buffers
Waste
Characteristics

Model:
Material construction:
Required volume:
Diameter:
Height:
Max linear flow rate:
Percent yield:
Sterilization:
Regeneration:
Purity:
Gel volume:
Affinity IgG:

Void fraction:

Input (kg/batch)

Output (kg/batch)

0.465
2125
0

0.437
702
1423

0.458
2125
0

0.430
702
1423

Resolute 280 Chromatography Column
Stainless steel, electropolished
18.0 L
280 mm
292 mm
1200 cm/hr
95%
CIP/SIP
5 times
≥ 90%
14.42 L
Mouse monoclonals: anti-blood Group A
antigen Ab [clone 9A] & anti-blood Group B
antigen Ab [HEB-29]
0.4
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Operating Conditions

Temperature:
Pressure:
Linear Flowrate:

Purchase Cost

$110,000

4ºC in cold room
5.0 atm
100 cm/hr
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15.10 Cryogel-based Affinity Chromatography Product Collection Container (P-7, PFD#3)
Description and Function

The flow-through of the cryogel-based affinity chromatography
column, which contains successfully converted RBCs, will be
collected in four single-use, disposable 2D bioprocess container in
equal volumetric amounts. All other column flow-through that came
into contact with the biological substances will be directed to the
waste tank for biowaste heat inactivation and neutralization.
Unconverted RBCs bound to the column will be released via
mechanical stress and also directed to the aforementioned waste tank.
Buffers that did not come into contact with biological material will be
directed to a waste tank for immediate neutralization.

Vendor

Thermo Fisher Scientific

Operation

Batch

Characteristics

Material Construction:
Volume:
Sterilization:

Sterile single-use CX5-14 multi-layer
plastic
200 L/bag
Disposable

Operating Conditions

Temperature:
Pressure:

4ºC in cold room
1.0 atm

Purchase Cost

$250/bag
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15.11 Diafiltration (P-8, PFD#3)
Description and Function

To remove any remaining enzyme from the converted RBCs to
prevent immunogenic responses in patients, diafiltration will be
performed using a Cogent Process-Scale Tangential Flow Filtration
System with 500 kD nominal molecular weight limit (NMWL)
microfiltration filters. The NMWL will allow RBCs to remain ni the
retentate and return to the storage tank while enzymes are
continuously removed from the system. Saline will continuously be
added to the process to ensure the suspension buffer of the RBCs
has an osmolality equivalent to biological conditions to prevent
hemolysis. It is assumed that 95% the treated RBCs will be
recovered in this step, with a 5% loss associated with filtration
through the cassette membrane or lysis. Assuming complete
removal of all buffer salts and components.

Vendor

EMD Millipore

Operation

Batch

Materials Handled

Input (kg/batch)
For type-A
RBC suspension
0.437
Buffer salts
702
Waste
0
For type-B
RBC suspension
0.430
Buffer salts
702
Waste
0
Model:
Membrane Filter Material:
Filtration Area:
Flow Rate:
Maximum Pressure Drop:
Sterilization:

Output (kg/batch)
0.410
0
1423

Percent Yield:

0.404
702
1423
Pellicon 3 cassettes
Regenerated cellulose, polyethylene
1.14m2
4 L/min
2 atm
Disposable cassettes, SIP for
stainless steel holder
95%

Operating Conditions

Temperature:
Pressure:

4 ºC in cold room
1 atm

Purchase Cost

Cogent Process Scale TFF System:
Stainless steel cassette holder:
100 pack of Ultracel membranes:

Characteristics

$47,999
$995
$479.08/pack
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15.4 Disk Stack Centrifuge (P-9, PFD#3)
Description and Function

The centrifuge will be used to separate the RBCs (solids)
from the spent enzymatic solution (liquid). The output will
be 60% by mass water and 40% by mass RBCs. This step
is taken to separate RBCs from any remaining buffer
solution. It also allows greater control of the final volume
in which the RBCs are suspended to facilitate final
packaging.

Vendor

Alfa Laval

Operation

Batch

Materials Handled

Characteristics

Input (kg/batch)

Output (kg/batch)

For type-A
RBC suspension

0.410

0.386

For type-B
RBC suspension

0.404

0.381

Model:
Centrifuge type:
Material construction:

Finish:
Hydraulic capacity:
G-force:
Bowl speed:
Percent Yield:
Sterilization
Operating Conditions

Temperature:
Pressure:
Flowrate:

Purchase Cost

$46,500/unit

Culturefuge 100
Disk stack
Mo-bearing austenitic steel
for body and cover; cast grey
iron bottom frame
Electro-polished
2,000 L/hr capacity
12,220 g maximum
9550 rpm maximum
95%
CIP/SIP
4ºC
1 atm
200 L/hr
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15.13 Product Storage Containers (P-10, PFD#3)
Description and Function

The centrifuged RBC mass will be directed and resuspended in
Adsol-1 additive solution (previously prepared in a mixing
tank) in four single-use, disposable 2D bioprocess container in
equal volumetric amounts. The stored converted RBCs will be
kept in a cold room on a rocker at gentle agitation to prevent
settling until they can be packaged

Vendor

Thermo Fisher Scientific

Operation

Batch

Characteristics

Material Construction:
Volume:
Sterilization:

Sterile plastic
200 L/bag
Disposable

Operating Conditions

Temperature:
Pressure:

4ºC in cold room
1 atm

Purchase Cost

$250/bag
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15.15 Small Peristaltic Pumps (All main pumps in PFDs)
Description and Function

Peristaltic pumps are used to transfer unit contents throughout
the process. All peristaltic pumps are specifically designated
for use in the E. coli upstream and downstream processes to the
high viscosity of the cell suspensions. The consistent flow
ensures accuracy in dispensing flow from unit to unit. A
brushless motor allows for speed control of the pump.

Vendor

Cole Parmer

Operation

Batch

Characteristics
Model:
Material construction:
Flow rate range:
Maximum Pressure Drop:
Power requirement:

Masterflex Model 77924-80
Stainless Steel AISI 304
0.001-3,400 mL/min
2.07 atm
253 W

Operating Conditions

Temperature:
Pressure:

4-37ºC
1.0 atm

Purchase Cost

$3,635/pump
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15.15 Large Peristaltic Pumps (Used for regeneration buffers)
Description and Function

Peristaltic pumps are used to transfer unit contents throughout
the process. All peristaltic pumps are specifically designated
for use in the E. coli upstream and downstream processes to the
high viscosity of the cell suspensions. The consistent flow
ensures accuracy in dispensing flow from unit to unit. A
brushless motor allows for speed control of the pump.

Vendor

Watson Marlow

Operation

Batch

Characteristics
Model:
Tubing:
Material construction:
Flow rate range:
Maximum Pressure Drop:
Power requirement:

840 Series Hygienic Pump
GORE® STA-PURE® PFL
Stainless Steel 316
120-8,000 L/hr
3.5 atm
0.2 W

Operating Conditions

Temperature:
Pressure:

4-37ºC
1.0 atm

Purchase Cost

$25,000/pump
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15.15 Quattroflow Quaternary Diaphragm Pumps (All pumps shown in PFD#3)
Description and Function

The Quattroflow quaternary diaphragm pumps mimic
cardiovascular pumping in the human body to prevent shearinduced hemolysis. All Quattroflow pumps are specifically
designated for use in the RBC conversion treatment process.
Each stroke of the 4-piston diaphragm is generated by an
eccentric shaft connected to an electric motor. Each
Quattroflow pump comes with an integrated PID controller for
optimal flow rate adjustments.

Vendor

PSG Dover

Operation

Batch

Characteristics
Model:
Material construction:
Flow rate range:
Maximum Pressure Drop:
Power requirement:

QF1200S-CV
Stainless Steel AISI 304
10-1,200 L/hr
6 atm
0.75 W

Operating Conditions

Temperature:
Pressure:
Flow rate:

4ºC
1.0 atm
350 L/hr

Purchase Cost

$10,772/pump
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16. Additional Equipment Description
There are a number of units that will be needed for the completion of this project but are
not shown in the process flow diagrams. These pieces of equipment are required for sterile cell
culture and storage, sterile buffer preparation, proper waste disposal, and product verification
steps, thus allowing for good manufacturing practices.
16.1. Biosafety Cabinet
Two class II biosafety cabinets will be required for sterile cell culture spaces. Each
biosafety cabinet will come equipped with mounted motor driven blowers to draw directional mass
airflow around a user and into the air grille to protect the operator. The airflow drawn into the air
grille will then be HEPA-filtered and exhausted into the environment. Additionally, a column of
HEPA filtered, sterile air is blown downward at the front of cabinet, over products and processes
to prevent contamination. The first biosafety cabinet will be designated to handle E. coli
BL21(DE3) cells exclusively and is provide a sterile environment to transfer the contents of
thawed vials of cells for inoculating the ambr® 250 bioreactor. The second biosafety cabinet will
be designated to handle any RBCs or other blood-derived materials/products for research purposes.
The rented laboratory space will provide both biosafety cabinets, which is factored in the rental
costs in annual expenses.
16.2. Cell Bank
Engineered E. coli BL21(DE3) will kept frozen in a -80ºC freezer in 1.5-mL vials at a
concentration of 7.95×106 cells/mL. 250 vials annually to allow for a year’s worth of production
of α-galactosidase and α-N-acetylgalactosaminidase, with additional an additional stock in the
event of complications with the cell line. The cell solution will also be 20% glycerol by volume.
The addition of glycerol stabilizes the frozen bacteria, preventing damage to the cell membranes
and keeping the cells alive. All vials will be prepared in a class II biosafety cabinet.
16.3. Refrigeration
A -80ºC freezer will be necessary to maintain the frozen cell stock and certain reagents for
long-term storage. A -20ºC freezer will also be purchased to maintain certain reagents at their
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proper storage temperature. Both the ultra-low temperature freezer and the -20ºC freezers will be
purchased from Thermo Fisher Scientific for $30,000 and $8,700, respectively.
16.4. Biowaste and Neutralization Tanks
All waste streams that have been in contact with cell culture or debris will directed to
10,000 L stainless steel tank, which will be purchased from Sharpsville Container for $2,500. The
tank’s contents will undergo proper heat inactivation before disposal to ensure that there are no
remaining proliferating E. coli cells that could cause environmental health hazards. This tank will
be jacketed to be able to reach and sustain a temperature of 121ºC for approximately 11 minutes
via a digital PID controller unit to complete a 25-log reduction of bacteria.
Cell-free waste streams will be directed to an additional 10,000 L stainless steel tank, also
purchased from Sharpsville Container. This tank will mainly collect the different buffers used in
the chromatography steps, which will undergo neutralization to adjust the waste to a pH of 7.0.
After neutralization, this waste will be discarded by the laboratory facility into the sewer line.
The disposal of non-liquid waste, which primarily includes all single-use, disposable bags,
containers, and reactor vessels, will be contracted to the biohazardous waste disposal unit of
Stericycle. The costs of outsourcing this task will be added to the annual expenses.
16.5. Water-for-Injection Generator
A multiple effect still will be used to purify water for use in preparing media, preparing all
buffers and additive solutions, and conducting SIP procedures. FDA standards require that
pharmaceutical and biological products injected or transfused into patients do not touch any water
other than water-for-injection (WFI) to ensure sterility and reduce contamination risks. The WFI
will also ensure sterility of the process equipment and eliminate cross-contamination issues. The
PyroPure Multiple Effect Still will be purchased from the Paul Mueller Company for $20,000.
16.6. Water Treatment Package
Although WFI will be used for the water requirements in the process, U.S. Pharmacopeia
(USP) grade water is needed for temperature control needs in the bioreactor processes. This water
will not be in direct contact with the cell culture suspension. It will be inserted into the reactors’
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for heating and cooling procedures. The cost for the water treatment package is included in the
operations costs of the annual expenses.
16.7. Clean Steam Generator
Clean steam will be necessary to conduct SIP procedures for numerous process units. The
generator for will produce clean steam from WFI, supplied by the WFI generator. The clean steam
generator will be purchased from BMT USA for $60,000.
16.8. Buffer Transfer Bags
Disposable bioprocess containers (Thermo Fisher Scientific) will be used to prepare the
equilibration, wash, elution, and regeneration buffers for all chromatography columns. Each
column will require five containers (with its respective holder): one for equilibration, wash,
elution, regeneration, and CIP reagents.
16.9. Filter Integrity
Although disposable filters are used throughout the process, they must be tested before
each use to ensure they are not clogged, torn, or generally unusable. The filter integrity test will
help minimize losses due to filter manufacturing error. The test will be purchased from and
performed by EMD Millipore for $3,500 upon ordering the filters.
16.10. Purified Air Generator
A purified, zero air generator for all space in the laboratory facilities will be purchased
from Domnick Hunter for $2,500 per unit. This device will produce a continuous stream of organic
impurity free air from an external dry compressed air source. The system will provide clean air to
bioreactors and fermenters, clean rooms, and process equipment.
16.11. Laboratory Information Management System
Laboratory information management system (LIMS) will be implemented for workflow,
data tracking support, and data exchange interfaces. It will be used to enforce standard operating
procedures (SOPs) and to provide defined workflows to analysts. Its functions will include, but
are not limited to: sample management (login, registration integrity, life cycle tracking), chain of
custody, instrument integration for data collection automation, automatic results reduction &
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flagging, integration with third party systems (ERP/HR/CDS), workflow management, work
allocation & scheduling to reduce as of yet unidentified bottlenecks, electronic document
management, lot & batch management, instrument management (maintenance, scheduling), data
security & integrity, multivariate data analysis, and quality assurance and control.
16.12. Portable Pump on Cart
In the event of pump malfunction in either the E. coli upstream/downstream processes or
the RBC treatment, two extra peristaltic pumps and two extra Quattroflow quaternary diaphragm
pumps will be stored as replacements. These pumps will be mounted onto carts for easy intrafacility movement in the event of a pump’s mechanical malfunction.
16.13. Quality Control Lab Equipment
Quality control analysis will be divided between the enzyme production and RBC
conversion steps. These product verification steps must be passed for conversion enzymes to be
used to treat RBCs and for successfully converted RBCs to proceed to final packaging. Less than
10 µg of each enzyme per batch will be required for quality control analysis. 500 mL of both
converted and non-converted blood will be aliquoted and kept for flow cytometry and thin layer
chromatography (TLC) analysis to ensure that the final product contains minimal traces of nonconverted RBCs.
16.13.1.

Protein Gel Materials

Protein gels will be run for each to confirm the identity of the isolated enzymes from the
E. coli culture. Additionally, the protein gels will help identify possible protein variations that
could be associated with genetic drift or mutations in the E. coli cell line. Thus, this control step
has a secondary purpose of validating cell productivity. The materials needed include hydrochloric
acid, 30% acrylamide solution, SDS ammonium persulfate, TEMED, glycine, EDTA, 50%
glycerol solution, mercaptoethanol, bromophenol blue, and pre-stained molecular weight markers.
These materials will be purchased from BioRad for $1,540 per batch.
16.13.2.

NanoDrop

The NanoDrop 2000 UV-Vis Spectrophotometer will be used to determine the
concentration of α-galactosidase and α-N-acetylgalactosaminidase in their respective final
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solutions. Once known, the concentration will be used to determine the appropriate volumes of
enzyme to use for treating RBCs. This unit will be purchased from Thermo Fisher Scientific for
$9,100.
16.13.3.

Endotoxin Test Kit

Endotoxin detection will be done using a Kinetic Turbidimetric Limulus Amebocyte
Lysate (LAL) test. A test kit will be purchased annually to ensure that all batches of conversion
enzyme have an endotoxin level below the FDA standard of 0.1 EU/mL. If a batch does not pass
this test, it will be discarded. The kit will be purchased from Lonza at $1,000 per kit. Each kit can
be used 192 times.
16.13.4.

Flow Cytometer

Flow cytometry analysis will be performed on native and enzymatically converted RBCs
using a BD LSR II flow cytometer (BD Biosciences) with mouse monoclonal antibody reagents
specific to human A or B antigens on the RBC surface. The flow cytometer will come equipped
with 488, 594, and 633 nm lasers. The final RBC population must have less than 1.0% nonconverted RBCs to be considered acceptable for transfusion.
The principle of action is that if any remaining antigens are not cleaved on the red blood
cell surface, then fluorophore-labeled primary antibodies specific to the antigens can be used to
bind to them. The fluorophores will be Alexa Fluor 546 or 547 secondary antibodies and will bind
specifically to the primary antibodies. The flow cytometer will perform a high-throughput analysis
of the liquid blood sample, one cell at a time, by shining lasers of specific wavelengths on them.
Successfully converted cells will emit no signal, while cells that still contain antigens will give off
signal when they are excited by 594 or 633 nm wavelength lasers.
16.13.5.

TLC for Glycolipid Analysis

The TLC of native and converted RBC glycolipids should show that converted cells no
longer have glycolipid bands associated with the sugars that constitute the A and B antigens. RBC
membranes will be extracted by homogenization in ten volumes of isopropanol/hexane/water
(55:25:20 vol/vol/vol), filtered, evaporated and partitioned by Folch extraction method. The upper
phase will be collected, evaporated, dialyzed and applied to a DEAE Sephadex column. The pass-
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through fraction will contain the total upper neutral lipids, and the monosialyl fraction will be
eluted with 0.05 M ammonium acetate, evaporated and dialyzed against water to remove acetate.
Total upper neutral and monosialyl glycolipid fractions will be analyzed by high-performance thinlayer chromatography. TLC plates (Merck) will be developed using the solvent system
chloroform/methanol/0.5 M CaCl2 in water (50:40:10, vol/vol/vol). Glycolipids will be stained by
heating with 0.05% orcinol in 0.5 M H2SO4.

154

Section 17:
Equipment Cost Summary

155

17.

Equipment Cost Summary

17.1. Major Unit Operation Costs
The total purchase cost for the major operation equipment is $1,948,914. Using a bare
module factor of 3.21, the bare module cost is approximately $6.23 million. This bare module
factor is determined assuming that the cost of installation materials is 71% of equipment purchase
cost; the cost of installation labor is 54%; the cost for freight, insurances, and taxes is 9%; the cost
of construction overhead is 57%; and the cost of contractor engineering expenses is 30%. A bare
module factor of 3.21 yields a highly conservative estimate of the bare module cost for a process
that relies heavily on off the shelf equipment as this process does. In reality, however, the cost of
installation materials and contractor engineering expenses will be significantly less since most
items are purchased already manufactured. The real bare module cost for this process is likely
lower than the estimated $6,231,443. However, for the purpose of the profitability analysis the
upper bound is used to provide a stricter analysis on the feasibility of this project. The breakdown
of the major unit operations costs, including manufacturer, number of units required, purchase
cost, and final bare module cost, is shown in Table 17.1.1.
The most expensive pieces of equipment are the Resolute chromatography chromatography
columns, followed by the production bioreactor and the WAVE bioreactor setup. It should be noted
that although the Resolute 280 chromatography column is used for the cryogel-based affinity
chromatography column, similar to the cobalt ion and endotoxin affinity chromatography steps,
an additional cost of $90,000 is added to the original purchase cost of $110,000 for customization
to add a piston to apply mechanical stress for releasing bound cells.
The costs of genetically engineering the E. coli cell lines was included in the major unit
operation costing given their similarity to purchasing equipment: it is a one-time investment. A
bare module factor of 1.0 was applied for the costing of the gene editing since it does not require
any of the previously aforementioned costs.
It should be noted that the major unit operation costs include two Cogent M1 Tangential
Flow Filtration systems that are not previously discussed in the process description. These two
units are being purchased as backups in the event that the Cogent Process Scale Tangential Flow
Filtration System suffers from a malfunction and cannot be used. The elimination of enzymes and
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buffers in these products are important for marketability purposes. If they cannot be eliminated,
the RBCs will have enzymatic content that could cause an immunogenic response in patients,
defeating the purpose of this project. Thus, for equipment functionality concerns, these units were
included in our calculations. The presence of these two units will also allow for more increasing
processing capability in the event that expansion occurs or if donated whole blood, which requires
a separate sets of ultrafiltration and diafiltration processes, becomes incorporated into the plant
design.
The unit operation costs associated with the E. coli process are significantly higher than
the treatment of RBCs (approximately 2.6-fold higher), as shown in Figure 17.1.1.
E. coli culture and purification

RBC treatment

28%

72%

Figure 17.1.1. Contributions of both the E. coli culture/purification and the conversion treatment
of RBCs to the total bare module costs of the major unit operation costs. Given the complexity of
ensuring that endotoxins concentrations are lowered to a concentration considered acceptable by
the FDA, the multiple incorporated chromatography column steps imposes significant costs on just
the microbial fermentation.

The total purchase cost for the additional equipment is $1.17 million. The costing of other
common units required in the processes is described in Table 17.1.2. Using a bare module factor
of 3.21, the bare module cost is $3.74 million. Of these units, only the cold rooms and hyperbaric
chamber will need to be designed and fabricated, which is accounted for in their total bare module
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costs. Other equipment, such as pumps, freezers, and refrigerators, will be purchased as off the
shelf units, which will likely result in a bare module cost lower than the predicted value. However,
we again choose to analyze the economics from this standard of 3.21 to provide a clear upper
bound on what equipment purchases costs will be for this project.
The most significant costs are associated with the construction of the several cold rooms
required throughout the process ($1.7 million). The price for construction of the cold room was
quoted at $170 per square foot (ANC Cold Storage Construction, Inc.). Each cold room was
designed to be 900 ft2 in area, but this number will be subject to change after further consultation
with Cummings Properties and process equipment vendors. For costing assessment, however, we
believe that this area is sufficiently large for each to house RBC transfusion units, downstream
purification equipment for the microbial culture, or the RBC treatment process equipment. This
will thus give us an upper bound on the cost estimation of the cold rooms and allow for more
stringent analysis of this process design.
The total breakdown of all equipment costs is shown in Figure 17.1.2. The total bare
module cost of all units is $9,976,534. Thus, it is estimated that just on equipment purchases alone,
an initial capital investment of $10 million would be required to just have the machinery with
which the bacterial growth and RBC treatment processes can be performed. For plant operating, a
complete, initial capital investment of $25.6 million will be required. This means that equipment
costs account for roughly 37.5% of the initial investment.
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0%
15%
24%

Bioreactors
Chromatography
Centrifuge

15%

High Pressure Homogenizer
Ultrafiltation/Diafiltration
Mixing
Pumps

7%

Gene editing

2%

29%
8%

Figure 17.1.2. Complete breakdown of all equipment that need to be purchased for plant operation.
The total mare module cost is $9.98 million. We expect this number to be lower given that the bare
module factor of 3.21 applied to nearly all units in this design was deemed too high by numerous
industrial consultations. Since these units are purchased off-shelf, there are no major installation
material costs will be lower.
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Table 17.1.1. Major equipment purchases costs, including information on manufacturers, number of units, and the final, expected bare
module cost associated with each unit.

Equipment Description

Vendor

Type

Units

Innoculum Bioreactor
Seed Bioreactor
Bioreactor
Cobalt Affinity
Chromatography
Endotoxin Affinity
Chromatography
Hydrophobic Interaction
Chromatography
Disk Stack Centrifuge
High Pressure Homogenizer
WAVE Bioreactor
Cryogel Affinity
Chromatography
Cogent Process Scale TFF
System
Cogent M1 TFF
HyPerforma Single-Use
Mixer
E. coli cell line engineering
Gene fabrication
Total

Sartorius
Eppendorf
Thermofisher

Process Machinery
Process Machinery
Process Machinery

1
1
2

Purchase Cost
(per unit)
$
45,799
$
100,000
$
150,000

Total Purchase
Total Bare
Cost
Module Cost
$
45,799 $
147,015
$
100,000 $
321,000
$
300,000 $
963,000

Pall

Process Machinery

1

$

110,000 $

110,000 $

353,100

Pall

Process Machinery

1

$

110,000 $

110,000 $

353,100

Pall

Process Machinery

1

$

250,000 $

250,000 $

802,500

Alfa-Laval
Microfluidics
Sartorius

Process Machinery
Process Machinery
Process Machinery

4
1
5

$
$
$

46,500 $
38,740 $
20,000 $

186,000 $
38,740 $
100,000 $

597,060
124,355
321,000

Pall

Process Machinery

1

$

200,000 $

200,000 $

642,000

EMD Millipore

Process Machinery

3

$

47,999 $

143,997 $

462,230

EMD Millipore

Process Machinery

2

$

12,000 $

24,000 $

77,040

Sartorius

Process Machinery

2

$

165,000 $

330,000 $

1,059,300

GenScript
GenScript

Biological Processing
Biological Processing

2
2

$
$

5,400 $
159 $
$

10,800 $
318 $
1,949,654 $

10,800
318
6,233,819
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Table 17.1.2. Additional, common equipment purchase costs, including information on manufacturers, number of units, and the final,
expected bare module cost associated with each unit.

Equipment Description

Vendor

Type

Units

Masterflex 77924-80 L/S
840 Series Hygienic Pump
Quattroflow Quaternary
Diaphragm Pump
Spark Multimode Microplate
Reader
Nanodrop VIS
Spectrophotometer
BD Biosciences LSRII Flow
Cytometer
4ºC Refrigerator
Freezer (-20ºC)
Freezer (-80ºC)
Clean Steam Generator
Clean Air Generator
Water for Injection Supplier

Cole-Palmer
Watson Marlow

Process Machinery
Process Machinery

39
4

Purchase Cost Total Purchase
Total Bare
(per unit)
Cost
Module Cost
$
3,635 $
141,765 $
455,066
$
25,000 $
100,000 $
321,000

PSG Dover

Process Machinery

10

$

10,772 $

107,720 $

345,781

Tecan

Process Machinery

1

$

2,450 $

2,450 $

7,865

Thermo Scientific

Process Machinery

1

$

9,140 $

9,140 $

29,339

Biosciences

Process Machinery

1

$

55,115 $

55,115 $

176,919

Thermo Scientific
Thermo Scientific
Thermo Scientific
BMT USA
Domnick Hunter
Paul Mueller Co.

Storage
Storage
Storage
Process Machinery
Process Machinery
Process Machinery
Computers, Software,
Etc.
Computers, Software,
Etc.
Fabricated Equipment
Fabricated Equipment

1
4
1
1
1
1

$
$
$
$
$
$

13,600
8,700
30,000
60,000
2,500
20,000

13,600
34,800
30,000
60,000
2,500
20,000

$
$
$
$
$
$

43,656
111,708
96,300
192,600
8,025
64,200

30

$

300 $

9,000 $

28,890

1

$

20,865 $

20,865 $

66,977

1
1

$
$

459,000 $
100,000 $
$

459,000 $
100,000 $
1,165,955 $

1,473,390
321,000
3,742,716

Digitial PID controller units

Omega

Control software

Omega

Cold room
Hyberbaric chamber
Total

N/A
N/A

$
$
$
$
$
$
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18.

Fixed Capital Investment Summary

A breakdown of the required investments costs, beginning with total bare module costs and ending
with the required total capital investment for the project is shown in Table 18.2. $14 million will
be requested to cover the minimum necessary costs to build the production facility.
Table 18.2. Summary of the investment for the entire plant, including both the E. coli processing
and the RBC conversion process.
Investment Summary
Total Bare Module Costs:
Fabricated Equipment
Process Machinery
Spares
Storage
Other Equipment
Catalysts
Computers, Software, Etc.

$
$
$
$
$
$
$

1,813,373
7,815,631
251,664
95,867

Total Bare Module Costs:

$

9,976,534

$

10,974,188

$

12,949,541

$

14,503,486
1.00
14,503,486

Direct Permanent Investment
Cost of Site Preparations:
Cost of Service Facilities:
Allocated Costs for utility plants and related facilities:

$
$
$

498,827
498,827
-

Direct Permanent Investment

Total Depreciable Capital
Cost of Contingencies & Contractor Fees

$

1,975,354

Total Depreciable Capital
Total Permanent Investment
Cost of Land:
Cost of Royalties:
Cost of Plant Start-Up:
Total Permanent Investment - Unadjusted
Site Factor
Total Permanent Investment

$
$
$

258,991
1,294,954

$
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19.

Operating Costs

19.1. Variable Costs
The purchase of raw materials per ECO RBC transfusion unit is approximately $43.75,
which leads to an annual cost of $8.75 million. These values are shown in Table 19.1.1.
Table 19.1.1. Estimated raw material pricing and their respective yearly costs. The following
table includes all materials needed for both the E. coli processing and the RBC treatment.
Raw Material
AGE
Ammonium sulfate
APS
Beta-Lactose
Chloramphenicol
Detergent
DMAAm
Ethanol
Ethylenediamine
Glucose
Glutaraldehyde
Glycerol
Guanadine HCl
HEPES
HisPur® Cobalt Resin
IgG
Imidazole
IPTG
Kanamycin
KH2PO4
MBAAm
MES
Magnesium sulfate
Sodium carbonate
Sodium phosphate heptahydrate
Sodium sulfate
Sodium borohydride
Sodium chloride
Sodium hydroxide
Ammonium chloride
Pierce Endotoxin Removal Resin
POROS Benzyl HIC Resin
Protein A
Sodium phosphate
TEMED
Urea
Total

Annual
Amount
Required
2.21 L
5.20 kg
0.29 kg
4.50 L
0.02 kg
432 kg
16.4 L
4154 L
78.2 kg
310 kg
130 L
180 L
2428 L
668 kg
50.0 L
1.30 g
312 kg
2.64 kg
0.03 kg
675 kg
5.71 kg
105 kg
270 kg
55.0 kg
1525 kg
319 kg
9.82 kg
2950 kg
1113 kg
225 kg
80.0 L
650 L
4.15 kg
58.0 kg
0.25 L
2146 kg

Cost of Raw
Material
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$

173.00
51.76
78.60
463.00
16,905.00
62.60
93.00
4.18
73.50
9.56
99.50
87.50
246.75
223.00
4,980.00
790.00
265.00
44,800.00
14,400.00
137.00
1,044.00
1,003.00
157.00
137.00
56.88
27.92
118.18
10.38
36.00
79.00
20,200.00
3,800.00
366.00
42.00
168.00
67.40

Cost per
RBC Unit
$/L
$/kg
$/kg
$/kg
$/kg
$/kg
$/L
$/L
$/L
$/kg
$/L
$/L
$/L
$/kg
$/L
$/mg
$/kg
$/kg
$/kg
$/kg
$/kg
$/kg
$/kg
$/kg
$/kg
$/kg
$/kg
$/kg
$/kg
$/kg
$/L
$/L
$/g
$/kg
$/L
$/kg

$ 0.0019
$ 0.0013
$ 0.0001
$ 0.0104
$ 1.7892
$ 0.1352
$ 0.0076
$ 0.0868
$ 0.0320
$ 0.0148
$ 0.0646
$ 0.0787
$ 2.9957
$ 0.0745
$ 1.2450
$ 5.1280
$ 0.4137
$ 0.5919
$ 0.0022
$ 0.4621
$ 0.0298
$ 0.5285
$ 0.2118
$ 0.0377
$ 0.4336
$ 0.0446
$ 0.0058
$ 0.1532
$ 0.2004
$ 0.0888
$ 8.0800
$ 12.3500
$ 7.6024
$ 0.1217
$ 0.0002
$ 0.7234
$ 43.75

Annual Cost
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$

381.81
259.71
22.45
2,082.28
357,845.04
27,034.21
1,521.26
17,359.76
6,391.45
2,968.04
12,917.37
15,740.76
599,133.68
14,901.70
249,000.00
1,025,600.36
82,747.84
118,373.71
448.36
92,420.75
5,963.54
105,708.18
42,365.13
7,541.15
86,711.91
8,914.14
1,160.76
30,631.91
40,072.52
17,764.57
1,616,000.00
2,470,000.00
1,520,484.99
24,349.93
41.44
144,670.03
8,749,530.74
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The total cost for raw materials for the process is $8.75 million. This cost estimate was
determined from prices quotes provided by vendors. All reagents are United States Pharmacopoeia
grade (USP), as required by the FDA. The resin for the endotoxin affinity chromatography column
is the most expensive raw material needed to perform the process, followed by protein A, and
guanidine HCl. Although relatively high, it should be noted that numerous steps in the purification
processes require costly resin. Additionally, the cryogel-based affinity chromatography column
requires expensive chemicals, polymers, and IgG antibodies that drastically increase this cost.
Although for the purposes of this design the amount of materials and costs required for this column
are reasonable, there are concerns that the possibility of expansion may cause financial strain if
antibodies need to be purchased more often.
In addition to the raw materials required for the process, there are a number of disposable
products that will be used for each batch. These costs are summarized in Table 19.1.2.

Table 19.1.2. Additional variables costs associated with the single-use, disposable technology that
is used annually.

$
$

Number
per Batch
650.00
1
155.00
1

Cost per
Annual Cost
RBC Unit
$ 0.36 $ 72,800.00
$ 0.09 $ 17,360.00

$

300.00

1

$

0.17 $ 33,600.00

$

300.00

1

$

0.17 $ 33,600.00

Thermo Fisher
Scientific

$

300.00

1

$

0.17 $ 33,600.00

200L 3D Bioprocess
Container

Thermo Fisher
Scientific

$

250.00

1

$

0.14 $ 28,000.00

50L 2D Labtainer
Bioprocess Bag
Final Product Holding Container
5L 2D Labtainer
(Enzyme)
Bioprocess Bag
Hyperbaric Chamber Collection 200L 3D Bioprocess
Container
Container
200L Flexsafe® RM
WAVE Bioreactor
Bag
Final Product Holding Container 500L 3D Bioprocess
(RBC)
Container
Blood Bags for Distribution
Terumo Blood Bags
Total

Thermo Fisher
Scientific
Thermo Fisher
Scientific
Thermo Fisher
Scientific

$

150.00

1

$

0.08 $ 16,800.00

$

150.00

10

$

0.84 $ 168,000.00

$

250.00

3

$

0.42 $ 84,000.00

$

200.00

6

$

0.67 $ 134,400.00

$

300.00

1

$

0.17 $ 33,600.00

$

0.90

1786

$
$

0.90 $ 180,028.80
4.18 $ 835,788.80

Unit

Disposable Unit

Vendor

Media Sterilization Filter
Innoculum Growth Reactor
Microfluidization Product
Resuspension Container
Cobalt Affinity Chromatography
Collection Container
Endotoxin Affinity
Chromatography Collection
Container
Endotoxin Affinity
Chromatography Collection
Container

Filter
ambr 250® Vessel
500L 3D Bioprocess
Container
500L 3D Bioprocess
Container

Millipore
Sartorius
Thermo Fisher
Scientific
Thermo Fisher
Scientific

500L 3D Bioprocess
Container

HIC Collection Container

Sartorius
Thermo Fisher
Scientific
Terumo BCT

Cost
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These include disposable bags for reactors, storage containers, and filters. The total annual
cost for these products is $835,789, which is an order of magnitude smaller than the total annual
cost for the raw materials. This also amounts to $4.18 per RBC unit, of which the cost of the final
distribution bag accounts for $0.90. All costs were obtained from vendors and requested quotes.
This result was particularly satisfactory as it justifies the use of single-use technology for all shortterm storage. Originally, industrial consultants, particularly Jeffrey Cohen (Johnson & Johnson)
and Daniel Green (GlaxoKlineSmith) were concerned that the cost of using single-use technology
would outweigh the benefits of reduced CIP/SIP times. Upon performing this financial assessment
of the annual costs required, though, single-use technology great increases the time with which
batches can be processed and greatly reduces the demand for steam in this plant.

19.2. Utilities
The total annual cost of utilities is $580,547, which is shown in Table 19.2.1. The cost per
RBC unit is $2.90 and includes WFI, lighting, HVAC, electricity, refrigeration, and steam costs.

Table 19.2.1. Annual utility cost estimates required with the respective costs per ECO RBC
transfusion unit made.

Annual Amount
Required
Water for Injection
41400
Lighting and HVAC
2120000
Electricity
2886000
Refrigeration
46200
Steam
2334
Total
Utility

Cost of
Utility
L
0.0050
kWh 0.0516
kWh 0.1541
kWh 0.0506
kg
0.0130

Cost per
RBC Unit
$/L $ 0.001
$/kWh $ 0.547
$/kWh $ 2.223
$/kWh $ 0.012
$/kg $ 0.012
$
2.79

Annual Cost
$
$
$
$
$
$

207
109,400
444,600
2,340
2,400
558,947

The WFI is produced by a WFI supplier, which treats tap water to later be used in the
process for SIP. WFI is required for all production processes since the facility is built to be
pharmaceutical grade. The water required for the WFI priced is based on estimates from the
Medford, Massachusetts Department of Public Works, Water and Sewer Division.
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Lighting and HVAC requirements were adapted from average values in established
literature “Energy Benchmarking in the Pharmaceutical Industry,” assuming a plant size of 6,000
square feet. 10.6 kWh of lighting/HVAC utility are required per unit RBCs. Electricity
requirements for each process unit were obtained from manufacturer brochures; 4.81 kWh per unit
of RBCs are required to power process equipment. The industrial cost of electricity in Medford,
MA, $0.0514/kWh, was used to determine the cost of electricity for operating all unit operations,
lighting, HVAC, and refrigeration. Lighting/HVAC and process electricity requirements are priced
at $0.547/unit RBCs and $0.74/unit RBCs, respectively.
Refrigeration is required to maintain the cold room, where blood bags for conversion will
be organized and stored until they are processed. Each cold room will have dimensions of 30 ft x
30 ft x 8 ft and is maintained at 4°C and 25% relative humidity. Thermal resistance values for wall,
ceiling, and floor materials are standard values for cold room building materials provided by North
Carolina State University. The service load, which accounts for lighting requirements, cold room
control equipment, and storage carts, people, and humid air entering and exiting the cold room,
are included in utilities analysis and assumed to be 10% of the heat conduction in the cold room.
The total heat load, including heat conduction and service load, is 15,500 kWh per year with a
requirement of 0.077 kWh/unit RBCs. The cost of refrigeration per unit product was determined
to be $0.0039/unit RBCs.
Lastly, low pressure steam is required in the process plant to sterilize the stainless steel
fermenters and to kill any live mass remaining the bio-waste tank. All cultures or surfaces that
were exposed to microbial cultures will be heated to 121ºC (see Appendix C) for approximately
11 minutes and then cooled to 80ºC. The steam is priced at $0.013 per kilogram, and it is assumed
that the process requires 2,334 kg annually (0.10 grams enzyme per mg enzyme). This leads to a
cost of $0.012/unit RBCs.

19.3. Fixed Operating Costs
The inputs for calculating fixed operating costs are shown in Table 19.3.1. To ensure
successful plant operation, it assumed that five daily operating shifts are necessary, each lasting
approximately 4.8 hours. It is assumed that there will be two operators for each shift, while there
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will be an quality control specialist for three of the five shifts. Although the number of operators
is quite high, they are necessary given that there are two separate processes being conducted in
parallel.
Table 19.3.1. Summary of the inputs for fixed cost analysis.
Fixed Costs
Operations
Operators per Shift:
Direct Wages and Benefits:
Direct Salaries and Benefits:
Operating Supplies and Services:
Technical Assistance to Manufacturing:
Control Laboratory:

13
$40
15%
6%
$60,000.00
$65,000.00

(assuming 5 shifts)
/operator hour
of Direct Wages and Benefits
of Direct Wages and Benefits
per year, for each Operator per Shift
per year, for each Operator per Shift

Wages and Benefits:
Salaries and Benefits:
Materials and Services:
Maintenance Overhead:

4.50%
25%
100%
5%

of Total Depreciable Capital
of Maintenance Wages and Benefits
of Maintenance Wages and Benefits
of Maintenance Wages and Benefits

General Plant Overhead:
Mechanical Department Services:
Employee Relations Department:
Business Services:

7.10%
2.40%
5.90%
7.40%

of Maintenance and Operations Wages and Benefits
of Maintenance and Operations Wages and Benefits
of Maintenance and Operations Wages and Benefits
of Maintenance and Operations Wages and Benefits

Maintenance

Operating Overhead

Property Taxes and Insurance
Property Taxes and Insurance:
Straight Line Depreciation
Direct Plant:
Allocated Plant:

2% of Total Depreciable Capital

8.00% of Total Depreciable Capital, less 1.18 times the Allocated Costs
for Utility Plants and Related Facilities
6.00% of 1.18 times the Allocated Costs for Utility Plants and Related Facilities

Other Annual Expenses
Rental Fees (Office and Laboratory Space):
Licensing Fees:
Miscellaneous:

$3,555,000
$0
$342,100

Depletion Allowance
Annual Depletion Allowance:

$0

The complete fixed cost summary is shown in Table 19.3.2. The combination of fixed
operating expenses, site maintenance costs, and general yearly expenses totals $15.2 million. It
should be noted that this value is quite high and exceeds the fixed costs associated with certain
industrial chemical processes. The reason behind these high costs is most likely associated with
having a large number of operators present. Additionally, operating overhead, property taxes and
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insurance, and other annual expenses may actually be lower than the assumptions made for this
project. However, it was assumed that all these values were useful in calculating an upper bound
on what the fixed costs would be, allowing for a strict feasibility analysis.
Table 19.3.2. Summary of all fixed costs, including operating expenses required per year for the
execution of plant duties, site maintenance, and general expense estimates.
Fixed Cost Summary

Operations
Direct Wages and Benefits
Direct Salaries and Benefits
Operating Supplies and Services
Technical Assistance to Manufacturing
Control Laboratory

$
$
$
$
$

5,408,000
811,200
324,480
780,000
845,000

Total Operations

$

8,168,680

$
$
$
$

582,729
145,682
582,729
29,136

$

1,340,278

General Plant Overhead:
Mechanical Department Services:
Employee Relations Department:
Business Services:

$
$
$
$

493,280
166,743
409,909
514,123

Total Operating Overhead

$

1,584,055

$

258,991

Rental Fees (Office and Laboratory Space):
Licensing Fees:
Miscellaneous:

$
$
$

3,555,000
342,100

Total Other Annual Expenses

$

3,897,100

$

15,249,104

Maintenance
Wages and Benefits
Salaries and Benefits
Materials and Services
Maintenance Overhead
Total Maintenance
Operating Overhead

Property Taxes and Insurance
Property Taxes and Insurance:
Other Annual Expenses

Total Fixed Costs
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20.

Economic and Profitability Analysis

20.1. Market Analysis Flux and Basic Approach
The service fee applied to the enzymatic treatment of RBC units is based on the current
cost for hospitals to collect and treat RBC units from donors. The average cost for RBC units to
hospitals has risen over the last 20 years, from $155 in the early 1990s to $243.10 in 2016 [25,26].
The price charged to patients is higher, at $219 in the early 1990s and $423 in 2016 [25,26]. The
enzymatic treatment of RBC units will be an additional service added to the collection and
treatment of existing RBC units. The price for this service will be a portion of the cost to collect
and treat RBC units and will be charged to hospitals, but ultimately the patient or insurance agency
will cover the fee.
Approximately 21 million units of RBCs are needed yearly in the United States and the
demand is steadily increasing as the population ages and more surgeries are required [2]. The
enzymatic conversion operation aims to reach 200,000 RBC units annually, or almost 1.0% of the
national market. This is enough to cover the demand for a large hospital system in the United
States. With further development of the process and expansion, a larger proportion of the market
could be reached.
20.2. Clinical Trial Considerations
The process for the enzymatic conversion of RBCs for transfusion medicine shows the
promise to be both lifesaving and somewhat profitable. No other blood product offers both nonimmunogenic properties and large scale production. The large scale production of universal RBCs
is revolutionary and could replace traditional packaged RBCs for most applications.
The plant produces 200,000 units of universal RBCs annually and generates $34,293,532
annual revenue in the third production year. The Return on Investment (ROI) for the plant at the
current selling price of $187.50 is 17.17% and the Internal Rate of Return (IRR) is 21.73%. The
Net Present Value (NPV) of this project in 2019 is $8,461,700.
The price of clinical trials for FDA approval was not included in the profitability analysis.
As previously mentioned, the projected cost for Phase I-III clinical trials is approximately $100200 million, as advised by Scott Diamond, Ph.D., from the University of Pennsylvania. The scale
of this plant is not sufficient to recoup the initial investment required to perform these trials.
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However, this plant is large enough to produce the requisite materials necessary to perform the
large scale Phase I-III trials and thus could initially operate as a pilot plant. Initial safety studies
and Phase I trials of the ECO-B enzyme have been successful, which paves the way for an
accelerated Phase I trial [4]. Phase II and III trials will need to be more comprehensive, with larger
patient populations [23]. These trials could take additional time, approximately 2-3 years and
subsequent approval a year later. However, the design and performance of these trials is out of the
scope of this project and will not be included in the profitability analysis.
Nonetheless, it is worth mentioning that the start-up nature of this project, if successful,
could make it an enticing partner with large biotechnological and pharmaceutical companies
present on the East Coast. Currently, GlaxoKlineSmith, Celgene Corporation, Kite
Pharmaceuticals, and Merck have all been developing their blood biology departments to address
numerous hematological diseases. If this project is deemed financially feasible, collaborations with
these conglomerates could help provide adequate funding to execute clinical trials without
imposing further costs. Additionally, it opens up the possibility of mergers with these companies
that could help with the recovery of initial investments and lead to additional profitability.
20.3. Pricing of ECO RBCs
Current blood transfusion unit prices tend to average around $309 in the Boston area. Using
this as a basis, the service price for the enzymatic treatment of RBCs to convert them to universal
type will be approximately 60% of the purchase cost hospitals pay for transfusion units. This
decision was done after performing a sensitivity analysis on the profitability of this venture by
varying the selling price of the transfusion unit. The service price for the enzymatically converted
RBCs is approximately half of the collection and treatment cost to hospitals. The selling price will
$187.50 per transfusion unit, and it increases by 4.34% up until the year 2024, shown in Table
18.3. Once 2024 begins, however, the price change will only happen in increments of 0.5% for the
duration of the facility’s production life. The increase in price is to account for the natural market
growth in demand for RBC units. Additionally, since it is difficult to protect how other blood
collecting organizations will evolve in the next decade, it may be a more realistic approach to
stabilize prices after some time to be competitive with other transfusion unit sources. Overall, the
price increases by $34.16 over the duration of the facility’s production life.
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Table 20.3.1. The projected selling price and yearly increase for enzymatically converted RBC
units. Up until the year 2024, the transfusion units will see a yearly increase of 4.34% in price,
reflecting the most recent trends in the transfusion market. Beginning in 2024, it has been decided
that the price will only increase by 0.5% annually.

Year

Manual Input Price

Percent Increase

2021

$187.50

2022

$195.64

2023

$204.13

2024

$212.99

2025

$214.05

2026

$215.12

2027

$216.20

2028

$217.28

2029

$218.37

2030

$219.46

2031

$220.55

2032

$221.66

-4.34%
4.34%
4.34%
0.50%
0.50%
0.50%
0.50%
0.50%
0.50%
0.50%
0.50%

20.4. Profitability Analysis
An initial capital investment of $25.6 million will be required. Table 20.4.1 summarizes
the working capital allotted to the project. It is assumed that one year will be needed for finalizing
design and an additional year for construction. The plant will be active for 12 years, leading to a
total duration of 14 years for the project. A conservative approach was taken and it was assumed
that the plant will operate at 90% of the desired production goal of 200,000 ECO RBC transfusion
units, beginning from year one.
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Table 20.4.1. Summary of working capital requirements for the first year of production.
Working Capital
Accounts Receivable
Cash Reserves
Accounts Payable
ECO RBCs Inventory
Raw Materials
Total

$
$
$
$
$
$

2020
8,321,918
870,676
(678,199)
3,624,658
647,260
12,786,313

$
$
$
$
$
$

-

$
$
$
$
$
$

-

Present Value at 15%

$

11,118,533

$

-

$

-

Total Capital Investment

2021

$

2022

25,622,019

Table 20.4.2 provides an overview of multiple profitability metrics for the process in its
third year of production. As previously mentioned, the plant will have an IRR of 21.73%, slightly
above the nominal rate of 15%. The ROI is calculated to be 17.17%. The net present value of the
project in 2019 is $8.46 million. The total capital investment involved in the project is $27.3
million. It should be noted that this process will require a significant amount of research and
specialized technology optimization, which will cause future cash flows to be reinvested with
return rates even greater than the estimated IRR.

Table 20.4.2. Summary of profitability metrics for the RBC conversion plant using a selling price
of $187.50 per ECO RBC transfusion unit.

Profitability Measures
The Internal Rate of Return (IRR) for this project is
The Net Present Value (NPV) of this project in 2019 is

21.73%
$

8,461,700

ROI Analysis (Third Production Year)
Annual Sales
Annual Costs
Depreciation
Income Tax
Net Earnings
Total Capital Investment
ROI

36,743,070
(28,146,775)
(1,160,279)
(2,751,326)
4,684,690
27,289,799
17.17%
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This financial analysis provides some initial insight into the feasibility of the project.
Assuming proper partnerships can be established with major hospitals and blood banks, this project
is slightly profitable. The successful profit in this analysis is also assuming that the process plant
continues to produce only 200,000 ECO RBC transfusions per year. Realistically, it is expected
that the start-up will expand to cover the blood demands of other major hospitals in the state of
Massachusetts and potentially other nearby metropolitan areas along the East Coast. This implies
that after several years of operation, the actual production goal and capacity will increase.
Although expansion will also imply increased equipment and operating costs, there will be
additional compounded profits. Our equipment selection was also careful to incorporate smaller
scale bioreactor towers that can actually handle the operation of more than one seed bioreactor,
providing an initial area in which costs will already be lower than expected upon expansion. Once
the process has been optimized, industrial consultant Arthur Etchells, Ph.D., states that the number
of batches completed in a week. This will naturally increase production capacity without investing
in further equipment costs.
The net present value of the studied base for the process over a production lifetime of 12
years was approximately $8.46 million with a selling price as described in Section 20.3. A plot of
the cumulative cash flow is shown in Figure 20.4.1.

Figure 20.4.1. Cumulative discounted free cash flow for project over a twelve year production
period. The base selling price of each ECO RBC unit is $187.50, which increases by 4.34% until
2024 and then only by 0.50% for the rest of the plant’s lifetime.
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20.5. Sensitivity Analysis
The cost to produce a unit of enzymatically converted RBCs can be broken down into
principal components to assess how changes would affect the overall cost. The total capital
investment is the largest component of the cost to produce the RBC units, at 46% of the cost. The
largest variable in the total capital investment is the bare module factor, which can change based
on the nature of the process machinery required for the plant. The next largest section are the raw
materials, contributes 16% to the total cost of the RBC units. The raw materials constitute a
majority of the variable costs associated with the production of the RBC units. This is followed
by direct wages and other expenses as the leading contributors to the cost of RBC unit production.

Figure 20.5.1: Distribution of costs per unit of RBCs.
To examine how key factors contribute to the plant’s profitability, a sensitivity analysis
was performed on the components that comprised the largest segments of the total cost of the RBC
unit. Variables, such as product price, variable costs, operator wages, and bare module cost were
studied to determine which were most influential on the profitability of the plant. The sensitivity
analysis was used to guide the selection of the final values for these variables.
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20.6.

Service Price and Variable Costs
The service price was studied in relation to the variable costs to determine its effect on the

Internal Rate of Return (IRR). The service price was varied between +/- 50% of the initial set
service price, which corresponds to approximately half the price of a traditional RBC unit.
Additionally, the variable costs were studied for +/- 50% of the set variable cost.
The plant becomes unprofitable below a product price of $122.50 and has an IRR of
48.54% at a service price of $262.50, 150% of the set price. The IRR varied from -0.80% to 31.57%
as the variable cost ranged from +/- 50% of the set variable cost. While the variable cost does
affect the profitability of the plant, the service price has a much larger effect on the profitability.
For the set service price of $175 the plant can be profitable for variable costs ranging from below
$7,165,373 to $20,063,045. For this reason variable costs were not considered as an important
metric for further studies of plant profitability, which is detailed in Figure 5.10.3.3.
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price.

Table 20.6.1: Internal Rate of Return (IRR) as a function of variable costs and product

The IRR sharply rises with small changes in the price of the RBC unit service, as shown in
Figure 5.10.3.2. The plant has a negative IRR when the service price is set below $150 per unit of
RBCs. The final service cost of $175 was chosen to maximize profitability and customer
requirements. At this value the plant has an internal rate of return of 16.22% and the customer
pays a service fee that is approximately half of the original cost of the RBC unit, which was
determined previously to be the upper limit for customer satisfaction.

Figure 20.6.1: Effect of service price per RBC unit on Internal Rate of Return (IRR)
The effect of variable costs on the IRR is much smaller than that of the service price, but
as shown in Figure 5.10.3.3 the profitability of the plant does marginally increase as the variable
costs decreases. As the variable costs ranged from $7 million to $21.5 million, or +/- 50% of the
original variable costs the IRR only increased 32.4%. In order to see increases in profitability,
dramatic reductions in the variable costs would have to be made. Because the variable costs didn’t
greatly influence the profitability as other factors did, optimization efforts were focused elsewhere.
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Figure 20.6.2: Effect of variable costs on Internal Rate of Return (IRR).
20.7.

Operator Wages
The operator wages account for $5,408,000 of the $28,145,384 annual costs, or 19.2% of

the total costs. This is the second largest cost, behind variable costs, excluding the capital
investment. Because of this, it is important to determine the effect changes in operator wages have
on the profitability of the plant.
As operator wages increased the IRR and ROI decreased linearly, suggesting a strong
relationship between profitability and the operator wages. The operator wage of $40/hour was
selected for its acceptable profitability measures and industry competitiveness. The technical
nature of the work in this plant and high quality control measures in place raise the operator wage
rate. However, even at high wage rates, the plant can be profitable, only becoming unprofitable at
wages higher than $60/hour.
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Figure 20.7.1: Effect of operator wages on Internal Rate of Return (IRR) and Return on Investment
(ROI).

20.8.

Bare Module Factor
The bare module factor is used to predict the final purchase and installation cost for

equipment. It is highly dependent on the nature of the equipment purchased. For instance,
machinery that needs to be custom designed, fabricated, and installed incurs a larger bare module
cost than equipment purchased off the shelf. Much of the equipment needed for this process falls
in the later category, and thus has a lower bare module cost.
The default bare module factor used for most applications is 3.21, however that likely
overestimates the bare module cost for this plant. A sensitivity analysis was performed to see how
the bare module factor affected the profitability of the plant. This is especially important, because
the equipment costs are a majority of the total capital investment.
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Figure 20.8.1: Effect of Bare Module Factor on the Internal Rate of Return (IRR) and the Return
on Investment (ROI).
The bare module factor had a modest effect on both profitability measures. Large changes
in the bare module factor showed only about a 20% change in the IRR and ROI values, but
corresponds to significant changes in the bare module cost. For the purpose of the profitability
analysis a bare module factor of 3.21 was used as an upper bound as further effort to quantify the
bare module factor would have a modest effect on the overall plant profitability.
20.9.

Facility Lifespan

The plant has an operation life expectancy of about 12 years. The anticipated lifespan of
the facility accounts for the manufacturers’ projected lifespans of the equipment and the projected
market for RBCs in general. New methods for producing universal RBCs are being studied, but
they will not be viable for large scale production for at least a decade until they begin to collect
human clinical trial data [11]. Enzymatically converted RBCs will therefore be the only competitor
in this market segment for the lifespan of the facility. If the plant were to shut down before the end
of its projected 12-year lifespan, there could be some value in the salvage of the purchased
equipment. It is recommended however to operate at full production capacity for its planned 12year occupancy.
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21.

Other Important Considerations

21.1. Steam-in-Place (SIP) Requirements
Unless otherwise specified, process equipment will be steam-sterilized in place (SIP) after
cleaning in place (CIP) to ensure neutralization of E. coli, unconverted A and B RBCs, used ECOA and ECO-B enzyme, and other biological process waste that could pose harm to the environment
or persons if disposed of before neutralization. SIP requires equipment sterilization with saturated
steam at 50 psi and 138°C to ensure that all equipment reaches 121°C for 11 minutes, complying
with FDA sterilization regulations.51 Flow of room temperature air through equipment tubing will
be used to cool the equipment post-SIP. Cooling times for equipment are according to
manufacturer brochures and/or equipment size.
21.2. Clean-in-Place (CIP) Requirements
Any and all equipment that processes cells, enzyme, or other biological material must be
treated as biological waste or cleaned according to FDA clean-in-place (CIP) regulations. Nondisposable equipment that contacts biological materials will be cleaned according to CIP protocol
between batches; CIP is accounted for on all process scheduling Gantt charts.
CIP for reusable process equipment will consist of a rinse with water for injection (WFI),
followed by two detergent flushes and an intermediate rinse with WFI. An acidic solution will be
used to ensure neutralization of all bio-waste and clearance of all protein and cell residue. A rinse
with WFI to rid the equipment of any remaining detergent and an air blow over the equipment to
remove moisture complete CIP. The amounts of detergent and acid solution required annually for
CIP and, correspondingly, the costs of these materials, are assumed negligible as compared to other
raw material costs in the economic analysis for the process.
21.3. Waste Treatment and Environmental Concerns
All live cells and cell cultures, particularly E. coli, may grow or accumulate in water supply
or elsewhere and become a hazard to the surrounding environment. Thus, it is critical to inactivate
E. coli cultures before disposal. For a 12-log reduction in E. coli population size, it was assumed

51

Effective Bactericidal Treatment , 21 C.F.R. Sect. 1240 (2017).

185

that E. coli must be treated at 121°C for 5 minutes.52 A D-value (thermal deactivation coefficient)
of 0.4167 minutes, the time required for one decimal reduction of the population, was calculated
based on this assumption. The number of cells to be inactivated was calculated from batch volumes
and final cell concentrations for ECO-A enzyme and ECO-B enzyme production assuming firstorder deactivation kinetics. To more thoroughly ensure cell death, it is optimal to achieve a 25-log
reduction in cell population; a thermal inactivation time of 10.4 minutes for both ECO-A and ECOB E. coli cells was calculated based on this criterion and final cell concentrations. Live cultures
will thus be heated to 121°C for 10-11 minutes to ensure cell death (see Appendix D). Any process
units that contact live cells or other biological materials will be autoclaved or otherwise thoroughly
sterilized. Waste transport and disposal may be contracted to a nearby facility in Cambridge due
to the costly nature of waste handling equipment for a startup venture.
In addition to CIP/SIP practices, hygienic conditions will be met for equipment and
operating personnel with quality materials and ventilation. Quality assessment may be performed
at various points in the process to assure batch uniformity; quality control in the form of limulus
amebocyte lysate (LAL) assay, flow cytometry, or thin layer chromatography will be performed
on the final product before packaging and shipping. Current good manufacturing practice (cGMP)
protocols will be strictly followed at every step of the process.
21.4. Water for Injection (WFI) Concerns
It is critical that all water for injection (WFI) generated for process operations be
maintained at the proper pH, have no microbial colonies, and contain no particulate matter. Thus,
the temperature of the WFI distribution at peak load will be maintained at 80°C. The WFI still will
be monitored daily for microbes. WFI samples with sizes of 100-300 mL per test will be taken
from various points in the supply loop for 20 working days. Tests for compliance with FDA
specifications for WFI will be taken over the course of one year to monitor changes in the WFI
chemical composition over time. Tests for residual chlorine, conductivity, and pH will be
performed on the WFI year-round. All growth media must pass growth promotion testing.
In addition to the routine testing for microbial growth previously described, the presence
of microbes in the WFI will be tested using a membrane filtration technique called total
52
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heterotrophic plate count. WFI will be plated using plate count agar to perform testing for presence
of microbiological agents; any colonies present on the agar filter will be identified and further
tested for potential safety concerns. For WFI to be considered safe according to FDA standards,
plate counts must be less than 10 CFU/mL.
Finally, sanitary clamped piping, instruments, and valves will be used to transport WFI to
distribution and storage systems. Piping and instruments will be labeled, properly sloped for
optimal flow, and maintained to pass integrity testing. A backflow valve will be installed with the
still to protect source water.
21.5. Intellectual Property Concerns and FDA Approval
Consideration of intellectual property concerns prompts consideration of the possibility of
licensing the process to a research institution that has conducted studies on enzymatic conversion
of RBCs. In addition, a Biologic License Application (BLA) for production, distribution, and
medical usage of ECO-RBCs would need to be filed with the FDA before plant startup. A BLA
requires extensive pre-clinical tests and successful passage of Phase I-III clinical trials. Pre-clinical
tests would study ECO-RBCs for their stability in storage, morphology, biochemistry, oxygen
dissociation, and hemolytic properties as compared to those of natural type O RBCs. Clinical trials
in human patients would examine the immunogenicity, circulatory half-life, hemoglobin
clearance, and blood clearance rate of ECO-RBCs relative to those of wild type O RBCs.
Indication selection of patients for clinical trial would need to be performed very carefully. While
Phase I clinical trials may be conducted in healthy patients, Phase II and III clinical trials would
need to be conducted with patients with measurable indications. Patients with indications such as
traumatic bleeding would not be selected, as obtaining informed consent is difficult and transfusion
challenging to control. Instead, patients with anemia or undergoing elective surgery would be
chosen to participate in clinical trial as response to WT RBCs is well-established and obtainment
of informed consent is easier. Consultation with Scott Diamond, Ph.D, of the Department of
Chemical and Biomolecular Engineering at the University of Pennsylvania led to an estimated cost
of $100-$200 million for FDA approval of ECO-RBCs. While this cost is considered out of scope
for the purposes of this project, it is vital to consider if the plant were to be realized.
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21.6. Alternative Applications
The primary alternative application of production of ECO-RBCs to use in hospitals and
distribution to blood banks for use in clinical application is production of ECO-RBCs to provide
a more universal blood supply to the US military. The high demand for blood products, particularly
universal RBCs and plasma for transfusion, on the battlefield could lead to defense funding for
ECO-RBC production if this application were to be pursued.
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22.

Conclusions and Recommendations
The design of a start-up-scale plant that produces the glycosidases for RBC conversion and

treats RBC units to create universal RBC units shows promise for profitability and expansion. The
plant requires an initial capital investment of $25.6 million and will operate over a 12 year lifespan.
During this time the plant will be able to produce 200,000 converted RBC units, enough to satisfy
the needs of a single hospital system near the plant’s location in Medford, MA. The start-up-scale
plant will have a 21.73% internal rate of return over its lifespan, and can maintain profitability
over a variety of operating conditions. The plant breaks even in its eighth year of operation, and
opportunities for expansion could enhance the profitability of this process.
The profitability of this plant does not account for the expected cost of clinical trials and
FDA approval, which is estimated to be $100-200 million. The high cost of the clinical trials
makes the start-up-plant unprofitable, however, the scale of this plant was not designed to recover
the initial costs of FDA approval. Instead, the start-up-scale plant is designed to be a proof of
concept and to produce enough converted RBC units to supply the Phase I-III clinical trials
necessary for approval. Once the blood product is approved for use in humans, the process could
be expanded beyond the start-up-scale plant. Large scale central production of the glycosidases
could be optimized for distribution to local treatment facilities. Under this expansion regime, the
process could provide universal RBCs to east coast cities with relative logistical ease and could
recover the initial capital investment required for approval.
Due to the high profitability of the start-up-scale plant, projected FDA approval, and the
potential for further expansion, it is recommended that this venture is pursued. The enzymatic
conversion of RBCs has the potential to alleviate many of the growing concerns in the blood
market, including blood wastage and incompatibility reactions. However, investors should be
mindful of the risks associated with the blood market. Shifts in the demand for different types of
blood products and the growing efficiency of surgeries could affect the demand for RBC units,
however, the scale of the process is not likely to ever exceed this demand.

190

Section 23:
Acknowledgements

191

23. Acknowledgements
We would like to thank our faculty advisor, Dr. Miriam Wattenbarger, for her helpful input,
intervention, and guidance throughout the course of this project. We also thank Professor Bruce Vrana for
his guidance during the semester. We would like to acknowledge Dr. Scott Diamond for his blood biology
expertise, his assistance with project conceptualization and proposal, and his input on the FDA approval
process for our product. We thank Dr. Don Siegel, Director of Transfusion Medicine and Therapeutic
Pathology at HUP, for his guidance on cold storage of blood products, cold room design, and pricing of
ECO-RBCs.
The complex particulars of our material balance and oxygen uptake calculations could not have
been completed without the support and guidance of Dr. Jeff Cohen. Additionally, we would like to thank
Dr. Daniel Green, Mr. Gary Sawyer, and Dr. Arthur Etchells for their expertise and support during weekly
meetings. Finally, we would like to thank Dr. Sean Holleran and Dr. Warren Seider for giving us the
necessary process design tools to complete this project.
The feedback and assistance that we have received from consultants, professors, and advisors has
been invaluable to the completion of this design project and to what bioprocess engineering is. We greatly
appreciate the time and consideration that you have devoted to us and to our project. Thank you.

192

Bibliography
Blood Facts and Figures
American Red Cross. Blood Facts and Statistics [Internet]. 2018 [cited 2018 Apr 15]. Available
from: https://www.redcrossblood.org/learn-about-blood/blood-facts-and-statistics
World Health Organization. WHO Model List of Essential Medicines, 19th List [Internet]. 2015
[cited 2018 Apr 15]. Available from:
http://www.who.int/medicines/publications/essentialmedicines/en/

Blood Product Collection, Usage, and Wastage
Ellingson KD et al. Continued decline in blood collection and transfusion in the United States2015. Transfusion 2017 Jun; 57(2); 1588-1598.
Engber D. The Business of Blood: Does the Red Cross sell your frozen plasma? [Internet]. Slate
2006 [cited 2018 Apr 15]. Available from:
http://www.slate.com/articles/news_and_politics/explainer/2006/09/the_business_of_blood.html
Kurup R et al. A study on blood product usage and wastage at the public hospital, Guyana. BMC
Res. Notes 2016 Jun; 9: 307.
Mohebbi Far R et al. Determination of rate and causes of wastage of blood and blood products in
Iranian hospitals. Turk. J. Haematol. 2014 Jun; 31(2): 161-167.
Sullivan L. Blood Industry Gets A Transfusion From An Aging Population. BCC Research 2017
[cited 2018 Apr 15]. Available from: http://blog.bccresearch.com/blood-industry-gets-atransfusion-from-an-aging-population
RBC Transfusion Facts and Statistics
Ah-Moye D et al. Clinical Biochemistry: Metabolic and Clinical Aspects. London: Churchill
Livingstone; c2014. Chapter 26, Introduction to haematology and transfusion science; p. 497–
514.
Carson JL et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Annals
of Internal Medicine 2007; 157: 49–58.
Forbes JM et al. Blood transfusion costs: a multicenter study. Transfusion 1991; 31(4): 318-323.
Lagerquist O et al. The cost of transfusing a unit of red blood cells: a costing model for Canadian
hospital use. ISBT Science Series 2017; 12(3):375-380.

193

Miraflor E et al. Emergency uncrossmatched transfusion effect on blood type alloantibodies. J.
Trauma Acute Care Surg. 2012; 72(1): 48-52.
Sazama K. Transfusion errors: scope of the problem, consequences, and solutions. Curr. Hematol.
Rep. 2003; 2(6): 518-521.
Schulson M. Blood transfusions decline 2011-14, study finds [Internet]. Cornell Chronicle 2018.
Web.
http://news.cornell.edu/stories/2018/02/blood-transfusions-decline-2011-14-new-studyfinds
Stainsby D et al. Serious Hazards of Transfusion Annual Report 2004. Serious Hazards of
Transfusion Office, Manchester Blood Centre, 2005.
Strobel E. Hemolytic transfusion reactions. Transfus. Med. Hemother. 2008; 35(5): 346-353.
Vasquez AM et al. Survey of blood collection centers and implementation of guidance for
prevention of transfusion-transmitted Zika virus infection-Puerto Rico, 2016. Morb. Mortal. Wkly.
Rep. 2016; 65: 375-378.
Enzymatic Conversion for Production of Universal RBCs
Kwan DH et al. Toward efficient enzymes for the generation of universal blood through structureguided directed evolution. J. Am. Chem. Soc. 2015; 137(7): 5965-5705.
Liu QP et al. Bacterial glycosidases for the production of universal red blood cells. Nature
Biotechnology 2007; 25(4): 454-464.
Olsson ML, Clausen L. Modifying the red cell surface: towards an ABO-universal blood supply.
British Journal of Haematology 2007; 140: 3-12.
Patents for Production of Universal RBCs
Acharya SA, Nacharaju P, Manjula BN. Universal red blood cells, methods of preparing same,
and uses thereof. 2009.
Clausen H, de la Vega H, Hill C, Liu Q. Enzymatic conversion of blood group A, B, and AB red
blood cells using alpha-N-acetylgalactosaminidases and alpha-galactosidases with unique
substrate specificities and kinetic properties.
Goldstein J, Lenny L, Hurst R. Method for conversion of blood type.

194

RBC Storage and Treatment
Brunskill S et al. What is the maximum time that a unit of red blood cells can be safely left out of
controlled temperature storage? Transfus. Med. Rev. 2012; 26(3): 209-223.
Kumar A, Srivastava A. Cell separation using cryogel-based affinity chromatography. Nature
Protocols. 2010Oct7;5(11):1737–47.
Ramirez-Arcos S et al. Evaluating the 4-hour and 30-minute rules: effects of room temperature
exposure on red blood cell quality and bacterial growth. Transfusion 2013; 53(4); 851-859.
Siegel DL. Re: Student questions on RBC storage in hospitals [Internet]. Message to: Miriam
Wattenbarger. 2018 Mar 14, 9:46 am [cited 2018 Apr 15]. [about 4 paragraphs].
FDA Regulations on RBC Products and FDA Approval of Reagent RBCs
Diamond SL. Re: Cost of FDA Approval of ECO-RBCs [Internet]. Message to: Carly Catella.
2018 Apr 2, 11:08 am [cited 2018 Apr 15]. [about 4 paragraphs].
Reagent Red Blood Cells, 21 C.F.R. Sect. 660.30 (2017).
Siegel DL. Re: Costing of ECO-RBC units [Internet]. Message to: Carly Catella. 2018 Apr 3,
10:00 pm [cited 2019 Apr 15]. [about 6 paragraphs].
Vosta J. FDA Evaluation of Red Cell Products. Laboratory of Cellular Hematology, U.S. Food
and Drug Administration, 2016.
White SJ, Hamilton, WA, Veronesi JF A comparison of field techniques used to pressure-infuse
intravenous fluids. Prehosp. Disaster Med. 1991; 6(4): 429-434.
Raw Materials
Adenine; MSDS No. PHR1383 [Online]; Sigma-Aldrich: Saint Louis, MO, Jan 11, 2017. accessed
Apr 10, 2018).
Ammonium sulfate, NF Grade; MSDS No. RES1427A-A7 [Online]; Sigma-Aldrich: Saint Louis,
MO, Sep 1, 2017.
(accessed Apr 10, 2018).
POROS Benzyl Ultra Hydrophobic Interaction Chromatography Resin; MSDS No. A32566
[Online]; Life Technologies Corporation: Carlsbad, CA, Oct 6, 2017. www.thermofisher.com
(accessed Apr 10, 2018).
Brij 35 for Synthesis; MSDS No. 801962 [Online]; EMD Millipore: Saint Louis, MO, Sep 16,
2014.
http://www.emdmillipore.com/Web-US-Site/en_CA/-/USD/ProcessMSDSStart?PlainSKU=MDA_CHEM-801962&Origin=PDP (accessed Apr 10, 2018).

195

Chloramphenicol, United States Pharmacopeia (USP) Reference Standard; MSDS No. 1107004
[Online]; Sigma-Aldrich: Saint Louis, MO, Jan 17, 2018. (accessed Apr 10, 2018).
Citric acid, Anhydrous; MSDS No. PHR1071 [Online]; Sigma-Aldrich: Saint Louis, MO, Jan 17,
2018. (accessed Apr 10, 2018).
D-(+)-Glucose monohydrate; MSDS No. 49159 [Online]; Sigma-Aldrich: Saint Louis, MO, Dec
21, 2015. (accessed Apr 10, 2018).
N,N-Dimethylacrylamide; MSDS No. 274135 [Online]; Sigma-Aldrich: Saint Louis, MO, Oct 3,
2017. (accessed Apr 10, 2018).
Ethylenediamine; MSDS No. E1649 [Online]; Sigma-Aldrich: Saint Louis, MO, May 27, 2016.
(accessed Apr 10, 2018).
Ethyl alcohol, pure; MSDS No. E7023 [Online]; Sigma-Aldrich: Saint Louis, MO, Oct 3, 2017.
(accessed Apr 10, 2018).
Glutaraldehyde soln; MSDS No. G7776 [Online]; Sigma-Aldrich: Saint Louis, MO, Feb 24, 2017.
(accessed Apr 10, 2018).
Guanidide hydrochloride; MSDS No. PHG0006 [Online]; Sigma-Aldrich: Saint Louis, MO, Aug
31, 2017. (accessed Apr 10, 2018).
HEPES; MSDS No. RES6003H-B7 [Online]; Sigma-Aldrich: Saint Louis, MO, Aug 31, 2017.
(accessed Apr 10, 2018).
HisPur Cobalt Resin; MSDS No. 89964 [Online]; Life Technologies Corporation: Carlsbad, CA,
Mar 15, 2016. www.thermofisher.com (accessed Apr 10, 2018).
Imidazole; MSDS No. 1336500 [Online]. Sigma-Aldrich: Saint Louis, MO, Jan 16, 2018.
26mode%3Dmatch%2520partialmax%26lang%3Den%26region%3DUS%26focus%3Dproduct
(accessed Apr 10, 2018).
Isopropyl β-D-1-thiogalactopyranoside; MSDS No. PHG0010 [Online]; Sigma-Aldrich: Saint
Louis, MO, Aug 31, 2017. (accessed Apr 10, 2018).
Kanamycin A (sulfate); MSDS No. 15321 [Online]; Cayman Chemical Company: Ann Arbor, MI,
Sep 30, 2014. https://www.caymanchem.com/msdss/15321m.pdf (accessed Apr 10, 2018).
Mannitol; MSDS No. 1375105 [Online]; Sigma-Aldrich: Saint Louis, MO, Mar 4, 2018. (accessed
Apr 10, 2018).
N,N′-Methylenebis(acrylamide); MSDS No. 146072 [Online]; Sigma-Aldrich: Saint Louis, MO,
Sep 5, 2017. (accessed Apr 10, 2018).

196

MES; MSDS No. M3671 [Online]; Sigma-Aldrich: Saint Louis, MO, May 11, 2016. (accessed
Apr 10, 2018).
Sodium phosphate monobasic monohydrate; MSDS No. RES20906-A7 [Online]; Sigma-Aldrich:
Saint Louis, MO, Aug 31, 2017. (accessed Apr 10, 2018).
Sodium phosphate; MSDS No. 342483 [Online]; Sigma-Aldrich: Saint Louis, MO, Oct 3, 2017.
(accessed Apr 10, 2018).
Sodium borohydride; MSDS No. 452882 [Online]; Sigma-Aldrich: Saint Louis, MO, Oct 3, 2017.
9 (accessed Apr 10, 2018).
Sodium chloride; MSDS No. S7653 [Online]; Sigma-Aldrich: Saint Louis, MO, Oct 2, 2017.
(accessed Apr 10, 2018).
Sodium hydroxide; MSDS No. S8045 [Online]; Sigma-Aldrich: Saint Louis, MO, Jun 2, 2016.
(accessed Apr 10, 2018).
Pierce High Capacity Endotoxin Removal Resin; MSDS No. 8743 [Online]; ThermoFisher
Scientific, Pierce Biotechnology, Waltham, MA, Feb 17, 2014. www.thermofisher.com (accessed
Apr 10, 2018).
Sodium citrate dihydrate; MSDS No. W302600 [Online]; Sigma-Aldrich: Saint Louis, MO, Oct
20, 2017. (accessed Apr 10, 2018).
N,N,N′,N′-Tetramethylethylenediamine; MSDS No. T7024 [Online]; Sigma-Aldrich: Saint Louis,
MO, Sep 11, 2015. (accessed Apr 10, 2018).
Urea; MSDS No. 1706698 [Online]; Sigma-Aldrich: Saint Louis, MO, Jan 16, 2018. (accessed
Apr 10, 2018).
Major Unit Operation Specifications
Cole-Parmer Instrument Company, LLC. Masterflex 77924-80 L/S Profibus Network-Compatible
Pump with Easy-Load II thin-wall Pump Head and Open-Head Sensor [Internet]. Masterflex
77924-80 L/S Profibus Network-Compatible Pump with Easy-Load II thin-wall Pump Head and
Open-Head Sensor. Vernon Hills, IL: Cole-Parmer Instrument Company, LLC; 2018 [cited 2018
Apr 16]. Available from: https://www.coleparmer.com/i/masterflex-77924-80-l-s-profibusnetwork-compatible-pump-with-easy-load-ii-thin-wall-pump-head-and-open-headsensor/7792480
Holland Applied Technologies. Spec Sheet QF1200S-CV [Internet]. Spec Sheet QF1200S-CV.
Chicago, IL: Holland Applied Technologies; 2015 [cited 2018 Apr 16]. Available from:
http://www.hollandapt.com/Documents/Ctrl_Hyperlink/doccopy11285_uid192018402382.pdf

197

EMD Millipore. Data Sheet: Millipore Express SHF Hydrophilic Filters [Internet]. Data Sheet:
Millipore Express SHF Hydrophilic Filters. St. Louis, MO: EMD Millipore; 2018 [cited 2018 Apr
16]. Available from: http://www.emdmillipore.com/US/en/product/Millipore-Express-SHFHydrophilic-Cartridge-Filters,MM_NF-C8873#anchor_DS

Sartorius Stedim Biotech GmbH. Data sheet: ambr 250 modular bioreactor [Internet]. Data sheet:
ambr 250 modular bioreactor. Goettingen, Germany: Sartorius Stedim Biotech GmbH; 2015 [cited
2018
Apr
16].
Available
from:
https://www.sartorius.com/_ui/images/h0c/h06/8870706315294.pdf

Sartorius Stedim Biotech GmbH. BIOSTAT® B: The Multi-Talented Bioreactor for Research and
Development [Internet]. BIOSTAT® B: The Multi-Talented Bioreactor for Research and
Development. Goettingen, Germany: Sartorius Stedim Biotech GmbH; 2014 [cited 2018 Apr 16].
Available from: https://www.sartorius.com/mediafile/Broch_BIOSTAT-B_SBI1513-e.pdf

Sartorius Stedim Biotech GmbH. UniVessel® Glass: Reliability and Continuity [Internet].
UniVessel® Glass: Reliability and Continuity. Goettingen, Germany: Sartorius Stedim Biotech
GmbH; 2017 [cited 2018 Apr 16]. Available from: http://www.emdmillipore.com/Web-USSite/en_CA/-/USD/ShowDocument-File?ProductSKU=MM_NFC173675&DocumentId=201504.204.ProNet&DocumentUID=17731154&DocumentType=DS&
Language=EN&Country=NF&Origin=PDP

Sartorius Stedim Biotech GmbH. BIOSTAT® D-DCU: Your “Fast Lane” to Production [Internet].
BIOSTAT® D-DCU: Your “Fast Lane” to Production. Goettingen, Germany: Sartorius Stedim
Biotech
GmbH;
2015
[cited
2018
Apr
16].
Available
from:
https://www.sartorius.com/mediafile/Broch_Biostat_D-DCU_SBI1512-e.pdf

Thermo Scientific. Data Sheet: HyPerforma 500 L Single-Use Mixer [Internet]. Data Sheet:
HyPerforma 500 L Single-Use Mixer. Waltham, MA: Thermo Scientific; 2017 [cited 2018 Apr
16]. Available from: https://www.thermofisher.com/order/catalog/product/SUM0500.9002

Alfa Laval AB. Culturefuge 100 Solid Ejecting Centrifuge [Internet]. Culturefuge 100 Solid
Ejecting Centrifuge. Lund, Sweden: Alfa Laval AB; 2018 [cited 2018 Apr 16]. Available from:
https://www.alfalaval.com/globalassets/documents/products/separation/centrifugalseparators/disc-stack-separators/culturefuge-100.pdf

198

Microfluidics. M-7125, M-7250 Enhanced BioPharmaceutical Microfluidizer® Processor
[Internet]. M-7125, M-7250 Enhanced BioPharmaceutical Microfluidizer® Processor. Westwood,
MA: Microfluidics International Corporation; 2010 [cited 2018Apr16]. Available from:
https://www.microfluidicscorp.com/sites/default/files/700bp-enhanced.pdf

Thermo Scientific. Single-Use BioProcess Containers [Internet]. Single-Use BioProcess
Containers. Waltham, MA: Thermo Scientific; 2017 [cited 2018 Apr 16]. Available from:
https://www.thermofisher.com/search/results?query=3D
bioprocess
containers&sort=relevancy&persona=DocSupport&focusarea=Search All

Pall Life Sciences. Resolute® Manual Chromatography Columns [Internet]. Resolute® Manual
Chromatography Columns. Port Washington, NY: Pall Corporation; 2017 [cited 2018 Apr 16].
Available from: https://shop.pall.com/us/en/biotech/chromatography/columns-pilot-and-processscale/resolute-manual-chromatography-columns-zidgri78lcv

Thermo Scientific. Instructions: HisPur™ Cobalt Resin [Internet]. Instructions: HisPur™ Cobalt
Resin. Rockford, IL: Pierce Biotechnology; 2012 [cited 2018 Apr 16]. Available from:
https://www.thermofisher.com/order/catalog/product/89964

Thermo Scientific. User Guide: POROS™ HIC Resins: Ethyl, Benzyl, and Benzyl Ultra [Internet].
User Guide: POROS™ HIC Resins: Ethyl, Benzyl, and Benzyl Ultra. Waltham, MA: Thermo
Scientific;
2017
[cited
2018
Apr
16].
Available
from:
https://www.thermofisher.com/order/catalog/product/88272?SID=srch-srp-88272

Thermo Scientific. Instructions: Pierce High-Capacity Endotoxin Removal Resin [Internet].
Instructions: Pierce High-Capacity Endotoxin Removal Resin. Rockford, IL: Pierce
Biotechnology;
2016
[cited
2018
Apr
16].
Available
from:
https://www.thermofisher.com/order/catalog/product/88272?SID=srch-srp-88272

EMD Millipore. Data Sheet: Cogent® Process-Scale Tangential Flow Filtration System [Internet].
Data Sheet: Cogent® Process-Scale Tangential Flow Filtration System. Darmstadt, Germany:
EMD
Millipore;
2015
[cited
2018
Apr
16].
Available
from:
http://www.emdmillipore.com/US/en/product/Cogent-Process-Scale-Tangential-Flow-FiltrationSystem,MM_NF-C173675#documentation

199

Millipore Sigma. Pellicon® 3 Cassettes with Ultracel® Membrane [Internet]. Pellicon® 3
Cassettes with Ultracel® Membrane . Burlington, MA: Millipore Sigma; 2018 [cited 2018 Apr
16].
Available
from:
http://www.emdmillipore.com/US/en/product/Pellicon-3Cassettes,MM_NF-C9947?CatalogCategoryID=#documentation

EMD Millipore. Data Sheet: Millidisk® Cartridges and Millipak® Disposable Capsules [Internet].
Data Sheet: Millidisk® Cartridges and Millipak® Disposable Capsules. Westwood, MA: EMD
Millipore;
2015
[cited
2018
Apr
16].
Available
from:
http://www.emdmillipore.com/US/en/product/Durapore-Membrane-Filters,MM_NFC7631?CatalogCategoryID=#documentation

Sartorius Stedim Biotech GmbH. BIOSTAT ® RM and Flexsafe® RM for Seed Production and
Small-scale Protein Supply [Internet]. BIOSTAT ® RM and Flexsafe® RM for Seed Production
and Small-scale Protein Supply. Goettingen, Germany: Sartorius Stedim Biotech GmbH; 2016
[cited 2018 Apr 16]. Available from: https://www.sartorius.com/mediafile/Broch_BiostatRM_SBT1501-e.pdf
Temperature/PID Controllers [Internet]. Omega. Omega; 2018 [cited 2018 Apr 17]. Available
from: https://www.omega.com/guides/tempcontrol.html

Other Equipment Descriptions
Custom-Engineered Pharmaceutical Storage Containers [Internet]. Sharpsville Container.
Sharpsville
Container;
2018
[cited
2018
Apr
16].
Available
from:
https://sharpsvillecontainer.com/pharmaceutical-hygienic-pressure-vessels/

Paul Mueller Company. PyroPure Wafter-for-Injection Multiple-Effect Still [Internet].
Springfield, MO: Paul Mueller Company; 2014 [cited 2018 Apr 16]. Available from:
https://www.paulmueller.com/hubfs/Pharmaceutical/Downloads/Paul-Mueller-CompanyPyroPure-Brochure.pdf

BMT USA. Steam Generators [Internet]. Steam Generators. Monroe, WA: BMT USA; 2018 [cited
2018
Apr
16].
Available
from:
https://docs.wixstatic.com/ugd/2d3146_5ecea836f0b64fd2bdbf40203dd438f2.pdf

Domnick Hunter. Laboratory Gas Generators [Internet]. Laboratory Gas Generators. Gateshead,
Tyne and Wear, England: Domnick Hunter; 2003 [cited 2018 Apr 16]. Available from:
https://www.sigmaaldrich.com/catalog/product/supelco/28353u?lang=en®ion=US
200

Thermo Scientific. Thermo Scientific NanoDrop Products [Internet]. Thermo Scientific NanoDrop
Products. Waltham, MA: Thermo Scientific; 2015 [cited 2018 Apr 16]. Available from:
https://www.thermofisher.com/order/catalog/product/ND-2000

Lonza. Traditional Kinetic Limulus Amebocyte Lysate (LAL) Assay User Quick Guide.
Walkersville, MD: Lonza Walkersville; 2014 [cited 2018 Apr 16]. Available from:
https://www.lonza.com/products-services/pharma-biotech/endotoxin-detection/endotoxindetection-assays/kinetic-turbidimetric-lal-assays.aspx

BD Biosciences. BD LSR II Flow Cytometer [Internet]. BD LSR II Flow Cytometer. Helsinki,
Finland:
BD
Biosciences;
2003
[cited
2018Apr16].
Available
from:
http://www.helsinki.fi/biosciences/corefacilities/flowcytometry/LSR II brochure.pdf

Bacterial Mass Balances and Media Formulation
Sivashanmugam A et al. Practical protocols for production of very high yields of recombinant
proteins using Escherichia coli. Protein Science 2009; 18:936–48.

Sartorius Stedim Biotech GmbH. High-cell-density Cultivation of Escherichia coli in a
BIOSTAT® D-DCU 10-3 Stainless Steel Bioreactor [Internet]. High-cell-density Cultivation of
Escherichia coli in a BIOSTAT® D-DCU 10-3 Stainless Steel Bioreactor . Goettingen, Germany:
Sartorius Stedim Biotech GmbH; 2013 [cited 2018 Apr 17]. Available from:
https://www.sartorius.com/mediafile/Appl_BIOSTAT_D-DCU_High-cell-densityCultivation_E_Coli_SBT1015-e.pdf

Heat Inactivation and Endotoxin Removal
Dufort EL, Etzel MR, and Ingham BH. Thermal processing parameters to ensure a 5-log reduction
of Escherichia coli O157:H7, Salmonella enterica, and Listeria monocytogenes in acidified
tomato-based foods. Food Protection Trends 2017; 37(6): 409-418.

Osaili T et al. Thermal inactivation studies of Escherichia coli O157:H7, Salmonella, and Listeria
monocytogenes in ready-to-eat chicken-fried beef patties. Journal of Food Protection 2006:
69(5):1080–1086.

201

Raetz RH and Whitfield C. Lipopolysaccharide endotoxins. Annual Review of Biochemistry 2002
Jul; 71: 635-700.

Bacterial Endotoxins/Pyrogens. Inspection Technical Guides, U.S. Foood and Drug
Administration (2015).

Effective Bactericidal Treatment , 21 C.F.R. Sect. 1240 (2017).
Utility Costing
City of Medford. Water and Sewer FAQs [Internet]. Water and Sewer FAQs. Medford, MA; 2017
[cited 17 Apr 2018]. Available from: http://www.medfordma.org/departments/department-ofpublic-works/dpw-links/water-and-sewer-division/water-and-sewer-faqs/
Caparella J. Energy benchmarking in the pharmaceutical industry. Pharmaceutical Engineering
2013 Oct.; 33(5): 1-6.
Boyette M, Wilson LG, and Estes E. Design of room cooling facilities: structural and energy
requirements. NC State Extension 1991 Jun.

202

Abstract

203

Appendix A: Cell Growth Analysis

Assumptions:
1. Prepared media begins with a glucose concentration of 2 g/L in all fermenters and
bioreactors.
2. During the exponential growth phase, there is negligible cell death. Therefore, the specific
growth rates is defined as: 𝜇𝑛𝑒𝑡 = 𝑢𝑔 = 0.25 ℎ𝑟 −1.
3. All glucose consumption is due to metabolic consumption by the cells.
4. The batch bioreactor is well mixed at all times. Therefore, the cell, nutrient, and oxygen
concentrations are uniform throughout the bioreactors’ contents.
5. Cell loss due to optical density testing of inoculum, growth, and production bioreactors is
considered negligible. The only loss that is not negligible is accounted for in the mass
balance during transfer out procedures.
6. Oxygen level is held constant in the production bioreactor to ensure aerobic cellular
respiration throughout the growth period.

Cell Growth Mathematical Modeling:
Equation (3) was used to determine all batch times required to achieve desired final cell
concentrations at the end of each bioreactor/fermentation step. The mathematical manipulation of
equation (3) is as follows:
𝑑𝑋
= 𝜇𝑛𝑒𝑡 𝑑𝑡
𝑋

𝑋

𝑡
𝑡
𝑑𝑋
= ∫ 𝜇𝑛𝑒𝑡 𝑑𝑡 = 𝜇𝑛𝑒𝑡 ∫ 𝑑𝑡
𝑋𝑜 𝑋
0
0

∫

𝑡=

1
𝜇𝑛𝑒𝑡

𝑋

𝑑𝑋
𝑋𝑜 𝑋

∫
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𝑡=

1
𝜇𝑛𝑒𝑡

𝑙𝑛

𝑋
𝑋𝑜

(𝐴. 1)

Where: t = time (hours)
X0 = initial cell concentration (cells/mL)
X = cell concentration at time t
µnet = specific growth rate for cell culture (hr-1)

Initial and final cell concentrations for the various steps taken in the process were obtained from
literature on high-density microbial cultures.

A. For inoculum culture:
𝑡=

1
4.42 × 108
𝑙𝑛
= 17.86 ℎ𝑟
0.25 ℎ𝑟 −1 5.09 × 106

Recommended growth times for E. coli inoculum growth range between 12 to 16 hours, which
validates this batch time calculation.

B. For growth bioreactor:
We assume that 5% of the cells cultured in the previous step are either lost or lysed, implying that
95% of the previous culture inoculates the new bioreactor.
For the culture to produce α-N-acetylgalactosaminidase:
1
3.45 × 109
𝑡=
𝑙𝑛
= 24.03 ℎ𝑟
0.25 ℎ𝑟 −1 8.50 × 106

For the culture to produce α-galactosidase:
1
3.17 × 109
𝑡=
𝑙𝑛
= 23.69 ℎ𝑟
0.25 ℎ𝑟 −1 8.50 × 106
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C. For production fermenters:
We assume that 5% of the cells cultured in the previous step are either lost or lysed, implying that
95% of the previous culture inoculates the new fermenters.
It was recommended from the literature that the initial concentration of E. coli in the fermenter be
adjusted to 4.50×107 cells/mL.
1
2.91 × 1010
𝑡=
𝑙𝑛
= 25.89 ℎ𝑟
0.25 ℎ𝑟 −1
4.50 × 107
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Appendix B: Required Protein Yield to Satisfy Production Goals
Assumptions:
All suggestions to account for losses were provided by Robert Luo, Ph.D. from GlaxoKlineSmith.
1. 200,000 universal RBC transfusion units will be prepared. Following the blood-type
distribution in the United States, nearly two-thirds of these prepared units will come from
type-A blood and the remaining one-third will from type-B.
2. Type-AB conversions will not be considered for this process since they make up such a
small percentage (<3%) of the donor population.
3. During RBC conversion treatment/processing, 35% of the RBCs will be lost. To satisfy the
RBC cell count in each blood bag, 307,693 RBC units are needed to account for losses and
meet production goals.
4. 40% of each enzyme product will be lost in downstream purifications steps.
5. 10% of the enzyme product will not be functional due to protein misfolding, denaturation,
or possible points mutations that altered amino acid sequence and affect functionality.
6. One unit of packed RBCs is 300 mL.

Required mass yield of α-galactosidase:
307,693 𝑢𝑛𝑖𝑡𝑠 × 0.67

𝑡𝑦𝑝𝑒 − 𝐴 𝑢𝑛𝑖𝑡𝑠
𝑚𝑔
1𝑔
1
1
× 60
×
×
×
𝑡𝑜𝑡𝑎𝑙 𝑢𝑛𝑖𝑡𝑠
𝑡𝑦𝑝𝑒 − 𝐴 𝑢𝑛𝑖𝑡
1000 𝑚𝑔 1 − 0.4 0.9
= 22,906 𝑔 of α − galactosidase

Required mass yield of for α-N-acetylgalactosaminidase:
307,693 𝑢𝑛𝑖𝑡𝑠 × 0.33

𝑡𝑦𝑝𝑒 − 𝐴 𝑢𝑛𝑖𝑡𝑠
𝑚𝑔
1𝑔
1
1
×2
×
×
×
𝑡𝑜𝑡𝑎𝑙 𝑢𝑛𝑖𝑡𝑠
𝑡𝑦𝑝𝑒 − 𝐴 𝑢𝑛𝑖𝑡
1000 𝑚𝑔 1 − 0.4 0.9

= 376.07 𝑔 of α − N − acetylgalactosaminidase
207

Appendix C: Biowaste System Design
Assumptions:
1. The final cell concentration in the production culture is 2.91×1010 cells/mL. Upon removal
from the process, the E. coli bacteria will be inactivated in the waste vessel.
2. Inactivation kinetics are first order.
3. The thermal deactivation coefficient is D = 0.4167 minutes. A literature review was
performed to determine what the decimal reduction time for E. coli at 121ºC was.
Numerous sources reported different values. Therefore, an average value was taken for
these inactivation times.
Using the production of α-galactosidase as the base case with which to determine the time for
thermal inactivation of E. coli since it requires a larger processing volume, the calculations the
time to reach the thermal death point are as follows:

2.91 × 1010

𝑐𝑒𝑙𝑙𝑠
𝐿
𝑚𝐿
𝑐𝑒𝑙𝑙𝑠 𝑡𝑜 𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒
× 396
× 1000
= 4.16 × 1016
𝑚𝐿
𝑏𝑎𝑡𝑐ℎ
𝐿
𝑏𝑎𝑡𝑐ℎ

First order inactivation kinetics:
𝑁
ln ( ) = −𝑘𝑡
𝑁0

(𝐶. 1)

Where: N = microbial population at any time, t
N0 = initial microbial population
D = decimal reduction time; time required for a 1-log (or 10-fold) cycle reduction in the
microbial population

The thermal inactivation constant is defined as:
𝑘=

2.303
𝐷
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Manipulating equation (B.1), the following expression for thermal inactivation is obtained:
𝑁
𝑡
log ( ) = −
𝑁0
𝐷

(𝐶. 2)

To determine heating time required for thermal inactivation:
25 − log 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑠𝑖𝑧𝑒
𝑡 = −𝐷 ∙ log (
)
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑡𝑜 𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒

𝑡 = −0.4167 𝑚𝑖𝑛 ∙ log (

(𝐶. 3)

4.16 × 10−9
)
4.16 × 1016

𝑡 = 10.42 𝑚𝑖𝑛𝑢𝑡𝑒𝑠

Therefore, bio-waste tank will be heated to 121C and maintained at this temperature for
approximately 11 minute to inactivate bacteria.
Conclusion: Thus, there is 4.16 × 10−9 chance that a single E. coli cell will be active after an
eleven minute heat inactivation in each batch.
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Appendix D: Batch Sizing
Assumptions:
1. The process to produce bacterial glycosidases is designed to run 114 batches per year: 112
for the production of α-N-acetylgalactosaminidase and 2 for α-galactosidase. The plant will
be operational for 24 hours, 7 days a week, 52 weeks per year. Six batches will be
completed each week. Although this exceeds calculated operation times, it provides
additional time to account for possible errors or malfunctions that may arise.
2. Accounting for losses and possible inactive enzyme, the ultimate goal is to produce 22.9
kg of α-N-acetylgalactosaminidase and 0.376 kg of α-galactosidase per year.
3. The specific growth rate for BL21(DE3) recombinant E. coli cells is 0.25 hr-1.
4. 20% of the inoculum died from both the freezing and thawing processes.
5. 5% of the cell population in the growth and production bioreactors will be dead or inactive.
6. Frozen stock of E. coli will be prepared at concentration of 7.95×106 cells/mL.
7. Oxygen limitations will not be a concern for the growth periods and will be held constant
using PID control at 40% dissolved O2.

All values were validated by Jeffrey Cohen, Ph.D. from GlaxoKlineSmith to confirm similarity
to commonly observed values in industrial fermentation.

For the production of α-N-acetylgalactosaminidase
Table D.1. Inoculum batch sizing details for α-N-acetylgalactosaminidase production. The
parameters for the predicted growth model were obtained from literature review. All final cell
concentrations were obtained from a report on high density microbial cultures.
Inoculum Growth Bioreactor
Working volume
0.110
L
6
Initial cell concentration
5.09×10
cells/mL
Specific growth time
0.25
hr-1
Batch time
17.86
hr
8
Target cell concentration
4.42×10
L
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Table D.2. Growth bioreactor batch sizing details for α-N-acetylgalactosaminidase
production. The parameters for the predicted growth model were obtained from literature review.
All final cell concentrations were obtained from a report on high density microbial cultures. It was
assumed that five percent of the inoculum culture was lost due to cell death or transfer
inefficiencies when inoculating the seed bioreactor.
Growth Bioreactor
Working volume
5.44
Initial cell concentration
8.50×106
Specific growth time
0.25
Batch time
24.03
Target cell concentration
3.45×109

L
cells/mL
hr-1
hr
L

Table D.3. Production fermentation batch sizing details for α-N-acetylgalactosaminidase
production. The parameters for the predicted growth model were obtained from literature review.
All final cell concentrations were obtained from a report on high density microbial cultures. Again,
five percent of the seed bioreactor culture was assumed lost due to cell death or transfer
efficiencies. In this step, the culture from the seed bioreactor was equally split between two
stainless steel fermenters to achieved productions goals. During IPTG induction, the temperature
of the reactor was lowered to 25ºC to inhibit cell growth.
Production Fermenters
Working volume
396
Initial cell concentration
4.50×107
Specific growth time
0.25
Batch time
25.89
Target cell concentration
2.91×1010
Protein production rate
85.4
Protein production time
5
Protein produced
0.205

L
cells/mL
hr-1
hr
cells/mL
ng/cell-day
hr
kg
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For the production of α-galactosidase
Table D.4. Inoculum batch sizing details for α-galactosidase production. The parameters for
the predicted growth model were obtained from literature review. All final cell concentrations were
obtained from a report on high density microbial cultures.
Inoculum Growth Bioreactor
Working volume
0.110
L
6
Initial cell concentration
5.09×10
cells/mL
Specific growth time
0.25
hr-1
Batch time
17.86
hr
8
Target cell concentration
4.42×10
L

Table D.5. Growth bioreactor batch sizing details for α-galactosidase production. The
parameters for the predicted growth model were obtained from literature review. All final cell
concentrations were obtained from a report on high density microbial cultures. It was assumed that
five percent of the inoculum culture was lost due to cell death or transfer inefficiencies when
inoculating the seed bioreactor. The final cell concentration in this seed bioreactor is slightly less
for α-galactosidase production than for α-galactosidase production since the volume of culture is
less to satisfy production goals.
Growth Bioreactor
Working volume
5.44
Initial cell concentration
8.50×106
Specific growth time
0.25
Batch time
23.69
Target cell concentration
3.17×109

L
cells/mL
hr-1
hr
L

212

Table D.6. Production fermentation batch sizing details for α-galactosidase production. The
parameters for the predicted growth model were obtained from literature review. All final cell
concentrations were obtained from a report on high density microbial cultures. Again, five percent
of the seed bioreactor culture was assumed lost due to cell death or transfer efficiencies. In this
step, the culture from the seed bioreactor was equally split between two stainless steel fermenters
to achieved productions goals. During IPTG induction, the temperature of the reactor was lowered
to 25ºC to inhibit cell growth.

Production Fermenters
Working volume
364
Initial cell concentration
4.50×107
Specific growth time
0.25
Batch time
25.89
Target cell concentration
2.91×1010
Protein production rate
85.6
Protein production time
5
Protein produced
0.189

L
cells/mL
hr-1
hr
cells/mL
ng/cell-day
hr
kg
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Appendix E: Culture Media Composition

Table E.1. High-salt medium will be used for high-density microbial fermentation. This
composition has been experimentally determined to promote optimal cell growth to OD600 values
up to 45, which corresponds to a cell concentration of 3.6×1010 cells/mL.
High-Mineral Salt Microbial Culture Media
Component
Concentration
Na₂HPO₄∙7H₂O
33.9 g/L
KH₂PO₄
15.0 g/L
NH4Cl
5.0 g/L
NaCl
2.5 g/L
Na₂SO₄
7.1 g/L
MgSO₄
6.0 g/L
Glycerol
0.4 % v/v
ß-lactose
0.01 % v/v
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Appendix F: Oxygen Transfer Limitations for Reactor Design
Assumptions:
1. The final cell concentration in the production culture is 2.91×1010 cells/mL.
2. Specific uptake rate of oxygen, 𝑞𝑂2 , is 12.0 mmole O2/g cells-hr for Escherichia coli.
3. The difference between the saturated oxygen solubility, 𝐶𝑂∗ , and the actual concentration
of dissolved oxygen in the culture broth, 𝐶𝑂 , is 1.13 mmole O2/L.
4. For the chosen bioreactor and impeller configurations, the volumetric oxygen transfer
coefficient,𝑘𝐿 𝑎, is 308 hr-1.
To find the maximum cell density at which the production bioreactor can provide enough oxygen
to maintain cell growth and viability, the oxygen uptake rate (OUR) was set equal to the oxygen
transfer rate (OTR).

OTR calculation:
𝑂𝑇𝑅 = 𝑘𝐿 𝑎(𝐶𝑂∗ − 𝐶𝑂 )

𝑂𝑇𝑅 = 308 ℎ𝑟 −1 (1.13

𝑂𝑇𝑅 = 348.04

(𝐹. 1)

𝑚𝑚𝑜𝑙𝑒 𝑂2
)
𝐿

𝑚𝑚𝑜𝑙𝑒 𝑂2
𝐿 − ℎ𝑟

Maximum cell density:
𝑂𝑈𝑅 = 𝑞𝑂2 𝑋 = 𝑂𝑇𝑅

(𝐹. 2)

𝑚𝑚𝑜𝑙𝑒 𝑂2
𝑂𝑇𝑅 348.04 𝐿 − ℎ𝑟
𝑋=
=
𝑚𝑚𝑜𝑙𝑒 𝑂2
𝑞𝑂2
12.0
𝑔 𝑐𝑒𝑙𝑙𝑠 − ℎ𝑟

𝑋 = 29.0

𝑔 𝑐𝑒𝑙𝑙𝑠
𝐿

215

Appendix G: Endotoxin Yield Calculations
Assumptions:
1. There is 1.00×10-10 grams of endotoxin for every 105 E. coli cells in the final culture.
2. The final cell concentration in the production fermenters is 2.91×1010 cells/mL. It is further
assumed that all endotoxin production is accounted for in the final cell concentration.

For α-N-acetylgalactosaminidase production:
Batch volume: V = 396 L
1.0 × 10−10 𝑔 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 2.91 × 1010 𝑐𝑒𝑙𝑙𝑠 1000 𝑚𝐿
∙
∙
∙ 396 𝐿 = 11.5 g endotoxin
105 𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
1𝐿

For α-galactosidase production:
Batch volume: V = 364 L
1.0 × 10−10 𝑔 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 2.91 × 1010 𝑐𝑒𝑙𝑙𝑠 1000 𝑚𝐿
∙
∙
∙ 364 𝐿 = 10.6 g endotoxin
105 𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
1𝐿
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Appendix H: Cobalt Affinity Chromatography Sizing and Timing
The cobalt affinity chromatography column size and volumes of solution needed were
calculated according to the manufacturer’s protocol for the HisPur® cobalt affinity resin. The
given binding capacity of the resin (20 grams of protein per liter of resin) and the mass of either
α-galactosidase or α-N-acetylgalactosaminidase entering the column were used to calculate the
volume of resin required per batch. This calculation assumes that all enzyme that passes through
the column will bind to the resin and disregards the 90% recovery from the unit. This assumption
ensures that recovery is not limited by the binding capacity of the resin. The void fraction of the
resin packaging is 0.30 according to the manufacturer’s protocol. The column volume was
calculated as follows:
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒 =

𝐸𝑛𝑧𝑦𝑚𝑒 𝑚𝑎𝑠𝑠 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝑐𝑜𝑙𝑢𝑚𝑛 (𝑔)
∙ 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦
𝑏𝑎𝑡𝑐ℎ

(𝐻. 1)

For α-N-acetylgalactosaminidase:
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𝑔
1 𝐿 𝑟𝑒𝑠𝑖𝑛
𝐿 𝑟𝑒𝑠𝑖𝑛
∙
= 10.25
𝑏𝑎𝑡𝑐ℎ 20 𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝑏𝑎𝑡𝑐ℎ

𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =

10.25 𝐿 𝑟𝑒𝑠𝑖𝑛 ∙

𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
1
∙
𝑏𝑎𝑡𝑐ℎ
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛

(𝐻. 2)

1
= 14.6 𝐿
1 − 0.30

The data sheet for the resin allows for 25 regenerations before resin must be replaced. The amount
of resin needed for processing α-N-acetylgalactosaminidase on an annual basis was calculated as
follows:

𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑅𝑒𝑠𝑖𝑛 𝐵𝑎𝑡𝑐ℎ𝑒𝑠
1
=
∙
∙
(𝐻. 3)
𝑦𝑒𝑎𝑟
𝐵𝑎𝑡𝑐ℎ 𝑦𝑒𝑎𝑟 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔

𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 10.25

𝐿 𝑟𝑒𝑠𝑖𝑛
1
∙ 112 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
= 45.92 𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
25
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For α-galactosidase:
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𝑔
1 𝐿 𝑟𝑒𝑠𝑖𝑛
𝐿 𝑟𝑒𝑠𝑖𝑛
∙
= 9.45
𝑏𝑎𝑡𝑐ℎ 20 𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝑏𝑎𝑡𝑐ℎ

𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =

9.45 𝐿 𝑟𝑒𝑠𝑖𝑛 ∙

𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
1
∙
𝑏𝑎𝑡𝑐ℎ
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛

1
= 13.5 𝐿
1 − 0.30

Assuming that we use new resin when switching over to the production of α-galactosidase, the
calculations for the total amount of resin needed on an annual basis for processing α-galactosidase.

𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑅𝑒𝑠𝑖𝑛 𝐵𝑎𝑡𝑐ℎ𝑒𝑠
1
=
∙
∙
𝑦𝑒𝑎𝑟
𝐵𝑎𝑡𝑐ℎ 𝑦𝑒𝑎𝑟 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔

𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 9.45

𝐿 𝑟𝑒𝑠𝑖𝑛
1
∙ 2 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
= 0.756 𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
25

From these calculations, the total volume of resin required to treat both enzymes is approximately
46.7 liters. An additional conclusion that can be made is that since the mass of α-Nacetylgalactosaminidase that will be processed is greater than the mass of α-galactosidase, its
minimal required will satisfy the volumetric requirements for both enzymes.
A conservative approach was used in calculating the batch time and amount of buffer
needed by using the maximum column volumes of buffer suggested in the protocol.
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Table H.1. Calculated Material Requirements for Chromatography Buffers. Compositions
and volumes required were obtained from the HisPur® Superflow Agarose resin vendor sheet.
Masses required were calculated using the maximum protocol volumes listed.

𝐶𝑜𝑙𝑢𝑚𝑛 𝑟𝑢𝑛 𝑡𝑖𝑚𝑒 = 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 ∙

𝐶𝑜𝑙𝑢𝑚𝑛 𝑟𝑢𝑛 𝑡𝑖𝑚𝑒 =

1
𝑙𝑖𝑛𝑒𝑎𝑟 𝑓𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 ∙ 𝑐𝑜𝑙𝑢𝑚𝑛 𝑐𝑟𝑜𝑠𝑠 𝑠𝑒𝑐𝑡𝑖𝑜𝑛

(𝐻. 4)

689,000 𝑚𝐿
= 7.46 ℎ𝑟
𝑐𝑚
150
∗ (14 𝑐𝑚)2 ∗ 𝜋
ℎ𝑟
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Appendix I: Hydrophobic Interaction Chromatography Sizing and Timing
The hydrophobic interaction chromatography column size and volumes of solution needed
were calculated according to the protocol for the POROS Benzyl HIC Resin. Note that endotoxin
here is denoted as LPS. The given binding capacity of the resin (2×106 endotoxin units per mL of
resin) and the mass of endotoxin entering the column were used to calculate the volume of resin
required per batch. This unit disregards any endotoxin loss that may have occurred in the past few
steps. Random packing was assumed with a void fraction of 0.40 as no other data could be found
in the literature. The column volume was calculated as follows:
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒 =

𝐸𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑚𝑎𝑠𝑠 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝑐𝑜𝑙𝑢𝑚𝑛 (𝑔)
∙ 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦
𝑏𝑎𝑡𝑐ℎ

(𝐼. 1)

For α-N-acetylgalactosaminidase:

11.5

𝑔 𝐿𝑃𝑆 1 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
1 𝐿 𝑟𝑒𝑠𝑖𝑛
1 𝐸𝑈
𝐿
∙
∙
∙
= 57.5
6
−10
𝑏𝑎𝑡𝑐ℎ 2 × 10 𝐸𝑈 1000 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛 1 × 10
𝑔 𝐿𝑃𝑆
𝑏𝑎𝑡𝑐ℎ

𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =

57.5 𝐿 ∙

𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
1
∙
𝑏𝑎𝑡𝑐ℎ
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛

(𝐼. 2)

1
= 95.8 𝐿
1 − 0.40

The data sheet for the resin allows for 10 regenerations before resin must be replaced. The
amount of resin needed on an annual basis was calculated as follows:

𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑅𝑒𝑠𝑖𝑛 𝐵𝑎𝑡𝑐ℎ𝑒𝑠
1
=
∙
∙
𝑦𝑒𝑎𝑟
𝐵𝑎𝑡𝑐ℎ 𝑦𝑒𝑎𝑟 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔

𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 57.5

(𝐼. 3)

𝐿 𝑟𝑒𝑠𝑖𝑛
1
∙ 112 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
= 644 𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
10
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For α-galactosidase:

10.6

𝑔 𝐿𝑃𝑆 1 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
1 𝐿 𝑟𝑒𝑠𝑖𝑛
1 𝐸𝑈
𝐿
∙
∙
∙
= 52.9
6
−10
𝑏𝑎𝑡𝑐ℎ 2 × 10 𝐸𝑈 1000 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛 1 × 10
𝑔 𝐿𝑃𝑆
𝑏𝑎𝑡𝑐ℎ

𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =

52.9 𝐿 𝑟𝑒𝑠𝑖𝑛 ∙

𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
1
∙
𝑏𝑎𝑡𝑐ℎ
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛

1
= 88.2 𝐿
1 − 0.40

Assuming that we use new resin when switching over to the production of α-galactosidase the
calculations for the total amount of resin needed on an annual basis for processing α-galactosidase.

𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑅𝑒𝑠𝑖𝑛 𝐵𝑎𝑡𝑐ℎ𝑒𝑠
1
=
∙
∙
𝑦𝑒𝑎𝑟
𝐵𝑎𝑡𝑐ℎ 𝑦𝑒𝑎𝑟 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔

𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 52.9

𝐿 𝑟𝑒𝑠𝑖𝑛
1
∙ 2 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
= 10.6 𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
10

A conservative approach was used in calculating the batch time and amount of buffer
needed, by using the maximum column volumes of buffer suggested in the protocol.
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Table I.1. Calculated Material Requirements for Chromatography Buffers. Compositions
and volumes required were obtained from the POROS Benzyl HIC Resin vendor sheet. Masses
required were calculated using the maximum protocol volumes listed.

𝐶𝑜𝑙𝑢𝑚𝑛 𝑟𝑢𝑛 𝑡𝑖𝑚𝑒 = 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 ∗

𝐶𝑜𝑙𝑢𝑚 𝑟𝑢𝑛 𝑡𝑖𝑚𝑒 =

1
𝑙𝑖𝑛𝑒𝑎𝑟 𝑓𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 ∗ 𝑐𝑜𝑙𝑢𝑚𝑛 𝑐𝑟𝑜𝑠𝑠 𝑠𝑒𝑐𝑡𝑖𝑜𝑛

(𝐼. 4)

3,532,200 𝑚𝐿
= 4.68 ℎ𝑟
𝑐𝑚
150
∗ (40 𝑐𝑚)2 ∗ 𝜋
ℎ𝑟
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Appendix J: Endotoxin Affinity Chromatography Sizing and Timing
The endotoxin affinity chromatography column size and volumes of solution needed were
calculated according to the manufacturer’s protocol for the Pierce High Capacity Endotoxin
Removal Resin. Note that endotoxin here is denoted as LPS. The given binding capacity of the
resin (2×106 endotoxin units per mL of resin) and the mass of endotoxin entering the column were
used to calculate the volume of resin required per batch. The void fraction of the resin packaging
is 0.40 according to the manufacturer’s protocol. The column volume was calculated as follows:
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒 =

𝐸𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑚𝑎𝑠𝑠 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝑐𝑜𝑙𝑢𝑚𝑛 (𝑔)
∙ 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦
𝑏𝑎𝑡𝑐ℎ

(𝐽. 1)

For α-N-acetylgalactosaminidase:

1.15

𝑔 𝐿𝑃𝑆 1 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
1 𝐿 𝑟𝑒𝑠𝑖𝑛
1 𝐸𝑈
𝐿
∙
∙
∙
= 5.75
𝑏𝑎𝑡𝑐ℎ 2 × 106 𝐸𝑈 1000 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛 1 × 10−10 𝑔 𝐿𝑃𝑆
𝑏𝑎𝑡𝑐ℎ

𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =

5.75 𝐿 ∙

𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
1
∙
𝑏𝑎𝑡𝑐ℎ
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛

(𝐽. 2)

1
= 9.58 𝐿
1 − 0.40

The data sheet for the resin allows for 10 regenerations before resin must be replaced. The
amount of resin needed on an annual basis was calculated as follows:

𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑅𝑒𝑠𝑖𝑛 𝐵𝑎𝑡𝑐ℎ𝑒𝑠
1
=
∙
∙
𝑦𝑒𝑎𝑟
𝐵𝑎𝑡𝑐ℎ 𝑦𝑒𝑎𝑟 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔

𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 5.75

(𝐽. 3)

𝐿 𝑟𝑒𝑠𝑖𝑛
1
∙ 112 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
= 64.4 𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
10
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For α-galactosidase:

1.06

𝑔 𝐿𝑃𝑆 1 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
1 𝐿 𝑟𝑒𝑠𝑖𝑛
1 𝐸𝑈
𝐿
∙
∙
∙
= 5.29
6
−10
𝑏𝑎𝑡𝑐ℎ 2 × 10 𝐸𝑈 1000 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛 1 × 10
𝑔 𝐿𝑃𝑆
𝑏𝑎𝑡𝑐ℎ

𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =

5.29 𝐿 𝑟𝑒𝑠𝑖𝑛 ∙

𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
1
∙
𝑏𝑎𝑡𝑐ℎ
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛

1
= 8.82 𝐿
1 − 0.40

Assuming that we use new resin when switching over to the production of α-galactosidase, the
calculations for the total amount of resin needed on an annual basis for processing α-galactosidase.

𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑅𝑒𝑠𝑖𝑛 𝐵𝑎𝑡𝑐ℎ𝑒𝑠
1
=
∙
∙
𝑦𝑒𝑎𝑟
𝐵𝑎𝑡𝑐ℎ 𝑦𝑒𝑎𝑟 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔

𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 5.29

𝐿 𝑟𝑒𝑠𝑖𝑛
1
∙ 2 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
= 1.06 𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
10

A conservative approach was used in calculating the batch time and amount of buffer
needed, by using the maximum column volumes of buffer suggested in the protocol.
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Table J.1. Calculated Material Requirements for Chromatography Buffers. Compositions
and volumes required were obtained from the Pierce High Capacity Endotoxin Removal Resin
vendor sheet. Masses required were calculated using the maximum protocol volumes listed.

𝐶𝑜𝑙𝑢𝑚𝑛 𝑅𝑢𝑛 𝑡𝑖𝑚𝑒 = 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 ∗

𝐶𝑜𝑙𝑢𝑚𝑛 𝑟𝑢𝑛 𝑡𝑖𝑚𝑒 =

1
𝑙𝑖𝑛𝑒𝑎𝑟 𝑓𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 ∗ 𝑐𝑜𝑙𝑢𝑚𝑛 𝑐𝑟𝑜𝑠𝑠 𝑠𝑒𝑐𝑡𝑖𝑜𝑛

(𝐽. 4)

499,090 𝑚𝐿 + 55,600 𝑚𝐿
= 3.01 ℎ𝑟
𝑐𝑚
150
∗ (20 𝑐𝑚)2 ∗ 𝜋
ℎ𝑟

225

Appendix K: Endotoxin Level Calculation
According to both manufacturer’s protocols, there is a 99% removal of endotoxin using the
POROS Benzyl HIC Resin and the Pierce High Capacity Endotoxin Removal Resin. However,
literature values report that the removal is actually closer to 90% in practice for the POROS Benzyl
HIC Resin. Thus, we assume that after each pass, 90% of the endotoxins are removed through the
hydrophobic interaction column and 99% through the endotoxin affinity chromatography column.
To be more stringent on the purity of our final product, we also assume that the
ultrafiltation/diafiltration step does not change the endotoxin concentration in the product solution.
This assumption is valid given that the endotoxins and the enzymes are all similar in molecular
weight and that there no filtration units that can provide decent separation. We also assume that
the product solution will undergo two passes through a bulk filtration step to further remove any
remaining endotoxins and impurities, each with an assumed 99% removal. Lastly, we for the
design of the chromatography columns, we assume that none of the endotoxin that was produced
in the original E. coli microbial culture that was introduced into downstream purification has been
lost. This is done to ensure that the chromatography column is designed to handle the highest
possible amount of endotoxin mass to treat. The final product solution will have a concentration
of 1 mg/mL.
A sample calculation for the production of α-N-acetylgalactosaminidase, which has a
higher endotoxin mass yield from the E. coli culture, is shown. The mass yield of α-Nacetylgalactosaminidase is 205 grams per batch.
11.5

𝑔 𝐿𝑃𝑆
1 𝐸𝑈
1
𝐸𝑈
∙ 0.10 ∙ 0.01 ∙ 0.01 ∙ 0.01 ∙ −10
∙
= 0.056
𝑏𝑎𝑡𝑐ℎ
10 𝑔 𝐿𝑃𝑆 205,000 𝑚𝐿
𝑚𝐿

This final values complies with FDA limitations.
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Appendix L: Cryogel-based Affinity Chromatography Sizing and Timing

The material composition of the cryogel used in the column is outlined in Table L.1. The
preparation of the affinity matrix by coupling of protein A to the cryogel packed into the
chromatography is outlined in Table L.2. Lastly, Table L.3 gives the composition of the storage
solution used to preserve the cryogel in the column.
Table L.1. Materials required for the synthesis of the cryogel used in the affinity chromatography
of RBCs.

Cryogel Composition
Material
Amount
Degassed water
100 mL
DMAAm
6.3 mL
AGE
0.85 mL
MBAAm
2.2 g
APS
110 mg
TEMED
95 uL
Total volume
107.245 mL

Table L.2. Materials required for the coupling of protein A to the cryogel.
Protein A Cryogel Coating Composition
Component
Reagent:Gel ratio
Water
86 L water/L gel
Ethanol
14 L EtOH/L gel
Na2CO3
2 moles/L gel
Ethylenediamine
5 moles/L gel
Sodium phosphate
1 moles/L gel
Glutaraldehyde
0.5 L glutaraldehyde/L water
Protein A
16 g protein A/L gel
Sodium borohydride
1 moles/L gel
Water
40 L water/L gel
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Table L.3. Composition of the storage solution used to preserve the cryogel.
Cryogel-Protein A Complex Storage Solution
Component
Reagent:Gel ratio
Sodium phosphate
1 moles/L gel
Ethanol
2 L EtOH/L gel
Water
8 L water/L gel

Given that the cryogel-based affinity chromatography column was originally used to
handle B lymphocytes from whole blood, a volumetric ratio was determined between B
lymphocytes and RBCs to approximate what volume of RBCs the column could be treated via this
cell separation technique. In this mathematical approach, lymphocytes are modeled as spheres and
RBCS as cylinders. The radii are 7 µm and 4 µm, respectively. The height of an RBC is
approximately 2 µm. This assumption is valid given that the blood that the RBC treatment process
handles only contains RBCs whereas the blood sample in the literature that was used in the column
only had B lymphocytes. Neither sample contains additional cell populations that may affect the
volumetric ratio.
B lymphocyte volume:
𝑉𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒 =

4 3
𝜋𝑟
3

(𝐿. 1)

4
𝑉𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒 = 𝜋(7𝜇𝑚)3 = 1,437 𝜇𝑚3
3
RBC volume:
𝑉𝑅𝐵𝐶 = 𝜋𝑟 2 ℎ

(𝐿. 2)

𝑉𝑅𝐵𝐶 = 𝜋(4𝜇𝑚)2 (2𝜇𝑚) = 100.5 𝜇𝑚3
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The fold-difference between the two is:
𝑉𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒
= 14.3
𝑉𝑅𝐵𝐶
The current plant design expects to produce three batches of universal RBCs per week, for a total
of 156 batches throughout the year. To be conservative, it is assumed that no RBCs have been lost
yet due to the previous unit operations. This maximizes the amount of cryogel that needs to be
prepared, providing the upper bound on cost estimates. The amount of cryogel required to treat
one batch of RBCs under this set up is:
𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑅𝐵𝐶𝑠 𝑡𝑜 𝑏𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑝𝑒𝑟 𝑏𝑎𝑡𝑐ℎ
=
# 𝑅𝐵𝐶𝑠 𝑝𝑟𝑜𝑐𝑒𝑠𝑠𝑒𝑑
𝑏𝑎𝑡𝑐ℎ
𝑚𝐿 𝑔𝑒𝑙

(𝐿. 3)

𝐿 𝑏𝑙𝑜𝑜𝑑 5 ∙ 1012 𝑅𝐵𝐶𝑠
1
𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 307,693 𝑅𝐵𝐶 𝑢𝑛𝑖𝑡𝑠 ∙ 0.3 𝑅𝐵𝐶 𝑢𝑛𝑖𝑡 ∙ 1 𝐿 𝑏𝑙𝑜𝑜𝑑 ∙ 156 𝑏𝑎𝑡𝑐ℎ𝑒𝑠
=
𝑏𝑎𝑡𝑐ℎ
3 ∙ 1010 𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒𝑠 𝑉𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒
14.3 𝑉𝑅𝐵𝐶 ∙ 1 𝑅𝐵𝐶
∙
∙
𝑚𝐿 𝑔𝑒𝑙
1 𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒 𝑉 𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒 𝑉𝑅𝐵𝐶

𝑅𝐵𝐶𝑠
2.96 × 1015
𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
𝑏𝑎𝑡𝑐ℎ
=
𝑅𝐵𝐶𝑠
𝑏𝑎𝑡𝑐ℎ
4.29 × 1011
𝑚𝐿 𝑔𝑒𝑙

𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
= 6,896 𝑚𝐿 ≈ 6.90 𝐿
𝑏𝑎𝑡𝑐ℎ

It is recommended that the cryogel occupy below 50% of the total column volume. Therefore:
𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =

𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑝𝑒𝑟 𝑏𝑎𝑡𝑐ℎ
1 − 0.5

(𝐿. 4)

6.90 𝐿
= 13.8 𝐿
1 − 0.50
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We assume that the cryogel complex can be used five times before requiring replacement.
Therefore, the total volume of cryogel needed for the 156 planned batches of production is:

𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑟𝑦𝑜𝑔𝑒𝑙 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝐵𝑎𝑡𝑐ℎ𝑒𝑠
1
=
∙
∙
(𝐿. 5)
𝑦𝑒𝑎𝑟
𝐵𝑎𝑡𝑐ℎ
𝑦𝑒𝑎𝑟 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔

𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑐𝑟𝑦𝑜𝑔𝑒𝑙 𝑛𝑒𝑒𝑑𝑒𝑑 = 6.90

𝐿 𝑐𝑟𝑦𝑜𝑔𝑒𝑙
1
∙ 156 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙ = 215 𝐿 𝑐𝑟𝑦𝑜𝑔𝑒𝑙
𝑏𝑎𝑡𝑐ℎ
5

A conservative approach was used in calculating the batch time and amount of buffer
needed, by using the maximum column volumes of buffer suggested in the protocol.

Table L.1. Calculated Material Requirements for Chromatography Buffers. Compositions
and volumes required were obtained from the HisPur® Superflow Agarose resin vendor sheet.
Masses required were calculated using the maximum protocol volumes listed.
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Appendix M: Utility Requirements for the Refrigerated Room
Assumptions:
1. Conduction was assumed to obey Fourier’s law.
2. Thermal resistance values (R-values) were adapted from values given in a paper titled
“Design of Cooling Facilities: Structure and Energy Requirements”; the R-values used are
for standard cold room construction materials.
3. The heat load for the cold room was determined as the amount of heat that would travel
through the walls, floor, and ceiling due to conduction.
4. An outside temperature of 21°C (69.8°F) was assumed, as the cold room is located in the
interior of the facility.
5. Service load, or field heat, accounting for lighting requirements, equipment requirements,
and transport of equipment, laborers, and humid air into and out of the cold room, was
assumed to be 10% of the total heat conduction

Three separate cold rooms are required for this process design: one for the downstream purification
of the enzymes, another for the RBC treatment process, and a third to store pre-converted and
converted RBC transfusion units. The three processes will be kept separate from each other to
prevent any type of cross-contamination. For design purposes, it is assumed that all three cold
rooms will have the same dimensions. The size of the cold room is estimated to be 900 ft2, with
dimensions of 30 ft x 30 ft x 8 ft (W x D x H). Total energy requirement was calculated by summing
heat conduction and service load. The energy requirement in kWh was calculated assuming 365
days/year of cold room operation. Cold room refrigeration calculations are summarized in Table
M.1.
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Table M.1. All parameters required to calculate the utilities requirements for the designed cold
rooms. .
Cold Room Dimensions
Room Width
30 ft
Room Depth
30 ft
Room Height
8 ft
Temperature Conditions
Inside Temperature
39.2 ºF
Outside Temperature
69.8 ºF
Temperature Difference
30.6 ºF
R-Values
Walls
Ceiling
Floor

16 sq. ft-ºF-hr/BTU
20 sq. ft-ºF-hr/BTU
11 sq. ft-ºF-hr/BTU

Heat Conduction
Walls
1836 BTU/hr
Ceiling
1377 BTU/hr
Floor
2504 BTU/hr
Total Heat Calculations
Total without service load
5717 BTU/hr
Total service load
572 BTU/hr
Total heat
6288 BTU/hr
Price Calculations
Price of Electricity
0.0514 ($/kWh)
Total Heat
1.843 kW
Total Power Requirement
16145 kWh
Total Cost of Refrigeration
830 dollars
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Appendix N: Flow Cytometry Quality Control Analysis Representation
Flow cytometry will be employed to determine cleavage of A and B antigens from ECO-A and
ECO-B RBCs produced. It also counts the number of individual cells and register their respective
signal intensities. This data will be analyzed using FloJo® FACS software. The information
provided by flow cytometry should show that <1% of the treated RBC population have a signal
corresponding to blood group antigens. If a sample fails this quality control test, the batch will
either be re-treated or discarded.

Figure N.1. Expected flow cytometry quality control data for (A) ECO-A and (B) ECO-B
RBCs. Flow cytometry measures signal intensity given off by antibodies conjugated with
fluorophores. Anti-blood Group A and anti-blood group B antibodies will be mixed with
enzymatically converted RBC units for one hour at room temperature to allow for specific binding
to blood group antigens. Successful conversion will be determined by signal similarities to pure
type-O blood cells – only background noise should be registered. Graphically, this is represented
as all the A- and B-ECO signals overlapping with the signal registered from type O-cells.
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Sensitive FACS/flow cytometry analysis may be conducted with anti-A and anti-B
antibodies. Analysis using FDA-licensed Anti-A blood group reagents should demonstrate total
cleavage of A antigen from ECO-A RBCs; similarly, FDA-licensed anti-B reagents should not
react or cleave antigen from ECO-B RBCs. Flow cytometry performed with anti-H antibody
should show exposure of the H antigen on ECO-A and ECO-B RBCs at similar levels to WT O
RBCs. ECO-A RBCs should then have characteristic peaks that align with those of native type-O
RBCs, while any A and B control RBCs should have peaks characteristic of A and B RBCs.
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Appendix O: TLC Quality Control Analysis Representation

Figure O.1. Representative image of expected results of TLC/SDS-PAGE Western blot analysis
of (a) ECO-A and (b) ECO-B RBC glycolipid extracts.

Thin layer chromatography (TLC) and SDS-PAGE Western blot will be conducted as additional
quality control tests on treated RBCs’ glycobiology (sugar groups). (A) Western blot analysis of
glycoprotein extracts from enzymatically converted cells should demonstrate no presence of
glycolipids active in A antigen (Aa, Ab , and Ac) and exposure of glycolipids common to native O
RBCs (H , H , and H ). (B) Similarly, ECO-B RBC glycolipid extracts should only show
1

2

3

expression of O glycolipids, not B glycolipids (B1, B2, and B3).
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Appendix P: Adsol-1 (AS-1) Composition

Table P.1: Composition of Adsol-1 (AS-1) preservative solution that will be used to package
and store RBCs. AS-1 consists of two major components: anticoagulant reagents that prevent
agglutination and additional reagents that increase RBC shelf life. This preservative solution
allows RBCs to be stored for 42 days at 4ºC. The full name of the preservative solution is CPDA1 Anticoagulant Citrate Phosphate Dextrose Adenine Solution USP.

Anticoagulant and Preservatives

AS-1 additives

CPDA-1 Anticoagulant Solution USP
Concentration
Components
Sodium Citrate (dihydrate)
26.3 g/L
Dextrose (monohydrate)
25.5 g/L
Citric Acid (anhydrous)
3.27 g/L
Monobasic Sodium Phosphate (monohydrate)
2.22 g/L
Sodium Chloride
0.900 g/L
Mannitol
0.750 g/L
Adenine
0.275 g/L
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Appendix S: Quattroflow Quaternary Diaphragm Blueprints
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In cell affinity chromatography, type-specific cell separation is based on the interaction between cell-surface receptors and
an immobilized ligand on a stationary matrix. This protocol describes the preparation of monolithic polyacrylamide and
polydimethylacrylamide cryogel affinity matrices that can be used as a generic type-specific cell separation approach. The
supermacroporous monolithic cryogel has highly interconnected large pores (up to 100 µm) for convective migration of large
particles such as mammalian cells. In this protocol, they are functionalized to immobilize a protein A ligand by a two-step
derivatization of epoxy-containing cryogel monolith (reaction with ethylenediamine and glutaraldehyde). Target cells were labeled
with specific antibodies and then they were captured in the cryogel through affinity with protein A. These specifically captured
cells were recovered in high yields while retaining their viability by mechanical squeezing of the spongy and elastic cryogel
matrices. The suggested cell separation protocol takes < 30 min for complete separation on a preprepared protein A–immobilized
cryogel column.

INTRODUCTION
Preparative cell separation is an important tool to provide a highly
purified population of specific cell type for diagnostic, biotechnological and biomedical applications1. However, challenges
remain associated in the development of effective methods for
cell separation on a large scale. An effective cell separation technique should deliver high purity and yield while maintaining
cell function. There are two basic approaches to separate cells.
The first type is based on physicochemical properties such as size
(centrifugal elutriation and density gradient centrifugation), density
(density gradient centrifugation), light scattering properties (cell
sorter), membrane potential, pH, electrical impedance and charge
(aqueous two-phase system and free-flow electrophoresis)1–3.
Methods of the first type are commonly used for prepurification
and concentration, but have low specificity and are difficult to
process on a large scale.
The second approach is more specific, is based on affinity interactions, and uses cell-surface molecules. Methods that follow this
approach include cell isolation on affinity matrices4,5. In flow
cytometry, target cells are labeled with an immunofluorescent
tag. The technique is accurate but can be time consuming and
expensive6–8. Similarly, magnetic bead separation technology9–11
has received attention within the fields of biomedical sciences.
Automated magnetic cell sorters are available that can process
up to 50 ml of sample volume, but the process is quite expensive
and different affinity matrices are required for the separation
of different cells. Other cell separation methods have also been
developed, such as aqueous two-phase systems12,13 that are based
on specific partition of cells in two immiscible aqueous polymer
solutions. This technique can be used for cell separation on a preparative scale, but it requires repetitive extractions of target product
to achieve desirable selectivity.
Cell affinity chromatography provides an efficient method
for preparative-scale cell separation. The main requirement for
cell affinity chromatography is the design of a suitable matrix.
Hence, chromatography columns can be either bead packed or
monolithic.

Bead-packed chromatography column
The chromatography column is comprised of granular beads
of similar or varying sizes. Fluidized bed chromatography, e.g.,
expanded bed affinity adsorption (EBA), has shown great promise
for a preparative-scale cell separation technique, in which the stationary phase is in the form of a fluidized bed made up of spherical
beads14,15. In one such example, an immunoaffinity EBA technique
was used for the separation of monocytes from human peripheral
blood15. The limitations associated with this technology have been
high shear stress for cells, long equilibration time, requirements for
large special columns, narrow range of flow velocity and detachment of bound cells. Furthermore, conventional chromatographic
adsorbents such as agarose16 or silica17, used in EBA, can cause
nonspecific interactions. The technique also suffers from the
inherent limitations of bead-packed chromatography, which
include the relatively time-consuming column-packing process
and the slow rate of diffusion of solutes within the pores of the
bead matrix. Hence, there has been an essential need for designing
suitable chromatographic matrix or adsorbents and an efficient
approach for the preparative cell separation process.
Monolithic chromatography columns
These columns have a continuous matrix rather than beads with
porous channels. The desired ways of designing such columns can
be the development of macroporous chromatographic matrices
with interconnected pores that are large enough (much bigger than
the cell size), allowing unhindered movement of large particles such
as mammalian cells. Moreover, chromatographic matrices should
govern the convective mass transport of particles, which is possible
if the columns are monolithic.
Therefore, new methods are desirable for the production
of hydrophilic macroporous material with a sufficiently large
pore size by displacing soluble polymeric chains from a porous
network to the walls of pores so that there will be high local polymer concentration in the pore walls (compared with hydrophilic
non-macroporous gels). This high local polymer concentration
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Figure 1 | Cryogelation process: polymer or monomer is mixed in aqueous
solvent and then the whole system is incubated at subzero temperature
for cryopolymerization and/or gelation, along with ice crystal formation
(ice crystals function as a porogen). After complete gelation, and when
incubated at room temperature and washed with water to remove unreacted
monomers or polymeric precursors, the ice crystals melt and leave behind
large interconnected pores.

in the pore walls provides an increasing mechanical stability
of the material. Such materials known as supermacroporous
monolithic ‘cryogels’ have been developed by carrying out gelation or polymerization at subzero temperature under frozen
conditions.
Supermacroporous monolithic cryogels
The process of cryotropic polymerization or gelation18 has been
established for the development of macroporous hydrophilic gels
known as cryogels. Although the polymeric nature of cryogeltype materials has been under study throughout the past decade,
their potential for biotechnological applications has been explored
only in recent years19. Here, cryogels are specially designed from
hydrophilic polymers for technologically challenging separation
processes such as cell separation.
Cryotropic gelation or polymerization is a process whereby
under frozen conditions, most of the solvent is frozen, and the dissolved solutes (monomers or polymer precursors) get concentrated
in small unfrozen regions called nonfrozen liquid microphase, in
which the polymerization or gelation proceeds. After complete
synthesis, the melting of solvent crystals (ice, in the case of aqueous media) that function as porogen leaves behind a system of
large, continuously interconnected pores. These pores function as
capillaries and provide channels for the flow of the mobile phase
(Fig. 1). The initial concentration of precursors in solution, their
physicochemical properties and the freezing conditions determine the pore size of the cryogel. In contrast to traditional hydrogels, cryogels have a system of interconnected macropores and,
because of the structure of pore walls formed as a result of high
polymer concentration in nonfrozen liquid microphase, provide
relatively higher mechanical strength. High polymer density within
pore walls retards solvent diffusion that causes poor swelling and
ensures elasticity of cryogels, which allows the flow of liquid at high
flow rates with minimal flow resistance. The physical strength of
cryogels largely depends on the polymer type and concentration
and temperature during cryogel formation. The concentration of
polymer in gel phase is higher in cryogels than in conventional
gels prepared by other preparation methods. It demonstrates the
higher mechanical stability of cryogels in spite of their macro
porous morphology.
Cryogels are suitable for the chromatography of bioparticles and cells. Inert cryogel matrices have been produced from
1738 | VOL.5 NO.11 | 2010 | nature protocols

different hydrophilic gel-forming polymers either by poly
merization of the appropriate monomers (e.g., polyacrylamide
and poly(dimethylacrylamide)) or by physical gelation (e.g.,
agarose). For bioseparation applications, these matrices provide
the convective flow of the solution through the pores wherein
the mass transfer resistance is practically negligible. Cryogel
matrices also provides sufficiently high flow-through charac
teristics; the flow rate of water through the monoliths has been
estimated in our laboratory at a hydrostatic pressure of 0.01
MPa and has shown a linear flow rate of 2,000–2,500 cm h − 1.
These gels have been designed and used by our group for a variety of challenging separation applications in a monolithic chromatographic mode, including cell separations. The application
of these cryogels in the area of cell separation is discussed in the
following section.
Cell separations using supermacroporous cryogels
The protocol describes the separation of mammalian cells using a
supermacroporous monolithic cryogel column. Cryogel monoliths
were prepared both in the column format20 and in 96-minicolumn
plate format21 for their application in cell chromatography. The
pore diameter of up to 100 µm (and even larger) enables its application for chromatography of cells of varying size (between 1 and
15 µm) without being mechanically entrapped in the column. It
was shown that a pulse of blood can be convectively transported by
liquid flow through the monolithic plain cryogel column without
any physical entrapment of blood cells (Fig. 2). Convectively transported cells do not experience large shear forces because of laminar
flow of liquid in the interconnected pores in the monolithic cryogel.
Cells can bind to the monolithic cryogel column through specific
interactions with some immobilized groups (charges, hydrophobic moieties or affinity ligands) introduced on the surface of their
pore walls. For example, Escherichia coli cells were captured on
an ion-exchange monolithic cryogel column at low ionic strength
and were then eluted with 70–80% recovery at 0.4 M NaCl concentration. The same cells can also bind to a Cu(II)-coupled cryogel
column and have been recovered using either 100 mM imidazole or
20 mM EDTA22. Moreover, different microbial cells having different
cell-surface properties can be specifically separated from the mixed
population. This was demonstrated on the mixtures of wild-type
E. coli and recombinant His-tagged E. coli cells as well as wild-type

1

2

3

4

Passage of blood through cryogel column

Figure 2 | Human blood is passed through a cryogel column showing the
convective movement of large particles such as mammalian cells.

protocol
Figure 3 | The cell separation strategy used for
stem cell separation from umbilical cord blood.
Monoclonal antibody was incubated with cell
population to label a specific cell type. The cell
population containing the labeled target cells
was then passed through a protein A–coupled
epoxy-activated cryogel column. After 10 min of
incubation, the affinity column was washed with
buffer to remove unbound cells. The target cells
bound on the affinity cryogel column were then
eluted by mechanical squeezing of the affinity
cryogel matrix as shown in Figure 4.

Target cells attached to
protein A–coupled
cryogel matrix

Loading antibody-incubated
mixture on the top of affinity
cryogel column

+

Washing unbound cells
after 10 min incubation

Antibody
Cell population

E. coli and Bacillus halodurans cells . This
approach was also used for the separation
of yeast and E. coli cells on immobilized
concanavalin A as ligand on the cryogel
monolith24. The cryogel matrices were also
applied for the separation of a variety of
bioparticles, such as inclusion bodies25,
mitochondria26 and viruses27.
Cell affinity chromatography using supermacroporous monolithic cryogels proved to be an efficient approach for the separation of specific cell types such as T and B lymphocytes 20,28.
Antibody-based affinity interactions are remarkable and highly
efficient as ligands for cell separation because of their great
diversity and specificity. The interaction of antibody with
a specific cell-surface antigen is generally used for isolation
of a particular cell type. The concept of affinity separation
follows either negative selection or positive selection of cells. In
negative selection, nonspecific cells attach to the affinity ligand
on the support matrix and the target cells pass through the
matrix unretained. In contrast, positive selection involves the
specific binding of target cells to the affinity adsorbent; after
washing, bound cells can be recovered from the matrix in a
purified form.
However, the cell affinity chromatographic method using cryogels has been used here in a more generic manner. A cryogel affi
nity matrix has been developed by covalent coupling of protein
A on the surface of the pore wall, which can capture IgG-labeled
specific cells. This provides an advantage over the existing
methods of cell separation such as magnetic affinity cell sorting and flow cytometry. Protein A consists of a 40- to 60-kD
protein present in the cell wall of Staphylococcus aureus that
has affinity to the Fc portion of the IgG from a wide range of
species. Protein A can be covalently coupled to epoxy-activated
cryogel monolith by two-step derivatization using functionalization of epoxy-activated cryogel with ethylenediamine and
then crosslinking of protein A using glutaraldehyde. The protein A-bound monolithic cryogel can be used as a generic affinity adsorbent for specific antibody (IgG type)-labeled cells and
can thus separate them from nonspecific cells in the mixture.
After treating cells with antibodies (IgG type) to the cell-surface
receptors, the cell mixture was loaded onto the cryogel-protein A
column. The antibody-labeled cells bound to protein A through
the Fc region of the labeled antibody, whereas nonlabeled cells
remained unbound and passed through the column (Fig. 3).
The results were compared with control experiments in which
lymphocytes and umbilical cord blood (UCB) without anti
body labeling were passed through both protein A–coupled and
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Target cells

Protein A–coupled
Elution of cells by
cryogel affinity column
a) mechanical deformaton
of matrix
OR
b) immunoglobulin solution

Protein A

protein A noncoupled cryogel columns. The protocol is detailed
in the PROCEDURE. With this separation strategy, the generic
protocol presented here describes the separation of mammalian
cell types, with the particular examples of fractionation of T and
B lymphocytes from human blood buffy coat (Step 16A(i–viii)
of PROCEDURE) and hematopoietic stem cells (CD34 + ) from
human UCB (Step 16B(i–ix) of PROCEDURE). The established
cell separation approach using affinity cryogels can be integrated
in many cell-based studies and for cell-based therapy in which a
large purified cell population is required.
Experimental design: cell separation strategy
Affinity cryogel matrix. Cryogel matrices were developed in
monolithic format to provide a suitable chromatography matrix
for cell separation. Two different matrices were developed on
the basis of acrylamide (AAm) derivatives such as AAm and/
or N,N-dimethyl acrylamide (DMAAm). Both of the cryogels
developed can be used as cell separation matrix. The epoxy
group was incorporated by copolymerization with allylglycidyl
ether (AGE). The final optimum concentration of monomers
can vary from 5% to 6% (wt/vol). Above this concentration of
monomers, the optimum pore size for convective movement of
cells in the cryogel decreases; below this concentration, the cryogel formed does not have enough mechanical strength and does
not retain its shape. The freezing temperature is very critical
for cryogel synthesis. Here, the cryogel was prepared at − 12 °C
to provide a sufficiently large pore size. However, the cryogel
can be prepared at a temperature range of − 10 to − 15 °C.
Below − 15 °C, the pore size of the cryogel decreases and
above − 10 °C the developed gels become loose with low poro
sity. The cryogel matrix was covalently coupled with protein A
(ligand) to capture different cell types labeled with a specific IgG
antibody. Scanning electron microscopy images of the prepared
cryogel should be taken to check the pore size of the synthesized column. The pore size should be 50–100 µm. The water
flow parameter should also be checked for its applicability
to chromatography. The volumetric flow rate of the aqueous
solvent should be around 5–8 ml min − 1. The synthesized cryogel column should be properly packed in a syringe without any
leakage (refer to TROUBLESHOOTING table).
nature protocols | VOL.5 NO.11 | 2010 | 1739

protocol

© 2010 Nature America, Inc. All rights reserved.

Cell recovery. Target cells were recovered by two different
approaches:
• Treatment with immunoglobulin (Ig) solution: In this approach,
cells can be specifically eluted. The fresh solution of secondary antibody was passed through the affinity cryogel matrix
bound with targeted cells. This step causes desorption of bound
cells because of its displacement with a higher-affinity secondary
antibody.
• Mechanical deformation of cryogel matrix: The recovery
of captured cells was carried out by the compression of an
affinity cryogel matrix to ~50% of its original length and the
collection of squeezed liquid. Thereafter, the compression force
was released and the compressed affinity matrix was reswollen
with buffer to regain its original size and shape, followed by
immediate flow of buffer (10 ml) at a flow rate of 2 ml min − 1
(Fig. 4).
The developed protocol for cell separation will remain the same
for all cell types. The step that might need optimization for some
cell types is the one that involves preclarification of unwanted

Piston

50% compression by

∆I = 50%

Cell binding. All the cell chromatography experiments were conducted under sterile conditions and inside a cell culture biosafety
laminar hood. Cells were incubated with a specific antibody, e.g.,
goat anti-human IgG and anti-human CD34 + . Labeled cells were
then applied to a protein A–coupled cryogel column. Here, the
cells were labeled before chromatography; this approach enhances
the binding capacity of cells. Labeling the matrix with an antibody before chromatography can cause disorientation of the
bound antibody, which does not provide an accessible antigenbinding fragment (Fab) for efficient cell binding. The cell binding on the protein A–monolithic cryogel column was carried out
as presented schematically in Figure 3. As a control experiment,
lymphocytes and UCB without antibody labeling were passed
through both protein A–coupled cryogel column and cryogel
column without protein A. The detailed protocol is presented in
the PROCEDURE.

Removal of external
force
Reswelling by addition
of buffer

Affinity cryogel
monolith containing
specific cell type

Squeezed liquid
containing cells

Liquid flow
containing cells

Figure 4 | Mechanical squeezing of the cryogel matrix for the recovery
of bound cells. Affinity-bound cells on cryogel matrix were removed by
compressing the cryogel column to up to 50% of its original length by using
an external piston that squeezes out the liquid that contains cells. In the
next step, the buffer was added to reswell the affinity cryogel matrix and
then the column was flushed with fresh cold buffer.

cells from the mixture to increase the binding and recovery of
cells after binding (see Box 1). As proposed in the above-mentioned cell recovery process, cells can be recovered by 50% compression of the cryogel column with a subsequent buffer wash.
However, for the separation of other cell types, it is possible that
compression percentages could be more (~80%) or a little less
(~30%) than what is proposed in PROCEDURE Step 16A(viii)
and B(ix).
An unlabeled sample mixture of cells is an appropriate control
to run in parallel to the chromatography of cells. It should pass
through the protein A–coupled cryogel column, and retention
of these unlabeled cells should be compared with that of the
labeled sample. The obvious result of the control experiment is
that there should not be any nonspecific binding of cells in the
cryogel column. In the present protocol, as a control experiment,
lymphocytes without antibody labeling were passed through
both a protein A–cryogel column and a cryogel column without
protein A.

Box 1 | Preparation and concentration of mononuclear cells or
lymphocytes
1. Add Ficoll-Paque PLUS (3 ml) to the centrifuge tube.
2. Carefully add a layer of diluted blood sample (4 ml) over Ficoll-Paque PLUS.
3. Centrifuge at 400g for 30–40 min at 18–20 °C.
4. Pipet out the upper layer using a clean Pasteur pipette, leaving the lymphocyte layer undisturbed at the interface. Do not disturb
the lymphocyte layer.
5. Now draw off the lymphocyte layer to a clean centrifuge tube by using a clean Pasteur pipette. It is critical to remove all the
material at the interface but in a minimum volume.
! CAUTION Removing excess Ficoll-Paque PLUS causes granulocyte contamination; removing excess supernatant results in platelet
contamination.
6. Add at least three volumes (6 ml total) of balanced salt solution to the lymphocyte-concentrated sample in the test tube and
gently suspend cells using a Pasteur pipette.
7. Centrifuge at 60–100g for 10 min at 18–20 °C.
8. Discard the supernatant.
9. Suspend cells in 6–8 ml of balanced salt solution by gently drawing them in and out using a Pasteur pipette.
10. Repeat Steps 7–8, and the lymphocyte-concentrated cell suspension should now be suspended in the medium appropriate to
the application.
 CRITICAL STEP To obtain a sufficiently pure preparation of lymphocytes, recentrifugation with Ficoll-Paque can be necessary to
remove contaminating red blood cells. When layering the sample, do not mix the Ficoll-Paque PLUS and the diluted blood sample.

1740 | VOL.5 NO.11 | 2010 | nature protocols

protocol

© 2010 Nature America, Inc. All rights reserved.

MATERIALS
REAGENTS
• Acrylamide (AAm, ≥99% (wt/wt); Sigma-Aldrich, cat. no. A9099, CAS no.
79-06-1) ! CAUTION It is an irritant, and is very toxic if inhaled, if it comes
in contact with skin, and if swallowed.
• N,N′-Dimehtylacrylamide (DMAAm, 99%; Sigma-Aldrich, cat. no. 274135,
CAS no. 2680—03-7) ! CAUTION It is toxic if inhaled; use eyeshields,
faceshields, full-face respirator, and gloves while handling.
• N,N′-methylenebisacrylamide (MBAAm, ≥98%; Sigma-Aldrich, cat. no.
M7279, CAS no. 110-26-9) ! CAUTION It is an irritant, and is very toxic if
inhaled, if it comes in contact with skin, and if swallowed.
• Allylglycidyl ether (AGE, > 99%; Sigma-Aldrich, cat. no. A32608, CAS no.
106-92-3) ! CAUTION It is an irritant and a moderate skin and severe eye
irritant on contact. Use protective gloves, eye and face shields.
• Ammonium persulfate (APS; Bio-Rad Labs, cat. no. 161-0700, CAS no.
7727-54-0) ! CAUTION It is an irritant and may cause fire on contact with
flammable materials. Use protective gloves and glasses.
• N,N,N′,N′-tetramethyleneethylenediamine (TEMED, Bio-Rad Labs, cat. no.
161-0801, CAS no. 110-18-9) ! CAUTION It is highly flammable and causes
burns. Use protective gloves and glasses. Keep away from heat and open flame.
• Glutaraldehyde solution (grade 1, 50% in water; Sigma-Aldrich, cat. no.
G7651, CAS no. 111-30-8) ! CAUTION It is highly flammable, and is toxic
if inhaled, if it comes in contact with skin and if swallowed. Keep the
container tightly closed and in a cool place.
• Ethylenediamine (99%; Sigma-Aldrich, cat. no. E26266, CAS no. 107-15-3)
! CAUTION It is corrosive and flammable. It is harmful on contact with skin
and if swallowed. It causes burns.
• Ethylenediaminetetraacetic acid (EDTA, tetrasodium salt dihydrate
> 99.5%, 50 mM solution; Sigma, cat. no. E6511, CAS no. 10378-23-1)
! CAUTION While handling all these chemicals and reagents, use protective
gloves and glasses and work in a fume hood.
• Goat anti-human IgG (Zymed Laboratories)
• Anti-human CD34 + was produced in ascites by injecting HSCA hybridoma
cells (Kaneka Chemical Industries) into mice, and purified using a protein
G column (1 ml; PerSeptive Biosystems)
• Protein A (Bangalore Genei, cat. no. 105254).  CRITICAL Store below 0 °C.
• Ficoll-Paque PLUS (GE Life Sciences)
• Penicillin-streptomycin solution (Sigma-Aldrich, 10,000 units penicillin and
10 mg ml–1 streptomycin, cat no. P4333)
• Hydroxyethyl cellulose, high viscosity (HEC; LOBA Chemie, cat no. 4137,
CAS no. 9004-62-0)
• Sodium citrate (Merck, cat no. 567446, CAS no. 6132-04-3)
• Citric acid, anhydrous (Merck, cat no. 61804105001730)
• Dextrose or glucose (Merck, cat no. 346351, CAS no. 50-99-7)
• Sodium borohydride (NaBH4; Merck, cat no. 1063710100, CAS no.
16940-66-2)
• Tris buffer (Merck, cat no. 61771401001730)
• Hydrochloric acid, 35% pure (HCl; Merck, cat no. 61752690251730)
• Sodium azide (Merck, cat no. 61824401001730)
• Ethanol (Merck, cat no. 1085430250, CAS no. 64-17-5) ! CAUTION Highly
flammable liquid and vapor. Keep away from heat/sparks/open flames/hot
surfaces.
• Calcium chloride (CaCl2; Merck, cat no. 1023780500, CAS no. 10043-52-4)
! CAUTION Causes serious eye irritation. In case of contact with eyes, rinse
with water for several minutes.
• Magnesium chloride (MgCl2; Merck, cat no. 8147330100, CAS no.
7786-30-3)
• Potassium chloride (KCl; Merck, cat no. 61753325001730)
• Sodium chloride (NaCl; Merck, cat no. 61751990201730)
• Sodium phosphate monobasic (NaH2PO4; Merck, cat no. 567545,
CAS no. 10049-21-5)
• Sodium phosphate dibasic (Disodium hydrogen phosphate) (Na2HPO4;
Merck, cat no. 567550, CAS no. 7558-79-4)
• Distilled water
• Nitrogen (N2) gas
• Bovine serum albumin (BSA; Merck, cat no. 12657, CAS no. 9048-46-8)
 CRITICAL store at 2–8 °C.
• Sodium chloride (NaCl; Merck, cat no. 567440, CAS no. 7647-14-5)
• Potassium dihydrogen phosphate (KH2PO4; Merck, cat no.
60487305001730)

• Hydrochloric acid (HCl; Merck, cat no. 60906005001730)
• Sodium hydroxide (NaOH; Merck, cat no. 61757390511730)
• Sodium carbonate (Na2CO3; Merck, cat no. 61784490511730)
• Sodium bicarbonate (NaHCO3; Merck, cat no. 61752090501730)
• Sodium acetate trihydrate (Merck, cat no. 61751890201730)
• HEPES (Merck, cat no. 1152310025, CAS no. 75277-39-3)
• Acetic acid, glacial (Merck, cat no. 61780790251730)
EQUIPMENT
• Thermostatic bath/circulator (Proline 1840; Lauda-Wobser,
cat no. LCK 1891)
• Laminar hood
• Florescent activated cell scanner (Cyflow; Partec, cat no. CY-S-3001)
• Sterile tubes for blood collection (50 ml; Tarsons Products, cat no. 546040)
• Conical flasks
• Filter (0.2-µm pore size)
• Vacuum pump (Rocker 300; Tarsons Products, Rocker 300, cat no. 7010)
• Magnetic stirrer and stir bars (Tarsons Products, cat no. 4020)
• Plastic syringes (any company with required size range of 2 ml to 20 ml)
• Peristaltic pump (P1; GE Healthcare, cat no. 18-1110-91)
• Centrifuge (Hermle Labortechnik Model Z323)
• Pasteur pipette
• Sterile vials (for collecting bound cells from compressed cryogel columns,
2 ml) (Tarsons Products, cat no. 500020)
• Polystyrene pipe (Tygon vacuum tubing; Tarsons Products, cat no. 740000)
REAGENT SETUP
Phosphate buffer (0.01 M), pH 7.4 Add 57 ml of 0.02 M sodium phosphate
monobasic and 243 ml of 0.02 M sodium phosphate dibasic heptahydrate.
Dilute the mixture with distilled water to bring the total volume up to
600 ml.
Phosphate buffer (10 mM) containing 0.15 M NaCl (pH 7.4) Recipe is the
same as that for the preparation of phosphate buffer (0.01 M) pH 7.4, with
the exception of the addition of 0.15 M NaCl.
Phosphate-buffered saline (PBS; pH 7.2) supplemented with 0.5% bovine
serum albumin (BSA) For 1 liter PBS, dissolve 8 g NaCl, 0.2 g KCl, 1.44 g
Na2HPO4 and 0.24 g KH2PO4 in 800 ml distilled water. Then adjust the pH
to 7.4 with HCl and NaOH and add distilled water to bring the volume to
1 liter. Add 0.5 % (wt/vol) bovine serum albumin.
Sodium carbonate buffer (pH 9.2) Mix 10 ml of 0.1M Na2CO3 and 90 ml
of 0.1M Na2HCO3
HEPES buffer (pH 7.4) Mix 20 mM HEPES in 100 ml distilled water and
then add 0.2 M NaCl.
Acetate buffer (pH 2.5) Mix 10 ml of 0.2 M sodium acetate trihydrate and
90 ml 0.2 M acetic acid.
Balanced salt solution Combine 0.145 M Tris-HCl (pH 7.6) containing
0.1% glucose, 0.05 mM CaCl2, 0.98 mM MgCl2, 5.4 mM KCl and 14 mM
NaCl.
Acid Citrate Dextrose (ACD) or sodium citrate (anticoagulant) This can
be prepared by performing the following steps:
• Dissolve 1.32 g of sodium citrate in 85 ml of distilled water
• Dissolve 0.48 g of citric acid in the solution from step 1
• Dissolve 1.47 g of dextrose in the solution from step 2
• Add distilled water and make up to 100 ml
• Filter-sterilize through a 0.2-µm-pore filter
• Use 0.25 ml of solution for 1 ml of blood
Umbilical cord blood Under aseptic conditions inside a laminar hood,
collect UCB into a sterile tube containing anticoagulant (ACD or sodium
citrate) and store at 4 °C. It is better to carry out experiments with fresh
blood (within 6 h after collection) to avoid contamination and to capture
the CD34 + cells. Delaying the process may lose CD34 + expression.
Peripheral blood Under sterile conditions, collect whole blood in a sterile
tube containing anticoagulant (heparin or ACD) and store at 4 °C. It is better
to carry out the experiment with fresh blood (within 6 h after collection)
to avoid contamination and to capture CD34 + cells. Delaying the process
may lose CD34 + expression.  CRITICAL Appropriate ethical approval
should be taken before the collection of UCB and peripheral blood for stem
cell isolation. Consent from parents should also be taken before the collection
of UCB after childbirth.
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PROCEDURE
Preparation of supermacroporous monolithic cryogel–protein A affinity matrix
1| To degas distilled water, fill the distilled water to half the volume in a conical flask provided with a nozzle on its neck.
Attach one end of a polystyrene pipe to the nozzle and the other end to a vacuum pump to create a vacuum in the conical
flask. During vacuum, the water should be under constant magnetic stirring. Allow the degassing to continue for ~1 h.
2| Choose which polymer is the most appropriate for your experiment. Two different types of AAm-based cryogels can be
prepared: (A) DMAAm-based cryogel and (B) AAm-based cryogel.
 CRITICAL STEP Both AAm and DMAAm are suitable polymers for the preparation of cryogel-based chromatography matrix.
Highly hydrophilic matrices are preferred for chromatography purposes to avoid nonspecific interactions during the separation process. Both the matrices are hydrophilic in nature and are appropriate for cryogel preparation. AAm is slightly more
hydrophilic than DMAAm and is a preferred choice of polymer for cryogel preparation. In contrast, DMAAm can be stored
more stably than AAm. However, the overall porosity, pore size and mechanical strength of the developed cryogel matrix are
approximately similar and they have the same physical morphology.
(A) DMAAm-based cryogel
(i) In 100 ml of degassed water, mix monomers, 6.3 ml of DMAAm and 0.85 ml of AGE.
(ii) Dissolve 2.2 g of MBAAm as a crosslinker in the monomer solution. A total concentration of 5% monomeric precursors
should be used for the cryogel formation.
(B) AAm-based cryogel
(i) Mix monomers, 4 g of AAm and 1 ml of AGE, in 100 ml of degassed water.
(ii) Dissolve 1 g of MBAAm as a crosslinking agent in monomer solution. A total concentration of 6% monomeric
precursors should be used for the cryogel formation.
3| Next, keep the mixture under constant N2 purging for 5–10 min to remove dissolved oxygen.
4| Cool the mixture at 4 °C and then add 110 mg of APS, followed by 95 µl of TEMED as initiator/activator agent.
 CRITICAL STEP Ensure that the water is properly degassed and purged with N2 before the addition of APS/TEMED to
remove O2 (to inhibit free-radical polymerization).
 CRITICAL STEP The mixture of monomers should be cooled to 1–4 °C before the addition of APS/TEMED to retard the
free-radical reaction.
5| After addition of APS/TEMED, quickly pour 1 ml of the mixture into precooled plastic syringes (diameter 0.9 cm) and
store at − 12 °C in a refrigerated circulatory bath for 12 h.
To process large sample volumes (up to 50 ml), we recommend an optimal column size of 20 ml (length 6.3 cm × diameter
2 cm). The column can be prepared as per the sample volume and scaling up of chromatography. To prepare such a column,
pour the desired volume of the monomer mixture into defined plastic syringes (e.g., 5 ml mixture into a 5 ml syringe, 10 ml
mixture into a 10 ml syringe and so on). However, it is not recommended to increase the column size beyond 20 ml, as it may
not be very uniform.
6| After a complete incubation period of 12 h, thaw the synthesized cryogel with ~20 ml of water at room temperature (25 °C),
followed by washing with another portion of 20 ml of water and water/ethanol mixture to remove any unreacted monomers.
7| After complete washing, dry the cryogel monolith in a vacuum and store it for further use.
 PAUSE POINT The cryogels in dried form can be stored from days to weeks or even for several months for further
modification and use. However, in the wet form, the gel needs to be modified soon after the cryogel washing in Step 5.
? TROUBLESHOOTING
Two-step derivatization of epoxy-containing cryogel monolith for the attachment of protein: reaction with
ethylenediammine
8| Place 1-ml cryogel columns (dried or freshly prepared wet) in a 50-ml plastic tube closed with a lid. One to five gel
columns can be placed in a single tube.
9| Wash cryogel columns with water (10 ml per gel) and then with 0.2 M Na2CO3 (pH > 10; 10 ml per gel).
10| Incubate cryogel columns with ethylenediamine (0.5 M in 0.2 M Na2CO3; 10 ml per gel) for 4 h and wash with water until
the pH is close to neutral.
 CRITICAL STEP Reactions and water washes are carried out by gently shaking the gels in the tube on a pedal shaker as
indicated or for a minimum of 5 min.
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Reaction with glutaraldehyde
11| Wash the ethylenediamine-treated cryogel columns with 0.1 M sodium phosphate buffer (pH 7.2; 10 ml per gel).
12| Next, incubate the cryogel columns in glutaraldehyde solution (5% (vol/vol); 10 ml per gel) in 0.1 M sodium phosphate
buffer (pH 7.2; for 5 h).
13| Wash the columns in distilled water (10 ml per gel, washing repeatedly three to five times).
14| Incubate the derivatized cryogel matrix with the solution of protein A (1.6 mg ml–1; 10 ml) in 0.1 M sodium phosphate
buffer (pH 7.2) at 4 °C for 24 h. The unreacted protein A solution after this step can be reused if needed.
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15| Finally, wash the protein A–coupled cryogel matrix with freshly prepared sodium borohydride (NaBH4) solution
(0.1 M in sodium carbonate buffer (pH 9.2); 10 ml per gel) to reduce Schiff ’s base formed between the protein and the
aldehyde-containing matrix.
 PAUSE POINT The protein A–coupled column can be stored in phosphate buffer (0.1 M, pH 7.2) at 4 °C for several months
in the presence of 0.02% (wt/vol) sodium azide or 20% (vol/vol) ethanol.
16| The column can now be used for cell separations. To illustrate how this is done, we have included procedures for two
examples: (A) fractionation of lymphocytes and (B) separation of CD34 + stem cells from UCB.
(A) Fractionation of lymphocytes
(i) Separate mononuclear cells (lymphocytes, buffy coat) from freshly collected human peripheral blood using
Ficoll-Paque PLUS density gradient separation medium by centrifugation at 400g for 40 min at room temperature
as per the manufacturer’s instructions. The detailed procedure as described in a handbook available from GE Life
Sciences29 can be found in Box 1. As a control experiment, lymphocytes without antibody labeling were passed
through both protein A–coupled cryogel column and cryogel column without protein A.
(ii) Place 2 ml of cryogel column into a sterile plastic syringe and wash thoroughly by passing 20 ml of 20 mM HEPES
buffer (pH 7.4) containing 0.2 M NaCl through it at a flow rate of 2 ml min − 1 using a peristaltic pump. (This process
can be scaled up. The column size can be increased to process a 50 ml sample. The optimum column size of 20 ml
(length 6.3 cm × diameter 2 cm) can be used to process a 50 ml sample volume in recycle mode).
? TROUBLESHOOTING
(iii) Next, add a small amount ( < 0.3 ml) of buffer above the top surface of the cryogel column.
(iv) Treat the lymphocytes (1 ml, 2.0–4.0 × 107 cells per ml) with 50 µl (0.1 µg µl − 1) of goat anti-human IgG and incubate
at 4 °C for 5 min. This will bind to B lymphocytes having surface IgG molecules.
(v) Centrifuge cells at 200g for 5 min and suspend the cells in 1 ml of balanced salt solution.
(vi) Add antibody-treated lymphocytes to the top of the column and collect 1.5 ml (about void volume of the column)
flow-through. Close the column outlet and allow the cells to bind efficiently to the matrix for 10 min without any
buffer flow, at room temperature.
(vii) After 10 min of incubation, run the cold HEPES buffer (20 ml) through the column at a flow rate of 1.5 ml min − 1 to
wash out unbound or loosely bound cells.
? TROUBLESHOOTING
(viii) Bound cells can be recovered by either of two ways. One approach is to recover cells with Ig solution after complete washing.
To do this, first incubate the column and the buffer at 37 °C for 10 min and then add 2 ml of IgG (30 mg ml− 1) through the
column. Thereafter, incubate the column at room temperature without buffer flow for 5 min. Next, run 20 ml of buffer through
the column at a flow rate of 1.5 ml min− 1 and collect a 4-ml aliquot containing a specific cell type. An alternative approach is to
compress the cryogel column gently with a syringe piston to up to 50% of its original length and collect the squeezed liquid in a
sterile vial. Thereafter, flow the buffer (10 ml) at a flow rate of 1.5 ml min− 1 to recover the remaining loosely bound cells on the
cryogel column. The process described here is used for the mechanical squeezing of cryogel for the recovery of bound cells.
? TROUBLESHOOTING
(B) Stem cell (CD34 + ) separation from UCB
(i) Sediment red blood cells (RBCs) from UCB by using hydroxyethyl cellulose (HEC) as the sedimenting agent. Add 6%
(vol/vol) HEC into the blood at a 5:1 ratio of blood:HEC, and mix properly. Thereafter, allow RBCs to settle down for
15–20 min, then remove the settled RBCs and store supernatants containing mononuclear cells.
 CRITICAL STEP To achieve high purification and high yield, preclarification is a desired step. The RBC and/or
platelets can be removed from whole blood by using sedimenting agents, e.g., Ficoll-Paque PLUS and HEC,
as discussed in step Box 1 and PROCEDURE Step 16B(i), respectively.
? TROUBLESHOOTING
(ii) Incubate the RBC-sedimented UCB (1 ml) and whole UCB (1 ml) with human anti-CD34 (1 µg ml − 1) at 4 °C for 5 min.
(iii) Centrifuge the cells at 200g for 5 min and suspend in 1 ml of PBS (pH 7.2, supplemented with 0.5% BSA).
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(iv) Sterilize the protein A–coupled cryogel column (1 ml; height × diameter: 1.0 cm × 0.9 cm) by passing 20 ml of
2% (vol/vol) penicillin-streptomycin solution in buffer (0.1 M PBS, pH 7.4) at a flow rate of 1.5 ml min − 1.
(v) Thereafter, equilibrate the sterilized protein A–cryogel matrix by passing 50 ml of PBS (pH 7.2 supplemented with
0.5% BSA) at a flow rate of 1.5 ml min − 1.
(vi) Close the lower end of the cryogel column and leave < 0.2 ml buffer above the top surface of the column.
(vii) Load 0.8 ml of antibody-treated, UCB and RBC-sedimented onto the top of the cryogel column. Thereafter, open the
lower end of the cryogel column and collect 0.6 ml of flow-through. Close the column outlet and allow the cells to
bind efficiently to the matrix for 10 min without any buffer flow at room temperature.
(viii) After 10 min of incubation time for cell binding, wash the column with 10 ml of buffer at a flow rate of 1.5 ml min − 1
to remove unbound or loosely bound cells.
(ix) Bound cells can be recovered by either of two ways. One approach is to recover cells with Ig solution after complete
washing. To do this, first, incubate the column and the buffer at 37 °C for 10 min and then add 1 ml of IgG
(30 mg ml − 1) through the column. Thereafter, incubate the column at room temperature without buffer flow for 5 min.
Now, run 10 ml of buffer through the column at a flow rate of 1.5 ml min − 1 and collect 3 ml of aliquot containing
a specific cell type. An alternative approach is to compress the cryogel column gently with the syringe piston to up to
50% of its original length and collect the squeezed liquid in a sterile vial. Thereafter, run the buffer (10 ml) at a flow
rate of 1.5 ml min − 1 to recover the remaining loosely bound cells on the cryogel column. The process described here is
used for the mechanical squeezing of cryogel for the recovery of bound cells.
 CRITICAL STEP If the recovery of cells by mechanical squeezing is < 70% in the first step, we suggest repeating it.
	  ? TROUBLESHOOTING
Regeneration of the column
17| Used columns (1 or 2 ml) can be regenerated by passing 10 column volumes of 50 mM acetate buffer (pH 2.5) at a flow
rate of 1 ml min − 1.
18| Equilibrate the column by passing 20 column volumes of 0.1 M PBS (pH 7.2).
? TROUBLESHOOTING
Troubleshooting advice can be found in Table 1.


Table 1 | Troubleshooting table.

Step

Problem

Solution

7

After synthesis, some of the
cryogels are irregular in shape

Choose only those synthesized cryogels with proper shape as shown in Figure 5

16A(ii)

Sample or liquid leaks from
the sides of the cryogel
matrix packed in the syringe

Use only those cryogels that are tightly packed in syringes. Incubate the packed cryogels
with water for complete swelling. Check each cryogel’s packing by inverting the packed
syringe to see whether the cryogel matrix moves or not. If the cryogel slides, the matrix
is not properly packed. Either change the matrix or swell the matrix for additional time

16A(vii)

The target cells are eluted
out of the column during
the washing procedure

Decrease the flow rate of washing buffer. Check the pH of washing buffer
Check for leakage of cells through the sides of the cryogel matrix in the syringe
or appropriate mold (refer to TROUBLESHOOTING advice for Step 16A(ii))

16A(viii)

Low recovery of bound cells

Repeat the cell release process two or three times

16A(viii),
16B(ix)

Bound cells do not release
after mechanical squeezing
of the cryogel

Compress the cryogel again with 70–80% compression followed by liquid flow at
1.5 ml min − 1. If cells are not coming out even after this treatment, then the developed
matrix does not have sufficient pore size. Please check the pore size of developed
cryogel before chromatography

Released cells are not viable

Carry out the viability test before and after the chromatography
Decrease the compression on cryogel, restrict the compression up to 25% of original
length, change in length followed by buffer flow (1 ml min − 1)
Maintain the temperature during chromatography; it should be less than room temperature. Pass cold buffer through the column to wash the column and to elute unbound cells
The complete chromatography process should not take more than 30 min

16B(i)

Very low recovery percentage
of CD34 + cells
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Process the UCB within 2 h after collection or refer to TROUBLESHOOTING advice for
Step 16A(vii), 16A(viii) and 16B(ix)

protocol
● TIMING
Steps 1–7: ~17 h
Steps 8–16: 40–48 h
Step 16A(i): ~1 h
Step 16A(ii–viii): 45–60 min
Step 16B(i): ~30 min
Step 16B(ii–ix): ~60 min
Steps 17 and 18: 30 min

a

ANTICIPATED RESULTS

c
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Affinity cryogel matrix design for cell chromatography

b

Dry

Swollen

Cryogel
chromatography
column

The cell chromatography matrix was synthesized by
copolymerization of AAm and AGE using MBAAm as crosslinker at − 12 °C for 12 h. The water-swollen poly(acrylamideco-allylglycidyl ether) (poly(AAm-co-AGE)) cryogel
maintained its shape and morphology even after complete
drying (Fig. 5a,b). Water-swollen poly(AAm-co-AGE) cryogels
were spongy in nature and water could be squeezed out
with compression. Analysis by scanning electron microscopy
500 µm
100 µm
demonstrated that the pore diameter of dried poly(AAm-coAGE) cryogels is in the range of 50–100 µm (Fig. 5c).
Figure 5 | Physical characteristics of the monolithic cryogel chromatography
column. (a) Cryogel chromatography column. (b) Physical shape of
The thick and smooth sidewalls of pores were observed by
poly(AAm-co-AGE) cryogels in dry and swollen form. (c) Scanning electron
scanning electron microscopy (Fig. 5c). These large intermicroscope images of poly(AAm-co-AGE) cryogels at different magnifications
connected pores in suitably designed cryogel matrix can
(×160 and ×795).
function as capillaries and can quickly absorb a large amount
of water. These swelling studies indicated that these matrices have a high rate of swelling. The flow properties were checked for protein A–coupled poly(AAm-co-AGE) cryogel matrix
and showed a high volumetric flow rate of around 8 ml min − 1 across the cryogel matrix. It was also observed that the cryogel
matrix allowed convective movement of large particles. The amount of protein A coupled to the cryogel matrix was found to
be ~2 mg per gel matrix, as measured by bicinconnic acid reagent.
Fractionation of lymphocytes

The interaction of protein A with cells bearing IgG antibodies on their surfaces has been successfully used for the fractionation
of blood lymphocytes in a chromatographic format. B lymphocytes are Ig-positive cells and express IgG on the cell surface.
The results were calculated by flow cytometry analysis, with the scatter gates set on the lymphocyte fraction. When loaded
with 1 ml of treated cells (3.0 × 107 cells per ml), ~91% of B cells were retained in the 2-ml column. With ~11.6% of B cells in
the total mononuclear cells, the B-cell–binding capacity was determined to be ~1.6 × 106 cells per ml of adsorbent. The cells
in the breakthrough fraction were enriched in T cells (81%). The viability of cells investigated in the breakthrough fraction
was > 90%, as measured by Trypan blue staining of cells. The electron micrograph image (Fig. 6) of bound cells on the protein
A–cryogel matrix clearly demonstrated the specific binding of the cells. The cells were attached to the pore walls rather than
mechanically entrapped in the dead-flow zones. In all, 70% of the total bound cells were recovered by the treatment of Ig
solution, and contain ~70% of B cells (Fig. 7). The overall recovery of B cells from lymphocyte fraction can further be
increased if the sample is passed through the column in recycle mode. Moreover, the capacity of the column can be amplified
by increasing the size of the affinity column to achieve > 90–95% cell recovery. The recovery percentage could be increased by
mechanical squeezing of gel. However, the recovered cells also contained ~20% of T cells. Probably, most of the T cells were
retained in the column through some weak interactions of cell receptors with protein A or through some cells aggregated
with B cells. To achieve higher purification of the recovered B cells, a pulse gradient of human Ig (10, 30 and 50 mg ml − 1) was
applied. At the highest concentration of IgG, 60% B-cell recovery was achieved with < 10% T cells. Furthermore, the cells that
were directly applied to protein A–cryogel without labeling with goat anti-human IgG were completely recovered by the flow of
buffer (Fig. 7). Affinity chromatography of human blood mononuclear cells on supermacroporous cryogel–protein A was found
in this study to result in about a twofold enrichment of T cells by negative selection. The very low B-cell contamination (~1%)
showed significant selectivity of the separation process. With mechanical squeezing of the cryogel matrix, ~95% of bound cells
were recovered, which contained ~70% of B cells. The viability of the recovered cells was ~90%.
Stem cell chromatography: purification and characterization
Stem cell (CD34 + ) capture. Fluorescence-activated cell sorting (FACS) analysis demonstrated that all unwanted cells were

washed out during the washing procedure. It was also found that ~8 × 106 nucleated cells were removed during washing and
nature protocols | VOL.5 NO.11 | 2010 | 1745

that washed-out nucleated cells may contain some unbound
CD34 + cells. The captured CD34 + cells were recovered by
mechanical squeezing of cryogel. The bound CD34 + cells were
released at 50% compression, followed by 10 ml of buffer
wash, to elute loosely bound CD34 + cells. The FACS analysis
showed > 95% cell recovery of bound cells (Fig. 7). It was
also observed that > 70% compression of cryogel leads to
increase in cell recovery but decrease in viability of
eluted CD34 + cells. Finally, the optimized procedure for cell
recovery through mechanical squeezing involves lengthwise
×950
20 µm
compression of up to 50–60%, followed by 10 ml of flushing by PBS. It leads to > 95% cell recovery, as confirmed by
Figure 6 | Scanning electron micrograph of the inner part of the
Trypan blue staining and FACS analysis. The FACS analyses
supermacroporous cryogel-protein A matrix loaded with lymphocytes.
demonstrated that the released or recovered cells were
The cells are affinity bound on the pore walls. Magnification (×950)
CD34 + . The pure population of 1 × 105 CD34 + hematopoietic
(adapted from Kumar et al.20 with permission).
stem cells can be recovered from 0.8 ml of labeled UCB using
1 ml of cryogel matrix. There was an increase in the overall
recovery of stem cells from RBC-sedimented UCB, with the recovered cell number of 7 × 105 cells per ml of cryogel column.
A control experiment was run to demonstrate that 1 × 106 nucleated cells can pass through without any nonspecific
interactions, and in another experiment, the unhindered movement of whole blood was observed through the cryogel
affinity column (Fig. 7). There were very few RBCs and platelets that were retained in the column nonspecifically, which
affects overall column efficiency as demonstrated in our result in which CD34 + cells were separated directly from UCB. The
overall efficiency of a 1-ml affinity cryogel column was estimated to be around 7 × 105 cells per ml of cryogel column (0.9%
of total nucleated cells) with > 90% purity. The efficiency of the cryogel column decreased to 1 × 105 cells per ml of cryogel
column (0.2% of total nucleated cells) when applying UCB directly in comparison with RBC-sedimented UCB. We have
found 20% CD34 + cell recovery from UCB and 90% cell recovery from RBC-sedimented UCB using the 1-ml cryogel column
(height × diameter: 1.0 × 0.9 cm2). The capacity of the cryogel column can be increased by changing the physical dimensions
to achieve a higher percentage of cell recovery. In another experiment, it was also demonstrated that bound CD34 + cells
can be recovered and concentrated (50% compression followed by 1 ml buffer wash) in 1.5 ml of an elution aliquot
containing > 90% of bound cells. Overall, the cell chromatographic process took ~30 min.
The isolated cells were grown for 3 weeks and then labeled with FITC-conjugated anti-CD34 + . The labeled cells were
observed under fluorescence microscope; results demonstrated that isolated stem cells maintained proliferation capacity
and retained CD34 + cell-surface markers. We have seen that, during the squeezing process, generally the antibody remains
attached to protein A and mostly antibody-free cells can be recovered because the binding strength of protein A to the Fc
portion of the IgG antibody is greater than the antibody interaction with the cell-surface markers. We confirmed this when
regenerating the protein A–cryogel column with low-pH buffer washing, wherein we observed some concentration of antibody
in the column wash. However, it is possible that some of the recovered cells could retain antibody on their surfaces. The antibody bound to recovered cells when kept in growth media can shed the surface-bound antibody during the culture process.
Although we have presented two model examples here for the separation of lymphocytes and CD34 + cells on a protein A–
coupled cryogel column, this approach can be used for other
2.0
cell types with similar efficiency. We have tried this with
other cell types as well. Moreover, the regenerated protein A
1.8
Total bound
columns can be reused at least two to three times without
cells
B cells (M)
1.6
showing much effect on the cell binding and recovery.
92% yield
Concentration of recovered cells per ml of adsorbent × 106
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1.4
1.2

B cells (Ig)
70% yield

1.0
+

0.8

CD34 (RS-UCB)
90% yield

0.6
0.4
CD34+(UCB) Total bound
cells (UCB)
83% yield

0.2
0
Separation of lymphocytes

CD34+ cell separation
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Total bound
cells (RS-UCB)

Figure 7 | The cell separation efficiency on an affinity-based cryogel
chromatographic column (per milliliter adsorbent). Separation of
lymphocytes (gray bars) showing B-cell recovery after incubation with
immunoglobulin (B cells (Ig)) with 70% yield, and recovery by mechanical
squeezing (B cells (M)) with 92% yield from total bound cells on the
cryogel adsorbent. CD34 + cell separation (white bars) showing recovery
of CD34 + cells (CD34 + (UCB)) with 83% yield directly from UCB and CD34 +
cell recovery (CD34 + (RS-UCB)) with 90% yield from RBC-sedimented UCB
from total CD34 + cells bound on cryogel adsorbent when direct UCB and
RBC-sedimented UCB (RS-UCB) were applied, respectively. In both types of
control experiments, i.e., when labeled cells were passed through a plain
cryogel column and when unlabeled cells were passed through an affinity
cryogel column, no cell binding was observed.
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Bacterial glycosidases for the production of universal red
blood cells
Qiyong P Liu1,9, Gerlind Sulzenbacher2,9, Huaiping Yuan1, Eric P Bennett3, Greg Pietz1,3, Kristen Saunders1,
Jean Spence1, Edward Nudelman1, Steven B Levery4, Thayer White1, John M Neveu5, William S Lane5,
Yves Bourne2, Martin L Olsson6,7, Bernard Henrissat2 & Henrik Clausen3,8
Enzymatic removal of blood group ABO antigens to develop universal red blood cells (RBCs) was a pioneering vision originally
proposed more than 25 years ago. Although the feasibility of this approach was demonstrated in clinical trials for group B RBCs,
a major obstacle in translating this technology to clinical practice has been the lack of efficient glycosidase enzymes. Here we
report two bacterial glycosidase gene families that provide enzymes capable of efficient removal of A and B antigens at neutral
pH with low consumption of recombinant enzymes. The crystal structure of a member of the a-N-acetylgalactosaminidase
family reveals an unusual catalytic mechanism involving NAD+. The enzymatic conversion processes we describe hold promise
for achieving the goal of producing universal RBCs, which would improve the blood supply while enhancing the safety of
clinical transfusions.

The ABO blood group system, discovered in 1900 (ref. 1), is the most
important blood group system to consider in transfusion medicine.
This system is based on the presence or absence of the blood group
antigens A and B. The corresponding blood group carbohydrate
structures, designated ABH, are found at the termini of oligosaccharide chains on glycoproteins and glycolipids on the surface of erythrocytes and of endothelial and most epithelial cells2,3. The
immunodominant monosaccharide that determines blood group A
specificity is a terminal a-1,3-linked N-acetylgalactosamine (GalNAc),
whereas the corresponding monosaccharide of blood group B specificity is an a-1,3-linked galactose (Gal) (Fig. 1). Group O cells lack
both of these monosaccharides at the termini of their oligosaccharide
chains, which instead are terminated with a-1,2-linked fucose (Fuc)
residues and designated the H antigen (see review2). The genetic basis
of ABO antigens has been elucidated; genes determining A and B
blood types encode glycosyltransferases in which a few amino acid
substitutions result in differing substrate specificities: the A enzyme for
UDP-GalNAc and the B enzyme for UDP-Gal, whereas the gene for
the O blood type encodes an inactive protein4.
Plasma of blood group A individuals contains naturally occurring
antibodies to the B antigen. Conversely, that of blood group B
individuals contains antibodies to the A antigen. Blood group AB
plasma has neither antibodies, and blood group O plasma has both
antibodies. Individuals with anti-A and/or anti-B antibodies cannot

receive a transfusion of blood containing the corresponding incompatible antigen(s). Inappropriate transfusion of ABO-incompatible
RBCs can cause complement activation and lysis of the incompatible
RBCs, often resulting in an acute intravascular hemolytic transfusion
reaction. Inadvertent mismatching of RBCs for ABO blood groups
remains one of the most common and persistent causes of serious and
sometimes fatal adverse events following transfusion, according to
hemovigilance monitoring systems5,6. Group O RBCs contain neither
A nor B antigens and can be transfused safely into recipients of any
ABO blood group, that is, group A, B, AB or O recipients. Thus, type
O blood is considered ‘universal’ and may be used for all RBC
transfusions. Hence, blood banks strive to maintain significant inventories of group O RBCs. In reality, however, there is a constant
shortage of group O units as these are always in great demand for
numerous reasons, including emergency situations in which the
patient’s blood group is unknown, shortages of blood from a particular blood group, pediatric transfusions, and lack of clarity regarding
the patient’s blood group (e.g., due to previous transfusions or
allogeneic stem cell transplantation). Enzymatic removal of the
immunodominant aGalNAc and aGal monosaccharides from group
A and B structures of non-O RBCs offers an appealing approach to
improve transfusion safety and the overall blood supply7.
Goldstein originally envisioned enzymatic conversion of the A and
B antigens on RBCs to H antigen by use of exoglycosidases for
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Figure 1 Structural basis of the ABO blood group antigens. The
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Increased complexity in ABH oligosaccharide structures are provided by the
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oligosaccharide carrier chain (R). On human RBCs most structures are
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based on type 2 polylactosamine chains with repeating Galb1-4GlcNAc
O
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disaccharide units (both glycolipids and N-linked glycoproteins). A minor
HO
amount of type 1 chain ABH structures with Galb1-3GlcNAc are found
OH
as glycolipids adsorbed from plasma3. A fraction of the blood group A
glycolipids with type 2 chain core structures are extended by a bGal residue (Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-R), which is further
preferentially modified to an A-associated H epitope in subgroup A2 RBCs (Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-R) and a repetitive A
epitope (GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-R) in subgroup A1 RBCs (see Fig. 4 for glycolipid structures). Cleavage of
the repetitive A structure by an a-N-acetylgalactosaminidase will result in exposure of the H disaccharide epitope.

selective removal of aGalNAc and aGal residues of the immunodominant A and B trisaccharide antigens, respectively, to expose the
underlying H antigen8 (Fig. 1). For conversion of group B RBCs, he
used an a-galactosidase derived from green coffee beans (Coffea
canephora), which has a very low pH optimum (pH 3.5) and required
as much as 1–2 g enzyme per unit of group B RBCs for adequate
conversion at acidic pH 5.5. A phase 2 crossover trial was completed
with full unit (B200–220 ml packed) transfusions of group B RBCs
enzyme-converted to group O (B-ECO), in which the converted cells
functioned and survived normally in group A and O patients9.
Although this study clearly demonstrated that enzymatic conversion
of RBCs is feasible and that B-ECO cells can function as well as

R

ABO-matched untreated cells in transfusions, a major obstacle to
clinical implementation of this method is the large quantities of
enzyme required. Other investigators have explored different a-galactosidases and protocols for conversion of group B RBCs but without
substantial improvements in enzyme consumption10,11.
Successful conversion of group A RBCs has not yet been achieved.
The biochemistry of A antigens is more complex than that of B
antigens. Subgroup A1 RBCs have B5 more A antigens than
subgroup A2, and, in addition, subgroup A1 cells have glycolipids
with a repeated A structure, which in A2 cells mainly exist as an
A-associated H structure (see Fig. 1 and Table 1 for structures)12,13.
Conversion of only the A2 subgroup to group O was achieved with a

Table 1 Substrate specificities analyzed by TLC assay
a-N-acetylgalactosaminidase

Substrate

Blood group specificity

GalNAca1-2(3,4)Gal Structures
GalNAca1-2Galb1-MCO

a-galactosidases

E. meningosepticum
(pH 6.8)

Coffee beana
(pH 5.5)

S. griseoplanusa
(pH 6.8)

B. fragilis
(FragA) (pH 6.8)

+

ND

ND

ND

GalNAca1-3Galb1-MCO
GalNAca1-3Galb1-4GlcNAcb1-MCO

A-di
Linear A-tri

+
+

ND
ND

ND
ND

ND
ND

GalNAca1-4Galb1-4Glcb1-MCO
GalNAca1-3(Fuca1-2)Gal

A-tri

+
+

ND
ND

ND
ND

ND
–

GalNAca1-3(Fuca1-2)Galb1-3GalNAcb1-AMC
GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)

A-tetra (type 3 chain)b
A-hepta (type 3 chain,

+ (0.25 U/mg)c
+ (0.25 U/mg)

–
ND

–
ND

–
ND

Galb1-4GlcNAcb1-AMC
Gala1-3Gal Structures

repetitive A)

Gala1-3Gal
Gala1-3Galb1-4GlcNAc

B-di
Linear B

ND
ND

ND
+

ND
–

–
–

Gala1-3(Fuca1-2)Gal
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-AMC

B-tri
B-tetra (type 2 chain)

–
–

+
+ (0.017 U/mg)

+
+

+
+ (6.6 U/mg)

Gala1-4Gal Structures
Gala1-4Gal

P1

–

+

–

–

Gala1-4Galb1-4Glc

Pk

–

+

–

–

aFrom published US patent application no. US 20,050,208,655. bCore structures of ABH antigens designated type 1–4, as described previously3. cSpecific activity determined using quantification
by fluorography of TLC analysis.

+, complete digestion of substrate using conditions that produce complete digestion of the AMC-labeled blood group A or B tetrasaccharide substrates. –, no detectable digestion of
substrate under the same conditions even after extended reaction time (10). ND, not determined.
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chicken liver a-N-acetylgalactosaminidase using 1 g of enzyme per
unit of RBCs at pH 5.5 (ref. 14). An a-N-acetylgalactosaminidase from
Clostridium perfringens has also been used15. Purification of an a-Nacetylgalactosaminidase from Arenibacter latericius with neutral pH
optimum, which appeared to convert both subgroup A1 and A2 cells
after 24 h incubation, has been reported16. The efficiency of the
conversion, however, was not confirmed by licensed typing methods,
and the gene has not been identified yet. It is, therefore, not clear
whether the difficulties with conversion of the A1 subgroup relate to
the complexity of A antigens or to the poor kinetic properties and
acidic pH optima of the enzymes used to date14,15.
In the past, a-N-acetylgalactosaminidases and a-galactosidases used
for removing the immunodominant aGalNAc and aGal residues from
the A and B antigens, respectively, have mainly been identified and
characterized by enzymatic assays using simple monosaccharide
p-nitrophenyl (pNP) substrates. We hypothesized that the use of
this strategy would fail to identify enzymes with selective or exclusive
substrate specificities for the more complex branched blood group A
and B structures. We therefore screened a large panel of bacterial and
fungal isolates to search for enzymes with the preferred substrate
specificities and a neutral pH optimum. Here we describe two
previously unknown prokaryotic glycosidase families, which contain
enzymes with favorable or exclusive substrate specificities for the
branched blood group structures, neutral pH optimum, and high
efficiency and selectivity in enzymatic conversion of group A, B and
AB RBCs to group O RBCs. The a-N-acetylgalactosaminidase functions with an unusual catalytic mechanism involving NAD+ and the
crystal structure of the enzyme reveals a structural fold that has not
been found previously in glycosidases. The availability of these
bacterial enzymes should allow efficient and cost-effective enzymatic
conversion of blood group A, B and AB RBCs to universal RBCs.

with the B tetrasaccharide-AMC substrate and not with the
monosaccharide Gala-pNP substrate, whereas two isolates showed
a-N-acetylgalactosaminidase activity with the A tetrasaccharide-AMC
substrate as well as the monosaccharide GalNAca-pNP substrate (data
not shown). Both activities exhibited neutral pH optima.
Improved enzymes for conversion of group A RBCs – family
GH109
The a-N-acetylgalactosaminidase activities identified in the screen
were similar to that of an Elizabethkingia meningosepticum (previously
termed Chryseobacterium meningosepticum, ATCC no. 13253)
a-N-acetylgalactosaminidase (GenBank accession no. AM039444),
which was originally identified and cloned using the same blood
group A tetrasaccharide-AMC substrate for screening17. The deduced
protein sequence of the E. meningosepticum enzyme was used in
GenBank searches to identify a family of enzymes found exclusively
in prokaryotes, classified as GH109 in the carbohydrate-active enzyme
database (http://www.CAZY.org/) (Supplementary Fig. 1 online). The
genes encoding five of these proteins were cloned and expressed
(Supplementary Methods online). One of two genes identified in
Bacteroides fragilis (AM039447) as well as those from Shewanella
oneidensis (AM039445) and Tannerella forsythensis (AM039448) were
found to encode functional a-N-acetylgalactosaminidases with properties similar to those of the E. meningosepticum enzyme (data not
shown). The second gene identified in B. fragilis (AM039446) and the
Streptomyces coelicolor gene (AM039449) did not appear to encode
proteins with a-N-acetylgalactosaminidase activity.
A distant relationship of these enzymes to oxidoreductases was
noted using the NCBI conserved domain search. We therefore
considered the possibility that these enzymes functioned with NAD+
and metal ions as cofactors. An N-terminal truncated construct
(amino acids 18–444) of the E. meningosepticum was expressed
efficiently in Escherichia coli with a yield of 1 g/l, purified to
homogeneity and used for the studies reported here. The purified
recombinant enzyme was not affected by EDTA/EGTA chelation of
potential metal ions, and exogenous addition of metal ions did not
enhance activity. Furthermore, addition of NAD+ or NADH had no
effect on enzyme activity (Supplementary Fig. 2 online). As a result of
these findings exogenous addition of metal ions and nucleotides were
not used in standard enzyme assays in the study. However, the enzyme
does in fact use NAD+ as a cofactor, but NAD+ is tightly bound, and
the enzyme is saturated in its purified recombinant form.
The substrate specificity and kinetic properties of the recombinant
E. meningosepticum a-N-acetylgalactosaminidase are presented in
Tables 1 and 2. The enzyme has a neutral pH optimum with
a relative high specificity for the blood group A AMC substrate
(0.25 U/mg) (Supplementary Figs. 3a and 4a online) compared
with the monosaccharide GalNAca-pNP substrate (410 U/mg).

RESULTS
Screening for prokaryotic exoglycosidases
To identify enzymes that might have preferred or exclusive specificity
for blood group A and B structures and neutral pH optima, we
screened a large panel of 2,500 fungal and bacterial isolates for
enzymes capable of cleaving A and B oligosaccharide substrates.
Most bacteria express high levels of known a-galactosidases that
have acidic pH optima and high activity with the Gala-pNP substrate,
and some also express a-N-acetylgalactosaminidases that have similarly high activity with the GalNAca-pNP substrate. We therefore used
differential screening with two assays; one with a blood group A or
B tetrasaccharide substrate labeled with 7-amino-4-methyl-coumarin
(A or B tetrasaccharide-AMC) substrate and one with the GalNAcapNP or Gala-pNP substrate (Table 2). Assays were performed at
neutral pH to select enzymes with the preferred pH optimum. Five of
the 2,500 isolates were found to display a-galactosidase activity

Table 2 Kinetic properties of the a-N-acetyl-galactosaminidase and a-galactosidase
E. meningosepticum a-N-acetyl-galactosaminidase

B. fragilis a-galactosidase A (FragA)

Substrate

kcat (s–1)

Km (mM)

kcat/Km (s–1 mM–1)

Gala-pNP

0.026 ± 0.001

25.1 ± 1.4

Galb-pNP
GalNAca-pNP

0.010 ± 0.000
9.84 ± 0.16

3.6 ± 0.3
0.077 ± 0.006

0.0031
127.6

0.00a
0.00

GalNAcb-pNP

0.015 ± 0.000

0.23 ± 0.01

0.087

0.00

0.0011

kcat (s–1)

Km (mM)

kcat/Km (s–1 mM–1)

0.38 ± 0.01

0.70 ± 0.02

0.54

NA
NA

NA
NA

NA

NA

Data represent the average of triple or more measurements.
aNo

activity was found with 60-longer reaction time than was required to readily detect the activity of Gala-pNP. NA, not applicable.
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Figure 2 Overall structure of the E. meningosepticum a-N-acetylgalactosaminidase. (a) Left panel. Cartoon representation of the overall structure of
the a-N-acetylgalactosaminidase dimer. In the left subunit, the dinucleotide
binding domain (residues 19–148) is shown in pink, the a-helices of the
C-terminal domain (residues 149–444) in cyan, the b-sheet forming the
dimer interface in yellow, and the a-helical bundle covering the NAD+binding tunnel in green. In the right subunit, a partial surface representation
shows the entry of the NAD+ binding tunnel and the active-site pocket.
NAD+ and GalNAc are shown as orange and red sticks, respectively. Right
panel. Close-up and clipped view of the NAD+ binding tunnel created at the
interface of the dinucleotide binding domain (pink) and the a-helical bundle
(green). (b) Side-by-side representation of a-N-acetylgalactosaminidase
(left) and Zymomonas mobilis glucose-fructose oxidoreductase (PDB 1OFG)
(right,) using the same coloring convention as in a. The NAD+ molecule and
GalNAc bound to the a-N-acetylgalactosaminidase and the NADP+ cofactor
bound to 1OFG are highlighted. (c) Stereo view of the active site of a-Nacetylgalactosaminidase oriented as in b. The GalNAc residue, part of the
NAD+ and the surrounding amino acid residues described in the text are
shown as ball-and-stick models. Maximum-likelihood/sA-weighted 2Fo-Fc
electron density (contoured at B1.5 s) is shown in blue for GalNAc and
NAD+ and in orange for protein residues. (d) Stereo view of the superimposition of the active sites of a-N-acetylgalactosaminidase (gray) and
B. subtilis 6-phospho-a-glucosidase (green) (PDB 1NRH).

© 2007 Nature Publishing Group http://www.nature.com/naturebiotechnology

a

b

c
oxidoreductases, lack of similarity to known glycosidases and the
unusual enzymatic properties motivated us to determine the structure
of the enzyme by X-ray crystallography.

d

Surprisingly, low but detectable activity was also observed with
GalNAcb-pNP as well as with Gala and Galb-pNP substrates
(Supplementary Fig. 5 online). Interestingly, the apparent Km value
for GalNAca-pNP is similar to that of GalNAcb-pNP, although kcat
values differ more than 1,000-fold. In contrast, the Km value for GalbpNP is over tenfold higher than that for the GalNAc counterpart.
Although glycoside hydrolases are usually extremely specific for the
anomeric configuration of the glycosidic bond, a member of glycosidase family GH4, namely Fusobacterium mortiferum phospho-aglucosidase, has been reported to be able to cleave both a- and
b-anomers of the nonnatural p-NP 6-phosphoglucosides substrates18.
We did not observe any cleavage of the natural globoside (Gb4)
glycolipid structure with a terminal b1-3GalNAc residue; however,
low but detectable cleavage of the disaccharide substrate GalNAcb14Galb1-O(CH2)8COOCH3 was observed (data not shown). Monitoring the hydrolysis of GalNAca-pNP by NMR showed that the
a-N-acetylgalactosaminidase functions with a mechanism leading to
overall retention of the anomeric configuration (Supplementary
Results online). The combined findings of sequence relatedness to

NATURE BIOTECHNOLOGY

VOLUME 25

NUMBER 4

APRIL 2007

Structural architecture of the a-N-acetylgalactosaminidase
The crystal structure of the E. meningosepticum a-N-acetylgalactosaminidase was solved by the multiple anomalous dispersion (MAD)
method, taking advantage of the anomalous dispersion of selenium,
and refined against native data to 2.3 Å resolution (Supplementary
Table 1 online). The structure of a complex with GalNAc was refined
to 2.4 Å resolution. The enzyme is present as a homodimer in the
crystal and appears to form a dimer in solution, as evidenced by
dynamic light-scattering analysis. However, analysis by size-exclusion
chromatography suggests that the enzyme exists as a monomer or a
dimer, depending on buffer conditions (data not shown). The final
structure of the enzyme comprises the entire mature protein (residues
18–444) and a molecule of NAD+. Although the distant sequence
relatedness with oxidoreductases suggested that the enzyme
could function with NAD+ as a cofactor, similarly to enzymes of the
GH4 family19–21, this was a surprise because we had observed no
stimulation of activity with exogenous addition of NAD+ or NADH in
our studies of the kinetic properties of the enzyme (Supplementary
Fig. 2 online).
Structurally, the protein consists of two independent and closely
associated domains, forming a narrow tunnel in which the NAD+
molecule is embedded (Fig. 2a). The N-terminal domain forms
a classical dinucleotide-binding Rossmann fold22, whereas the
C-terminal domain consists of an a/b domain with a large openfaced, seven-stranded, anti-parallel b-sheet, adjacent to nine a-helices
and an a-helical bundle covering the dinucleotide-binding tunnel. The
open-faced b-sheet, with a surface area of 2,800 Å2, representing 15%
of the total surface of a monomer, makes up the dimer interface. The
NAD+ molecule, copurified with the recombinant enzyme, is
anchored within a 10 Å long, narrow tunnel, almost entirely shielded
from the solvent; the nicotinamide ring is located in a narrow pocket
situated at the bottom of a large depression at the surface of the
protein. Because exogenous addition of NAD+ did not stimulate
the enzyme, we developed a method for depletion of NAD+ by
precipitating the protein with ammonium sulfate under acidic
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conditions. The release of NAD+ was confirmed by high-performance
liquid chromatography analysis using standards (data not shown). The
acid ammonium-sulfate–treated enzyme was inactive after resolubilization; complete activity was restored by exogenous addition of
NAD+, but not by related compounds including NADH (Supplementary Fig. 6 online). The same dependence of NAD+ was also found for
the activity with GalNAcb-pNP, confirming that this is an intrinsic
activity of the enzyme (Supplementary Fig. 7 online).
The overall fold of the a-N-acetylgalactosaminidase is unique
among the more than 370 glycosidases with known three-dimensional
structures (carbohydrate-active enzyme database at http://www.CAZY.
org/). A Dali search23 for structural homologs within the nonredundant set of protein structures from the Protein Data Bank revealed
that the closest structural relatives belong to the Gfo/Idh/MocA
oxidoreductase family (Z-score of 29.4 and r.m.s. deviation of 3.0 Å
for 329 equivalent Ca-atoms for the closest structural neighbor,
namely Zymomonas mobilis glucose-fructose oxidoreductase,
1OFG24) (Fig. 2b). More distant structural homologs are all identified
by means of the classical Rossmann fold. The structural similarity
extends to the level of the active-site architecture, where the spatial
arrangement of the cofactor and several key residues is conserved,
suggesting a common ancestor that has evolved its NAD+-based
molecular mechanism to adapt to diverse metabolic requirements.
Active site of the a-N-acetylgalactosaminidase
The complex with the reaction product, GalNAc, showed the carbohydrate inside a narrow pocket situated in the middle of a large crater.
The wide opening of the crater appears suitable for the accommodation of large aglycon structures such as the blood group A antigen. The
GalNAc moiety is found close to NAD+ with the C-3 atom of the
sugar 3 Å away from the C-4 atom of the nicotinamide ring (Fig. 2c).
Four residues, Tyr307, Tyr225, His228 and Glu149, which appear to be
important for the interactions with the carbohydrate (Supplementary
Fig. 8 online), are invariant within the GH109 family (Supplementary
Fig. 9b online).
What governs the preference of the enzyme for GalNAc over Gal?
Replacement of the C-2 acetamido group by a hydroxyl substantially
impairs enzyme-substrate interaction, as suggested by a 2,000-fold
reduction in kcat for the hydrolysis of Gala-pNP compared with
GalNAca-pNP and by a more than tenfold increase in Km
(Table 2). The structure of a-N-acetylgalactosaminidase in complex
with GalNAc shows that the interaction of Tyr307 with the carbonyl
oxygen of the acetamido group of the substrate is probably responsible
for the preference for GalNAc substrates.
Our finding that the second family member from B. fragilis
(AM039446) did not exhibit a-N-acetylgalactosaminidase activity
suggests that the family includes enzymes acting on different substrates. Alternative substrate specificity might originate from chemical
variability at C-4, C-5 and/or C-6, as NAD+ and the invariant residues
impose invariant interactions with the C-2 and C-3 substituents of the
carbohydrate. Indeed, in the complex structure, OH-4 establishes
hydrogen bonds with the conserved Tyr179 and residue Arg213,
whereas no hydrogen bonding partner could be observed for OH-6.
This exo-cyclic hydroxyl is surrounded by residues Leu183, Val186,
Glu209 and Arg213. Whereas Leu183 is strictly conserved in all
members of GH109, the three latter residues are conserved only in
the branch of the evolutionary tree comprising E. meningosepticum
and the enzymes from Flavobacterium sp. MED217 and Robigitalea
biformata HTCC2501 (Supplementary Figs. 1a and 9a online). These
three enzymes are also characterized by a B15-residue insertion at the
tip of the a-helical bundle.
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The catalytic mechanism of the a-N-acetylgalactosaminidase
Although the a-N-acetylgalactosaminidase and the glycosidases from
family GH4 differ in their overall protein folds, their active-site
architectures show striking similarities (Fig. 2d), thereby constituting
a beautiful example of convergent evolution. The glycoside hydrolase
family GH4 groups together a- and b-glycosidases that have been
shown recently to use an NAD+-dependent mechanism that is
highly unusual for glycosidic bond cleavage19–21. The structural
superimposition of the active site of a-N-acetylgalactosaminidase
onto those of Bacillus subtilis phospho-a-glucosidase, GlvA20 and
Thermotoga maritima 6-phospho-b-glycosidase, BglT25, reveals a
perfect overlap of the dinucleotide cofactors, the sugar rings and a
tyrosine residue.
Family GH4 enzymes contain a divalent metal ion coordinated by a
conserved cysteine, a conserved histidine and the nicotinamide group
and thought to stabilize an enodiolate-reaction intermediate20. Notably, the crystal structure of the a-N-acetylgalactosaminidase is devoid
of any metal ion, in agreement with the observation that the enzyme
does not display any metal ion requirements (Supplementary Fig. 2
online). Monitoring of the reaction catalyzed by a-N-acetylgalactosaminidase indicated that the enzyme proceeds with a mechanism that
leads to retention of the anomeric configuration and concomitant
exchange of the GalNAc H-2 atom for a solvent proton (Supplementary Results online). These results parallel exactly those of family GH4
glycosidases and therefore indicate that GH109 enzymes most likely
operate by a similar mechanism. In this mechanism, an ‘onboard’
NAD+ molecule oxidizes the substrate at C-3, thereby acidifying
the proton at C-2. Deprotonation of C-2 by an enzymatic base
with concomitant elimination of the glycosidic oxygen generates a
1,2-unsaturated intermediate. The reaction is completed by addition
of water to the Michael-like acceptor and reduction of the resulting
ketone by the onboard NADH molecule, which returns to the initial
NAD+ state, ready for another catalytic cycle (Supplementary Fig. 10
online). This mechanism, found first in family GH4 enzymes, allows
cleavage of thioglycosides26, a feature that is extremely rare among
‘classical’ glycosidases. Thin layer chromatography (TLC) analysis
showed that a-N-acetylgalactosaminidase is indeed able to cleave
benzyl-1-thio-a-N-acetylgalactosaminide (data not shown).
During the reaction catalyzed by GH4 glycosidases, departure of the
aglycone is thought to be acid catalyzed20,25, but the role and identity
of the acid catalyst is still uncertain. Interestingly, the structure of the
a-N-acetylgalactosaminidase does not reveal any suitable residue to
protonate the interosidic atom and suggests that this step is perhaps
unnecessary in family GH109. This is perfectly compatible with the
observed activity with benzyl-1-thio-a-N-acetylgalactosaminide and
provides a structural explanation of the hydrolysis of both a- and
b-anomers of pNP substrates; indeed only a minor adjustment of the
side chain of His181 is necessary to accommodate a b-linked substrate.
After family GH4, family GH109 constitutes the second glycosidase
family that displays structural and mechanistic relatedness to oxidoreductases. There is nothing in the a-N-acetylgalactosaminidase
sequence that suggested hydrolytic activity on glycosides. In consequence it is conceivable that other distant homologs of known
oxidoreductases may also correspond to glycosidases and the repertoire of this category of enzymes might further develop. We note a
very distant but intriguing similarity between family GH109 members
and a recently discovered T. forsythensis sialidase27.
Improved enzymes for conversion of group B RBCs – family GH110
Of the five isolates found to express a-galactosidase activity with the
B tetrasaccharide-AMC at neutral pH, one isolate (no. 2,357) from a
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Table 3 Blood group typing of ECO RBCs with enzyme dose titrations
ABO typing resultsa
Ortho anti-A
ECO RBCs

© 2007 Nature Publishing Group http://www.nature.com/naturebiotechnology

A1-ECO RBCs

A-zyme dose/ml pRBCs (mg)

aTyping

Diagast anti-B

IS

4 1C

IS

4 1C

0.02
0.01

0
0

0
0

0
0

0
0

0.005
0.0025

0
0

0
w

vw
1

w
2

0.0013
0.0006

0
w

2
2

1
2

3
3

IS

4 1C

IS

4 1C

0.73

0

0

0

0

0.60
0.50

0
0

0
0

0
0

0
0

0.37
0.23

0
0

0
0

0
Vw+

0
0

0.13
0.03

0
0

0
0

W+
1+

W+
1+

B-ECO RBCs

A1B-ECO RBCs

Ortho anti-B

B-zyme dose/ml pRBCs (mg)

ES-15

0.73
0.60

0.02
0.01

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0.50
0.37

0.005
0.0025

0
0

0
0

0
0

0
0

0
0

0
vw+

0
w+

0
w+

0.23
0.13

0.0013
0.0006

0
0

0
0

0
vw+

0
w+

0
0

w+
1+

w+
1+

1+
1+

0.03

0.0003

1+

2+

2+

2+

vw+

2+

1+

2+

with licensed ABO typing reagents and methods as indicated using agglutination score 0 to 4+.

IS, immediate spin reactions; pRBCs, packed RBCs.

Streptomyces griseoplanus strain exhibited the highest enzyme activity
in lysates and was found to secrete the a-galactosidase enzyme into the
medium. Initial attempts to purify the enzyme from the medium
failed because of an insufficient amount of enzyme, and we therefore
screened different nutrient carbon sources using minimal medium in
an attempt to enhance secretion. A 10- to 40-fold induction of
secretion was achieved with galactose and lactose (Supplementary
Methods online), and an enzyme with a molecular weight of
B75 kDa was isolated from the medium. A number of peptide
sequences (S1-S7) were obtained by Edman degradation and
tandem mass spectrometry, and database searches identified weak
sequence similarities with a putative protein from Streptomyces
avermitilis. Further searches with the S. avermitilis sequence identified
four additional genes with substantial similarity from Bacteriodes
fragilis and Bacteriodes thetaiotaomicron (Supplementary Figs. 1b
and 9b and Supplementary Methods online). All five identified
genes were cloned by PCR from their corresponding genomic
DNA, expressed in E. coli as His6-tagged proteins, and shown to
encode a-galactosidases when analyzed with a B tetrasaccharide-AMC
substrate (data not shown). The lack of sequence similarity
between the newly identified a-galactosidases and any known glycosidase in the CAZY database allows us to define the glycosidase family
GH110. One of the two a-galactosidase homologs found in B. fragilis
NCTC 9343 (designated FragA, EMBL Nucleotide Sequence
Database accession no. AM109955) was expressed in E. coli without
its N-terminal signal sequence (amino acids 23–605) with a yield of
500 mg/l, purified to homogeneity, and used for further studies.
The substrate specificity and kinetic properties of the recombinant
FragA a-galactosidase are presented in Tables 1 and 2. The enzyme has
a broad pH optimum between 5 and 7.5 with the B tetrasaccharideAMC substrate (Supplementary Fig. 3b online). Interestingly, the
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recombinant FragA enzyme exhibited low activity with the Gala-pNP
substrate (0.3 U/mg) compared to the blood group B substrate (6.6
U/mg) (Table 2), whereas the purified endogenous enzyme from
S. griseoplanus did not exhibit detectable activity with the Gala-pNP
substrate (data not shown). The substrate specificity was remarkably
stringent for a-1,3-linked galactose in the branched blood group B
structure (Table 1 and Supplementary Fig. 4b online). The enzyme
cleaved neither a4Gal linkages found in P1 and Pk blood group
antigens nor the a3Gal linkage in the linear B structure without
fucose (the so-called Galili antigen). The FragA a-galactosidase has
more than 300-fold higher activity with the blood group B tetrasaccharide-AMC substrate than the coffee bean enzyme, whereas the
inverse (100-fold) is the case for the Gala-pNP substrate (Tables 1 and
2). One a-galactosidase with neutral pH optimum has been isolated
previously from the marine bacterium Pseudoalteromonas sp. (KMM
701) with a specific activity of 9.8 U/mg with the Gala-pNP substrate11, but given the different properties reported, this enzyme is
probably unrelated to the genes described here. We are attempting to
crystallize the a-galactosidase to further elucidate the catalytic
mechanism of this enzyme family.
Enzymatic conversion of blood group A, B and AB RBCs at
neutral pH
The two glycosidase families described here contain enzymes that have
highly suitable kinetic properties for enzymatic removal of A and B
antigens from the surface of RBCs. We first developed a buffer system
for enzymatic conversion of RBCs with the recombinant E. meningosepticum. The recombinant enzyme has an isoelectric point of 7.6 as
shown by isoelectrofocusing, and analysis of the electrostatic surface of
the crystal structure indicated that the protein surface near the
catalytic region is slightly positive. We therefore hypothesized that

459

© 2007 Nature Publishing Group http://www.nature.com/naturebiotechnology

ARTICLES
the enzyme at neutral pH could interact with the strong negative
charges of primarily sialic acids on the surface of RBCs leading to local
concentration of the enzyme at substrate sites. Enzyme conversion was
performed at low ionic strength in glycine buffer with varying
concentrations of NaCl. Complete removal of A antigens was achieved
in 200 mM glycine (pH 6.8) with 3 mM NaCl as evaluated by
agglutination typing with routine licensed reagents and methods as
well as by sensitive fluorescence-activated cell sorting (FACS) analysis
(Table 3 and Fig. 3). In this buffer system 490% of the enzyme was
associated with the RBCs after centrifugation. In contrast, increasing
the NaCl concentration to 10 mM or more resulted in release of the
enzyme from the RBCs. In agreement with our hypothesis, increased
NaCl also negatively affected the conversion efficiency, showing that
the interaction is important for efficiency (data not shown). Importantly, this feature also allowed a simple and efficient wash-removal
process of the enzyme involving three wash cycles in isotonic PBS. The
residual enzyme load associated with washed cells was consistently less
than 40 ng/ml of packed RBCs as measured with a sensitive capture
enzyme-linked immunosorbent assay using total detergent lysates of
cells (data not shown). The conversion process is linear with enzyme
dose and time, and has a low enzyme consumption of 300 mg/ml
packed RBCs for 60 min of incubation. RBCs from more than 200
group A1 and A2 donor units have been analyzed and all were
converted efficiently. Approximately 60 mg enzyme is required to
convert one unit (B200 ml packed RBCs) of blood group A1 cells.
Conversion of the weak blood group A2 subgroup, however, requires
only 15 mg enzyme. The conversion process does not affect physiologic and metabolic parameters of RBCs, including osmotic fragility,
levels of 2,3-DPG, ATP and methemoglobin (data not shown).
We selected the recombinant FragA a-galactosidase because it has a
slightly basic isoelectric point similar to the E. meningosepticum
enzyme; using the same glycine buffer system as for group A RBCs,
we effectively produced, by enzymatic conversion of blood group B
RBCs with the FragA enzyme, B-ECO RBCs that type as group O by
licensed reagents and methods used in clinical blood bank practice
(Table 3). Similar to our findings with the A conversion process, the
low ionic strength is required for efficient conversion, and increasing
NaCl concentration in the glycine buffer or use of other buffer systems
with higher ionic strength such as PBS and phosphate-citrate
decreases the efficiency. The conversion process is linear with enzyme
dose and time, and has a very low enzyme consumption of 10 mg/ml
packed RBCs for 60 min incubation period. RBCs from more than 50
group B donors have been analyzed in repeat studies and all were
converted efficiently with 10 mg/ml packed RBCs (data not shown).
Thus, less than 2 mg enzyme are required to convert one unit of blood
group B cells. Because the two enzymes used for conversion of A and B
RBCs were selected for similar properties and function efficiently in
the same conversion buffer system, we were able to convert blood
group AB RBCs efficiently both by sequential enzyme digest as well as
with a one-pot enzyme digest with the a-N-acetylgalactosaminidase
and a-galactosidase (Table 3).
The efficiency of the conversion processes was evaluated by sensitive
FACS analysis using anti-A and anti-B reagents (Fig. 3). FDA-licensed
anti-A blood grouping reagents showed complete removal of A
antigens on a homogenous population of RBCs. The high sensitivity
of the assay was demonstrated by clear detection of the low amount of
A antigen present on the weak Ax subgroup RBCs. We also included a
highly sensitive anti-A monoclonal antibody, ES-15, that detects the
minimal amount of A antigen, which is present naturally on group B
RBCs28. ES-15 clearly detected both the A antigen on Ax subgroup
RBCs and on group B RBCs. The ES-15 reactivity with B RBCs was
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sensitive to treatment with the a-N-acetylgalactosaminidase, confirming that the antibody does detect the minor amounts of A antigens on
B RBCs. The ES-15 reagent, but not licensed anti-A reagents, did show
a tendency toward a shift in the histogram curve (Fig. 3a, middle
panel) of A-ECO RBCs, indicating that miniscule amounts of A
antigens at a level considerably lower than on group B RBC could
be detected on A1-ECO but not on A2-ECO RBCs. Similarly, FDAlicensed anti-B reagents showed a homogeneous B-ECO cell population almost nonreactive with anti-B. The high sensitivity of this assay
was demonstrated by including ABweak subgroup cells, on which the
weakly expressed B antigens were readily detected. Several licensed
anti-B typing reagents were tested (data not shown), and one CEapproved anti-B blood grouping reagent, Diagast, was found to
exhibit higher sensitivity with the ABweak cells and a minor proportion
of B-ECO cells were weakly labeled by the Diagast anti-B
antibody, although at a level lower than the weak ABweak subgroup
cells. Analysis with an anti-H antibody was included to demonstrate
appearance of the appropriate H antigen product after removal of
either aGalNAc or aGal terminal residues, and both A-ECO and
B-ECO RBCs expressed H similar to group O RBCs as expected
(Fig. 3, lower panels).
Further biochemical analysis of ECO cells included TLC of glycolipids as well as SDS-PAGE western blot of total membrane (glyco)protein extracts. TLC of glycolipid extracts revealed essentially
complete conversion of blood group A and B glycolipid species to
the corresponding H species, including the major monosialyl A and B
gangliosides designated G9A and G9B (Fig. 4). This was further
confirmed by mass spectrometric analysis of the glycolipid fractions
migrating in the region of the most abundant A-active glycolipid
species, designated Aa and Ab, which showed a complete absence of
the A glycolipid species in extracts from converted RBCs and the
presence of only the corresponding H1 and H2 products (data not
shown). The blood group A antigens are believed to be more complex
than B antigens in that a fraction of the A active glycolipids have a
repeated A structure13. This structure has been found only on
glycolipids and not on glycoproteins. Cleavage of the terminal GalNAc
residue of these glycolipids will result in exposure of an H structure
extended from an internal A structure in H-Aa and H-Ab glycolipids
(Fig. 4). Both subgroups A1 and A2 RBCs contain these glycolipids,
and after enzyme conversion the A1 subgroup RBCs will contain more
than the A2 subgroup. This H antigen resembles the mucin-type H
structure (Fuca1-2Galb1-3GalNAca1-O-Ser/Thr) expressed in epithelial tissues of all ABO groups29 and is not reactive with typing anti-A
antibodies. It is therefore our hypothesis that these A-associated H-A
structures found only on glycolipids do not represent antigens
recognized by human anti-A immunity, but clinical studies are
required to address this. The analysis of glycolipids from converted
cells also showed that the E. meningosepticum a-N-acetylgalactosaminidase does not cleave the major glycolipid globoside (Gb4, blood
group P antigen terminating by a GalNAcb1-3 linkage) in RBC
membranes (Fig. 4), despite the finding that the enzyme has low
but detectable activity with GalNAcb-pNP (Table 2). The glycolipid
analysis clearly demonstrated the effectiveness of the process as well as
how selective the process is in digesting only the blood group A and B
terminating glycolipids. Western blot with the sensitive ES-15 anti-A
and the Diagast anti-B monoclonal antibodies revealed very faint
diffuse staining of membrane glycoproteins of A-ECO and B-ECO
RBCs, respectively (data not shown), which is in agreement with
the findings that FACS analysis with the most sensitive monoclonal antibody reagents reveal minute amounts of residual A and B
antigens (Fig. 3).
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Figure 3 FACS of native and ECO RBCs. Histograms show the degree
of staining of RBCs with different blood grouping reagents. The x-axis
represents the fluorescence intensity on a logarithmic scale whereas the
y-axis shows the number of RBCs evaluated. Solid lines represent untreated
native RBCs and dashed lines in the same color are the enzyme-treated
RBCs from the same individual (see color code below). The dotted black line
in the H-antigen staining histogram (lower panels) represents the negative
control, RBCs from a Bombay (Oh) donor lacking any A, B or H antigen on
RBCs. To facilitate interpretation of the histograms, enzyme-treated group O
and subgroup RBC were not included. However, their curves completely
overlap the result for native group O (data not shown). (a) RBCs were
stained with licensed monoclonal anti-A blood grouping reagent (upper
panel), the monoclonal ES-15 anti-A research reagent (middle panel) and
direct-conjugated monoclonal anti-H (lower panel). Red, blood group A1;
green, A2; blue, Ax; orange, B; black, O. The weak Ax subgroup control was
from a serologically and genetically characterized test RBC donor with the
Ax-1 O1 genotype. Group B RBCs were tested only with ES-15 as licensed
anti-A reagents do not detect any A antigen on their surface. (b) RBCs were
stained with the monoclonal licensed anti-B blood grouping reagents from
Ortho (US FDA-licensed) (upper panel), Diagast (CE-approved in European
Union) (middle panel), and direct-conjugated monoclonal anti-H (lower
panel). Red, blood group B; green, subgroup A2Bw; black, O.
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DISCUSSION
The present study identified two prokaryotic glycosidase gene families,
not previously described, containing a-N-acetylgalactosaminidase
(GH109) and a-galactosidase (GH110) activities with neutral pH
optima and high activity with blood group A and B substrates,
respectively. The GH109 a-N-acetylgalactosaminidase family represents to our knowledge the only known source of enzymes suitable
for efficient enzymatic conversion of blood group A RBCs. The
GH110 a-galactosidase family has unprecedented restricted specificity
for blood group B substrates. The enzymes are expressed with high
yields in E. coli and because they have similar properties, a single
common conversion buffer system and process can be used to remove
A and B antigens and produce ECO RBCs from A, B and AB RBCs
that type as blood group O with routine licensed typing reagents and
methods. Extensive FACS and biochemical analyses confirm the
efficient removal of the immunodominant A and B antigens and
exposure of the underlying H antigens. The current process, which is
performed manually at neutral pH, is scalable to automated full-unit
conversions, and ECO cells produced by this method are predicted to

a

survive and function in a manner equivalent to native group O RBCs
in non-ABO matched individuals as reported previously for B-ECO
RBCs9. The process has a projected consumption of B60 mg
(A-ECO) and 2 mg (B-ECO) recombinant enzyme with 60-min
enzyme treatment per unit RBCs. This is B30- (A-ECO) and
1,000-fold less (B-ECO) enzyme than the conversion protocol developed for group B RBCs with the Coffee bean a-galactosidase9.
Accordingly, we believe that automated cost-effective processes can
be developed for practical use in transfusion medicine.
Glycosidases are grouped in over 100 sequence-based families that
have been shown to correlate with the 3-D structure and molecular
mechanisms of catalysis30,31. The glycosidase families identified in this
study exhibit no substantial sequence similarity to any other glycosidase families, including families GH4, GH27, GH36 and GH57 (CAZY
database at http://afmb.cnrs-mrs.fr/CAZY/), which contain all previously reported a-N-acetylgalactosaminidases and a-galactosidases,
including the two most studied enzymes for blood group B red-cell
conversion derived from green coffee and from soy beans32,33, as well
as enzymes used previously to convert weak blood group A2 RBCs14,34.

b

Figure 4 TLC analysis of native and ECO RBC
A-ECO Process
B-ECO Process
glycolipids. (a,b) Total upper neutral (UN) and
UN
MS
UN
MS
monosialyl (MS) glycolipid fractions from RBC’s
Gb4
Gb4
were separated on high-performance thin layer
GM3
H1
H1
GM3
Aa
chromatography plates. Arrows indicate mobility
B1
a
SPG
SPG
H-A Ab
H2
H
2
of major blood group ABH glycolipids as well as
B2
b
c
H-A A
H3
H3
Gb4 (globoside) and SPG (sialyl-paragloboside,
G9H
G9H
G9A
B3
G9B
NeuAca2-6Galb1-4GlcNAca1-3Galb1-4Glcb1B
B
A1 A2 A1 A2 O
A1 A2 A1 A2 O
O B B
Cer). The nomenclature of ABH active glycolipids
ECO
ECO ECO
ECO ECO
ECO
used for type 2 chain ABH active glycolipids is
H1/B1/Aa, H2/B2/Ab and H3/B3/Ac with increasing
number of Galb1-4GlcNAc disaccharide units3. Although, glycolipid bands separated by TLC may contain multiple species, the H1 (Fuca1-2Galb14GlcNAcb1-3Galb1-4Glcb1-Ceramide), H2 (as H1 with one lactosamine unit Galb1-4GlcNAcb1-3 inserted) and H3 (as H1 with two lactosamine units Galb14GlcNAcb1-3 inserted) bands in O UN clearly represent major distinct bands with different mobilities. The corresponding A (a) and B (b) structures Aa/B1,
Ab/B2 and Ac/B3 GalNAc/Gala1-3 added to the penultimate bGal residues in H structures in A and B UN are similarly distinct bands. Comparison with the
profile of ECO reveals disappearance of A and B variants and appearance of the corresponding H bands. This includes the branched G9A/B glycolipid
(GalNAc/Gala1-3[Fuca1-2]Galb1-4GlcNAcb1-3[NeuAca2-3Galb1-4GlcNAcb1-6]Galb1-4GlcNAcb1-3Galb1-4Glcb1-Ceramide), which is a branched structure
with one branch terminated by sialic acid and one branch with an ABH determinant. Group A active glycolipids are more complex than B in that they include
the internal A structures A-associated H (designated H-Aa and H-Ab), which migrate just below the H2 and H3 glycolipids, respectively. The Ab glycolipid
band contains a mixture of type 2 chain Ab and the repetitive A-Aa glycolipid (GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb14Galb1-4Glcb1-Ceramide), whereas the Ac band contains type 2 chain Ac and the repetitive A-Aa glycolipid3. The loading corresponds to glycolipid fractions
derived from 4 ml of packed RBCs.
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The human lysosomal a-galactosidase and a-N-acetylgalactosaminidase are close homologs to each other and are both members of family
GH27. All of these enzymes are characterized by having exclusively a
classical catalytic machinery and molecular mechanism leading to
retention of the anomeric configuration35,36, with the exception of
family GH4 enzymes that use NAD+ and Mn2+ as cofactors19–21. The
a-N-acetylgalactosaminidase family described here is unusual in that it
uses an NAD+-based mechanism, similarly to family GH4 enzymes.
Interestingly, the proposed mechanism of the a-N-acetylgalactosaminidase is not prone to transglycosylation, a known side reaction of
retaining glycosidases, which can fortuitously give rise to nonnatural
structures at high substrate concentration.
Preferred properties of an exoglycosidase suitable for enzymatic
conversion of RBCs include the following parameters: (i) high substrate specificity for the blood group antigens to restrict the reaction to
the immunodominant blood group A and B antigens; (ii) reaction
conditions suitable for maintenance of RBC integrity and functions;
(iii) high efficiency in cleavage of antigens on the RBC surface to
minimize residual antigens and enzyme consumption; and (iv) properties to facilitate enzyme removal from the RBCs by routine cell-washing
techniques. The glycosidases presented in this study offer all of these
characteristics. In particular, the a-galactosidases represent, to our
knowledge, the only a3-linkage–specific exo-galactosidases reported
and their specificity for the branched blood group B trisaccharide
structure suggests restricted substrate specificity. This has practical
implications as human RBCs express other aGal-terminating structures, including a4Gal residues in the P1 and Pk blood group antigens,
which are cleaved by the a-galactosidases used in previous studies32,33.
The two enzyme families described here perform efficiently in conversion of RBCs; ECO cells type as group O with all licensed reagents; and
sensitive FACS and glycolipid analyses confirm efficient removal of A
and B antigens (Figs. 3 and 4). Finally, enzymes from both families are
slightly basic and associate with the negatively charged RBCs through
ionic interactions, thereby enabling efficient removal with isotonic
buffer solutions, such as PBS, used for cell washing.
The availability of enzymes from these glycosidase families has
resulted in the development of a simple and efficient process for
producing universal RBCs that type as blood group O. Clinical
translation of this approach may allow improvement of the blood
supply and enhancement of patient safety in transfusion medicine.
METHODS
Enzyme assays. Structures of substrates are shown in Tables 1 and 2. The AMC
derivatives were custom synthesized by Alberta Chemical Research Council.
The 8-methoxycarbonyloctyl ((CH2)8COOCH3, MCO) oligosaccharides were
obtained from the same source, and other substrates were obtained from
Sigma-Aldrich, V-LABS and Oxford Glyco Sciences. Assays with oligosaccharide structures were performed at 26 1C in reaction mixtures of 10 ml. Product
formation was analyzed by TLC using silica gel–coated TLC plates (Merck). The
AMC-labeled tetrasaccharides were used for screening and one unit of enzyme
activity was defined as the amount of enzyme required to cleave 1 mmole of A
or B tetrasaccharide-AMC substrate per minute using a 10-ml reaction volume
with 100 mM NaPO4, pH 6.8, 50 mM NaCl, 0.25 mg/ml of BSA and 0.1 mM
substrate. Importantly, calculation of the specific activities with these substrates
was based on complete cleavage of the substrate in the reaction volume. Assays
with chromogenic pNP substrates were carried out at 26 1C in reaction
mixtures of 400 ml with 100 mM NaPO4, pH 6.8, 50 mM NaCl and 2.5 mM
substrate. Reactions were terminated by addition of 600 ml 1 M
Na2CO3 and pNP formation was quantified at 405 nm (e ¼ 18,300 cm–1
M–1 at pH 4 10). In the chromogenic assays all results were based on reactions
with consumption of o10% of the substrate. Determination of kinetic
parameters was performed using substrate concentrations of 0.5 to 3–10
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times the obtained Km. Reactions with the a-N-acetylgalactosiminidase and
Gala-pNP, however, were carried out using 1–12 mM substrate, which is
substantially lower that the apparent Km.
Crystallization and data collection. Before crystallization the purification
buffer was extensively exchanged with 10 mM HEPES buffer at pH 7.5.
Recombinant a-N-acetylgalactosaminidase was crystallized using the hanging
drop vapor diffusion method by mixing equal amounts of protein at 21 mg/ml
with a solution consisting of 46–50% 2-methyl-2,4-pentanediol (MPD) and
75 mM sodium citrate at pH 6.25. Rod-shaped crystals appeared within 1 d and
belong to space group P6522 with cell dimensions of 88  88  300 Å and one
molecule per asymmetric unit. A MAD data set for a selenomethionylated
protein crystal, as well as a native data set was collected at beam line ID23-EH1
(ESRF, Grenoble) and a data set for a complex with GalNAc was collected at
beam line ID14-EH2 (ESRF, Grenoble). Before data collection, crystals were
flash-frozen in a nitrogen gas stream at 100 1K. Data were indexed and
integrated with MOSFLM37 and scaled with the program SCALA38. Data
collection statistics are summarized in Supplementary Table 1 online.
Structure solution and refinement. Data were prepared for phasing with
XPREP (Bruker). The selenium substructure was solved with SHELXD39,
taking advantage of data up to the highest resolution shell, and phasing
combined with solvent flattening was carried out with SHELXE40, leading to
a pseudo-free correlation coefficient of 70.5%. Starting from experimental
phases, an initial model comprising 361 residues (out of 429), 257 of which
docked into sequence, was automatically built with the ARP/wARP package41
and completed manually using TURBO-FRODO42. The resulting model was
refined against native data extending to 2.3-Å resolution with REFMAC43.
A random set of 4% (1,231) reflections was set aside for cross validation
purposes. Automated solvent building was performed with ARP/wARP41. For
the structure solution of the enzyme-GalNAc complex, the final native model
was subjected to rigid body refinement with REFMAC43 and further refinement
was carried out as described above, with 4.1% (1,111) of reflections, taken over
from the native data set, set apart for cross validation. The final protein
structures encompass residues Lys19 to Tyr444 and have correct stereochemical
properties, with all residues contained in the allowed regions of the Ramachandran plot, as verified with WHATCHECK44. Refinement and structure quality
statistics are listed in Supplementary Table 1 online. Figure 1 was drawn with
ChemDraw, CambridgeSoft Corporation, and Figure 2 was generated with
PYMOL (DeLano, W.L. The PyMOL Molecular Graphics System (2002) on
http://www.pymol.org/).
Enzymatic conversion of RBCs with glycosidases at neutral pH. Standard
enzymatic conversion reactions were performed in 1 ml reaction mixtures
containing 200 mM glycine, pH 6.8 and 3 mM NaCl with 30% packed red
blood cells and enzyme as indicated. Fresh whole blood was obtained from
Oklahoma Blood Institute and buffy coat removed. RBCs were prewashed 1:1
and 1:4 vol/vol in conversion buffer before addition of enzyme. The conversion
reaction was incubated for 60 min with gentle mixing at 26 1C, followed by four
repeat washing cycles with 1:4 vol/vol of saline by centrifugation at 1,000 r.p.m.
The washed enzyme-treated ECO RBCs were ABO-typed according to standard
blood banking techniques using licensed monoclonal antibody reagents45.
Murine monoclonal Anti-A reagent obtained from Ortho. Undiluted, concentrated murine monoclonal anti-A typing reagent supplied for further manufacturing purposes by Celliance. Murine monoclonal Anti-B reagents obtained
from Ortho and Diagast.
Flow cytometry. Flow cytometry analysis of native and ECO RBCs was
performed using a FACScan flow cytometer (Becton Dickinson) with
monoclonal antibody reagents and phycoerythrin-labeled rat-anti-mouse kappa immunoglobulin (Becton Dickinson). An FITC-conjugated monoclonal
anti-H (BRIC 231 from BITS/IBGRL) was also used. Briefly, 500,000 RBCs
were suspended in PBS in 96-well plates in a 50-ml reaction volume. Cells were
fixed for 10 min in 0.1% glutaraldehyde in PBS to prevent agglutination of
antigen-positive cells. After washing 3 in 150 ml PBS, cells were again
suspended in 50 ml PBS, after which 5 ml of undiluted primary antibody was
added and incubated for 10 min. After three washes and resuspension in 50 ml
PBS, 5 ml of undiluted secondary antibody was added. Cells were then analyzed
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after another three washes (as above) and resuspension in 300 ml PBS. All
incubations were carried out in darkness at 20 1C under gentle agitation. A total
of 10,000 events were evaluated and an RBC gate corresponding to B90% of all
cells was set during analysis of the data.
Glycolipid analysis. Glycosphingolipids were prepared essentially as previously
described46. Briefly, RBC membranes were extracted by homogenization in ten
volumes of isopropanol/hexane/water (55:25:20, vol/vol/vol), filtered, evaporated and partitioned by Folch extraction method. The upper phase was
collected, evaporated, dialyzed and applied to a DEAE Sephadex column.
The pass-through fraction contained the total upper neutral lipids, and the
monosialyl fraction was eluted with 0.05 M ammonium acetate, evaporated
and dialyzed against water to remove acetate. Total upper neutral (UN) and
monosialyl (MS) glycolipid fractions were analyzed by high-performance thinlayer chromatography. TLC plates (Merck) were developed using the solvent
system chloroform/methanol/0.5 M CaCl2 in water (50:40:10, vol/vol/vol).
Glycolipids were stained by heating with 0.05% orcinol in 0.5 M H2SO4.
Accession codes. EMBL Nucleotide Sequence Database: the nucleotide
sequences of the cloned genes reported in this paper were deposited with
accession nos. AM039444, AM039445, AM039446 AM039447, AM039448 and
AM039449 for the a-N-acetylgalactosaminidases and homologs; AM109953,
AM109954, M109955, AM109956 and AM109957 for the a-galactosidases.
Protein Data Bank: coordinates of the crystal structures have been deposited
with accession reference nos. 2IXA and 2IXB.
Note: Supplementary information is available on the Nature Biotechnology website.
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ambr® 250 modular

Performance Data
ambr® 250 modular provides a scale down model
for bench top and pilot plant scale bioreactors.
ambr 250 modular is a high performance system
that is easy to set up and allows users to run
multiple parallel bioreactors.

Precise and Accurate Control
Good control is essential if the ambr 250 modular is to be used for multi
parallel experiments, where any process deviation needs to be eliminated.
Figure 1:
Results showing very well controlled process pH and temperature for
a high cell density microbial fermentation. Precision and consistency
is crucial if experiments are to be run in parallel for comparison.
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Due to the precise control of all process parameter, the cultures run
under the same condition have very good consistency and repeatability;
an essential characteristic for any multi parallel bioreactor system.
Figure 2:
Results showing DO control of 8 bioreactor system
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Figure 3:
Showing carbon dioxide evaluation in 4 bioreactor in parallel
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ambr® 250
Fully Automated Single-Use
Bioreactor System

A New Bioreactor System for
Parallel Fermentation or Cell Culture
ambr® 250 is a new bioreactor system for parallel fermentation or
cell culture using 100 - 250 mL single-use bioreactors controlled by an
automated liquid handling platform. The new system, developed with two
major industrial partners, builds on TAP’s successful micro bioreactor
technology pioneered in the original ambr microscale system.
ambr® 250 takes ambr technology to the next level with a new platform
that adds increased working fermentation volumes as well as individual
control on all process parameters. This enhanced environment supports
the culture requirements for high demanding microbial fermentation and
mammalian cultures and applications where larger sample volumes are
required. ambr 250 provides an efficient and rapid high throughput
scale-down system at 100 - 250 mL volumes to explore a wide range of
conditions and strains with scalability to bench top stirred tank bioreactors.

- A better tool for process development
ambr 250 dramatically improves
productivity and enables full DoE
experiments to be performed at a
fraction of the cost and with higher
throughput than can be done in
traditional bench top reactors.
- Reduced infrastructure
The low volume, compact, single use,
fully disposable reactors remove the
need for extensive cleaning and
sterilization facilities and minimize the
lab footprint. In addition the rapid
turnaround means more experiments
with less resources.

- Excellent scalability to large scale
bench top bioreactors
ambr 250 is designed and tested to
show that results from this scale-down
system are predictive of full size
bioreactors and fermenters up to 30 L.

ambr® 250 provides an efficient, high throughput scale-down
model for process development and offers a step change
improvement in lab productivity

- Rapid evaluation of a wide range
of conditions and cell line/strain
performance
ambr 250 provides a highly parallel
system to rapidly develop processes
for clones or strainsclones in a real
bioreactor environment with full
control of the culture conditions.
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ambr® 250 System Combines 12 or 24
‘Easy Connect’ Single-Use Bioreactors, Fully
Automated Platform, Bioreactor Controller
and Flexible System Control Software
ambr® 250 platform
Fully automated - including media fill, inoculation, sampling
and feeding with minimal operator interaction during the day

3 step ‘Easy Connect’ installation –
for all gas, liquid and sensor connections
- Step 1 – place vessel in holder and secure with clamp
- Step 2 – connect pH probe
- Step 3 – Clamp the vessel liquid manifold to the pump feed port

Integrated pH and DO sensors –
vessel design incorporates disposable sensors to simplify the
process of system preparation

100 - 250 mL working volume –
reduces reagent costs while supporting enhanced off-line
analysis using standard techniques

Disposable single-use bioreactors - no need to clean
bioreactors and sensors between runs

12 or 24 single-use bioreactors in parallel – integrated control
of multiple bioreactors offers efficient set-up and control and
makes it simple to automate DoE experimental designs
Integrated biological safety cabinet enclosure for contamination free processing

ambr® 250
Bioreactor Vessels

Automated liquid handler (10 mL and 300 uL pipettes) for system set-up (media combination and addition),
inoculation, bolus feeding and sampling into plates or tubes
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Mammalian vessels
- 100 - 250 mL working
volume with baffles
- Dual pitch blade impeller
- Spot based DO sensor
- Disposable pH electrode
- Integrated gas and liquid
inlet filters
- Sparge and headspace
gassing options
- Robotic compatible cap for
sampling
- Integrated exhaust gas
condenser

Microbial vessels
- 100 - 250 mL working
volume with baffles
- Dual 20 mm Rushton
impeller
- Spot based DO sensor
- Disposable pH electrode
- Integrated gas and liquid
inlet filters
- Robotic compatible cap for
sampling
- Sparge and overlay gassing
options
- Integrated condenser for
output to exhaust gas
analysis (OUR/CER)
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Functions

Applications

- Biofuels feedstock preparation R&D

- Automation of DoE approaches to process automation

- Process robustness experimentation in support of QbD studies

- R&D and process development for industrial biotech

- R&D and process development for biopharma

ambr® 250 is configurable for microbial fermentation or mammalian
cell culture and able to model a wide range of requirements in a
variety of applications across biopharm as well as individual biotech.

Control software
- Fully flexible set up and control
interface with simple, dialogue based
interaction for quick
and easy process creation.
- Fine tuning options including
programmable
PID control loops and other advanced
features
- ambr 250 software is fully integrated
with Umetrics MODDE Design of
Experiment (DoE) application, enabling
streamlined operation in execution of
large DoE studies.
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ambr® 250 automatically controls, feeds and samples 12 or 24
bioreactor/fermenter vessels in parallel
Bioreactor controller
- Three gasses per bioreactor with mass
flow sensor:
- Mammalian
- O2
- CO2
- N2/air
- Microbial
- O2
- Air
- N2
- Four positive displacement liquid pumps
per bioreactor for high precision at low
flow rates
- Individual bioreactor temperature
control with heating or cooling
- Individual impeller speed control per
bioreactor
- Optional exhaust gas analysis for OUR/CER
- Integrated CIP/SIP for pumps and
liquid lines
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BIOSTAT ® B
The Multi-Talented Bioreactor for
Research and Development

BIOSTAT® B
at a Glance
Our BIOSTAT® B is the ideal benchtop bioreactor for your
lab. The multi-talented control tower opens up a new
world of flexibility for your changing requirements. Use
it as single or twin configuration, chose your cultivation
chamber from our proven range of options:
– Conventional stirred tank glass vessels
– Single-use stirred tank vessel Univessel® SU
– Wave-mixed Flexsafe RM bags

Applications
– Process development
and optimization
– Scale-up and scaledown
studies
– Seed expansion
– Cell bank production
– Protein supply

Cells
– Mammalian
– Insect
– Microbial
– Yeast
– Fungi

Industries
– Biopharmaceuticals
– Vaccines
– Cell therapies
– Industrial biotechnology
– Basic research
– Education

Process Modes
– Batch
– Fed-batch
– Continuous
– Perfusion

Proven Technology
With several thousand installations in
over 50 countries, BIOSTAT® B is the most
successful benchtop bioreactor in the
world. Benefit from our experience and
collaboration with customers worldwide.

Configurable Design
Contact your Sartorius representative
and configure your BIOSTAT® B bioreactor
solution matching your specific needs.
Benefit from our flexible and scalable
options.

Reliable Quality
Every BIOSTAT® B is thoroughly tested
before it leaves our production facilities in
Germany. Benefit from our global service
and application specialist network for
professional installation and training.

UniVessel® Glass
Our proven autoclavable borosilicate
glass culture vessel is available in four
different volumes: 1 L, 2 L, 5 L and 10 L,
for all kinds of cell culture and microbial
applications.

Benefits
− Classic stirred-tank design simplifies
your scale-up and scale-down studies
− Extensive performance and
engineering data package available
− Save additional investment and use
our special design for small autoclaves

Fully interchangable glass
and single-use stirred-tank
culture vessels.

UniVessel® SU
Our single-use 2 L stirred tank vessel
for cell culture applications combines
scalable design with all benefits of
disposable solutions. No more worries
about challenging timelines, workload
or cross-contamination. Get started
within minutes.

Benefits
− Fully single-use vessel, DO and
pH sensors
− Proven, scalable stirred tank design
− Connection kit to upgrade existing
bioreactor controllers

BIOSTAT® B –
The Universal Controller
for Your Lab

Main Applications
−
−
−
−

Mammalian, insect, microbial and plant cell culture
Process development, optimization, characterization
Seed and small scale production
Protein supply

Main Applications
−
−
−
−

Mammalian, insect and plant cell culture
Process development, optimization, characterization
Seed and small scale production
Production of cell banks

Watch Video:
www.sartorius.com/ video-biostat-b

Main Applications
− Mammalian, insect, plant and low density
microbial culture
− Seed and small scale production
− Protein supply
− Stem cell expansion and production

RM Rocker
Our proven wave-mixed bioreactor consists of a rocker unit with
bag holder and pillow-shaped Flexsafe RM single-use bags for
culture volumes from 100 mL to 25 L. Use it as basic system or in
combination with the BIOSTAT® B control tower and single-use
optical pH and DO sensors to enable advanced control strategies
for batch, fed-batch and continuous perfusion.

Benefits

ns
plant and low density

e production

n and production

− Optimized film formula, traceability of
raw materials and control of the entire
Flexsafe RM bag manufacturing process
assure excellent and consistent cell
growth of the most sensitive cell lines
− Space-saving, individual control of two
RM bags on the same rocker platform
− Easy-to-use rocker with advanced alarms
and safety features for reliable cultivation

12” Touch Screen
with closed frame; protected
against water splashes and
dust deposits. Easy-to-use and
reliable operation of your
BIOSTAT® B due to intuitive
design of human-machineinterface and advanced touchscreen technology – even while
wearing laboratory gloves.

New Standards for
Interference-Free
Measurements
All inlets and ports for, e.g.
cooling water, process gasses,
electricity, ethernet and potential-free alarm contact are
located on the rear panel of the
control tower. An equipotential
bonding conductor shields the
bioreactor against electromagnetic current and ensures interference-free measurements
during your processes.

Control Tower
The control tower contains
both the aeration, pump and
temperature control modules,
saving valuable bench space in
your lab.

BIOSTAT® B
Configurable Flexibility
Single | Twin Control Tower
One BIOSTAT® B control tower can control up to two vessels completely
independently to save valuable lab space. Select culture vessel types
and volumes from our range of options, e.g. glass vessel, single-use vessel
or wave-mixed Flexsafe® RM bags.

Fast Load Peristaltic
Pumps
Insert the tubing in seconds:
Open, insert tube, close, done!
No more pinched fingers or
torn gloves. Up to four internal
pumps can be selected per
vessel. Choose between speedcontrolled pumps and fixedspeed pumps for feed and
corrective agent addition.

Connections for
Sensors and External
Accessories
Quick-connect couplings make
it easy to attach all cables and
supplies to the culture vessels.
All connections are clearly
marked with the same names
used on the rear control tower
panel and in the local control
software menu for fast, error
proof identification.

Storage Tray
A storage tray for accessories
helps you organize your
workplace.

Aeration Strategies
A series of flexible aeration options turns the BIOSTAT® B into a multitalented bioreactor for a wide range of different applications, including
high-cell density microbial fermentation requiring considerable amounts
of oxygen to high-cell density cell culture applications requiring removal
of excessive carbon dioxide.

Microbial Applications
in Combination with UniVessel® Glass
Various controller and hardware configurations enable aeration strategies using air
or oxygen or classical O2 enrichment of air.
For anaerobic processes, the air inlet can
be used for nitrogen. The standard built-in
solenoid valves in combination with a flow
meter ensure reliable gas supply for simple
applications. Optional mass flow controllers provide exact flow rate control of
individual gases. In combination with
BioPAT® Xgas off-gas analysis, this allows
mass balancing consumed and produced
gases.

Gas Inlet

Solenoid Valve MFC*
(max. 2)
(max. 2)

Air

Flow
Meter

Gas Outlet

Sparger

O2
*MFC = mass flow controller

Cell Culture and Multi-Purpose Applications
in Combination with UniVessel® Glass and UniVessel® SU
Gas Inlet

Solenoid Valve MFC *
(4 max.)
(4 max.)

Flow Meter

Gas Outlet

Overlay

Air

Sparger

O2
N2
CO2
Switching CO2 from sparger to overlay
*MFC = mass flow controller

Five different gas lines, equipped with
solenoid valves and|or up to four optional
mass flow controllers and flow meters
deliver ultimate flexibility and accuracy.
The BIOSTAT® B allows you to optionally
switch between sparger and overlay supply
of CO2 for pH control. In addition, a constant air | CO2 mixture can be created in
the overlay line to reproduce conditions
like those prevailing in a CO2 incubator.

Cell Culture Applications
in Combination with Our Rocking-Motion Bioreactor
The wave generated in the RM bags due
to the rocking motion ensures effective
gas exchange through the gas-liquid
interface. Four different gas lines for air,
O2, N2 and CO2 are equipped with flow
meters and four high-precision mass flow
controllers. An integrated pressure sensor
continuously measures the pressure inside
the bag. To ensure process safety, aeration
is switched off when an upper threshold
is reached.

Gas Inlet

MFC*

Flow
Meter

Gas Outlet

Overlay

Air
O2
N2
CO2
*MFC = mass flow controller

You can configure your BIOSTAT® B
aeration system in a similar way as your
BIOSTAT® STR single-use stirred tank
bioreactor. Get ready for seamless scale-up
and -down, from laboratory scale to
large scale single-use production.

DCU – Local Control
Since we introduced the first DCU-controlled bioreactors back in the late
80’s, we have installed thousands of such bioreactors to date at leading
companies in the pharmaceutical and biotech industry worldwide. We have
continuously improved our robust, intuitive-use and industry-proven DCU
control technology, now available in its fourth generation. It is our standard
local control platform for our BIOSTAT® bioreactors, SARTOFLOW® crossflow
filtration units and FlexAct® configurable systems available for a large
number of unit operations.
The intuitive touch screen on the control tower is used to locally operate the BIOSTAT® B:
Aeration control

Balances and gravimetric flow control

Overview
of process
parameters

Pump
module

Submenus

Overview and close-up
Culture vessels

Status display

Automatic Feed Control and
Continuous Processing
Design your process strategy or select different options. Configure your BIOSTAT® B
with gravimetric feed control, gravimetric
level control or substrate addition profiles.
This enables you to run your BIOSTAT® B
in batch, fed-batch, continuous or perfusion mode.

Automatic DO Control
Besides classic DO cascade control, we
have developed the unique advanced DO
controller that gives you more flexibility
to develop and optimize your DO control
strategy.
The advanced DO controller supports parallel adjustment of all DO affecting parameter settings like stirrer speed and gas flow
rates of air and pure oxygen, automatically
and simultaneously to control the DO set
point. Optionally, you can keep the total
gas flow rate constant and the ratio of
pure oxygen in the gas mixture is increased
automatically to match the oxygen consumption of the culture. This gives you ultimate flexibility to adapt your aeration
strategy to your process requirements.

Automatic pH Control
Control the pH of your culture by automatic acid and base addition or by CO2
aeration and base addition. If you want
to use your BIOSTAT® B for both microbial
and cell culture you can configure your
bioreactor system with a combined acid
control via CO2 aeration and acid addition.

CO2

Base Acid

BioPAT® MFCS – SCADA Process Control
BioPAT® MFCS is a multi-functional supervisory control and data acquisition software,
specifically developed for bioprocessing applications in upstream and downstream.
Every BIOSTAT® bioreactor comes with basic data recording functionality of our BioPAT®
MFCS. Rely on more than 7,000 installations worldwide and over 25 years of experience.
– Multi-user network access for up to 16 process units
– On-line and off-line sample data management, visualization, evaluation
– Remote monitoring, control and alarming

BioPAT® MFCS | win
In addition to providing a genuine SCADA system for conventional and single-use
bioprocess applications, the optional advanced version of BioPAT® MFCS includes
a series of add-on modules:
– Bioprocess optimization with Design
of Experiments module (DoE)
– Automation with recipes according to
ANSI | ISA-88.01
– 21 CFR, Part 11 compatibility
– Secure integration into company
networks

– Flexible device connection facility
through OPC
– Expanded data recording and data
archiving capabilities
– Alarm recording and transmission
to multimedia devices

Our Mission Is Your Productivity
We are well aware of how important smooth-running equipment is for effective process
development and efficient production. That is why we at Sartorius offer you a broad range
of preventive technical service, repair and application specialist support. Our ISO certified
quality management system ensures that you receive equipment and services that meet
the strictest quality requirements. Become one of our many customers who benefit from
our local presence worldwide, highly qualified specialists and well-versed technicians.

Services Offered for BIOSTAT® B
− On-site installation and application
specialist support, ensuring that your
equipment is perfectly up and unning
right from the start
− Factory acceptance and site-acceptance
testing
− On-site preventive maintenance and
repair
− Consumable and spare part kits

Technical Specifications
BIOSTAT® B
Control Tower Weight
Single | Twin

~ 40 | 55 kg (88 | 121 lbs.)

Control Tower Dimensions (W + H + D)
Single | Twin

410 + 810 + 520 mm (16“ + 32“ + 20“)

Utility Connections
Power supply

– 230 V (± 10%), 50 Hz, max. power consumption 10 A
– 120 V (± 10%), 60 Hz, max. power consumption 12 A
– Potential equalisation

International protection rating

IP21

Gases

– Gas supply pressure, 1.5 barg
– Dry, oil and dust-free
– Hose barb for tubing, external dia. = 6 mm

Water

– Water supply pressure, 2 – 8 barg
– Flow rate up to 20 lpm
– Temperature min. = 4°C
– Discharge pressure-less
– Hose barb for tubing, external dia. = 10 mm
– Degree of hardness: 12 dH max.

Control Tower
Housing

Stainless steel, AISI 304

Display

Touch screen, 12”, glass, capacitive

Resolution

125 dpi

SCADA communication

Industrial Ethernet

Potential-free (common) alarm contact

•

Safety valve gas pressure

1 bar (14.5 psi) for UniVessel® Glass and SU | 100 mbar for RM

Water inlet pressure reduction

1.5 bar (22 psi), integrated pressure control

Motor Drive (Univessel® Glass | SU)
Maintenance-free, quiet direct drive

Power: 200 W

Maintenance-free top drive with
magnetic motor coupling

Power: 200 W

Rotation speed motor, direct coupling

1L: 20 – 2,000 rpm
2L: 20 – 2,000 rpm
5L: 20 – 1,500 rpm
10L: 20 – 800 rpm
2L SU: 20 – 400 rpm

Rocker Platform
Power supply

– 230 V (± 10%), 50 Hz, power consumption 10 A
– 120 V (± 10%), 60 Hz, power consumption 12 A

Power consumption

600 W

International protection rating

IP23

Rocking speed

8 – 42 ± 1 (r/min)

Rocking angle

4 –10 ± 0.3 (°)

Process Control | Sensors
Sensor | Measurement Range |
Display Accuracy

UniVessel®
Glass

UniVessel®
SU

Rocking
Motion
•

Temperature

Pt100 | 0–150°C (temperature control
0-80°C) | 0.1°C

•

•

Dissolved oxygen, reusable

Polarographic or optical | 0–100 % | 0.1 %

•

•

Dissolved oxygen, single-use

Range: 0 –100 %
Precision: 0.1%

pH, reusable

Combined measuring electrode
Range: 2–12 pH
Precision: 0.01 pH

pH, single-use

Range: 6.5 - 8.5 pH
Precision: 0.1 pH

Foam control

Electrical conductive sensor,
stainless steel, ceramic insulated

•

Level

Electrical conductive sensor, stainless
steel, ceramic insulated

•

Turbidity

1-channel NIR absorption sensor |
0–6 AU | 0,01 AU

•

Redox

Combined measurement with
pH sensor | -1,000 – 1,000 mV | 1 mV

•

•

Balance substrate

7 kg max. | 1 g
60 kg max. | 2 g
300 kg max. | 100 g

•

•

Balance culture vessel

60 kg max. | 2 g

•

•

RM load cells

30 kg max. | 10 g
Weight: 9 kg
Dimensions: 609 | 536 | 60-68 mm
100–240 V VAC | 24 VDC | 15 W

External signal input

0–10 V or 4-20 mA
UniVessel® Glass | SU: 4 max.
Rocker: 2 max.

•
•

•

•
•

•

•

•

•

•

•

Aeration Module
Outlet to culture vessel | bag
®

UniVessel Glass MO (Microbial)

Hose coupling d external = 6 mm
Two-gas mixing with sparger outlet

AIR with O2 Enrichment or Gas Flow Ratio mixing along with anaerobic fermentation; for further information,
please see page on “aeration strategies”
Max. total flow

Up to 20 l/min total volume flow

Flow rate controllers

2

Flow rate controller range

Various models available: 0.1-20 liters per min. [lpm] (sparger)

Accuracy of flow rate controllers

± 5 % full scale

Mass flow controllers (optional)

2 max.

Flow rates of mass flow controllers

Various models available: 0.03-20 lpm (sparger)

Accuracy of mass flow controllers

± 1 % full scale

®

UniVessel Glass CC (Cell Culture) |
UniVessel® SU

Four-gas mxing with sparger and headspace outlet

Additive flow, 4-gas (Air, O2, N2, CO2) mixture; for further information, please see page on “Aeration Strategies”
Max. total flow

Up to 13 l/min total volume flow

Number of flow rate controllers

5

Flow rate controller range

Various models available:
3.3 ccm – 1.6 lpm (sparger)
0.16 lpm – 13 lpm (headspace)

Accuracy of flow rate controllers

± 5 % FS

Mass flow controllers (optional)

4 max.

Flow rates of mass flow controllers

Various models available:
1 ccm – 1.5 lpm (sparger)
0.03 lpm – 10 lpm (headspace)

Precision of mass flow controllers

± 1 % FS

UniVessel® Glass, Dual Use

Four-gas mixing with sparger and headspace outlet

Additive flow, 4-gas (Air, O2, N2, CO2) mixture; for further information, please see page on “Aeration Strategies”
Max. total flow

Up to 20 l/min total volume flow

Flow rate controllers

5

Flow rate controller range

Various models available:
3.3 ccm – 20 lpm (sparger)
50 ccm – 20 lpm (headspace)

Accuracy of flow rate controllers

± 5% full scale

Mass flow controllers (optional)

4 max.

Flow rates of mass flow controllers

Various models available:
0.6 ccm – 20 lpm (sparger)
10 ccm – 20 lpm (headspace)

Precision of mass flow controllers

± 1 % FS

Rocker

Four-gas mixing with sparger and headspace outlet

Additive flow, 4-gas (Air, O2, N2, CO2) mixture; for further information, please see page on “Aeration Strategies”
Max. total flow

Up to 10 l/min total volume flow

Max. CO2 flow

One bag: 1 + 1 lpm
Twin bag: 2 + 0.5 lpm

CO2 concentration controller

0.8 % – 15% | ± 5%

Flow rate controllers

4

Flow rate controller range

Various models available:
16 ccm – 36 lpm (headspace)

Accuracy of flow rate controllers

± 5% full scale

Mass flow controllers (optional)

2 max.

Flow rates of mass flow controllers

Various models available:
3 ccm – 3 lpm (headspace)

Precision of mass flow controllers

± 1% full scale

Pump Module
Built-in Pumps
Fixed speed (on | off controlled)

Watson Marlow 114, Fast Load pump head

– Speed 5 rpm
Flow rate (tubing wall thickness 1.6 mm)

ID: 0.5 mm: 0–0.1 ml/min
ID: 0.8 mm: 0.05–2.4 ml/min
ID: 1.6 mm: 0.01–0.7 ml/min
ID: 2.4 mm: 0.03–1.5 ml/min
ID: 3.2 mm: 0.05–2.4 ml/min
ID: 4.8 mm: 0.09–4.3 ml/min

– Speed 44 rpm
Flow rate (tubing wall thickness 1.6 mm)

ID: 0.5 mm: 0.02–0.9 ml/min
ID: 0.8 mm: 0.04–1.8 ml/min
ID: 1.6 mm: 0.12–6.2 ml/min
ID: 2.4 mm: 0.26–12.8 ml/min
ID: 3.2 mm: 0.41–20.7 ml/min
ID: 4.8 mm: 0.75–37.4 ml/min

Speed-controlled

Watson Marlow 114, Fast Load pump head

– Speed 0.15–5 rpm
Flow rate (tubing wall thickness 1.6 mm)

ID: 0.5 mm: 0–0.1 ml/min
ID: 0.8 mm: 0.01–0.2 ml/min
ID: 1.6 mm: 0.02–0.7 ml/min
ID: 2.4 mm: 0.04–1.5 ml/min
ID: 3.2 mm: 0.07–2.4 ml/min
ID: 4.8 mm: 0.13–4.3 ml/min

– Speed 5–150 rpm
Flow rate (tubing wall thickness 1.6 mm)

ID: 0.5 mm: 0.1–3 ml/min
ID: 0.8 mm: 0.2–6 ml/min
ID: 1.6 mm: 0.7–21 ml/min
ID: 2.4 mm: 1.45–43.5 ml/min
ID: 3.2 mm: 2.35–70.5 ml/min
ID: 4.8 mm: 4.25–127.5 ml/min

External Pumps
Speed-controlled

Watson Marlow 120, Fast Load pump head,
up to 200 rpm

Temperature Control Module
Heating and Cooling

Heating Only

®

For UniVessel Glass Single-wall Culture Vessels
Electrical heating system and automatic cooling water valve;
connection to heating blanket and cooling finger

–

Temperature control of 8°C above cooling-water inlet temperature up to 60°C

–

Heating blanket capacities 1 L | 2 L | 5 L | 10 L: 100 | 170 | 400 | 780 W

–

For UniVessel® Glass Double-wall (Jacketed) Culture Vessels
Open thermostat system with recirculation pump and automatic cooling
water valve

–

Temperature control of 8°C above cooling-water inlet temperature of up to 80°C –
Heating capacity: 600 W

–

For UniVessel® SU Single-use Culture Vessels
Open thermostat system with recirculation pump and automatic cooling
water valve; connection to heating | cooling jacket

Electrical heating blanket

Temperature control up to 50°C

Temperature control up to 50°C
Heating capacity 2L : 200 W

For BIOSTAT® RM Rocking-motion Bioreactor
Open thermostat system with recirculation pump and automatic cooling
water valve

Electrical heating plates

Temperature control of 8°C above cooling-water inlet temperature of up to 40°C

Temperature control from room
temperature up to 40°C

Heating capacity: 600 W

Heating plates: 2 + 140 W

Culture Vessel UniVessel® Glass
Autoclavable Single-wall or Double-wall
(Jacketed) Glass Vessel

1L

Material

Borosilicate glass, stainless steel AISI 316L, EPDM

Sizes [L]

1

2

5

10

Total volume [L]

1.6

3

6.6

13

Working volume [L]

0.4 –1

0.6 – 2

0.6 – 5

1.5 | 5 –10

Top port 19 mm | 12 mm | 6 mm

3|2|6

3|2|9

3|3|8

5|2|9

UniVessel®, Single-wall

1L

2L

5L

10 L

Weight1 [kg]

6

7

12

19

200 + 540 + 270

230 + 600 + 300

260 + 730 + 340

330 + 860 + 420

480 + 410 + 300

530 + 510 + 410

540 + 630 + 420

Space requirements in autoclave
[W + H + D mm]
2

Space requirements in autoclave, reduced
[W + H + D mm]

2

5L

10 L

UniVessel®, Double-wall

1L

2L

5L

10 L

Weight1 [kg]

7

8

14

23

Space requirements in autoclave
[W + H + D mm]

330 + 540 + 270

380 + 600 + 300

410 + 730 + 340

450 + 860 + 420

480 + 410 + 300

530 + 510 + 410

540 + 630 + 420

Space requirements in autoclave, reduced2
[W + H + D mm]
1

2L

With tripod and head plate, without medium
Adapter for exhaust cooler to reduce height in the autoclave optionally available

Culture Vessel UniVessel® SU
Single-use vessel made of pre-sterilized polycarbonate for cell culture applications
Total volume [L]

2.6

Working volume [L]

0.6–2

Max. temperature

50 °C

Operating pressure

< 0.5 barg

Basic Configurations
The BIOSTAT® B is a highly flexible and modular system that can be individually adapted to the
requirements of your application. Below you will find an overview of the basic equipment which
you can extend with diverse options. Please contact your Sartorius Stedim Field Representative
or Application Specialist for additional information.
Microbial Packages for UniVessel® Glass
Volume
Single
Twin
Digital controller, color display with touch screen
Control temperature, pH, DO, stirrer speed
Maintenance-free, quiet motor
Storage tray for accessories
Aeration module with 2 solenoid valves
2 flow rate controllers for manual flow rate control (AIR | N2, O2)
Software configured for microbial applications
4-stage DO cascade
BioPAT® MFCS software for data acquisition
2 integrated pumps for pH control (acid | base)
Temperature control module for double-wall vessels
2 external signals 0 –10 V
Standard test and documentation
Installation set for the gas and water connections
Power cable
Double-wall culture vessel
Stirrer shaft with single-mechanical seal and direct coupling
2 addition bottles for correction agents
Exhaust cooler
Aeration filters
Rushton impellers
Ring sparger
4-way addition port
Inoculation port
Harvest pipe, height-adjustable
Manual sampler
Tool set for disassembly of vessel
Pt100 temperature sensor
pH sensor
DO sensor, amperometric

Cell Culture Packages for UniVessel® Glass
Volume
Single
Twin
Digital controller, color display with touch screen
Control temperature, pH, DO, stirrer speed
Maintenance-free, quiet motor
Storage tray for accessories
Aeration module with 4 solenoid valves
5 flow rate controllers for manual flow rate control
(AIR Overlay, AIR sparger, N2, O2, CO2)
Software configured for cell culture applications
4-stage DO cascade
BioPAT® MFCS software for data acquisition
1 integrated pump for pH control (base)
Temperature control module for single-wall vessels
2 external signals 0 –10 V
Standard test and documentation
Installation set for the gas and water connections
Power cable
Single-wall culture vessel with tripod
Heating blanket 120 | 230 V
Stirrer shaft with single mechanical seal and direct coupling
1 addition bottle for correction agent
Exhaust cooler
Aeration filters
3-blade segment impeller
Microsparger
4-way addition port
Harvest pipe, height-adjustable
Manual sampler
Tool set for vessel dismantling
Pt100 temperature sensor
pH sensor
DO sensor, amperometric

Options
Control System
Advanced DO controller
Flexible switching CO2 from sparger to headspace
Software for dual use MO | CC
Mass flow controller
Antifoam control via sensor
Mechanical foam destroyer (MO applications)
Level control via sensor
Weight measurement substrates | culture vessel
Gravimetric feed | level control
Substrate addition via time profile
Redox (ORP) measurement
Turbidity measurement
BioPAT® Xgas O2 | CO2 off-gas analysis
System IQ | OQ
BioPAT® MFCS SCADA system
UniVessel® Glass
Double-wall culture vessel
Magnetic coupling for drive motor
STT connectors for safe inoculation and media transfer
Cooling finger (single-wall culture vessels)
Spin filter for perfusion mode
Aeration basket for organisms sensitive to shear stress
Rushton impellers | 3-blade segment impellers
Baffles
Bottle holder
Adapter for height reduction of exhaust cooler for the autoclave
Inoculation port
3-way addition port
Universal adapter ID 3.2 mm
Harvest pipe bent for complete draining
Port adapter 19 mm – 12 mm
Set of consumables
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BIOSTAT ® D-DCU
Your “Fast Lane” to Production

BIOSTAT ® D-DCU
Your “Fast Lane” to Production
The BIOSTAT ® D-DCU is a compact bioprocess system available in microbial
or cell culture versions with vessel choices from 10 to 200L working volume.
The optimized and proven design of the BIOSTAT® D-DCU is the result of
thorough analysis of the most required features and functions from over
thirty years of stainless steel fermenter | bioreactor design experience.
This standardized solution eliminates design times, allows faster delivery,
reduces cost, guarantees trouble free operation, allows for global service
support as well as spare part availability.
The BIOSTAT® D-DCU incorporates many
desirable and advanced features to
fulfill virtually any demand for modern
bioprocess application, such as: Automatic
Sterilization in Place (SIP), Cleaning in
Place (CIP), dual pH and DO measurement
capability, lid lifting device, Water Intrusion Test (WIT)-Ready filter housings, dual
exhaust filter housing line, tube and shell
exhaust cooler, exhaust heater, automatic
or manual addition arrays as well as other
accessories. Furthermore, the BIOSTAT®
D-DCU is designed to interface single-use
storage bags for media addition and harvest as well as the TAKEONE® aseptic sampling system. The modular approach allows
multiple configurations (from baseline
to fully featured) to meet every need and
budget.

The jacketed stainless steel culture vessel,
with spiral baffles for efficient and
homogenous heat transfer, are available in
3:1 or 2:1 aspect height to diameter ratio.
The gear free bottom drive agitation system
provides long-term operation at minimal
noise. The zero dead volume sanitary radial
diaphragm harvest and radial type sampling
valves provide fresh samples without
residual pockets and are easy to clean and
maintain.

Three subsystems comprise every
BIOSTAT® D-DCU:
– Control tower with integrated gas mixing
and pump module
– Culture vessel with bottom agitation
system
– Supply Unit, open frame skid and compact
stainless steel piping module

An extended documentation and
qualification package is available to
support regulatory requirements.

The control tower features best-in class
control capabilities utilizing proven
industrial hardware. It is operated via a
simple and intuitive 19” touch screen
which keeps staff training to a minimum.
The compact design of the stainless steel
housing reduces the footprint and saves
precious space.

The supply unit includes all process piping
for temperature control as well as the
exhaust and gas inlet lines. Due to the open
frame design direct access for operation
and easy maintenance is ensured. Furthermore, minimal floor contact points allow
easy cleaning even underneath the skid.

The BIOSTAT® D-DCU is available in both
Single and Twin controller configuration.
It increases flexibility and allows control
of two separate processes at the same
time – even with different size culture
vessels – but independently from each
other.

Features
– Single or Twin Configurations
– Available in incremental sizes from
10 to 200 L
– Preconfigured systems or choose from
an extensive list of options
– Powerful industrial rated DCU control
system with 19” TFT color touch screen
– Automatic Sterilization in Place (SIP)
included
– Automatic Cleaning in Place (CIP)
optional
– Designed to interface single-use bags
and sampling systems including the new
TAKEONE® aseptic sampling system
– Measurement and control opportunities
of pH, DO, temperature, foam, level,
vessel pressure, vessel weight, substrate
addition, gas mixing, agitation, gravimetric feed and harvest control, constant
total gas flow control, redox and
turbidity, weight of storage vessels etc.
– Up to six integrated peristaltic pumps per
vessel with options for fixed or variable
speed control
– Choice of polarographic or optical
DO sensors
– Superior gas mixing with up to six
flow meters and mass flow controllers
– Extended documentation package
available, including logbook and 3-Level
password protection
– Minimal floor contact points for ease
of cleaning
– Global spare part and service availability

Configure a System Utilizing Options
(Like Gasmix, CIP) from a Baseline Unit
Supply Unit
The Supply Unit includes all process piping for temperature
control as well as the exhaust and gas inlet lines. The open piping
frame and ergonomic design of the skid allows for good and
direct access to valves filter housings etc. All sanitary piping
is sloped | self drained. The Supply Unit for culture vessels with
10 – 30 L offers a choice of lockable casters or leveling | support
feet. The Supply Unit for culture vessel with 50 – 200 L is
equipped with leveling | support feet. Furthermore, the Supply
Units can be separated in two pieces allowing easy movement
to the site of installation.

Supply Unit

Culture vessel
Available culture vessels from 10 L, 20 L, 30 L, 50 L, 100 L to
200 L working volume, with a total volume aspect ratio of (H:D)
2:1 or 3:1.
Sterilization in Place (SIP)
For ease of operation, automatic sterilization of the culture
vessel, gas inlet and exhaust gas flow path are included. Addition
groups, sampling valves and drain valves are either manually or
automatically sterilized.
NEW Cleaning in Place (CIP)
The BIOSTAT® D-DCU offers state of the art CIP solutions with integrated SIP | CIP headers and now also with an optional mobile CIP
cart or the ability to connect to 3rd party CIP systems providing
an electronic handshake between the control systems. Integrated
CIP features allow the operator to effectively, reproducibly and
automatically clean the complete system including the culture
vessel, gas inlets, exhaust lines, addition lines and transfer groups.

Culture Vessel

NEW Single-use sampling
The TAKEONE® aseptic sampling system
is single-use and delivered ready to use.
While traditional sampling devices require
cleaning, preparation and sterilization
after each use, the TAKEONE® single-use
sampling system saves valuable time by
being fully disposable.
Agitation
Bottom drive agitation is available with a double mechanical seal.
The high performance servo drive motor assembly combines low
shear, gentle agitation for cell cultures and high speed mixing for
microbial high cell density cultivation, ensuring high oxygen
transfer rates. The motor is gear-free for quiet operation – even
at high speed ranges.

Agitation

Control Tower
The Control Tower is available in single or twin configurations.
The integrated DCU control system belongs to the most proven
and advanced bioprocess controllers ever developed. Utilizing
proven technology and expert engineering, our existing in-house
systems bring powerful control capabilities to the sophisticated
biotechnology market. Proven industrial control hardware ensures
reliable system performance.
The DCU can be easily expanded and reconfigured to meet
evolving research or process requirements, including scale-up
from laboratory fermenters or scale-down to mimic production
process conditions.
For data logging, the Digital Control Unit (DCU) includes
a PC interface for SCADA software connection (for example
BioPAT® MFCS). DCU OPC communication software is available
for interface to other OPC compliant SCADA and DCS packages.
Using a local controller for local process control in combination
with a high level SCADA system ensures process control safety.

Control Tower

Intuitive Touchscreen
The control system presents an “intuitive-to-use”, large 19“ TFT
color touch screen for excellent local operation and process
control for each culture vessel. Clearly designed screens provide
an excellent process value overview and operation.

Intuitive
Touchscreen

Gassing Systems

Dosing Pumps

Gassing Systems
A variety of spargers are available for microbial and cell culture
use. All systems provide individual flow rates and gas blending for
each culture vessel. Gas flow rates are adjustable via precision
flow meters with optional thermal mass flow controllers available
for each flow path (each gas).
Dosing Pumps
Up to six integrated fast load peristaltic pumps per vessel may
be chosen for addition of corrective agents, feeding, as well as
culture volume control. Up to four of the six can be analog speed
controlled pumps. Several ranges are available for both fixed and
speed controlled pumps. Additionally, external pumps for feeding
can be easily connected.

BIOSTAT ® D-DCU
Gassing Strategies
Airflow
Utilizing one flow path for air, a flow meter visually indicates
and controls the sparger flow rate. An optional mass flow
controller may be integrated to control and measure the flow
range via manual adjustment or automatically in conjunction
with the DO controller.

Air

Sparger

O2-Enrichment
Utilizing two flow paths for Air and O2 flows, the flow meters
visually indicate and allow manual adjustments of the sparger
flow rate. O2 is pulsed via solenoid valve, flowing only when
required to maintain the dissolved oxygen (DO) setpoint.
Air is not provided at this time. A mass flow controller can be
integrated to measure and control the total gas flow range via
manual adjustment or automatically in conjunction with the
DO controller.

O2-Enrichment, design up to 50 L/min

Air

Sparger

O2

O2-Enrichment, design up to 300 L/min

Air

O2

Sparger

Flow meter
Optional Gas switch
Dosing shut-off valve
Optional dosing shut-off valve
3-way dosing valve
Optional Mass Flow Controller
Mass Flow Controller

Gas Flow Ratio
Utilizes two flow paths with mass flow control valves for Air
and O2 flow. Flow meters visually indicate the flow of Air and O2.
Both mass flow controllers can be operated manually or automatically in conjunction with the DO controller.

Air

Sparger

O2

Advanced Additive Flow
Allows up to six gas flow paths. Solenoid valves select air, O2, N2
and CO2 for simultaneous flow to the sparger and air to overlay.
Up to six flow meters visually indicate and set the flow rate for
each gas. One additional gas flow path can be added to sparger
or overlay outlet. Furthermore, two 3-way solenoid valves can
be installed to switch the dedicated gas from sparger to overlay
(incl. soft switch). The design does support the installation of up
to six mass flow controllers, which makes constant sparger gas
flow control as well as constant overlay gas flow control possible.

Overlay

Air

O2
Flow meter
Optional Gas switch

N2

Dosing shut-off valve
Optional dosing shut-off valve
3-way dosing valve
Optional Mass Flow Controller
Mass Flow Controller

CO2

Sparger

BioPAT ® DCU – Automation Solutions
for Advanced Process Control and Documentation
Our DCU (digital control unit) controller belongs to the most proven, reliable
and advanced bioprocess controllers ever developed. Use of a modular system
design has enabled us to offer a broad range of flexible and cost-effective
solutions for reusable and single-use systems from R&D to production. DCU
control systems are specially tailored for fermentation, cell culture and down
stream processing like cross flow filtration applications.
DCU control systems allow for independent and simultaneous operation of
multiple processes.

Discover the potential of our
standard software…
– Superior process value overview
– Sensor calibration
– In-process recalibration
– Alarm monitoring
– Trend display
– Automatic Sterilization in Place

… and profit from advanced features
– Overview of all vessels or single
vessel display
– Controller status indication
– Single or group calibration
– Advanced DO controller
– Gravimetric flow control for very precise
feeding
– Gravimetric harvest control
– Constant total gas flow control
– Automatic Cleaning in Place

SYNCHRONIZED

PAT
SOLUTIONS

BioPAT ® MFCS –
The Bioprocess SCADA System
BioPAT® MFCS is our SCADA software for supervisory bioprocess control and
data acquisition. Provides GMP compliant documentation of your valuable
process data and ensures reliable process control in combination with the
advanced BIOSTAT® D-DCU for local process control. Supplied with every
BIOSTAT ® D-DCU package, the new BioPAT® MFCS is ideal for efficient data
acquisition and trend monitoring.

The optional, advanced version of
BioPAT® MFCS includes modules such as:
– Multi-user network access for up to
16 process units
– Automation with recipes according
to ANSI | ISA 88.01
– 21 CFR, Part 11 compatibility
– Multivariate Data Analysis modules

Learn more about the new BioPAT® MFCS:
www.sartorius-stedim.com/biopatmfcs

BioPAT ® SIMCA-Online
for Continuous Real-time Quality Control
Continuous real-time quality control and assurance is highly desired in
biopharmaceutical manufacturing. Unique on the market and developed
according to GAMP 5, BioPAT® SIMCA-online is your software solution
for real-time multivariate statistical process monitoring and control.
The software permits early detection of process deviations. It provides user
guidance to simplify root-cause analysis by displaying easy-to-understand
graphics.

MVDA

Online Multivariate
Data Analysis

BIOSTAT ® D-DCU MO – Package Overview: O2-Enrichment
Package overview
Cat. No. 208 VAC | Culture vessel H:D ratio
Cat. No. 400 VAC | Culture vessel H:D ratio
Control Unit
Digital controller, color display with touch screen
Control capabilities
Temperature, pH, DO (Multi stage cascade), Stirrer speed
Substrate A and Substrate B
Foam via conductive sensor
High foam alarm
Automatic full vessel sterilization sequence
Gear and maintenance free agitation motor
Gassing strategy
Flow meter
Solenoid valve for oxygen enrichment
Peristaltic pumps (integrated)
Supervisory Process Control Software
BioPAT® MFCS
Supply frame
Temperature control system
Piping with valves and steam traps for automatic in-situ sterilization
Culture Vessel
Stirrer shaft with Double Mechanical Seal (DMS)
Condensate pressurization of buffer system DMS steam | compressed air
6-blade disk impeller
Stainless steel filter housing for air Inlet and exhaust filter incl.
filter cartridges
Pressure gauge –1 | 3 barg
Aeration tube with Ring sparger
Exhaust cooler
4-Baffles (removable)
Resterilizable sampling valve
1-Channel Sacova valve for needle free additions
3-Channel Sacova valve for needle free additions
Lamp for vessel illumination
Storage bottles
Bottom harvest valve
pH Electrode, cable
DO Electrode, cable
Pressure sensor, cable
Foam sensor, cable
Temperature sensor Pt 100
High-foam sensor with installation adaptor, cable
Options
Mobile CIP unit with DCU interface
Culture vessel weight measurement | control
Automatic vessel pressure control
Pressure hold test
Lid lifting device 10-20 L | 30-200 L
Dual pH measurement | Dual DO measurement
Containment sampling system
WIT ready filter housings for Inlet and Exhaust filter
Exhaust heater | Dual Exhaust filter line (parallel)
Temperature measurement of condensate trap
Cleaning in Place (CIP)
Resterilizable 4-valve addition array manual | automatic
Automatic harvest valve
Transfer group
Speed controlled pumps for feeding
Broad range of accessories available. Please contact us for further details.

10 L
RDD-M10L
OBRES3 | 2:1
RDD-M10L
OBRET4 | 3:1

20 L
RDD-M20L
OBRES3 | 2:1
RDD-M20L
OBRET4 | 3:1

30 L
50 L
RDD-M30L
RDD-M50L
OBRES3 | 2:1 OBRES3 | 2:1
RDD-M30L
RDD-M50L
OBRET4 | 3:1
OBRET4 | 3:1
Twin configuration optional
•

100 L
RDD-M1HL
OBRES3 | 2:1
RDD-M1HL
OBRET4 | 3:1

200 L
RDD-M2HL
OBRES3 | 2:1
RDD-M2HL
OBRET4 | 3:1

•
•
•
•
•
•
O2-Enrichment (Airflow and Gas Flow Ratio optional)
•
• (Mass Flow Controller optional)
3 for Acid | Base | Antifoam unused pump can be configured as substrate pump
(Up to 6 pumps per site)
•
Open frame design
Closed loop system with recirculation pump and heat exchanger for heating and cooling
•
Jacketed stainless steel vessel with vertical sight glass and bottom agitation
•
•|O
3
•
•
•
•
•
•
•
•
•
3
•
•
•
•
•
•
•
O
O|O
O
O
-- | O
O|O
O
O
O|O
O
O
O|O
O
O
O
• = included, — — = unavailable, O = option

BIOSTAT ® D-DCU CC – Package Overview:
Advanced Additive Flow
Package overview
Cat. No. 208 VAC | Culture vessel H:D ratio
Cat. No. 400 VAC | Culture vessel H:D ratio
Control Unit
Digital controller, color display with touch screen
Control capabilities
Temperature, pH, DO (Multi stage cascade), stirrer speed
Substrate A – D
Foam via conductive sensor
High Foam alarm
Automatic full and empty vessel sterilization sequence
Gear and maintenance free agitation motor
Gassing strategy
Flow meter sparger
Flow meter overlay
Automatic Gassing strategy of Air, O2, N2, CO2 for sparger
Peristaltic pumps (integrated)
Data acquisition and trend monitoring software
BioPAT® MFCS
Supply frame
Temperature control system
Solenoid valves and steam traps automatic in-situ sterilization
Culture Vessel
Stirrer shaft with Double Mechanical Seal (DMS)
Condensate pressurization of buffer system DMS steam | compressed air
3-blade segment impeller
Stainless steel filter housing for Air Inlet (Sparger and Overlay)
and Exhaust filter incl. filter cartridges
Pressure gauge –1 | 3 barg
Aeration tube with micro sparger
Exhaust Cooler
4-Baffles (removable)
Resterilizable sampling valve
1-Channel Sacova valve for needle free additions
3-Channel Sacova valve for needle free additions
Lamp for vessel illumination
Storage bottles
Bottom harvest valve
pH Electrode, cable
DO Electrode, cable
Pressure sensor, cable
Foam sensor, cable
Temperature sensor Pt 100
High-foam sensor with installation adaptor, cable
Options
Mobile CIP unit with DCU interface
Culture vessel weight measurement | control
Automatic vessel pressure control
Pressure hold test
Lid lifting device 10-20 L | 30-200 L
Dual pH measurement | Dual DO measurement
Containment sampling system
WIT ready filter housings for Inlet and Exhaust filter
Exhaust heater | Dual Exhaust filter line (parallel)
Temperature measurement of condensate trap
Cleaning in Place (CIP)
Resterilizable 4-valve addition array manual | automatic
Automatic harvest valve
Transfer group
Speed controlled pumps
Broad range of accessories available. Please contact us for further details.

10 L
RDD-C10L
ABRES3 | 2:1
RDD-C10L
ABRES4 | 2:1

20 L
RDD-C20L
ABRES3 | 2:1
RDD-C20L
ABRES4 | 2:1

30 L
50 L
RDD-C30L
RDD-C50L
ABRES3 | 2:1 ABRES3 | 2:1
RDD-C30L
RDD-C50L
ABRES4 | 2:1 ABRES4 | 2:1
Twin configuration optional
•

100 L
RDD-C1HL
ABRES3 | 2:1
RDD-C1HL
ABRES4 | 2:1

200 L
RDD-C2HL
ABRES3 | 2:1
RDD-C2HL
ABRES4 | 2:1

•
•
•
•
•
•
Advanced Additive Flow
• for Air, O2 N2, CO2
• for Air
• via solenoid valves (Mass Flow Controller optional)
2 for Base | Afoam unused pump can be configured as substrate pump (Up to 6 pumps per system)
•
Open frame design
Closed loop system with recirculation pump and heat exchanger for heating and cooling
•
Jacketed stainless steel vessel with vertical sight glass and bottom agitation
•
•|O
2
•
•
•
•
•
•
•
•
•
2
•
•
•
•
•
•
•
O
O|O
O
O
-- | O
O|O
O
O
O|O
O
O
O|O
O
O
O
• = included, — — = unavailable, O = option

BIOSTAT ® D-DCU – Technical Specification
Technical Specification

10 L

Space requirement Single [W + H + D]

58.3 + 82.7 + 43.3 58.3 + 82.7 + 44.5 58.3 + 82.7 + 45.3 76.8 + 92.9 + 61.8

[“]
[m]
Space requirement Twin [W + H + D]
[“]
[m]
Required wall opening dimensions [W + H] [“]
[m]
Culture vessel weight (approx.)
[kg]
Supply Unit weight (approx.)
[kg]
Control Tower weight (approx.)
[kg]
Single | Twin
Ambient temperature | relative humidity
(non-condensating)
Utilities Requirements

1.48 + 2.1 + 1.1

20 L
1.48 + 2.1 + 1.13

30 L

50 L

1.48 + 2.1 + 1.15

1.95 + 2.36 + 1.57

84.6 + 82.7 + 43.3 84.6 + 82.7 + 44.5 84.6 + 82.7 + 45.3 122 + 92.9 + 61.8
2.15 + 2.1 + 1.1
2.15 + 2.1 + 1.13 2.15 + 2.1 + 1.15
3.1 + 2.36 + 1.57

31.9 + 78.8
0.81 + 2
80
170

31.9 + 78.8
0.81 + 2
100
170

31.9 + 78.8
0.81 + 2
120
170

41.8 + 67
1.06 + 1.7
300
320

100 L

200 L

76.8 + 100.8 + 61.8
1.95 + 2.56 + 1.57
122 + 100.8 + 61.8
3.1 + 2.56 + 1.57
41.8 + 67
1.06 + 1.7
450
320

76.8 + 120.1 + 70.9
1.95 + 3.05 + 1.8
122 + 120.1 + 70.9
3.1 + 3.05 + 1.8
41.8 + 67
1.06 + 1.7
600
320

Vessel Size
30 L
50 L
45 |
75 |
3/30
5/50
45 |
75 |
3/15
5/25
N|A
N|A
3 | 15
5 | 25
N|A
N|A
3 | 15
5 | 25
15
50
5
8
5
25
5
25
33

100 L
150 |
10/100
150 |
10/50
N|A
10 | 50
N|A
10 | 50
90
10
25
35
43

160 | 205
5 – 40°C | 85%
Conditions

Max.
Flow

20 L
30 |
2/20
30 |
2/10
N|A
2 | 10
N|A
2 | 10
15
5
5
5
on request

Process Air MO |
CC Sparger | Overlay
O2 MO Sparger |
CC Sparger | Overlay
CO2 MO Sparger |
CC Sparger | Overlay
N2 MO Sparger |
CC Sparger | Overlay
Utility steam
Clean steam
Cooling water
Cooling water return
CIP, cleaning and rinsing fluid

4 barg | 58 psig, controlled,
Class 2 (ISO 8573-1)
4 barg | 58 psig, controlled, prefiltered

[L/min]

4 barg | 58 psig, controlled, prefiltered

[L/min]

4 barg | 58 psig, controlled, prefiltered

[L/min]

4 barg | 58 psig, controlled, prefiltered
1.5 barg | 21.8 psig, controlled, prefiltered
4 barg | 58 psig, controlled (15°C) prefiltered
Atmospheric pressure to 1.5 barg | 21.8 psig
1.5 barg | 21.8 psig, controlled

[kg/h]
[kg/h]
[L/min]
[L/min]
[L/min]

Condensate

Atmospheric pressure (max. Temp. 98°C)

Instrument air
Power supply (TNS net):
5 wire: 3 + phase, 1 + ground, 1 + neutral
Power supply for electrical heater (TNS net):
5 wire: 3 + phase, 1 + ground, 1 + neutral
Control Tower
Controller
Housing material
Display | Operation
Host communication
External connections
Balance connection
External Inputs | Off gas analyzer input
External feed pumps
Gassing System
MO application
CC application
Flow meter
Flow range

6 barg | 87 psig, controlled
208 VAC/24A (FI switch intern 300mA) or 400 VAC/20A (FI switch intern 300mA)

Accuracy
Thermal Mass Flow Controller
Flow range
Accuracy
Integrated pumps
Pump head
For tubings with 1.6 mm | 1/16“ wall thickness
Rotation speed [rpm]
Flow range [mL/min] Bore 0.5 mm 1/50“
4.8 mm 3/16“
8.0 mm 5/16“

[L/min]

10 L
15 |
1/10
15 |
1/5
N|A
1|5
N|A
1|5
15
5
5
5

208 VAC/16A or 400 VAC/10A
Integrated DCU-Controller, Gassing System and Pumps Single or Twin configuration
Industrial PC (Siemens)
Stainless steel AISI 304
Touch Panel 19“ | Touch screen
Industrial Ethernet
Expandable process I/O
3 per vessel; expandable of up to 6 per vessel
2 per vessel; Analog in (0 – 10 V) | 2 per vessel Analog in (4 – 20 mA)
up to 4 per vessel; 2 per vessel; Analog out (0 – 10 V)
Up to 6 integrated Mass Flow Controllers and Flowmeter
Air aeration, O2-Enrichment or Gas Flow Ratio; Max. total flow rate: 1.5 vvm
Advanced Additive Flow; Max. total flow rate: Overlay 1 vvm | Sparger 0.1 vvm
Air calibrated @ 4 barg 20°C | scale lenght 120 mmm
0.12–1.06 L/min up to 70–330 L/min

+/– 4% FS
Air | N2, O2 or CO2 calibrated
0.02–1.0 sLpm up to 6–300 sLpm
+/– 1% FS
Up to 6 per vessel (2 + digital + 2 + digital | speed controlled + 2 + speed controlled)
Watson Marlow 114
Watson Marlow 314
For tubings with bore 0.5-4.8 [mm] | 1/50-3/16[“]
For tubings with bore 0.5-8.0 [mm] | 1/50-5/16[“]
5
44
up to 200
6
60
up to 200
0.1
0.02 – 0.9
0.4 – 4
0.0 – 0.18
0.04 – 1.8
0.6 – 6
0.09 – 4.3
0.75 – 37.4
17 – 170
2.3 – 11.4
2.3 – 114
38 – 380
N|A
N|A
N|A
0.48 – 24
4.8 – 240
80 – 800

200 L
300 |
20/200
300 |
20/100
N|A
20 | 100
N|A
20 | 100
160
26
50
50
70

Supply Unit

Piping Skid in open frame design

Material | Surface finish (product wetted parts)
Temperature control system – steam version
Temperature control (operation | sterilization):
Heat exchanger (cooling | heating – steam version)
Electrical heater (optional)
Culture vessel
H:D ratio
Total volume
Working volume
Minimal working volume
Jacketed cylindrical part | Jacketed bottom
Weight lid with blind plugs [kg]
Agitation speed ranges for MO
(max. impeller tip speed ≥ 5 m/s)
Motorpower | torque [kW | Nm]
Agitation speed ranges for CC
(max. impeller tip speed ≥ 2 m/s)
Motorpower | torque [kW | Nm]

Stainless steel AISI 316L | MO: Ra < 0.8 µm (31.5 Ra or better) | CC: Ra < 0.4 µm (15.7 Ra or better)
Closed loop thermostat system with recirculation pump, heat exchanger for cooling and heating or | and electrical heater
8°C above cooling water to 90°C | up to 130°C
Stainless steel, copper soldered, optional stainless steel | welded version available upon request
6 kW (10–30 L: complete electrical heated; 50–200 L: auxiliary electrical heater only)
10 L
20 L
30 L
50 L
100 L
200 L
2:1
3:1
2:1
3:1
2:1
3:1
2:1
3:1
2:1
3:1
2:1
3:1
14 L
15 L
29 L
31 L
42 L
41 L
74 L
77 L
152 L
152 L
313 L
323 L
10 L
10 L
20 L
20 L
30 L
30 L
50 L
50 L
100 L
100 L
200 L
200 L
3.5 L
2.5 L
5.5 L
3.5 L
6.4 L
5.4 L
13 L
13L
24 L
24 L
47 L
41 L
yes | no yes | no yes | no yes | no yes | no yes | no yes | no yes | no
yes | yes yes | no yes | yes yes | no
12
11
16
14
18
16
34
22
45
35
95
68
20 –
20 –
20 –
20 –
20 –
20 –
20 –
20 –
20 –
20 –
20 –
20 –
1500
1500
1200
1200
1100
1100
900
900
700
700
570
570
2.3 | 5 2.3 | 5
3.1 | 9.4 3.1 | 9.4 3.1 | 9.4 3.1 | 9.4 4.2 | 16.2 4.2 | 16.2 4.9 | 26.7 4.9 | 26.7 6.6 | 48.2 6.6 | 48.2

Impeller to vessel diameter
[Rushton impeller]
Impeller to vessel diameter
[3-blade segment impeller]
Lid ports

Upper side wall

Lower side wall

Bottom
Jacket
Vessel design
Material (product wetted parts)
Surface finish product wetted
Pressure design criteria vessel | jacket
Sensors | measurement ranges | resolution
Dissolved oxygen
pH
Foam | Level | High Foam
Temperature sensor Vessel/Jacket
Redox
Pressure
Turbidity
Regulatory compliance

350

N|A

300

N|A

260

N|A

220

N|A

180

N|A

130

2.3 | 5

N|A

2.3 | 5

N|A

2.3 | 5

N|A

3.1 | 9.4

N|A

4.2 | 16.2 N | A

4.2 | 16.2 N | A

0.4

0.4

0.4

0.4

0.4

0.4

0.4

0.4

0.4

0.4

0.4

0.4

0.5

N|A

0.5

N|A

0.5

N|A

0.5

N|A

0.5

N|A

0.5

N|A

1 + sight glass for illumination
1 + port for Exhaust
9 + 19 mm port

N|A

1 + sight glass for illumination
1 + spare port DN 50
1 + port for CIP – connection
1 + port for Exhaust
8 + 19 mm port
3 + lifting eye
4 + 25 mm port
3 + 25 mm port
1 + Sparger aeration
1 + Sparger aeration
1 + Overlay aeration | Bypass Sparger
1 + Overlay aeration | Spare
1 + port for rupture disc | safety valve
1 + port for rupture disc
1 + rectangular sight glass
1 + spare DN50
1 + rectangular sight glass
5 + 25 mm port
5 + 25 mm port
1 + sanitary TC port
1 + sanitary TC port
1 + port for temperature sensor
1 + port for temperature sensor
1 + flange for agitator
1 + flange for agitator
1 + Harvest | Drain valve
1 + Harvest | Drain valve
1 + fluid in
1 + fluid in
1 + fluid out
1 + fluid out
Jacketed stainless steel vessel with torospherical bottom and vertical sight glass Bottom agitation system
Stainless steel AISI 316 L | Borosilicat glass | EPDM (FDA aprroved)
2:1 Vessel Ra ≤ 0.4 µm (15.7 Ra or better), electropolished | 3:1 vessel: Ra ≤ 0.8 µm (31.5 Ra or better), electropolished
–1/3 barg @ 150°C | –1/4 barg @ 150°C
Polarographic or optical | 0–100% | 1% | 0.1%
Gel filled | 2–12 | 0.01 pH
Conductive probe, stainless steel ceramic isolated
Pt100 | 0–150°C | 0.1 C / Pt100 | 0–150°C | 0.1 C
Gel filled | –1000 – 1000 mV | 1 mV
Piezoresistive sensor | –0.5–2 [barg] | 1 mbar
Single Channel NIR Absorption Probe, 0–6 AU | 0.01 AU
CE | UL | CSA (EN61010, UL61010); Culture vessel: ASME or PED or China pressure vessel regulation

MO: Microbial Application; CC: Cell Culture Application
Specifications are subject to change without notice

NEW Mobile CIP Unit – Technical Specification
Technical Specification
Design

Dimensions (approx.) [W + H + D]

[“]
[mm]
Weight (approx.)
[kg]
Material | Surface finish (product wetted parts)
Utility Requirements
Water (WFI | PW | RO)
Drain
Drain CIP pump
Instrument air
CIP supply line
CIP return line
Power supply (TNS net):
5 wire: 3 + phase, 1 + ground, 1 + neutral
CIP pump
Type
Material pump head
Flow
Valves
Water
Recirculation
Drain
Drain valve pump housing

Mobile stainless steel skid
72.9 + 64.6 + 30.7
1851 + 1640 + 780
100
Stainless steel AISI 316L | Ra < 0.8 µm (31.5 Ra or better) | EPDM | PVC | PE | PTFE | others
Conditions | Flow
Connection | Height
min. 1 barg
TC 64 | TC 2.5“ | 401 mm | 15.8“
gravity | max. flow 3.5 m³
TC 64 | TC 2.5“ | 684 mm | 26.9“
gravity
TC 25 | TC 1“ | 135 mm | 5.31“
6 barg | 87 psig, controlled
Quick coupling
TC 64 | TC 2.5“
TC 64 | TC 2.5“
208 VAC | 60 Hz or 400 VAC | 50 Hz

Centrifugal pump
Stainless steel 316 L
max. 3.5 m3/h @ 3 barg
Pneumatic operated diaphragm valve
Pneumatic operated diaphragm valve
Pneumatic operated diaphragm valve
Manual operated diaphragm valve

Detergent dosing unit
Number of dosing units
Pump | Flow rate
Storage container volume | Material
Instrumentation | Measurement range
Function
Conductivity sensor (high)
Conductivity sensor (low)
Level switch
Pressure gauge
External connections

1 (2nd optional)
Diaphragm pump | up to 25 L/h
40 L | PE

1010 – 2000 mS
0.04 – 500 µS
Dry run protection for pump
– 1/5 bar
Connection to BIOSTAT® D-DCU for automated CIP sequence control (valves and recirculation pump)

Sales and Service Contacts
For further contacts, visit www.sartorius-stedim.com

America

Germany
Sartorius Stedim Biotech GmbH
August-Spindler-Strasse 11
37079 Goettingen

Netherlands
Sartorius Stedim Netherlands B.V.

Phone +49.551.308.0
Fax +49.551.308.3289

filtratie.nederland@sartorius-stedim.com

Sartorius Stedim Systems GmbH
Robert-Bosch-Strasse 5 – 7
34302 Guxhagen

Poland
Sartorius Stedim Poland Sp. z o.o.
ul. Wrzesinska 70
62-025 Kostrzyn

Phone +49.5665.407.0
Fax +49.5665.407.2200

Phone +48.61.647.38.40
Fax +48.61.879.25.04

France
Sartorius Stedim FMT S.A.S.
ZI des Paluds
Avenue de Jouques – CS 91051
13781 Aubagne Cedex

Russian Federation
LLC “Sartorius ICR”and LLC “Biohit”
Uralskaya str. 4, Lit. B
199155, Saint-Petersburg

Phone +33.442.845600
Fax +33.442.845619

Phone +31.30.60.25.080
Fax +31.30.60.25.099

Phone +7.812.327.5.327
Fax +7.812.327.5.323

USA
Sartorius Stedim North America Inc.
5 Orville Drive, Suite 200
Bohemia, NY 11716
Toll-Free +1.800.368.7178
Fax +1.631.254.4253
Argentina
Sartorius Argentina S.A.
Int. A. Ávalos 4251
B1605ECS Munro
Buenos Aires
Phone +54.11.4721.0505
Fax +54.11.4762.2333
Brazil
Sartorius do Brasil Ltda
Avenida Senador Vergueiro 2962
São Bernardo do Campo
CEP 09600-000 - SP- Brasil
Phone +55.11.4362.8900
Fax + 55.11.4362.8901

Sartorius Stedim France SAS
ZI des Paluds
Avenue de Jouques – CS 71058
13781 Aubagne Cedex

Spain
Sartorius Stedim Spain, S.A.U.
Avda. de la Industria, 32
Edificio PAYMA
28108 Alcobendas (Madrid)

Phone +33.442.845600
Fax +33.442.846545

Phone +34.902.110.935
Fax +34.91.358.96.23

Austria
Sartorius Stedim Austria GmbH
Franzosengraben 12
1030 Vienna

Switzerland
Sartorius Stedim Switzerland AG
Ringstrasse 24 a
8317 Tagelswangen

Phone +43.1.7965763.18
Fax +43.1.796576344

Phone +41.52.354.36.36
Fax +41.52.354.36.46

Belgium
Sartorius Stedim Belgium N.V.
Leuvensesteenweg, 248/B
1800 Vilvoorde

U.K.
Sartorius Stedim UK Ltd.
Longmead Business Centre
Blenheim Road, Epsom
Surrey KT19 9 QQ

Australia
Sartorius Stedim Australia Pty. Ltd.
Unit 5, 7-11 Rodeo Drive
Dandenong South Vic 3175

Phone +44.1372.737159
Fax +44.1372.726171

Phone +61.3.8762.1800
Fax +61.3.8762.1828

Ukraine
LLC “Biohit”
Post Box 440 “B”
01001 Kiev, Ukraine

China
Sartorius Stedim Biotech (Beijing) Co. Ltd.
No. 33 Yu’an Road
Airport Industrial Park Zone B
Shunyi District, Beijing 101300

Phone +32.2.756.06.80
Fax +32.2.756.06.81
Hungary
Sartorius Stedim Hungária Kft.
Kagyló u. 5
2092 Budakeszi
Phone +36.23.457.227
Fax +36.23.457.147
Italy
Sartorius Stedim Italy S.p.A.
Via dell’Antella, 76/A
50012 Antella-Bagno a Ripoli (FI)

Phone +380.44.411.4918
Fax +380.50.623.3162

Phone +39.055.63.40.41
Fax +39.055.63.40.526

Mexico
Sartorius de México S.A. de C.V.
Circuito Circunvalación Poniente
No. 149
Ciudad Satélite
53100, Estado de México
México
Phone +52.5555.62.1102
Fax +52.5555.62.2942

Asia |Pacific

Phone +86.10.80426516
Fax +86.10.80426580
Sartorius Stedim Biotech (Beijing) Co. Ltd.
Shanghai Branch Office
3rd Floor, North Wing, Tower 1
No. 4560 Jin Ke Road
Pudong District, Shanghai 201210
Phone +86.21.68782300
Fax +86.21.68782332 | 68782882
Sartorius Stedim Biotech (Beijing) Co. Ltd.
Guangzhou Representative Office
Unit K, Building 23
Huihua Commerce & Trade Building
No. 80 Xianlie Middle Road
Guangzhou 510070
Phone +86.20.37618687 | 37618651
Fax +86.20.37619051

www.sartorius-stedim.com

India
Sartorius Stedim India Pvt. Ltd.
#69/2-69/3, NH 48, Jakkasandra
Nelamangala Tq
562 123 Bangalore, India
Phone +91.80.4350.5250
Fax +91.80.4350.5253
Japan
Sartorius Stedim Japan K.K.
4th Fl., Daiwa Shinagawa North Bldg.
8-11, Kita-Shinagawa 1-chome
Shinagawa-ku, Tokyo, 140-0001 Japan
Phone +81.3.4331.4300
Fax +81.3.4331.4301
Malaysia
Sartorius Stedim Malaysia Sdn. Bhd.
Lot L3-E-3B, Enterprise 4
Technology Park Malaysia
Bukit Jalil
57000 Kuala Lumpur, Malaysia
Phone +60.3.8996.0622
Fax +60.3.8996.0755
Singapore
Sartorius Stedim Singapore Pte. Ltd.
1 Science Park Road,
The Capricorn, #05-08A,
Singapore Science Park II
Singapore 117528
Phone +65.6872.3966
Fax +65.6778.2494
South Korea
Sartorius Korea Biotech Co., Ltd.
8th Floor, Solid Space B/D,
PanGyoYeok-Ro 220, BunDang-Gu
SeongNam-Si, GyeongGi-Do, 463-400
Phone +82.31.622.5700
Fax +82.31.622.5799
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HyPerforma 500 L Single-Use Mixer

HyPerforma Single-Use Mixer
The next generation of efficiency and performance
The Thermo Scientific™ HyPerforma™ Single-Use Mixer
(S.U.M.) provides you with enhanced functionality, ease
of use, and efficiency. The complete HyPerforma S.U.M.
system consists of a mixer tank with a motor controller,
available in sizes of 50, 100, 200, 500, 1,000, and
2,000 L with a 5:1 turndown mixing ratio. The redesigned
HyPerforma S.U.M. maintains traditional stirred-tank mixer
design principles with a directly coupled motor impeller
drive assembly and a cylindrical tank with a specific heightto-diameter ratio, allowing for quick turnaround times for
liquid-to-liquid mixing and powder-to-liquid mixing.
Critical upstream application steps
• Media preparation
• Final formulation steps
• Buffer preparation
• Harvest vessels
• Large-volume mixing (up to 2,000 L)
Critical downstream application steps
• Pooling and liquid transfer
• Product suspension
• Mixing and storing multiple batches
• Buffer preparation
• Viral inactivation

HyPerforma S.U.M. options
• Powder hanger for 1 kg, 5 kg, and 25 kg Thermo
Scientific™ Powdertainer™ BioProcess Containers (BPCs)
• AC and DC motor options; electrical box only available
on AC option
• 3x load cell weighing system with summing box
(options for displaying signal output)
• Cable management system to organize process
tubing lines
• Available in either water-jacketed or non-jacketed
(no heat transfer) design
• pH and conductivity probes and display
• Open-top or closed-top Thermo Scientific™ BPC design
• BPCs available in Thermo Scientific™ CX5-14 Film and
Aegis™5-14 Film options
Options outside of the above list may be reviewed
with a Thermo Fisher Scientific sales representative
and considered for customizations to the standard
mixer design.

Standard S.U.M. hardware ordering information
Note: Models without water jackets may have slightly different dimensions than the water-jacketed
model shown here. See the drawings provided with your unit for exact dimensions for non-jacketed
models. Non-jacketed models do not have the capability to heat or cool the liquid inside the tank.

Description

Cat. No.

Non-jacketed, DC motor, with load cell

SUM0500.9001

Jacketed, DC motor, with load cell

SUM0500.9002

Non-jacketed, 120 VAC, AC motor, with load cell

SUM0500.9003

Jacketed, 120 VAC, AC motor, with load cell

SUM0500.9004

Non-jacketed, 240 VAC, AC motor, with load cell

SUM0500.9005

Jacketed, 240 VAC, AC motor, with load cell

SUM0500.9006

Design features
1

5
14

2
3

Front view

15

Back view

16

6
4

17
7

8
18
12

9

13

10

11

20

19

1. Powdertainer arm (optional)

12. Liquid sight windows

2. Mixing assembly with shield

13. Bleed valve (water-jacketed models only)

3. Bearing port receiver with clamp
4. Mixer motor

14. Standard tool set: 3⁄8-in., 150 in.-lb. square torque
wrench, load cell and motor cap lockout wrench

5. Stainless steel (grade 304) outer support container

15. Bearing hub (for open-top mixing only)

6. Electrical control panel (optional)

16. Handles

7. Driveshaft (stored)

17. Cutout for BPC loading

8. 3⁄8 in. dimpled jacket (side and bottom)

18. Bottom cutouts/pins for BPC attachment and alignment

9. Probe access window

19. 1½ inch tri-clamp connection ports for water inlet/outlet
(water-jacketed models only)

10. Probe hanger bracket
11. Cart assembly

20. Casters (3 swiveling and 2 fixed)

Note: Models without water jackets include the same features as the water-jacketed models shown here, but without the jacket and inlet/outlet ports.
Optional load cells and cable management system are not shown. See the accessories section for more information about these items.

Top view

81 cm (32.0 in.)
Cart width

258 cm (101.8 in.) Powdertainer height

40 cm (15.6 in.)
Electrical box
width

198 cm (77.8 in.) Motor height
164 cm (64.4 in.) Tank height
(32.1
6682
cmcm
(26.0
in.)in.)
Cartlength
length
Cart

129 cm (50.7 in.)
80
cm
in.)
89
cm(31.4
(34.9
in.)
Overall
length
Overall
length
Overall
length

94
cm
(37.0
in.)in.)
122
cm
(48.2
Overall
width
Overall
width

33 cm (13.1 in.) Tank bottom
24 cm (9.5 in.) Cart height

Standard 500 L S.U.M. hardware

0 cm (0 in.)
Front view

500 L S.U.M. specifications

Support container Misc.

Fluid jacket

AC motor

DC motor

Non-jacketed

Jacketed

Non-jacketed

Jacketed

Jacket area: full/half volume

–

2.2 m (23.9 ft. )/
1.4 m2 (14.8 ft.2)

–

2.2 m2 (23.9 ft.2)/
1.4 m2 (14.8 ft.2)

Jacket volume
Jacket flow rate at 50 psi

–

11 L (2.9 gal)

–

11 L (2.9 gal)

–

96.8 L/min (25.5 gal/min)

–

96.8 L/min (25.5 gal/min)

2

2

Process connection

–

1 in. sanitary tri-clamp

–

1 in. sanitary tri-clamp

Temperature Control Unit (TCU) model:
Maximum heating/cooling

–

TF2500: 2,800/2,500 W

–

TF2500: 2,800/2,500 W

Approximate liquid heat-up time (5–37°C)

–

2.6 hr

–

2.6 hr

Approximate liquid chill-down time (37–5°C)

–

3.7 hr

–

3.7 hr

RTD or thermocouple, 1/8 in.
(3.18 mm) OD

RTD: Pt-100 (standard)

Overall width

122.5 cm (48.23 in.) with e-box

86.4 cm (34 in.) without e-box

Overall length

130.2 cm (51.25 in.) with e-box

130.2 cm (51.25 in.) without e-box

Overall height

251.1 cm (98.9 in.)

Dry skid weight (mass)

333 kg (734 lb)

431 kg (951 lb)

333 kg (734 lb)

431 kg (951 lb)

Wet skid weight, rated
working volume (mass)

833 kg (1,836 lb)

931 kg (2,053 lb)

833 kg (1,836 lb)

931 kg (2,053 lb)

General

Ceiling height required for
standard driveshaft loading
Ceiling height required for optional,
non-standard 2-piece drive shaft loading
Electrical power supply requirement
(voltage, phase, current)

Recommended
operating
parameters

pH and dissolved oxygen (DO) probe,
autoclavable type (AppliSens™, Broadley
James™, Mettler Toledo™)
Noise level
Operating temperature range

320 cm (126 in.)
275.6 cm (108.5 in.)
120/240 VAC, single, 20/10 A

Dependent on controller

12 mm diameter x 215–235 mm insertion length x 13.5 PG (pipe) thread
< 70 dB at 1.5 m
2–40°C ±0.1°C (36–104°F ±0.2°F)

Motor speed

30–350 rpm

Volume range

100–500 L

Maximum BPC pressure
Maximum BPC pressure during operation
Continuous operating time

0.03 bar (0.5 psi)
0.007 bar (0.1 psi)
21 days mixing time at nominal volume only

Load cells
Load cells are typically radially mounted in sets of three.
The mounting location varies slightly for each size in order
to allow easy access to the bottom drain or sparging
mechanisms and tubing.
Load cell displays
Harsh mount load cell displays are available as an option
for all HyPerforma S.U.M. systems. They are normally
mounted on the electrical box or a wall and are available
with four different interfaces.

Channels for
additional lines

Harvest line hook

Adjustable arm

Powdertainer arm
A Powdertainer arm is available as an option for
powder–liquid applications. It holds the container of
powder above the mixer and attaches it to the BPC with
a clamp. The arm adjusts vertically and swivels to enable
convenient lifting of the Powdertainer onto the hanger.
pH and conductivity monitoring devices
Mettler Toledo pH and conductivity sensors with a display
monitor are available in single pH, dual pH, and pH and
conductivity configurations. The monitor is mounted on the
post behind the electrical box, and includes a color touch
screen and control and alarm-management features.
Description

Cat. No.

Cable management system (500 L)

SV50992.03

3x load cell with summation box,
without display

SV50988.03

Mettler Toledo IND331 display, with analog
interface (STD), 120 VAC U.S. line cord/plug

SV50177.306

Mettler Toledo IND331 display, with
Allen-Bradley™ RIO interface, 120 VAC U.S.
line cord/plug

SV50177.307

Mettler Toledo IND331 display, with DeviceNet
interface, 120 VAC U.S. line cord/plug

SV50177.308

Mettler Toledo IND331 display, with Ethernet/
IP and Modbus TCP interface, 120 VAC U.S.
line cord/plug

SV50177.309

Mettler Toledo IND331 display, with Profibus
interface, 120 VAC U.S. line cord/plug

SV50177.310

Powdertainer arm for 50–1,000 L mixers

SV51002.01

Mettler Toledo pH monitoring device,
single channel

SV51004.01

Mettler Toledo pH monitoring device,
dual channel

SV51004.02

Mettler Toledo pH and conductivity monitoring
device, dual channel

SV51004.07

Mettler Toledo MTB load cell for
50–1,000 L S.U.M. units.

Mettler Toledo IND331 harshmount load cell display for all
S.U.M. systems.

Powdertainer hook

Powdertainer-to-BPC
port clamp

Tank attachment
mechanism
Powdertainer arm

pH and conductivity monitoring device

Autoclave tray and probe assembly
The autoclave tray holds the electrochemical probes and
bellows in place during the autoclave sterilization process.
Design elements include the following:

Threaded probe
attachment

Probe

Cable tie

Handle

• Fabricated from stainless steel
• Plastic handle provides for easy transport right
out of the autoclave
• Positions probes on 15% incline for greater probe and
membrane longevity

Molded
bellows cover
Autoclave tray

• Prevents probe bellows from collapsing
during sterilization
• Probe holder accommodates two probes
Probe clips
Stainless steel probe clips are used to hold the probes
in place on the S.U.M. tank. The independently movable
probe clips hang on a thin brace above the probe port
tank cutout and are held in place by an adjustable spring
plunger. The probes are inserted into the clip mechanism
and held in place by a half-spring clip.
Heavy-duty tubing clamps
Heavy-duty clamps are used for pinching off line sets
that are not in use in order to prevent process fluids from
escaping. Prior to sterile probe insertion, tubing clamps
must be in place to close off probe ports.
Description

Cat. No.

Autoclave tray (stainless steel with plastic
carry handle)

SV50177.01

4 probe clips

SV50177.23

Heavy-duty tubing clamp (single)

SV20664.01

Heavy-duty tubing clamp (10 pack)

SV20664.04

Probe clip

Heavy-duty
tubing clamps

1. Addition line

Impeller
3. Bottom drain

Back face
4. Powder addition port

Front face

2. Recirculation/sample line

Standard 500 L BPC for powder–liquid applications without probe ports
Line

Description

Tubing set (inner diameter x outer diameter x length)

End treatment

1

Addition line

12.7 mm (1/2 in.) x 15.9 mm (5/8 in.) C-Flex™ x 152 cm (60 in.)

Plugged 12.7 mm (1/2 in.) MPX body

2

Recirculation/sample line

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 137 cm (54 in.) splits to
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)

Capped 12.7 mm (1/2 in.) MPX insert
Plugged 12.7 mm (1/2 in.) MPX body

3

Bottom drain

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.)

Capped 12.7 mm (1/2 in.) MPX body

4

Powder addition port

7.6 mm (3 in.) sanitary fitting, tri-clamp tube ports

Capped with gasket
Impeller

2. Recirculation/sample line

3. Fill line

Front face

Back face

1. Bottom drain

4. Vent filter

5. Addition line

Standard 500 L BPC for liquid–liquid applications without probe ports
Line

Description

Tubing set (inner diameter x outer diameter x length)

End treatment

1

Bottom drain

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.)

Capped 12.7 mm (1/2 in.) MPX body

2

Recirculation/
sample line

Capped 12.7 mm (1/2 in.) MPX insert
Plugged 12.7 mm (1/2 in.) MPX body

3

Fill line

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 168 cm (66 in.) splits to
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
19.1 mm (3/4 in.) x 25.4 mm (1 in.) C-Flex x 152 cm (60 in.)

4

Vent filter

6.4 mm (1/4 in.) x 12.7 mm (1/2 in.) C-Flex x 10.2 cm (4 in.)

5

Addition line

9.5 mm (3/8 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.)

Sterile hydrophobic vent filter
(0.2 μm PVDF, Acro™ 50)
Plugged 9.5 mm (3/8 in.) MPX insert

38.1 mm (1 1/2 in.) tri-clamp (SterilEnz™)

2. Addition line
Impeller

3-4. Probe ports (2)

Front face
5. Unused

1. Recirculation/sample line

6. Thermowell/small-volume sample line
7. Bottom drain

Back face

8. Powder addition port

Standard 500 L BPC for powder–liquid applications with probe ports
Line Description
1

Tubing set (inner diameter x outer diameter x length)

End treatment

2

Recirculation line 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 137 cm (54 in.) splits to Capped 12.7 mm (1/2 in.) MPX insert
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
Plugged 12.7 mm (1/2 in.) MPX body
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Addition line
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.)
Plugged 12.7 mm (1/2 in.) MPX insert

3–4

Probe ports (2)

None

5

Unused

None

6

Thermowell/
small-volume
sample line
Bottom drain

Thermowell adapter for 3.2 mm (1⁄8 in.) diameter 3.2 mm (1⁄8 in.) x
6.4 mm (1/4 in.) x 30 cm (12 in.)

Luer and SmartSite™ valve port

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.)

Capped 12.7 mm (1/2 in.) MPX body

7.6 mm (3 in.) sanitary fitting, tri-clamp

Cap with gasket

7
8

Powder addition
port

Kleenpak™ aseptic connector
KPCHT series (female)
Plug

Impeller

1-2. Probe ports (2)

9. Unused

Front face

Back face

4. Recirculation/sample line
3. Thermowell/small-volume sample line
8. Bottom drain

5. Fill line

7. Addition line
6. Vent filter

Standard 500 L BPC for liquid–liquid applications with probe ports
Line Description

Tubing set (inner diameter x outer diameter x length)

End treatment

1—2

Probe ports (2)

None

3

Kleenpak aseptic connector KPCHT
series (female)
Luer and SmartSite valve port

5

Thermowell/
Thermowell adapter for 3.2 mm (1⁄8 in.) diameter 3.2 mm (1⁄8 in.) x
small-volume
6.4 cm (1⁄4 in.) C-Flex x 30 cm (1⁄2 in.)
sample line
Recirculation line 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 168 cm (66 in.) splits to Capped 12.7 mm (1/2 in.) MPX insert
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
Plugged 12.7 mm (1/2 in.) MPX body
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Fill line
12.7 mm (1/2 in.) x 25.4 mm (1 in.) C-Flex x 152 cm (60 in.)
38.1mm (1 1/2 in.) tri-clamp (SterilEnz)

6

Vent filter

6.4 mm (1⁄4 in.) x 12.7 mm (1⁄2 in.) C-Flex x 10.2 cm (4 in.)

7

Addition line

9.5 mm (3/8 in.) x 15.9 mm (5/8 in.) C-Flex x 61 cm (24 in.)

Sterile hydrophobic vent filter
(0.2 μm PVDF, Acro 50)
Plugged 12.7 mm (1/2 in.) MPX insert

8

Bottom drain

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.)

Plugged 12.7 mm (1/2 in.) MPX body

9

Unused

None

Plug

4

Bottom drain
Quick-connect fitting

Impeller

Sleeve (3/4 in. inner diameter tubing)

Standard open-top liners

Standard impeller sleeve

Description

Cat. No.

Description

Cat. No.

500 L standard open-top liner,
0 probes, CX3-9 film

SH30762.06

500 L impeller sleeve for open-top mixing*

SH30749.10

* The bearing hub needed for open-top mixing is automatically supplied with the tank hardware.

Custom BPC products
Category

Options/capability

Notes

Tubing type

C-Flex, platinum-cured silicone, PVC, PharMed™, PharmaPure™.

More information is available in
the tubing selection guide.

Tubing size

Ranges from 3.18 mm (1/8 in.) to 25.4 mm (1 in.) inner diameter in
various lengths.

More information is available in
the tubing selection guide.

Connectors

Luer, Colder Products Company™ (CPC) quick connects, SIP connectors, More information is available in
tri-clamp, Kleenpak, SmartSite, Clave™, Lynx™ steam-thru, CPC steamthe connection system selection
thru, Gore™ steam valve, Gore™ Mini TC, BioQuate™, SterilEnz, end plug.
guide. Note: the only option
for probe port connections is
Kleenpak connectors.

Probe ports/line
addition ports

Ports may be added if they are compatible with the hardware.

The reusable probe port
connection uses a
Kleenpak connector.

Disposable sensors

Pressure sensor: PendoTECH™ and Finesse Solutions (PendoTECH
comes standard on 500 L and 1,000 L S.U.M.); DO and pH sensor:
Finesse Solutions and PreSens™; pH sensor: Mettler Toledo.

Choice of qualified
vendors available.

Port sizes

Limited engineer-to-order customization only.

Dependent on location in BPC
and fit with hardware (e.g., 1 in.
ID port on harvest line).

Rearrangement of
lines on existing
ports

Limited customization possible, such as moving sample/thermowell port
to a probe tube port, or swapping exhaust outlet line with liquid lines.

Dependent on location in BPC
and fit with hardware.

Dip tube lines

Limited customization possible.

Length cannot interfere with
impeller and shaft.

Filters on media and
supplement inlets

Limited engineer-to-order customization only. Choice of filters used to
sterilize incoming media or supplements are available.

Note: Not all options are available for all ports. It is not possible to customize port type, port location, chamber dimensions, or mixing assembly.
For additional information, please see the selection guides in the BPC Catalog.

BPC packaging
Description

Details

Outer packaging

Supplied “flat-packed” with two polyethylene outer layers

Label

Description, product code, lot number, and expiry date on outer packaging and shipping container

Sterilization

Irradiation (25 to 38 kGy) inside outer packaging

Shipping container

Durable cardboard carton

Documentation

Certificate of analysis provided with each lot for each delivery

Ordering information
500 L S.U.M. BPC

Size

Probe ports*

Film type

Cat. No.

500 L

0

CX5-14

SH30751.01

500 L

0

Aegis5-14

SH30973.03

500 L

0

CX5-14

SH30754.01

500 L

0

Aegis5-14

SH30983.03

500 L

3

CX5-14

SH30751.02

500 L

3

Aegis5-14

SH30974.03

500 L

3

CX5-14

SH30754.02

500 L

3

Aegis5-14

SH30982.03

Standard powder–liquid BPC

Standard liquid–liquid BPC

Standard powder–liquid BPC*

Standard liquid–liquid BPC*
* All 500 L BPCs with probe ports are designed to allow probes to work properly at 5:1 turndown levels. These BPCs are only compatible with the HyPerforma hardware shown in this document. If you are
using an older version of the S.U.M. hardware, do not use these items; instead refer to the legacy S.U.M. user manual or data sheets.

Find out more at thermofisher.com/sum
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.
© 2017 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless
otherwise specified. Allen Bradley is a trademark of Allen-Bradley Company. Applisens is a trademark of Applikon B.V. Corporation. BioQuate
and PreSens are trademarks of General Electric Company. Broadley James is a trademark of Broadley-James Corporation. Clave is a trademark
of ICU Medical, Inc. Colder Products Company is a trademark of Dover Corporation. Gore is a trademark of W. L. Gore & Associates. Kleenpak
and Acro are trademarks of Pall Corporation. Lynx is a trademark of Merck KgAA. Mettler Toledo is a trademark of Mettler-Toledo AG. PharMed
and PharmaPure are trademarks of Saint-Gobain Performance Plastics Corporation. PendoTECH is a trademark of PendoTECH. SmartSite is a
trademark of Carefusion 303, Inc. SterilEnz is a trademark of PAW BioScience Products, Inc. COL05436 1117

#ULTUREFUGE 
3OLIDS EJECTING CENTRIFUGE
-ANY NEW BIOLOGICAL PRODUCTS ARE DERIVED FROM FRAGILE ORGAN
ISMS !LTHOUGH RELATIVELY EASY TO SEPARATE THE TRICK IS ACCOM
PLISHING THE SEPARATION IN A GENTLE MANNER WITHOUT DESTROY
ING THE SHEAR SENSITIVE CELL WALL MEMBRANES THAT ISOLATE THE
COMPLEX INTRACELLULAR PROTEINS FROM THE EXTRACELLULAR LIQUID )F
THIS CAN BE AVOIDED DOWNSTREAM PURIFICATION OF THE TARGET
PROTEINS BECOMES MUCH EASIER
!PPLICATIONS
4HE MACHINE IS DESIGNED FOR CLARIlCATION DUTY %SPECIALLY WHEN
CLARIFYING LIQUIDS FROM SHEAR SENSITIVE PARTICLES !PPLICATIONS
THAT REQUIRES LOW OXYGEN PICK UP CAN ALSO TAKE ADVANTAGE OF
THE HERMETIC FEATURES THIS MACHINE OFFERS
3TANDARD DESIGN
4HE MACHINE CONSISTS OF A FRAME THAT HAS A HORIZONTAL DRIVE
SHAFT WORM GEAR LUBRICATING OIL BATH AND HOLLOW VERTICAL
BOWL SPINDLE IN THE LOWER PART 4HE BOWL IS MOUNTED ON TOP
OF THE SPINDLE INSIDE THE SPACE FORMED BY THE UPPER PART
OF THE FRAME THE RING SOLIDS COVER THE COLLECTING COVER AND
THE FRAME HOOD 4HE LIQUID DISCHARGE SYSTEM ALSO RESTS ON
THIS STRUCTURE !LL PARTS IN CONTACT WITH THE PROCESS LIQUID
ARE MADE OF STAINLESS STEEL 4HE BOWL IS OF THE SOLIDS EJECT
ING DISC TYPE WITH AN AUTOMATIC HYDRAULIC OPERATING SYSTEM
FOR DISCHARGING )T IS A SO CALLED TIMER TRIGGERED PARTIAL DIS
CHARGE SYSTEM MEANING THAT ONLY PART OF THE BOWL CONTENT
IS EMPTIED DURING PRE SET DISCHARGE INTERVALS 4HE DISCHARGE
TAKES PLACE AT FULL SPEED WITHOUT ANY INTERRUPTION OF THE FEED
4HE CENTRIFUGE IS AVAILABLE WITH MAIN CONNECTIONS AS SANI
TARY FLANGES AND ALL OTHER UTILITY CONNECTIONS CLAMP TYPE 4HE
ELECTRIC MOTOR IS OF STANDARD TYPE AND HAS A BUILT IN VARI
ABLE FREQUENCY DRIVE 4HE DESIGN CONFORMS WITH A NUMBER
OF %# DIRECTIVES AND MACHINE IS MADE IN ACCORDANCE WITH
THE GENERAL DIRECTIVES FOR MACHINERY &INALLY THE CENTRIFUGE IS
EQUIPPED WITH NOZZLES FOR FLUSHING OF THE BOWL TOP THE BOWL
BOTTOM AND THE CYCLONE

&IG  #ULTUREFUGE  CENTRIFUGE

ELECTRIC MOTOR IN AND OUTLET CONNECTIONS SPARE PARTS KIT AND
SET OF TOOLS
-ATERIAL DATA
"OWL BODY HOOD AND LOCK RING

3OLIDS COVER AND FRAME HOOD SS !3-% 3!  5.3 
#YCLONE
"OTTOM FRAME

3TANDARD EQUIPMENT
%ACH #ULTUREFUGE  CENTRIFUGE COMES WITH CONTROL UNIT

SS  5.3 3

)N AND OUTLET
'ASKETS AND / RINGS

SS !3-% 3!  5.3 
#AST GREY IRON
SS MOSTLY  5.3 
%0$- RUBBER &$! APPROVED



/PERATING PRINCIPLES
4HE FEED IS INTRODUCED TO THE ROTATING CENTRIFUGE BOWL FIG 
FROM THE BOTTOM THROUGH A HOLLOW SPINDLE  AND IS ACCEL
ERATED IN A DISTRIBUTOR  BEFORE ENTERING THE DISC STACK 
WHERE THE SEPARATION TAKES PLACE 4HE SEPARATED LIQUID PHASE
LEAVES THROUGH THE LIQUID OUTLET  AT THE TOP OF THE BOWL 4HE
COLLECTED SOLIDS IN THE SOLID SPACE  ARE INTERMITTENTLY DIS
CHARGED FROM THE PERIPHERY OF THE BOWL $URING NORMAL PRO
DUCTION THE OPERATING WATER KEEPS THE SLIDING BOWL BOTTOM 
CLOSED AGAINST THE BOWL HOOD   $URING DISCHARGE THE SLIDING
BOWL BOTTOM DROPS FOR A SHORT TIME LESS THAN A SECOND AND
THE SOLIDS ARE EJECTED THROUGH THE DISCHARGE PORTS   4HE
HIGH VELOCITY OF THE EJECTED SOLIDS IS REDUCED IN THE CYCLONE



2A 

"OWL SPINDLE

2A  AND ELECTROPOLISHED






!VAILABLE MODELS
4HE #ULTUREFUGE  CENTRIFUGE IS AVAILABLE IN PRESSURE VESSEL
DESIGNS ACCORDING TO !3-% OR TO 0%$ )N ADDITION DIFFERENT
SURFACE lNISH EXECUTIONS ARE AVAILABLE
"OWL SPINDLE






&IG  4YPICAL BOWL FOR A HERMETIC SOLIDS EJECTING CENTRIFUGE 4HE
DETAILS ILLUSTRATED DO NOT NECESSARILY CORRESPOND TO THE CENTRIFUGE

-ACHINE TOP PART

)NSIDE 2A  /UTLET COVER 2A 
AND ELECTROPOLISHED

4ECHNICAL SPECIlCATION

-ACHINE TOP PART

)NSIDE 2A  /UTLET COVER 2A 

(YDRAULIC CAPACITY

MAX  MH 

-ACHINE TOP PART

)NSIDE 2A  /UTLET COVER 2A 

3EPARATOR BOWL

)NSIDE 2A  AND ELECTROPOLISHED
/UTSIDE 2A 

' FORCE
"OWL SPEED

MAX  G
MAX  RPM

3EPARATOR BOWL

)NSIDE 2A  /UTSIDE 2A 

3OUND PRESSURE

3EPARATOR BOWL

)NSIDE 2A  /UTSIDE 2A 

/VERHEAD HOIST LIFTING CAPACITY

-OTOR POWER INSTALLED




 K7
 D"!



MIN  KG

!CTUAL CAPACITY DEPENDS ON FEED MATERIAL AND SEPARATION DEMANDS
)N COMPLIANCE TO %. )3/ 

5TILITIES CONSUMPTION
$IMENSIONS APPROXIMATE

%LECTRIC POWER
/PERATING WATER
#YCLONE mUSH

 MM

#OOLING FOR SEALS

 K7
 LDISCHARGE
  LDISCHARGE
MAX  LH

&LUSHING ABOVE THE BOWL

  LDISCHARGE

&LUSHING UNDER THE BOWL

  LDISCHARGE

3TEAM PER STERILIZATION CYCLE

  KG

3HIPPING DATA APPROXIMATE

 MM

00-%. 

(OW TO CONTACT !LFA ,AVAL
#ONTACT DETAILS FOR ALL COUNTRIES
ARE CONTINUALLY UPDATED ON OUR WEBSITE
0LEASE VISIT WWWALFALAVALCOM TO
ACCESS THE INFORMATION DIRECT

 MM

#ENTRIFUGE WITH BOWL WITH MOTOR

 KG

'ROSS WEIGHT

 KG

6OLUME

 M

!LFA ,AVAL RESERVES THE RIGHT TO CHANGE SPECIlCATIONS WITHOUT PRIOR NOTIlCATION
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Resolute® Manual Chromatography Columns

Process columns for optimized, contained,
and scalable operation
!

High resolution flow path provides optimum efficiency, capacity, and peak symmetry.

!

Central nozzle valve provides all column functions required for packing, unpacking, and running the
column within a closed system.

!

Scalable, reproducible packing methods reduce validation efforts as processes scale up.

!

Common design from 280 to 1200 mm diameter (and up to 2000 mm on request).

!

Designed to minimize packing events and buffer usage to optimize process economics.

!

Options for manual or remote controlled nozzle valves.

Applications
Resolute columns have proven performance with a wide range of chromatography sorbents and
chromatographic modes including ion exchange, mixed-mode, affinity and hydroxyapatite.

Principle of Slurry Transfer
Resolute columns can be packed and unpacked with the
column fully assembled. At the center of the operation is
a nozzle valve in both the top and bottom of the column.
Process liquids can enter and exit the column via either
nozzle valve depending on which packing method is
employed. Top and bottom nozzle valves are identical,
making the flow profile the same in either direction.
The ability to pack media with the top end cell in place
contributes to process hygiene by reducing exposure to
the external environment.

Figure 1
Nozzle valve in pack position

There are three positions for each nozzle valve (Figure 1).

Effective Column Packing
Contained Operation
All column operations are performed in a closed system;
therefore, there is less risk of the operator coming into
contact with hazardous materials or the process being
exposed to contamination. This results in improved safety
and hygienic operation of the column process.

Nozzle valve in run position

Reproducibility
By eliminating labor intensive column handling operations,
the packing parameters can be set and applied within
a standard operating procedure. This improves the
reproducibility of the packed column performance.

Scalability
All design elements within the column mobile phase flow
path are maintained throughout the range (up to 2000 mm
diameter). Unlike conventional columns that are based on
different seal and distributor cell designs as size increases,
the Resolute column sealing arrangement and flow path
follow a single design principle that delivers proven and
consistent column performance.

Nozzle valve in unpack position

Reduced Process Validation
Resolute columns and packing systems maintain identical
linear velocities and pressure profiles during the packing
process, whether in a 400 mm pilot-scale column or a
2000 mm process-scale column. Using the same packing
methods reduces the effort required during preparation
of standard operating procedure (SOP) for large-scale
manufacturing packing methods.
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Optimized for Efficiency and Scale Up

Consistent Chromatography Performance

Resolute columns are equipped with Pall’s proprietary
high resolution mobile phase flow path which consists of
a mobile phase flow path within the nozzle valve body,
distribution end cells, and a fully flushed piston seal
arrangement. The performance of these important column
components is essential for optimal process efficiency,
capacity, and peak symmetry.

Resolute columns’ high resolution mobile phase flow path
enables operation at high linear velocities up to 1000 cm/h.
The flow distribution cells and mobile phase flow path
support near plug flow conditions irrespective of column
diameter. Figure 3 shows pressure flow curves for
Resolute columns and alternative manufacturers’ columns.
The columns were filled with water, and pressure and flow
instruments were used to measure pressure drop across
the filled column under process flow conditions. Resolute
columns exhibit identical pressure flow curves, linear up
to 1000 cm/h, at which the pressure drop is 0.1 barg
(1.5 psig). Alternative column designs exhibit high,
exponential pressure flow curves. During normal operations,
actual pressure drop will be the sum of the value shown
below and the additional value from the packed bed.

Resolute columns maintain identical design parameters
throughout both the standard column range (from 280 mm
to 1200 mm diameter) and the larger capacity columns (up
to 2000 mm diameter). Operation at high linear velocities
is free from non-linear column effects and assures true
linear scalability of column performance, enabling users to
scale up simply without method redevelopment or impact
on the reproducibility of the packing process.
Key flow path features:
!

Nozzle valve mobile phase path delivers consistent low
pressure drop across column for true linear scale up.

!

Distribution with coned end cell channels provides near
plug flow conditions.

!

Secondary cone on support ribs provides unimpeded
route via top central nozzle for simple and effective
removal of entrapped air as well as effective recovery of
slurry via bottom central nozzle when unpacking.

!

Nozzle tip retracts flush with bed support with no
protrusion into packed bed.

Figure 2
High resolution mobile phase flow path

Resolute columns support true linear scale up of both the
purification performance and column packing methods:
!

Elimination of non-linear interference from column
design enables monitoring of actual column pressure
resulting from media bed properties.

!

Pressure versus bed height relationship for a specific
media, packed at the same compression, remains
constant up to at least 1000 cm/h linear flow in any
diameter of Resolute column.

Figure 3
Pressure vs. flow for Resolute columns and alternative
columns fitted with stainless steel mesh bed supports
(column Ø mm)
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Designed for Durability, Reliability, Versatility
and Ease of Use

Figure 5
Manual nozzle

Resolute columns are available in diameters from 280 mm
to 1200 mm, with 200 mm bed height adjustment and
choice of bed heights up to 600 mm. Alternative bed
height adjustment and diameters up to 2000 mm are
available on request. Resolute manual columns feature:
!

Manually operated nozzle valves. (See column options
for pneumatically-actuated nozzle valves.)

!

Choice of bed supports in polyethylene or 316L
stainless steel.

!

Acrylic column tube provides visibility of the packed bed.

!

Simple, constant compression, adjuster seal, and
precision bore eliminate need for additional mechanical
or pneumatic activation of adjuster seals.

!

Stainless steel support frame equipped with lockable
castors (available up to 1000 mm column).

Figure 4
Resolute manual 1000 mm internal diameter (ID) column

Column Options
!

Remote controlled pneumatic nozzle valve: a pneumatic
actuator positions the nozzle to pre-set positions (Run,
Pack, Unpack) with pneumatic controller and position
feedback for increased process security. (Not available
on 280 mm column.)

!

Bed supports are available in stainless steel (10/20/50 µm)
and polyethylene (10/20/60 µm), which offers a lowercost alternative when frequent bed support changes
are required.

!

Robust stainless steel column tube with increased
chemical compatibility. (Not available on 280 mm column.)

!

Fixed bed capacity with no bed height adjustment
available for media-specific or process requirements.

!

Extended adjuster range (300 mm) adds packing flexibility.

Figure 6
Remote controlled pneumatic nozzle

Sanitary Design
Sanitary design features ensure the longevity, consistency,
and reliability of your process:
!

Fully flushed flow path and adjuster seal facilitate
clean-in-place (CIP).

!

Minimum dead space fixed cell seal arrangement.

!

Non-metallic mobile phase flow path is ideal for high
salt, low pH conditions, and eliminates the risk of
corrosion within the nozzle valve.

!

Phthalate-free acrylic tube and peroxide-cured EPDM
(ethylene-propylene-diene monomer) seals.

!

Low-profile central nozzle retaining ring on the bottom
bed support reduces media hold-up during unpacking.

Valve control

Valve actuator
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Column Specifications
Maximum allowable pressure

280 mm Ø column: 5.0 barg (72.5 psig); 400 –1200 mm Ø column: 4.2 barg (60.9 psig)

Operating temperature

2 – 30 ºC

Bed support type and rating

Stainless steel mesh: 10, 20, 50 µm; Polyethylene sinter: 10, 20, 60 µm

Stainless steel surface finish

Product flow path:
Exterior components:
Pressure retaining plates:
Column frame:

Adjuster seal

Precision bore with compression seals

Media transfer nozzle

Manual or pneumatic remote controlled

< 0.6 µm Ra, electropolished
< 0.9 µm Ra, electropolished
< 1.5 µm Ra, 240 (UK) grit sateen
bright polished

Materials of Construction
Process Wetted Components

Material

Column tube

Acrylic

Distribution cell

Polypropylene

Nozzle body

280 –1000 mm Ø column: polyvinylidene fluoride (PVDF); 1200 mm Ø column: polypropylene

Mobile phase termination

280 –1000 mm Ø column: polyetheretherketone (PEEK); ≥1200 mm Ø column: stainless steel 316L

Slurry nozzle tip

PEEK

Slurry inlet port

280 mm Ø column: PEEK; 400 –1200 mm Ø column: stainless steel 316L

Bed support

Polyethylene sinter or stainless steel mesh

Main seals

EPDM (peroxide cured)

Nozzle tip seals

Fluorinated ethylene propylene (FEP) encapsulated silicone

Wiper ring

Polytetrafluoroethylene (PTFE)

External Components
Stand

Stainless steel 316L

Castor

Stainless steel 304L

Wheel

280 –600 mm Ø column: polyurethane; 800 –1000 mm Ø column: nylon

Foot

1200 mm Ø column: stainless steel 316L

Design
The basis of design for Resolute columns is PD5500. Columns, where applicable, are CE marked in accordance with the
European Pressure Equipment Directive 97/23/EC.
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Port Sizes and Pressure Flow Kit (PFK)
Below are the termination sizes for the column and PFK, and a schematic showing the scope of the column PFK kit. All
connections are sanitary Tri-Clamp! connections with EPDM gaskets. PFK kits are available to complement the standard
columns and are also available within an 8 weeks lead time.
Note that the standard PFK does not include sight glasses.
Figure 7
Scope of column PFK kit and termination sizes for column and PFK
G1

Mobile
phase
upper

PI

Slurry inlet
upper
NV3

Slurry waste
upper

TC1
NV2

NV1

BD1
TC2

Hard pipe
Flexible hose
Tri-Clamp
connections
Burst disk

Resolute Manual Column

H1

PI

Pressure gauge
2-way diaphragm
valve (manual)
Sight glass
(applicable only
to steel tubed
columns)

TC3
NV4

NV5

TC4

NV6

Slurry waste
lower

Mobile
phase
lower

Column Ø
(mm)

Slurry inlet
lower

Nozzle Valve Termination Size*
NV1

NV2

NV3

NV4

NV5

NV6

Pressure
Gauge

Burst
Disk

Block Valve Termination Size*

Flexible
Hose Size*

Wika!:
233.50

BS&B:
GCR-S!

GEMU! 3-Way Manual Diaphragm Valve
673 / 671 Bonnet

Pharmaline!

G1

BD1

TC1

TC2

TC3

TC4

H1

300

0.5 in. 0.5 in. 0.5 in. 0.5 in. 0.5 in. 0.5 in. 1.0 in.

1.0 in.

0.5 in.

0.5 in.

0.5 in.

0.5 in.

0.5 in.

400–450

0.75 in. 0.75 in. 0.75 in. 0.75 in. 0.75 in. 0.75 in. 1.0 in.

1.0 in.

0.75 in.

0.75 in.

0.75 in.

0.75 in.

0.75 in.

600–630

1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in.

1.0 in.

1.0 in.

1.0 in.

1.0 in.

1.0 in.

1.0 in.

800–1000

1.5 in. 1.5 in. 1.5 in. 1.5 in. 1.5 in. 1.5 in. 1.0 in.

1.5 in.

1.5 in.

1.5 in.

1.5 in.

1.5 in.

1.5 in.

* (ASME BPE standard)
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Chemical Compatibility
Substance/Concentration
Acetic acid < 1 M
Ethanol < 40% (v/v)
Benzyl alcohol < 2% (v/v)
Isopropyl alcohol < 30% (v/v)
Hydrochloric acid 0.1 M
Nitric acid 0.1 M
Phosphoric acid 25%
Sodium chloride < 2 M
Sodium hydroxide < 2 M
Triton! X-100
Guanidine HCl < 6 M
Urea < 8 M
+ Compatible

Acrylic
+
+
•
+
+
+
+
+
+
+
+
+

SS
+
+
+
+
•
+
•
•
+
+
•
+

PVDF
+
+
+
+
+
+
+
+
+
+
+
+

PP
+
+
+
+
+
+
+
+
+
+
+
+

EPDM/FEP
+
+
+
+
+
+
+
+
+
+
+
+

PE
+
•
+
+
+
•
•
+
+
+
+
+

PEEK
+
+
+
+
+
+
+
+
+
+
+
+

PTFE
+
+
+
+
+
+
+
+
+
+
+
+

• Conditional compatibility; contact Pall for details

Abbreviations: EPDM = Ethylene propylene di-monomer, FEP = Fluoroethylene polymer, PE = Polyethylene, PEEK = Polyether ether ketone, PP = Polypropylene,
PTFE = Polytetrafluoroethylene, PVDF = Polyvinylidene fluoride, SS = Stainless steel

Installation and Validation Documentation

Additional Column and Equipment Needs

Resolute columns are supplied with a comprehensive
validation and support package including an operator’s
manual. The validation support package contains
comprehensive protocols and provides the required
documentation and procedures to support factory
acceptance test (FAT), installation qualification (IQ) and
operational qualification (OQ). To support validation efforts
and efficient commissioning, the documentation includes
records of the pre-shipment test results.

!

Column maximum allowable pressure up to 10 barg
(145 psig)

!

Pressure vessel certification to ASME

!

Alternative column diameters may be specified
(440 and 700 mm) up to 2000 mm

!

Electric actuation of adjustable end cell (not available on
280 mm column)

!

Fully automated AutoPak systems for packing, unpacking,
repacking and CIP

!

Integrated column maintenance assist system
(not available on 280 mm column)
Automated column packing systems

Column manual documentation includes:
!

Operating guide

!

Materials and compatibility data

!

Comprehensive parts list

!

!

Spare parts recommendation

!

Maintenance recommendation

Figure 8
Resolute slurry packing system

Packing Station
Resolute slurry packing systems (SPS) simplify column
packing and unpacking operations. Two system capacity
options provide flow rates suitable for packing and
unpacking columns up to 1200 mm diameter (2000 mm
columns are also supported). Complete column packing
solutions for Resolute columns include:
!

Resolute SPS with optional control module for remote
operation of slurry and buffer tank valves

!

Media preparation system

!

Hose kits for connection of column, system, and tanks

!

Pressure and flow monitoring

!

Media and buffer tanks ready for use with Resolute
columns and SPS systems
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For more information on the Resolute slurry packing system, contact your
local Pall representative or visit www.pall.com/biopharm.

www.pall.com/biopharm

Columns Available Within 8 Weeks Lead Time
The following standard columns are available within 8 weeks from the point of receipt of purchase order.

Ordering Information
All columns are acrylic tubed, with manual nozzles and a stroke length of 100–400 mm. Different diameter and bed height
ranges are available on request.
Part Number

Resolute Column Ø (mm)

Mesh Material

Mesh Pore Size (µm)

M-DM0301040AP10

300

PE*

10

M-DM0301040AP20
M-DM0301040AS10

20
300

SS 1.4404*

M-DM0301040AS20
M-DM0401040AP10

400

PE

M-DM0401040AP20
M-DM0401040AS10

400

SS 1.4404

450

PE

450

SS 1.4404

600

PE

600

SS 1.4404

630

PE

630

SS 1.4404

800

PE

800

SS 1.4404

10
20

1000

PE

M-DM1001040AP20
M-DM1001040AS10

10
20

M-DM0801040AS20
M-DM1001040AP10

10
20

M-DM0801040AP20
M-DM0801040AS10

10
20

M-DM0631040AS20
M-DM0801040AP10

10
20

M-DM0631040AP20
M-DM0631040AS10

10
20

M-DM0601040AS20
M-DM0631040AP10

10
20

M-DM0601040AP20
M-DM0601040AS10

10
20

M-DM0451040AS20
M-DM0601040AP10

10
20

M-DM0451040AP20
M-DM0451040AS10

10
20

M-DM0401040AS20
M-DM0451040AP10

10
20

10
20

1000

SS 1.4404

M-DM1001040AS20

10
20

* PE = Polyethylene; SS 1.4404 = Stainless steel 1.4404

Pressure Flow Kit (PFK)
Part Number

Applicable Column Diameter (mm)

Part Number

Applicable Column Diameter (mm)

M-PFK-030

300

M-PFK-063

630

M-PFK-040

400

M-PFK-080

800

M-PFK-045

450

M-PFK-100

1000

M-PFK-060

600
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Column Accessories
!

Endcell rotation frame for safe maintenance procedures
(suitable for Resolute 400 to 1200 mm Ø columns)

!

Column transportation system

!

Bed support transportation device for safe and secure
handling

!

Column spanner set (metric)

!

Packing flow kit

Contact Pall for details.

Services
Pall has the resources necessary to help our customers
maintain Pall systems and columns for optimum
performance and maximum service duty. This includes
comprehensive service maintenance programs, validation
services, and training packages such as:
!

Factory acceptance testing

!

Site acceptance testing

!

Installation and commissioning

!

IQ/OQ documentation and execution

!

Operator training (on-site or in a Pall facility)

!

Planned maintenance programs

!

Applications support and packing assistance

!

Packing studies conducted at one of Pall’s
chromatography application laboratories.

Contact Pall for details.
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www.pall.com/biopharm

Chromatography Process Solutions From Pall
Fully Automated Unit Operations with Pall Resolute
Linear Columns with AutoPak Functionality
The Resolute linear column
range offers a unique
combination of active multiaxis piston control, precision
linear actuation, and fully
automated unit operations.
Building upon the proven
Resolute linear column
functionality, the AutoPak
system is a combination of
hardware and software that
automates three of the key unit operations necessary in
process chromatography. These key unit operations,
particularly packing, can be regarded as labor intensive,
high risk events. The risks include human error, packing
failure and the possible absence of experienced operators
which can result in plant downtime, loss of product or
sorbent, and inefficient use of resources.
By adopting a full automation approach, AutoPak
functionality greatly simplifies operation, effectively
eliminating operator error during sequence execution and
reducing the burden on key operators. The automated
sequences assure that reproducible, consistent operation
is the norm.
Key features of the AutoPak system:
!
!
!

!

Ability to pack all the slurry in the tank, eliminating
sorbent carry over or wastage
Simple operator orientated operation for packing,
unpacking, and CIP
Simplified set-up, departing from traditional pump
pack methods for quicker turnaround of packing and
unpacking operations
Consistent operation and reproducible results

PK and PKP Chromatography Systems
The PK and PKP chromatography
systems range incorporates
proven component technology
that delivers accurate
precision gradients and
in-line buffer dilution. It
maintains the performance
necessary to make your
chromatography process
consistent from batch-tobatch and optimal at pilot
and manufacturing scales.
Covering a range from 1 to greater than 4000 L/h, PK and
PKP systems ensure robust operation and flexibility for all
biochromatography applications.
These systems can be used with Resolute chromatography
columns as well as Mustang® membrane adsorber products.
Chromatography Sorbents
Pall offers a comprehensive,
versatile, and environmentally
friendly range of chromatography sorbents that greatly
simplifies protein purification
challenges from lab to process
scale. Pall chromatography
sorbents can improve
downstream purification
accuracy, speed, safety,
and reliability, and decrease purification costs. Sorbent
chemistries include ion exchange, mixed-mode, affinity,
hydroxyapatite and solvent detergent removal.

Visit us on the Web at www.pall.com/biopharm
E-mail us at biopharm@pall.com
Corporate Headquarters
Port Washington, NY, USA
+1 800 717 7255 toll free (USA)
+1 516 484 5400 phone
biopharm@pall.com e-mail
European Headquarters
Fribourg, Switzerland
+41 (0)26 350 53 00 phone
LifeSciences.EU@pall.com e-mail
Asia-Pacific Headquarters
Singapore
+65 6389 6500 phone
sgcustomerservice@pall.com e-mail

International Offices
Pall Corporation has offices and plants throughout the world in locations such as:
Argentina, Australia, Austria, Belgium, Brazil, Canada, China, France, Germany,
India, Indonesia, Ireland, Italy, Japan, Korea, Malaysia, Mexico, the Netherlands,
New Zealand, Norway, Poland, Puerto Rico, Russia, Singapore, South Africa, Spain,
Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, the United States, and
Venezuela. Distributors in all major industrial areas of the world. To locate the Pall
office or distributor nearest you, visit www.pall.com/contact.
The information provided in this literature was reviewed for accuracy at the time of
publication. Product data may be subject to change without notice. For current
information consult your local Pall distributor or contact Pall directly.
© 2017, Pall Corporation. Pall,
, Mustang and Resolute are trademarks of Pall
Corporation. Filtration.Separation.Solution is a service mark of Pall Corporation.
! Triton is a trademark of The Dow Chemical Company. Tri-Clamp is a trademark of
Alfa Laval. WIKA is a trademark of WIKA Alexander Wiegand GmbH. GCR-S is a
trademark of BS&B Safety Systems LLC. GEMU is a trademark of Gebruder Muller
Apparatebau GmbH. Pharmaline is a trademark of Aflex Hose Ltd. ® indicates a
trademark registered in the USA.
9/17, PDF, GN17.10014
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M-7125, M-7250 Aseptic BioPharmaceutical
Microfluidizer® Processor

TB-BP7.A-1

Key features
• Up to 15 lpm (4.0 gpm) flow
rates at 690 bar (10,000 psi)
• 7.5 lpm product flow (2.0 gpm)
at 1,379 bar (20,000 psi)
• 4 lpm product flow (1.0 gpm)
at 2,068 bar (30,000 psi)
• Low product holdup volume
(<1 liter)
• Small batch capable
(minimum 12 liters)
• Complete package unit
including motor starter panel
and process interlocks
• All product paths are sanitary
grade and BPE compliant
• All instruments and valves are
anitary grade, BPE compliant
• On board data acquisition for
complete batch record audit trail

Model shown is subject to change depending on options selected

M-7125 and M-7250 Aseptic Microfluidizer
Processors Provide Superior Results For Pilot
and Production Environments
Recommended for sterile processing

• Multi-point temperature
sensing for assured SIP process

Nano-emulsions (with and without API)

• On board flow meter to measure
product and CIP flow rates

Microencapsulation

• Ultra Clean In Place (UCIP)
using supplied feed pump or
your CIP system pump

Cell disruption

• PID control of process chilled
water for product temperature
management
• Factory Acceptance Testing (FAT)
• Complete document turn over
package for validation support
including IQ/OQ, materials
certifications and calibrations
• On site start-up assistance,
operator and maintenance
training, SAT and IQ/OQ
execution by our technical staff

Nano-dispersions
Deagglomeration

Key benefits
Guaranteed scale up from lab and pilot Microfluidizer processors
Validatable sterility that always passes Sterile Fill Test
Easy to operate with simple manual controls
Easy to maintain with most maintenance points easily accessed
Highly secure batch records, 21 CFR Part 11 compliant
CIP process with no equipment takedown
Thermally sensitive materials processed safely
More efficient processing, usually requiring fewer passes than other
processing machinery
Batch to batch process reproducibility assured

Since 1984, Microfluidics has provided life
sciences and formulation scientists with
critical tools used in the development and
production of pharmaceutical formulations
and recombinant technologies. High shear
fluid processing, Microfluidics’ proprietary
technology, uniformly reduces droplet and
particle size to enable the production of
stable nano-emulsions, nano-suspensions,
liposomes and the nano-encapsulation
of actives. In addition it offers the most
efficient method for disruption of yeast,
E.coli, plant and mammalian cells.

Specifications
M-7125
Pressure Range

Cell Disruption for
Biotechnology
From the gentle disruption of cultured cells for
virus isolation to the challenging disruption
of yeast and other fungi, Microfluidics
offers technologies to meet the variable and
demanding needs for cell membrane disruption.
This technology provides exacting process
control for highly reproducible and efficient
cell breakage while keeping temperatures under
precise control to prevent denaturing.

Getting To Full Production
Results obtained on all laboratory units
will scale up easily and in a linear manner
to production volumes when the same
operating conditions are employed.
Asceptic Microfluidizer processors include
Steam in Place (SIP) and Ultra Clean In
Place (UCIP) eliminating the need for
disassembly and Clean Out of Place (COP).
Data recording and validation support
documentation including IQ/OQ is included
to ensure your ability to comply with 21CFR
part 11 guidelines.

Up to 689, 1379, or 2068 bar (10,000, 20,000 or 30,000 psi)

Product Flow Rate

Up to 7.56 lpm (2.0 gpm)

Product Feed
Temperature Range
Utility Requirements

Up to 15.12 lpm (4.0 gpm)

-10ºC to 75ºC (14ºF to 165ºF)

Power Requirement
•
•
•

Discovery to
Commercialization
As a result of recent advances in high
throughput screening and drug discovery, many
new chemical compounds have been identified
as possible drug candidates. Unfortunately,
many of these compounds show poor water
solubility and often are only marginally soluble
in oil-based solvents. The ultrahigh shear
force developed by Microfluidizer processors
solves this problem by reducing the particle
size of active pharmaceutical ingredients to
therapeutically relevant sizes that enables the
production of drug products with improved
bioavailability and stability.

M-7250

•
•

18.6 kw (25 hp)
37.3 kw (50 hp)
Cooling water for hydraulic oil heat exchanger, preferably tower or city
water
Cooling water for product heat exchanger, preferably chilled water loop
3
Compressed air for feed pump and cycling control switches requires
0.65 m /min @ 6.2 bar (23 scfm @ 90 psi) with -37º C to –18º C
(-35º F to 0º F) dew point
Sterile steam 22.6 kg/hr @ 2.4 bar (50 lbs/hr @ 35 psi) minimum
Sterile compressed air for product path cool/dry down, 0.085 m 3/min @ 1
bar (3 scfm @ 15 psi)

Dimensions (L x W x H)*

272 x 161 x 211 cm (107” x 63.3” x 83”)

Weight with oil*

1,592 kg (3,510 lbs)

*all weights and dimensions are approximate

Aseptic Package Includes
• Steam In Place (SIP) with multiple RTDs to assure complete sterilization
• Ultra-Clean-In-Place (UCIP)
• Heat exchanger with product temperature control, pharma grade, double
tubesheet style
• Flow meter for batch monitoring and validation
• Yokogawa data acquisition station for temperatures, pressures and flows
• Product wetted surfaces at 20Ra max
• IQ/OQ documentation and execution
• Factory Acceptance Testing (FAT) and Site Acceptance Test (SAT)
• Feed pump, sanitary cGMP grade
• 21 CFR part 11 compliant for electronic signature and batch record keeping
• Motor starter panel with machine and process interlocks
• CE compliant

Available Options

• Motor voltage as needed
• ATEX compliant version available
• Explosion proof (XP) version available

Global Headquarters
90 Glacier Drive, Suite 1000
Westwood, MA 02090 USA
Tel: 1-800-370-5452 or: 617-969-5452
Fax: 617-965-1213
e-mail: mixinginfo@idexcorp.com
www.microfluidicscorp.com

European Office

Bramley Drive, Vale Park West,
Evesham, Worcestershire, WR11 1JH, UK
Tel: (+44) (0) 1386 769 007
Fax: (+44) (0) 870 1911116
Email: mixinginfo@idexcorp.com
www.microfluidicscorp.com

© 2009 by Microfluidics. All rights reserved. Printed in U.S.A. on
recycled FSC certified stock using vegetable based inks. 12/13 CDI .2K

BIOSTAT ® RM and Flexsafe® RM
for Seed Production and
Small-scale Protein Supply

BIOSTAT ® RM and Flexsafe® RM Bags
The BIOSTAT ® RM, a fully GMP compliant, single-use, wave-mixed
bioreactor and Flexsafe® bags are proven for a broad range of different
cell lines incl. CHO, NS0, SF9, E.coli and mesenchymal stem cells.
Benefit from our excellent global application support and
technical service and get started right away.

Process Step
– Protein and cell supply for
preclinical purposes
– Seed production for large
bioreactors
– GMP production

Cells
– Mammalian, insect and
plant cells
– Suspension cells and
adherent cells
on microcarriers
– Low to medium density
microbial cultures
– Shear sensitive cells such
as stem cells

Purpose

Volumes

– Scale-up from shake
– 100 mL to 100 L culture
or T-flasks
volume
– Rapid material supply
– Two rocker sizes: 20/50
for pre-clinical trials
and 200
– Expansion and differentiation of stem cells
– Production of recombinant
proteins, mAbs and vaccines
– Continuous cultures with
reported cell densities
of 150 million cells/mL

Excellent Cell Growth
and Robustness

Security of Supply &
Consistent Quality
Easy-to-use Rocker
with Advanced
Control Capabilities

New

Bag Family

Use our Flexsafe® RM bags in your seed train and scale-up to our BIOSTAT STR®
single-use stirred tank bioreactors equiped with Flexsafe STR® bags. Benefit
from the same polyethylene film material across all your cell culture steps.
Our Flexsafe® RM bags fit on rocking motion bioreactors from several manufacturers.
Benefit from excellent cell growth, robustness and unprecedented assurance of supply.

Cell Growth

Cell Density

Flexsafe® ensures an excellent and reproducible growth behavior with the most sensitive
production cell lines. The complete control of our raw materials, the extrusion process and
the bag assembling guarantees consistent lot to lot cell growth performance.
To ensure consistent cell growth performance,
we optimized the resin and minimized the
additive package in collaboration with our resin
and film suppliers.

Reference: Borosilicate Glass
Flexsafe® Bags
Standard Bags

Time

The bags are proven to be free of cytotoxic
leachables by independent labs. No bDtBPP
identified in WFI extract of Flexsafe® bags.

Robustness
The thickness, strength and flexibility of the new
polyethylene film enhances the mechanical
robustness of Flexsafe®, making it ideal for all bioprocessing applications. The strength of Flexsafe®
significantly reduces the risk of accidental damage
to the bag due to inappropriate handling. Its
flexibility enables convenient installation and
self-deployment of the bag in its container.

Bag A
Bag B
Bag C
Flexsafe®
Energy at Break

Assurance of Supply

Flexsafe® provides you with an unprecedented assurance of supply and enables
robust business continuity plans. Our
strategic partnership with resin and film
suppliers ensures full traceability of raw
materials and control over the entire
manufacturing process from the resins
to the final assembled bags.

Watch Video:
www.sartorius.com/video-flexsafe

New Bag Family

– 10-year contract with the film
manufacturer
– Last time buy option for minimum
of 2 years resin demand
– Up to 2 years safety stock of film
– Multiple manufacturing sites

One for All
1L

Flexsafe® RM

200 L

Designs
The bags come in 7 different sizes supporting working volumes from 100 mL up to 100 L.
Standard designs are available from stock.
Basic Bag
For cultivation under constant conditions without
pH and DO control for seed train
With single-use pH and DO sensors installed
in bag for advanced applications
With integrated perfusion membrane, fixed at the
bottom of the bag, for continuous processing with
low membrane fouling and long cultivation times
With single-use viable biomass sensors
(BioPAT® ViaMass)
Available with screw caps for bulk additions
Customized bag designs
Can be used on competitor systems

Optical Bag

Perfusion Bag

•
•

•
•

•

•

•

•
•
•

•
•

•
•

ne for All

BIOSTAT ® RM 20 | 50 Basic
The BIOSTAT ® RM 20 | 50 basic is a perfectly
sized, stand-alone bioreactor for benchtop use. It features an exchangeable bag
holder to fit bags from 1 L to 50 L total
volume. The BIOSTAT ® RM basic rocker with
integrated local controller, Air | CO2 mixing
module and load cells is the optimal choice
for straight forward applications such as
seed generation.
– Space-saving, individual control of two
bags on the same platform
– Advanced alarming and safety features
for safe cultivation
– Reduced manual handling via automated
sampling function

Advanced Control System
Do you want to run fully automated and controlled batch, fed-batch or high cell density
perfusion cultures? Combine your basic rocker with our BIOSTAT ® B control tower and use
Flexsafe® RM bags equiped with single-use pH, DO and now also viable biomass probes.
– Advanced control of gas mixture and flow rate, filling volume and substrate addition
– Extra small space requirement with TWIN configuration – two culture systems
controlled by one controller at the same time

Your BIOSTAT ® B controller is designed to work with a conventional glass vessel,
the single-use UniVessel® SU and the RM rocker, making it a real multi talent.
It allows you to use the same controller platform for research purposes, process
development and preclinical supply.

Watch Video:
www.sartorius.com/video-biostat-b

NEW BioPAT ® ViaMass* –
single-use biomass sensor
for non-invasive measurement of viable biomass. BIOSTAT ® RM is the only rocking motion
bioreactor with inline single-use biomass monitoring.
– Reduce your contamination risk by using inline single use cell growth monitoring,
e.g. in cell therapy or other critical applications

* Manufactured under license from HAMILTON.

BIOSTAT ® B with RM 200 Rocker
The system consists of the BIOSTAT ® RM 200 Rocker, BIOSTAT ® B control tower on lab-cart
and Flexsafe® RM cultivation bag. It is your choice for larger scale seed expansion and
production of material for preclinical and clinical studies. It supports working volumes
from 10 L up to 100 L. Together with our proven BIOSTAT ® B control tower, flexible
process strategies can be enabled.

– Low consumable costs compared to stirred single-use
bioreactors
– Reliable single-use probes
for measurement of pH,
DO and viable biomass

– Designed for automated
batch, fed-batch and
perfusion processes using an
external cell retention unit
– Flexible arrangement of
control tower and rocker
unit on individual trolleys

Technical Specifications
Flexsafe® RM Bags
Total Volume (L)

1

2

10

20

50

100

200

Working volume (L)*

0.1– 0.5

0.2 –1

1– 5

2 –10

5 – 25

10 – 50

20 –100

•

•

•

•

•

•

•

Bag Types
Basic

•

•

•

•

Basic and optical with screw cap

•

•

•

•

Optical

•

•

•

•

Perfusion with integrated membrane

•

•

•

•

Perfusion with connection to ATF** System

•

•

•

•

•

•

•

Basic, optical, perfusion & perfusion ATF
with ViaMass
Main Components

Basic

Optical

Perfusion

Connectors

Female | Male Luer
Female | Male MPC

Female | Male Luer
Female | Male MPC

Female | Male Luer
Female | Male MPC

Filters

Air Inlet | Air Outlet

Air Inlet | Air Outlet

Air Inlet | Air Outlet

Ports

Sampling
Fill | harvest with
dip tube
Acid | Base

Sampling
Fill | harvest with
dip tube
Acid | Base

Sampling
Fill | harvest with dip tube
Acid | Base
Perfusion feed | harvest

Sensors

–

Optical chemical pH
Optical chemical DO
Single-use viable
biomass

Optical chemical pH
Optical chemical DO
Single-use viable biomass

Perfusion

–

–

Perfusion membrane PES 1.2 µm | Opta
aseptic connector to ATF** System

Tubing material

C-Flex®*** 374, Silicone, PharMed®*** Natvar ABL-1222 TPE

Material of the bag

Contact layer: LLDPE | gas barrier: EVOH | outer layer: LLDPE

Production conditions

Cleanroom environment of at least ISO 8

Biological reactivity

USP for plastics Class VI

Sterility

ISO 11137 – sterility assurance level (SAL) of 10-6

TSE/BSE status

Compliant to EMA410/01/rev.3 guideline

Endotoxin

USP<85> for sterile water for injection; < 0.25 EU/ml

Irradiated

25 – 40 kGy

*
()
**
***

Bags with sensors might require higher minimum working volumes depending on rocking rate and angle.
– optional, needs to be ordered separately
ATF cell retention system from Repligen
C-Flex® and PharMed® are registered trademarks of Saint-Gobain Performance Plastics Corporation.

Ordering Information
Flexsafe® RM

Basic
Basic ViaMass

Basic screw cap
Optical screw cap

Optical
Optical ViaMass

Perfusion
Perfusion ViaMass

Perfusion ATF
Perfusion ATF ViaMass

1L

DFB001L
–

–
–

–
–

–
–

–
–

2L

DFB002L
–

DFB002L----01SC
DFO002L----01SC

DFO002L
–

DFP002L--SM
–

DFP002L--AT
–

10 L

DFB010L
DFB010L----VM

DFB010L----01SC
DFO010L----01SC

DFO010L
DFO010L----VM

DFP010L--SM
DFP010L--SMVM

DFP010L--AT
DF010L--ATVM

20 L

DFB020L
DFB020L----VM

DFB020L----01SC
DFO020L----01SC

DFO020L
DFO020L----VM

DFP020L--SM
DFP020L—SMVM

DFP020L--AT
DFP020L--ATVM

50 L

DFB050L
DFB050L----VM

DFB050L----01SC
DFO050L----01SC

DFO050L
DFO050L----VM

DFP050L--SM
DFP050L—SMVM

DFP050L--AT
DFP050L--ATVM

50 L *

DFB050L----01US

–

–

–

–

100 L

DFB100L
–

–
–

DFO100L
–

–
–

DFP100L--AT
–

200 L

DFB200L
–

–
–

DFO200L
–

–
–

DFP200L--AT
–

* alternative dimension – 740 + 720 mm – suitable for competitor rockers

Technical Specifications
Facility and Utility Requirements
BIOSTAT ® RM 20 | 50
Basic

BIOSTAT ® B
with RM 20 | 50 Rocker

BIOSTAT ® B
with RM 200 Rocker

Power Supply (Country Specific) | Frequency | Electricity | Consumption | Protection Class
Rocker platform

100 (240 V) | 60 (50) Hz |
600 W | IP23

100 (240) V | 60 (50) Hz |
600 W | IP23

120 (230) V |
60 (50) Hz | 10 (5.2) A |
1200 W | IP21

Control Tower

–

230 V | 50 Hz | 10 A | IP21
or
120 V | 60 Hz | 12 A | IP21

230 V | 50 Hz | 10 A | IP21
or
120 V | 60 Hz | 12 A | IP21

Load cells

100 – 240 V | 15 W

100 – 240 V | 15 W

Inlet pressure (barg)

1.0 –1.5

1.0 –1.5

1.0 – 1.5

Quick coupling for gas tubes,
Festo Type

d 4 mm

(d 6 mm)

(d 6 mm)

Connection hose coupling, external

–

d 6 mm

d 6 mm

Gas Supply

Gas Specification According to ISO 8573-1: dry, free of oil and dust
Particle size: < 0.1 mm

•

•

•

Max. amount 0.1 mg/m (class 1)

•

•

•

Condensate: dew point < 3°C (class 4)

•

•

•

Oil < 0.01 mg/m (class 1)

•

•

•

Germs (class 0)

•

•

•

Water supply pressure (barg)

–

2–8

2–8

Connection hose coupling, external

–

d 10 mm

d 10 mm

Cooling water
(for heating | cooling system only)

–

(•)

(•)

Temperature

–

min. 4°

min. 4°

Degree of hardness

–

max. 12 dH

max. 12 dH

3

3

Water

Operative Environment
Ambient temperature

5-40°C

Relative humidity range

50% (40 °C) – 80% (31°C)

System Characteristics
Weight

Material

BIOSTAT B Control Tower Single | Twin 410 + 520 + 810 mm
16 + 20 + 32 in

40 | 55 kg
88 | 121 lbs

Stainless steel AISI 304

BIOSTAT ® RM 20 Rocker complete

765 + 600 + 510 mm
30 + 24 + 16 in

30 kg
66 lb

Stainless steel, ABS

Bag holder 20

765 + 600 + 60 mm
30 + 24 + 2.4 in

5.5 kg
12 lb

Stainless steel, ABS

Lid 20

765 + 600 + 255 mm
30 + 24 + 10 in

2.5 kg
5.5 lb

ABS

BIOSTAT ® RM 50 Rocker complete

1085 + 600 + 510 mm
43 + 24 + 18 in

31.3 kg
69 lb

Stainless steel, ABS

Bag holder 50

1085 + 600 + 60 mm
43 + 24 + 2.4 in

7.8 kg
17 lb

Stainless steel, ABS

Lid 50

1085 + 600 + 255 mm
43 + 24 + 10 in

3.7 kg
8 lb

ABS

Load cells for BIOSTAT ® RM 20 | 50

609 + 536 + 60-68 mm
24 + 21 + 2.4 – 2.7 in

9 kg
20 lb

Stainless steel, ABS

BIOSTAT ® RM 200 Rocker
in 45° transport position

1940 + 905 + 1285 mm
77 + 36 + 51 in

197 kg
434 lb

Stainless steel, ABS

BIOSTAT ® RM 200 Rocker
in horizontal position

1940 + 1080 + 1155 mm
76 + 43 + 46 in

197 kg
434 lb

Stainless steel, ABS

Lab-cart

800 + 800 + 900 mm
32 + 32 + 36 in

88 kg
194 lb

Stainless steel

Dimensions W + D + H
®

Process Control
BIOSTAT ® RM 20 | 50
Basic

BIOSTAT ® B
with RM 20 | 50 Rocker

BIOSTAT ® B
with RM 200 Rocker

Temperature Module
Heating Only - Electrical Heating Plates
Temperature control

RT-40°C

RT-40°C

RT-40°C

Heating capacity

2 + 140 W (48 V)

2 + 140 W (48 V)

2 + 410 W

Heating | Cooling (Option) - Open Thermostat System with Circulation Pump and Automatic Cooling Water Valve
Temperature control

–

8°C above cooling water
up to 40°C

(8°C above cooling water
up to 40°C)

Heating capacity

–

1 + 600 W

2 + 600 W

Over temperature protection

•

•

•

Max. total flow (ml/min)
Controlled by MFC

One bag: 1 + 1 lpm
Twin bag: 2 + 0.5 lpm

–

–

Fixed CO2 gassing (%) measured
by IR sensor

0.8 -15 ± 5 %

–

–

Internal air pump

(•)

–

–

Gassing Module Control Tower

4-Gas mix (O2, N2, CO2, air) with headspace outlet

Rotameters

–

Gassing Module Rocker - Optional

– flow rates
– accuracy
MFC

–

– flow rates
– accuracy

max. 4

max. 4

0.016 lpm – 8.3 lpm

0.016 lpm – 13 lpm

± 5% full scale

± 5% full scale

max. 4

max. 4

0.003 lpm – 5 lpm

0.06 lpm – 10 lpm

± 1% full scale

± 1% full scale

4-stage DO cascade

–

•

•

Advanced DO controller

–

(•)

(•)

Temperature probe Pt 100

•

•

•

– temperature range

0 – 150°C

0 – 150°C

0 – 150°C

– display resolution

0.1°C

0.1°C

0.1°C

– amplifiers

2

1 (single) | 2 (twin)

2

pH single use

–

Sensors & Measurement

•

•

– measurement range

6.5–8.5

6.5–8.5

– display resolution

0.1 pH

0.1 pH

– amplifiers

1 (single) | 2 (twin)

2

– recalibration function

•

•

•

•

– measurement range

0 – 250%

0 – 250%

– display resolution

0.1%

0.1%

– amplifiers

1 (single) | 2 (twin)

2

– recalibration function

•

•

DO single-use

–

Single-use viable biomass
(BioPAT® ViaMass)

–

(•)

(•)

Load cells

(•)

(•)

(•)

– weight range | accuracy

max. 30 kg | 10 g

max. 30 kg | 10 g

max. 120 kg | 100 g

Balance substrate

–

(up to 2) per side

(up to 2) per side

External signal input

–

max. 2
0 –10 V or 4 – 20 mA

2

() – optional, needs to be ordered separately

Pump Module

BIOSTAT® B with RM 20 | 50 Rocker and BIOSTAT® B with RM 200 Rocker

max. 4 internal and 2 external pumps, thereof 3 speed controlled per side
Built-in Pumps
Fixed Speed

Watson Marlow 114, Fast Load pump head

– Speed 5 rpm
Flow rate (tubing wall thickness
1.6 mm)

ID: 0.5 mm: 0-0.1 ml/min
ID: 0.8 mm: 0.05-2.4 ml/min
ID: 1.6 mm: 0.01-0.7 ml/min
ID: 2.4 mm: 0.03-1.5 ml/min
ID: 3.2 mm: 0.05-2.4 ml/min
ID: 4.8 mm: 0.09-4.3 ml/mi

– Speed 44 rpm
Flow rate (tubing wall thickness
1.6 mm)

ID: 0.5 mm: 0.02-0.9 ml/min
ID: 0.8 mm: 0.04-1.8 ml/min
ID: 1.6 mm: 0.12-6.2 ml/min
ID: 2.4 mm: 0.26-12.8 ml/min
ID: 3.2 mm: 0.41-20.7 ml/min
ID: 4.8 mm: 0.75-37.4 ml/min

Speed Controlled

Watson Marlow 114, Fast Load pump head

– Speed 0.15 – 5 rpm
Flow rate (tubing wall thickness
1.6 mm)

ID: 0.5 mm: 0-0.1 ml/min
ID: 0.8 mm: 0.01-0.2 ml/min
ID: 1.6 mm: 0.02-0.7 ml/min
ID: 2.4 mm: 0.04-1.5 ml/min
ID: 3.2 mm: 0.07-2.4 ml/min
ID: 4.8 mm: 0.13-4.3 ml/min

– Speed 5 – 150 rpm
Flow rate (tubing wall thickness
1.6 mm)

ID: 0.5 mm: 0.1-3 ml/min
ID: 0.8 mm: 0.2-6 ml/min
ID: 1.6 mm: 0.7-21 ml/min
ID: 2.4 mm: 1.45-43.5 ml/min
ID: 3.2 mm: 2.35-70.5 ml/min
ID: 4.8 mm: 4.25-127.5 ml/min

External Pumps
Speed Controlled

Watson Marlow 520, Fast Load pump head, up to 200 rpm
Watson Marlow 323

Communication
BIOSTAT ® RM 20 | 50
Basic

BIOSTAT ® B
with RM 20 | 50 Rocker

BIOSTAT ® B
with RM 200 Rocker

Industrial Ethernet

1

1

1

Profibus DP

(1)

–

–

The BIOSTAT ® RM rocker is designed to communicate with with
industrial SCADA or DCS systems (e.g. DeltaV) through the
standard Modbus RTU or an optional Profibus DP interfaces.

Technical Data
BIOSTAT ® RM 20 | 50
Basic

BIOSTAT ® B
with RM 20 | 50 Rocker

BIOSTAT ® B
with RM 200 Rocker

Max. total volume (L)

50

50

200

Working volume (L)

0.1– 25

0.1– 25

10 –100

Rocking rate (r/min)

8 – 42 ± 1

8 – 42 ± 1

2 – 20 ± 1

Rocking angle (°)

4 –10 ± 0.3

4 –10 ± 0.3

2 –10 ± 0.3

Clamping rails for bag fixation

•

•

•

Sensor clamps for secure fixation of
glass fiber cables

–

2 (single) | 4 (twin)

4

Filter heater

2

1 (single) | 2 (twin)

2

Integrated Rocker Controler

•

•

–

BIOSTAT B Control Tower

–

•

•

Color touch screen

•

•

•

Potential-free alarm contact

• (max. 0.5 A)

•

•

Safety measurement and shut-off

30 mbar (in combination
with gassing module)

30 mbar

30 mbar

Additional safety valve gasses (mbar)

–

100 mbar

100 mbar

Water inlet pressure reduction value

–

1.5 bar, integrated
pressure control

1.5 bar, integrated
pressure control

Different user level log in

•

(•)

(•)

Logbook function

–

(•)

(•)

–

•

®

®

Lab-cart for BIOSTAT B Control Tower –
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Chapter 1

Dimensional Analysis

1.1 Introduction
Before beginning the material on dimensional analysis, it is worth considering
a simple example that demonstrates what we are doing. One that qualifies
as simple is the situation of when a object is thrown upwards. The resulting
mathematical model for this is an equation for the height x(t) of the projectile
from the surface of the Earth at time t. This equation is determined using
Newton’s second law, F = ma, and the law of gravitation. The result is
d2 x
=
dt2

gR2
,
(R + x)2

for 0 < t,

(1.1)

where g is the gravitational acceleration constant and R is the radius of the
Earth. Finding the solution x of this equation requires two integrations. Each
will produce an integration constant, and we need more information to find
these constants. This is done by specifying the initial conditions. Assuming
the projectile starts at the surface with velocity v0 then the initial conditions
are as follows
x(0) = 0,
dx
(0) = v0 .
dt

(1.2)
(1.3)

The resulting initial value problem for x consists in finding the solution of
(1.1) that satisfies (1.2) and (1.3). Mathematically, the problem is challenging
because it involves solving a second-order nonlinear di↵erential equation. One
option for finding the solution is simply to use a computer. However, the
limitation with this is that it does not provide much insight into how the
solution depends on the terms in the equation. One of the primary objectives
of this text is to use mathematics to derive a fundamental understanding of
how and why things work the way they do, and so, we are very interested in

M.H. Holmes, Introduction to the Foundations of Applied Mathematics,
Texts in Applied Mathematics 56, DOI 10.1007/978-0-387-87765-5 1,
c Springer Science+Business Media, LLC 2009

1

2

1 Dimensional Analysis

#
#"

!"

!!"

!

Figure 1.1 The solution (1.5) of the projectile problem in a uniform gravitational
field.

obtaining at least an approximate solution of this problem. This is the same
point-of-view taken in most physics books and it is worth looking at how
they might address this issue. Adopting for the moment the typical Physics I
approach, in looking at the equation in (1.1) it is not unreasonable to assume
R is significantly larger than even the largest value of x. If true then we should
be able to replace the x+R term with just R. In this case the problem reduces
to solving
d2 x
= g, for 0 < t.
(1.4)
dt2
Integrating and then using the two initial conditions yields
x(t) =

1 2
gt + v0 t.
2

(1.5)

This solution is shown schematically in Figure 1.1. We have what we wanted,
a relatively simple expression that serves as an approximation to the original
nonlinear problem. To complete the derivation we should check that the assumption made in the derivation is satisfied, namely x is much smaller than
R. Now, the maximum height for (1.5) occurs when
dx
= 0.
dt

(1.6)

Solving this equation yields t = v0 /g and from this it follows that the maximum height is
v2
xM = 0 .
(1.7)
2g
Therefore, we must require that v 2 /(2g) is much less than R, which we write
as v02 /(2g) << R.
It is now time to critique the above derivation. The first criticism is that
the approach is heuristic. The reason is that even though the argument for
replacing x + R with R seems plausible, we simply ignored a particular term
in the equation. The projectile problem is not particularly complicated so
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dropping a term as we did is straightforward. However, in the real world
where problems can be quite complicated, dropping a term in one part of the
problem can lead to inconsistencies in another part. A second criticism can be
made by asking a question. Specifically, what exactly is the e↵ect of the nonlinearity on the projectile? Our reduction replaced the nonlinear gravitational
force, which is the right-hand side of (1.1), with a uniform gravitational field
given by g. Presumably if gravity decreases with height then the projectile
will be going higher than we would expect based on our approximation in
(1.5). It is of interest to understand quantitatively what this nonlinear e↵ect
is and whether it might interfere with our reduction.
Based on the comments of the previous paragraph we need to make the
reduction process more systematic. The procedure that is used to simplify
the problem should enable us to know exactly what is large or small in the
problem, and it should also enable us to construct increasingly more accurate
approximations to the problem. Explaining what is involved in a systematic
reduction occurs in two steps. The first, which is the objective of this chapter,
involves the study of dimensions and how these can be used to simplify the
mathematical formulation of the problem. After this, in Chapter 2, we develop
techniques to construct accurate approximations of the resulting equations.

1.2 Examples of Dimensional Reduction
The first idea that we explore will, on the surface, seem to be rather simple,
but it is actually quite profound. It has to do with the dimensions of the
physical variables, or parameters, in a problem. To illustrate, suppose we
know that the speed s of a ball is determined by its radius r and the length
of time t it has been moving. Implicit in this statement is the assumption that
the speed does not depend on any other physical variable. In mathematical
terms we have that s = f (r, t). The function f is not specified and all we
know is that there is some expression that connects the speed with r and
t. The only possible way to combine these two quantities to produce the
dimension of speed is through their ratio r/t. For example, it is impossible
to have s = ↵r + t without ↵ and having dimensions. This would mean
↵ and are physical parameters, and we have assumed there are no others
in the problem. This observation enables us to conclude that based on the
original assumptions that the only function we can have is s = ↵r/t, where
↵ is a number.
What we are seeing in this example is that the dimensions of the variables
in the problem end up dictating the form of the function. This is very useful
information and we will spend some time exploring how to exploit this idea.
To set the stage we need to introduce some of the terminology. The first is
the concept of a fundamental dimension. As is well known, physical variables
such as force, density, and velocity can be broken down into length L, time
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Quantity

Dimensions
2

Acceleration

LT

Angle

1

Angular Acceleration

T

Angular Momentum

M L2 T

Angular Velocity

T

Area

L2

2

1

2

Energy, Work

ML T

Force

M LT

Frequency

T

1

Concentration

L

3

Length

L

Mass

M

Mass Density

1

2
2

3

ML

1

Momentum

M LT

Power

M L2 T

Pressure, Stress,
Elastic Modulus

ML

1

Surface Tension

MT

2

3

2

T

Time

T

Torque

M L2 T

Velocity

LT

Viscosity (Dynamic)

ML

1

Viscosity (Kinematic)

L2 T

1

Volume

Quantity

Dimensions

Enthalpy

M L2 T

2

Entropy

M L2 T

2

Gas Constant

L2 T

Internal Energy

M L2 T

Specific Heat

L2 T

Temperature

✓

Thermal Conductivity

M LT

Thermal Di↵usivity

L2 T

1

Heat Transfer
Coefficient

MT

3

Capacitance

M

Charge

TI

Charge Density

L

Conductivity

M

Electric Current
Density

L

Electric Current

I

Electric Displacement

L

Electric Potential
2

2

3

L

2

I

2

TI

2

ML T

Magnetic Field
Intensity

L

Magnetic flux

L2 M T

L3

Permeability

M LT

Wave Length

L

Permittivity

M

Strain

1

Electric Resistance

1

1

2

T 4I 2

3

T 3I 2

3

I

TI

1

M L2 T

1

1

✓

✓

L

Inductance
T

1

✓
3

Electric Field Intensity M LT

1

1

✓
2

2

1

1

✓

3

1
1

I
2

I

2

2

I

1

I

I

2

L

3

T 4I 2

M L2 T

3

I

1

2

2

Table 1.1 Fundamental dimensions for commonly occurring quantities. A quantity
with a one in the dimensions column is dimensionless.

T , and mass M (see Table 1.1). Moreover, length, time, and mass are independent in the sense that one of them cannot be written in terms of the
other two. For these two reasons we will consider L, T , and M as fundamental
dimensions. For problems involving thermodynamics we will expand this list
to include temperature (✓) and for electrical problems we add current (I). In
conjunction with this, given a physical variable x we will designate the fundamental dimensions of x using the notation [x]. For example, [velocity] = L/T ,
[f orce] = M L/T 2 , [g] = L/T 2 , and [density] = M/L3 .
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It is important to understand that nothing is being assumed about which
specific system of units is used to determine the values of the variables or
parameters. Dimensional analysis requires that the equations be independent
of the system of units. For example, both Newton’s law F = ma and the
di↵erential equation (1.1) do not depend on the specific system one selects.
For this reason these equations are said to be dimensionally homogeneous.
If one were to specialize (1.1) to SI units and set R = 6378 km and g =
2
9.8 m/sec they would end up with an equation that is not dimensionally
homogeneous.

1.2.1 Maximum Height of a Projectile
The process of dimensional reduction will be explained by applying it to
the projectile problem To set the stage, suppose we are interested in the
maximum height xM of the projectile. Based on Newton’s second law, and
the initial conditions in (1.2) and (1.3), it is assumed that the only physical
parameters that xM depends on are g, v0 , and the mass m of the projectile.
Mathematically this assumption is written as xM = f (g, m, v0 ). The function
f is unknown but we are going to see if the dimensions can be used to simplify
the expression. The only way to combine g, m, v0 to produce the correct
dimensions is through a product or ratio. So, our start-o↵ hypothesis is that
there are numbers a, b, c so that
[xM ] = [ma v0b g c ].

(1.8)

Using the fundamental dimensions for these variables the above equation is
equivalent to
L = M a (L/T )b (L/T 2 )c
= M a Lb+c T

b 2c

.

(1.9)

Equating the exponents of the respective terms in this equation we conclude
L:
T :
M:

b

b + c = 1,
2c = 0,
a = 0.

Solving these equations we obtain a = 0, b = 2, and c = 1. This means
the only way to produce the dimensions of length using m, v0 , g is through
the ratio v02 /g. Given our start-o↵ assumption (1.8), we conclude that xM
is proportional to v02 /g. In other words, the original assumption that xM =
f (g, m, v0 ) dimensionally reduces to the expression
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xM = ↵

v02
,
g

(1.10)

where ↵ is an arbitrary number. With (1.10) we have come close to obtaining
our earlier result (1.7) and have done so without solving a di↵erential equation
or using calculus to find the maximum value. Based on this rather minimal
e↵ort we can make the following observations:
• If the initial velocity is increased by a factor of 2 then the maximum height
will increase by a factor of 4. This observation o↵ers an easy method for
experimentally checking on whether the original modeling assumptions are
correct.
• The constant ↵ can be determined by running one experiment. Namely, for
a given initial velocity v0 = v̄0 we measure the maximum height xM = x̄M .
With these known values, ↵ = gx̄M /v̄02 . Once this is done, the formula in
(1.10) can be used to determine xM for any v0 .
The steps we have used are the basis for the method of dimensional reduction,
where an expression is simplified based on the fundamental dimensions of the
quantities involved. Given how easy it was to obtain (1.10) the method is very
attractive as an analysis tool. It does have limitations and one is that we do
not know the value of the number ↵. It also requires us to be able to identify
at the beginning what parameters are needed. The importance of this and
how this relies on understanding the physical laws underlying the problem
will be discussed later.
The purpose of the above example is to introduce the idea of dimensional
reduction. What it does not show is how to handle problems with several
parameters and this is the purpose of the next two examples.

1.2.2 Drag on a Sphere
In the design of automobiles, racing bicycles, and aircraft there is an overall
objective to keep the drag on the object as small as possible. It is interesting
to see what insight dimensional analysis might provide in such a situation,
but since we are beginners it will be assumed the object is very simple and
is a sphere (see Figure 1.2). The modeling assumption that is made is that
the drag force DF on the sphere depends on the radius R of the sphere, the
velocity v of the sphere, the density ⇢ of the air, and the dynamic viscosity µ
of the air. The latter is a measure of the resistance force of the air to motion
and we will investigate this in Chapter 8. For the moment all we need is its
fundamental dimensions and these are given in Table 1.1. In mathematical
terms the modeling assumption is
DF = f (R, v, ⇢, µ),

(1.11)
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(a)

(b)

Figure 1.2 Air flow around an object can be visualized using smoke. The flow around
a golf ball is shown in (a) (Brown [1971]), and around a tennis ball in (b) (Bluck
[2000]). In both cases the air is moving from left to right.

and we want to use dimensional reduction to find a simplified version of this
expression. Similar to the last example, the first question is whether we can
find numbers a, b, c, d so that
[DF ] = [Ra v b ⇢c µd ].

(1.12)

Expressing these using fundamental dimensions yields
M LT

2

= La (L/T )b (M/L3 )c (M/LT )d
= La+b

3c d

T

b d

M c+d .

As before we equate the respective terms and conclude
L: a+b
T :
M:

3c d = 1,
b d = 2,
c + d = 1.

(1.13)

We have four unknowns and three equations, so it is anticipated that in solving the above system of equations one of the unknowns will be undetermined.
From the T equation we have b = 2 d, and from the M equation c = 1 d.
The L equation then gives us a = 2 d. With these solutions, and based on
our assumption in (1.12), we have that
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DF = ↵⇢R2

d 2 d 1 d d

= ↵⇢R2 v 2

v
✓

⇢

µ
◆d
µ
,
Rv⇢

where ↵ is an arbitrary number. This can be written as
DF = ↵⇢R2 v 2 ⇧ d ,
where

⇧=

µ
,
Rv⇢

(1.14)
(1.15)

and d, ↵ are arbitrary numbers. This is the general product solution for how
DF depends on the given variables. The quantity ⇧ is dimensionless, and
it is an example of what is known as a dimensionless product. Physically, it
can be thought of as the ratio of the viscous force (µ) to the inertial force
(Rv⇢) in the air. Calling it a product is a bit misleading as ⇧ involves both
multiplications and divisions. Some avoid this by calling it a dimensionless
group. We will use both expressions in this book.
The formula for DF in (1.14) is not the final answer. What remains is to
determine the consequence of the arbitrary exponent d. The key observation
is that given any two sets of values for (↵, d), say (↵1 , d1 ) and (↵2 , d2 ), then
DF = ↵1 ⇢R2 v 2 ⇧ d1 + ↵2 ⇢R2 v 2 ⇧ d2
= ⇢R2 v 2 (↵1 ⇢⇧ d1 + ↵2 ⇧ d2 )
is also a solution. Extending this observation we conclude that another solution is
DF = ⇢R2 v 2 (↵1 ⇧ d1 + ↵2 ⇧ d2 + ↵3 ⇧ d3 + · · · ),
(1.16)

where d1 , d2 , d3 , . . . are arbitrary numbers as are the coefficients ↵1 , ↵2 , ↵3 , . . ..
To express this in a more compact form, note that the expression within the
parentheses in (1.16) is simply a function of ⇧. From this observation we
obtain the general solution, which is
DF = ⇢R2 v 2 F (⇧),

(1.17)

where F is an arbitrary function of the dimensionless product ⇧. We have,
therefore, been able to use dimensional analysis to reduce (1.11), which involves an unknown of four variables, down to an unknown function of one
variable. Although this is a significant improvement, the result is perhaps not
as satisfying as the one obtained for the projectile example, given in (1.10),
because we have not been able to determine F . However, there are various
ways to address this issue, and some of them will be considered below.
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Representation of Solution
Now that the derivation is complete a few comments are in order. First, it
is possible for two people to go through the above steps and come to what
looks to be very di↵erent conclusions. For example, the general solution can
also be written as
µ2
DF =
H(⇧),
(1.18)
⇢
where H is an arbitrary function of ⇧. The proof that this is equivalent to
(1.17) comes from the requirement that the two expressions must produce
the same result. In other words, it is required that
µ2
H(⇧) = ⇢R2 v 2 F (⇧).
⇢
Solving this for H yields
H(⇧) =

1
F (⇧).
⇧2

The fact that the right-hand side of the above equation only depends on ⇧
shows that (1.18) is equivalent to (1.17). As an example, if F (⇧) = ⇧ in
(1.17), then H(⇧) = 1/⇧ in (1.18).
Another representation for the general solution is
DF = ⇢R2 v 2 G(Re),
where
Re =

Rv⇢
,
µ

(1.19)
(1.20)

and G is an arbitrary function of Re. This form is the one usually used in
fluid dynamics, where the dimensionless product Re is known as the Reynolds
number. The function G is related to the drag coefficient CD , through the
equation G = ⇡2 CD . Because of its importance in fluids, G has been measured
for a wide range of Reynolds numbers, producing the curve shown in Figure
1.3. To transform between the representation in (1.19), and the one in (1.17),
note Re = 1/⇧. From the requirement
⇢R2 v 2 G(Re) = ⇢R2 v 2 F (⇧),
we obtain

G(Re) = F (1/Re).

The reason for the di↵erent representations is that there are four unknowns
in (1.12) yet only three equations. This means one of the unknowns is used
in the general solution and, as expressed in (1.14), we used d. If you were to
use one of the others then a di↵erent looking, but mathematically equivalent,
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3

10

2

G(Re)

10

1

10

0

10

−1

10

−2

10

0

10

2

4

10

10

6

10

8

10

Re

Figure 1.3 The measured values of the function G(Re) that arises in the formula
for the drag on a sphere, as given in (1.19).

expression would be obtained. The fact that there are multiple ways to express
the solution can be used to advantage. For example, if one is interested in the
value of DF for small values of the velocity then (1.19) would be a bit easier
to use. The reason is that to investigate the case of small v it is somewhat
easier to determine what happens to G for Re near zero than to expand
F for large values of ⇧. For the same reason, (1.17) is easier to work with
for studying large velocities. One last comment to make is that even though
there are choices on the form of the general solution, they all have exactly
the same number of dimensionless products.
Determining F
A more challenging question concerns how to determine the function F in
(1.17). The mathematical approach would be to solve the equations for fluid
flow around a sphere and from this find F . This is an intriguing idea and
one that will be used from time to time in this book. There is, however,
another more applied approach that makes direct use of (1.17). Specifically,
a sequence of experiments is run to measure F (r) for 0 < r < 1. To do
this a sphere with a given radius R0 , and a fluid with known density ⇢0 and
viscosity µ0 , are selected. In this case (1.17) can be written as
F (r) =

DF
v2

(1.21)

where = 1/(⇢0 R02 ) is known and fixed. The experiment consists of taking
various values of v and then measuring the resulting drag force DF on the
sphere. To illustrate, suppose our choice for the sphere and fluid give R = 1,
⇢0 = 2, and µ0 = 3. Also, suppose that running the experiment using v = 4
produces a measured drag of DF = 5. In this case r = µ0 /(R0 v⇢0 ) = 3/8
and DF /v 2 = 5/32. Our conclusion is therefore that F (3/8) = 5/32. In this
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way, picking a wide range of v values we will be able to determine the values
for the function F (r). This approach is used extensively in the real world and
the example we are considering has been a particular favorite for study. The
data determined from such experiments are shown in Figure 1.3.
A number of conclusions can be drawn from Figure 1.3. For example,
there is a range of Re values where G is approximately constant. Specifically,
if 103 < Re < 105 then G ⇡ 0.7. This is the reason why in the fluid dynamics
literature you will occasionally see the statement that the drag coefficient
CD = ⇡2 G for a sphere has a constant value of approximately 0.44. For
other Re values, however, G is not constant. Of particular interest, is the
dependence of G for small values of Re. This corresponds to velocities v that
are very small, what is known as Stokes flow. The data in Figure 1.3 show
that G decreases linearly with Re in this region. Given that this is a log-log
plot, then this means that log(G) = a b log(Re), or equivalently, G = ↵/Reb
where ↵ = 10a . Curve fitting this function to the data in Figure 1.3 it is found
that ↵ ⇡ 17.6 and ⇡ 1.07. These are close to the exact values of ↵ = 6⇡
and = 1, which are obtained by solving the equations of motion for Stokes
flow. Inserting these values into (1.19), the conclusion is that the drag on the
sphere for small values of the Reynolds number is
DF ⇡ 6⇡µRv.

(1.22)

This is known as Stokes formula for the drag on a sphere, and we will have
use for it in Chapter 4 when studying di↵usion.
Scale Models
Why all the work to find F ? Well, knowing this function allows for the use of
scale model testing. To explain, suppose it is required to determine the drag
on a sphere with radius Rf for a given velocity vf when the fluid has density
⇢f and viscosity µf . Based on (1.17) we have DF = ⇢f Rf2 vf2 F (⇧f ), where
⇧f =

µf
.
Rf vf ⇢f

(1.23)

Consequently, we can determine DF if we know the value of F at ⇧f . Also,
suppose that this cannot be measured directly as Rf is large and our experimental equipment can only handle small spheres. We can still measure
F (⇧f ) using a small value of R if we change one or more of the parameters
in such a way that the value of ⇧f does not change. If Rm , µm , ⇢m and vm
are the values used in the experiment then we want to select them so that
µm
µf
=
,
Rm vm ⇢m
Rf vf ⇢f

(1.24)
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Figure 1.4 Scale model testing. Dimensional analysis is used in the development of
scale models used in wind tunnels. On the left there is a flight test of an F-18 model
in NASA’s 11 ft transonic wind tunnel (NASA [2008]), and on the right a wind tunnel
test of a 1:160 scale model of the Owensboro Bridge (Hsu [2009]).

or equivalently
vm =

µm Rf ⇢f
vf .
µf Rm ⇢m

(1.25)

This equation relates the values for the full-scale ball (subscript f ) to those
for the model used in the experiment (subscript m). As an example, suppose
we are interested in the drag on a very large sphere, say Rf = 100 m, but our
equipment can only handle smaller values, say Rm = 2 m. If the fluid for the
two cases is the same, so ⇢m = ⇢f and µm = µf , then according to (1.25),
in our experiment we should take vm = 50vf . If the experimental apparatus
is unable to generate velocities 50 times the value of vf then it would be
necessary to use a di↵erent fluid to reduce this multiplicative factor.
The result in the above example is the basis of scale model testing used
in wind tunnels (see Figure 1.4). Usually these tests involve more than just
keeping one dimensionless product constant as we did in (1.24). Moreover, it
is evident in Figure 1.4 that the models look like the originals, they are just
smaller. This is the basis of geometric similarity, where the lengths of the
model are all a fraction of the original. For example, the bridge in Figure 1.4
1
is a 20
th scale model of the Owensboro Bridge. Other scalings are sometimes
used and the most common are kinematic similarity, where velocities are
scaled, and dynamic similarity, where forces are scaled.
Endnotes
One question that has not been considered so far is, how do you know to
assume that the drag force depends on the radius, velocity, density, and
dynamic viscosity? The assumption comes from knowing the laws of fluid
dynamics, and identifying the principal terms that contribute to the drag.
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For the most part, in this chapter the assumptions will be stated explicitly, as
they were in this example. Later in the text, after the basic physical laws are
developed, it will be possible to construct the assumptions directly. However,
one important observation can be made, and that is the parameters used in
the assumption should be independent. For example, even though the drag
on a sphere likely depends on the surface area and volume of the sphere it
is not necessary to include them in the list. The reason is that it is already
assumed that DF depends on the radius R and both the surface area and
volume are determined using R.
The problem of determining the drag on a sphere is one of the oldest in
fluid dynamics. Given that the subject is well over 150 years old, you would
think that whatever useful information can be derived from this particular
problem was figured out long ago. Well, apparently not, as research papers
still appear regularly on this topic. A number of them come from the sports
industry, where there is interest in the drag on soccer balls (Asai et al. [2007]),
golf balls (Smits and Ogg [2004]), tennis balls (Goodwill et al. [2004]), as well
as nonspherical-shaped balls (Mehta [1985]). Others have worked on how to
improve the data in Figure 1.3, and an example is the use of a magnetic
suspension system to hold the sphere (Sawada and Kunimasu [2004]). A more
novel idea is to drop di↵erent types of spheres down a deep mine shaft, and
then use the splash time as a means to determine the drag coefficient (Maroto
et al. [2005]). The point here is that even the most studied problems in science
and engineering still have interesting questions that remain unanswered.

1.2.3 Toppling Dominoes
Domino toppling refers to the art of setting up dominoes, and then knocking
them down. The current world record for this is 4,000,000 plus dominoes for a
team, and 300,000 plus for an individual. One of the more interesting aspects
of this activity is that as the dominoes fall it appears as if a wave is propagating along the line of dominoes. The objective of this example is to examine
what dimensional analysis might be able to tell us about the velocity of this
wave. A schematic of the situation is shown in Figure 1.5. The assumption is
that the velocity v depends on the spacing d, height h, thickness t, and the
gravitational acceleration constant g. Therefore, the modeling assumption is
v = f (d, h, t, g) and we want to use dimensional reduction to find a simplified
version of this expression. As usual, the first step is to find numbers a, b, c,
e so that
[v] = [da hb tc g e ].
Expressing these using fundamental dimensions yields
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LT

1

= La Lb Lc (L/T 2 )e
= La+b+c+e T

2e

.

Equating the respective terms we obtain
L : a + b + c + e = 1,
T :
2e = 1.
Solving these two equations gives us that e =
we have that

1
2

and b =

1
2

a

c. With this

v = ↵da h1/2 a c tc g 1/2
✓ ◆a ✓ ◆c
p
d
t
= ↵ hg
h
h
p
a c
= ↵ hg⇧1 ⇧2 ,

(1.26)

where ↵ is an arbitrary number, and the two dimensionless products are
d
,
h
t
⇧2 = .
h
⇧1 =

The expression in (1.26) is the general product solution. Therefore, the general solution for how the velocity depends on the given parameters is
p
v = hg F (⇧1 , ⇧2 ),
(1.27)
where F is an arbitrary function of the two dimensionless products. The proof
of how (1.27) follows from (1.26) is very similar to the method used to derive
(1.17) from (1.15).
Dimensional analysis has been able to reduce the original assumption involving a function of four-dimensional parameters down to one involving two
dimensionless products. This example is also informative as it demonstrates
how to obtain the general solution when more than one dimensionless product
is involved. The question remains, however, if this really applies to toppling
#
!
"
$

Figure 1.5 Schematic of toppling dominoes, creating a wave
that propagates with velocity v.
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Figure 1.6 Data for two di↵erent types of toppling dominoes (Stronge and Shu
[1988]). In these experiments, t = 0.12h, so the thin domino approximation is appropriate.

dominoes. It does, but in using this formula it is usually assumed the dominoes are very thin, or more specifically that t << h. This means that it is
possible to assume ⇧2 = 0, and (1.27) simplifies to
p
v = hg G(⇧1 ),
(1.28)
where G is an arbitrary function. Some e↵ort has been made to measure G,
and the measurements for two di↵erent types of dominoes are given in Figure
1.6. Although the data show that G decreases with ⇧1 , it is approximately
constant over the range of ⇧1 values used in the experiments. Therefore, as
an approximation
we conclude that the speed at which dominoes topple is
p
v ⇡ 1.5 hg. A typical domino has h = 5 cm, which results in a velocity of
v ⇡ 1 m/s. To obtain a more explicit formula for G, however, requires the
solution of a challenging mathematical problem, and an expanded discussion
of this can be found in Efthimiou and Johnson [2007].

1.2.4 Endnotes
Based on the previous examples, the benefits of using dimensional reduction
are apparent. However, a word of caution is needed here as the method gives
the impression that it is possible to derive useful information without getting involved with the laws of physics or potentially difficult mathematical
problems. One consequence of this is that the method is used to comment
on situations and phenomena that are simply inappropriate (e.g., to study
psychoacoustic behavior). The method relies heavily on knowing the fundamental laws for the problem under study, and without this whatever conclusions made using dimensional reduction are limited. For example, we earlier
considered the drag on a sphere and in the formulation of the problem we
assumed that the drag depends on the dynamic viscosity. Without knowing
the equations of motion for fluids it would not have been possible to know
that this term needed to be included or what units it might have. By not in-
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cluding it we would have concluded that d = 0 in (1.14) and instead of (1.17)
we would have DF = ↵⇢R2 v 2 where ↵ is a constant. In Figure 1.3 it does
appear that DF is approximately independent of Re when 103 < Re < 105 .
However, outside of this interval, DF is strongly dependent on Re, and this
means ignoring the viscosity would be a mistake. Another example illustrating the need to know the underlying physical laws arises in the projectile
problem when we included the gravitational constant. Again, this term is
essential and without some understanding of Newtonian mechanics it would
be missed completely. The point here is that dimensional reduction can be
a very e↵ective method for simplifying complex relationships, but it is based
heavily on knowing what the underlying laws are that govern the systems
being studied.

1.3 Theoretical Foundation
The theoretical foundation for dimensional reduction is contained in the
Buckingham Pi Theorem. To derive this result assume we have a physical
quantity q that depends on physical parameters or variables p1 , p2 , . . . , pn .
In this context, the word physical means that the quantity is measurable.
Each can be expressed in fundamental dimensions and we will assume that
the L, T, M system is sufficient for this task. In this case we can write

and

[q] = L`0 T t0 M m0 ,

(1.29)

[pi ] = L`i T ti M mi .

(1.30)

Our modeling assumption is that q = f (p1 , p2 , . . . , pn ). To dimensionally
reduce this expression we will determine if there are numbers a1 , a2 , . . . , an
so that
[q] = [pa1 1 pa2 2 · · · pann ].
(1.31)
Introducing (1.29) and (1.30) into the above expression, and then equating
exponents, we obtain the equations
L:
`1 a1 + `2 a2 + · · · + `n an = `0 ,
T :
t1 a1 + t2 a2 + · · · + tn an = t0 ,
M : m1 a1 + m2 a2 + · · · + mn an = m0 .
This can be expressed in matrix form as
Aa = b,
where

(1.32)

1.3 Theoretical Foundation

17

0

1
`1 `1 · · · `n
A = @ t1 t 2 · · · tn A ,
m1 m2 · · · mn
0 1
a1
0 1
`0
B a2 C
B C
a = B . C,
b = @ t0 A .
@ .. A
m0
an

(1.33)

(1.34)

The matrix A is known as the dimension matrix. As expressed in (1.33) it
is 3 ⇥ n but if we were to have used L, T, M, ✓ as the fundamental system
then it would be 4 ⇥ n. In other words, the number of rows in the dimension
matrix equals the number of fundamental units needed, and the number of
columns equals the number of parameters that q is assumed to depend on.
With (1.32) we have transformed the dimensional reduction question into
a linear algebra problem. To determine the consequences of this we first
consider the situation that (1.32) has no solution. In this case the assumption
that q depends on p1 , p2 , . . . , pn is incomplete and additional parameters are
needed. This situation motivates the following definition.
Definition 1.1. The set p1 , p2 , . . . , pn is dimensionally incomplete for q if
it is not possible to combine the pi ’s to produce a quantity with the same
dimension as q. If it is possible, the set is dimensionally complete for q.
From this point on we will assume the pi ’s are complete and there is at
least one solution of (1.32). To write down the general solution we consider
the associated homogeneous equation, namely Aa = 0. The set of solutions
of this equation form a subspace K(A), known as the kernel of A. Letting k
be the dimension of this subspace then the general solution of Aa = 0 can
be written as a = 1 a1 + 2 a2 + · · · + k ak , where a1 , a2 , . . . , ak is a basis
for K(A) and 1 , 2 , . . . , k are arbitrary. It is understood here that if k = 0
then a = 0. With this, the general solution of (1.32) can be written as
a = ap +

1 a1

+

2 a2

+ ··· +

where ap is any vector that satisfies (1.32) and
numbers.

k ak ,
1, 2, . . . , k

(1.35)
are arbitrary

Example: Drag on a Sphere
To connect the above discussion with what we did earlier consider the drag
on a sphere example. Writing (1.13) in matrix form we obtain
0 1
0
1 a
0 1
1 1 3 1 B C
1
@ 0 1 0 1 A B b C = @ 2A .
@cA
0 0 1 1
1
d
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This is the matrix equation (1.32) for this particular example. Putting this
in augmented form, and row reducing, yields the following
0
1
0
1
1 1 3 1 1
1 0 0 1 2
@0 1 0 1 2A ! @0 1 0 1 2A.
0 0 1 1 1
0 0 1 1 1
From this we conclude that a = 2 d, b = 2 d, and c = 1 d. To be
consistent with the notation in (1.35), set d = , so the solution is
0 1 0 1
0 1
a
2
1
B b C B2C
B 1C
B C = B C + B C,
@ c A @1A
@ 1A
d
0
1
where

is arbitrary. Comparing this with (1.35) we have that k = 1,
0 1
0 1
2
1
B2C
B 1C
C
B C
ap = B
@1A , and a1 = @ 1A . ⌅
0
1

It is now time to take our linear algebra conclusions and apply them to
the dimensional reduction problem. Just as the appearance of d in (1.14)
translated into the appearance of a dimensionless product in the general
solution given in (1.17), each of the i ’s in (1.35) gives rise to a dimensionless
product in the general solution for the problem we are currently studying.
To be specific, writing the ith basis vector ai in component form as
0 1
↵
B C
B C
ai = B . C ,
(1.36)
@ .. A
then the corresponding dimensionless product is
⇧ i = p↵
1 p2 · · · p n .

(1.37)

Moreover, because the ai ’s are independent vectors, the dimensionless products ⇧1 , ⇧2 , . . . , ⇧k are independent.
As for the particular solution ap in (1.35), assuming it has components
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0 1
a
BbC
B C
ap = B . C ,
@ .. A

(1.38)

Q = pa1 pb2 · · · pcn

(1.39)

c

then the quantity

has the same dimensions as q.
Based on the conclusions of the previous two paragraphs, the general product solution is q = ↵Q⇧11 ⇧22 · · · ⇧kk , where ↵, 1 , 2 , . . . , k are arbitrary
constants. From this we obtain the following theorem.
Theorem 1.1. Assuming the formula q = f (p1 , p2 , . . . , pn ) is dimensionally
homogeneous and dimensionally complete, then it is possible to reduce it to
one of the form q = Q F (⇧1 , ⇧2 , . . . , ⇧k ), where ⇧1 , ⇧2 , . . . , ⇧k are independent dimensionless products of p1 , p2 , . . . , pn . The quantity Q is a dimensional
product of p1 , p2 , . . . , pn with the same dimensions as q.
According to this theorem, the original formula for q can be reduced from
a function of n variables down to one with k. The value of k, which equals
the nullity of the dimension matrix, ranges from 0 to n 1 depending on the
given quantities p1 , p2 , . . . , pn . In the case that k = 0 the function F reduces
to a constant and the conclusion is that q = ↵Q, where ↵ is an arbitrary
number.
The importance of this theorem is that it establishes that the process used
to reduce the drag on a sphere and toppling dominoes examples can be applied
to much more complex problems. It also provides insight into how the number
of dimensionless products is determined. There are still, however, fundamental questions left unanswered. For example, those with a more mathematical
bent might still be wondering if this result can really be true no matter how
discontinuous the original function f might be. Others might be wondering
if the fundamental units used here, particularly length and time, are really
independent. This depth of inquiry, although quite interesting, is beyond the
scope of this text. Those wishing to pursue further study of these and related
topics should consult Penrose [2007] and Bluman and Anco [2002].

1.3.1 Pattern Formation
The mechanism responsible for the colorful patterns on seashells, butterfly
wings, zebras, and the like has intrigued scientists for decades. An experiment
that has been developed to study pattern formation involves pouring chemicals into one end of a long tube, and then watching what happens as they
interact while moving along the tube. This apparatus is called a plug-flow
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Figure 1.7 Spatial pattern created in a plug-flow reactor (Bamforth et al. [2000]).
The tube occupies the interval 0  x  100, and starting at t = 0 the chemicals are
poured into the left end. As they flow along the tube a striped pattern develops.

reactor and the outcome of one such experiment is shown in Figure 1.7. It
was found in these experiments that patterns appear only for certain pouring
velocities v. According to what is known as the Lengyel-Epstein model, this
velocity depends on the concentration U of the chemical used in the experiment, the rate k2 at which the chemicals interact, the di↵usion coefficient D
of the chemicals, and a parameter k3 that has the dimensions of concentration
squared. The model is therefore assuming
v = f (U, k2 , D, k3 ).

(1.40)

From Table 1.1 we have that [v] = L/T , [U ] = 1/L3 , [D] = L2 /T , and [k3 ] =
1/L6 . Also, from the Lengyel-Epstein model one finds that [k2 ] = L3 /T .
Using dimensional reduction we require
[v] = [U a k2b Dc k3d ].

(1.41)

Expressing these using fundamental dimensions yields
LT

1

= (L
=L

) (L3 T

3 a

) (L2 T

1 b

3a+3b+2c 6d

T

b c

) (L

1 c

)

6 d

.

As before we equate the respective terms and conclude
L:
T :

3a + 3b + 2c

6d = 1
b c = 1.

These equations will enable us to express two of the unknowns in terms of
the other two. There is no unique way to do this, and one choice yields
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product solution is
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3a

6d. From this it follows that the general

v = ↵U a k23a+6d

1

D2

= ↵k2 1 D2 (U k23 D

3a 6d d
k3
3 a 6
) (k2 D 6 k3 )d .

This can be rewritten as
v = ↵k2 1 D2 ⇧1a ⇧2d ,
where
⇧1 =

U k23
,
D3

(1.42)

(1.43)

and

k26 k3
.
(1.44)
D6
The dimensionless products ⇧1 and ⇧2 are independent, and this follows
from the method used to derive these expressions. Independence is also evident from the observation that ⇧1 and ⇧2 do not involve exactly the same
parameters. From this result it follows that the general form of the reduced
equation is
v = k2 1 D2 F (⇧1 , ⇧2 ).
(1.45)
⇧2 =

It is of interest to compare (1.45) with the exact formula obtained from
solving the di↵erential equations coming from the Lengyel-Epstein model. It
is found that
p
v = k2 DU G( ),
(1.46)
where = k3 /U 2 and G is a rather complicated square root function (Bamforth et al. [2000]). This result appears to di↵er from (1.45). To investigate
this, note that = ⇧2 /⇧12 . Equating (1.45) and (1.46) it follows that
3/2

k2 U 1/2
G( )
3/2
D
p
= ⇧1 G(⇧2 /⇧12 ).

F (⇧1 , ⇧2 ) =

Because the right-hand side is a function of only ⇧1 and ⇧2 then (1.45) does
indeed reduce to the exact result (1.46). Dimensional reduction has therefore
successfully reduced the original unknown function of four variables in (1.40)
down to one with only two variables. However, the procedure is not able to
reduce the function down to one dimensionless variable, as given in (1.46).
In this problem that level of reduction requires information only available
from the di↵erential equations, something that dimensional arguments are
not able to discern.
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1.4 Similarity Variables
Dimensions can be used not just to reduce formulas, they can be also used
to simplify complex mathematical problems. The degree of simplification depends on the parameters, and variables, in the problem. One of the more
well-known examples is the problem of finding the density u(x, t) of a chemical over the interval 0 < x < 1. In this case the density satisfies the di↵usion
equation
@2u
@u
D 2 =
,
(1.47)
@x
@t
where the boundary conditions are
u|x=0 = u0 ,
and the initial condition is

u|x!1 = 0,

u|t=0 = 0.

(1.48)
(1.49)

The constant D is called the di↵usion coefficient, and its dimensions can
be determined from the terms in the di↵erential equation. In particular, the
dimensions of the left and right sides of (1.47) must be the same, and this
means [Duxx ] = [ut ]. Because [u] = M/L3 then [uxx ] = [u]/L2 = M/L5
and [ut ] = [u]/T = M/(T L3 ). From this we have [D]M/L5 = M/(T L3 ), and
therefore [D] = L2 /T . In a similar manner, in boundary condition (1.48),
[u0 ] = [u] = M/L3 . As a final comment, the physical assumptions underlying
the derivation of (1.47) are the subject of Chapter 4. In fact, the solution we
are about to derive is needed in Section 4.5.2 to solve the di↵usion equation.
Dimensional Reduction
The conventional method for solving the di↵usion equation on a semi-infinite
spatial interval is to use an integral transform, and this will be considered
in Chapter 4. It is also possible to find u using dimensional reduction. The
approach is based on the observation that the only dimensional variables, and
parameters, appearing in the problem are u, u0 , D, x, and t. In other words,
it must be true that u = f (x, t, D, u0 ). With this we have the framework
for dimensional reduction, and the question is whether we can find numbers
a, b, c, d so that
[u] = [xa tb Dc (u0 )d ].
(1.50)
Using fundamental dimensions yields
ML

3

= La T b (L2 /T )c (M/L3 )d
= La+2c

3d

Tb

c

M d,

and then equating the respective terms gives us
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L : a + 2c 3d = 3,
T :
b c = 0,
M:
d = 1.

(1.51)

The solution of the above system can be written as d = 1 and b = c = a/2.
Given the assumption in (1.50), we conclude that the general product solution
is
✓
◆a
x
u = ↵u0 p
.
Dt
The general solution therefore has the form

where

u = u0 F (⌘),

(1.52)

x
⌘=p
.
Dt

(1.53)

In this case, ⌘ is called a similarity variable as it is a dimensionless product
that involves the independent variables in the problem.
When working out the drag on a sphere example, we discussed how it is
possible to derive di↵erent representations of the solution. For the current
example, when solving (1.51), instead of writing b = c = a/2, we could
just as well state that a = 2b and c = b. In this case (1.52) is replaced
with u = u0 G(⇠) where ⇠ = Dt/x2 . Although the two representations are
equivalent, in the sense that one can be transformed into the other, it does
make a di↵erence which one is used when deriving a similarity solution. The
reason is that we will be di↵erentiating the solution, and (1.52) leads to much
simpler formulas than the other representation. The rule of thumb here is that
you want x in the numerator of the similarity variable. If you would like a
hands on example of why this is true, try working out the steps below using
the representation u = u0 G(⇠) instead of (1.52).
Similarity Solution
Up to this point we have been using a routine dimensional reduction argument. Our result, given in (1.52), is interesting as it states that the solution
has a very specific dependence on the independent variables x and t. Namely,
u can be written as a function of a single intermediate variable ⌘. To determine F we substitute (1.52) back into the problem and find what equation
F satisfies. With this in mind note, using the chain rule,
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@u
@⌘
= u0 F 0 (⌘)
@t
@t
⇣

x

= u0 F (⌘)
0

=

2D1/2 t3/2
⌘
u0 F 0 (⌘) .
2t

⌘

In a similar manner one can show that
@2u
1
= u0 F 00 (⌘)
.
2
@x
Dt
Substituting these into (1.47) yields
F 00 =

1 0
⌘F ,
2

for 0 < ⌘ < 1.

(1.54)

We must also transform the boundary and initial conditions. The boundary
condition at x = 0 takes the form
F (0) = 1,

(1.55)

while the condition as x ! 1 and the one at t = 0 both translate into
F (1) = 0.

(1.56)

With this we have transformed a problem involving a partial di↵erential
equation (PDE) into one with an ordinary di↵erential equation (ODE). As
required, the resulting problem for F is only in terms of ⌘. All of the original
dimensional quantities, including the independent variables x and t, do not
appear anywhere in the problem. This applies not just to the di↵erential
equation, but also to the boundary and initial conditions.
The problem for F is simpler than the original di↵usion problem and, by
itself, makes the use of dimensional analysis worthwhile. In this particular
problem it is so simple that it is possible to solve for F . This can be done
by letting G = F 0 , so the equation takes the form G0 = 12 ⌘G. The general
solution of this is G = ↵ exp( ⌘ 2 /4). Because F 0 = G, we conclude that the
general solution is
Z
F (⌘) =

⌘

+↵

e

s2 /4

ds.

(1.57)

0

From (1.55) we have that

= 1 and from (1.56) we get
Z 1
2
1+↵
e s /4 ds = 0.
0

Given that

R1
0

e

s2 /4

ds =

p

⇡, then

(1.58)
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1
p
⇡

Z

⌘

e

s2 /4

ds.

(1.59)

0

Expressions like this arise so often that they have given rise to a special
function known as the complementary error function erfc(⌘). This is defined
as
Z ⌘
2
2
erfc(⌘) = 1 p
e r dr.
(1.60)
⇡ 0
Therefore, we have found that the solution of the di↵usion problem is
✓
◆
x
u(x, t) = u0 erfc p
.
(1.61)
2 Dt
As the above example demonstrates, using similarity variables and dimensional analysis provides a powerful tool for solving PDEs. It is, for example,
one of the very few methods known that can be used to solve nonlinear problems. Its limitation is that the problem must have a specific form to work. We
were able to solve the above di↵usion problem because dimensional analysis
reduced the form of the solution down to a function of one variable. This
does not always happen and in such cases the method provides no insight
into how the problem can be solved. As an example, if the spatial interval in
the above di↵usion problem is changed to one that is finite, so 0 < x < `,
then dimensional analysis will show that there are two independent similarity
variables. This represents no improvement as we already know it is a function
of two independent variables, so a reduction is not possible. Even with these
limitations, however, similarity variables and their use in solving di↵erential
equations is a thriving area and a good introduction of the material can be
found in Bluman and Cole [1974].

1.5 Nondimensionalization and Scaling
Another use we will have for dimensional analysis is to transform a problem
into dimensionless form. The reason for this is that the approximation methods that are used to reduce difficult problems are based on comparisons. For
example, in the projectile problem we simplified the di↵erential equation by
assuming that x was small compared to R. In contrast there are problems
where the variable of interest is large, or it is slow or that it is fast compared
to some other term in the problem. Whatever the comparison, it is important
to know how all of the terms in the problem compare and for this we need
the concept of scaling.
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1.5.1 Projectile Problem
The reduction of the projectile equation (1.1) was based on the assumption
that x is not very large, and so x + R could be replaced with just R. We
will routinely use arguments like this to find an approximate solution and it
is therefore essential we take more care in making such reductions. The way
this is done is by first scaling the variables in the problem using characteristic
values. The best way to explain what this means is to work out an example
and the projectile problem is an excellent place to start.
Change Variables
The first step in nondimensionalizing a problem is to introduce a change of
variables, which for the projectile problem will have the form
t = tc s,
x = xc u.
In the above formula, xc is a constant and it is a characteristic value of the
variable x. It is going to be determined using the physical parameters in
the problem, which for the projectile problem are g, R, and v0 . In a similar
manner, tc is a constant that has the dimensions of time and it represents
a characteristic value of the variable t. In some problems it will be clear at
the beginning how to select xc and tc . However, it is assumed here that we
have no clue at the start what to choose and will not select them until the
problem is studied a bit more. All we know at the moment is that whatever
the choice, the new variables u, s are dimensionless. To make the change of
variables note that from the chain rule
d
ds d
=
dt
dt ds
1 d
=
,
tc ds
and

d2
d
=
2
dt
dt

✓

d
dt

◆

=

(1.62)
1 d2
.
t2c ds2

(1.63)

With this the projectile equation (1.1) takes the form
1 d2
(xc u) =
t2c ds2

gR2
.
(R + xc u)2

(1.64)

The method requires us to collect the parameters into dimensionless groups.
There is no unique way to do this, and this can cause confusion when first
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learning the procedure as there is no fixed method or answer. For example,
to nondimensionalize the denominator in (1.64) one can factor it as either
R(1 + xc u/R) or as xc (R/xc + u). The first has the benefit of enabling us to
cancel the R in the numerator. Making this choice yields
xc d2 u
=
gt2c ds2

1
,
(1 + xc u/R)2

(1.65)

where the initial conditions (1.2), (1.3) are
u(0) = 0,
du
tc
(0) = v0 .
ds
xc

(1.66)
(1.67)

Find the Dimensionless Groups
Our change of variables has resulted in three dimensionless groups appearing
in the transformed problem. They are
xc
,
gt2c
xc
⇧2 =
,
R
tc v0
⇧3 =
.
xc
⇧1 =

(1.68)
(1.69)
(1.70)

There are a few important points that need to made here. First, the ⇧’s
do not involve the variables u, s and only depend on the parameters in the
problem. Second, they are dimensionless and to accomplish this it was necessary to manipulate the projectile problem so the parameters end up grouped
together to form dimensionless ratios. The third, and last, point is that the
above three dimensionless groups are independent in the sense that it is not
possible to write any one of them in terms of the other two. For example, ⇧1
is the only one that contains the parameter g while ⇧2 is the only one containing R. It is understood that in making the statement that the three groups
are independent that xc and tc can be selected, if desired, independently of
any of the parameters in the problem.
Before deciding on how to select xc and tc , it is informative to look a little closer at the above dimensionless groups. We begin with ⇧2 . In physical
terms it is a measure of a typical, or characteristic, height of the projectile
compared to the radius of the Earth. In comparison, ⇧3 is a measure of a
typical, or characteristic, velocity xc /tc compared to the velocity the projectile starts with. Finally, the parameter group ⇧1 measures a typical, or
characteristic, acceleration xc /t2c in comparison to the acceleration due to
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gravity in a uniform field. These observations can be helpful when deciding
on how to nondimensionalize a problem as will be shown next.
Use Dimensionless Groups to Determine Scaling
It is now time to actually decide on what to take for xc and tc . There are
whole papers written on what to consider as you select these parameters,
but we will take a somewhat simpler path. For our problem we have two
parameters to determine, and we will do this by setting two of the above
dimensionless groups equal to one. What we need to do is decide on which
two to pick, and we will utilize what might be called rules of thumb.
Rule of Thumb 1 : Pick the ⇧’s that appear in the initial and/or boundary
conditions.
We only have initial conditions in our problem, and the only dimensionless
group involved with them is ⇧3 . So we set ⇧3 = 1 and conclude
xc = v0 tc .

(1.71)

Rule of Thumb 2 : Pick the ⇧’s that appear in the reduced problem.
To use this rule it is first necessary to explain what the reduced problem is.
This comes from the earlier assumption that the object does not get very
high in comparison to the radius of the Earth, in other words, ⇧2 is small.
The reduced problem is the one obtained in the extreme limit of ⇧2 ! 0.
Taking this limit in (1.65)-(1.67), and using (1.71), the reduced problem is
⇧1

d2 u
=
ds2

1,

where

du
(0) = 1.
ds
According to the stated rule of thumb, we set ⇧1 = 1, and so
u(0) = 0,

and

xc = v02 /g.

(1.72)

This choice for xc seems reasonable based on our earlier conclusion that the
maximum height for the uniform field case is v02 /(2g).
Combining (1.71) and (1.72), we have that xc = v02 /g and tc = v0 /g. With
this scaling then (1.65) - (1.67) take the form
d2 u
=
ds2

1
,
(1 + ✏u)2

(1.73)
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where
u(0) = 0,
du
(0) = 1.
ds

(1.74)
(1.75)

The dimensionless parameter appearing in the above equation is
✏=

v02
.
gR

(1.76)

This parameter will play a critical role in our constructing an accurate approximation of the solution of the projectile problem. This will be done in
the next chapter but for the moment recall that since R ⇡ 6.4 ⇥ 106 m and
2
g ⇡ 9.8 m/s then ✏ ⇡ 1.6 ⇥ 10 8 v02 . Consequently for baseball bats, sling
shots, BB-guns, and other everyday projectile-producing situations, where
v0 is not particularly large, the parameter ✏ is very small. This observation
is central to the subject of the next chapter.
Changing Your Mind
Before leaving this example it is worth commenting on the nondimensionalization procedure by asking a question. Namely, how bad is it if di↵erent
choices would have been made for xc and tc ? For example, suppose for some
reason one decides to take ⇧2 = 1 and ⇧3 = 1. The resulting projectile
problem is
d2 u
1
✏ 2 =
,
(1.77)
ds
(1 + u)2
where u(0) = 0, du
ds (0) = 1, and ✏ is given in (1.76). No approximation has
been made here and therefore this problem is mathematically equivalent to
the one given in (1.73)-(1.75). Based on this, the answer to the question would
be that using this other scaling is not so bad. However, the issue is amenability
and what properties of the solution one is interested in. To explain, earlier we
considered how the solution behaves if v0 is not very large. With the scaling
that produced (1.77), small v0 translates into looking at what happens when
✏ is near zero. Unfortunately, the limit of ✏ ! 0 results in the loss of the
highest derivative in the di↵erential equation and (1.77) reduces to 0 = 1.
How to handle such singular limits will be addressed in the next chapter
but it requires more work than is necessary for this problem. In comparison,
letting ✏ approach zero in (1.73) causes no such complications and for this
reason it is more amenable to the study of the small v0 limit. The point here
is that if there are particular limits, or conditions, on the parameters that it
is worth taking them into account when constructing the scaling.
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1.5.2 Weakly Nonlinear Di↵usion
To explore possible extensions of the nondimensionalization procedure we
consider a well-studied problem involving nonlinear di↵usion. The problem
consists of finding the concentration c(x, t) of a chemical over an interval
0 < x < `. The concentration satisfies
@2c
@c
D 2 =
@x
@t

(

c)c,

(1.78)

where the boundary conditions are
c|x=0 = c|x=` = 0,

(1.79)

c|t=0 = c0 sin(5⇡x/`).

(1.80)

and the initial condition is

The nonlinear di↵usion equation (1.78) is known as Fisher’s equation, and
it arises in the study of the movement of genetic traits in a population. A
common simplifying assumption made when studying this equation is that the
nonlinearity is weak, which means that the term c2 is small in comparison
to the others in the di↵erential equation. This assumption will be accounted
for in the nondimensionalization.
Before starting the nondimensionalization process we should look at the
fundamental dimensions of the variables and parameters in the problem.
First, c is a concentration, which corresponds to the number of molecules
per unit volume, and so [c] = L 3 . The units for the di↵usion coefficient D
were determined earlier, and it was found that [D] = L2 /T . As for , the
c term in the di↵erential equation requires these two quantities to have
the same dimensions, and so [ ] = [c]. Similarly, from the di↵erential equation
3
1
we have [ (
c)c] = [ @c
. Finally,
@t ], and from this it follows that [ ] = L T
from the initial condition we have that [c0 ] = [c]. It is important to make an
observation related to dimensions, and this will be done by asking a question:
is it possible to replace the initial condition (1.80) with c|t=0 = c0 sin(5⇡x)
or with c|t=0 = c0 sin(x)? The answer in both cases is no, and the reason is
that the argument of the sine function must be dimensionless. For exactly
the same reason it is not possible to use c|t=0 = c0 ex . It is possible, however,
to use c|t=0 = c0 x or c|t=0 = c0 x2 , although the dimensions of c0 di↵er from
what we found earlier.
Now, to nondimensionalize the problem we introduce the change of variables
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x = xc y,
t = tc s,
c = cc u.

(1.81)
(1.82)
(1.83)

In this context, xc has the dimensions of length and is a characteristic value
of the variable x. Similar statements apply to tc and cc . Using the chain rule
as in (1.62) the above di↵erential equation takes the form
Dcc @ 2 u
cc @u
=
2
2
xc @y
tc @s

cc (

cc u)u.

It is necessary to collect the parameters into dimensionless groups, and so in
the above equation we rearrange things a bit to obtain
Dtc @ 2 u
@u
=
2
2
xc @y
@s

tc cc ( /cc

u)u.

(1.84)

In conjunction with this we have the boundary conditions
u|y=0 = u|y=`/xc = 0,

(1.85)

u|s=0 = (c0 /cc ) sin(5⇡xc y/`).

(1.86)

and the initial condition is

The resulting dimensionless groups are
Dtc
,
x2c
= tc cc ,
= /cc ,
= `/xc ,
= c0 /cc .

⇧1 =

(1.87)

⇧2
⇧3
⇧4
⇧5

(1.88)
(1.89)
(1.90)
(1.91)

It is important to note that the five dimensionless groups given above are
independent in the sense that it is not possible to write one of them in terms
of the other four. As before this statement is based on our ability to select,
if desired, the scaling parameters xc , tc , cc independently of each other and
the other parameters in the problem. Also, in counting the dimensionless
groups one might consider adding a sixth. Namely, in the initial condition
(1.86) there is ⇧6 = 5⇡xc /`. The reason it is not listed above is that it is
not independent of the others because ⇧6 = 5⇡/⇧4 . The 5⇡ is a number and
does not play a role in determining dimensional independence.
We have three scaling parameters to specify, namely xc , tc , cc . Using Rule
of Thumb 1, the ⇧’s that appear in the boundary and initial conditions are
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set equal to one. In other words, we set ⇧4 = 1 and ⇧5 = 1, from which it
follows that xc = ` and cc = c0 .
To use Rule of Thumb 2, we need to investigate what it means to say that
the nonlinearity is weak. The equation (1.84) is nonlinear due to the term
tc cc u2 , and the coefficient tc cc is the associated strength of the nonlinearity.
For a weakly nonlinear problem one is interested in the solution for small
values of tc cc . Taking the extreme limit we set tc cc = 0 in (1.84) to produce
the reduced equation. The only group that remains in this limit is ⇧1 , and for
this reason this is the group we select. So, setting ⇧1 = 1 then we conclude
tc = `2 /D.
The resulting nondimensional di↵usion equation is
@2u
@u
=
2
@y
@s

✏(b

u)u,

(1.92)

with boundary conditions
u(0, s) = u(1, s) = 0,

(1.93)

u(y, 0) = sin(5⇡y).

(1.94)

and the initial condition

The dimensionless parameters appearing in the above equation are ✏ =
c0 `2 /D and b = /c0 . With this, weak nonlinearity corresponds to assuming
that ✏ is small.

1.5.3 Endnotes
As you might have noticed, the assumption of a weak nonlinearity was used in
the projectile problem, although it was stated in more physical terms. In both
examples the reduced problem, obtained setting ✏ = 0, is linear. It is certainly
possible that a physical problem is not weakly nonlinear but involves some
other extreme behavior. As an example, in nonlinear di↵usion problems you
come across situations involving weak di↵usion. What this means for (1.84) is
that Dtc /x2c has a small value. In the extreme limit that this term is zero then
the only group that remains in the reduced problem is ⇧2 . Setting ⇧2 = 1
then tc = c0 / . With this, (1.84) becomes
✏

@2u
@u
=
+ (b
2
@x
@t

u)u,

(1.95)

where ✏ = Dc0 /( `2 ) and b = /c0 . With this, weak di↵usion corresponds to
assuming that ✏ is small.
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For those keeping track of the rules of thumb used to nondimensionalize
a problem we have two. The first we ran across is the rule that the dimensionless groups in the initial and boundary conditions are set to one. The
second rule arose when setting the dimensionless groups in the reduced problem to one. Although these can be e↵ective rules, it is certainly possible to
find problems where another scaling should be considered, and examples are
given in Exercises 1.17 and 3.8. The overall objective in all cases is that the
nondimensionalization is based on characteristic values of the variables.

Exercises
1.1. The amount of noise permitted from the large rollers used in road construction was recently limited by changes in the environmental laws. Rather
than build multiple full-sized rollers in an attempt to find one that satisfied
the new law a manufacturer decided that dimensional analysis could be used.
The assumption they made was that the frequency f of the sound coming
o↵ the roller depends on the elastic modulus E and the density ⇢ of the steel
used to construct the roller as well as on the length ` of the roller.
(a) Find a dimensionally reduced form for f .
(b) In building a scale model for testing the manufacturer selected the parameters so that
s
fm
`f ⇢f Em
=
,
ff
`m ⇢m Ef
where the subscript f designates full-sized and the subscript m designates
scale model. Explain why this was done.
1.2. For a pendulum that starts from rest, the period p depends on the length
` of the rod, on gravity g, on the mass m of the ball, and on the initial angle
✓0 at which the pendulum is started.
(a) Use dimensional analysis to determine the functional dependence of p on
these four quantities.
(b) For the largest pendulum ever built, the rod is 70 ft and the ball weighs
900 lbs. Assuming that ✓0 = ⇡/6 explain how to use a pendulum that fits
on your desk to determine the period of this largest pendulum.
(c) Suppose it is found that p depends linearly on ✓0 , with p = 0 if ✓0 = 0.
What does your result in part (a) reduce to in this case?
1.3. The velocity v at which flow in a pipe will switch from laminar to turbulent depends on the diameter d of the pipe as well as on the density ⇢ and
dynamic viscosity µ of the fluid.
(a) Find a dimensionally reduced form for v.
(b) Suppose the pipe has diameter d = 100 and for water (where ⇢ = 1 and
µ = 10 2 ) it is found that v = 0.25 . What is v for olive oil (where ⇢ = 1
and µ = 1)? The units here are in cgs.
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1.4. The luminosity of certain giant and supergiant stars varies in a periodic
manner. It is hypothesized that the period p depends upon the star’s average
radius r, its mass m, and the gravitational constant G.
(a) Newton’s law of gravitation asserts that the attractive force between two
bodies is proportional to the product of their masses divided by the square
of the distance between them, that is,
F =

Gm1 m2
,
d2

where G is the gravitational constant. From this determine the (fundamental) dimensions of G.
(b) Use dimensional analysis to determine the functional dependence of p on
m, r, and G.
(c) Arthur Eddington used the theory for thermodynamic heat engines to
show that
r
3⇡
p=
,
2 G⇢
where ⇢ is the average density of the star and is the ratio of specific
heats for stellar material. How does this di↵er from your result?
(d) In Figure 1.8 the data for a pulsating star are given. Explain how you
could use data like this to complete the formula you derived in part (b).

1.5. When a drop of liquid hits a wetted surface a crown formation appears,
as shown in Figure 1.9(a). It has been found that the number of points N on
the crown depends on the speed U at which the drop hits the surface, the
radius r and density ⇢ of the drop, and the surface tension of the liquid
making up the drop. How N depends on these quantities has been studied
extensively and some of the reasons why are given in Rioboo et al. [2003].
(a) Use dimensional reduction to determine the functional dependence of N
on U , r, ⇢, and . Express your answer in terms of the Weber number
We = ⇢U 2 r/ .

Magnitude

14
12
10
8
6
1998

2003
Time

2008

Figure 1.8 Luminosity of a Mira type variable star, 1621+19 U Herculis (AAVSO
[2009]).
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150
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Figure 1.9 (a) Formation of a crown when a liquid drop hits a wetted surface. (b)
The measured values of the number of points N (Hobbs and Kezweent [1967]).

(b) The value of N has been measured as a function of the initial height h of
the drop and the results are shown in Figure 1.9(b). Express your answer
in part (a) in terms of h by writing U in terms of h and g. Assume the
drop starts with zero velocity.
(c) The data in Figure 1.9(b) show a piecewise linear dependence on h, specifically, N can be described as a continuous function made up of two linear
segments. Use this, and your result from part (b), to find the unknown
function in part (a). In the experiments, r = 3.6 mm, ⇢ = 1.1014 gm/cm3 ,
and = 50.5 dyn/cm.
(d) According to your result from part (c), what must the initial height of the
drop be to produce at least 80 points?
(e) According to your result from part (c), how many points are generated
for a drop of mercury when h = 200 cm? Assume r = 3.6 mm, ⇢ = 13.5
gm/cm2 , and = 435 dyn/cm.
1.6. The frequency ! of waves on a deep ocean is found to depend on the
wavelength of the wave, the surface tension of the water, the density ⇢
of the water, and gravity.
(a) Use dimensional reduction to determine the functional dependence of !
on , , ⇢, and g.
(b) In fluid dynamics it is shown that
s
k3
,
! = gk +
⇢
where k = 2⇡/ is the wavenumber. How does this di↵er from your result
in (a)?
1.7. A ball is dropped from a height h0 and it rebounds to a height hr .
The rebound height depends on the elastic modulus E, radius R, and the
mass density ⇢ of the ball. It also depends on the initial height h0 and the
gravitational constant g.
(a) Find a dimensionally reduced form for hr .
(b) Suppose it is found that hr depends linearly on h0 , with hr = 0 if h0 = 0.
What does your formula from part (a) reduce to in this case?
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(c) Suppose the density of the ball is doubled. Use the result in (a) to explain
how to change E so the rebound height stays the same.
1.8. A ball, when released underwater, will rise towards the surface with
velocity v. This velocity depends on the density ⇢b and radius R of the ball,
on gravity g, and on the density ⇢f and kinematic viscosity ⌫ of the water.
(a) Find a dimensionally reduced form for v.
(b) In fluid mechanics, using Stokes’ Law, it is found that
v=

2gR2 (⇢b ⇢f )
.
9⌫⇢f

How does this di↵er from your result from part (a)? It is interesting to note
that this formula is used by experimentalists to determine the viscosity of
fluids. They do this by measuring the velocity in an apparatus called a
falling ball viscometer, and then solving for ⌫ in the above formula.
1.9. In electric image tomography the objective is to determine the properties
inside an object and this is done by applying a potential U to the surface.
What is measured is the resulting electric current j on the surface. Suppose
that it is found that the electric potential u within a spherical body depends
on the object’s radius R and conductivity as well as depends on U and j.
(a) Find a dimensionally reduced form for u.
(b) Suppose that given a particular object that doubling the applied potential
U causes the internal potential u to increase by a factor of four. How does
this help simply your result in (a)?
(c) Suppose it is necessary to know the internal potential u when using a large
applied potential, say U = 2500V . However, for legal reasons it is required
that only applied potentials less than 250V can be used. Explain, using
your result from (a), how to legally determine the large applied potential
value.
1.10. The velocity v of water through a circular pipe depends on the pressure
di↵erence p between the two ends of the pipe, the length ` and radius r of
the pipe, as well as on the dynamic viscosity µ and density ⇢ of the water.
(a) Use dimensional analysis to determine the functional dependence of v on
the above quantities.
(b) Suppose it is found that v depends linearly on p, with v = 0 if p = 0.
What does your formula from part (a) reduce to in this case?
(c) Your formula from part (b) should contain a general function of one, or
more, dimensionless products. Explain how to experimentally determine
this function. Be specific about which parameters are fixed, and which are
varied, in the experiment. Also, your experiment should vary as few of the
parameters as possible in determining this function.
1.11. In a high energy explosion there is a very rapid release of energy E
that produces an approximately spherical shock wave that expands in time
(Figure 1.10).
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Figure 1.10 Shock wave produced by a nuclear explosion, at 6 msec, 16 msec, 25
msec, and 90 msec. The width of the white bar in each figure is 100m (Brixner [2009]).

(a) Assuming the radius R of the shock wave depends on E, the length of
time t since the explosion, and the density ⇢ of the air, use dimensional
reduction to determine how the radius depends on these quantities. This
expression is known as the Taylor-Sedov formula.
(b) It was shown by G. I. Taylor that if E = 1J and ⇢ = 1 kg/m3 then
R = t2/5 m/s2/5 . Use this information and the result from (a) to find the
exact formula for R.
(c) Use the photographs in Figure 1.10, and your result from (b) to estimate
the energy released. The air density is ⇢ = 1 kg/m3 .
(d) The blast wave from a supernova can be modeled using the Taylor-Sedov
formula. Explain how this can be used to estimate the date the supernova
took place, using your result from part (b). As an example, use Tycho,
which currently has a radius of about 33.2 light years, an estimated energy
of 1044 J, and density ⇢ = 2 ⇥ 10 21 kg/m3 .
1.12. The vertical displacement u(x) of an elastic string of length ` satisfies
the boundary value problem
⌧

d2 u
+ µu = p,
dx2

for 0 < x < `,

where u(0) = 0, u(`) = U . Also, p is a constant and has the dimensions of
force per length.
(a) What are the dimensions for the constants ⌧ and µ?
(b) Show how it is possible to nondimensionalize this problem so it takes the
form
d2 v
+ ↵v = , for 0 < s < 1,
ds2
where v(0) = 0, v(1) = 1. Make sure to state what ↵, are.
1.13. From Newton’s second law, the displacement y(t) of the mass in a mass,
spring, dashpot system satisfies
m

d2 y
= Fs + Fd ,
dt2

for 0 < t,

where m is the mass, Fs is the restoring force in the spring, and Fd is the
damping force. To have a compete IVP we need to state the initial conditions,
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and for this problem assume
y(0) = 0,

dy
(0) = v0 .
dt

(a) Suppose there is no damping, so Fd = 0, and the spring is linear, so
Fs = ky. What are the dimensions for the spring constant k? Nondimensionalize the resulting IVP. Your choice for yc and tc should result in
no dimensionless products being left in the IVP.
(b) Now, in addition to a linear spring, suppose linear damping is included,
so,
dy
Fd = c .
dt
What are the dimensions for the damping constant c? Using the same
scaling as in part (a), nondimensionalize the IVP. Your answer should
contain a dimensionless parameter ✏ that measures the strength of the
damping. In particular, if c is small then ✏ is small. The system in this
case is said to have weak damping.
1.14. The velocity v(t) of the waves on a deep ocean satisfies the equation
dv
+ kv 2 = `v,
dt

for 0 < t,

where v(0) = V .
(a) What are the dimensions of the constants k, `, and V ?
(b) Assuming a weak nonlinearity, use the Rules of Thumb given in Section
1.5 to nondimensionalize this problem.
1.15. The equation for an elastic beam is
EI

@4u
@2u
+
⇢
= 0,
@x4
@t2

where the boundary conditions are u = u0 sin(!t) and @u
@x = 0 at x = 0, while
@u
u = @x = 0 at x = `. Assume the initial conditions are u = 0 and @u
@t = 0
at t = 0. Here E is the elastic modulus, I is the moment of inertia, and ⇢
is the mass per unit length of the beam. Nondimensionalize the problem in
such a way that the resulting boundary conditions contain no nondimensional
groups.
1.16. When an end of a slender strip of paper is put into a cup of water,
because of absorption, the water rises up the paper. The density ⇢ of the
water along the strip satisfies the di↵erential equation
@⇢ @J
+
= 0,
@t
@x
where J is known as the flux.
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(a) What are the dimensions of J?
(b) The flux J depends on the gravitational constant g, the strip width d,
@⇢
the density gradient @x
, and the surface tension of the water. Find a
dimensionally reduced form for J.
(c) What does your result in (b) reduce to if it is found that J depends linearly
on the density gradient, with J = 0 if ⇢x = 0? What is the resulting
di↵erential equation?
(d) If the strip has length h the boundary conditions are ⇢ = ⇢0 at x = 0 and
J = 0 at x = h. The initial condition is ⇢ = 0 at t = 0. With this, and
your di↵erential equation from (c), nondimensionalize the problem for ⇢
in such a way that no nondimensional groups appear in the final answer.
1.17. A thermokinetic model for the concentration u and temperature q of a
mixture consists of the following equations (Gray and Scott [1994])
du
= k1 k2 uek3 q ,
dt
dq
= k4 uek3 q k5 q.
dt
The initial conditions are u = 0 and q = 0 at t = 0.
(a) What are the dimensions of the ki ’s?
(b) Explain why the rule of thumb for scaling used in the projectile problem
does not help here.
(c) Find the steady-state solution, that is, the solution of the di↵erential equations with u0 = 0 and q 0 = 0.
(d) Nondimensionalize the problem using the steady-state solution from (c) to
scale u and q. Make sure to explain how you selected the scaling for t.
1.18. The equations that account for the relativistic motion of a planet
around the sun are
✓ ◆2
d2 r
d✓
Gm
b
r
=
+ 3,
2
2
dt
dt
r
r
✓
◆
d
d✓
r2
= 0,
dt
dt
where b is a constant. Assume the initial conditions are r = r0 , r0 = 0, and
✓ = 0 at t = 0.
(a) What are the dimensions of r0 , b?
(b) Nondimensionalize the problem. The scaling should be chosen so the only
nondimensional group appearing in the problem involves b.
1.19. Suppose you are given a dimensionless function f (⇧) where ⇧ is a
dimensionless group. Also, suppose ⇧ = Aa B b C c where A, B, C are dimensional parameters and the exponents a, b, c are nonzero numbers.
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(a) Show that if f (⇧) is found to be linear in A then it must be that f (⇧) =
↵⇧ 1/a + where ↵, are arbitrary numbers.
p
(b) What can you conclude if it is found that ABf (⇧) is linear in A?
(c) Suppose it is found that if A is doubled that the value of F increases by a
factor of four. Can this be used to determine F ?
1.20. This problem explores some consequences of dimensional quantities.
(a) If g is the gravitational acceleration constant, explain why sin(g) and eg
make no sense.
(b) Explain why density, volume, and velocity can be used in place of length,
mass, and time as fundamental units.
(c) Explain why volume, velocity, and acceleration cannot be used in place of
length, mass, and time as fundamental units.
1.21. In quantum chromodynamics three parameters that play a central role
are the speed of light c, Planck’s constant ~, and the gravitational constant
G.
(a) Explain why it is possible to use [c], [~], [G] as fundamental units.
(b) The distance `p at which the strong, electromagnetic and weak forces become equal depends on c, ~, G. Find a dimensionally reduced form for how
`p depends on these three parameters. Based on this result, if the speed
of light were to double what happens to `p ?
(c) The Bohr radius a of an electron depends on ~, the electron’s charge e,
and the mass me of the electron. Find a dimensionally reduced form for a.
1.22. The speed cm at which magnetonsonic waves travel through a plasma
depends on the intensity B of the magnetic field, the permeability µ0 of free
space, and the density ⇢ and pressure p of the plasma.
(a) Use dimensional reduction to determine the functional dependence of cm
on B, µ0 , ⇢, and p.
(b) From the basic laws for plasmas it is shown that
q
cm = VA2 + c2s ,

p
p
where VA = B/ µ0 ⇢ is the Alfven speed and cs =
p/⇢ is the sound
speed in the gas. In the latter expression, is a number. How does this
di↵er from your result in (a)?

1.23. In the study of the motion of particles moving along the x-axis one
comes across the problem of finding the velocity u that satisfies the nonlinear
partial di↵erential equation
ut + uux = 0,
where
u(x, 0) =

⇢

0
u0

if x < 0
if 0 < x.

(1.96)

(1.97)
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Assume that u0 is a positive constant. The equation (1.96) is derived in
Chapter 5, and it is known as the inviscid Burgers’ equation. It, along with
the jump condition in (1.97), form what is known as a Riemann problem.
(a) What three physical quantities does u depend on?
(b) Use dimensional reduction, and a similarity variable, to reduce this problem to a nonlinear ordinary di↵erential equation with two boundary conditions.
(c) Use the result from part (b) to solve the Riemann problem. The solution,
which is known as an expansion fan, must be continuous for t > 0.
(d) What is the solution if the initial condition (1.97) is replaced with u(x, 0) =
u0 ?
(e) Suppose that, rather than velocity, the variable u is displacement. Explain
why it is not possible for u to satisfy (1.96).
1.24. Consider the partial di↵erential equation
ut + Duxxxx = 0,
where u = u0 at x = 0, u ! 0 as x ! 1, and u = 0 at t = 0. Use dimensional
reduction, and a similarity variable, to reduce this problem to an ordinary
di↵erential equation.
1.25. The equation of the concentration c, on an interval of length `, is
@2c
@c
= D 2 + µc,
@t
@x
where the boundary conditions are c(x, 0) = 0, c(0, t) = c0 , and c(`, t) = 0.
(a) What are the dimensions of D, c0 , and µ?
(b) Nondimensionalize the problem so it has the form
@u
@2u
=
+ ↵u,
@s
@y 2
where the boundary conditions are u(y, 0) = 0, u(0, s) = 1, and u(1, s) = 0.
1.26. One of the standard experimental tests used in the study of fluid motion
through porous materials consists of determining the displacement u when
the material is given a constant load. The governing di↵erential equation in
this case is
"
✓ ◆3 # 2
@u
@ u
@u
H 1+
=
.
2
@x
@x
@t
The boundary conditions are
@u
=
@x
and

1,

at x = 0,
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1 Dimensional Analysis

u = 0,
The initial condition is

as x ! 1.

u = 0,

at t = 0.

(a) What are the dimensions of the constant H?
(b) Find a dimensionally reduced form for the solution and then use this to
transform the above di↵usion problem into one involving a nonlinear ordinary di↵erential equation. Make sure to state what happens to the boundary and initial conditions. You do not need to solve this problem.
(c) In the experiment the surface displacement u(0, t) is measured. Without
solving the problem use your results from (b) to sketch u(0, t) as a function
of t.
(d) Suppose the experimental data show that u(0, t) = 16t cm/sec. Using your
result from part (c), explain why the mathematical model is incorrect.
Also, explain why changing the di↵erential equation to either Huxx = ut
or to H[1 + (ux )5 ]uxx = ut will also produce an incorrect model.
1.27. Consider the problem of solving the di↵usion equation
D

@u
@2u
=
,
2
@x
@t

where the boundary conditions are
u = 0,

as x ! ±1.

Instead of an initial condition, assume the solution satisfies
Z 1
udx = , 8t > 0.
1

(a) What are the dimensions of ?
(b) Find a dimensionally reduced form for the solution and then use this to
transform the above di↵usion equation into an ordinary di↵erential equation. How do the boundary conditions transform? The integral condition
should be considered in the dimensional reduction but its conversion using
the similarity variable will wait until part (d).
(c) Find the solution of the problem from part (b). You can assume F 0 ! 0
and ⌘F ! 0 as ⌘ ! ±1. As a hint, you might want to look for the
expression (⌘F )0 in your equation.
(d) The solution from part (c) should contain an arbitrary constant. Find its
value using the given integral condition and with this show that
u= p

⇡Dt

e

x2 /(4Dt)

.

This is known as the fundamental, or point source, solution of the di↵usion
equation.

http://www.springer.com/978-0-387-87749-5
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Pumps

Where Innovation Flows
MULTIPLE-USE QUATERNARY DIAPHRAGM PUMPS
SINGLE-USE QUATERNARY DIAPHRAGM PUMPS

quattroflow.com

The Idea:

Pump Follows Evolution
How does a pump have to be designed to convey extremely delicate
biologically active molecules? The solution is in nature itself!
Millions of years of evolution developed the perfect device to pump
blood that contains albumin, gamma globulins, clotting factors and
cells. It is the heart!
The Quattroflow displacement pump is based on this principle.
The 4-piston (quaternary) diaphragm technology enables a
gentle pumping through soft “heartbeats”. Each stroke of the four
diaphragms is generated by an eccentric shaft, which is connected to
the electric motor.
The method of operation of Quattroflow pumps allows them to gently,
safely and securely convey aqueous solutions and biologic products
that are sensitive to shear force with minimal impact. The four-piston
design does not require a mechanical seal or wetted rotating parts,
ensuring total product containment without abrasion and minimum
particle generation. Additionally, the four-piston pumping principle
enables risk-free dry-running, low pulsation, self-priming and a high
turn-down ratio.
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MARKETS SERVED
BIOPHARMACEUTICAL:
Quattroflow™ develops and manufactures single-use and multiple-use Quaternary (Four-Piston) Diaphragm Pumps for critical
applications in the biopharmaceutical industry. This technology is CIP/SIP capable and offers disposable solutions that increase
flexibility, reduce down-time, eliminate costs of cleaning validation, and risks of cross-contamination.
Quattroflow pumps can be found in all areas of biologic manufacturing such as cross-flow filtration systems, chromatography, and
centrifuges. Quattroflow ensures safety, efficiency and reliability for handling biologics such as plasma products, therapeutic proteins,
monoclonal antibodies, vaccines, and other high value products.
Typical Applications and Products Handled:
• Chromatography systems

• Reaction dosing

• Virus cultures

• Antibodies

• Cross-flow systems, TFF

• Virus or sterile filtration

• Bacterial and viral vaccines

• Virus inactivation

• Centrifuges

• Depth filtration

• Cell cultures

• Homogenizers

• Buffer mixing systems

• Cell cultures supernatants

• Direct flow filters

• Blood plasma fractionation

• Enzyme solutions

Quattroflow Pumps in the Up- and Downstream Processing of Monoclonal Antibodies
Buffer & Media
Prepatation

Bioreactor

Separator

Microfiltration

Protein A
Chromatography

QuattroMix
Column
Packing

Sterile
Filtration
Column
Packing
Virus
Inactivation
and
pH Adjustment

TFF Buffer
Exchange

Permeate
(Waste)

TFF
Concentration

Permeate
(Waste)

Cation Exchange
Chromatography
Column
Packing
Virus
Filtration
Anion Exchange
Chromatography

Bulk Formulation and Filling
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Multiple-Use Pumps
Pump Development for
Special Applications
Biopharmaceutical processes require the highest level of purity,
containment and cleanability. Quattroflow pumps meet these
requirements as they are specially designed for such applications.
Quattroflow provides the most versatile and efficient stainless-steel
multiple-use pumps for worldwide applications in laboratories,
pilot plants and production plants.

QF-Series Multiple-Use Biopharma Pumps
The QF150S, QF1200S, QF4400S, QF5050S and QF20k Series
quaternary diaphragm positive displacement pumps do not
utilize mechanical shaft seals or wetted rotating parts, ensuring
total product containment without abrasion and minimum particle
creation. Moreover, the pumping principle of the Quattroflow
pumps allows risk-free dry running.

QF4400S
Multiple-Use Quaternary
Diaphragm Pump
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Single-Use Pumps
The Single-Use Advantage
Quattroflow single-use pumps have a disposable product wetted chamber constructed of
solid polypropylene (PP) or injection-molded polyethylene (PE) that can be replaced as a
complete unit. The simple disposability of the pump chamber saves time and money by
eliminating cleaning validation, sterilization and product cross-contamination. Single-use
pumps are critical to reduce equipment turnaround times in the development biosimilar
processes. In general, multi-product facilities is the typical field of application of the singleuse pumps (e.g. process development, production of clinical reference samples, contract
manufacturing).

QF150SU, QF1200SU, QF4400SU and QF5050SU
Single-Use Quaternary Diaphragm Pumps
The Quattroflow single-use pumps are self-priming and can be run dry. Inside the pump
chamber, there are no rotating parts that are subject to friction that might cause particle
generation and/or product modification/degradation due to heat generation. A single-use
pump chamber can be replaced and ready for a new batch in a few minutes. Its simple
design requires only one tool. An exchange kit is available to retrofit a multi-use pump into
a single-use pump.

PALL Allegro™ Single-Use Tangential Flow
Filtration System” using a Quattroflow
QF1200SU as recirculation pump.

PALL Allegro™ MVP Single-Use System” also
with a Quattroflow QF1200SU pump, for
different applications like virus filtration, sterile
filtration, membrane chromatography, etc.

Images supplied courtesy of Pall Corporation
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TECHNOLOGY: 4-PISTON DIAPHRAGM

Multiple-Use and Single-Use
Quaternary Diaphragm Pumps

Quattroflow multiple-use pumps have a vast array of options and flow rates to
accommodate many biopharmaceutical applications. Whether your requirement
is 1 lph (0.017 lpm) or 20,000 lph (333 lpm) Quattroflow has your application
covered with high purity, easily cleanable, multiple use units. From OEM’s and
small scale automated systems, to large laboratories and crossflow systems, the
QF Series provides the purity needed for the most demanding pharmaceutical
and bio-technology applications.
Quattroflow single-use combines convenience with the ability to save time
and money by eliminating the cost of cleaning and decontamination. Gammairradiated upon request, these pumps ensure the integrity of your process and
production output by providing the safe, clean and reliable transfer of your high
purity process fluids.

QF150S
Multiple-Use Quaternary
Diaphragm Pump

Applications and Products
• Chromatography systems
• Cross-flow systems, TFF
• Centrifuges
• Homogenizers
• Direct flow filters
• Reaction dosing
• Virus or sterile filtration
• Depth filtration
• Buffer mixing systems

•
•
•
•
•
•
•
•
•

Blood plasma fractionation
Virus cultures
Bacterial and viral vaccines
Cell cultures
Cell cultures supernatants
Enzyme solutions
Antibodies
Virus inactivation
DF/MF/UF filters

Features and Benefits
• Minimal maintenance
• Minimal downtime
• Low pulsation
• Superior containment
• Variable wide flow
• Capable of dry run
• Self-priming
• Cleanable outer surface
• Linear turndown
• Compact design

•
•
•
•
•
•
•
•
•
•

Low heat input
High purity
Minimum particle shedding
Quiet operation
Lower life cycle cost
Ease of use
Quick start-up
Scaleable
No cell damage
Low shear

Technical Data
• Stainless steel materials of construction
• Single-use pump chamber: Solid polypropylene or injection-molded
polyethylene
• Valves: EPDM
• Diaphragm: TPE (EPDM/PP)
QF1200SU
Single-Use Quaternary
Diaphragm Pump

Performance Data
• Flow range: 1 lph - 20,000 lph (0.017 - 333 lpm)
• Max. discharge pressure: 6 bar (87 psi)
• Max. temperature: 130°C (266°F)
Certifications & Associations
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PUMP SELECTION GUIDE
Multiple-Use Pumps

Pump
Size

QF150S

QF1200S

QF1200S-CV

QF4400S

QF5050S

QF20k

Flow
Range

1 – 180 lph
0.017 - 3 lpm

10 – 1,200 lph
0.167 - 20 lpm

10 – 1,200 lph
0.167 - 20 lpm

150 – 5,000 lph
2.5 - 83 lpm

50 – 5,000 lph
0.83 - 83 lpm

1,000 – 20,000 lph
16.7 - 333 lpm

More Data
On Page

8

9

10

11

12

13

Single-Use Pumps

Pump
Size

QF150SU

QF1200SU

QF1200SU-M

QF1200SU-XAQ

QF1200SU-CV

QF4400SU

QF5050SU

Flow
Range

1 – 180 lph
0.017 - 3 lpm

10 – 1,200 lph
0.167 - 20 lpm

10 – 1,200 lph
0.167 - 20 lpm

10 – 1,200 lph
0.167 - 20 lpm

10 – 1,200 lph
0.167 - 20 lpm

150 – 5,000 lph
2.5 - 83 lpm

50 – 5,000 lph
0.83 - 83 lpm

More Data
On Page

14

15

16

17

18

19

20

For Accessories please see page 21.
All Quattroflow pump sizes are available with different options, such as controller, housing, ports and motor. Consider the standard versions
of all sizes for the technical data presented on the following pages.
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QF150S

Quaternary Diaphragm Pumps
Multiple-Use
• Integrated controller
• Digital key pad for manual operation
• Small and portable format
• Ideal for R&D and process development

Technical Data
QF150S Standard Motor
Flow Rate Maximum:
Flow Rate Minimum:
Pressure:

Maximum
Temperature:

Eccentric Shaft 5°

180 lph (3 lpm)

Eccentric Shaft 5°

1 lph (0.017 lpm)

Temperature of Fluid < 40° C (104° F)

4 bar (58 psi)

Fluid

80° C (176° F)

CIP

90° C (194° F)

SIP

130° C (266° F)

Autoclave

130° C (266° F)

Suction Lift Dry
at 3000 rpm:

Eccentric Shaft 5°

Volume
Specifications:

Approximated Volume per
Revolution at Free Output

1.2 ml

Filling Volume Without Connectors

15 ml

Connectors

1/4" TC

Position of Connectors

Inline

Connection
Specification
(Standard):

Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

Motor (Standard):

Pump Dimension with
Motor and Housing:

Number of Flow Directions

2 -3 m
(6.6 - 9.8 ft)

4

Pump Housing

SS316L

Valve Plate

SS316L

Diaphragms
Valves

TPE
EPDM

O-rings
EPDM
Elastomere
USP <88> Cl. VI;
(product wetted) FDA21CFR177; BSE/TSE Safe
Stainless Steel Parts 3.1; Surface Roughness;
(product wetted)
Ferrite Content
Rated speed
3000 min-1
Voltage

230 V (110 V as option)

Power

0.05 KW

Length

280.5 mm (11.04")

Width

115 mm (4.53")

Height

184 mm (7.24")

Pump Weight with
Motor and Housing:
Other connection specifications, materials and motors available on request.
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6 bar (87 psi)

Temperature of Fluid > 40° C (104° F)

8.4 kg (19 lb.)

Performance Charts
Eccentric Shaft: 5º

QF1200S

Quaternary Diaphragm Pumps
Multiple-Use
• Separate control box for manual operation available
• ATEX version available

Technical Data
QF1200S Standard Motor
Flow Rate
Maximum:
Flow Rate
Minimum*:
Pressure:

Maximum
Temperature:
Pump Speed
Range:
Suction Lift Dry
at 1800 rpm:
Volume
Specifications:
Connection
Specification
(Standard):

Product Wetted
Materials
(Standard):

Certificates/
Proofs
(Optional):

Motor
(Standard):
Pump Dimension
with Motor and
Housing:

Eccentric Shaft 3° 800 lph (13.3 lpm)
Eccentric Shaft 5° 1200 lph (20 lpm)
Eccentric Shaft 3° 10 lph (0.167 lpm)
Eccentric Shaft 5° 20 lph (0.333 lpm)
Temperature of Fluid < 40° C (104° F)

6 bar (87 psi)

Temperature of Fluid > 40° C (104° F)

4 bar (58 psi)

Fluid

80° C (176° F)

CIP

90° C (194° F)

SIP

130° C (266° F)

Autoclave

130° C (266° F)

rpm

Eccentric Shaft: 3º

30 - 2,400

Eccentric Shaft 3° 2.5 - 3 m (8.2-9.8 ft)
4 - 4.5 m
Eccentric Shaft 5°
(13.1-14.7 ft)
Approximated Volume per
9.6 ml (5°)
Revolution at Free Output
5.8 ml (3°)
Filling Volume Without Connectors
75 ml
Connectors

3/4" TC

Position of Connectors

Inline

Number of Flow Directions

4

Pump Housing

SS316L

Valve Plate

SS316L

Diaphragms

TPE

Valves

EPDM

O-rings

EPDM
USP <88> Cl. VI;
FDA21CFR177; BSE/
TSE Safe
3.1; Surface
Roughness;
Ferrite Content
1375 min-1 (50 Hz)

Elastomere
(product wetted)
Stainless Steel Parts
(product wetted)
Rated speed
Voltage

Depending on the selected motor/frequency drive combination,
the motor frequency and the resulting pump speed might differ.

230/400 V

Power

0.37 KW

Length

487 mm (19.17")

Width

159 mm (6.26")

Height

210 mm (8.27")

Pump Weight
with Motor and
Housing:

Performance Charts

Eccentric Shaft: 5º

24 kg (53 lb.)

Other connection specifications, materials and motors available on request.
* When using pump with control box: 20 lph (0.333 lpm) and 40 lph (0.667 lpm)
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QF1200S-CV

Quaternary Diaphragm Pumps
Multiple-Use
• Integrated controller
• Digital key pad for manual operation
• Compact size
• 230V motor

Technical Data
QF1200S-CV Standard Motor
Flow Rate Maximum:

Eccentric Shaft 5°

1200 lph (20 lpm)

Flow Rate Minimum:

Eccentric Shaft 5°

10 lph (0.167 lpm)

Pressure:

Maximum
Temperature:

6 bar (87 psi)

Temperature of Fluid > 40° C (104° F)

4 bar (58 psi)

Fluid

80° C (176° F)

CIP

90° C (194° F)

SIP

130° C (266° F)

Autoclave

130° C (266° F)

Pump Speed Range:

rpm

Suction Lift Dry
at 1800 rpm:

Eccentric Shaft 5°

Volume
Specifications:

Filling Volume Without Connectors

75 ml

Connection
Specification
(Standard):

Connectors

3/4" TC

Position of Connectors

Inline

Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

Motor:

Pump Dimension with
Motor and Housing:
Pump Weight with
Motor and Housing:
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Temperature of Fluid < 40° C (104° F)

Number of Flow Directions

10 - 2200
4 - 4.5 m
(13.1-14.7 ft)

4

Pump Chamber

SS316L

Valve Plate

SS316L

Diaphragms

TPE

Valves

EPDM

O-rings

EPDM
USP <88> Cl. VI;
FDA21CFR177;
BSE/TSE Safe
3.1; Surface Roughness;
Ferrite Content
2200 min-1

Elastomere
(product wetted)
Stainless Steel Parts
(product wetted)
Rated speed
Voltage

230 V

Power

0.75 kW

Length

487 mm (19.17")

Width

200 mm (7.87")

Height

210 mm (8.27")
25 kg (55 lb.)

Performance Charts
Eccentric Shaft: 5º

QF4400S

Quaternary Diaphragm Pumps
Multiple-Use
• Separate control box for manual operation available
• ATEX version available

Technical Data
QF4400S Standard Motor
Flow Rate Maximum:

Eccentric Shaft 6°

5000 lph (83 lpm)

Flow Rate Minimum:

Eccentric Shaft 6°

150 lph (2.5 lpm)

Pressure:

Maximum
Temperature:

Temperature of Fluid < 40° C (104° F)

6 bar (87 psi)

Temperature of Fluid > 40° C (104° F)

4 bar (58 psi)

Fluid

80° C (176° F)

CIP

90° C (194° F)

SIP

130°C (266° F)*

Autoclave

130°C (266° F)*

Suction Lift Dry at
1200 rpm:

Eccentric Shaft 6°

Volume Specifications:

Approximated Volume per
Revolution at Free Output
Filling Volume Without Connectors

820 ml

Connectors

1.5" TC

Position of Connectors

Front

Connection
Specification
(Standard):

Pump Housing
Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

Valve Plate
Diaphragms

SS316L
SS316L or PP
TPE

O-rings

EPDM
USP <88> Cl. VI;
FDA21CFR177;
BSE/TSE Safe
3.1; Surface Roughness;
Ferrite Content
1410 min-1 (50 Hz)

Rated speed

Pump Dimension with
Motor and Housing:

95 ml

EPDM/SS316L

Stainless Steel Parts (product wetted)

Motor (Standard):

4 - 4.5 m (13.1-14.7 ft)

Valves

Elastomere (product wetted)

Voltage

230/400 V

Power

2.2 KW

Length

776.4 mm (30.57")

Width

256 mm (10.08")

Height

330 mm (12.99")

Pump Weight with
Motor and Housing:

Performance Charts
Eccentric Shaft: 6º

96 kg (212 lb.)

Other connection specifications, materials and motors available on request.
*With SS316L valve plate only

Depending on the selected motor/frequency drive combination, the motor frequency and the resulting pump speed might differ.
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QF5050S

Quaternary Diaphragm Pumps
Multiple-Use
• Compact footprint
• High turn-down ratio
• Multi-option installation flexibility
• Separate control box for manual operation available

Technical Data
QF5050S Servo Motor
Eccentric Shaft 6°

5000 lph (83 lpm)

Flow Rate Minimum:

Eccentric Shaft 6°

50 lph (0.83.lpm)
4 bar (58 psi)

Fluid

80° C (176° F)

CIP

90° C (194° F)

SIP

130°C (266° F)*

Autoclave

130°C (266° F)*

Suction Lift Dry at
1200 rpm:

Eccentric Shaft 6°

Volume Specifications:

Approximated Volume per
Revolution at Free Output
Filling Volume Without Connectors

820 ml

Connectors

1.5" TC

Position of Connectors

Front

Connection
Specification
(Standard):

Pump Housing
Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

Valve Plate
Diaphragms

TPE

O-rings

EPDM
USP <88> Cl. VI;
FDA21CFR177;
BSE/TSE Safe
3.1; Surface Roughness;
Ferrite Content
3000 min -1
(2.66:1 reduction)
400 V

Elastomere (product wetted)

Voltage
Power

3 KW

Length

440 mm (17.32")

Width

325 mm (12.80")

Height

320 mm (12.60")

Pump Weight with
Motor and Housing:
Other connection specifications, materials and motors available on request.
*With SS316L valve plate only

Performance Charts
Eccentric Shaft: 6º

SS316L
SS316L or PP
EPDM/SS316L

Rated speed

Pump Dimension with
Motor and Housing:

95 ml

Valves

Stainless Steel Parts (product wetted)

Motor (Standard):

4 - 4.5 m (13.1-14.7 ft)

66 kg (146 lb.)

Flow Rate [lph]

Maximum
Temperature:

6 bar (87 psi)

Temperature of Fluid > 40° C (104° F)

Flow Rate [GPH]

Pressure:

Temperature of Fluid < 40° C (104° F)

Flow Rate [l/min]

Flow Rate Maximum:

Depending on the selected motor/frequency drive combination, the motor frequency and the resulting pump speed might differ.
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QF20k

Quaternary Diaphragm Pumps
Multiple-Use
• Separate control box for manual operation available
• ATEX version available

Technical Data

QF20k Standard Motor

Flow Rate Maximum:

Eccentric Shaft 7°

20000 lph (333 lpm)

Flow Rate Minimum:

Eccentric Shaft 7°

1000 lph (16.7 lpm)
4 bar (58 psi)

Fluid

80° C (176° F)

CIP

90° C (194° F)

SIP

130° C (266° F)

Autoclave

130° C (266° F)

Eccentric Shaft 7°

Volume Specifications:

Approximated Volume per
Revolution at Free Output
Filling Volume Without Connectors

Connection
Specification
(Standard):

Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

2950 ml

Connectors

2" TC
Front

Pump Housing

SS316L

Valve Plate

SS316L

Diaphragms

TPE

Valves

EPDM/SS316L

O-rings

EPDM
USP <88> Cl. VI;
FDA21CFR177;
BSE/TSE Safe
3.1; Surface Roughness;
Ferrite Content
1460/474 min-1 (50 Hz)

Elastomere (product wetted)

Rated speed

Pump Dimension with
Motor and Housing:

470 ml

Position of Connectors

Stainless Steel Parts (product wetted)

Motor (Standard):

4 - 4.5 m (13.1-14.7 ft)

Voltage

230/400 V

Power

4 KW

Length

1152.5 mm (45.37")

Width

400 mm (15.75")

Height

416 mm (16.38")

Pump Weight with
Motor and Housing:
Other connection specifications, materials and motors available on request.

217 kg (478 lb.)

Flow Rate [l/min]

Suction Lift Dry
at 330 rpm:

Performance Charts
Eccentric Shaft: 7º

Flow Rate [lph]

Maximum
Temperature:

6 bar (87 psi)

Temperature of Fluid > 40° C (104° F)

Flow Rate [GPH]

Pressure:

Temperature of Fluid < 40° C (104° F)

Depending on the selected motor/frequency drive combination, the motor frequency and the resulting pump speed might differ.
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QF150SU

Quaternary Diaphragm Pumps
Single-Use
• Disposable wetted product chamber
• Integrated controller
• Digital key pad for manual operation
• Small and portable format
• Ideal for R&D and process development

Technical Data
QF150SU Standard Motor
Flow Rate Maximum:

Eccentric Shaft 5°

180 lph (3 lpm)

Flow Rate Minimum:

Eccentric Shaft 5°

1 lph (0.017 lpm)

Pressure:
Maximum
Temperature:

Temperature of Fluid < 40° C (104° F)

4 bar (58 psi)

Temperature of Fluid > 40° C (104° F)

4 bar (58 psi)

Fluid

60° C (140° F)

Autoclave*

130° C (266° F)

Suction Lift Dry at
3000 rpm:

Eccentric Shaft 5°

Volume Specifications:

Approximated Volume per
Revolution at Free Output
Filling Volume Without Connectors

Connection
Specification
(Standard):

Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

Pump Dimension with
Motor and Housing:

15 ml
1/4" TC

Position of Connectors

Inline

Number of Flow Directions

4

Pump Chamber

PP

Valve Plate

PP

Diaphragms

TPE

Valves

EPDM

O-rings

EPDM
USP <88> Cl. VI;
FDA21CFR177;
BSE/TSE Safe; USP
87/381/661
3000 min-1

Elastomere (product wetted)

Voltage

230 V (110 V as option)

Power

0.05 KW

Length

285 mm (11.22")

Width

115 mm (4.53")

Height

184 mm (7.24")

Pump Weight with
Motor and Housing:
Other connection specifications, materials and motors available on request.
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1.2 ml

Connectors

Rated speed
Motor (Standard):

2 - 3 m (6.6 - 9.8 ft)

7 kg (15.8 lb.)

Performance Charts
Eccentric Shaft: 5º

QF1200SU

Quaternary Diaphragm Pumps
Single-Use
• Disposable wetted product chamber
• Pump chamber made of solid polypropylene
• Separate control box for manual operation available
• ATEX version available

Technical Data

Performance Charts

QF1200SU Standard Motor
Flow Rate Maximum:
Flow Rate Minimum*:
Pressure:
Maximum
Temperature:

Eccentric Shaft 3°

800 lph (13.3 lpm)

Eccentric Shaft 5°

1200 lph (20 lpm)

Eccentric Shaft 3°

10 lph (0.167 lpm)

Eccentric Shaft 5°

20 lph (0.333 lpm)

Temperature of Fluid < 40° C (104° F)

4 bar (58 psi)

Temperature of Fluid > 40° C (104° F)

4 bar (58 psi)

Fluid

60° C (140° F)

Autoclave

130° C (266° F)

Pump Speed Range:

rpm

Suction Lift Dry at
1800 rpm:

Eccentric Shaft 3°

Volume Specifications:
Connection
Specification
(Standard):

Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

Eccentric Shaft 5°
Approximated Volume per
Revolution at Free Output
Filling Volume Without Connectors

Pump Dimension with
Motor and Housing:

4 - 4.5 m (13.1-14.7 ft)
9.6 ml (5°)
5.8 ml (3°)
75 ml

Connectors

3/4" TC

Position of Connectors

Inline

Number of Flow Directions

4

Pump Chamber

PP

Valve Plate

PP

Diaphragms

TPE

Valves

EPDM

O-rings

EPDM
USP <88> Cl. VI;
FDA21CFR177;
BSE/TSE Safe; USP
87/381/661
1375 min-1 (50 Hz)

Elastomere (product wetted)
Rated speed

Motor (Standard):

30 - 2,400
2.5 - 3 m (8.2-9.8 ft)

Voltage

0.37 KW

Length

497 mm (19.56")

Width

159 mm (6.26")

Height

210 mm (8.27")

Other connection specifications, materials and motors available on request.
* When using pump with control box: 20 lph (0.333 lpm) and 40 lph (0.667 lpm)

Eccentric Shaft: 5º

230/400 V

Power

Pump Weight with
Motor and Housing:

Eccentric Shaft: 3º

21 kg (46 lb.)
Depending on the selected motor/
frequency drive combination, the motor
frequency and the resulting pump speed
might differ.
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QF1200SU-M

Quaternary Diaphragm Pumps
Single-Use
• Disposable wetted product chamber
• Pump chamber made of injection-molded polyethylene
• Separate control box for manual operation available
• ATEX version available
• Front side connections

Technical Data
QF1200SU-M Standard Motor
Flow Rate Maximum:
Flow Rate Minimum*:
Pressure:
Maximum
Temperature:
Pump Speed Range:
Suction Lift Dry at
1800 rpm:
Volume Specifications:
Connection
Specification
(Standard):

Eccentric Shaft 3°

800 lph (13.3 lpm)

Eccentric Shaft 5°

1200 lph (20 lpm)

Eccentric Shaft 3°

10 lph (0.167 lpm)

Eccentric Shaft 5°

20 lph (0.333 lpm)

Temperature of Fluid < 40° C (104° F)

4 bar (58 psi)

Temperature of Fluid > 40° C (104° F)

4 bar (58 psi)

Fluid

50° C (122° F)

rpm

30 - 2,400

Eccentric Shaft 3°

2-2.5 m (6.6-8.2 ft)

Eccentric Shaft 5°
Approximated Volume per
Revolution at Free Output
Filling Volume Without Connectors

3-3.5 m (9.8-11.5 ft)
9.6 ml (5°)
5.8 ml (3°)
75 ml

Connectors
Position of Connectors
Pump Chamber

Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

Valve Plate
Diaphragms

Pump Dimension with
Motor and Housing:

Front
PE injection molded
TPE
EPDM

O-rings

EPDM
USP <88> Cl. VI;
FDA21CFR177;
BSE/TSE Safe; USP
87/381/661
1375 min-1 (50 Hz)

Elastomere (product wetted)

Voltage

230/400 V

Power

0.37 KW

Length

503 mm (19.8")

Width

159 mm (6.26")

Height

210 mm (8.27")

Pump Weight with
Motor and Housing:

Eccentric Shaft: 3º

PE injection molded**

Valves

Rated speed
Motor (Standard):

3/4" TC

Performance Charts

Eccentric Shaft: 5º

20 kg (44 lb.)

Other connection specifications, materials and motors available on request.
* When using pump with control box: 20 lph (0.333 lpm) and 40 lph (0.667 lpm)
** Connectors PP
Depending on the selected motor/
frequency drive combination, the motor
frequency and the resulting pump speed
might differ.
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QF1200SU-XAQ

Pre-Gamma-Irradiated Single-Use Pump Chamber
with CPC™ AseptiQuik® Connector
The use of aseptic connectors of CPC enables simple and flexible aseptic integration of gamma irradiated
Quattroflow single-use pump chambers in biopharmaceutical processes. Depending on the process tubing
requirements it allows users to flexibly and aseptically connect the pump chambers with bags, tubing and filters,
which are also equipped with matching aseptic connectors.
• Disposable wetted product chamber
• Pre-gamma-irradiated
• Fast & easy aseptic integration
• Easy replacement

Technical Data with Standard Drive (QF1200SU Pump)
QF1200SU-XAQ Standard Motor
Flow Rate Maximum:
Flow Rate Minimum*:

Eccentric Shaft 3°

800 lph (13.3 lpm)

Eccentric Shaft 5°

1200 lph (20 lpm)

Eccentric Shaft 3°

10 lph (0.167 lpm)

Eccentric Shaft 5°

20 lph (0.333 lpm)

Pressure: Temperature of Fluid ≤ 40° C (104° F)
Maximum
Fluid
Temperature:
Eccentric Shaft 3°
Suction Lift Dry at
1800 rpm:
Eccentric Shaft 5°

4 bar (58 psi)
40° C (104° F)
2.5 - 3 m (8.2 - 9.8 ft)
4 - 4.5 m (13.1 - 14.7 ft)
5.8 ml (3°)
9.6 ml (5°)
75 ml

Volume Specifications:

Approximated Volume per
Revolution at Free Output
Filling Volume Without Connectors

Connection
Specification
(Standard):

Connectors

AseptiQuik® G

Sanitary Clamp

Sanisure® 3/4"

Number of Flow Directions

4

Pump Chamber / Valve Plate

PP

Pump Diaphragms
Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

EPDM

Valves / O-rings

EPDM

Connector Seals / TC Gasket

Platinum-Cured Silicone

Connector Main Components

Polycarbonate
USP <88> Cl. VI; FDA21CFR177;
BSE/TSE Safe
25 kGy

Elastomere (product wetted)
Gamma dose

Gamma Irradiation:

TPE

Pump Valves

Certificate

Included

Comment

Double bagged package

Other connection specifications, materials and motors available on request.
* When using pump with control box: 20 lph (0.333 lpm) and 40 lph (0.667 lpm)
For the performance charts, please refer to the QF1200SU pump specifications on page 15.
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QF1200SU-CV

Quaternary Diaphragm Pumps
Single-Use
• Disposable wetted product chamber
• Integrated controller
• Digital key pad for manual operation
• Compact size

Technical Data
QF1200SU-CV
Flow Rate Maximum:

Eccentric Shaft 5°

1200 lph (20 lpm)

Flow Rate Minimum:

Eccentric Shaft 5°

10 lph (0.167 lpm)

Pressure:
Maximum
Temperature:
Pump Speed Range:
Suction Lift Dry at
1800 rpm:
Volume Specifications:
Connection
Specification
(Standard):

Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

Temperature of Fluid < 40° C (104° F)

4 bar (58 psi)

Temperature of Fluid > 40° C (104° F)

4 bar (58 psi)

Fluid

60° C (140° F)

Autoclave

130° C (266° F)

rpm
Eccentric Shaft 5°
Approximated Volume per
Revolution at Free Output
Filling Volume Without Connectors

Pump Dimension with
Motor and Housing:
Pump Weight with
Motor and Housing:

4 - 4.5 m (13.1-14.7 ft)
9.6 ml
75 ml

Connectors

3/4" TC

Position of Connectors

Inline

Number of Flow Directions

4

Pump Chamber

PP

Valve Plate

PP

Diaphragms

TPE

Valves

EPDM

O-rings

EPDM
USP <88> Cl. VI;
FDA21CFR177;
BSE/TSE Safe; USP
87/381/661
2200 min-1

Elastomere (product wetted)
Rated speed

Motor:

10 - 2200

Voltage

230 V

Power

0.75 kW

Length

497 mm (19.56")

Width

200 mm (7.87")

Height

210 mm (8.27")
21 kg (46 lb.)

Technical data for the QF1200SU-CV-M (pump chamber made of injection-molded PE) available on request.
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Performance Charts
Eccentric Shaft: 5º

QF4400SU

Quaternary Diaphragm Pumps
Single-Use
• Disposable wetted product chamber
• Separate control box for manual operation available
• ATEX version available

Technical Data
QF4400SU Standard Motor
Flow Rate Maximum:

Eccentric Shaft 6°

5000 lph (83 lpm)

Flow Rate Minimum:

Eccentric Shaft 6°

150 lph (2.5 lpm)

Pressure:
Maximum
Temperature:

Temperature of Fluid < 40° C (104° F)

4 bar (58 psi)

Temperature of Fluid > 40° C (104° F)

4 bar (58 psi)

Fluid

60° C (140° F)

Autoclave

130° C (266° F)

Suction Lift Dry at
1800 rpm:

Eccentric Shaft 6°

Volume Specifications:

Approximated Volume per
Revolution at Free Output
Filling Volume Without Connectors

820 ml

Connectors

1.5" TC

Position of Connectors

Front

Connection
Specification
(Standard):

Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

Pump Dimension with
Motor and Housing:

95 ml

Pump Chamber

PP

Valve Plate

PP

Diaphragms

EPDM / SS316L

O-rings

EPDM
USP <88> Cl. VI;
FDA21CFR177;
BSE/TSE Safe; USP
87/381/661
1410 min-1 (50 Hz)

Elastomere (product wetted)

Voltage

230/400 V

Power

2.2 KW

Length

776.4 mm (30.57")

Width

256 mm (10.08")

Height

330 mm (12.99")

Pump Weight with
Motor and Housing:

Performance Charts
Eccentric Shaft: 6º

TPE

Valves

Rated speed
Motor:

4 - 4.5 m (13.1-14.7 ft)

81 kg (178 lb.)

Other connection specifications, materials and motors available on request.

Depending on the selected motor/frequency drive combination, the motor frequency and the resulting pump speed
might differ.
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QF5050SU

Quaternary Diaphragm Pumps
Single-Use
• Disposable wetted product chamber
• Compact footprint
• High turn-down ratio
• Multi-option installation flexibility
• Separate control box for manual operation available

Technical Data
QF5050SU Servo Motor
Flow Rate Maximum:

Eccentric Shaft 6°

5000 lph (83 lpm)

Flow Rate Minimum:

Eccentric Shaft 6°

50 lph (0.83.lpm)

Temperature of Fluid > 40° C (104° F)

4 bar (58 psi)

Fluid

60° C (140° F)

Autoclave

130° C (266° F)

Suction Lift Dry at
1800 rpm:

Eccentric Shaft 6°

Volume Specifications:

Approximated Volume per
Revolution at Free Output
Filling Volume Without Connectors

820 ml

Connectors

1.5" TC

Position of Connectors

Front

Product Wetted
Materials (Standard):

Certificates/Proofs
(Optional):

Valve Plate

PP
TPE

Valves

EPDM / SS316L

O-rings

EPDM
USP <88> Cl. VI;
FDA21CFR177;
BSE/TSE Safe; USP
87/381/661
3000 min -1
(2.66:1reduction)
400 V

Rated speed
Motor:

Pump Dimension with
Motor and Housing:

PP

Diaphragms

Elastomere (product wetted)

Voltage
Power

3 KW

Length

440 mm (17.32")

Width

325 mm (12.80")

Height

320 mm (12.60")

Pump Weight with
Motor and Housing:
Other connection specifications, materials and motors available on request.

Performance Charts
Eccentric Shaft: 6º

51 kg (112 lb.)

Flow Rate [l/min]

Pump Chamber

95 ml

Flow Rate [GPM]

Connection
Specification
(Standard):

4 - 4.5 m (13.1-14.7 ft)

Flow Rate [lph]

Maximum
Temperature:

4 bar (58 psi)

Flow Rate [GPH]

Pressure:

Temperature of Fluid < 40° C (104° F)

Depending on the selected motor/frequency drive combination, the motor frequency and the resulting pump speed might differ.
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Accessories
Control Box
• Variable speed controller with integrated key
pad for manual speed control
• Configurable for remote speed control with
4 –20 mA analogue input
• 230V / 50 Hz or 115 V / 60 Hz for model 1200
(image left)
• 400V, 3P for models 4400/5050/20k
(image right)
• Hygienic 1.4301 housing, IP 54
• Easy plug & play installation

Power Box
• Plug & Play installation
• Protects system and pump from overpressure
• Configurable pressure switch setpoint
• Reset button for pump reset
• To be used with pressure switch (also available)
• For multiple-use models only

Diaphragm Sensor
• Sensor installed in ring drive unit
• Detection of all liquids
• Signal output to a controller,
if diaphragm is ruptured

PID Pressure Controller
• Ideal for processes, where the Quattroflow pump
should be controlled to a defined pressure or
flow rate (e.g. for filtration)
• 4 – 20mA input for pressure or flow sensor
• 24VDC voltage supply for sensors
• Autotune function for optimization of PID
parameters
• 0 – 5VDC output signal for use with QF150 or
QF1200CV (requires optional analogue input)
• Configurable alarm setpoints for automatic
shutoff of pump

21

Concerned about

Quattroflow™ pumps and
peristaltic pumps:

Particle Generation?

Particle generation compared
Facts about peristaltic pumps used for biopharmaceutical production
processes:
• Particle generation caused by pump design.
• Permanent mechanical stress of the hose may lead to a
substantial source of particles entering the fluid stream.
• Possible contamination of the pumped liquid and the
pharmaceutical end product.
• Drop-in flow rate over time
• Some are not capable of reaching more than 1 bar

Do you want to avoid this in your product?

Quattroflow
Clear Membrane Pores

The images on the right show micrographs of filter membranes,
which were used to quantify particles created during a pumping
process.
• Particles from the peristaltic pump are visible as bright objects
obstructing the pores of the membrane (lower image).
• The filter membrane of the Quattroflow test does not show
particles just open membrane pores. The gentle working
principle of the 4-piston Quattroflow pump minimizes
mechanical stress and thus the generation of particles (upper
image).

Test conditions:
Third party comparison between Quattroflow QF150SU and
peristaltic pump using pharma-grade pumping hose. 8h
continuous recirculation through 12µm filter filter at approximately
100 lph (1.67 lpm)

200 µm

Peristaltic Pump
Membrane Pores Blocked with Particles

Result:
• 2 Mio particles with sizes between 6.1 and 12.7 µm for the
peristaltic pump.
• No particles identifiable for the Quattroflow pump.

Quattroflow pumps help minimize particle contamination of your
product, reduce heat, and are suitable for securing the handling
of expensive and/or sensitive liquids.
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200 µm

™
Quattroflow
Pumps
make the difference
Besides the particle generation and product contamination facts mentioned on the first page, peristaltic pumps
have some further operational limitations, which can be a disadvantage and risk for your process:
Pulsation
Due to their operational design, peristaltic pumps
create a pulsing flow, which can adversely affect the
process.

Particle generation outside the hose
Spallation release may also occur outside the
hose. This may compromise the fluid path but also
contaminate the external clean room environment.

Tube failure
High mechanical stress can result in tube rupture,
which can lead to a catastrophic failure, costly
product loss, downtime and maintenance.

Pump technology change
Limited flow and pressure capabilities of peristaltic
pumps means changing pump technologies as
processes move from process development to cGMP
creating scale up issues.

Flow rate consistency
With increasing operating time of the tube,
mechanical stress changes the hose geometries over
time and can lead to an inconsistent flow.

These disadvantages inherent in peristaltic pumps
ultimately mean potential threats to the quality
of the process and the final product. Spallation,
performance loss and rupture are also described in
scientific literature (see Bahal and Romansky, “Spalling and sorption of tubing for peristaltic pumps”) in
Pharmaceutical Development and Technology, 7(3),
317-323 (2002).
Single-use technologies have created improved
production opportunities in bio-pharmaceutical
production processes. The correct pump technology
can make a significant contribution.
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250 mL Blood Bag System
CPDA-1 Anticoagulant

TERUFLEX®

TERUFLEX

®

250mL Blood Bag System
with 16 Gauge Needle
s &OR WHOLE BLOOD COLLECTION
From pediatric, elderly or small autologous donors who
may not tolerate larger blood collections
As directed by a patient’s physician

s 2ED CELL STORAGE UP TO  DAYS
s 4AMPER %VIDENT .EEDLE 0ROTECTOR
The black lines of the needle protector
and hub are conveniently aligned to:
Show evidence of a broken seal
Indicate bevel up position

4%25&,%8® BLOOD BAGS AND ACCESSORIES
CONTAIN NO LATEX COMPONENTS

Flexibility and Performance
s 4HICK 7ALL 4UBING
Reduces kinks which facilitates
smooth blood flow

s /UTLET 0ORT 0EEL 4AB
Easy to open
Visual assurance of seal integrity

s "AG $ESIGN
Tall narrow design enhances blood
component separation
Rounded corners facilitate mixing
of blood and anticoagulant

s 3HARP $EPENDABLE .EEDLE
Double Bevel Design
Ultra-thin Wall Needle

Corporate Brand Mark

TERUMO MEDICAL CORPORATION
2101 Cottontail Lane Somerset,
New Jersey 08873
Tel: 800.283.7866
Corporate Brand Mark

Ordering Information:
Product Code: 1BB*SCD256A
Quantity: 90 blood bags/case
Shelf Life: 30 months
Contains no latex components

TERUFLEX® and
TERUMO are registered in U.S. Patent and Trademark Office by Terumo Corporation.
Manufactured by Terumo Corporation in Japan. © 2010 TERUMO CORPORATION.

10252010-1019

Single-Use BioProcess Containers
Standard and customized 2D and 3D
fluid containment systems

Single-use technologies
Whether you are looking for an economical catalog product or require a specific
custom-designed and custom-built system, we offer proven solutions at every scale.
With a wealth of experience, knowledge, and solid quality processes behind every
Thermo Scientific™ product, we will help you feel assured that your bioproduction
process performs at its best.
We take pride in offering one of the largest libraries and
catalog components in the industry, allowing us to integrate
connectors, tubing, and sensors to design a custom
Thermo Scientific™ BioProcess Container (BPC) or a
customized tubing assembly to fit your specific needs. Our
services organization is here to assist you with drawings,
implementation, and technical support to help ensure
optimum production performance.
Our products and services are designed to enable proven
performance through innovative and highly effective
upstream or downstream applications. You can optimize
production, improve process efficiency, add flexibility, and
ensure fast-track product development and introduction
to market by selecting product components and services
from a single supplier.
Quality control and assurance
To help ensure that BPC systems conform to the
quality standards expected in the bioprocess industry,
BPC systems are subject to rigorous quality control in
compliance with current good manufacturing practices
(cGMP) (21 CFR Part 820) and ISO 9001:2000 from the
receipt of components to the release of final product.
Our production control processes help ensure complete
lot traceability for each batch. The process control
document becomes the stepwise manufacturing record
that physically accompanies the lot through every
step of the manufacturing process. At the end of the
process, the production record is reviewed by the quality
assurance team for completeness, and correctness prior
to the release of the lot and issuance of the certificate
of analysis (CoA).
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What is a Single-Use BioProcess Container?
The heart of our single-use solutions is our BioProcess
Containers (BPCs). BPCs are single-use, flexible container
systems commonly used for critical liquid-handling
applications in the biopharmaceutical industry.
BPC systems are cost-effective alternatives to conventional
stainless steel systems. They employ a novel design
approach that is highly valued for its versatility and utility.
BPC components are readily integrated into a variety of
high-performance systems for all steps in the production
of biologics.
Key features
• All BPCs are produced in state-of-the-art cGMP facilities
with common processes for manufacturing redundancy
• Production of chambers from 50 mL to 10,000 L capacity
• Automated lines for producing BPC chambers
• Strong engineering support to design and maintain
products and processes

BPC manufacturing process
Chamber manufacture—the main components of a
BPC chamber are the ports that enable tubing to be
attached to the chamber. There are a number of different
port designs depending on the type of chamber.
All BPC chambers and related components are produced
in an ISO 7–certified cleanroom at our manufacturing
facilities. Additional components are then attached to the
BPC chamber to produce a complete BPC. BPC assembly
is a manual process, which provides the required flexibility
in BPC configuration. Thermo Scientific™ fluid transfer
assemblies are also produced to complement BPC
systems. Final assembly is done under the same controlled
environment and to the same level of quality.
Each lot of BPCs is 100% visually inspected against
product specifications, and packaged and sealed in two
independent outer layers while still in the ISO 7–certified
area. They are then placed in cardboard cartons labeled
with product and lot identification.

Main types of BPC chambers
The 3 main types of BPCs are highlighted below, which are Thermo Scientific™
2D Labtainer™ and 3D Productainer™ BPCs, and tank liners. Specialty BPCs are
also available for specific applications and use in bioprocess equipment.

2D Labtainer BPC systems
This design is used for small, simple
BPCs and is produced from two
sheets of film that are heat-sealed
around the perimeter to form a
pillow-shaped chamber. The ports are
heat-sealed into the end seal or onto
one of the faces of the chamber.

3D Productainer BPC systems
This design is used for larger and
more complicated BPCs. A square
tube is formed by heat-sealing sheets
of film together. Top- and bottomporting options are available, and a
greater range of size and complexity
of chamber designs is possible.

Tank Liner BPC systems
This design is used with commercially
available overhead mixers. Tank liners
remove the need for tank cleaning and
helps reduce cycle times. Tank liners
are optimized for use with Thermo
Scientific™ drums and commonly used
industry-standard cylindrical tanks.
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BPC films
Films engineered for the most
demanding applications
The Thermo Scientific™ films are engineered to meet the
most demanding requirements of your bioproduction
processes. Choose between:

Film formulations
• Aegis5-14 and CX5-14 films are five-layer films produced
in a cGMP facility—the outer layer is a polyester lastomer
coextruded with an EVOH barrier layer and a low-density
polyethylene product contact layer

• Aegis™ 5-14 film—for high-value applications

• The ASI 26/77 polyethylene (PE) single-use bag systems
are produced in a cGMP facility, utilizing two webs: a fluid
contact film and a durable, coextruded outer-layer film

• CX5-14 film—one of the most widely used films
in the industry, proven over 10 years
• ASI™ 26/77 film—a two-layered film, for
high-value applications
• ASI™ 28 film—a robust, four-layer film with excellent
oxygen- and moisture-barrier properties
• CX3-9 film—a three-layered film with a polyester
elastomer coextruded outer layer with a low-density
polyethylene product contact layer
• ASI™ 26 film—a single-web film with good toughness
and puncture resistance
• ASI™ 77 film—a single-web film constructed from nylon
with an ethylene vinyl alcohol EVOH barrier layer and a
linear low-density polyethylene (LLDPE) layer
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• The ASI 28 film is an ethylene vinyl acetate (EVA)
coextruded film produced in a cGMP facility—this film
provides an excellent, highly durable moisture and
oxygen barrier
• The CX3-9 film is a three-layer, 9 mil cast film, which is
used primarily for open-top tank liners
• The ASI 26 film is a single-web, 5 mil cast film, which is
also used primarily for open-top tank liners
• The ASI 77 film is a single-web, 7 mil cast film, which
is used primarily for the Thermo Scientific™ Three60™
Sampling System

2D Labtainer BPC systems
Key features
• 2D Labtainer systems are 2-panel, pillow-style BPCs

Applications
• Harvest from bioreactors or fermentors

• Chambers are constructed from CX5-14, Aegis5-14,
ASI 26/77, and ASI 28 films

• Feed into bioreactors or fermentors

• Labtainer BPC systems have 2–3 edge ports along
one end with a handle on the opposing end
• 2-port Labtainer BPCs are available in sizes from
50 mL to 2,000 mL
• 3-port Labtainer BPCs are available in sizes from
2 to 50 L
• Line sets can be customized for easy integration with
existing process operations and equipment

• Sample collection from bioreactors or fermentors
• Buffer preparation and storage
• Culture media preparation and storage
• Process liquid preparation and storage
• Chromatography feed and fraction collection
• Harvest, storage, and transport of bulk drug product
and bulk drug precursors

• Labtainers can be customized into multi-container
manifold configurations
• Labtainers can be added as sample container adjuncts
to 2D or 3D BPCs
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3D Productainer BPC systems
Key features
• Use this system to eliminate post-use cleaning steps
required with reusable containers, and to reduce
cross-contamination risks

Customize catalog BPC systems for optimized
single-use technology
Choose from the industry’s largest component library—
with over 2,000 unique components that include:

• All 3D BPCs are constructed in an ISO 7–certified
cleanroom under cGMP conditions

• Fittings—straight, reducing, elbow, T-style, X-style,
and cross-style

• All 3D BPCs are designed to fit the full range of
support containers, both square and cylindrical,
from 50 to 3,000 L

• Connectors—quick connectors and disconnectors,
aseptic connectors and disconnectors, steam-to and
steam-through connectors

Applications
• Hydration and filtration of process buffers, liquids,
and culture media

• Filters—used for bioburden reduction; sterilization-grade
filters and vent filters are available

• Chromatography feed and fraction collection
• Storage and transport of bulk drug product and bulk
drug precursors
• Harvest from and feed into bioreactors and fermentors
• Dispensing, packaging, and storage of cell culture media,
buffers, and process liquids

• Tubing—thermoplastic elastomers, platinumcured silicone
• Sample ports—septum-style and needle-free ports
• Clamps—sliders, pinch, and crimp bands

Tank liner BPC systems
Key features
• Tank liners are designed for use with commercially
available overhead mixers (not supplied)

Associated applications
• Hydration of powdered media and buffers
• Pooling of nonsterile solutions and fluids

• Removes the need for tank cleaning and helps reduce
cycle times.
• Chambers are constructed from CX3-9 and ASI 26 films
(and Aegis5-14 film for bottom-drain) with dimensions
optimized for Thermo Scientific™ catalog drums and
commonly used industry-standard cylindrical tanks
• Top entry for catalog products for maximum recovery
using industry-standard cylindrical tanks in unit volumes
of 50, 100, 200, 300, and 500 L
• Supplied gamma-irradiated to minimize bioburden
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Powdertainer BPC system
Thermo Scientific™ Powdertainer™ BPCs are specifically
designed for powder containment and discharge
applications, and maintain a closed system for
maximum recovery of powder while minimizing the
risk of cross-contamination.
Key features
• Designed for powder containment and powder
hydration applications

Applications
• Storage and delivery of Thermo Scientific™ powder culture
media and buffers
• Storage and dispensing of preweighed chemicals or other
process powders
Handle
For support
during emptying

Tube with quick connector
For washdown to remove any
powder residue

• Employ a closed system to help minimize dust
contaminant and cross-contamination risk
• Three-inch tri-clamp port designed for secure connection
to, and easy integration with, hydration vessels
• Suspensor handle for support during discharge and neck
clamp to retain powder prior to discharge
• Two models, including one with a washdown line to
remove residual powder, enabling maximal recovery
• Three sizes for process flexibility: 1, 5, and 25 kg
• Constructed from CX3-9 film
• Stainless steel filling stand to facilitate the powder
discharge process

Clamp
To retain powder
prior to emptying

Three-inch tri-clamp
connector
For secure connection to
formulation vessel

Harvestainer Microcarrier Separation BPC system
The Thermo Scientific™ Harvestainer™ BioProcess
Container (BPC) system is a closed, single-use
microcarrier separation system that helps to increase
product yields compared to traditional methods, while
reducing clean-in-place (CIP) and steam-in-place
(SIP) requirements.
Unique design features
The Harvestainer system enables separation of
microcarrier beads and harvesting of the cell culture
supernatant in a single-step, closed system.
The Harvestainer system is designed for both small- and
large-scale applications. When 12 L or less of microcarrier
beads are required to be separated, the 3 L or 12 L
Harvestainer system is ideal. These systems are designed
around our 2D pillow-style BPC in a preassembled
tray, designed for secondary containment and optimal
supernatant recovery.

The large-scale Harvestainer system features a
dual-chamber system that comprises a 200 L 3D BPC
with either one or two interior 25 L microbarrier 2D BPCs.
These unique design features help enable the separation
of cell culture supernatant from the microcarrier beads.

Three60 Single-Use Sampling System
The simple design behind the Three60 Sampling System
allows you to take a representative sample of your product
with minimal effort. For a small-volume liquid transfer, use a
CIP or SIP process to prepare your tank. The pre-irradiated
BPCs and assemblies help ensure an integral fluid path
while the quick-turn valve and pinch-and-cut disconnectors
maintain liquid transfer and removal from BPCs.
The Three60 system is compatible with your vessel
through a sanitary connector; no expensive hardware is
needed. Each Three60 package contains a valve and four
assemblies with pinch-and-cut disconnectors.
Kit to tank
The Three60 system is pre-irradiated and assembled into a
one-piece kit. Simply remove the device from the kit
and apply to the vessel.
• Quick-turn Three60 valve—the face of the Three60 valve
can be sterilized with the tank through traditional CIP/SIP
processes. The valve has four assemblies. This helps keep
the product and technician contamination-free.

• Pinch-and-cut disconnectors—the pinch-and-cut
disconnectors allow the technician to quickly separate the
sample and eliminate the need for tools or tube sealing.
• Injection ports—Luer lock injection site; extract through
either the septum or twist-off Luer lock to pour.
• Pre-irradiated BPC assemblies—the Three60 system
is provided with pre-irradiated BPC assemblies in sizes
ranging from 50 mL to 2 L produced using the ASI 77 film.

Services and support
Thermo Scientific™ Bioproduction services involve both fieldand office-based teams. The office-based team is located in
Logan, Utah, and includes technical support, BioProduction
Xpress (BPX), quality, and services management teams. On
a global scale, there are field application specialists (FAS)
who are trained on hardware installation, servicing, and also
offer other post-sales support such as training, consulting,
and process optimization assistance.
Key services
• Field support
– Hardware installation—factory acceptance test (FAT)
and site acceptance test (SAT)
– Training—single-use bioreactors, mixers, fermentors,
outer support containers, and BPCs
– Validation service—installation qualification (IQ),
operation qualification (OQ), and performance
qualification (PQ)
– Warranty
– Service contracts

• BioProduction Xpress
– R&D scientists and engineers specializing in single-use
bioreactor (S.U.B.), single-use mixer (S.U.M.), single-use
fermentor (S.U.F.) processes
– Scale-up studies
– Customer-specific application studies
– Quality testing
– Non-GMP quick-response studies or tests
• Technical support
– Phone support for sales, service, technical
questions, and troubleshooting
– Interfaces with quality, product management,
and R&D teams

Integrated solutions for bioproduction

Liquid- and dry-format media
We offer both custom manufacturing
and a full range of chemically
defined performance media
and supplement products

Single-Use Mixers (S.U.M.s)
A variety of options up to
5,000 L for both upstream
and downstream applications

BioProcess Containers (BPCs)
A variety of configurations up
to 2,000 L for liquid harvest,
storage, and transportation

Sera
Our sera are well
known for consistent
quality and reliability

Single-Use
Bioreactors (S.U.B.s)
50–2,000 L bioreactors
capable of integrating with an
existing control system

Buffers and process liquids
Custom and standard buffers, and
process liquids, including Gibco™
Water for Injection (WFI)

Integrity testing systems
A true point-of-use integrity testing system
to confirm the integrity of BPCs before use

Find out more at thermofisher.com/bpc
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.
© 2017 Thermo Fisher Scientifi c Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientifi c and its subsidiaries
unless otherwise specifi ed. COL03900 0417

Product datasheet

Anti-Blood Group A Antigen antibody [9A] ab20131
2 References
Overview
Product name

Anti-Blood Group A Antigen antibody [9A]

Description

Mouse monoclonal [9A] to Blood Group A Antigen

Host species

Mouse

Specificity

ab20131 cross reacts with EGF receptor in A431 cells only due to glycosylation defects in these
cells which reveals otherwise cryptic sugar structures.

Tested applications

Suitable for: ELISA, IP

Species reactivity

Reacts with: Human

Immunogen

Cell preparation: A431 cells (human vulval squamous carcinoma cell line).

Properties
Form

Liquid

Storage instructions

Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze /
thaw cycle.

Storage buffer

Preservative: None
Constituents: PBS

Clonality

Monoclonal

Clone number

9A

Myeloma

P3-x63-Ag8

Isotype

IgG3

Light chain type

unknown

Applications
Our Abpromise guarantee covers the use of ab20131 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application
ELISA

Abreviews

Notes
Use at an assay dependent dilution.
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Application

Abreviews

IP

Notes
Use at an assay dependent dilution.

Target
Relevance

Blood-group antigens are generally defined as molecules formed by sequential addition of
saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and
certain epithelial cells. The A, B and H antigens are reported to undergo modulation during
malignant cellular transformation. Blood group related antigens represent a group of
carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually
mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain
individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong
to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor
type 1 chain antigens.

Cellular localization

Cell Membrane

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Our Abpromise to you: Quality guaranteed and expert technical support
Replacement or refund for products not performing as stated on the datasheet
Valid for 12 months from date of delivery
Response to your inquiry within 24 hours
We provide support in Chinese, English, French, German, Japanese and Spanish
Extensive multi-media technical resources to help you
We investigate all quality concerns to ensure our products perform to the highest standards
If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise,
please visit http://www.abcam.com/abpromise or contact our technical team.

Terms and conditions
Guarantee only valid for products bought direct from Abcam or one of our authorized distributors
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Safety Data Sheet
________________________________________________________________________________________________________________

SECT I ON 1 : I de nt ific a t ion of t he subst a nc e /m ix t ure a nd of t he c om pa ny/unde rt a k ing
Identification of the substance or mixture
Product code
Product name

89964
HisPur(tm) Cobalt Resin, 10 mL

Company/undertaking identification
Life Technologies Corporation
5781 Van Allen Way
PO Box 6482
Carlsbad, CA 92008
+1 760 603 7200

Life Technologies
5250 Mainway Drive
Burlington, ONT
CANADA L7L 6A4
800/263-6236

Thermo Fisher Scientific
Pierce Biotechnology
P.O. Box 117
Rockford, IL 61105
United States
1.815.968.0747 or
1.800.874.3723
24 hour Emergency Response:

866-536-0631
301-431-8585
Outside of the U.S. +1-301-431-8585

Country specific Emergency Number (if available):
CHEMTREC Brazil (Rio De Janeiro)
+(55)-2139581449 (português)
Use as laboratory reagent. Scientific research and development.
SECT I ON 2 : H a za rds ide nt ific a t ion
GHS - Classification
Signal Word
DANGER

Health hazards
Carcinogenicity
Reproductive Toxicity

Category 1A
Category 1B

________________________________________________________________________________________________________________
Revision date
Product code

15-Mar-2016
89964
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Product name HisPur(tm) Cobalt Resin, 10 mL
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Physical hazards
GHS Physical Hazard 1
GHS Physical Hazard Category Number

Flammable liquids
Category 3

Hazard Statements
H226 - Flammable liquid and vapor
H350 - May cause cancer
H360F - May damage fertility
H411 - Toxic to aquatic life with long lasting effects
Precautionary Statements
P370 + P378 - In case of fire, use water/water spray/water jet/carbon dioxide/sand/foam/alcohol resistant
foam/chemical powder for extinction
P303 + P361 + P353 - IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower
P201 - Obtain special instructions before use
P273 - Avoid release to the environment
P210 - Keep away from heat/sparks/open flames/hot surfaces. - No smoking
P280 - Wear protective gloves/protective clothing/eye protection/face protection
Principle Routes of Exposure
Potential Health Effects
eyes
Skin
inhalation
Ingestion

May cause eye irritation with susceptible persons.
May be harmful in contact with skin.
May cause irritation of respiratory tract.
May be harmful if swallowed.

Specific effects
Carcinogenic effects
Mutagenic effects
Reproductive toxicity
Sensitization

May cause cancer.
None.
May cause harm to the unborn child.
None.
None under normal use conditions.

Target Organ Effects
HMIS
Health
Flammability
Reactivity

4 * Chronic Hazard
3
0

SECT I ON 3 : Com posit ion/inform a t ion on ingre die nt s
Component
Cobalt(II) chloride hexahydrate
7791-13-1 ( 0.5-1 )

CAS-No
7791-13-1

EINECS-No
-

Weight %
0.5-1

We recommend handling all chemicals with caution.

SECT I ON 4 : First a id m e a sure s
________________________________________________________________________________________________________________
Revision date
Product code
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Product name HisPur(tm) Cobalt Resin, 10 mL
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Wash off immediately with plenty of water for at least 15 minutes. Take off all
contaminated clothing and wash it before reuse. Immediate medical attention is
required.
Rinse immediately with plenty of water, also under the eyelids, for at least 15
Eye contact
minutes. Immediate medical attention is required.
Call a physician or poison control center immediately. Never give anything by
Ingestion
mouth to an unconscious person. Do not induce vomiting without medical advice.
Remove to fresh air. If not breathing, give artificial respiration. Call a physician or
inhalation
poison control center immediately.
Most important symptoms and effects, both acute and delayed
H226 - Flammable liquid and vapor, H350 - May cause cancer, H360F - May damage fertility, H411 - Toxic to aquatic
life with long lasting effects
Skin contact

Treat symptomatically.

Notes to Physician

SECT I ON 5 : Fire fight ing m e a sure s
Suitable extinguishing media
Special protective equipment for firefighters
Specific hazards arising from the chemical

Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Wear self-contained breathing apparatus and protective
suit.
Not known

SECT I ON 6 : Ac c ide nt a l re le a se m e a sure s
Ensure adequate ventilation. Avoid contact with skin, eyes or clothing. Use
personal protection equipment.
Soak up with inert absorbent material.

Personal precautions
Methods for cleaning up
Environmental precautions

Prevent further leakage or spillage if safe to do so. Prevent product from entering drains.
See Section 12 for more information.
SECT I ON 7 : H a ndling a nd st ora ge
Always wear reccommended Personal Protective Equipment. No special handling
advices are necessary.
Keep in a dry, cool and well-ventilated place. Keep in properly labeled containers.

Handling
Storage

SECT I ON 8 : Ex posure c ont rols/pe rsona l prot e c t ion
Exposure Limits
Chemical Name
Cobalt(II) chloride
hexahydrate

Engineering measures

OSHA PEL
None

OSHA PEL (Ceiling)
None

ACGIH OEL (TWA)
0.02 mg/m3

ACGIH OEL (STEL)
None

Ensure adequate ventilation, especially in confined areas.

Personal Protective Equipment
Personal Protective Equipment requirements are dependent on the user institution's risk assessment and are specific
to the risk assessment for each laboratory where this material may be used.
Respiratory protection

In case of insufficient ventilation, wear suitable respiratory equipment.

________________________________________________________________________________________________________________
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Hand protection
Eye protection
Skin and Body Protection
Hygiene measures
Environmental exposure
controls

Impervious gloves.
Wear safety glasses with side shields (or goggles).
Lightweight protective clothing.
Handle in accordance with good industrial hygiene and safety practice.
Prevent product from entering drains. Should not be released into the
environment.

SECT I ON 9 : Physic a l a nd c he m ic a l prope rt ie s
General information
Form
Appearance
Odor
Odor Threshold
Boiling point / boiling range
Melting point / melting range
flash point
Autoignition Temperature
Evaporation rate
Flammability (solid, gas)
Oxidizing properties
Water solubility
Upper explosion limit
Lower explosion limit

Liquid
No information available
Mixture has not been tested
Mixture has not been tested
°C No data available
°C No data available
°C 32.222
°C No data available
No data available
No data available
Mixture has not been tested
No data available
No data available
No data available

Partition coefficient:
n-octanol/water
Vapor Pressure
vapor density
Viscosity
pH value

No data available

°F
°F
°F
°F

No data available
No data available
89.996
No data available

No data available
No data available
Mixture has not been tested
No data available
SECT I ON 1 0 : St a bilit y a nd re a c t ivit y

Stability

Stable under normal conditions.

Materials to avoid

No information available.

Possibility of hazardous
reactions

Hazardous reaction has not been reported

Hazardous decomposition
products

No information available.

polymerization

None under normal processing.

Conditions to avoid

None under normal processing.
SECT I ON 1 1 : T ox ic ologic a l inform a t ion

Acute Toxicity
________________________________________________________________________________________________________________
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Chemical Name
Cobalt(II) chloride hexahydrate

LD50 (oral,rat/mouse)
= 766 mg/kg (Rat) = 80 mg/kg (Rat)

Principle Routes of Exposure
Potential Health Effects
eyes
Skin
inhalation
Ingestion

LD50 (dermal,rat/rabbit)
No data available

LC50 (inhalation,rat/mouse)
No data available

May cause eye irritation with susceptible persons.
May be harmful in contact with skin.
May cause irritation of respiratory tract.
May be harmful if swallowed.

Carcinogenic effects
Mutagenic effects
Reproductive toxicity
Sensitization

May cause cancer.
None.
May cause harm to the unborn child.
None.

Target Organ Effects

None under normal use conditions
SECT I ON 1 2 : Ec ologic a l inform a t ion

Ecotoxicity
Chronic aquatic toxicity
Mobility
Biodegradation
Bioaccumulation

Hazardous to the Aquatic Environment.
Category 2.
No information available.
No information available.
No information available.

SECT I ON 1 3 : Disposa l c onside ra t ions
Dispose of contents/containers in accordance with local regulations.
SECT I ON 1 4 : T ra nsport inform a t ion
IATA
Proper Shipping Name
Hazard Class
Subsidiary class
Packing group
UN-No
Environmental hazards

Flammable liquids, n.o.s. (ethanol, mixture)
3
None
III
UN1993
No

________________________________________________________________________________________________________________
Revision date
Product code

15-Mar-2016
89964

Page 5 / 6
Product name HisPur(tm) Cobalt Resin, 10 mL
www.thermofisher.com

SECT I ON 1 5 : Re gula t ory inform a t ion
Component
Cobalt(II) chloride hexahydrate
7791-13-1 ( 0.5-1 )

US TSCA
-

US Federal Regulations
SARA 313

This product contains the following toxic chemical(s) subject to the notification requirements of section 313 of Title III of the
Superfund Amendments and Reauthorization Act of 1986. This law requires certain manufacturers to report on annual emissions of
specified chemicals and chemical categories. Please note that if you repackage, or otherwise redistribute, this product to industrial
customers, a notice similar to this one should be sent to those customers:.
Chemical Name
Cobalt(II) chloride hexahydrate

CAS-No
7791-13-1

Weight %
0.5-1

SARA 313 - Threshold Values
0.1

Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product contains the following HAPs:.
Component
Cobalt(II) chloride hexahydrate
7791-13-1 ( 0.5-1 )

CAS-No
7791-13-1

Weight %
0.5-1

HAPS data
Present (including any unique
chemical substance that contains
Cobalt as part of its infrastructure)

US State Regulations
California Proposition 65

This product does not contain any Proposition 65 chemicals.

WHMIS Hazard Class
B3 - Combustible liquid
D2A - Very toxic materials

This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the
MSDS contains all the information required by the CPR.

SECT I ON 1 6 : Ot he r inform a t ion
Reason for revision

SDS sections updated.

Use as laboratory reagent. Scientific research and development.
"The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE"
End of Safety Data Sheet
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INSTRUCTIONS

HisPur™ Cobalt Resin
89964 89965 89966

1851.2

Number

Description

89964

HisPur Cobalt Resin, 10mL settled resin

89965

HisPur Cobalt Resin, 100mL settled resin

89966

HisPurCobalt Resin, 500mL settled resin
Binding Capacity: ≥ 10mg at > 90% purity of a 28kDa His-tagged protein from a bacterial source per
milliliter of settled resin
Resin: Crosslinked 6% agarose in a 20% ethanol solution
Storage: Upon receipt store at 4°C. Product shipped at ambient temperature.

Introduction
The Thermo Scientific HisPur Cobalt Resin enables efficient purification of polyhistidine-tagged proteins from bacterial,
mammalian and baculovirus-infected cells. His-tagged proteins are purified from total soluble protein extract using a cobaltcharged tetradentate chelator immobilized onto 6% crosslinked agarose. The cobalt resin is compatible using native or
denaturing conditions and can be used in multiple formats including conventional gravity flow chromatography, spin column
and FPLC.
Many immobilized metal affinity chromatography (IMAC) resins use nickel (Ni+2) as the metal source for purifying Histagged proteins. Although Ni+2 chelate resins achieve high protein yields, purity is often suboptimal, resulting in the need for
additional optimization of wash and elution steps. Cobalt achieves both high protein yield and purity with minimal
optimization. Furthermore, HisPur Cobalt Resin displays less metal leaching compared with Ni+2 resins.

Important Product Information
•

Protein yield and purity are dependent upon the expression level, conformation and solubility characteristics of the
recombinant fusion protein. Therefore, it is important to optimize these parameters before attempting a large-scale
purification. For best results, perform a small-scale test to estimate the expression level and determine the solubility of
each His-tagged protein.

•

Optimization of the lysis procedure is critical for maximizing protein yield. Some methods for protein extraction include
using commercially available detergent-based reagents, such as Thermo Scientific B-PER Bacterial Protein Extraction
Reagent (Product No. 78248), and mechanical methods, such as freeze/thaw cycles, sonication or French press.

•

Sometimes overexpressed proteins are sequestered in inclusion bodies. Inclusion bodies of His-tagged proteins can be
solubilized in 8M urea, 6M guanidine or Inclusion Body Solubilization Reagent (Product No. 78115) and purified with
the cobalt resin, but a denaturant must be added to buffers so the protein remains soluble throughout the procedure.

•

One advantage of using cobalt is its low nonspecific binding. Although the buffer conditions described in these
instructions work well for many samples, optimization may be required to further reduce nonspecific binding. To
optimize conditions, adjust the imidazole concentration in the Equilibration/Wash Buffer or decrease the buffer’s pH to
protonate a greater proportion of histidine groups.

•

IMAC relies on cobalt chelation to both the tetradentate chelator and the target histidine tag. Avoid using protease
inhibitors or other additives that contain chelators, such as EDTA, or strong reducing agents, such as DTT or
β-mercaptoethanol, which will disrupt the function of the cobalt resin.

Pierce Biotechnology

PO Box 117

(815) 968-0747

3747 N. Meridian Road

Rockford, lL 61105 USA

(815) 968-7316 fax

www.thermoscientific.com/pierce

Additional Materials Required
•

MES Buffer: 20mM 2-(N-morpholine)-ethanesulfonic acid, 0.1M sodium chloride; pH 5.0

For native conditions prepare the following buffers:
•

Equilibration/Wash Buffer: 50mM sodium phosphate, 300mM sodium chloride, 10mM imidazole; pH 7.4

•

Elution Buffer: 50mM sodium phosphate, 300mM sodium chloride, 150mM imidazole; pH 7.4

For denaturing conditions prepare the following buffers:
•

Equilibration/Wash Buffer: 50mM sodium phosphate, 300mM sodium chloride, 6M guanidine•HCl, 10mM imidazole;
pH 7.4

•

Elution Buffer: 50mM sodium phosphate, 300mM sodium chloride, 6M guanidine•HCl, 150mM imidazole; pH 7.4.

Procedure for Purification of His-Tagged Proteins by Batch Method
The HisPur Cobalt Resin allows customization of a purification strategy. Purification conditions detailed within these
instructions can be scaled as desired. The procedure may be performed at room temperature or at 4°C.
1.

Add an appropriate amount of cobalt resin to a tube. Centrifuge tube for 2 minutes at 700 × g and carefully remove and
discard the supernatant.

2.

Add two resin-bed volumes of Equilibration/Wash Buffer and mix until the resin is fully suspended.

3.

Centrifuge tube for 2 minutes at 700 × g and carefully remove and discard buffer.

4.

Prepare sample by mixing the protein extract with an equal volume of Equilibration/Wash Buffer.

5.

Add the prepared protein extract to the tube and mix on an end-over-end rotator for 30 minutes.

6.

Centrifuge the tube for 2 minutes at 700 × g. If desired, save supernatant for downstream analysis.

7.

Wash the resin with two resin-bed volumes of Equilibration/Wash Buffer. Centrifuge the tube for 2 minutes at 700 × g. If
desired, save supernatant for downstream analysis.

8.

Repeat wash step and monitor supernatant by measuring its absorbance at 280nm until baseline is reached.

9.

Elute bound His-tagged proteins using one resin-bed volume of Elution Buffer. Centrifuge tube for 2 minutes at 700 × g.
Carefully remove and save the supernatant. Repeat this step twice, saving each supernatant fraction in a separate tube.

10. Monitor protein elution by measuring the absorbance of the fractions at 280nm or by Coomassie Plus (Bradford) Assay
(Product No. 23236). The eluted protein can be directly analyzed by SDS-PAGE. To remove excess imidazole for
downstream applications use gel filtration (e.g., Thermo Scientific Zeba Spin Desalting Columns) or dialysis (e.g.,
Thermo Scientific Slide-A-Lyzer Dialysis Cassettes). Samples containing 6M guanidine•HCl must be dialyzed against a
buffer containing 8 M urea before SDS-PAGE analysis. The Thermo Scientific Pierce SDS-PAGE Sample Prep Kit
(Product No. 89888) may also be used to remove guanidine.

Procedure for Purification of His-tagged Proteins using a Gravity-flow Column
The HisPur Cobalt Resin allows customization of a purification strategy. Purification conditions detailed within these
instructions can be scaled as desired. Perform the procedure at room temperature or at 4°C.
1.

Pack column with an appropriate amount of cobalt resin. Allow storage buffer to drain from resin by gravity flow.

2.

Prepare sample by mixing the protein extract with an equal volume of Equilibration/Wash Buffer.

3.

Equilibrate column with two resin-bed volumes of Equilibration/Wash Buffer. Allow buffer to drain from resin, flow rate
should be 0.5-1mL/minute.

4.

Add the prepared protein extract onto the resin. Collect the flow-through in a tube. If desired, re-apply the flow-through
once to maximize binding.

5.

Wash resin with two resin-bed volumes of Equilibration/Wash Buffer and collect the flow-through. Repeat this step
using a new collection tube until the absorbance of the flow-through fraction at 280nm approaches baseline.

Pierce Biotechnology

PO Box 117
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6.

Elute His-tagged proteins from the resin with two resin-bed volumes of Elution Buffer. Repeat this step twice, collecting
each fraction in a separate tube.

7.

Monitor protein elution by measuring the absorbance of the fractions at 280nm or by Coomassie Plus (Bradford) Assay
(Product No. 23236). The eluted protein can be directly analyzed by SDS-PAGE. To remove excess imidazole for
downstream applications use gel filtration (e.g., Zeba™ Spin Desalting Columns) or dialysis (e.g., Slide-A-Lyzer®
Dialysis Cassettes). Samples containing 6M guanidine•HCl must be dialyzed against buffer containing 8M urea before
SDS-PAGE analysis. The Pierce® SDS-PAGE Sample Prep Kit (Product No. 89888) may also be used to remove
guanidine.

Procedure for Cobalt Resin Regeneration
The cobalt resin may be used up to three times without affecting protein yield or purity. Between each use, perform the
procedure as described below to remove residual imidazole and any nonspecifically adsorbed protein. To prevent crosscontamination of samples, designate a given column to one specific fusion protein.
1.

Wash resin with 10 resin-bed volumes of 20mM MES Buffer , 0.1M sodium chloride; pH 5.0.

2.

Wash resin with 10 resin-bed volumes of ultrapure water.

3.

Store resin as a 50% slurry in 20% ethanol.

Troubleshooting
Problem
Low protein yield

Possible Cause
Poor expression of soluble
protein
His-tagged protein forms
inclusion bodies

Solution
Optimize bacterial expression conditions

Insufficient cell lysis and
extraction
Fusion protein does not bind
to the column
Poor protein purity

Insufficient washing

Slow column flow

Column is overloaded

Alter bacterial growth conditions to minimize inclusion body
formation and maximize soluble protein yield; alternatively,
solubilize inclusion bodies and perform the purification with a
compatible denaturant (e.g., Inclusion Body Solubilization
Reagent, Product No. 78115)
Optimize cell lysis protocol
Verify the sequence or perform an ELISA or Western blot using
an antibody against the His tag to make sure the His-tag is
present
Wash resin additional times or modify imidazole concentration
and pH of the Equilibration/Wash Buffer
Apply less protein extract onto the column and make sure the
extract is not too viscous or highly particulate

Additional Information
Please visit the website for additional information including the following items:
•

Tech Tip #43: Protein stability and storage

•

Tech Tip #40: Convert between times gravity (× g) and centrifuge rotor speed (RPM)

•

Tech Tip #6: Extinction coefficients guide

•

Tech Tip #7: Remove air bubbles from columns to restore flow rate

•

Tech Tip #13: Pack beaded affinity resin into affinity columns
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Related Thermo Scientific Products
16100

Pierce Glutathione Agarose, 10mL

88270

Pierce High Capacity Endotoxin Removal Resin, 10mL

88282

Pierce LAL Chromogenic Endotoxin Quantitation Kit

88221

HisPur Ni-NTA Resin, 10mL

89967

HisPur Cobalt Spin Columns, 0.2mL, 25 each

89968

HisPur Cobalt Spin Columns, 1.0mL, 5 each

89969

HisPur Cobalt Spin Columns, 3.0mL, 5 each

78248

B-PER® Bacterial Protein Extraction Reagent, 500mL

78260

B-PER II Bacterial Protein Extraction Reagent, 250mL

89802

I-PER® Insect Cell Protein Extraction Reagent, 250mL

78410

Halt™ Protease Inhibitor Cocktail, EDTA-Free, 1mL

78115

Inclusion Body Solubilization Reagent, 100mL

89835

DNAse I, 5000 units

23236

Coomassie Plus (Bradford) Assay

89890

Zeba Spin Desalting Columns, 7K MWCO, 2mL, 25/pkg

89892

Zeba Spin Desalting Columns, 7K MWCO, 5mL, 25/pkg

89894

Zeba Spin Desalting Columns, 7K MWCO, 10mL, 25/pkg

66385

Slide-A-Lyzer Dialysis Cassettes Kit, 10K MWCO, 0.1-0.5mL

66382

Slide-A-Lyzer Dialysis Cassettes Kit, 10K MWCO, 0.5-3mL

66807

Slide-A-Lyzer Dialysis Cassettes Kit, 10K MWCO, 3-12mL

This product (“Product”) is warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale,
as set forth in the Product documentation, specifications and/or accompanying package inserts (“Documentation”) and to be free from defects in material and
workmanship. Unless otherwise expressly authorized in writing, Products are supplied for research use only. No claim of suitability for use in applications
regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the
Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This
warranty does not extend to anyone other than the original purchaser of the Product (“Buyer”).
No other warranties, express or implied, are granted, including without limitation, implied warranties of merchantability, fitness for any particular
purpose, or non infringement. Buyer’s exclusive remedy for non-conforming Products during the warranty period is limited to replacement of or
refund for the non-conforming Product(s).
There is no obligation to replace Products as the result of (i) accident, disaster or event of force majeure, (ii) misuse, fault or negligence of or by Buyer, (iii)
use of the Products in a manner for which they were not designed, or (iv) improper storage and handling of the Products.
Current product instructions are available at www.thermoscientific.com/pierce. For a faxed copy, call 800-874-3723 or contact your local distributor.
© 2012 Thermo Fisher Scientific Inc. All rights reserved. Unless otherwise indicated, all trademarks are property of Thermo Fisher Scientific Inc. and its
subsidiaries. Printed in the USA.
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INSTRUCTIONS

Pierce High-Capacity Endotoxin
Removal Resin
MAN0016351
Rev A.0
Pub. Part No. 2162373.3

Number

Description

88270

Pierce High-Capacity Endotoxin Removal Resin, 10mL of settled resin supplied as 50% slurry in
20% ethanol

88271

Pierce High-Capacity Endotoxin Removal Resin, 100mL of settled resin supplied as 50% slurry in
20% ethanol

88272

Pierce High-Capacity Endotoxin Removal Resin, 250mL of settled resin supplied as 50% slurry in
20% ethanol

88273

Pierce High-Capacity Endotoxin Removal Spin Column, 0.25mL, 5 columns, each column contains
25% slurry in 20% ethanol

88274

Pierce High-Capacity Endotoxin Removal Spin Column, 0.50mL, 5 columns, each column contains
25% slurry in 20% ethanol

88275

Pierce High-Capacity Endotoxin Removal Spin Column, 0.50mL, 25 columns, each column
contains 25% slurry in 20% ethanol

88276

Pierce High-Capacity Endotoxin Removal Spin Column, 1.0mL, 5 columns, each column contains
25% slurry in 20% ethanol

88277

Pierce High-Capacity Endotoxin Removal Spin Column, 1.0mL, 25 columns, each column contains
25% slurry in 20% ethanol
Storage: Upon receipt store at 4°C. Product shipped at ambient temperature.

Introduction
The Thermo Scientific™ Pierce™ High Capacity Endotoxin Removal Resin contains porous cellulose beads that have been
surface modified with covalently attached, modified ε-poly-L-lysine. Modified polylysine has a high affinity for endotoxins
with the affinity ligand eliminating toxicity associated with alternative technologies using polymixin B ligands and sodium
deoxycholate buffers. The binding capacity of 2,000,000 Endotoxin Units (EU)/mL allows endotoxin levels to be reduced by
99% in samples containing 10,000EU/mL; typical protein samples processed with the resin have a final endotoxin
concentration below 5EU/mL. The resin is offered in a slurry format for custom packing of endotoxin removal columns for
gravity flow or continuous flow (10-15 mL/hour) applications or a spin column format for the fast, single-use batch method.
Removal of endotoxins from differing volumes of biological samples can be done in ≥ 1 hour (see Table 1).
Endotoxins consist of lipopolysaccharides (LPS), which are biologically active, structural components of the outer cell
membrane of all gram-negative bacteria. Small amounts of endotoxin in recombinant protein preparations can cause side
effects, including endotoxin shock, tissue injury and death in host organisms; therefore, it is essential to remove endotoxins
from drugs, injectables and other biological products.
One milliliter of this resin can reduce the endotoxin concentration from a 1mL sample containing 10,000EU to < 5EU.
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Procedure Summary

Important Product Information
•

All materials (e.g., containers, buffers and pipette tips) must be endotoxin-free. Use endotoxin-free water to prepare
buffers and other solutions.

•

Endotoxin binding to the resin occurs at pH 6-8; Equilibrate the resin with an endotoxin-free buffer at neutral pH that
includes 10-50mM sodium phosphate buffer or Tris-HCl buffer containing 0.1-0.2M NaCl. Check the sample pH and
adjust to pH 6-8 with 0.1M NaOH or 0.1M HCl.

•

The speed of sample application and wash depends on the sample endotoxin state. Free endotoxin can bind quickly to the
resin, but protein-bound endotoxin may require longer incubation, slower flow rates and/or multiple recycling of the
sample through the column. Tightly bound endotoxin may be incubated overnight at room temperature or 4°C in batch
mode with gentle shaking.

•

Resins can be used a minimum of five times without loss of endotoxin-removal efficiency.

•

Sample volumes vary depending on the chosen pre-loaded column size (see Table 1).
Table 1. Sample volumes for the Thermo
Scientific Pierce High-Capacity Endotoxin
Removal Columns.
Column size (mL)

Sample volume (mL)

0.25
0.50
1.0

0.5-1.0
1.0-4.0
2.0-10.0

Additional Materials Required
•

Endotoxin-free, ultrapure water

•

Endotoxin-free 15mL conical collection tubes (for 0.25mL and 0.5mL spin columns)

•

Endotoxin-free 50mL conical collection tubes (for 1.0mL spin columns)

•

Regeneration buffer: 0.2N NaOH for overnight incubation at room temperature OR 0.2N NaOH and 95% ethanol for
1-2 hours of incubation at room temperature
Note: Regenerate the column before the first use and after each subsequent use.

•

2M NaCl solution: If possible, use ready-made endotoxin-free NaCl solution; alternatively, dissolve pure sodium
chloride crystals in endotoxin-free water

•

Variable-speed centrifuge with rotor and carriers capable of handling 15mL and 50mL conical collection tubes
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Endotoxin Removal Procedure using the Column Method
•
•
•

Regenerate the resin before the first use and after each subsequent use.
Equilibrate all solutions and the resin to room temperature before use.
Degas the resin slurry before applying to the column to prevent air bubbles from clogging the column and reducing flow.

1.

To degas the resin, place slurry in a suction filter flask and degas with gentle stirring.

2.

Pour the degassed resin slurry into an appropriately sized column and allow the resin to settle.

3.

Regenerate the resin by washing with five resin-bed volumes of 0.2N NaOH overnight at room temperature OR five
resin-bed volumes of 0.2N NaOH in 95% ethanol for 1-2 hours at room temperature.

4.

Wash with five resin-bed volumes of 2M NaCl.

5.

Wash with five resin-bed volumes of endotoxin-free, ultrapure water.

6.

Equilibrate with five resin-bed volumes of endotoxin-free buffer.

7.

Apply sample to the column at a flow rate of 10-15mL/hr and collect the flow-through (see the Important Product
Information Section).

8.

Elute the protein by adding endotoxin-free buffer and collecting fractions; one or two resin-bed volume elutions are
sufficient.

9.

Determine the endotoxin concentration of the processed sample. Use caution to prevent sample contamination from
dust or contaminated tubes subsequent to endotoxin removal. Store solutions frozen or assay them before use to
ensure sterility.

10. Regenerate the resin as described in Steps 3-5 and store the column in 20% ethanol at 2-8°C.

Endotoxin Removal Procedure using the Batch Method with Spin Columns
•

Regenerate the resin before the first use and after each subsequent use. For regeneration and equilibration (steps 1-10),
use regeneration buffer in 2mL volumes for the 0.25mL column, 3.5mL volumes for the 0.5mL column and 8mL
volumes for the 1mL column.

•

Wear appropriate gloves while handling the spin columns. Use caution to prevent sample contamination during the
endotoxin-removal procedure.

1.

Equilibrate the spin column to room temperature.

2.

Twist off the column’s bottom closure and loosen the top cap. Place the spin column into a collection tube. Centrifuge
the column at 500 × g for 1 minute to remove the storage solution. Discard the storage solution.

3.

Remove the column cap and insert the bottom plug. To regenerate, add 0.2N NaOH, replace the cap, invert the column
several times until the resin is suspended in the solution and incubate overnight at room temperature, OR add 0.2N
NaOH in 95% ethanol, replace the cap, invert the column several times until the resin is suspended in the solution and
incubate 1-2 hours at room temperature.

4.

Loosen the cap and remove the bottom plug. Place the column in a collection tube and centrifuge at 500 × g for 1 minute
to remove the solution. Discard the solution.

5.

Remove the cap and insert the bottom plug. Add 2M NaCl, replace the cap and invert the column several times until the
resin is suspended in the solution.

6.

Loosen the cap and remove the bottom plug. Place the column in a collection tube and centrifuge at 500 × g for 1 minute
to remove the solution. Discard the solution.

7.

Remove the cap and insert the bottom plug. Add endotoxin-free, ultrapure water. Replace the cap and invert the column
several times until the resin is suspended in the solution.

8.

Loosen the cap and remove the bottom plug. Place the column in a collection tube and centrifuge at 500 × g for 1 minute
to remove the solution. Discard the solution.

9.

Remove the cap and insert the bottom plug. Add endotoxin-free buffer, replace the cap and invert the column several
times until the resin is suspended in the solution.
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10. Loosen the cap and remove the bottom plug. Place the column in a collection tube and centrifuge at 500 × g for 1 minute
to remove the solution. Discard the solution. Repeat steps 9 and 10 two additional times.
11. Remove the cap and insert the bottom plug. Add the sample to the resin, replace the cap and invert the column several
times until the resin is suspended in the solution.
12. Incubate the column with gentle end-over-end mixing at room temperature or 4°C for 1 hour. Incubation time can be
extended depending on the sample type and requirements (see the Important Product Information Section).
13. Loosen the cap and remove the bottom plug. Place column in a collection tube and centrifuge at 500 × g for 1 minute to
collect the sample.
14. Determine the endotoxin concentration of the processed sample. Use caution to prevent sample contamination after
endotoxin removal. Store solutions at -20°C or assay before use to ensure sterility.
15. Regenerate the resin as described in step 3 and store the column in 20% ethanol at 2-8°C.

Troubleshooting
Problem
Low endotoxin
removal efficiency

Low protein/sample
recovery

Possible Cause

Solution

Sample pH was not within a neutral range

Adjust sample to pH 6-8

Incubation time was not sufficient

Increase the incubation time for the
batch method

Endotoxin was bound to the target protein

Recycle the sample through the column
several times

The removal or detection system was contaminated by
extrinsic LPS

Use endotoxin-free labware and buffers

Target protein aggregated with endotoxin and was
removed

Increase NaCl concentration in the
sample and equilibration buffer to 0.4M

Nonspecific binding of sample to the resin

Related Thermo Scientific Products
88282

Pierce LAL Chromogenic Endotoxin Quantitation Kit

89896, 7, 8

Pierce Centrifuge Columns, (2mL, 5mL and 10mL, respectively), 25/pkg

23225

Pierce BCA Protein Assay Kit

22660

Pierce 660nm Protein Assay

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in
the Product documentation, specifications and/or accompanying package inserts (“Documentation”). No claim of suitability for use in applications regulated
by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this
warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to
anyone other than Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that
any Product will conform to such model or sample.
NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED, INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF
MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER’S EXCLUSIVE REMEDY FOR NONCONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NONCONFORMING PRODUCT(S) AT SELLER’S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS
AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER,
(III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF
THE PRODUCTS.
Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to
be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or
any type of consumption by or application to humans or animals.
Current product instructions are available at thermofisher.com. For a faxed copy, call 800-874-3723 or contact your local distributor.
© 2016 Thermo Fisher Scientific Inc. All rights reserved. Unless otherwise indicated, all trademarks are property of Thermo Fisher Scientific Inc. and its
subsidiaries. Printed in the USA.
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SAFETY DATA SHEET
Endotoxin Removal Resin

Section 1. Identification
GHS product identifier

: Endotoxin Removal Resin

Other means of identification

SDS #

: Endotoxin Removal Resin, High Capacity; Endotoxin Removal Resin, Ultra Capacity;
Pierce High Capacity Endotoxin Removal Resin
: Liquid.
: 0088270 0088271 0088272 0088273 0088274 0088275 0088276 0088277 1862581
1862582 1896231 1896254
: 8743

Chemical formula

: Not applicable.

CAS #

: Not applicable.

Product type
Product code

Relevant identified uses of the substance or mixture and uses advised against
Not applicable.
Supplier's details

: Thermo Fisher Scientific
Pierce Biotechnology
P.O. Box 117
Rockford, IL 61105
United States
815.968.0747 or
800.874.3723
7 AM - 5 PM Central Time (GMT -06:00)

Emergency telephone
number (with hours of
operation)

: CHEMTREC: 800.424.9300
Outside US: 703.527.3887

Section 2. Hazards identification
OSHA/HCS status
Classification of the
substance or mixture

: This material is considered hazardous by the OSHA Hazard Communication Standard
(29 CFR 1910.1200).
: FLAMMABLE LIQUIDS - Category 4
SKIN CORROSION/IRRITATION - Category 2
SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2A
CARCINOGENICITY - Category 2
TOXIC TO REPRODUCTION (Fertility) - Category 1A
TOXIC TO REPRODUCTION (Unborn child) - Category 1B

GHS label elements
Hazard pictograms

:

Signal word
Hazard statements

: Danger
: Combustible liquid.
Causes serious eye irritation.
Causes skin irritation.
May damage fertility or the unborn child.
Suspected of causing cancer.

Precautionary statements
Prevention

Date of issue/Date of revision

: Obtain special instructions before use. Do not handle until all safety precautions have
been read and understood. Use personal protective equipment as required. Wear
protective gloves. Wear eye or face protection. Keep away from flames and hot
surfaces. - No smoking. Wash hands thoroughly after handling.

: 2/17/2014.

Date of previous issue

: No previous validation.

Version

:1

1/13

Endotoxin Removal Resin

Section 2. Hazards identification
Response

Storage
Disposal
Hazards not otherwise
classified

: IF exposed or concerned: Get medical attention. IF ON SKIN: Wash with plenty of soap
and water. Take off contaminated clothing. Wash contaminated clothing before reuse.
If skin irritation occurs: Get medical attention. IF IN EYES: Rinse cautiously with water
for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
If eye irritation persists: Get medical attention.
: Store locked up. Store in a well-ventilated place. Keep cool.
: Dispose of contents and container in accordance with all local, regional, national and
international regulations.
: None known.

Section 3. Composition/information on ingredients
Substance/mixture
Other means of
identification

: Mixture
: Endotoxin Removal Resin, High Capacity; Endotoxin Removal Resin, Ultra Capacity;
Pierce High Capacity Endotoxin Removal Resin

CAS number/other identifiers
CAS number

: Not applicable.

Ingredient name

%

CAS number

ethanol

10 - 20

64-17-5

Any concentration shown as a range is to protect confidentiality or is due to batch variation.
There are no additional ingredients present which, within the current knowledge of the supplier and in the
concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in
this section.
Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures
Description of necessary first aid measures
Eye contact

Inhalation

Skin contact

Ingestion

: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower
eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10
minutes. Get medical attention.
: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not
breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial
respiration or oxygen by trained personnel. It may be dangerous to the person providing
aid to give mouth-to-mouth resuscitation. Get medical attention. If unconscious, place in
recovery position and get medical attention immediately. Maintain an open airway.
Loosen tight clothing such as a collar, tie, belt or waistband.
: Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes.
Wash contaminated clothing thoroughly with water before removing it, or wear gloves.
Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before
reuse. Clean shoes thoroughly before reuse.
: Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and
keep at rest in a position comfortable for breathing. If material has been swallowed and
the exposed person is conscious, give small quantities of water to drink. Stop if the
exposed person feels sick as vomiting may be dangerous. Do not induce vomiting
unless directed to do so by medical personnel. If vomiting occurs, the head should be
kept low so that vomit does not enter the lungs. Get medical attention. Never give
anything by mouth to an unconscious person. If unconscious, place in recovery position
and get medical attention immediately. Maintain an open airway. Loosen tight clothing
such as a collar, tie, belt or waistband.

Most important symptoms/effects, acute and delayed
Potential acute health effects
Eye contact
Inhalation
Date of issue/Date of revision

: Causes serious eye irritation.
: No known significant effects or critical hazards.
: 2/17/2014.

Date of previous issue

: No previous validation.

Version

:1

2/13
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Section 4. First aid measures
Skin contact

: Causes skin irritation.

Ingestion

: Irritating to mouth, throat and stomach.

Over-exposure signs/symptoms
Eye contact

Inhalation

Skin contact

Ingestion

: Adverse symptoms may include the following:
pain or irritation
watering
redness
: Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations
: Adverse symptoms may include the following:
irritation
redness
reduced fetal weight
increase in fetal deaths
skeletal malformations
: Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations

Indication of immediate medical attention and special treatment needed, if necessary
Notes to physician
Specific treatments
Protection of first-aiders

: Treat symptomatically. Contact poison treatment specialist immediately if large
quantities have been ingested or inhaled.
: No specific treatment.
: No action shall be taken involving any personal risk or without suitable training. If it is
suspected that fumes are still present, the rescuer should wear an appropriate mask or
self-contained breathing apparatus. It may be dangerous to the person providing aid to
give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water
before removing it, or wear gloves.

See toxicological information (Section 11)

Section 5. Fire-fighting measures
Extinguishing media
Suitable extinguishing
media
Unsuitable extinguishing
media
Specific hazards arising
from the chemical
Hazardous thermal
decomposition products

Special protective actions
for fire-fighters

Special protective
equipment for fire-fighters

Date of issue/Date of revision

: Use dry chemical, CO₂, water spray (fog) or foam.
: Do not use water jet.

: Combustible liquid. In a fire or if heated, a pressure increase will occur and the container
may burst, with the risk of a subsequent explosion. Runoff to sewer may create fire or
explosion hazard.
: Decomposition products may include the following materials:
carbon dioxide
carbon monoxide
: Promptly isolate the scene by removing all persons from the vicinity of the incident if
there is a fire. No action shall be taken involving any personal risk or without suitable
training. Move containers from fire area if this can be done without risk. Use water spray
to keep fire-exposed containers cool.
: Fire-fighters should wear appropriate protective equipment and self-contained breathing
apparatus (SCBA) with a full face-piece operated in positive pressure mode.

: 2/17/2014.

Date of previous issue

: No previous validation.

Version

:1

3/13
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Section 6. Accidental release measures
Personal precautions, protective equipment and emergency procedures
For non-emergency
personnel

For emergency responders

Environmental precautions

: No action shall be taken involving any personal risk or without suitable training.
Evacuate surrounding areas. Keep unnecessary and unprotected personnel from
entering. Do not touch or walk through spilled material. Shut off all ignition sources. No
flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide
adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on
appropriate personal protective equipment.
: If specialised clothing is required to deal with the spillage, take note of any information in
Section 8 on suitable and unsuitable materials. See also the information in "For nonemergency personnel".
: Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and
sewers. Inform the relevant authorities if the product has caused environmental pollution
(sewers, waterways, soil or air).

Methods and materials for containment and cleaning up
Small spill
: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and
explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively,
or if water-insoluble, absorb with an inert dry material and place in an appropriate waste
disposal container. Dispose of via a licensed waste disposal contractor.
Large spill
: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and
explosion-proof equipment. Approach release from upwind. Prevent entry into sewers,
water courses, basements or confined areas. Wash spillages into an effluent treatment
plant or proceed as follows. Contain and collect spillage with non-combustible,
absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in
container for disposal according to local regulations (see Section 13). Dispose of via a
licensed waste disposal contractor. Contaminated absorbent material may pose the
same hazard as the spilled product. Note: see Section 1 for emergency contact
information and Section 13 for waste disposal.

Section 7. Handling and storage
Precautions for safe handling
Protective measures

Advice on general
occupational hygiene

Conditions for safe storage,
including any
incompatibilities

Date of issue/Date of revision

: Put on appropriate personal protective equipment (see Section 8). Avoid exposure obtain special instructions before use. Avoid exposure during pregnancy. Do not handle
until all safety precautions have been read and understood. Do not get in eyes or on skin
or clothing. Do not ingest. Avoid breathing vapor or mist. Use only with adequate
ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter
storage areas and confined spaces unless adequately ventilated. Keep in the original
container or an approved alternative made from a compatible material, kept tightly closed
when not in use. Store and use away from heat, sparks, open flame or any other ignition
source. Use explosion-proof electrical (ventilating, lighting and material handling)
equipment. Use only non-sparking tools. Empty containers retain product residue and
can be hazardous. Do not reuse container.
: Eating, drinking and smoking should be prohibited in areas where this material is handled,
stored and processed. Workers should wash hands and face before eating, drinking and
smoking. Remove contaminated clothing and protective equipment before entering
eating areas. See also Section 8 for additional information on hygiene measures.
: Store in accordance with local regulations. Store in a segregated and approved area.
Store in original container protected from direct sunlight in a dry, cool and well-ventilated
area, away from incompatible materials (see Section 10) and food and drink. Store
locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep
container tightly closed and sealed until ready for use. Containers that have been
opened must be carefully resealed and kept upright to prevent leakage. Do not store in
unlabeled containers. Use appropriate containment to avoid environmental
contamination.

: 2/17/2014.

Date of previous issue

: No previous validation.

Version

:1
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Section 8. Exposure controls/personal protection
Control parameters
Occupational exposure limits
Ingredient name

Exposure limits

ethanol

ACGIH TLV (United States, 2000).
TWA: 1880 mg/m³ 8 hours.
OSHA (United States, 0/1989).
CEIL: 7600 ppm
TWA: 1000 ppm
TWA: 1900 mg/m³
MSHA (United States).
TWA: 1900 mg/m³
NIOSH (United States, 0/1994).
TWA: 1000 ppm
TWA: 1900 mg/m³
ACGIH (United States, 0/1996).
TWA: 1880 mg/m³
ACGIH (United States).
TWA: 1000 ppm
ACGIH TLV (United States, 6/2013).
STEL: 1000 ppm 15 minutes.
NIOSH REL (United States, 4/2013).
TWA: 1900 mg/m³ 10 hours.
TWA: 1000 ppm 10 hours.
OSHA PEL (United States, 2/2013).
TWA: 1900 mg/m³ 8 hours.
TWA: 1000 ppm 8 hours.
OSHA PEL 1989 (United States, 3/1989).
TWA: 1900 mg/m³ 8 hours.
TWA: 1000 ppm 8 hours.

Appropriate engineering
controls

Environmental exposure
controls

: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or
other engineering controls to keep worker exposure to airborne contaminants below any
recommended or statutory limits. The engineering controls also need to keep gas, vapor
or dust concentrations below any lower explosive limits. Use explosion-proof ventilation
equipment.
: Emissions from ventilation or work process equipment should be checked to ensure they
comply with the requirements of environmental protection legislation. In some cases,
fume scrubbers, filters or engineering modifications to the process equipment will be
necessary to reduce emissions to acceptable levels.

Individual protection measures
Hygiene measures

Eye/face protection

Skin protection
Hand protection

Date of issue/Date of revision

: Wash hands, forearms and face thoroughly after handling chemical products, before
eating, smoking and using the lavatory and at the end of the working period. Appropriate
techniques should be used to remove potentially contaminated clothing. Wash
contaminated clothing before reusing. Ensure that eyewash stations and safety showers
are close to the workstation location.
: Safety eyewear complying with an approved standard should be used when a risk
assessment indicates this is necessary to avoid exposure to liquid splashes, mists,
gases or dusts. If contact is possible, the following protection should be worn, unless the
assessment indicates a higher degree of protection: chemical splash goggles.
: Chemical-resistant, impervious gloves complying with an approved standard should be
worn at all times when handling chemical products if a risk assessment indicates this is
necessary. Considering the parameters specified by the glove manufacturer, check
during use that the gloves are still retaining their protective properties. It should be noted
that the time to breakthrough for any glove material may be different for different glove
manufacturers. In the case of mixtures, consisting of several substances, the protection
time of the gloves cannot be accurately estimated.

: 2/17/2014.

Date of previous issue

: No previous validation.

Version

:1
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Section 8. Exposure controls/personal protection
Body protection

Other skin protection

Respiratory protection

: Personal protective equipment for the body should be selected based on the task being
performed and the risks involved and should be approved by a specialist before handling
this product.
: Appropriate footwear and any additional skin protection measures should be selected
based on the task being performed and the risks involved and should be approved by a
specialist before handling this product.
: Use a properly fitted, air-purifying or air-fed respirator complying with an approved
standard if a risk assessment indicates this is necessary. Respirator selection must be
based on known or anticipated exposure levels, the hazards of the product and the safe
working limits of the selected respirator.

Section 9. Physical and chemical properties
Appearance
Physical state

: Liquid. [Slurry]

Color

: White-grayish

Odor
Odor threshold
pH

: Not available.
: Not available.

Melting point

: Not available.
: Not available.

Boiling point

: Not available.

Flash point

: Closed cup: 76.667°C (170°F)

Burning time

: Not applicable.

Burning rate

: Not applicable.

Evaporation rate

: Not available.

Flammability (solid, gas)

: Not available.

Lower and upper explosive
(flammable) limits

: Not available.

Vapor pressure

: Not available.

Vapor density
Relative density

: Not available.
: Not available.

Solubility

: Insoluble in the following materials: cold water.

Solubility in water

: Not available.

Partition coefficient: noctanol/water

: Not available.

Auto-ignition temperature

: Not available.

Decomposition temperature

: Not available.

SADT

: Not available.

Viscosity

: Not available.

Section 10. Stability and reactivity
Reactivity

: No specific test data related to reactivity available for this product or its ingredients.

Chemical stability

: The product is stable.

Possibility of hazardous
reactions

: Under normal conditions of storage and use, hazardous reactions will not occur.

Conditions to avoid

: Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld,
braze, solder, drill, grind or expose containers to heat or sources of ignition.

Incompatible materials

: Reactive or incompatible with the following materials:
oxidizing materials

Date of issue/Date of revision

: 2/17/2014.

Date of previous issue

: No previous validation.

Version

:1
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Section 10. Stability and reactivity
Hazardous decomposition
products

: Under normal conditions of storage and use, hazardous decomposition products should
not be produced.

Section 11. Toxicological information
Information on toxicological effects
Acute toxicity
Product/ingredient name

Result

Species

ethanol

LC50 Inhalation Vapor
LD50 Oral

Rat
Rat

Conclusion/Summary

Dose

Exposure

124700 mg/m³
7 g/kg

4 hours
-

: To the best of our knowledge, the toxicological properties of this product have not been
thoroughly investigated.

Irritation/Corrosion
Product/ingredient name

Result

Species

Score

Exposure

Observation

ethanol

Eyes - Mild irritant

Rabbit

-

-

Eyes - Moderate irritant

Rabbit

-

Eyes - Moderate irritant

Rabbit

-

Eyes - Severe irritant
Skin - Mild irritant
Skin - Moderate irritant

Rabbit
Rabbit
Rabbit

-

24 hours 500
milligrams
0.066666667
minutes 100
milligrams
100
microliters
500 milligrams
400 milligrams
24 hours 20
milligrams

-

Sensitization
Not available.
Mutagenicity
Product/ingredient name

Test

Experiment

Result

ethanol

DNA Damage
DNA Damage
Mutation in
Microorganisms
Mutation in
Microorganisms
Gene Conversion and
Mitotic Recombination
Sex chromosome loss
and nondisjunction.
Cytogenetic Analysis
Cytogenetic Analysis
Cytogenetic Analysis
Cytogenetic Analysis
DNA Adduct
DNA Adduct
DNA Damage
Micronucleus Test
Other Mutation Test
Systems
Other Mutation Test
Systems
Sister Chromatid
Exchange
Specific Locus Test
Sperm Morphology
Cytogenetic Analysis
Cytogenetic Analysis

Subject: Bacteria
Subject: Bacteria
Subject: Bacteria

Positive
Positive
Positive

Subject: Bacteria

Positive

Subject: Bacteria

Positive

Subject: Insect

Positive

Subject: Mammalian-Animal
Subject: Mammalian-Animal
Subject: Mammalian-Animal
Subject: Mammalian-Animal
Subject: Mammalian-Animal
Subject: Mammalian-Animal
Subject: Mammalian-Animal
Subject: Mammalian-Animal
Subject: Mammalian-Animal
Subject: Mammalian-Animal

Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive

Subject: Mammalian-Animal

Positive

Subject: Mammalian-Animal

Positive

Subject: Mammalian-Animal
Subject: Mammalian-Animal
Subject: Mammalian-Human
Subject: Mammalian-Human
Cell: Germ
Subject: Mammalian-Human

Positive
Positive
Positive
Positive

Micronucleus Test
Date of issue/Date of revision

: 2/17/2014.

Date of previous issue

: No previous validation.

Positive
Version
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Section 11. Toxicological information
Cell: Somatic
Subject: Mammalian-Human
Subject: Mammalian-Human
Subject: Mammalian-Human
Subject: Mammalian-Human
Subject: Mammalian-Human
Subject: Mammalian-Human

Micronucleus Test
DNA Inhibition
Cytogenetic Analysis
Cytogenetic Analysis
Cytogenetic Analysis
Sister Chromatid
Exchange

Positive
Positive
Positive
Positive
Positive
Positive

Carcinogenicity
Product/ingredient name

Result

Species

Dose

Exposure

ethanol

Equivocal - Oral - TD

Mouse

400 g/kg

Equivocal - Unreported - TDLo Mouse

120 g/kg

Equivocal - Oral - TDLo

320 mg/kg

57 weeks
Intermittent
18 weeks
Intermittent
50 weeks
Intermittent

Mouse

Classification
Product/ingredient name

OSHA

IARC

NTP

ethanol

+

1

-

Reproductive toxicity
Product/ingredient name

Maternal
toxicity

Fertility

Development
toxin

Species

Dose

Exposure

ethanol

-

-

-

Mouse

Intraperitoneal:

8 days

2.9 g/kg
-

-

-

Mouse

Intraperitoneal:

8 days

2900 mg/
kg
-

-

-

Dog - Male

-

Positive

-

Rat

Positive

-

-

-

Positive

-

Mammal - species
unspecified
Rat - Male

-

-

Positive

Mouse

-

Positive

-

Rat - Female

-

Positive

-

Woman - Female

-

Positive

-

Dog

-

Positive

-

-

-

Positive

Mammal - species
unspecified
Mouse

-

-

Positive

Mouse

-

-

Positive

Rat

-

Positive

Positive

Mouse

-

-

Positive

-

-

-

Mammal - species
unspecified
Mouse - Male

Unreported: 1 days

100 mg/kg
Intraperitoneal:

15 days
600 mg/kg
Oral: 206 g/kg
Unreported: 1 days
400 mg/kg
Intraperitoneal: 8 days
15 g/kg
Unreported: 10 days
2400 mg/
kg
Unreported: 5 days
200 mg/kg
Oral: 221 g/kg
Oral: 78 g/ kg
Intraperitoneal: 8 days
22.8 g/kg
Intraperitoneal: 5 days
5.8 g/kg
Intraperitoneal: 15 days
600 mg/kg
Intraperitoneal: 8 days
2900 mg/
kg
Intravenous Oral:
1680 g/kg

70 days

Teratogenicity
Date of issue/Date of revision

: 2/17/2014.

Date of previous issue

: No previous validation.
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Section 11. Toxicological information
Product/ingredient name

Result

Species

Dose

ethanol

Positive - Oral

Woman - Female 41 g/kg

Exposure
-

Specific target organ toxicity (single exposure)
Not available.
Specific target organ toxicity (repeated exposure)
Not available.
Aspiration hazard
Not available.
Information on the likely
routes of exposure

: Routes of entry anticipated: Oral, Dermal, Inhalation.

Potential acute health effects
Eye contact
: Causes serious eye irritation.
Inhalation

: No known significant effects or critical hazards.

Skin contact

: Causes skin irritation.

Ingestion

: Irritating to mouth, throat and stomach.

Symptoms related to the physical, chemical and toxicological characteristics
Eye contact
: Adverse symptoms may include the following:
pain or irritation
watering
redness
Inhalation
: Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations
Skin contact
: Adverse symptoms may include the following:
irritation
redness
reduced fetal weight
increase in fetal deaths
skeletal malformations
Ingestion
: Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations
Delayed and immediate effects and also chronic effects from short and long term exposure
Short term exposure
Potential immediate
: Not available.
effects
Potential delayed effects
Long term exposure
Potential immediate
effects
Potential delayed effects

: Not available.
: Not available.
: Not available.

Potential chronic health effects
Not available.
General

: No known significant effects or critical hazards.

Carcinogenicity

: Suspected of causing cancer. Risk of cancer depends on duration and level of exposure.

Mutagenicity

: No known significant effects or critical hazards.

Teratogenicity

: May damage the unborn child.

Date of issue/Date of revision

: 2/17/2014.

Date of previous issue

: No previous validation.
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Section 11. Toxicological information
Developmental effects

: No known significant effects or critical hazards.

Fertility effects

: May damage fertility.

Numerical measures of toxicity
Acute toxicity estimates
Not available.

Section 12. Ecological information
Toxicity
Product/ingredient name

Result

Species

Exposure

ethanol

Acute EC50 17.921 mg/l Marine water
Acute EC50 2000 µg/l Fresh water
Acute LC50 25500 µg/l Marine water

Algae - Ulva pertusa
Daphnia - Daphnia magna
Crustaceans - Artemia
franciscana - Larvae
Fish - Oncorhynchus mykiss
Algae - Ulva pertusa
Fish - Gambusia holbrooki Larvae

96 hours
48 hours
48 hours

Acute LC50 42000 µg/l Fresh water
Chronic NOEC 4.995 mg/l Marine water
Chronic NOEC 0.375 ul/L Fresh water

4 days
96 hours
12 weeks

Persistence and degradability
Product/ingredient name

Aquatic half-life

Photolysis

Biodegradability

ethanol

-

-

Readily

Product/ingredient name

LogPow

BCF

Potential

ethanol

-0.35

0.66

low

Bioaccumulative potential

Mobility in soil
Soil/water partition
coefficient (KOC)
Other adverse effects

: Not available.

: No known significant effects or critical hazards.

Section 13. Disposal considerations
Disposal methods

Date of issue/Date of revision

: The generation of waste should be avoided or minimized wherever possible. Disposal of
this product, solutions and any by-products should at all times comply with the
requirements of environmental protection and waste disposal legislation and any regional
local authority requirements. Dispose of surplus and non-recyclable products via a
licensed waste disposal contractor. Waste should not be disposed of untreated to the
sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Waste packaging should be recycled. Incineration or landfill should only be considered
when recycling is not feasible. This material and its container must be disposed of in a
safe way. Care should be taken when handling emptied containers that have not been
cleaned or rinsed out. Empty containers or liners may retain some product residues.
Vapor from product residues may create a highly flammable or explosive atmosphere
inside the container. Do not cut, weld or grind used containers unless they have been
cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact
with soil, waterways, drains and sewers.

: 2/17/2014.

Date of previous issue

: No previous validation.
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Section 14. Transport information
DOT Classification

IATA

UN number

NA1993

Not regulated.

UN proper
shipping name

Combustible liquids, n.o.s. (ethanol)

-

Transport
Combustible liquid.
hazard class(es)

-

Packing group

III

-

Environmental
hazards

No.

No.

Additional
information

Non-bulk packages (less than or
equal to 119 gal) of combustible
liquids are not regulated as hazardous
materials.

Special precautions for user

: Transport within user’s premises: always transport in closed containers that are
upright and secure. Ensure that persons transporting the product know what to do in the
event of an accident or spillage.

Transport in bulk according
to Annex II of MARPOL
73/78 and the IBC Code

: Not available.

Section 15. Regulatory information
U.S. Federal regulations

: TSCA 8(a) CDR Exempt/Partial exemption: Not determined
United States inventory (TSCA 8b): All components are listed or exempted.

Clean Air Act Section 112
(b) Hazardous Air
Pollutants (HAPs)

: Not listed

Clean Air Act Section 602
Class I Substances

: Not listed

Clean Air Act Section 602
Class II Substances

: Not listed

DEA List I Chemicals
(Precursor Chemicals)

: Not listed

DEA List II Chemicals
(Essential Chemicals)

: Not listed

SARA 302/304
Composition/information on ingredients
No products were found.
SARA 304 RQ

: Not applicable.

SARA 311/312
Classification

: Fire hazard
Immediate (acute) health hazard
Delayed (chronic) health hazard
Composition/information on ingredients

Date of issue/Date of revision

: 2/17/2014.

Date of previous issue

: No previous validation.
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Section 15. Regulatory information
Name

%

Fire
Sudden
hazard release of
pressure

Reactive

Immediate
(acute)
health
hazard

Delayed
(chronic)
health
hazard

ethanol

10 - 20

Yes.

No.

Yes.

Yes.

No.

State regulations
Massachusetts

: The following components are listed: CELLULOSE; ETHYL ALCOHOL

New York

: None of the components are listed.

New Jersey

: The following components are listed: CELLULOSE; ETHYL ALCOHOL; ALCOHOL

Pennsylvania

: The following components are listed: CELLULOSE; DENATURED ALCOHOL

California Prop. 65
WARNING: This product contains a chemical known to the State of California to cause birth defects or other reproductive
harm.
Ingredient name

Cancer

Reproductive

No significant risk
level

Maximum
acceptable dosage
level

ethanol

No.

Yes.

No.

No.

Canada inventory

: All components are listed or exempted.

International regulations
International lists

Chemical Weapons
Convention List Schedule I
Chemicals

: Australia inventory (AICS): All components are listed or exempted.
China inventory (IECSC): All components are listed or exempted.
Japan inventory: All components are listed or exempted.
Korea inventory: All components are listed or exempted.
Malaysia Inventory (EHS Register): Not determined.
New Zealand Inventory of Chemicals (NZIoC): All components are listed or exempted.
Philippines inventory (PICCS): All components are listed or exempted.
Taiwan inventory (CSNN): Not determined.
: Not listed

Chemical Weapons
Convention List Schedule
II Chemicals

: Not listed

Chemical Weapons
Convention List Schedule
III Chemicals

: Not listed

Section 16. Other information
Hazardous Material Information System (U.S.A.)
Health

2

Chronic Health Hazard *
Flammability

2

Physical hazards

0

National Fire Protection Association (U.S.A.)
Health

2

Flammability

2

Instability/Reactivity

0

Special

The customer is responsible for determining the PPE code for this material.

Date of issue/Date of revision

: 2/17/2014.

Date of previous issue

: No previous validation.
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Section 16. Other information
Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4
representing significant hazards or risks Although HMIS® ratings are not required on SDSs under 29 CFR 1910.
1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS®
program. HMIS® is a registered mark of the National Paint & Coatings Association (NPCA). HMIS® materials may
be purchased exclusively from J. J. Keller (800) 327-6868.
Reprinted with permission from NFPA 704-2001, Identification of the Hazards of Materials for Emergency
Response Copyright ©1997, National Fire Protection Association, Quincy, MA 02269. This reprinted material is
not the complete and official position of the National Fire Protection Association, on the referenced subject
which is represented only by the standard in its entirety.
Copyright ©2001, National Fire Protection Association, Quincy, MA 02269. This warning system is intended to be
interpreted and applied only by properly trained individuals to identify fire, health and reactivity hazards of
chemicals. The user is referred to certain limited number of chemicals with recommended classifications in NFPA
49 and NFPA 325, which would be used as a guideline only. Whether the chemicals are classified by NFPA or not,
anyone using the 704 systems to classify chemicals does so at their own risk.
History
Date of printing

: 2/17/2014.

Date of issue/Date of
revision
Date of previous issue

: 2/17/2014.

Version

: 1

Prepared by

: MSDS (Regulatory Specialist)

Key to abbreviations

References

: No previous validation.

: ATE = Acute Toxicity Estimate
BCF = Bioconcentration Factor
GHS = Globally Harmonized System of Classification and Labelling of Chemicals
IATA = International Air Transport Association
IBC = Intermediate Bulk Container
IMDG = International Maritime Dangerous Goods
LogPow = logarithm of the octanol/water partition coefficient
MARPOL 73/78 = International Convention for the Prevention of Pollution From Ships,
1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)
UN = United Nations
: Not available.

Indicates information that has changed from previously issued version.
Notice to reader
To the best of our knowledge, the information contained herein is accurate. However, neither the above-named
supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the
information contained herein.
Final determination of suitability of any material is the sole responsibility of the user. All materials may present
unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot
guarantee that these are the only hazards that exist.

Date of issue/Date of revision

: 2/17/2014.

Date of previous issue

: No previous validation.

Version

:1
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USER GUIDE

POROS™ HIC Resins: Ethyl, Benzyl, and Benzyl Ultra
Pub. No. 100063752 Rev. A
WARNING! Read the Safety Data Sheets (SDSs) and follow the
handling instructions. Wear appropriate protective eyewear,
clothing, and gloves. Safety Data Sheets (SDSs) are available
from thermofisher.com/support.

■
■
■
■
■
■
■

Specifications
Table 1 Ligands, hydrophobicity, and applications
Resin

Ligand

Relative
hydrophobicity

Application

Ethyl

Novel ethyl

Low

Benzyl

Low-density
benzyl/
aromatic

Moderate

Benzyl
Ultra

High-density
benzyl/
aromatic

High

Bind/elute mode to bind
moderately to strongly
hydrophobic molecules.
Bind/elute or flow‑through
mode depending on the
hydrophobicity of the
molecule.
Flow-through mode in lower
salt concentration to bind
impurities such as
aggregates.

[1]

Product information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Pack and qualify the column . . . . . . . . . . . . . . . . . . . . . . . . . 2
Chromatography condition optimization . . . . . . . . . . . . . . . . 4
Resin cleaning and storage . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Ordering information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Support . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Limited product warranty . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
[1]

Hydrophobicity results are based on lysozyme gradient elution. Column size:
0.66 cmD × 20 cmL; 1.7-M ammonium sulfate, 50-mM sodium phosphate pH 7.0;
Gradient elution: 1.7-M ammonium sulfate/50 mM sodium phosphate pH 7.0 to
50‑mM sodium phosphate pH 7.0 over 10 column volumes; Flow rate: 100 cm/hr.

Product information

Table 2 Characteristics and stability

Product description

Characteristic
Support matrix
Shipping solution
Average particle size
Mechanical
resistance
pH range
Ionic strength range
Buffer additives

™

POROS Hydrophobic Interaction Chromatography (HIC) resins are
rigid, 50-µL polymeric resins with a range of hydrophobic
functionalities for the purification of antibody fragments, antibody
drug conjugates (ADCs), recombinant proteins, viruses, and other
biomolecules. The resin backbone consists of crosslinked poly(styrenedivinylbenzene) with a unique pore structure that provides rapid
mass transport and enables enhanced productivity. The particle
surface is coated with a novel polymer coating, which is then further
derivatized with a range of hydrophobic ligands for flexible
purification process design.
™

POROS HIC resins are suitable for bind/elute and flow‑through
applications at lower salt concentrations. These resins have superior
resolution capability, high capacity, and differentiating selectivity for a
range of biomolecules, and this performance is independent of flow
rate.

Salts

Storage
Store resins at 2– 30°C. Do not freeze.
Solvents

Shrinkage/swelling
Operating
temperature
™

Description
Crosslinked poly(styrene-divinylbenzene)
18% ethanol
50 µm
100 bar (1450 psi, 10 MPa)
1–14
0 to 5 M, all common salts
All common agents, including 1 M sodium
hydroxide, 8 M urea, 6 M guanidine hydrochloride,
ethylene glycol, and detergents
Ammonium sulfate, sodium sulfate, sodium
chloride, sodium acetate, sodium citrate and other
common salts
IMPORTANT! POROS™ Benzyl and POROS™ Benzyl
Ultra are designed for use with lower salt
concentration than traditional HIC resins. With
some molecules, high salt concentration can cause
poor recovery due to a strong interaction between
the target and the ligand.
Water, 0–100% alcohol, acetonitrile, 1 to 2 M acids
(for example, acetic, hydrochloric, phosphoric),
other common organic solvents
Do not expose to strong oxidizers (such as
hypochlorite), oxidizing acids (such as nitric), strong
reducing agents (such as sulfite), acetone, or benzyl
alcohol.
<1% from 1–100% solvent
2– 30°C
Do not freeze

POROS HIC resins can be operated at high linear flow rates with a
pressure drop that allows use with conventional low-pressure
™
chromatography columns and systems. POROS HIC resins have
linear and predictable pressure flow responses as column diameter
increases (Figure 1 and Figure 2).

Product usage: See "Ordering information" on page 5.

Prepare slurry: lab-scale columns (£ 100 mL)
Buffer‑exchange using a 0.2–0.45 µm bottle‑top filter or sintered-glass
filter:
1. Transfer the required volume of resin slurry to the top of a
bottle‑top filter.
2. Apply vacuum to remove the shipping solution.
3. Resuspend the resin cake to the starting resin slurry volume with
water. Mix with a plastic or rubber spatula. Do not grind the resin
bed or tear the filter membrane.
4. Repeat the vacuum and resuspension steps for a total of three
exchanges.
5. Resuspend the exchanged resin to the original slurry
concentration, then proceed with column packing.
6. Verify that the slurry concentration is 50–70% (see “Determine the
slurry concentration“ on page 2).
7. If needed, adjust the slurry concentration to 50–70%.
Fig. 1 Pressure-flow properties of POROS™ Ethyl resin—20-cm bed
height

Prepare slurry: lab-scale and larger scale columns
(> 100 mL)
Buffer‑exchange using repeated gravity settling:
1. Allow the resin to settle in the shipping container. Settling
requires > 8 hours because the density of the resin is
approximately that of water.
2. Carefully decant the supernatant. Do not disturb the bed.

3.
4.
5.
6.
7.
8.

Some particles/turbidity may be present in the decant as beads
slough off the settled bed or come loose from the carboy side
walls. This is not problematic.
Replace the supernatant with the same volume of the desired
packing solution.
Replace the supernatant with the same volume of water.
Resuspend the resin by gentle agitation, then allow the resin to
settle by gravity.
Repeat steps 1 to 4 two to three times to thoroughly exchange into
water.
Verify that the slurry concentration is 50–70% (see “Determine the
slurry concentration“ on page 2).
If needed, adjust the slurry concentration to 50–70%.

Determine the slurry concentration
Fig. 2 Pressure-flow properties of POROS™ Benzyl Ultra resin—20-cm
bed height

Pack and qualify the column
Packing guidelines
• Resins are supplied in 18% ethanol. For column packing, exchange
the shipping solution with water to remove the ethanol.
• Resins are mechanically rigid and incompressible and can be
packed effectively in low-pressure glass columns and in
high-pressure stainless steel columns. The lack of wall support
with increasing column diameter has minimal impact on
chromatography performance because the beads support
themselves, allowing for flexible column packing approaches and
consistent and robust results. Columns can be packed with
traditional flow pack, axial compression, or pack-in-place/stall
pack packing methods.
• Standard 10–23 µm screens (frits) can be used.

2

1. Separate the slurry using either of the following methods.
• Gravity settling—Add 100 mL of slurry in water to a 100-mL
graduated cylinder, then allow to settle for >72 hours.
Note: The time that POROS™ HIC resins take to gravity settle
can be inconsistent due to hydrophobicity. We recommend
using the centrifugation method for faster, more consistent
results.
• Centrifugation—Add 10 mL of slurry in water to three (3)
15-mL conical tubes. Centrifuge at 3,000 rpm for 10 minutes at
20°C with the brake off. Remove the tubes from the centrifuge
and allow the tubes to sit for 5 minutes before determining the
concentration.
2. Calculate the concentration: Volume of resin/total volume in the
graduated cylinder or conical tube.

POROS™ HIC Resins: Ethyl, Benzyl, and Benzyl Ultra User Guide

Pack the column

Qualify the column

When you adjust the flow rate to form the bed, you may observe some
turbidity in the eluent as packing starts. Turbidity will clear as packing
proceeds and 1–2 bed volumes of packing buffer pass through the
column.
1. Determine the required slurry volume:

To qualify the integrity of a packed column, determine HETP (height
equivalent to a theoretical plate) and asymmetry using a non-binding
analyte (a “plug”).

Example for a POROS™ Ethyl 40 cmD × 20 cmL 25-L column using
slurry with a 50% slurry ratio:
25 L / 0.56 × 1.06 = 47.3 L slurry required
The 1.06 packing factor above accounts for the difference in bed
volume between a centrifuged bed in water and a 3-bar pressurepacked bed. Use a 1.12 packing factor for POROS™ Benzyl and
POROS™ Benzyl Ultra.
2. Ensure that the column outlet is closed and plumbed directly to
waste. Do not connect the column outlet to the chromatography
system. Plumbing into the system creates backpressure that fights
against the inlet pressure trying to settle the bed and pack the
column.
3. Ensure that the column is level and locked in place before starting
the pack.
4. Deliver the required slurry volume to the column by hand or with
a diaphragm pump, as dictated by your equipment and the
intended packing procedure. Use a squirt bottle containing
packing solution to remove any residual resin from the column
wall.
™

5.

6.
7.
8.

POROS resin beads have a skeletal density similar to the density
of water and do not settle rapidly. Do not allow the resin to
gravity‑settle in the column before packing.
With the column inlet line connected to the system and the
bottom outlet closed, bring the primed top flow adapter to 1–2 cm
from the slurry level, then tighten the O-ring. Do not push up the
resin and over the O-ring. Change the top valve to force the air
and liquid out the top of the adapter and to waste using the
bypass line. Continue to lower the adapter slowly to remove the
bubbles from the top of the column. Do not allow large air
bubbles between the top adaptor and the top of the resin slurry.
Change the valve back to flow through the system on the top,
then open the column bottom.
Increase the flow rate to the maximum or desired flow rate and
pressure obtainable with the equipment used.
After the bed is formed, bring the adapter into contact with the
top of the bed without pushing the resin over the O-ring by
closing the column outlet and displacing liquid through the top of
the adapter to waste through the bypass line.

Recommended column qualification conditions
Condition
Flow rate
Equilibration buffer
Plug solution
Plug volume

Recommendation
50 cm/hour
Water
0.5 M sodium chloride
1% of column volume

Guidelines for qualification
• Ensure uniform column plumbing:
– Avoid using reducers to connect different tubing sizes.
– Minimize and keep consistent the column tubing lengths
between the plug solution to the column inlet and the column
outlet to the detector(s).
• Equilibrate with at least 4 CVs of equilibration buffer before
injection.

Setting specifications
Qualification results depend on several factors, including the:
• Solutions and method used
• Scale
• Column hardware
• Chromatography system
After you define a column qualification procedure for a specific
system (column plus chromatography system), base the qualification
acceptance criteria on historical values and ranges instead of
theoretical qualification results. Performing the column qualification
method consistently and reproducibly is critical to obtaining
meaningful results.

POROS™ resin does not shrink or swell, so an open headspace is
not recommended.
9. Flow at the packing flow rate again for 1–2 CVs, taking note of
the bed height at the desired pressure. Adjust the adapter again
to the noted bed height by displacing the liquid through the top
of the adapter and to waste.
10. After the column is packed, flow 2–3 CVs of packing solution
through the packed bed at the operating flow rate to stabilize the
bed.
The flow rate used should generate no more than 80% of the final
packing pressure.
11. If you will reverse the flow of the column during operation,
condition the column in upflow:
• Flow 2–3 CVs in upflow at the operating flow rate.
• Flow 2–3 CVs in downflow at the operating flow rate, then
adjust the adapter if needed.
• Flow 2 CVs after you adjust the adapter.
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Chromatography condition optimization
General guidelines
Standardized conditions or platform-type evaluations are not
recommended. Different HIC resins that are operated with the same
process conditions can yield variable results.
When optimizing conditions:
• Test different loading and elution conditions to evaluate static
binding capacity and yield based on the target molecule
characteristics and process challenges.
• Limit static binding load incubation time to 15 minutes.
• Optimize the chromatography step for peak separation: Use
conditions that remove some of the bound impurities during the
flow‑through/wash phase and that retain other bound impurities
until elution during the strip and cleaning-in-place (CIP) steps.
• Use buffer salts and reagents of the highest purity.
• Filter (0.22 or 0.45 µm) all buffers, solutions, and load before use.

Resin selection guidelines
• If the hydrophobicity of the target molecule is unknown:
– Run a small-scale bind/elute gradient separation on POROS™
Benzyl resin to determine the elution conductivity of the target
molecule, contaminants, and impurities.
– Optimize conditions on POROS™ Benzyl Ultra resin (higher
hydrophobicity) or POROS™ Ethyl resin (lower
hydrophobicity).
– If needed, continue to optimize conditions on POROS™ Benzyl
resin (mid-range hydrophobicity).
• If the target molecule is hydrophobic, optimize conditions on
POROS™ Ethyl resin or on POROS™ Benzyl with lower salt
concentration.
• For flow‑through applications where the target molecule is less
hydrophobic, optimize conditions on POROS™ Benzyl or POROS™
Benzyl Ultra with lower salt concentration.
After you select the resin, continue to optimize other process
conditions.

Binding capacity and loading condition screening guidelines
Perform high-throughput static binding capacity testing in spin
columns or in a 96-well plate to screen POROS™ HIC resin. Optimize
loading conditions as needed.
Note: A 96-well high-throughput protocol is available on request. This
protocol can be used to evaluate static binding capacity and to screen
several resins and loading conditions per resin in a single 96-well
plate.

Bind/elute chromatography optimization guidelines
Binding conditions guidelines
™

• Salt and salt concentration — POROS HIC resins are designed to
use less lyotropic salts and to bind at lower concentrations than
traditional HIC resins with similar functional groups (Table 3).
Table 3 Typical salts used in hydrophobic interaction
chromatography in order of decreasing lyotropic ("salting out")
effect and increasing chaotropic ("salting in") effect
Effect
Most lyotropic

Most chaotropic

4

Anionic salts
C6H5O7 3–
PO4 3–
SO4 2–
CH3COO–
ClBr–
NO3 –
CIO4 –
I–

Cationic salts
NH4 +
Rb+
K+
Na+
Cs+
Li+
Mg2+
Ca2+
Ba2+

Note the following:
– You can perform initial binding experiments with lower salt
concentrations than are typically used for HIC chromatography.
For example, you can start with 25%, 50% and 75% of the
salting out concentration, instead of the typical 10–15% lower
than the salting out concentration.
– The optimized ionic salt concentration for the salts listed above
can differ from ammonium sulfate, which has been traditionally
used for HIC chromatography.
– Different salts can provide different selectivity.
Optimize the salt concentration for the target molecule by using a
"salting out" experiment: increase the ionic strength of the loading
buffer until the sample precipitates. Alternatively, you can
measure increasing optical density of the loading buffer to detect
aggregation (~350 nm, but this value may differ with each salt).
Salts that are commonly used to perform salting out experiments
are ammonium sulfate, sodium chloride, sodium citrate, sodium
sulfate, and sodium acetate.
• Buffer system—Buffer systems are not as critical for HIC processes
as they are for ion-exchange chromatography steps. Citrate,
acetate, Bis-Tris propane, HEPES, MES, sodium phosphate,
succinate, and Tris are commonly used.
The buffer system is typically dictated by the upstream
purification step. When selecting the upstream buffer system,
consider molecule stability in the buffer, binding optimization, and
buffering capacity.
• pH—pH is not typically critical for HIC processes, but it can affect
the binding strength and selectivity. Because pH effects are
unpredictable on HIC, test a few pH values over the stability range
of the target molecule.
• Flow rate—The target operating flow rate is flexible. Start
optimization at 4-minute residence time (300 cm/hr in a 20-cmL
column).
• Temperature—Temperature can significantly impact HIC
performance. Perform all optimization at the final intended
process temperature.

Elution conditions guidelines
Start elution optimization with a gradient elution. Most often, after
elution performance is determined, you can implement a step elution.
• Salt gradient—To determine where the target molecule and
contaminants/ impurities elute, start with a 20-CV gradient from
high salt to buffer only. To do so, assay fractions across the peaks
(~1/10 CV). Based on this information, the process can be further
optimized.
• Dynamic binding capacity (DBC)—Assess separation as a
function of DBC. The maximum DBC depends on several factors,
including sample solubility, column selectivity, buffer pH, and
loading buffer conductivity.
• Bed height—Initial screening can be run with shorter bed heights
and a constant residence time. Use the final desired bed height for
scale up development (typically 15 cm to 30 cm).

Flow-through chromatography optimization guidelines
An optional flow‑through step can be used remove trace product and
process-related impurities such as aggregates from the target
molecule. You can add the flow‑through step as the second or third
chromatography step for polishing in a downstream process. Different
target molecules have different degrees of hydrophobicity and other
biophysical characteristics. Therefore, it is essential to optimize the
process conditions to achieve the desired aggregate clearance and
recovery of the target molecule.
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Resin cleaning and storage

Loading conditions guidelines
• Initial study —Perform an initial study using a decreasing salt
gradient in bind/elute mode:
– Load approximately 1 mg of protein per 1 ml of resin at 0.5–
1.0 M sodium chloride (or other preferred salt), then elute using
a gradient over 10 column volumes (CVs) in a buffered solution
to determine aggregates, impurities, and target molecule
elution profiles.
– Use the elution conductivity at peak maximum to determine the
highest approximate salt concentration that is required to
remove impurities, but that allows the target molecule to flow
through (Figure 3).

Resin cleaning guidelines
™

• POROS resins can tolerate harsh cleaning conditions that allow
acceptable column life.
• Clean the resin with 3 to 5 CVs of water followed by 3 to 5 CVs of
1 M NaOH.
• For more stringent cleaning, use 20% ethanol/1 M acetic acid.
• Other solutions may be required for column cleaning if the resin is
used for capture chromatography.
• Degas more viscous solutions such as 1 M acetic acid or
20% ethanol before use on the column to avoid gassing out during
operation.
Note: Low-level gassing out does not impact column performance.

Store the resin
Store the resin in 20% ethanol or 0.1 M NaOH at 2–30°C.
Start flow-through
optimization at
~7 mS/cm

Ordering information
Table 4 POROS™ HIC bulk resins
Resin
Ethyl

Fig. 3 Example screening chromatogram to obtain the ideal low
salt condition for flow-through conditions. Process screening
for a monoclonal antibody using POROS™ Benzyl Ultra resin in
flow-through mode. Gradient: High conductivity to low
conductivity using sodium citrate. Based on this chromatogram,
the resin was further optimized in flow-through mode at low
salt conditions starting at 7 mS/cm.
• Buffer system—Buffer systems are not as critical for HIC processes
as they are for ion-exchange chromatography steps. Citrate,
acetate, Bis-Tris propane, HEPES, MES, sodium phosphate,
succinate, and Tris are commonly used.

•

•

•

•

•

The buffer system is typically dictated by the upstream
purification step. When selecting the upstream buffer system,
consider molecule stability in the buffer, binding optimization, and
buffering capacity.
pH—pH is not typically critical for HIC processes, but it can affect
the binding strength and selectivity. Because pH effects are
unpredictable on HIC, test a few pH values over the stability range
of the target molecule.
Flow rate—The target operating flow rate is flexible. Good
impurity binding has been demonstrated at flow rates up to
600 cm/hour on a 20 cmL column (1.6-minute residence time).
Temperature—Temperature can significantly impact HIC
performance. Perform all optimization at the final intended
process temperature.
Dynamic binding capacity (DBC)—A conservative starting point
for DBC determination is 100–250 mg of the target molecule per
mL of resin. Determine the DBC for each impurity by using
breakthrough analysis under the desired load pH and conductivity
conditions.
Bed height—A bed height of 15 cm to 30 cm can be used for this
step.
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Benzyl

Benzyl
Ultra

Cat. No.
A32552
A32553
A32554
A32555
A32556
A32557
A32558
A32559
A32560
A32561
A32562
A32563
A32564
A32565
A32566
A32567
A32568
A32569

Amount
10,000 mL
5,000 mL
1,000 mL
250 mL
50 mL
25 mL
10,000 mL
5,000 mL
1,000 mL
250 mL
50 mL
25 mL
10,000 mL
5,000 mL
1,000 mL
250 mL
50 mL
25 mL

Product usage
Pharmaceutical Grade Reagent. For
Manufacturing and Laboratory Use
Only.
For Research Use Only. Not for use
in diagnostic procedures.
Pharmaceutical Grade Reagent. For
Manufacturing and Laboratory Use
Only.
For Research Use Only. Not for use
in diagnostic procedures.
Pharmaceutical Grade Reagent. For
Manufacturing and Laboratory Use
Only.
For Research Use Only. Not for use
in diagnostic procedures.

Support
For service and technical support, go to thermofisher.com/poros or
call toll-free in US: 1.800.831.6844.
For the latest service and support information at all locations, or to
obtain Certificates of Analysis or Safety Data Sheets (SDSs; also known
as MSDSs), go to thermofisher.com/support, or contact you local
Thermo Fisher Scientific representative.

Limited product warranty
Life Technologies Corporation and/or its affiliate(s) warrant their
products as set forth in the Life Technologies' General Terms and
Conditions of Sale found on Life Technologies' website at
www.thermofisher.com/us/en/home/global/terms-andconditions.html. If you have any questions, please contact Life
Technologies at www.thermofisher.com/support.
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Manufacturer: Life Technologies Corporation | 35 Wiggins Avenue | Bedford, MA 01730

The information in this guide is subject to change without notice.
DISCLAIMER: TO THE EXTENT ALLOWED BY LAW, LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE,
MULTIPLE, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT.
Revision history: Pub. No. 100063752
Revision
A

Date
10 July 2017

Description
New document.

Important Licensing Information: These products may be covered by one or more Limited Use Label Licenses. By use of these products, you accept the terms and conditions of all
applicable Limited Use Label Licenses.
©2017 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.
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Safety Data Sheet
___________________________________________________________________________________________________________________

SECT I ON 1 : I de nt ific a t ion of t he subst a nc e /m ix t ure a nd of t he c om pa ny/unde rt a k ing
Identification of the substance or mixture
Product code
Product name

A32561
POROS Benzyl Hydrophobic Interaction Chromatography Resin

Company/undertaking identification
Life Technologies Corporation
5781 Van Allen Way
PO Box 6482
Carlsbad, CA 92008
+1 760 603 7200

Life Technologies
5250 Mainway Drive
Burlington, ONT
CANADA L7L 6A4
800/263-6236

24 hour Emergency Response for Hazardous Materials Within the USA + Canada: 1-800-424-9300 and +1
703-527-3887
[or Dangerous Goods] Incident. Spill, Leak, Fire,
Outside the USA + Canada: +1 703-741-5970
Exposure, or Accident. Call CHEMTREC
Country specific Emergency Number (if available):
CHEMTREC Brazil (Rio De Janeiro)
+(55)-2139581449 (português)
Pharmaceutical Grade Reagent. For Manufacturing and Laboratory Use Only.
SECT I ON 2 : H a za rds ide nt ific a t ion
GHS - Classification
Signal Word
WARNING
Hazard pictograms

Health hazards
Not Hazardous
Physical hazards
GHS Physical Hazard 1

Flammable liquids
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Revision date
Product code

09-Oct-2017
A32561

Page 1 / 9
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Chromatography Resin
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GHS Physical Hazard Category Number

Category 3

Environmental hazards
Not Hazardous
Hazard Statements
H226 - Flammable liquid and vapor
Precautionary Statements
Prevention
P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P233 - Keep container tightly closed
P243 - Take action to prevent static discharges
P240 - Ground/bond container and receiving equipment
Response
P370 + P378 - In case of fire: Use dry sand, dry chemical or alcohol-resistant foam for extinction
P303 + P361 + P353 - IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower
Storage
P403 + P235 - Store in a well-ventilated place. Keep cool
Disposal
P501 - Dispose of contents/ container to an approved waste disposal plant

Other hazards
Not Applicable
HMIS
Health
Flammability
Reactivity

0
3
0

SECT I ON 3 : Com posit ion/inform a t ion on ingre die nt s
Component
Ethyl alcohol
64-17-5 ( 15-22 )

CAS-No
64-17-5

EINECS-No
200-578-6

Weight %
15-22

We recommend handling all chemicals with caution.
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SECT I ON 4 : First a id m e a sure s
Description of first aid measures
Rinse with plenty of water . Immediate medical attention is not required.
Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do
.
Not expected to present a significant ingestion hazard under anticipated conditions
of normal use. If you feel unwell, seek medical advice.
Not expected to be an inhalation hazard under anticipated conditions of normal
use of this material. Consult a physician if necessary.
Treat symptomatically.

Skin contact
Eye contact
Ingestion
Inhalation
Notes to Physician

Most important symptoms and effects, both acute and delayed
H226 - Flammable liquid and vapor
Indication of any immediate medical attention and special treatment needed
IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water/ shower.
SECT I ON 5 : Fire fight ing m e a sure s
Extinguishing media
Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
No information available.

Suitable extinguishing media
Unsuitable extinguishing media

Special hazards arising from the substance or mixture Not known.
Standard procedure for chemical fires.

Advice for fire-fighters

SECT I ON 6 : Ac c ide nt a l re le a se m e a sure s
Personal precautions, protective equipment and emergency procedures
Ensure adequate ventilation. Always wear recommended Personal Protective Equipment. Use personal protection
equipment. See Section 8 for more detail.
Environmental precautions
No special environmental precautions required.
Methods and material for containment and cleaning up
Soak up with inert absorbent material.
Reference to other sections
See section 8 for more information.
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SECT I ON 7 : H a ndling a nd st ora ge
Precautions for safe handling
Use personal protective equipment as required. No special handling advices are necessary.
Conditions for safe storage, including any incompatibilities
Keep in a dry, cool and well-ventilated place. Keep in properly labeled containers.
Specific end use(s)
Pharmaceutical Grade Reagent. For Manufacturing and Laboratory Use Only.
SECT I ON 8 : Ex posure c ont rols/pe rsona l prot e c t ion
Control parameters
Chemical Name
Ethyl alcohol

OSHA PEL
1000 ppm
1900 mg/m3

Engineering measures

OSHA PEL (Ceiling)
None

ACGIH OEL (TWA)
None

ACGIH OEL (STEL)
1000 ppm

Ensure adequate ventilation, especially in confined areas

Exposure controls
Personal Protective Equipment
Respiratory protection

In case of insufficient ventilation wear respirators and components tested and
approved under appropriate government standards.

Hand protection

Wear suitable gloves Glove material: Compatible chemical-resistant gloves.

Eye protection

Tight sealing safety goggles

Skin and Body Protection

Wear suitable protective clothing

Hygiene measures

Handle in accordance with good industrial hygiene and safety practice

Environmental exposure controls
No special environmental precautions required.
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SECT I ON 9 : Physic a l a nd c he m ic a l prope rt ie s
Information on basic physical and chemical properties
Appearance
Odor
pH
Melting point / melting range
Boiling point / boiling range
Flash point
Autoignition Temperature
Decomposition temperature
Evaporation rate
Flammability (solid, gas)
Upper explosion limit
Lower explosion limit
Vapor Pressure
Relative density
Specific gravity
Solubility
Partition coefficient:
n-octanol/water
Explosive properties

suspension
No data available
6-8
°C Mixture has not been tested
°C Mixture has not been tested
°C 36-49
°C Mixture has not been tested
°C Mixture has not been tested
No data available
No data available
Mixture has not been tested
Mixture has not been tested
Mixture has not been tested
Mixture has not been tested
No data available
No data available
No data available

Other information

No data available

°F
°F
°F
°F
°F

Mixture has not been tested
Mixture has not been tested
96.8-120.2
Mixture has not been tested
Mixture has not been tested

Mixture has not been tested

SECT I ON 1 0 : St a bilit y a nd re a c t ivit y
Reactivity

None known.

Chemical stability

Stable under normal conditions.

Possibility of hazardous
reactions

Hazardous reaction has not been reported.

Conditions to avoid

No information available.

Incompatible materials

No dangerous reaction known under conditions of normal use.

Hazardous decomposition
products

No data available.
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SECT I ON 1 1 : T ox ic ologic a l inform a t ion
Information on toxicological effects
Chemical Name
Ethyl alcohol

LD50 (oral,rat/mouse)
= 7060 mg/kg (Rat)

LD50 (dermal,rat/rabbit)
No data available

LC50 (inhalation,rat/mouse)
=124.7mg/L(Rat)

Principal Routes of Exposure
Irritation

Conclusive but not sufficient for classification

Corrosivity

Conclusive but not sufficient for classification

Sensitization

Conclusive but not sufficient for classification

STOT - Single Exposure

Conclusive but not sufficient for classification

STOT - Repeated Exposure

Conclusive but not sufficient for classification

Carcinogenicity

Conclusive but not sufficient for classification

Mutagenicity

Conclusive but not sufficient for classification

Reproductive toxicity

May cause adverse reproductive effects - such as birth defect, miscarriages, or
infertility

Aspiration hazard

Conclusive but not sufficient for classification
SECT I ON 1 2 : Ec ologic a l inform a t ion

Toxicity
The environmental impact of this product has not been fully investigated.
Chemical Name
Ethyl alcohol

Freshwater Algae
Data
No data available

Water Flea Data
Daphnia magna
EC50=10800 mg/L (24
h) Daphnia magna
EC50=2 mg/L (48 h)
Daphnia magna
LC509268 - 14221
mg/L (48 h)

Persistence and degradability

No information available.

Bioaccumulative potential

No information available.

Freshwater Fish
Species Data
No data available

Microtox Data

log Pow

No data available

logPow-0.32

Results of PBT and vPvB assessment
No information available.
Other adverse effects

No information available.
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SECT I ON 1 3 : Disposa l c onside ra t ions
Waste treatment methods
The generation of waste should be avoided or minimized wherever possible. Empty containers or liners may retain
some product residues. This material and its container must be disposed of in according to approved disposal
technique. Disposal of this product, its solutions or of any by-products, shall comply with the requirements of all
applicable local, regional or national/federal regulations
SECT I ON 1 4 : T ra nsport inform a t ion
IATA / ADR / DOT-US / IMDG
This product is subjected to UN special provision A58 (144): An aqueous solution containing 24% or less alcohol by
volume is not subject to IATA Dangerous Goods Regulations.
UN number

1170

UN proper shipping name

Ethanol Solution

Transport hazard class(es)

3

Packing group

III

Environmental hazards

Not Hazardous

Special precautions for user

Not Applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not Applicable.
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SECT I ON 1 5 : Re gula t ory inform a t ion
Component
Ethyl alcohol
64-17-5 ( 15-22 )

US TSCA
Listed

US Federal Regulations
SARA 313

This product is not regulated by SARA.

Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product does not contains HAPs.

US State Regulations
California Proposition 65

This product contains the following Proposition 65 chemicals.
Chemical Name
Ethyl alcohol

CAS-No
64-17-5

Weight %
15-22

Category
Carcinogen
Developmental

WHMIS Hazard Class
B3 - Combustible liquid

This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the
MSDS contains all the information required by the CPR.

SECT I ON 1 6 : Ot he r inform a t ion
Reason for revision
Revision number
Revision date

SDS sections updated.
3
09-Oct-2017

Pharmaceutical Grade Reagent. For Manufacturing and Laboratory Use Only.
References
• ECHA: http://echa.europa.eu/
• TOXNET: http://toxnet.nlm.nih.gov/
• eChemPortal: http://www.echemportal.org/
• LOLI database: https://www.chemadvisor.com/loli-database
"The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRANTY, EXPRESSED OR
IMPLIED,INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR
PURPOSE"
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.2
Revision Date 01/11/2017
Print Date 04/10/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Adenine

Product Number
Brand

:
:

PHR1383
Sigma-Aldrich

CAS-No.

:

73-24-5

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H301
Precautionary statement(s)
P264
P270
P301 + P310 + P330
P405
P501

2.3

Danger
Toxic if swallowed.
Wash skin thoroughly after handling.
Do not eat, drink or smoke when using this product.
IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse
mouth.
Store locked up.
Dispose of contents/ container to an approved waste disposal plant.

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances

Sigma-Aldrich - PHR1383

Page 1 of 7

Molecular weight
CAS-No.
EC-No.

:
:
:

135.13 g/mol
73-24-5
200-796-1

Hazardous ingredients according to Regulation (EC) No 1272/2008
Component
Classification
Adenine
CAS-No.
EC-No.

73-24-5
200-796-1

Acute Tox. 3; H301

Concentration
<= 100 %

For the full text of the H-Statements mentioned in this Section, see Section 16.
4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.
Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.

6.2

Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for
disposal.

Sigma-Aldrich - PHR1383

Page 2 of 7

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration
before additional processing occurs.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature 2 - 8 °C
Keep in a dry place. Keep in a dry place.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.
Hazardous components without workplace control parameters

8.2

Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate
government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected according to
the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type
N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the
sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: powder
Colour: light yellow

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

No data available

Sigma-Aldrich - PHR1383

Page 3 of 7

9.2

e)

Melting point/freezing
point

360 °C (680 °F)

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

No data available

n)

Water solubility

No data available

o)

Partition coefficient: noctanol/water

No data available

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong oxidizing agents

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx)
Other decomposition products - No data available
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx)
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 227 mg/kg
Remarks: Behavioral:Convulsions or effect on seizure threshold. Behavioral:Muscle weakness. Lungs, Thorax, or
Respiration:Other changes.
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Inhalation: No data available
Dermal: No data available
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1
12.2

Toxicity
No data available
Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available
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13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a
chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
UN number: 2811
Class: 6.1
Packing group: III
Proper shipping name: Toxic solids, organic, n.o.s. (Adenine)
Reportable Quantity (RQ):
Poison Inhalation Hazard: No
IMDG
UN number: 2811
Class: 6.1
Packing group: III
Proper shipping name: TOXIC SOLID, ORGANIC, N.O.S. (Adenine)

EMS-No: F-A, S-A

IATA
UN number: 2811
Class: 6.1
Packing group: III
Proper shipping name: Toxic solid, organic, n.o.s. (Adenine)
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Acute Health Hazard
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
Adenine

CAS-No.
73-24-5

Revision Date

CAS-No.
73-24-5

Revision Date

New Jersey Right To Know Components
Adenine

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
H301

Toxic if swallowed.

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Sigma-Aldrich - PHR1383
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Physical Hazard

0

NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

2
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.2
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Print Date: 04/10/2018
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.2
Revision Date 09/01/2017
Print Date 03/24/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Ammonium sulfate, NF Grade

Product Number
Brand

:
:

RES1427A-A7
Sigma

CAS-No.

:

7783-20-2

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
Not a hazardous substance or mixture.

2.2

GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.

2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Formula
Molecular weight
CAS-No.
EC-No.

:
:
:
:

H8N2O4S
132.14 g/mol
7783-20-2
231-984-1

No components need to be disclosed according to the applicable regulations.

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
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If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid breathing dust.
For personal protection see section 8.

6.2

Environmental precautions
Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for
disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid formation of dust and aerosols.Further processing of solid materials may result in the formation of combustible
dusts. The potential for combustible dust formation should be taken into consideration before additional processing
occurs.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

8.2

Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards such as
NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and
to the specific work-place., The type of protective equipment must be selected according to the concentration
and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: crystalline
Colour: colourless

b)

Odour

odourless

c)

Odour Threshold

No data available

d)

pH

5.0 - 6 at 132 g/l at 25 °C (77 °F)

e)

Melting point/freezing
point

> 280 °C (> 536 °F) - Decomposition

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) The product is not flammable.

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

1.770 g/cm3

n)

754 g/l at 25 °C (77 °F)

Water solubility
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9.2

o)

Partition coefficient: noctanol/water

log Pow: -5.1

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
Bulk density

ca.1,200 kg/m3

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong oxidizing agents, Strong bases

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Nitrogen oxides (NOx), Sulphur oxides
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 4,250 mg/kg
(OECD Test Guideline 401)
Inhalation: No data available
LD50 Dermal Dermal - Rat - > 2,000 mg/kg
No data available
Skin corrosion/irritation
Skin - Rabbit
Result: No skin irritation
Serious eye damage/eye irritation
Eyes - Rabbit
Result: No eye irritation
Respiratory or skin sensitisation
Maximisation Test - Guinea pig
Result: Does not cause skin sensitisation.
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:
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probable, possible or confirmed human carcinogen by IARC.
NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: BS4500000
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1

12.2

Toxicity
Toxicity to fish

LC50 - Leuciscus idus (Golden orfe) - > 460 mg/l - 96 h

Toxicity to daphnia and
other aquatic
invertebrates

LC50 - Daphnia (water flea) - 129 mg/l - 48 h

Persistence and degradability
The methods for determining biodegradability are not applicable to inorganic substances.

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
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IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
CAS-No.
7783-20-2

Revision Date
1993-04-24

Ammonium sulphate

CAS-No.
7783-20-2

Revision Date
1993-04-24

Ammonium sulphate

CAS-No.
7783-20-2

Revision Date
1993-04-24

CAS-No.
7783-20-2

Revision Date
1993-04-24

Ammonium sulphate
Pennsylvania Right To Know Components

New Jersey Right To Know Components
Ammonium sulphate

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

1
0
0
0
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.2
Sigma - RES1427A-A7

Revision Date: 09/01/2017

Print Date: 03/24/2018
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SAFETY DATA SHEET

according to the (US) Hazard Communication Standard (29 CFR 1910.1200)
Revision Date 09/16/2014

Version 3.0

SECTION 1. Identification
Product identifier
Product number

801962

Product name

Brij® 35 for synthesis

CAS-No.

9002-92-0

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

Chemical for synthesis

Details of the supplier of the safety data sheet
Company

Emergency telephone

EMD Millipore Corporation | 290 Concord Road, Billerica, MA 01821,
United States of America | General Inquiries: +1-978-715-4321 |
Monday to Friday, 9:00 AM to 4:00 PM Eastern Time (GMT-5)
800-424-9300 CHEMTREC (USA)
+1-703-527-3887 CHEMTREC (International)
24 Hours/day; 7 Days/week

SECTION 2. Hazards identification
GHS-Labeling
Not a dangerous substance according to GHS.
Other hazards
None known.
SECTION 3. Composition/information on ingredients
Chemical nature
Formula

Alcohol
(C₂H₄O) nC₁₂H₂₆O

Remarks

No hazardous ingredients according to the OSHA Hazard
Communication Standard 29 CFR 1910.1200.

(C₂H₄O) nC₁₂H₂₆O (Hill)

SECTION 4. First aid measures
Description of first-aid measures

Inhalation

After inhalation: fresh air.
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SAFETY DATA SHEET
according to the (US) Hazard Communication Standard (29 CFR 1910.1200)
Product number
Product name

801962
Brij® 35 for synthesis

Version 3.0

Skin contact

After skin contact: wash off with plenty of water. Remove contaminated clothing.

Eye contact

After eye contact: rinse out with plenty of water.

Ingestion

After swallowing: make victim drink water (two glasses at most). Consult doctor if feeling unwell.

Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed
We have no description of any toxic symptoms.
Indication of any immediate medical attention and special treatment needed
No information available.
SECTION 5. Fire-fighting measures
Extinguishing media

Suitable extinguishing media

Water, Carbon dioxide (CO2), Foam, Dry powder

Unsuitable extinguishing media

For this substance/mixture no limitations of extinguishing agents are given.

Special hazards arising from the substance or mixture
Combustible.
Forms explosive mixtures with air on intense heating.
Development of hazardous combustion gases or vapors possible in the event of fire.
Advice for firefighters

Special protective equipment for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Further information

Prevent fire extinguishing water from contaminating surface water or the ground water system.

SECTION 6. Accidental release measures
Personal precautions, protective equipment and emergency procedures
Advice for non-emergency personnel: Avoid inhalation of dusts. Evacuate the danger area,
observe emergency procedures, consult an expert.
Advice for emergency responders: Protective equipment see section 8.
Environmental precautions
Do not empty into drains.
Methods and materials for containment and cleaning up
Cover drains. Collect, bind, and pump off spills.
Observe possible material restrictions (see sections 7 and 10).
Take up dry. Dispose of properly. Clean up affected area. Avoid generation of dusts.
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SAFETY DATA SHEET
according to the (US) Hazard Communication Standard (29 CFR 1910.1200)
Product number
Product name

801962
Brij® 35 for synthesis

Version 3.0

SECTION 7. Handling and storage
Precautions for safe handling
Observe label precautions.
Conditions for safe storage, including any incompatibilities
Tightly closed. Dry.
Store at +15°C to +25°C (+59°F to +77°F).
SECTION 8. Exposure controls/personal protection
Exposure limit(s)
Contains no substances with occupational exposure limit values.
Engineering measures
Technical measures and appropriate working operations should be given priority over the use of personal
protective equipment.
Individual protection measures
Protective clothing should be selected specifically for the workplace, depending on concentration and quantity of
the hazardous substances handled. The chemical resistance of the protective equipment should be inquired at
the respective supplier.

Hygiene measures

Change contaminated clothing. Wash hands after working with substance.

Eye/face protection
Safety glasses

Hand protection

Chemical-resistant, impervious gloves complying with an approved standard should be worn at
all times when handling chemical products if a risk assessment indicates this is necessary.

Respiratory protection

required when dusts are generated.
Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment
indicates this is necessary. Respirator selection must be based on known or anticipated exposure levels, the
hazards of the product and the safe working limits of the selected respirator.
SECTION 9. Physical and chemical properties
Physical state

solid

Color

white

Odor

fatty odor

Odor Threshold

No information available.

pH

5.5 - 7.0
at 100 g/l
68 °F ( 20 °C)
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SAFETY DATA SHEET
according to the (US) Hazard Communication Standard (29 CFR 1910.1200)
Product number
Product name

801962
Brij® 35 for synthesis

pour point

33 °C

Boiling point/boiling range

ca. 212 °F ( 100 °C)
at 1,013 hPa

Flash point

> 300 °F ( > 149 °C)

Evaporation rate

No information available.

Flammability (solid, gas)

No information available.

Lower explosion limit

No information available.

Upper explosion limit

No information available.

Vapor pressure

< 1 hPa
at 68 °F ( 20 °C)

Relative vapor density

No information available.

Density

1.05 g/cm³
at 68 °F ( 20 °C)

Relative density

No information available.

Water solubility

at 77 °F ( 25 °C)
soluble

Partition coefficient: noctanol/water
Autoignition temperature

No information available.
No information available.

Decomposition temperature

No information available.

Viscosity, dynamic

No information available.

Explosive properties

Not classified as explosive.

Oxidizing properties

none

Version 3.0

SECTION 10. Stability and reactivity
Reactivity
The following applies in general to flammable organic substances and mixtures: in
correspondingly fine distribution, when whirled up a dust explosion potential may generally be
assumed.
Forms explosive mixtures with air on intense heating.
Chemical stability
Sensitivity to light
Page 4 of 8
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according to the (US) Hazard Communication Standard (29 CFR 1910.1200)
Product number
Product name

801962
Brij® 35 for synthesis

Version 3.0

Possibility of hazardous reactions
Violent reactions possible with:
Strong acids, Bases, Oxidizing agents
Conditions to avoid
Strong heating.
A range from approx. 15 Kelvin below the flash point is to be rated as critical.
Incompatible materials
no information available
Hazardous decomposition products
no information available
SECTION 11. Toxicological information
Information on toxicological effects

Likely route of exposure

Eye contact, Skin contact, Ingestion

Acute oral toxicity

LD50 Rat: > 78,000 mg/kg (External MSDS)

Skin irritation

Rabbit
Result: No irritation
(External MSDS)

Eye irritation

Rabbit
Result: slight irritation
(External MSDS)

Sensitization

Patch test: human
Result: negative
(External MSDS)

Specific target organ systemic toxicity - single exposure

The substance or mixture is not classified as specific target organ toxicant, single exposure.

Specific target organ systemic toxicity - repeated exposure

The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Aspiration hazard

Regarding the available data the classification criteria are not fulfilled.

Carcinogenicity
IARC

No ingredient of this product present at levels greater than or
equal to 0.1% is identified as probable, possible or confirmed
human carcinogen by IARC.

OSHA

No ingredient of this product present at levels greater than or
equal to 0.1% is identified as a carcinogen or potential
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carcinogen by OSHA.
NTP

No ingredient of this product present at levels greater than or
equal to 0.1% is identified as a known or anticipated carcinogen
by NTP.

ACGIH

No ingredient of this product present at levels greater than or
equal to 0.1% is identified as a carcinogen or potential
carcinogen by ACGIH.

Further information
Hazardous properties cannot be excluded but are unlikely when the product is handled
appropriately.
Handle in accordance with good industrial hygiene and safety practice.
SECTION 12. Ecological information
Ecotoxicity
No information available.
Persistence and degradability

Biodegradability

89 %
OECD Test Guideline 301B
Readily biodegradable.

Bioaccumulative potential
No information available.
Mobility in soil
No information available.

SECTION 13. Disposal considerations
The information presented only applies to the material as supplied. The identification based on characteristic(s)
or listing may not apply if the material has been used or otherwise contaminated. It is the responsibility of the
waste generator to determine the toxicity and physical properties of the material generated to determine the
proper waste identification and disposal methods in compliance with applicable regulations. Disposal should be
in accordance with applicable regional, national and local laws and regulations.
SECTION 14. Transport information
Land transport (DOT)
Not classified as dangerous in the meaning of transport regulations.
Air transport (IATA)
Not classified as dangerous in the meaning of transport regulations.
Sea transport (IMDG)
Not classified as dangerous in the meaning of transport regulations.
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SECTION 15. Regulatory information
United States of America
SARA 313
This material does not contain any chemical components with known CAS numbers that exceed
the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 302
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302.
Clean Water Act
This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311,
Table 116.4A.
This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311,
Table 117.3.
DEA List I
Not listed
DEA List II
Not listed
US State Regulations
Massachusetts Right To Know
Remarks
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know

Ingredients

polymer of ethylene glycol and 1-dodecyl alcohol with >20 mol ethylene oxide
New Jersey Right To Know

Ingredients

polymer of ethylene glycol and 1-dodecyl alcohol with >20 mol ethylene oxide
California Prop 65 Components
This product does not contain any chemicals known to the State of California to cause cancer,
birth, or any other reproductive defects.
Notification status
TSCA:
DSL:

All components of the product are listed in the TSCA-inventory.
All components of this product are on the Canadian DSL.

SECTION 16. Other information
Training advice
Provide adequate information, instruction and training for operators.
Key or legend to abbreviations and acronyms used in the safety data sheet
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Used abbreviations and acronyms can be looked up at www.wikipedia.org.
Revision Date09/16/2014
The information contained herein is based on the present state of our knowledge. It characterizes the product with regard to
appropriate safety precautions. It does not represent a warranty of any product properties and we assume no liability for any
loss or injury which may result from the use of this information. Users should conduct their own investigations to determine
the suitability of the information.

All rights reserved. Millipore and the “M” Mark are registered trademarks of Merck KGaA, Darmstadt, Germany.
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Print Date 04/10/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Chloramphenicol, United States Pharmacopeia
(USP) Reference Standard

Product Number
Brand

:
:

1107004
USP

CAS-No.

:

56-75-7

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Carcinogenicity (Category 2), H351
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H351
Precautionary statement(s)
P201
P202
P280
P308 + P313
P405
P501

2.3

Warning
Suspected of causing cancer.
Obtain special instructions before use.
Do not handle until all safety precautions have been read and
understood.
Wear protective gloves/ protective clothing/ eye protection/ face
protection.
IF exposed or concerned: Get medical advice/ attention.
Store locked up.
Dispose of contents/ container to an approved waste disposal plant.

Hazards not otherwise classified (HNOC) or not covered by GHS - none

USP - 1107004
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3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Molecular weight
CAS-No.

:
:

323.13 g/mol
56-75-7

Hazardous components
Component
Chloramphenicol

Classification

Carc. 2; H351
For the full text of the H-Statements mentioned in this Section, see Section 16.

Concentration
90 - 100 %

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate
ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.

6.2

Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

USP - 1107004
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6.3

Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for
disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration
before additional processing occurs.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): 13: Non Combustible Solids

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Component
CAS-No.
Value
Control
parameters
Chloramphenicol
56-75-7
TWA
0.500000
mg/m3

8.2

Basis
USA. Workplace Environmental
Exposure Levels (WEEL)

Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved
under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Body Protection
Impervious clothing, The type of protective equipment must be selected according to the concentration and
amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type
N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the
sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

USP - 1107004

Form: crystalline
Colour: light yellow
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9.2

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

No data available

e)

Melting point/freezing
point

149 °C (300 °F)

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

No data available

n)

Water solubility

practically insoluble

o)

Partition coefficient: noctanol/water

No data available

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
Solubility in other
solvents

Ethanol

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
acids, Acid chlorides, Acid anhydrides, Oxidizing agents

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Hydrogen
chloride gas
In the event of fire: see section 5

USP - 1107004
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11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 2,500 mg/kg
Inhalation: No data available
Dermal: No data available
LD50 Intraperitoneal - Rat - 1,811 mg/kg
LD50 Intraperitoneal - Mouse - 1,100 mg/kg
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals.
Germ cell mutagenicity
Laboratory experiments have shown mutagenic effects.
Rat
Liver
DNA damage
Mouse
Cytogenetic analysis
Carcinogenicity
This product is or contains a component that has been reported to be probably carcinogenic based on its IARC, OSHA,
ACGIH, NTP, or EPA classification.

Suspected human carcinogens
IARC:

2A - Group 2A: Probably carcinogenic to humans (Chloramphenicol)

NTP:

RAHC - Reasonably anticipated to be a human carcinogen (Chloramphenicol)
RAHC - Reasonably anticipated to be a human carcinogen (Chloramphenicol)

OSHA:

No component of this product present at levels greater than or equal to 0.1% is on OSHA’s
list of regulated carcinogens.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
USP - 1107004
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Nausea, Headache, Vomiting
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Liver - Irregularities - Based on Human Evidence
Liver - Irregularities - Based on Human Evidence
12. ECOLOGICAL INFORMATION
12.1

Toxicity
Toxicity to daphnia and
other aquatic
invertebrates

12.2

EC50 - Daphnia magna (Water flea) - 345 mg/l - 48 h

Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Offer surplus and
non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Chronic Health Hazard
Massachusetts Right To Know Components
Chloramphenicol
USP - 1107004

CAS-No.
56-75-7
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Pennsylvania Right To Know Components
Chloramphenicol

CAS-No.
56-75-7

Revision Date
1989-12-01

Chloramphenicol

CAS-No.
56-75-7

Revision Date
1989-12-01

CAS-No.
56-75-7

Revision Date
1989-12-01

New Jersey Right To Know Components
Chloramphenicol

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Carc.
H351

Carcinogenicity
Suspected of causing cancer.

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard

1
*
0
0

NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

0
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.0

USP - 1107004

Revision Date: 01/17/2018

Print Date: 04/10/2018
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SIGMA-ALDRICH
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SAFETY DATA SHEET
Version 5.2
Revision Date 05/12/2015
Print Date 04/08/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Citric acid, Anhydrous

Product Number
Brand

:
:

PHR1071
Sigma-Aldrich

CAS-No.

:

77-92-9

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Manufacture of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Eye irritation (Category 2A), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word

Warning

Hazard statement(s)
H319

Causes serious eye irritation.

Precautionary statement(s)
P264
P280
P305 + P351 + P338

Wash skin thoroughly after handling.
Wear eye protection/ face protection.
IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
If eye irritation persists: Get medical advice/ attention.

P337 + P313
2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Formula

Sigma-Aldrich - PHR1071

:

C6H8O7
Page 1 of 7

Molecular weight
CAS-No.
EC-No.

:
:
:

192.12 g/mol
77-92-9
201-069-1

Hazardous components
Component

Classification

Concentration

Citric acid
Eye Irrit. 2A; H319
No components need to be disclosed according to the applicable regulations.
For the full text of the H-Statements mentioned in this Section, see Section 16.

<= 100 %

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Move out of dangerous area.Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
Carbon oxides

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate
ventilation. Avoid breathing dust.
For personal protection see section 8.

6.2

Environmental precautions
Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for
disposal.

6.4

Reference to other sections
For disposal see section 13.

Sigma-Aldrich - PHR1071
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7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible
dust formation should be taken into consideration before additional processing occurs.Avoid contact with skin and
eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Store at Room Temperature.
Storage class (TRGS 510): Non Combustible Solids

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

8.2

Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved
under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the concentration and
amount of the dangerous substance at the specific workplace.

Sigma-Aldrich - PHR1071
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Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher level
protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.
9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

9.2

Information on basic physical and chemical properties
a)

Appearance

Form: crystalline
Colour: white

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

1.8 at ca.50 g/l at 25 °C (77 °F)

e)

Melting point/freezing
point

Melting point/freezing point: 155 - 157 °C (311 - 315 °F)

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

Lower explosion limit: 8 %(V)

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

No data available

n)

Water solubility

383 g/l at 25 °C (77 °F)

o)

Partition coefficient: noctanol/water

log Pow: -1.639 at 20 °C (68 °F)

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

Sigma-Aldrich - PHR1071
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10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Oxidizing agents, Bases, Reducing agents, Nitrates

10.6

Hazardous decomposition products
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 5,400 mg/kg
(OECD Test Guideline 401)
Inhalation: No data available
LD50 Dermal - Rat - > 2,000 mg/kg
(OECD Test Guideline 402)
No data available
Skin corrosion/irritation
Skin - Rabbit
Result: Mild skin irritation
(OECD Test Guideline 404)
Serious eye damage/eye irritation
Eyes - Rabbit
Result: Irritating to eyes.
(OECD Test Guideline 405)
Respiratory or skin sensitisation
Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals.
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: GE7350000
Sigma-Aldrich - PHR1071
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Vomiting, Diarrhoea, Damage to tooth enamel., Dermatitis, To the best of our knowledge, the chemical, physical, and
toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1

Toxicity
Toxicity to fish

mortality LC50 - Leuciscus idus melanotus - 440 mg/l - 48 h
(OECD Test Guideline 203)

Toxicity to daphnia and
other aquatic
invertebrates

static test - Daphnia magna (Water flea) - 1,535 mg/l - 24 h

12.2

Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste
disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Acute Health Hazard
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
CAS-No.
Sigma-Aldrich - PHR1071

Revision Date
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Citric acid

77-92-9

New Jersey Right To Know Components
CAS-No.
77-92-9

Citric acid

Revision Date

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Eye Irrit.
H319

Eye irritation
Causes serious eye irritation.

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

2
0
0
2
0
0

Further information
Copyright 2015 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.2

Sigma-Aldrich - PHR1071

Revision Date: 05/12/2015

Print Date: 04/08/2018
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 4.5
Revision Date 12/21/2015
Print Date 04/08/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

D-(+)-Glucose monohydrate

Product Number
Brand

:
:

49159
Sigma-Aldrich

CAS-No.

:

14431-43-7

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
Not a hazardous substance or mixture.

2.2

GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.

2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Synonyms

:

Dextrosemonohydrate
Glucose

Formula
Molecular weight
CAS-No.
EC-No.

:
:
:
:

C6H12O6 · H2O
198.17 g/mol
14431-43-7
218-914-5

No components need to be disclosed according to the applicable regulations.
4. FIRST AID MEASURES
4.1

Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.

Sigma-Aldrich - 49159
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In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
Carbon oxides

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.

6.2

Environmental precautions
Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Keep in a dry place. Keep in a dry place.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

8.2

Exposure controls
Appropriate engineering controls
General industrial hygiene practice.

Sigma-Aldrich - 49159
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Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards such as
NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and
to the specific work-place., The type of protective equipment must be selected according to the concentration
and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.
9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: powder
Colour: white

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

No data available

e)

Melting point/freezing
point

No data available

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or

Sigma-Aldrich - 49159

No data available
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explosive limits

9.2

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

No data available

n)

Water solubility

No data available

o)

Partition coefficient: noctanol/water

No data available

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong oxidizing agents

10.6

Hazardous decomposition products
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
No data available
Inhalation: No data available
Dermal: No data available
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available

Sigma-Aldrich - 49159
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Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
12. ECOLOGICAL INFORMATION
12.1

Toxicity
No data available

12.2

Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Sigma-Aldrich - 49159
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Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
D-Glucose monohydrate

CAS-No.
14431-43-7

Revision Date

CAS-No.
14431-43-7

Revision Date

New Jersey Right To Know Components
D-Glucose monohydrate

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

0
0
0
0
0
0

Further information
Copyright 2015 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 4.5

Sigma-Aldrich - 49159

Revision Date: 12/21/2015

Print Date: 04/08/2018
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.5
Revision Date 10/03/2017
Print Date 04/07/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

N,N-Dimethylacrylamide

Product Number
Brand

:
:

274135
Aldrich

CAS-No.

:

2680-03-7

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Flammable liquids (Category 4), H227
Acute toxicity, Oral (Category 3), H301
Acute toxicity, Dermal (Category 3), H311
Serious eye damage (Category 1), H318
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H227
H301 + H311
H318
Precautionary statement(s)
P210
P264
P270
P280
P301 + P310 + P330
P302 + P352 + P312

Aldrich - 274135

Danger
Combustible liquid.
Toxic if swallowed or in contact with skin
Causes serious eye damage.
Keep away from heat/sparks/open flames/hot surfaces. No smoking.
Wash skin thoroughly after handling.
Do not eat, drink or smoke when using this product.
Wear protective gloves/ eye protection/ face protection.
IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse
mouth.
IF ON SKIN: Wash with plenty of soap and water. Call a POISON
Page 1 of 8

CENTER or doctor/ physician if you feel unwell.
IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing. Immediately
call a POISON CENTER/doctor.
Remove/Take off immediately all contaminated clothing.
Wash contaminated clothing before reuse.
In case of fire: Use dry sand, dry chemical or alcohol-resistant foam for
extinction.
Store in a well-ventilated place. Keep cool.
Store locked up.
Dispose of contents/ container to an approved waste disposal plant.

P305 + P351 + P338 + P310
P361
P363
P370 + P378
P403 + P235
P405
P501
2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Formula
Molecular weight
CAS-No.
EC-No.

:
:
:
:

C5H9NO
99.13 g/mol
2680-03-7
220-237-5

Hazardous components
Component
N,N-Dimethylacrylamide

Classification

Concentration

Flam. Liq. 4; Acute Tox. 3; Eye 90 - 100 %
Dam. 1; H227, H301 + H311,
H318
For the full text of the H-Statements mentioned in this Section, see Section 16.

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a
physician.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Aldrich - 274135
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5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
Use water spray to cool unopened containers.

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all sources of
ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations. Vapours
can accumulate in low areas.
For personal protection see section 8.

6.2

Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in
container for disposal according to local regulations (see section 13). Keep in suitable, closed containers for disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic charge.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed
and kept upright to prevent leakage.
Light sensitive.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

8.2

Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.
Personal protective equipment
Eye/face protection
Tightly fitting safety goggles. Faceshield (8-inch minimum). Use equipment for eye protection tested and
approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: butyl-rubber
Minimum layer thickness: 0.3 mm
Break through time: 480 min

Aldrich - 274135
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Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M)
Splash contact
Material: Nature latex/chloroprene
Minimum layer thickness: 0.6 mm
Break through time: 48 min
Material tested:Lapren® (KCL 706 / Aldrich Z677558, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected according to
the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multipurpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls.
If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: liquid

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

7 - 10 at 200 g/l

e)

Melting point/freezing
point

-39.99 °C (-39.98 °F)

f)

Initial boiling point and
boiling range

80 - 81 °C (176 - 178 °F) at 27 hPa (20 mmHg) - lit.

g)

Flash point

70 °C (158 °F) - closed cup

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

Lower explosion limit: 0.68 %(V)

k)

Vapour pressure

0.65 hPa (0.49 mmHg) at 20 °C (68 °F)

l)

Vapour density

No data available

m) Relative density

0.962 g/cm3 at 25 °C (77 °F)

n)

Water solubility

1,000 g/l at 20 °C (68 °F)

o)

Partition coefficient: noctanol/water

log Pow: -0.3 at 23 °C (73 °F)

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available
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9.2

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.
Contains the following stabiliser(s):
Mequinol (0.05 %)

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
Heat, flames and sparks.

10.5

Incompatible materials
Strong oxidizing agents, Strong bases, polymerisation initiators

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx)
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - > 215 - 464 mg/kg
(OECD Test Guideline 401)
LD50 Dermal - Rabbit - 519 mg/kg
Remarks: Behavioral:Somnolence (general depressed activity). Behavioral:Tremor. Liver:Other changes.
No data available
Skin corrosion/irritation
Skin - Rabbit
Result: Mild skin irritation
Serious eye damage/eye irritation
Eyes - Rabbit
Result: Risk of serious damage to eyes.
(OECD Test Guideline 405)
Eyes - Rabbit
Result: Moderate eye irritation
Respiratory or skin sensitisation
- Guinea pig
Result: Did not cause sensitisation on laboratory animals.
(OECD Test Guideline 406)
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.
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NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Stomach - Irregularities - Based on Human Evidence (Mequinol)
12. ECOLOGICAL INFORMATION
12.1

12.2

Toxicity
Toxicity to fish

LC50 - Oncorhynchus mykiss (rainbow trout) - > 120 mg/l - 96 h
(OECD Test Guideline 203)

Toxicity to daphnia and
other aquatic
invertebrates

EC50 - Daphnia magna (Water flea) - > 120 mg/l - 48 h
(OECD Test Guideline 202)

Toxicity to algae

EC50 - Pseudokirchneriella subcapitata (green algae) - > 400 mg/l - 72 h
(OECD Test Guideline 201)

Toxicity to bacteria

EC50 - Bacteria - > 1,000 mg/l
(OECD Test Guideline 209)

Persistence and degradability
Biodegradability
Result: - Not readily biodegradable.
(OECD Test Guideline 301C)

12.3

Bioaccumulative potential
No bioaccumulation is to be expected (log Pow <= 4).

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
This combustible material may be burned in a chemical incinerator equipped with an afterburner and scrubber. Offer
surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal
service to dispose of this material.
Contaminated packaging
Dispose of as unused product.
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14. TRANSPORT INFORMATION
DOT (US)
UN number: 2810
Class: 6.1
Packing group: III
Proper shipping name: Toxic, liquids, organic, n.o.s. (N,N-Dimethylacrylamide)
Reportable Quantity (RQ):
Poison Inhalation Hazard: No
IMDG
UN number: 2810
Class: 6.1
Packing group: III
EMS-No: F-A, S-A
Proper shipping name: TOXIC LIQUID, ORGANIC, N.O.S. (N,N-Dimethylacrylamide)
IATA
UN number: 2810
Class: 6.1
Packing group: III
Proper shipping name: Toxic liquid, organic, n.o.s. (N,N-Dimethylacrylamide)
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Fire Hazard, Acute Health Hazard
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
N,N-Dimethylacrylamide

CAS-No.
2680-03-7

Revision Date

CAS-No.
2680-03-7

Revision Date

New Jersey Right To Know Components
N,N-Dimethylacrylamide

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox.
Eye Dam.
Flam. Liq.
H227
H301
H301 + H311
H311
H318

Acute toxicity
Serious eye damage
Flammable liquids
Combustible liquid.
Toxic if swallowed.
Toxic if swallowed or in contact with skin
Toxic in contact with skin.
Causes serious eye damage.

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Aldrich - 274135

2
2
0
2
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Fire Hazard:
Reactivity Hazard:

2
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.5

Aldrich - 274135

Revision Date: 10/03/2017

Print Date: 04/07/2018
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.4
Revision Date 05/27/2016
Print Date 04/10/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Ethylenediamine

Product Number
Brand
Index-No.

:
:
:

E1649
Sigma-Aldrich
612-006-00-6

CAS-No.

:

107-15-3

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Flammable liquids (Category 3), H226
Acute toxicity, Oral (Category 4), H302
Acute toxicity, Inhalation (Category 4), H332
Acute toxicity, Dermal (Category 3), H311
Skin corrosion (Category 1B), H314
Serious eye damage (Category 1), H318
Respiratory sensitisation (Category 1), H334
Skin sensitisation (Category 1), H317
Acute aquatic toxicity (Category 2), H401
Chronic aquatic toxicity (Category 3), H412
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word

Danger

Hazard statement(s)
H226
H302 + H332
H311
H314

Flammable liquid and vapour.
Harmful if swallowed or if inhaled
Toxic in contact with skin.
Causes severe skin burns and eye damage.

Sigma-Aldrich - E1649
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H317
H334
H401
H412

May cause an allergic skin reaction.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Toxic to aquatic life.
Harmful to aquatic life with long lasting effects.

Precautionary statement(s)
P210
P233
P240
P241
P242
P243
P261
P264
P270
P271
P272
P273
P280

Keep away from heat/sparks/open flames/hot surfaces. No smoking.
Keep container tightly closed.
Ground/bond container and receiving equipment.
Use explosion-proof electrical/ ventilating/ lighting/ equipment.
Use only non-sparking tools.
Take precautionary measures against static discharge.
Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
Wash skin thoroughly after handling.
Do not eat, drink or smoke when using this product.
Use only outdoors or in a well-ventilated area.
Contaminated work clothing should not be allowed out of the workplace.
Avoid release to the environment.
Wear protective gloves/ protective clothing/ eye protection/ face
protection.
In case of inadequate ventilation wear respiratory protection.
IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell.
IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
IF ON SKIN (or hair): Remove/ Take off immediately all contaminated
clothing. Rinse skin with water/ shower.
IF INHALED: Remove victim to fresh air and keep at rest in a position
comfortable for breathing.
IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Immediately call a POISON CENTER/doctor.
Specific measures (see supplemental first aid instructions on this label).
If skin irritation or rash occurs: Get medical advice/ attention.
Remove/Take off immediately all contaminated clothing.
Wash contaminated clothing before reuse.
In case of fire: Use dry sand, dry chemical or alcohol-resistant foam for
extinction.
Store in a well-ventilated place. Keep cool.
Store locked up.
Dispose of contents/ container to an approved waste disposal plant.

P285
P301 + P312
P301 + P330 + P331
P303 + P361 + P353
P304 + P340
P305 + P351 + P338
P310
P322
P333 + P313
P361
P363
P370 + P378
P403 + P235
P405
P501
2.3

Hazards not otherwise classified (HNOC) or not covered by GHS
Lachrymator.
Rapidly absorbed through skin.

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Synonyms

:

1,2-Diaminoethane

Formula
Molecular weight
CAS-No.
EC-No.
Index-No.

:
:
:
:
:

C2H8N2
60.10 g/mol
107-15-3
203-468-6
612-006-00-6

Hazardous components
Component

Classification

Concentration

Flam. Liq. 3; Acute Tox. 4;
Acute Tox. 3; Skin Corr. 1B;
Eye Dam. 1; Resp. Sens. 1;

<= 100 %

Ethylenediamine

Sigma-Aldrich - E1649
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Skin Sens. 1; Aquatic Acute 2;
Aquatic Chronic 3; H226,
H302 + H332, H311, H314,
H317, H318, H334, H401,
H412
For the full text of the H-Statements mentioned in this Section, see Section 16.
4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Take victim
immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.Continue rinsing eyes during
transport to hospital.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a
physician.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
Use water spray to cool unopened containers.

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all sources
of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations.
Vapours can accumulate in low areas.
For personal protection see section 8.

6.2

Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment
must be avoided.

6.3

Methods and materials for containment and cleaning up
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in
container for disposal according to local regulations (see section 13).

Sigma-Aldrich - E1649
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6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic charge.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully
resealed and kept upright to prevent leakage.
Air and moisture sensitive. Handle and store under inert gas.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Component
CAS-No.
Value
Control
parameters
Ethylenediamine
107-15-3
TWA
10.000000 ppm
Remarks

8.2

Basis

USA. ACGIH Threshold Limit Values
(TLV)
Not classifiable as a human carcinogen
Danger of cutaneous absorption
TWA
10 ppm
USA. ACGIH Threshold Limit Values
(TLV)
Not classifiable as a human carcinogen
Danger of cutaneous absorption
TWA
10.000000 ppm USA. Occupational Exposure Limits
25.000000
(OSHA) - Table Z-1 Limits for Air
mg/m3
Contaminants
The value in mg/m3 is approximate.
TWA
10 ppm
USA. Occupational Exposure Limits
25 mg/m3
(OSHA) - Table Z-1 Limits for Air
Contaminants
The value in mg/m3 is approximate.
TWA
10.000000 ppm USA. NIOSH Recommended
25.000000
Exposure Limits
mg/m3
PEL
10 ppm
California permissible exposure
25 mg/m3
limits for chemical contaminants
(Title 8, Article 107)

Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.
Personal protective equipment
Eye/face protection
Tightly fitting safety goggles. Faceshield (8-inch minimum). Use equipment for eye protection tested and
approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact

Sigma-Aldrich - E1649
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Material: butyl-rubber
Minimum layer thickness: 0.3 mm
Break through time: 480 min
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M)
Splash contact
Material: Nature latex/chloroprene
Minimum layer thickness: 0.6 mm
Break through time: 72 min
Material tested:Lapren® (KCL 706 / Aldrich Z677558, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
Complete suit protecting against chemicals, Flame retardant antistatic protective clothing., The type of
protective equipment must be selected according to the concentration and amount of the dangerous substance
at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multipurpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls.
If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: liquid

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

12.2 at 110 g/l at 20 °C (68 °F)

e)

Melting point/freezing
point

Melting point/range: 8.5 °C (47.3 °F) - lit.

f)

Initial boiling point and
boiling range

118 °C (244 °F) - lit.

g)

Flash point

38 °C (100 °F) - closed cup

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

Upper explosion limit: 16 %(V)
Lower explosion limit: 2.7 %(V)

k)

Vapour pressure

13 hPa (10 mmHg) at 20 °C (68 °F)

l)

Vapour density

2.07 - (Air = 1.0)

m) Relative density

0.899 g/cm3 at 25 °C (77 °F)

n)

Water solubility

soluble

o)

Partition coefficient: noctanol/water

log Pow: -2.04

Sigma-Aldrich - E1649
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9.2

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
Relative vapour density

2.07 - (Air = 1.0)

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
Heat, flames and sparks.

10.5

Incompatible materials
Oxidizing agents, Phosphorus halides, Aldehydes, Organic halides

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx)
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 1,200 mg/kg
Remarks: Behavioral:Ataxia.
LC50 Inhalation - Rat - 4 h - 14.7 mg/l
LD50 Dermal Dermal - Rabbit - 560 mg/kg
No data available
Skin corrosion/irritation
Skin - Rabbit
Result: Causes burns.
Serious eye damage/eye irritation
Eyes - Rabbit
Result: Corrosive
Respiratory or skin sensitisation
Maximisation Test - Guinea pig
Result: Causes sensitisation.
May cause allergic respiratory and skin reactions
Germ cell mutagenicity
No data available
Carcinogenicity
Carcinogenicity - This product is or contains a component that is not classifiable as to its carcinogenicity based on its
IARC, ACGIH, NTP, or EPA classification.

Sigma-Aldrich - E1649
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IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: KH8575000
Vomiting, Diarrhoea, Abdominal pain, To the best of our knowledge, the chemical, physical, and toxicological properties
have not been thoroughly investigated.
Liver - Irregularities - Based on Human Evidence
Liver - Irregularities - Based on Human Evidence
12. ECOLOGICAL INFORMATION
12.1

Toxicity
Toxicity to fish

LC50 - Pimephales promelas (fathead minnow) - 115.7 mg/l - 96 h

Toxicity to daphnia and
other aquatic
invertebrates

EC50 - Daphnia magna (Water flea) - 3 mg/l - 48 h

NOEC - Daphnia magna (Water flea) - 0.16 mg/l - 21 d
Toxicity to algae

EC50 - Pseudokirchneriella subcapitata (green algae) - 151 mg/l - 96 h

12.2

Persistence and degradability
Biodegradability
Biotic/Aerobic - Exposure time 28 d
Result: 94 % - Readily biodegradable

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
An environmental hazard cannot be excluded in the event of unprofessional handling or disposal.
Toxic to aquatic life.
Avoid release to the environment.

Sigma-Aldrich - E1649
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13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this
material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a
licensed professional waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
UN number: 1604
Class: 8 (3)
Proper shipping name: Ethylenediamine
Reportable Quantity (RQ): 5000 lbs

Packing group: II

Poison Inhalation Hazard: No
IMDG
UN number: 1604
Class: 8 (3)
Proper shipping name: ETHYLENEDIAMINE

Packing group: II

IATA
UN number: 1604
Class: 8 (3)
Proper shipping name: Ethylenediamine

Packing group: II

EMS-No: F-E, S-C

15. REGULATORY INFORMATION
SARA 302 Components
The following components are subject to reporting levels established by SARA Title III, Section 302:
CAS-No.
Revision Date
Ethylenediamine
107-15-3
2007-03-01
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Fire Hazard, Acute Health Hazard, Chronic Health Hazard
Massachusetts Right To Know Components
Ethylenediamine

CAS-No.
107-15-3

Revision Date
2007-03-01

CAS-No.
107-15-3

Revision Date
2007-03-01

CAS-No.
107-15-3

Revision Date
2007-03-01

Pennsylvania Right To Know Components
Ethylenediamine
New Jersey Right To Know Components
Ethylenediamine

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Sigma-Aldrich - E1649
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Acute Tox.
Aquatic Acute
Aquatic Chronic
Eye Dam.
Flam. Liq.
H226
H302
H302 + H332
H311
H314
H317
H318
H332
H334
H401
H412

Acute toxicity
Acute aquatic toxicity
Chronic aquatic toxicity
Serious eye damage
Flammable liquids
Flammable liquid and vapour.
Harmful if swallowed.
Harmful if swallowed or if inhaled
Toxic in contact with skin.
Causes severe skin burns and eye damage.
May cause an allergic skin reaction.
Causes serious eye damage.
Harmful if inhaled.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Toxic to aquatic life.
Harmful to aquatic life with long lasting effects.

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard

3
*
2
0

NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

3
2
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.4

Sigma-Aldrich - E1649

Revision Date: 05/27/2016

Print Date: 04/10/2018
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 4.13
Revision Date 10/03/2017
Print Date 04/08/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Ethyl alcohol, pure

Product Number
Brand
Index-No.

:
:
:

E7023
Sigma-Aldrich
603-002-00-5

CAS-No.

:

64-17-5

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Flammable liquids (Category 2), H225
Eye irritation (Category 2A), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H225
H319
Precautionary statement(s)
P210
P233
P240
P241
P242
P243
P264
P280
P303 + P361 + P353

Sigma-Aldrich - E7023

Danger
Highly flammable liquid and vapour.
Causes serious eye irritation.
Keep away from heat/sparks/open flames/hot surfaces. No smoking.
Keep container tightly closed.
Ground/bond container and receiving equipment.
Use explosion-proof electrical/ ventilating/ lighting/ equipment.
Use only non-sparking tools.
Take precautionary measures against static discharge.
Wash skin thoroughly after handling.
Wear protective gloves/ eye protection/ face protection.
IF ON SKIN (or hair): Take off immediately all contaminated clothing.
Page 1 of 8

Rinse skin with water/shower.
IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
If eye irritation persists: Get medical advice/ attention.
In case of fire: Use dry sand, dry chemical or alcohol-resistant foam to
extinguish.
Store in a well-ventilated place. Keep cool.
Dispose of contents/ container to an approved waste disposal plant.

P305 + P351 + P338
P337 + P313
P370 + P378
P403 + P235
P501
2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Synonyms
Formula
Molecular weight
CAS-No.
EC-No.
Index-No.

:

Absolute alcohol

:
:
:
:
:

C2H6O
46.07 g/mol
64-17-5
200-578-6
603-002-00-5

Hazardous components
Component
Ethanol

Classification

Flam. Liq. 2; Eye Irrit. 2A;
H225, H319
For the full text of the H-Statements mentioned in this Section, see Section 16.

Concentration
90 - 100 %

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a
physician.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Sigma-Aldrich - E7023
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5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
Use water spray to cool unopened containers.

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all
sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive
concentrations. Vapours can accumulate in low areas.
For personal protection see section 8.

6.2

Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in
container for disposal according to local regulations (see section 13).

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Use explosion-proof equipment.Keep away from sources of ignition - No smoking.Take measures to prevent the build up
of electrostatic charge.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed
and kept upright to prevent leakage.
Hygroscopic.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Component
CAS-No.
Value
Control
parameters
Ethanol
64-17-5
TWA
1,000.000000
ppm
Remarks

Sigma-Aldrich - E7023

Basis
USA. ACGIH Threshold Limit Values
(TLV)

Upper Respiratory Tract irritation
Confirmed animal carcinogen with unknown relevance to humans
TWA
1,000 ppm
USA. OSHA - TABLE Z-1 Limits for
1,900 mg/m3
Air Contaminants - 1910.1000
TWA
1,000 ppm
USA. Occupational Exposure Limits
1,900 mg/m3
(OSHA) - Table Z-1 Limits for Air
Contaminants
The value in mg/m3 is approximate.
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TWA

1,000.000000
USA. Occupational Exposure Limits
ppm
(OSHA) - Table Z-1 Limits for Air
1,900.000000
Contaminants
mg/m3
The value in mg/m3 is approximate.
TWA
1,000.000000
USA. NIOSH Recommended
ppm
Exposure Limits
1,900.000000
mg/m3
STEL
1,000.000000
USA. ACGIH Threshold Limit Values
ppm
(TLV)
Upper Respiratory Tract irritation
Confirmed animal carcinogen with unknown relevance to humans
8.2

Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate
government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: butyl-rubber
Minimum layer thickness: 0.3 mm
Break through time: 480 min
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.2 mm
Break through time: 38 min
Material tested:Dermatril® P (KCL 743 / Aldrich Z677388, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
Impervious clothing, Flame retardant antistatic protective clothing., The type of protective equipment must be
selected according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multipurpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls.
If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

Sigma-Aldrich - E7023
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9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

9.2

Information on basic physical and chemical properties
a)

Appearance

Form: liquid, clear
Colour: colourless

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

No data available

e)

Melting point/freezing
point

-143.99 °C (-227.18 °F)

f)

Initial boiling point and
boiling range

78.0 - 80.0 °C (172.4 - 176.0 °F)

g)

Flash point

14.0 °C (57.2 °F) - closed cup

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

Upper explosion limit: 19 %(V)
Lower explosion limit: 3.3 %(V)

k)

Vapour pressure

59.5 hPa (44.6 mmHg) at 20.0 °C (68.0 °F)

l)

Vapour density

No data available

m) Relative density

0.7974 g/cm3

n)

Water solubility

completely soluble

o)

Partition coefficient: noctanol/water

log Pow: -0.349 at 24 °C (75 °F)

p)

Auto-ignition
temperature

363.0 °C (685.4 °F)

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
Vapours may form explosive mixture with air.

10.4

Conditions to avoid
Heat, flames and sparks.

10.5

Incompatible materials
Alkali metals, Oxidizing agents, Peroxides

10.6

Hazardous decomposition products
Other decomposition products - No data available
Hazardous decomposition products formed under fire conditions. - Carbon oxides

Sigma-Aldrich - E7023
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In the event of fire: see section 5
11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 10,470 mg/kg
LC50 Inhalation - Rat - 4 h - 30,000 mg/l
LD50 Dermal - Rabbit - 15,800 mg/kg
No data available
Skin corrosion/irritation
Skin - Rabbit
Result: No skin irritation - 24 h
(OECD Test Guideline 404)
Serious eye damage/eye irritation
Eyes - Rabbit
Result: Moderate eye irritation
(OECD Test Guideline 405)
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
Carcinogenicity - Mouse - Oral
Tumorigenic:Equivocal tumorigenic agent by RTECS criteria. Liver:Tumors. Blood:Lymphomas including Hodgkin's
disease.
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
Reproductive toxicity - Human - female - Oral
Effects on Newborn: Apgar score (human only). Effects on Newborn: Other neonatal measures or effects. Effects on
Newborn: Drug dependence.
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: KQ6300000
Central nervous system depression, narcosis, Damage to the heart., To the best of our knowledge, the chemical,
physical, and toxicological properties have not been thoroughly investigated.
Stomach - Irregularities - Based on Human Evidence
Stomach - Irregularities - Based on Human Evidence

Sigma-Aldrich - E7023
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12. ECOLOGICAL INFORMATION
12.1

Toxicity
Toxicity to fish

LC50 - Pimephales promelas (fathead minnow) - 14,200 mg/l - 96 h

Toxicity to daphnia and
other aquatic
invertebrates

LC50 - Ceriodaphnia dubia (water flea) - 5,012 mg/l - 48 h

NOEC - Daphnia magna (Water flea) - 9.6 mg/l - 9 d
Toxicity to algae
12.2

EC50 - Chlorella vulgaris (Fresh water algae) - 275 mg/l - 72 h
(OECD Test Guideline 201)

Persistence and degradability
Biodegradability
Result: 95 % - Readily biodegradable.

12.3

Bioaccumulative potential
Due to the distribution coefficient n-octanol/water, accumulation in organisms is not expected.

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this
material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a
licensed professional waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
UN number: 1170
Class: 3
Proper shipping name: Ethanol
Reportable Quantity (RQ):
Poison Inhalation Hazard: No

Packing group: II

IMDG
UN number: 1170
Class: 3
Proper shipping name: ETHANOL

Packing group: II

IATA
UN number: 1170
Class: 3
Proper shipping name: Ethanol

Packing group: II

EMS-No: F-E, S-D

15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
Sigma-Aldrich - E7023
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SARA 311/312 Hazards
Fire Hazard, Acute Health Hazard, Chronic Health Hazard
Massachusetts Right To Know Components
Ethanol

CAS-No.
64-17-5

Revision Date
2007-03-01

CAS-No.
64-17-5

Revision Date
2007-03-01

CAS-No.
64-17-5

Revision Date
2007-03-01

Pennsylvania Right To Know Components
Ethanol
New Jersey Right To Know Components
Ethanol

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Eye Irrit.
Flam. Liq.
H225
H319

Eye irritation
Flammable liquids
Highly flammable liquid and vapour.
Causes serious eye irritation.

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard

2
*
3
0

NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

2
3
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 4.13

Sigma-Aldrich - E7023
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 3.14
Revision Date 02/24/2017
Print Date 04/08/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Glutaraldehyde solution

Product Number
Brand

:
:

G7776
Sigma-Aldrich

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Acute toxicity, Oral (Category 3), H301
Acute toxicity, Inhalation (Category 3), H331
Skin corrosion (Category 1B), H314
Serious eye damage (Category 1), H318
Respiratory sensitisation (Category 1), H334
Skin sensitisation (Category 1), H317
Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335
Acute aquatic toxicity (Category 1), H400
Chronic aquatic toxicity (Category 2), H411
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H301 + H331
H314
H317
H334
H335
H400
H411

Sigma-Aldrich - G7776

Danger
Toxic if swallowed or if inhaled
Causes severe skin burns and eye damage.
May cause an allergic skin reaction.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
May cause respiratory irritation.
Very toxic to aquatic life.
Toxic to aquatic life with long lasting effects.
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Precautionary statement(s)
P261
P264
P270
P271
P272
P273
P280

Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
Wash skin thoroughly after handling.
Do not eat, drink or smoke when using this product.
Use only outdoors or in a well-ventilated area.
Contaminated work clothing should not be allowed out of the workplace.
Avoid release to the environment.
Wear protective gloves/ protective clothing/ eye protection/ face
protection.
In case of inadequate ventilation wear respiratory protection.
IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse
mouth.
IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
IF ON SKIN (or hair): Take off immediately all contaminated clothing.
Rinse skin with water/shower.
IF INHALED: Remove person to fresh air and keep comfortable for
breathing. Immediately call a POISON CENTER/doctor.
IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing. Immediately
call a POISON CENTER/doctor.
If skin irritation or rash occurs: Get medical advice/ attention.
If experiencing respiratory symptoms: Call a POISON CENTER/doctor.
Wash contaminated clothing before reuse.
Collect spillage.
Store in a well-ventilated place. Keep container tightly closed.
Store locked up.
Dispose of contents/ container to an approved waste disposal plant.

P285
P301 + P310 + P330
P301 + P330 + P331
P303 + P361 + P353
P304 + P340 + P310
P305 + P351 + P338 + P310
P333 + P313
P342 + P311
P363
P391
P403 + P233
P405
P501
2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.2

Mixtures
Synonyms
Formula
Molecular weight

:

Pentane-1,5-dial
Glutaric dialdehydesolution

:
:

C5H8O2
100.12 g/mol

Hazardous components
Component
Glutaral
CAS-No.
EC-No.
Index-No.

111-30-8
203-856-5
605-022-00-X

Classification

Concentration

Flam. Liq. 4; Acute Tox. 3;
Acute Tox. 2; Skin Corr. 1B;
Eye Dam. 1; Resp. Sens. 1;
Skin Sens. 1; STOT SE 3;
Aquatic Acute 1; Aquatic
Chronic 2; H227, H301, H314,
H317, H330, H334, H335,
H400, H411

70 - 90 %

Methanol
CAS-No.
67-56-1
Flam. Liq. 2; Acute Tox. 3;
EC-No.
200-659-6
STOT SE 1; H225, H301 +
Index-No.
603-001-00-X
H311 + H331, H370
Registration number 01-2119433307-44-XXXX
For the full text of the H-Statements mentioned in this Section, see Section 16.

Sigma-Aldrich - G7776
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4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Move out of dangerous area.Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Take victim immediately
to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.Continue rinsing eyes during
transport to hospital.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a
physician.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to
safe areas.
For personal protection see section 8.

6.2

Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment
must be avoided.

6.3

Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for
disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
For precautions see section 2.2.

Sigma-Aldrich - G7776
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7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed
and kept upright to prevent leakage.
Recommended storage temperature -20 °C
Store under inert gas. Air sensitive.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Component
CAS-No.
Value
Control
parameters
Glutaral
111-30-8
C
0.200000 ppm
0.800000
mg/m3
Remarks
See Appendix C
C
0.050000 ppm

Methanol

67-56-1

Basis
USA. NIOSH Recommended
Exposure Limits

USA. ACGIH Threshold Limit Values
(TLV)
Central Nervous System impairment
Upper Respiratory Tract irritation
Eye irritation
Skin irritation
Not classifiable as a human carcinogen
Sensitizer
C
0.05 ppm
USA. ACGIH Threshold Limit Values
(TLV)
Dermal Sensitization
Respiratory sensitization
Central Nervous System impairment
Upper Respiratory Tract irritation
Eye irritation
Skin irritation
Not classifiable as a human carcinogen
C
0.05 ppm
California permissible exposure
0.2 mg/m3
limits for chemical contaminants
(Title 8, Article 107)
TWA
200.000000
USA. ACGIH Threshold Limit Values
ppm
(TLV)
Headache
Nausea
Dizziness
Eye damage
Substances for which there is a Biological Exposure Index or Indices
(see BEI® section)
Danger of cutaneous absorption
STEL
250.000000
USA. ACGIH Threshold Limit Values
ppm
(TLV)
Headache
Nausea
Dizziness
Eye damage
Substances for which there is a Biological Exposure Index or Indices
(see BEI® section)
Danger of cutaneous absorption
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TWA

200.000000
USA. NIOSH Recommended
ppm
Exposure Limits
260.000000
mg/m3
Potential for dermal absorption
ST
250.000000
USA. NIOSH Recommended
ppm
Exposure Limits
325.000000
mg/m3
Potential for dermal absorption
TWA
200.000000
USA. Occupational Exposure Limits
ppm
(OSHA) - Table Z-1 Limits for Air
260.000000
Contaminants
mg/m3
The value in mg/m3 is approximate.
TWA
200 ppm
USA. ACGIH Threshold Limit Values
(TLV)
Headache
Nausea
Dizziness
Eye damage
Substances for which there is a Biological Exposure Index or Indices
(see BEI® section)
Danger of cutaneous absorption
STEL
250 ppm
USA. ACGIH Threshold Limit Values
(TLV)
Headache
Nausea
Dizziness
Eye damage
Substances for which there is a Biological Exposure Index or Indices
(see BEI® section)
Danger of cutaneous absorption
TWA
200 ppm
USA. NIOSH Recommended
260 mg/m3
Exposure Limits
Potential for dermal absorption
ST
250 ppm
USA. NIOSH Recommended
325 mg/m3
Exposure Limits
Potential for dermal absorption
TWA
200 ppm
USA. Occupational Exposure Limits
260 mg/m3
(OSHA) - Table Z-1 Limits for Air
Contaminants
The value in mg/m3 is approximate.
STEL
250 ppm
USA. OSHA - TABLE Z-1 Limits for
325 mg/m3
Air Contaminants - 1910.1000
Skin notation
TWA
200 ppm
USA. OSHA - TABLE Z-1 Limits for
260 mg/m3
Air Contaminants - 1910.1000
Skin notation
C
1,000 ppm
California permissible exposure
limits for chemical contaminants
(Title 8, Article 107)
Skin
PEL
200 ppm
California permissible exposure
260 mg/m3
limits for chemical contaminants
(Title 8, Article 107)
Skin

Sigma-Aldrich - G7776
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STEL

250 ppm
325 mg/m3

California permissible exposure
limits for chemical contaminants
(Title 8, Article 107)

Skin
Biological occupational exposure limits
Component
CAS-No.
Parameters
Methanol

67-56-1
Remarks

8.2

Methanol

Value

Biological
specimen

15.0000
mg/l

Urine

Basis

ACGIH - Biological
Exposure Indices
(BEI)
End of shift (As soon as possible after exposure ceases)
Methanol
15 mg/l
Urine
ACGIH - Biological
Exposure Indices
(BEI)
End of shift (As soon as possible after exposure ceases)

Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.
Personal protective equipment
Eye/face protection
Tightly fitting safety goggles. Faceshield (8-inch minimum). Use equipment for eye protection tested and
approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.4 mm
Break through time: 480 min
Material tested:Camatril® (KCL 730 / Aldrich Z677442, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 30 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected according to
the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multipurpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls.
If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
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9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

9.2

Information on basic physical and chemical properties
a)

Appearance

Form: clear, liquid
Colour: colourless

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

No data available

e)

Melting point/freezing
point

No data available

f)

Initial boiling point and
boiling range

101 °C (214 °F) at 1,013 hPa (760 mmHg)

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

20 hPa (15 mmHg) at 20 °C (68 °F)

l)

Vapour density

No data available

m) Relative density

1.143 g/cm3

n)

Water solubility

soluble

o)

Partition coefficient: noctanol/water

No data available

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong bases, Acids, Oxidizing agents, Alkali metals, Strong oxidizing agents, Strong acids, Acid chlorides, Acid
anhydrides, Reducing agents

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides
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Other decomposition products - No data available
In the event of fire: see section 5
11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
No data available
Inhalation: No data available
Dermal: No data available
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
Material is extremely destructive to tissue of the mucous membranes and upper respiratory tract, eyes, and skin., spasm,
inflammation and edema of the larynx, spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary edema,
burning sensation, Cough, wheezing, laryngitis, Shortness of breath, Headache, Nausea
Liver - Irregularities - Based on Human Evidence
Liver - Irregularities - Based on Human Evidence (Glutaral)
Stomach - Irregularities - Based on Human Evidence (Methanol)
12. ECOLOGICAL INFORMATION
12.1
12.2

Toxicity
No data available
Persistence and degradability
No data available
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12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
An environmental hazard cannot be excluded in the event of unprofessional handling or disposal.
Very toxic to aquatic life.

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a
chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
UN number: 2922
Class: 8 (6.1)
Packing group: II
Proper shipping name: Corrosive liquids, toxic, n.o.s. (Glutaral)
Reportable Quantity (RQ):
Poison Inhalation Hazard: No
IMDG
UN number: 2922
Class: 8 (6.1)
Packing group: II
Proper shipping name: CORROSIVE LIQUID, TOXIC, N.O.S. (Glutaral)
Marine pollutant:yes

EMS-No: F-A, S-B

IATA
UN number: 2922
Class: 8 (6.1)
Packing group: II
Proper shipping name: Corrosive liquid, toxic, n.o.s. (Glutaral)
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Acute Health Hazard, Chronic Health Hazard
Massachusetts Right To Know Components
Glutaral

CAS-No.
111-30-8

Revision Date
1993-04-24

CAS-No.
111-30-8
7732-18-5
67-56-1

Revision Date
1993-04-24

CAS-No.
111-30-8
7732-18-5

Revision Date
1993-04-24

Pennsylvania Right To Know Components
Glutaral
Water
Methanol

2007-07-01

New Jersey Right To Know Components
Glutaral
Water
Sigma-Aldrich - G7776

Page 9 of 11

Methanol
California Prop. 65 Components
WARNING: This product contains a chemical known to the
State of California to cause birth defects or other reproductive
harm.
Methanol

67-56-1

2007-07-01

CAS-No.
67-56-1

Revision Date
2012-03-16

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox.
Aquatic Acute
Aquatic Chronic
Eye Dam.
Flam. Liq.
H225
H227
H301
H301 + H311 +
H331
H314
H317
H318
H330
H331
H334
H335
H370
H400
H411
Resp. Sens.
Skin Corr.
Skin Sens.
STOT SE

Acute toxicity
Acute aquatic toxicity
Chronic aquatic toxicity
Serious eye damage
Flammable liquids
Highly flammable liquid and vapour.
Combustible liquid.
Toxic if swallowed.
Toxic if swallowed, in contact with skin or if inhaled.
Causes severe skin burns and eye damage.
May cause an allergic skin reaction.
Causes serious eye damage.
Fatal if inhaled.
Toxic if inhaled.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
May cause respiratory irritation.
Causes damage to organs.
Very toxic to aquatic life.
Toxic to aquatic life with long lasting effects.
Respiratory sensitisation
Skin corrosion
Skin sensitisation
Specific target organ toxicity - single exposure

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard

4
*
0
1

NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

3
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Sigma-Aldrich - G7776
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.4
Revision Date 08/31/2017
Print Date 04/10/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Guanidine hydrochloride

Product Number
Brand
Index-No.

:
:
:

PHG0006
Sigma
607-148-00-0

CAS-No.

:

50-01-1

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Acute toxicity, Oral (Category 4), H302
Acute toxicity, Inhalation (Category 4), H332
Skin irritation (Category 2), H315
Eye irritation (Category 2A), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H302 + H332
H315
H319
Precautionary statement(s)
P261
P264
P270
P271
P280
P301 + P312 + P330

Sigma - PHG0006

Warning
Harmful if swallowed or if inhaled
Causes skin irritation.
Causes serious eye irritation.
Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
Wash skin thoroughly after handling.
Do not eat, drink or smoke when using this product.
Use only outdoors or in a well-ventilated area.
Wear protective gloves/ eye protection/ face protection.
IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell.
Page 1 of 7

Rinse mouth.
IF ON SKIN: Wash with plenty of soap and water.
IF INHALED: Remove person to fresh air and keep comfortable for
breathing. Call a POISON CENTER/doctor if you feel unwell.
IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
If skin irritation occurs: Get medical advice/ attention.
If eye irritation persists: Get medical advice/ attention.
Take off contaminated clothing and wash before reuse.
Dispose of contents/ container to an approved waste disposal plant.

P302 + P352
P304 + P340 + P312
P305 + P351 + P338
P332 + P313
P337 + P313
P362
P501
2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Formula
Molecular weight
CAS-No.
EC-No.
Index-No.

:
:
:
:
:

CH5N3 · HCl
95.53 g/mol
50-01-1
200-002-3
607-148-00-0

Hazardous components
Component
Guanidinium chloride

Classification

Acute Tox. 4; Skin Irrit. 2; Eye
Irrit. 2A; H302 + H332, H315,
H319
For the full text of the H-Statements mentioned in this Section, see Section 16.

Concentration
90 - 100 %

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Sigma - PHG0006
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5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate
ventilation. Avoid breathing dust.
For personal protection see section 8.

6.2

Environmental precautions
Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for
disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration
before additional processing occurs.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.
Hazardous components without workplace control parameters

8.2

Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved
under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected according to
the concentration and amount of the dangerous substance at the specific workplace.

Sigma - PHG0006
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Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher level
protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.
9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

9.2

Information on basic physical and chemical properties
a)

Appearance

Form: crystalline
Colour: white

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

4.5 - 6 at 573 g/l at 25 °C (77 °F)

e)

Melting point/freezing
point

185 - 189 °C (365 - 372 °F)

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

1.345 g/cm3 at 20 °C (68 °F)

n)

Water solubility

573 g/l at 20 °C (68 °F) - completely soluble

o)

Partition coefficient: noctanol/water

log Pow: -1.7 at ca.20 °C (68 °F)

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

> 310 °C (> 590 °F) -

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

Sigma - PHG0006
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10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong oxidizing agents

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Hydrogen
chloride gas
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 475 mg/kg
Remarks: Behavioral:Altered sleep time (including change in righting reflex). Behavioral:Excitement. Diarrhoea
LD50 Oral - Mouse - 571 mg/kg
Remarks: Behavioral:Altered sleep time (including change in righting reflex). Behavioral:Muscle contraction or spasticity.
Behavioral:Irritability.
LD50 Oral - Rat - 1,120 mg/kg
LC50 Inhalation - Rat - female - 4 h - 3.181 mg/l
(OECD Test Guideline 403)
Dermal: No data available
No data available
Skin corrosion/irritation
Skin - Rabbit
Result: Skin irritation
Serious eye damage/eye irritation
Eyes - Rabbit
Result: Irritating to eyes.
Respiratory or skin sensitisation
Buehler Test - Guinea pig
Did not cause sensitisation on laboratory animals.
Germ cell mutagenicity
Not mutagenic in Ames Test
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Sigma - PHG0006
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Additional Information
RTECS: MF4300000
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Liver - Irregularities - Based on Human Evidence
Liver - Irregularities - Based on Human Evidence
12. ECOLOGICAL INFORMATION
12.1

Toxicity
Toxicity to fish

12.2

LC50 - Leuciscus idus (Golden orfe) - 1,759 mg/l

Persistence and degradability
Biodegradability
Result: - Not readily biodegradable.

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a
chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Acute Health Hazard, Chronic Health Hazard
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
Sigma - PHG0006
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CAS-No.
50-01-1

Revision Date

Guanidinium chloride

CAS-No.
50-01-1

Revision Date

Guanidinium chloride

CAS-No.
50-01-1

Revision Date

New Jersey Right To Know Components
Guanidinium chloride

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox.
Eye Irrit.
H302
H302 + H332
H315
H319

Acute toxicity
Eye irritation
Harmful if swallowed.
Harmful if swallowed or if inhaled
Causes skin irritation.
Causes serious eye irritation.

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard

2
*
0
0

NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

2
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.4

Sigma - PHG0006

Revision Date: 08/31/2017

Print Date: 04/10/2018
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.8
Revision Date 08/31/2017
Print Date 04/10/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

HEPES

Product Number
Brand

:
:

RES6003H-B7
Sigma

CAS-No.

:

7365-45-9

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
Not a hazardous substance or mixture.

2.2

GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.

2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Formula
Molecular weight
CAS-No.
EC-No.
Registration number

:
:
:
:
:

C8H18N2O4S
238.3 g/mol
7365-45-9
230-907-9
01-2120054645-54-XXXX

No components need to be disclosed according to the applicable regulations.

4. FIRST AID MEASURES
4.1

Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.

Sigma - RES6003H-B7
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In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.

6.2

Environmental precautions
No special environmental precautions required.

6.3

Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust
formation should be taken into consideration before additional processing occurs.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

Sigma - RES6003H-B7

Page 2 of 7

8.2

Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards such as
NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and
to the specific work-place., The type of protective equipment must be selected according to the concentration
and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
No special environmental precautions required.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: Crystalline powder
Colour: colourless

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

5.0 - 6.5 at 238 g/l at 25 °C (77 °F)

e)

Melting point/freezing
point

Melting point/range: 212.6 °C (414.7 °F) - Decomposes before melting.

f)

Initial boiling point and
boiling range

Decomposes below the boiling point.

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) The product is not flammable. - Flammability (solids)

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

1.439 g/cm3 at 20 °C (68 °F)

n)

Water solubility

703.6 g/l at 20 °C (68 °F) - OECD Test Guideline 105

o)

Partition coefficient: noctanol/water

log Pow: < -3.85

p)

Auto-ignition
temperature

does not ignite

q)

Decomposition
temperature

No data available

Sigma - RES6003H-B7
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9.2

r)

Viscosity

No data available

s)

Explosive properties

Not explosive

t)

Oxidizing properties

The substance or mixture is not classified as oxidizing.

Other safety information
Surface tension

63.98 mN/m at 20 °C (68 °F)

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong oxidizing agents

10.6

Hazardous decomposition products
Other decomposition products - No data available
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Sulphur oxides
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
No data available
LD50 Oral - Rat - > 2,000 mg/kg
Inhalation: No data available
Inhalation: No data available
Dermal: No data available
LD50 Dermal - Rat - > 2,000 mg/kg
(OECD Test Guideline 402)
No data available
No data available
Skin corrosion/irritation
No data available
Skin - Rabbit
Result: No skin irritation
(OECD Test Guideline 404)
Serious eye damage/eye irritation
No data available
Eyes - Rabbit
Result: No eye irritation
(OECD Test Guideline 405)
Respiratory or skin sensitisation
No data available
Maximisation Test - Guinea pig
Did not cause sensitisation on laboratory animals.
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Germ cell mutagenicity
No data available
in vitro assay
Result: negative
Lymphoma Mutation Assay
Chromosome aberration test in vitro
Result: negative
Result: Not mutagenic in Ames Test
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
Did not show teratogenic effects in animal experiments.
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
Repeated dose
toxicity
RTECS: TL6809000

Rat - Oral - 28 d - Subacute oral toxicity - NOAEL : 1,000 mg/kg - OECD Test
Guideline 407

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1

Toxicity
No data available
Toxicity to fish

LC50 - Brachydanio rerio (zebrafish) - > 100 mg/l - 96 h
(OECD Test Guideline 203)

Toxicity to daphnia and
other aquatic
invertebrates

EC50 - Daphnia magna (Water flea) - > 100 mg/l - 48 h

Toxicity to algae

static test EC50 - Pseudokirchneriella subcapitata (green algae) - > 100 mg/l 72 h
(OECD Test Guideline 201)
NOEC - Pseudokirchneriella subcapitata (green algae) - 100 mg/l - 72 h
(OECD Test Guideline 201)

Toxicity to bacteria
12.2

EC50 - Sludge Treatment - > 1,000 mg/l - 3 h
(OECD Test Guideline 209)

Persistence and degradability
No data available
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12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
CAS-No.
7365-45-9

Revision Date

4-(2-Hydroxyethyl)piperazin-1-ylethanesulphonic acid

CAS-No.
7365-45-9

Revision Date

4-(2-Hydroxyethyl)piperazin-1-ylethanesulphonic acid

CAS-No.
7365-45-9

Revision Date

New Jersey Right To Know Components
4-(2-Hydroxyethyl)piperazin-1-ylethanesulphonic acid

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
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16. OTHER INFORMATION
HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

0
0
0
0
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.8

Sigma - RES6003H-B7

Revision Date: 08/31/2017

Print Date: 04/10/2018
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.0
Revision Date 01/16/2018
Print Date 04/10/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Imidazole (200 mg)

Product Number
Brand

:
:

1336500
USP

CAS-No.

:

288-32-4

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Acute toxicity, Oral (Category 4), H302
Skin corrosion (Category 1C), H314
Serious eye damage (Category 1), H318
Reproductive toxicity (Category 1B), H360D
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H302
H314
H360D
Precautionary statement(s)
P201
P202
P260
P264
P270
P280

USP - 1336500

Danger
Harmful if swallowed.
Causes severe skin burns and eye damage.
May damage the unborn child.
Obtain special instructions before use.
Do not handle until all safety precautions have been read and
understood.
Do not breathe dust or mist.
Wash skin thoroughly after handling.
Do not eat, drink or smoke when using this product.
Wear protective gloves/ protective clothing/ eye protection/ face
Page 1 of 8

protection.
IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell.
Rinse mouth.
IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
IF ON SKIN (or hair): Take off immediately all contaminated clothing.
Rinse skin with water/shower.
IF INHALED: Remove person to fresh air and keep comfortable for
breathing. Immediately call a POISON CENTER/doctor.
IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing. Immediately
call a POISON CENTER/doctor.
IF exposed or concerned: Get medical advice/ attention.
Wash contaminated clothing before reuse.
Store locked up.
Dispose of contents/ container to an approved waste disposal plant.

P301 + P312 + P330
P301 + P330 + P331
P303 + P361 + P353
P304 + P340 + P310
P305 + P351 + P338 + P310
P308 + P313
P363
P405
P501
2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Molecular weight
CAS-No.

:
:

68.08 g/mol
288-32-4

Hazardous components
Component
Imidazole

Classification

Acute Tox. 4; Skin Corr. 1C;
Eye Dam. 1; Repr. 1B; H302,
H314, H360D
For the full text of the H-Statements mentioned in this Section, see Section 16.

Concentration
90 - 100 %

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.Continue rinsing eyes during
transport to hospital.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a
physician.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

USP - 1336500
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5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate
ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.

6.2

Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for
disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust
formation should be taken into consideration before additional processing occurs.Avoid contact with skin and eyes. Avoid
formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): 6.1D: Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials
causing chronic effects

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.
Hazardous components without workplace control parameters

8.2

Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate
government standards such as NIOSH (US) or EN 166(EU).

USP - 1336500
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Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected according to
the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type
N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the
sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

9.2

Information on basic physical and chemical properties
a)

Appearance

Form: crystalline
Colour: white

b)

Odour

amine-like

c)

Odour Threshold

No data available

d)

pH

9 - 11 at 100 g/l at 23 °C (73 °F)

e)

Melting point/freezing
point

89 - 91 °C (192 - 196 °F)

f)

Initial boiling point and
boiling range

256 °C (493 °F) at 1,013 hPa (760 mmHg)

g)

Flash point

145 °C (293 °F) - closed cup

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

0.003 hPa (0.002 mmHg) at 20 °C (68 °F)

l)

Vapour density

No data available

m) Relative density

1.030 g/cm3

n)

Water solubility

633 g/l at 20 °C (68 °F)

o)

Partition coefficient: noctanol/water

log Pow: -0.02 at 25 °C (77 °F)

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
Bulk density

550 kg/m3

Dissociation constant

7.15 at 25 °C (77 °F)

USP - 1336500
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10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
acids, Acid anhydrides, Strong oxidizing agents

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Hydrogen
cyanide (hydrocyanic acid)
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 970 mg/kg
Inhalation: No data available
Dermal: No data available
No data available
Skin corrosion/irritation
Skin - Rabbit
Result: Corrosive, category 1C - where responses occur after exposures between 1 hour and 4 hours and observations
up to 14 days.
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
Did not show mutagenic effects in animal experiments. Tests on bacterial or mammalian cell cultures did not show
mutagenic effects.
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is on OSHA’s
list of regulated carcinogens.

Reproductive toxicity
Presumed human reproductive toxicant May damage the unborn child.
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
USP - 1336500
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Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1

12.2

Toxicity
Toxicity to fish

static test LC50 - Leuciscus idus (Golden orfe) - 280 mg/l - 48 h

Toxicity to daphnia and
other aquatic
invertebrates

EC50 - Daphnia (water flea) - 341.5 mg/l - 48 h

Toxicity to algae

static test EC50 - Scenedesmus quadricauda (Green algae) - 133 mg/l - 72 h

Toxicity to bacteria

see user defined free text - other microorganisms - 45 mg/l - 0.5 h

Persistence and degradability
Biodegradability
aerobic - Exposure time 19 d
Result: 86 % - Readily biodegradable.

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Offer surplus and
non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
UN number: 3263
Class: 8
Packing group: III
Proper shipping name: Corrosive solid, basic, organic, n.o.s. (Imidazole)
Reportable Quantity (RQ):
Poison Inhalation Hazard: No
IMDG
UN number: 3263
Class: 8
Packing group: III
EMS-No: F-A, S-B
Proper shipping name: CORROSIVE SOLID, BASIC, ORGANIC, N.O.S. (Imidazole)
IATA
UN number: 3263
Class: 8
Packing group: III
Proper shipping name: Corrosive solid, basic, organic, n.o.s. (Imidazole)

USP - 1336500
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15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Acute Health Hazard, Chronic Health Hazard
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
CAS-No.
288-32-4

Revision Date

Imidazole

CAS-No.
288-32-4

Revision Date

Imidazole

CAS-No.
288-32-4

Revision Date

New Jersey Right To Know Components
Imidazole

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox.
Eye Dam.
H302
H314
H318
H360D
Repr.
Skin Corr.

Acute toxicity
Serious eye damage
Harmful if swallowed.
Causes severe skin burns and eye damage.
Causes serious eye damage.
May damage the unborn child.
Reproductive toxicity
Skin corrosion

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard

3
*
1
0

NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

3
1
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.

USP - 1336500
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Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.0
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.3
Revision Date 03/04/2018
Print Date 04/10/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Mannitol

Product Number
Brand

:
:

1375105
USP

CAS-No.

:

69-65-8

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
Not a hazardous substance or mixture.

2.2

GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.

2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Synonyms
Formula
Molecular weight
CAS-No.
EC-No.

:

D-Mannitol
Mannite

:
:
:
:

C6H14O6
182.17 g/mol
69-65-8
200-711-8

No components need to be disclosed according to the applicable regulations.

USP - 1375105
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4. FIRST AID MEASURES
4.1

Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.

6.2

Environmental precautions
No special environmental precautions required.

6.3

Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust
formation should be taken into consideration before additional processing occurs.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Keep in a dry place.
Storage class (TRGS 510): 13: Non Combustible Solids

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

USP - 1375105
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

8.2

Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards such as
NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and
to the specific work-place., The type of protective equipment must be selected according to the concentration
and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
No special environmental precautions required.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: powder
Colour: white

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

5.0 - 6.5 at 182 g/l at 25 °C (77 °F)

e)

Melting point/freezing
point

165 °C (329 °F)

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

No data available

n)

Water solubility

182 g/l at 20 °C (68 °F) - completely soluble

o)

Partition coefficient: n-

No data available

USP - 1375105
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octanol/water

9.2

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong oxidizing agents

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 13,500 mg/kg
Inhalation: No data available
Dermal: No data available
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is on OSHA’s

USP - 1375105
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list of regulated carcinogens.
Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1
12.2

Toxicity
No data available
Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
USP - 1375105
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This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
CAS-No.
69-65-8

Revision Date

D-Mannitol

CAS-No.
69-65-8

Revision Date

D-Mannitol

CAS-No.
69-65-8

Revision Date

New Jersey Right To Know Components
D-Mannitol

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

0
0
0
0
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.3
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Print Date: 04/10/2018
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.6
Revision Date 09/05/2017
Print Date 04/07/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

N,N′-Methylenebis(acrylamide)

Product Number
Brand

:
:

146072
Sigma-Aldrich

CAS-No.

:

110-26-9

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word

Warning

Hazard statement(s)
H302

Harmful if swallowed.

Precautionary statement(s)
P264
P270
P301 + P312 + P330

Wash skin thoroughly after handling.
Do not eat, drink or smoke when using this product.
IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell.
Rinse mouth.
Dispose of contents/ container to an approved waste disposal plant.

P501
2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Synonyms

Sigma-Aldrich - 146072

:

Bis-acrylamide
Page 1 of 7

Formula
Molecular weight
CAS-No.
EC-No.

:
:
:
:

C7H10N2O2
154.17 g/mol
110-26-9
203-750-9

Hazardous components
Component
N,N'-Methylenediacrylamide

Classification

Acute Tox. 4; H302
For the full text of the H-Statements mentioned in this Section, see Section 16.

Concentration
90 - 100 %

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate
ventilation. Avoid breathing dust.
For personal protection see section 8.

6.2

Environmental precautions
Do not let product enter drains.
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6.3

Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for
disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration
before additional processing occurs.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature 2 - 8 °C
Air and light sensitive.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.
Hazardous components without workplace control parameters

8.2

Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved
under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
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Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected according to
the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher level
protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.
9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

9.2

Information on basic physical and chemical properties
a)

Appearance

Form: solid

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

No data available

e)

Melting point/freezing
point

Melting point/range: > 300 °C (> 572 °F)

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

No data available

l)

Vapour density

5.32 - (Air = 1.0)

m) Relative density

No data available

n)

Water solubility

20 g/l at 20 °C (68 °F) - completely soluble

o)

Partition coefficient: noctanol/water

No data available

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
Relative vapour density

5.32 - (Air = 1.0)

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.
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10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
Exposure to air.

10.5

Incompatible materials
Acids, Bases, Oxidizing agents, Reducing agents, Iron and iron salts., Copper, Aluminum, Brass, Free radical initiators

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx)
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 390 mg/kg
Remarks: Sense Organs and Special Senses (Nose, Eye, Ear, and Taste):Eye:Other. Behavioral:Tremor. Lungs, Thorax,
or Respiration:Other changes.
Inhalation: No data available
Dermal: No data available
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
Overexposure may cause reproductive disorder(s) based on tests with laboratory animals.
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: AS3678000
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
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12. ECOLOGICAL INFORMATION
12.1

Toxicity
Toxicity to fish

12.2

LC50 - Oncorhynchus mykiss (rainbow trout) - > 100 mg/l - 96 h

Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a
chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Acute Health Hazard
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
CAS-No.
110-26-9

Revision Date

N,N'-Methylenediacrylamide

CAS-No.
110-26-9

Revision Date

N,N'-Methylenediacrylamide
Sigma-Aldrich - 146072
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New Jersey Right To Know Components
CAS-No.
110-26-9

N,N'-Methylenediacrylamide

Revision Date

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox.
H302

Acute toxicity
Harmful if swallowed.

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard

2
*
0
1

NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

2
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.6
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 4.5
Revision Date 05/11/2016
Print Date 04/08/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

MES

Product Number
Brand

:
:

M3671
Sigma

CAS-No.

:

4432-31-9

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
Not a hazardous substance or mixture.

2.2

GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.

2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Synonyms

:

4-Morpholineethanesulfonic acid
2-(N-Morpholino)ethanesulfonic acid

Formula
Molecular weight
CAS-No.
EC-No.

:
:
:
:

C6H13NO4S
195.24 g/mol
4432-31-9
224-632-3

No components need to be disclosed according to the applicable regulations.
4. FIRST AID MEASURES
4.1

Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
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In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.

6.2

Environmental precautions
Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Keep in a dry place.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.
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8.2

Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards such as
NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and
to the specific work-place., The type of protective equipment must be selected according to the concentration
and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: powder
Colour: white

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

2.5 - 4 at 97.6 g/l at 25 °C (77 °F)

e)

Melting point/freezing
point

300 °C (572 °F)

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available
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9.2

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

No data available

n)

Water solubility

97.6 g/l at 20 °C (68 °F) - completely soluble

o)

Partition coefficient: noctanol/water

No data available

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong oxidizing agents

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Sulphur
oxides
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
No data available
Inhalation: No data available
Dermal: No data available
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
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Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: QE3479500
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
12. ECOLOGICAL INFORMATION
12.1

Toxicity
No data available

12.2

Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.
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14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
2-Morpholinoethanesulphonic acid

CAS-No.
145224-94-8

Revision Date

CAS-No.
145224-94-8

Revision Date

New Jersey Right To Know Components
2-Morpholinoethanesulphonic acid

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

0
0
0
0
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.6
Revision Date 08/31/2017
Print Date 04/08/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Sodium phosphate monobasic monohydrate

Product Number
Brand

:
:

RES20906-A7
Sigma

CAS-No.

:

10049-21-5

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
Not a hazardous substance or mixture.

2.2

GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.

2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Synonyms

Formula
Molecular weight
CAS-No.
EC-No.

:

Monosodium phosphate
Sodium dihydrogen phosphate monohydrate
Sodium phosphate monobasic monohydrate

:
:
:
:

NaH2PO4 · H2O
137.99 g/mol
10049-21-5
231-834-5

No components need to be disclosed according to the applicable regulations.
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4. FIRST AID MEASURES
4.1

Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.

6.2

Environmental precautions
No special environmental precautions required.

6.3

Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust
formation should be taken into consideration before additional processing occurs.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

8.2

Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards such as
NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and
to the specific work-place., The type of protective equipment must be selected according to the concentration
and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
No special environmental precautions required.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: crystalline
Colour: white

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

4.1 - 4.5 at 50 g/l at 25 °C (77 °F)

e)

Melting point/freezing
point

No data available

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

No data available

n)

Water solubility

No data available

o)

Partition coefficient: n-

No data available
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octanol/water

9.2

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong oxidizing agents, Strong acids

10.6

Hazardous decomposition products
Other decomposition products - No data available
Hazardous decomposition products formed under fire conditions. - Oxides of phosphorus, Sodium oxides
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
No data available
Inhalation: No data available
Dermal: No data available
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
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carcinogen or potential carcinogen by OSHA.
Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1
12.2

Toxicity
No data available
Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
Sigma - RES20906-A7
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This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
CAS-No.
10049-21-5

Revision Date

Sodium dihydrogenorthophosphate monohydrate

CAS-No.
10049-21-5

Revision Date

Sodium dihydrogenorthophosphate monohydrate

CAS-No.
10049-21-5

Revision Date

New Jersey Right To Know Components
Sodium dihydrogenorthophosphate monohydrate

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

0
0
0
0
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.6
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Revision Date: 08/31/2017

Print Date: 04/08/2018
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 4.10
Revision Date 10/03/2017
Print Date 04/07/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Sodium phosphate

Product Number
Brand

:
:

342483
Aldrich

CAS-No.

:

7601-54-9

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Skin irritation (Category 2), H315
Eye irritation (Category 2A), H319
Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H315
H319
H335
Precautionary statement(s)
P261
P264
P271
P280
P302 + P352
P304 + P340
P305 + P351 + P338
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Warning
Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
Wash skin thoroughly after handling.
Use only outdoors or in a well-ventilated area.
Wear protective gloves/ eye protection/ face protection.
IF ON SKIN: Wash with plenty of soap and water.
IF INHALED: Remove victim to fresh air and keep at rest in a position
comfortable for breathing.
IF IN EYES: Rinse cautiously with water for several minutes. Remove
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contact lenses, if present and easy to do. Continue rinsing.
Call a POISON CENTER/doctor if you feel unwell.
Specific treatment (see supplemental first aid instructions on this label).
If skin irritation occurs: Get medical advice/ attention.
If eye irritation persists: Get medical advice/ attention.
Take off contaminated clothing and wash before reuse.
Store in a well-ventilated place. Keep container tightly closed.
Store locked up.
Dispose of contents/ container to an approved waste disposal plant.

P312
P321
P332 + P313
P337 + P313
P362
P403 + P233
P405
P501
2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Synonyms
Formula
Molecular weight
CAS-No.
EC-No.

:

Trisodium phosphate

:
:
:
:

Na3O4P
163.94 g/mol
7601-54-9
231-509-8

Hazardous components
Component
Trisodium orthophosphate

Classification

Skin Irrit. 2; Eye Irrit. 2A;
STOT SE 3; H315, H319,
H335
For the full text of the H-Statements mentioned in this Section, see Section 16.

Concentration
90 - 100 %

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
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5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate
ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.

6.2

Environmental precautions
Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for
disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration
before additional processing occurs.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Moisture sensitive.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Component
CAS-No.
Value
Control
parameters
Trisodium
7601-54-9
STEL
5.000000
orthophosphate
mg/m3

8.2

Basis
USA. Workplace Environmental
Exposure Levels (WEEL)

Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved
under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Aldrich - 342483

Page 3 of 8

Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
Impervious clothing, The type of protective equipment must be selected according to the concentration and
amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher level
protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.
9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: solid

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

11 at 20 °C (68 °F)

e)

Melting point/freezing
point

75 °C (167 °F) - Decomposes before melting.

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

No data available

n)

Water solubility

121 g/l at 20 °C (68 °F)

o)

Partition coefficient: noctanol/water

No data available

p)

Auto-ignition
temperature

No data available
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9.2

q)

Decomposition
temperature

75 °C (167 °F) - Decomposes before melting.

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong acids

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Oxides of phosphorus, Sodium oxides
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
No data available
Inhalation: No data available
Dermal: No data available
No data available
Skin corrosion/irritation
Skin - Rabbit
Result: Irritating to skin.
Serious eye damage/eye irritation
Eyes - Rabbit
Result: Moderate eye irritation
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
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known or anticipated carcinogen by NTP.
No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.
OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.
No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: TC9490000
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1
12.2

Toxicity
No data available
Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste
disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
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IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Acute Health Hazard
Massachusetts Right To Know Components
Trisodium orthophosphate

CAS-No.
7601-54-9

Revision Date
2007-03-01

CAS-No.
7601-54-9

Revision Date
2007-03-01

CAS-No.
7601-54-9

Revision Date
2007-03-01

Pennsylvania Right To Know Components
Trisodium orthophosphate
New Jersey Right To Know Components
Trisodium orthophosphate
California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Eye Irrit.
H315
H319
H335
Skin Irrit.
STOT SE

Eye irritation
Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
Skin irritation
Specific target organ toxicity - single exposure

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

2
0
0
2
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
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Version: 4.10
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 6.13
Revision Date 10/03/2017
Print Date 04/08/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Sodium borohydride

Product Number
Brand

:
:

452882
Aldrich

CAS-No.

:

16940-66-2

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Substances and mixtures, which in contact with water, emit flammable gases (Category 1), H260
Acute toxicity, Oral (Category 3), H301
Skin corrosion (Category 1B), H314
Serious eye damage (Category 1), H318
Reproductive toxicity (Category 1B), H360
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H260
H301
H314
H360
Precautionary statement(s)
P201
P202
P223
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Danger
In contact with water releases flammable gases which may ignite
spontaneously.
Toxic if swallowed.
Causes severe skin burns and eye damage.
May damage fertility or the unborn child.
Obtain special instructions before use.
Do not handle until all safety precautions have been read and
understood.
Do not allow contact with water.
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P231 + P232
P260
P264
P270
P280

Handle under inert gas. Protect from moisture.
Do not breathe dust or mist.
Wash skin thoroughly after handling.
Do not eat, drink or smoke when using this product.
Wear protective gloves/ protective clothing/ eye protection/ face
protection.
IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse
mouth.
IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
IF ON SKIN (or hair): Take off immediately all contaminated clothing.
Rinse skin with water/shower.
IF INHALED: Remove person to fresh air and keep comfortable for
breathing. Immediately call a POISON CENTER/doctor.
IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing. Immediately
call a POISON CENTER/doctor.
IF exposed or concerned: Get medical advice/ attention.
Brush off loose particles from skin. Immerse in cool water/ wrap in wet
bandages.
Wash contaminated clothing before reuse.
In case of fire: Use dry sand, dry chemical or alcohol-resistant foam to
extinguish.
Store in a dry place. Store in a closed container.
Store locked up.
Dispose of contents/ container to an approved waste disposal plant.

P301 + P310 + P330
P301 + P330 + P331
P303 + P361 + P353
P304 + P340 + P310
P305 + P351 + P338 + P310
P308 + P313
P335 + P334
P363
P370 + P378
P402 + P404
P405
P501
2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Synonyms
Formula
Molecular weight
CAS-No.
EC-No.

:

Sodium tetrahydridoborate
VenPure®

:
:
:
:

H4BNa
37.83 g/mol
16940-66-2
241-004-4

Hazardous components
Component
Sodium borohydride

Classification

Water-react. 1; Acute Tox. 3;
Skin Corr. 1B; Eye Dam. 1;
Repr. 1B; H260, H301, H314,
H360F
For the full text of the H-Statements mentioned in this Section, see Section 16.

Concentration
90 - 100 %

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

Aldrich - 452882

Page 2 of 8

In case of skin contact
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Take victim immediately
to hospital. Consult a physician.
In case of eye contact
Continue rinsing eyes during transport to hospital.Rinse thoroughly with plenty of water for at least 15 minutes and
consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a
physician.
4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Dry powder

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.
Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.

6.2

Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Sweep up and shovel. Contain spillage, and then collect with an electrically protected vacuum cleaner or by wetbrushing and place in container for disposal according to local regulations (see section 13). Do not flush with water.
Keep in suitable, closed containers for disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration
before additional processing occurs.
Provide appropriate exhaust ventilation at places where dust is formed.Keep away from sources of ignition - No smoking.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Never allow product to get in contact with water during storage.
Air and moisture sensitive. Store under inert gas. Keep in a dry place.
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7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

8.2

Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate
government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
Complete suit protecting against chemicals, Flame retardant protective clothing, The type of protective
equipment must be selected according to the concentration and amount of the dangerous substance at the
specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type
N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the
sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: powder
Colour: white

b)

Odour

No data available

c)

Odour Threshold

No data available
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9.2

d)

pH

No data available

e)

Melting point/freezing
point

Melting point/range: > 300 °C (> 572 °F) - dec.

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

Lower explosion limit: 3.02 %(V)

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

No data available

n)

Water solubility

55 g/l at 25 °C (77 °F) - soluble

o)

Partition coefficient: noctanol/water

No data available

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
Bulk density

1,074 kg/m3 at 20 °C (68 °F)

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
Reacts violently with water.

10.4

Conditions to avoid
Exposure to moisture

10.5

Incompatible materials
Oxidizing agents, Chemically active metals, acids, Reacts violently with water.

10.6

Hazardous decomposition products
Other decomposition products - No data available
Hazardous decomposition products formed under fire conditions. - Borane/boron oxides, Sodium oxides
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 162 mg/kg
Inhalation: No data available
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LD50 Dermal - Rabbit - 4,000 - 8,000 mg/kg
No data available
Skin corrosion/irritation
Skin - Human
Result: Corrosive
Serious eye damage/eye irritation
Eyes - Human
Result: Corrosive to eyes
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
Clear evidence of adverse effects on sexual function and fertility, based on animal experiments.
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: ED3325000
Material is extremely destructive to tissue of the mucous membranes and upper respiratory tract, eyes, and skin., spasm,
inflammation and edema of the larynx, spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary edema,
burning sensation, Cough, wheezing, laryngitis, Shortness of breath, Headache, Nausea, Vomiting, To the best of our
knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1

Toxicity
Toxicity to fish

12.2

mortality LC50 - Gambusia affinis (Mosquito fish) - 5,600 mg/l - 96 h

Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available
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13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this
material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a
licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
UN number: 1426
Class: 4.3
Proper shipping name: Sodium borohydride
Reportable Quantity (RQ):
Poison Inhalation Hazard: No

Packing group: I

IMDG
UN number: 1426
Class: 4.3
Packing group: I
Proper shipping name: SODIUM BOROHYDRIDE
IATA
UN number: 1426
Class: 4.3
Proper shipping name: Sodium borohydride
IATA Passenger: Not permitted for transport

EMS-No: F-G, S-O

Packing group: I

15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Reactivity Hazard, Acute Health Hazard, Chronic Health Hazard
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
Sodium borohydride

CAS-No.
16940-66-2

Revision Date
2007-03-01

CAS-No.
16940-66-2

Revision Date
2007-03-01

New Jersey Right To Know Components
Sodium borohydride

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox.
Eye Dam.
H260
Aldrich - 452882

Acute toxicity
Serious eye damage
In contact with water releases flammable gases which may ignite spontaneously.
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H301
H314
H318
H360
H360F
Repr.
Skin Corr.

Toxic if swallowed.
Causes severe skin burns and eye damage.
Causes serious eye damage.
May damage fertility or the unborn child.
May damage fertility.
Reproductive toxicity
Skin corrosion

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard

3
*
4
2

NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:
Special hazard.I:

3
4
2
W

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 6.13
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.10
Revision Date 10/02/2017
Print Date 03/24/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Sodium chloride

Product Number
Brand

:
:

S7653
Sigma-Aldrich

CAS-No.

:

7647-14-5

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
Not a hazardous substance or mixture.

2.2

GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.

2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Formula
Molecular weight
CAS-No.
EC-No.

:
:
:
:

NaCl
58.44 g/mol
7647-14-5
231-598-3

No components need to be disclosed according to the applicable regulations.

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.

Sigma-Aldrich - S7653
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If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid breathing dust.
For personal protection see section 8.

6.2

Environmental precautions
Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for
disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid formation of dust and aerosols.Further processing of solid materials may result in the formation of combustible
dusts. The potential for combustible dust formation should be taken into consideration before additional processing
occurs.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

8.2

Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards such as
NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and
to the specific work-place., The type of protective equipment must be selected according to the concentration
and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: solid
Colour: colourless

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

7

e)

Melting point/freezing

Melting point/range: 801 °C (1,474 °F)

Sigma-Aldrich - S7653
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point

9.2

f)

Initial boiling point and
boiling range

1,413 °C (2,575 °F)

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

1.33 hPa (1.00 mmHg) at 865 °C (1,589 °F)

l)

Vapour density

No data available

m) Relative density

2.1650 g/cm3

n)

Water solubility

358 g/l at 20 °C (68 °F) - soluble

o)

Partition coefficient: noctanol/water

No data available

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong oxidizing agents

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Hydrogen chloride gas, Sodium oxides
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 3,550 mg/kg
LC50 Inhalation - Rat - 1 h - > 42,000 mg/m3
LD50 Dermal - Rabbit - > 10,000 mg/kg
No data available
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Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: VZ4725000
Vomiting, Diarrhoea, Dehydration and congestion may occur in internal organs. Hypertonic salt solutions can produce
inflammatory reactions in the gastrointestinal tract., To the best of our knowledge, the chemical, physical, and
toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1

Toxicity
Toxicity to fish

LC50 - Lepomis macrochirus (Bluegill) - 5,840 mg/l - 96 h

Toxicity to daphnia and
other aquatic
invertebrates

NOEC - Daphnia (water flea) - 1,500 mg/l - 7 d

LC50 - Daphnia magna (Water flea) - 1,661 mg/l - 48 h
12.2

Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available
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13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
Sodium chloride

CAS-No.
7647-14-5

Revision Date

CAS-No.
7647-14-5

Revision Date

New Jersey Right To Know Components
Sodium chloride

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

1
0
0
1
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
Sigma-Aldrich - S7653
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product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 5.10
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Revision Date: 10/02/2017

Print Date: 03/24/2018
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 3.8
Revision Date 10/20/2017
Print Date 04/08/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Sodium citrate dihydrate

Product Number
Brand

:
:

W302600
Aldrich

CAS-No.

:

6132-04-3

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
Not a hazardous substance or mixture.

2.2

GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.

2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Synonyms

Formula
Molecular weight
CAS-No.
EC-No.
Registration number

:

Sodium citrate tribasicdihydrate
Trisodium citratedihydrate
Citric acidtrisodium saltdihydrate

:
:
:
:
:

C6H5Na3O7 · 2H2O
294.1 g/mol
6132-04-3
200-675-3
01-2119457027-40-XXXX

No components need to be disclosed according to the applicable regulations.
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4. FIRST AID MEASURES
4.1

Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.

4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.

6.2

Environmental precautions
Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Keep in a dry place.
Storage class (TRGS 510): 13: Non Combustible Solids

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

8.2

Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards such as
NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and
to the specific work-place., The type of protective equipment must be selected according to the concentration
and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: powder
Colour: white

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

7.5 - 9 at 29.4 g/l at 25 °C (77 °F)

e)

Melting point/freezing
point

Melting point/range: > 300 °C (> 572 °F) - lit.
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9.2

f)

Initial boiling point and
boiling range

309.6 °C (589.3 °F) at 1,013 hPa (760 mmHg)

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

No data available

n)

Water solubility

29.4 g/l at 20 °C (68 °F) - completely soluble

o)

Partition coefficient: noctanol/water

No data available

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong oxidizing agents

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides
Other decomposition products - No data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
No data available
Inhalation: No data available
Dermal: No data available
No data available

Aldrich - W302600

Page 4 of 7

Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1
12.2

Toxicity
No data available
Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
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Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
CITRIC ACID TRISODIUM SALT Dihydrate

CAS-No.
6132-04-3

Revision Date

CAS-No.
6132-04-3

Revision Date

New Jersey Right To Know Components
CITRIC ACID TRISODIUM SALT Dihydrate

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

0
0
0
0
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 4.6
Revision Date 09/11/2015
Print Date 04/08/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

N,N,N′,N′-Tetramethylethylenediamine

Product Number
Brand
Index-No.

:
:
:

T7024
Sigma
612-103-00-3

CAS-No.

:

110-18-9

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
Flammable liquids (Category 2), H225
Acute toxicity, Oral (Category 3), H301
Acute toxicity, Inhalation (Category 3), H331
Skin corrosion (Category 1B), H314
Serious eye damage (Category 1), H318
For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2

GHS Label elements, including precautionary statements
Pictogram
Signal word

Danger

Hazard statement(s)
H225
H301 + H331
H314

Highly flammable liquid and vapour.
Toxic if swallowed or if inhaled
Causes severe skin burns and eye damage.

Precautionary statement(s)
P210
P233
P240
P241

Keep away from heat/sparks/open flames/hot surfaces. No smoking.
Keep container tightly closed.
Ground/bond container and receiving equipment.
Use explosion-proof electrical/ ventilating/ lighting/ equipment.
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P242
P243
P261
P264
P270
P271
P280

Use only non-sparking tools.
Take precautionary measures against static discharge.
Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
Wash skin thoroughly after handling.
Do not eat, drink or smoke when using this product.
Use only outdoors or in a well-ventilated area.
Wear protective gloves/ protective clothing/ eye protection/ face
protection.
IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
IF ON SKIN (or hair): Remove/ Take off immediately all contaminated
clothing. Rinse skin with water/ shower.
IF INHALED: Remove victim to fresh air and keep at rest in a position
comfortable for breathing.
IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Immediately call a POISON CENTER or doctor/ physician.
Specific treatment (see supplemental first aid instructions on this label).
Wash contaminated clothing before reuse.
In case of fire: Use dry sand, dry chemical or alcohol-resistant foam for
extinction.
Store in a well-ventilated place. Keep container tightly closed.
Store in a well-ventilated place. Keep cool.
Store locked up.
Dispose of contents/ container to an approved waste disposal plant.

P301 + P310
P301 + P330 + P331
P303 + P361 + P353
P304 + P340
P305 + P351 + P338
P310
P321
P363
P370 + P378
P403 + P233
P403 + P235
P405
P501
2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Synonyms

:

TMEDA
1,2-Bis(dimethylamino)ethane
TEMED

Formula
Molecular weight
CAS-No.
EC-No.
Index-No.

:
:
:
:
:

C6H16N2
116.2 g/mol
110-18-9
203-744-6
612-103-00-3

Hazardous components
Component

Classification

Concentration

N,N,N',N'-Tetramethylethylenediamine
Flam. Liq. 2; Acute Tox. 3;
Skin Corr. 1B; Eye Dam. 1;
H225, H301 + H331, H314
For the full text of the H-Statements mentioned in this Section, see Section 16.

<= 100 %

4. FIRST AID MEASURES
4.1

Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Take victim
immediately to hospital. Consult a physician.
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In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.Continue rinsing eyes during
transport to hospital.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a
physician.
4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
Use water spray to cool unopened containers.

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all sources
of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations.
Vapours can accumulate in low areas.
For personal protection see section 8.

6.2

Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in
container for disposal according to local regulations (see section 13).

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Use explosion-proof equipment.Keep away from sources of ignition - No smoking.Take measures to prevent the build
up of electrostatic charge.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully
resealed and kept upright to prevent leakage.
Handle and store under inert gas. Air and moisture sensitive.

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

8.2

Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.
Personal protective equipment
Eye/face protection
Tightly fitting safety goggles. Faceshield (8-inch minimum). Use equipment for eye protection tested and
approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.4 mm
Break through time: 125 min
Material tested:Camatril® (KCL 730 / Aldrich Z677442, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It
should not be construed as offering an approval for any specific use scenario.
Body Protection
Complete suit protecting against chemicals, Flame retardant antistatic protective clothing., The type of
protective equipment must be selected according to the concentration and amount of the dangerous substance
at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multipurpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls.
If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: liquid, clear
Colour: colourless

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

No data available

e)

Melting point/freezing
point

Melting point/range: -55 °C (-67 °F)

f)

Initial boiling point and
boiling range

120 - 122 °C (248 - 252 °F)

g)

Flash point

20 °C (68 °F) - closed cup
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9.2

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

Upper explosion limit: 9.08 %(V)
Lower explosion limit: 0.98 %(V)

k)

Vapour pressure

No data available

l)

Vapour density

No data available

m) Relative density

0.775 g/mL at 20 °C (68 °F)

n)

Water solubility

soluble

o)

Partition coefficient: noctanol/water

log Pow: 0.3

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
No data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
Vapours may form explosive mixture with air.

10.4

Conditions to avoid
Heat, flames and sparks. Extremes of temperature and direct sunlight.

10.5

Incompatible materials
Strong oxidizing agents, Carbon dioxide (CO2), Copper

10.6

Hazardous decomposition products
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 268 mg/kg
LC50 Inhalation - Rat - 4 h - 1318 ppm
LD50 Dermal - Rabbit - 5,390 mg/kg
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
Eyes - Rabbit
Result: Severe eye irritation
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Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: KV7175000
Material is extremely destructive to tissue of the mucous membranes and upper respiratory tract, eyes, and skin.,
spasm, inflammation and edema of the larynx, spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary
edema
12. ECOLOGICAL INFORMATION
12.1

Toxicity
No data available

12.2

Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this
material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a
licensed professional waste disposal service to dispose of this material.
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Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
UN number: 3286
Class: 3 (6.1, 8)
Packing group: II
Proper shipping name: Flammable liquid, toxic, corrosive, n.o.s.
Poison Inhalation Hazard: No
IMDG
UN number: 2372
Class: 3
Packing group: II
Proper shipping name: 1,2-DI-(DIMETHYLAMINO)ETHANE

EMS-No: F-E, S-D

IATA
UN number: 2372
Class: 3
Packing group: II
Proper shipping name: 1,2-Di-(dimethylamino) ethane
15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Fire Hazard, Acute Health Hazard
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
N,N,N',N'-Tetramethylethylenediamine

CAS-No.
110-18-9

Revision Date
2007-03-01

CAS-No.
110-18-9

Revision Date
2007-03-01

New Jersey Right To Know Components
N,N,N',N'-Tetramethylethylenediamine

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox.
Eye Dam.
Flam. Liq.
H225
H301
H301 + H331
H314
H318

Acute toxicity
Serious eye damage
Flammable liquids
Highly flammable liquid and vapour.
Toxic if swallowed.
Toxic if swallowed or if inhaled
Causes severe skin burns and eye damage.
Causes serious eye damage.

HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Sigma - T7024
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Physical Hazard

0

NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

3
3
0

Further information
Copyright 2015 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 4.6

Sigma - T7024

Revision Date: 09/11/2015

Print Date: 04/08/2018
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SIGMA-ALDRICH

sigma-aldrich.com

SAFETY DATA SHEET
Version 5.0
Revision Date 01/16/2018
Print Date 04/10/2018

1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

Urea (200 mg)

Product Number
Brand

:
:

1706698
USP

CAS-No.

:

57-13-6

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Synthesis of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

+1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
Not a hazardous substance or mixture.

2.2

GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.

2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1

Substances
Molecular weight
CAS-No.

:
:

60.06 g/mol
57-13-6

Hazardous components
Component
Urea

Classification

Concentration
90 - 100 %

4. FIRST AID MEASURES
4.1

Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
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In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
No data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
No data available

5.3

Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.

5.4

Further information
No data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.

6.2

Environmental precautions
No special environmental precautions required.

6.3

Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust
formation should be taken into consideration before additional processing occurs.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): 13: Non Combustible Solids

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
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8.2

Component

CAS-No.

Value

Urea

57-13-6

TWA

Control
parameters
10.000000
mg/m3

Basis
USA. Workplace Environmental
Exposure Levels (WEEL)

Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards such as
NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and
to the specific work-place., The type of protective equipment must be selected according to the concentration
and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
No special environmental precautions required.

9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: solid
Colour: white

b)

Odour

No data available

c)

Odour Threshold

No data available

d)

pH

7.5 - 9.5 at 480 g/l at 25 °C (77 °F)

e)

Melting point/freezing
point

133 - 135 °C (271 - 275 °F)

f)

Initial boiling point and
boiling range

No data available

g)

Flash point

No data available

h)

Evaporation rate

No data available

i)

Flammability (solid, gas) No data available

j)

Upper/lower
flammability or
explosive limits

No data available

k)

Vapour pressure

0.009 hPa (0.007 mmHg) at 20 °C (68 °F)

l)

Vapour density

No data available

m) Relative density

1.335 g/cm3

n)

Water solubility

480 g/l at 20 °C (68 °F) - completely soluble

o)

Partition coefficient: noctanol/water

log Pow: -2.59 - -1.59
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9.2

p)

Auto-ignition
temperature

No data available

q)

Decomposition
temperature

No data available

r)

Viscosity

No data available

s)

Explosive properties

No data available

t)

Oxidizing properties

No data available

Other safety information
Bulk density

700 - 800 kg/m3 at 20 °C (68 °F)

10. STABILITY AND REACTIVITY
10.1

Reactivity
No data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
No data available

10.4

Conditions to avoid
No data available

10.5

Incompatible materials
Strong oxidizing agents

10.6

Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx)
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
LD50 Oral - Rat - 8,471 mg/kg
Inhalation: No data available
Dermal: No data available
No data available
Skin corrosion/irritation
Skin - Rabbit
Result: No skin irritation
Serious eye damage/eye irritation
Eyes - Rabbit
Result: No eye irritation
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is on OSHA’s
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list of regulated carcinogens.
Reproductive toxicity
No data available
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
12. ECOLOGICAL INFORMATION
12.1

12.2

Toxicity
Toxicity to fish

LC50 - Poecilia reticulata (guppy) - 17,500 mg/l - 96 h

Toxicity to daphnia and
other aquatic
invertebrates

EC50 - Daphnia magna (Water flea) - 3,910 mg/l - 48 h

Persistence and degradability
No data available

12.3

Bioaccumulative potential
No data available

12.4

Mobility in soil
No data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
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15. REGULATORY INFORMATION
SARA 302 Components
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De
Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
CAS-No.
57-13-6

Revision Date

Urea

CAS-No.
57-13-6

Revision Date

Urea

CAS-No.
57-13-6

Revision Date

New Jersey Right To Know Components
Urea

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.

16. OTHER INFORMATION
HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

0
0
0
0
0
0

Further information
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
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